article_title,journal_title,journal_abbre,article_date,abstract,article_type,pub_days,citation,abstract_clean,Breast Cancer,Lung Cancer,Leukemia,Prostate Cancer,Colorectal Cancer,Lymphoma,Bone Cancer,Melanoma,Liver Cancer,Kidney Cancer,Ovarian Cancer,Pancreatic Cancer,Brain Tumor,Head and Neck Cancer,Acute Myeloid Leukemia (AML),Multiple Myeloma,Sarcoma,Bladder Cancer,Skin Cancer,Gastric Cancer,Gastrointestinal Tumor,Endometrial Cancer,Acute Lymphoblastic Leukemia (ALL),Chronic Lymphocytic Leukemia (CLL),Cardiac Tumors,Cervical Cancer,Esophageal Cancer,Thyroid Cancer,Rectal Cancer,text_clean_seq,text_length,pmid,w2v_similarity_rank_chronic_myelogenous_leukemia_(cml)
Chronic myelogenous leukemia: update on biology and treatment.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",1999-02-01,"Chronic myelogenous leukemia (CML) is a myeloproliferative disorder that follows a characteristic clinical course in which a chronic phase of variable duration precedes an accelerated, and ultimately blastic, phase, which is generally fatal. This disorder results from a clonal expansion of transformed hematopoietic progenitor cells and includes myeloid, monocytic, erythroid, megakaryocytic, and lymphoid lineages. At the molecular level, CML is characterized by the bcr-abl fusion gene, which results from the reciprocal translocation t(9;22)(q34;q11), creating the Philadelphia (Ph) chromosome. Chronic myelogenous leukemia was the first human disease for which a specific karyotype abnormality was demonstrated and could be linked to pathogenetic events of leukemogenesis. The outlook for patients with CML has changed dramatically over the last decade. The median survival time of patients has doubled to 5 to 7 years, with up to 50% of patients alive at 5 years. This development is due to refinements in allogeneic stem-cell transplantation and growing expertise in the use of interferon-alfa (Intron A, Roferon-A), a biological agent that has been shown to suppress the leukemic clone and to prolong survival in patients with CML. This review provides a concise update of the biology of CML, as well as current therapeutic options and management strategies.",Comparative Study,7659.0,73.0,Chronic myelogenous CML is a disorder that follows a characteristic clinical course in which a chronic phase of variable duration precedes an accelerated and ultimately blastic phase which is generally fatal This disorder results from a clonal expansion of transformed hematopoietic progenitor cells and includes myeloid monocytic erythroid megakaryocytic and lymphoid lineages At the molecular level CML is characterized by the bcr-abl fusion gene which results from the reciprocal translocation t 9 22 q34 q11 creating the Philadelphia Ph chromosome Chronic myelogenous was the first human disease for which a specific karyotype abnormality was demonstrated and could be linked to pathogenetic events of leukemogenesis The outlook for patients with CML has changed dramatically over the last decade The median survival time of patients has doubled to 5 to 7 years with up to 50 of patients alive at 5 years This development is due to refinements in allogeneic stem-cell transplantation and growing expertise in the use of interferon-alfa Intron A Roferon-A a biological agent that has been shown to suppress the leukemic clone and to prolong survival in patients with CML This review provides a concise update of the biology of CML as well as current therapeutic options and management strategies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 16, 8, 2645, 17, 2962, 8, 2037, 38, 906, 4, 92, 8, 442, 124, 1, 1347, 654, 20146, 35, 2241, 2, 2050, 6529, 124, 92, 16, 1228, 3034, 26, 2645, 99, 29, 8, 1946, 1422, 1, 2423, 1007, 2520, 37, 2, 1920, 533, 9003, 7839, 14385, 2, 2303, 7234, 28, 3, 219, 301, 903, 16, 765, 20, 3, 1062, 1425, 1212, 145, 92, 99, 29, 3, 8020, 2006, 102, 83, 350, 16609, 11532, 6147, 3, 3006, 2058, 1170, 442, 2194, 10, 3, 157, 171, 34, 9, 92, 8, 112, 3385, 3698, 10, 264, 2, 359, 40, 1199, 6, 10781, 281, 1, 5661, 3, 8628, 9, 7, 5, 903, 71, 2368, 2729, 252, 3, 1060, 2025, 3, 52, 25, 98, 1, 7, 71, 8431, 6, 33, 6, 67, 60, 5, 126, 6, 212, 1, 7, 1701, 28, 33, 60, 26, 193, 16, 520, 6, 10518, 4, 1063, 452, 31, 497, 2, 1921, 4935, 4, 3, 119, 1, 1688, 4443, 6259, 8, 42793, 8, 8, 1037, 420, 17, 71, 85, 443, 6, 3134, 3, 2015, 3910, 2, 6, 3615, 25, 4, 7, 5, 903, 26, 206, 777, 8, 11071, 2991, 1, 3, 891, 1, 903, 22, 149, 22, 291, 189, 838, 2, 284, 422]",1298.0,10079468,138
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.,Blood,Blood,2002-01-01,"The adenosine triphosphate binding-site-directed agent STI571 and the tyrphostin adaphostin are undergoing evaluation as bcr/abl kinase inhibitors. The current study compared the effects of these agents on the survival of K562 cells, bcr/abl-transduced FDC-P1 cells, and myeloid progenitors from patients with chronic myelogenous leukemia (CML) compared with healthy donors. Treatment of K562 cells with 10 microM adaphostin resulted in decreased p210(bcr/abl) polypeptide levels in the first 6 hours, followed by caspase activation and accumulation of apoptotic cells in less than 12 hours. By 24 hours, 90% of the cells were apoptotic and unable to form colonies. In contrast, 20 microM STI571 caused rapid inhibition of bcr/abl autophosphorylation without p210(bcr/abl) degradation. Although this was followed by the inhibition of Stat5 phosphorylation and the down-regulation of Bcl-x(L) and Mcl-1, only 7% +/- 3% and 25% +/- 9% of cells were apoptotic at 16 and 24 hours, respectively. Instead, the cytotoxic effects of STI571 became more pronounced with prolonged exposure, with IC90 values greater than 20 microM and 1.0 +/- 0.6 microM after 24 and 48 hours, respectively. Consistent with these results, 24-hour adaphostin exposure inhibited CML granulocyte colony-forming units (CFU-G) (median IC50, 12 microM) but not normal CFU-G (median IC50, greater than 20 microM), whereas 24-hour STI571 treatment had no effect on CML or normal CFU-G. Additional experiments revealed that STI571-resistant K562 cells remained sensitive to adaphostin. Moreover, the combination of STI571 + adaphostin induced more cytotoxicity in K562 cells and in CML CFU-G than either agent alone did. Collectively, these results identify adaphostin as a mechanistically distinct CML-selective agent that retains activity in STI571-resistant cell lines.",Journal Article,6594.0,100.0,The adenosine triphosphate binding-site-directed agent STI571 and the tyrphostin adaphostin are undergoing evaluation as bcr/abl kinase inhibitors The current study compared the effects of these agents on the survival of K562 cells bcr/abl-transduced FDC-P1 cells and myeloid progenitors from patients with chronic myelogenous CML compared with healthy donors Treatment of K562 cells with 10 microM adaphostin resulted in decreased p210 bcr/abl polypeptide levels in the first 6 hours followed by caspase activation and accumulation of apoptotic cells in less than 12 hours By 24 hours 90 of the cells were apoptotic and unable to form colonies In contrast 20 microM STI571 caused rapid inhibition of bcr/abl autophosphorylation without p210 bcr/abl degradation Although this was followed by the inhibition of Stat5 phosphorylation and the down-regulation of Bcl-x L and Mcl-1 only 7 +/- 3 and 25 +/- 9 of cells were apoptotic at 16 and 24 hours respectively Instead the cytotoxic effects of STI571 became more pronounced with prolonged exposure with IC90 values greater than 20 microM and 1.0 +/- 0.6 microM after 24 and 48 hours respectively Consistent with these results 24-hour adaphostin exposure inhibited CML granulocyte colony-forming units CFU-G median IC50 12 microM but not normal CFU-G median IC50 greater than 20 microM whereas 24-hour STI571 treatment had no effect on CML or normal CFU-G. Additional experiments revealed that STI571-resistant K562 cells remained sensitive to adaphostin Moreover the combination of STI571 adaphostin induced more cytotoxicity in K562 cells and in CML CFU-G than either agent alone did Collectively these results identify adaphostin as a mechanistically distinct CML-selective agent that retains activity in STI571-resistant cell lines,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 4938, 7345, 791, 606, 1166, 420, 5735, 2, 3, 25963, 10028, 32, 479, 451, 22, 1062, 1425, 216, 222, 3, 291, 45, 72, 3, 176, 1, 46, 183, 23, 3, 25, 1, 5208, 37, 1062, 1425, 5042, 14728, 9538, 37, 2, 533, 4321, 29, 7, 5, 442, 2194, 903, 72, 5, 1331, 2344, 24, 1, 5208, 37, 5, 79, 3550, 10028, 627, 4, 340, 11538, 1062, 1425, 8720, 148, 4, 3, 157, 49, 1459, 370, 20, 1469, 363, 2, 1835, 1, 1631, 37, 4, 299, 76, 133, 1459, 20, 259, 1459, 424, 1, 3, 37, 11, 1631, 2, 4253, 6, 1297, 8633, 4, 748, 179, 3550, 5735, 1546, 1321, 297, 1, 1062, 1425, 8146, 187, 11538, 1062, 1425, 2373, 242, 26, 10, 370, 20, 3, 297, 1, 5517, 982, 2, 3, 1328, 863, 1, 1044, 1006, 805, 2, 1308, 14, 158, 67, 27, 2, 243, 83, 1, 37, 11, 1631, 28, 245, 2, 259, 1459, 106, 3496, 3, 759, 176, 1, 5735, 3451, 80, 3517, 5, 1069, 645, 5, 42814, 1030, 378, 76, 179, 3550, 2, 14, 13, 13, 49, 3550, 50, 259, 2, 576, 1459, 106, 925, 5, 46, 99, 259, 2583, 10028, 645, 879, 903, 2764, 1975, 4525, 2960, 10388, 499, 52, 5211, 133, 3550, 84, 44, 295, 10388, 499, 52, 5211, 378, 76, 179, 3550, 547, 259, 2583, 5735, 24, 42, 77, 254, 23, 903, 15, 295, 10388, 499, 402, 2332, 553, 17, 5735, 436, 5208, 37, 958, 745, 6, 10028, 1393, 3, 150, 1, 5735, 10028, 277, 80, 1408, 4, 5208, 37, 2, 4, 903, 10388, 499, 76, 361, 420, 279, 205, 2535, 46, 99, 255, 10028, 22, 8, 4187, 834, 903, 1094, 420, 17, 10785, 128, 4, 5735, 436, 31, 285]",1782.0,11781252,104
"Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2002-02-01,"To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia. Study participants were patients with refractory or relapsed acute myeloid (AML) or lymphocytic (ALL) leukemia, myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP). Troxacitabine was provided as an intravenous infusion for more than 30 minutes daily for 5 days at a dose of 8.0 mg/m(2)/d (40 mg/m(2) per course). Courses were given every 3 to 4 weeks according to antileukemic efficacy. Forty-two patients (AML, 18 patients; MDS, one patient; ALL, six patients; CML-BP, 17 patients) were treated. Median age was 51 years (range, 23 to 80 years); 22 patients were male. Stomatitis was the most significant adverse event, with three patients (7%) and two patients (5%), respectively, experiencing grade 3 or 4 toxicity. Ten patients (24%) had grade 3 hand-foot syndrome, and two patients (5%) had grade 3 skin rash. One patient (2%) had grade 3 fatigue and anorexia. Marrow hypoplasia occurred between days 14 and 28 in 12 (75%) of 16 assessable patients with AML. Two complete remissions and one partial remission (18%) were observed in 16 assessable patients with AML. None of six patients with ALL responded. Six (37%) of 16 assessable patients with CML-BP experienced a return to chronic-phase disease. Troxacitabine has significant antileukemic activity in patients with AML and CML-BP.",Clinical Trial,6563.0,69.0,To investigate the activity of a novel dioxolane L-nucleoside analog troxacitabine L- -OddC BCH-4556 in patients with refractory Study participants were patients with refractory or relapsed acute myeloid AML or lymphocytic ALL syndromes MDS or chronic myelogenous in blastic phase CML-BP Troxacitabine was provided as an intravenous infusion for more than 30 minutes daily for 5 days at a dose of 8.0 mg/m 2 /d 40 mg/m 2 per course Courses were given every 3 to 4 weeks according to antileukemic efficacy Forty-two patients AML 18 patients MDS one patient ALL six patients CML-BP 17 patients were treated Median age was 51 years range 23 to 80 years 22 patients were male Stomatitis was the most significant adverse event with three patients 7 and two patients 5 respectively experiencing grade 3 or 4 toxicity Ten patients 24 had grade 3 hand-foot syndrome and two patients 5 had grade 3 rash One patient 2 had grade 3 fatigue and anorexia Marrow hypoplasia occurred between days 14 and 28 in 12 75 of 16 assessable patients with AML Two complete remissions and one partial remission 18 were observed in 16 assessable patients with AML None of six patients with ALL responded Six 37 of 16 assessable patients with CML-BP experienced a return to chronic-phase disease Troxacitabine has significant antileukemic activity in patients with AML and CML-BP,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[6, 963, 3, 128, 1, 8, 229, 42835, 805, 4032, 3497, 10949, 805, 52719, 52720, 37077, 4, 7, 5, 430, 45, 776, 11, 7, 5, 430, 15, 591, 286, 533, 329, 15, 1193, 62, 2040, 1223, 15, 442, 2194, 4, 6529, 124, 903, 3044, 10949, 10, 1052, 22, 35, 1262, 904, 9, 80, 76, 201, 2511, 391, 9, 33, 162, 28, 8, 61, 1, 66, 13, 81, 188, 18, 427, 327, 81, 188, 18, 379, 906, 1993, 11, 447, 454, 27, 6, 39, 244, 768, 6, 4512, 209, 1213, 100, 7, 329, 203, 7, 1223, 104, 69, 62, 437, 7, 903, 3044, 269, 7, 11, 73, 52, 89, 10, 725, 60, 184, 382, 6, 493, 60, 350, 7, 11, 1045, 4486, 10, 3, 96, 93, 290, 774, 5, 169, 7, 67, 2, 100, 7, 33, 106, 2985, 88, 27, 15, 39, 155, 1618, 7, 259, 42, 88, 27, 2833, 4100, 681, 2, 100, 7, 33, 42, 88, 27, 1641, 104, 69, 18, 42, 88, 27, 613, 2, 3373, 581, 20991, 489, 59, 162, 213, 2, 339, 4, 133, 481, 1, 245, 3120, 7, 5, 329, 100, 236, 3166, 2, 104, 450, 734, 203, 11, 164, 4, 245, 3120, 7, 5, 329, 1292, 1, 437, 7, 5, 62, 2211, 437, 567, 1, 245, 3120, 7, 5, 903, 3044, 592, 8, 4656, 6, 442, 124, 34, 10949, 71, 93, 4512, 128, 4, 7, 5, 329, 2, 903, 3044]",1351.0,11821445,90
Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.,Blood,Blood,2002-03-01,"In haploidentical transplantation, the mismatched haplotype of the donor can originate from either of the parents. We refer to such mismatched haplotypes as noninherited maternal antigens (NIMA haplotype) or noninherited paternal antigens (NIPA haplotype). To determine whether exposure to maternal HLA antigens benefits patients undergoing bone marrow transplantation, we analyzed graft failure and graft-versus-host disease (GVHD) after transplantations from parental or haploidentical sibling donors. We studied 269 patients receiving 1 or 2 HLA-A, -B, -DR antigen-mismatched sibling or parental non-T-cell-depleted bone marrow transplants for acute myelogenous leukemia, acute lymphoblastic leukemia, or chronic myelogenous leukemia between 1985 and 1997 that were reported to the International Bone Marrow Transplant Registry. Included were 121 (45%) NIMA-mismatched and 148 (55%) NIPA-mismatched transplantations. Sixty-three (52%) of the NIMA-mismatched transplants and 69 (47%) of the NIPA-mismatched transplants were from haploidentical sibling donors. Sibling transplantations mismatched for NIMA had similar rates of graft failure but lower rates of acute GVHD (P <.02) than NIPA-mismatched sibling transplantations. In the first 4 months after transplantation, mother-to-child transplantations involved significantly less chronic GVHD than father-to-child transplantations (P <.02). Treatment-related mortality (TRM) was significantly higher after parental transplantations (P =.009 for mother; P =.03 for father) than after haploidentical sibling transplantations mismatched for the NIMA. Non-T-cell-depleted bone marrow transplants donated by haploidentical siblings to recipients mismatched for NIPA and transplants donated by parents caused more acute and chronic GVHD and TRM than transplants donated by haploidentical siblings mismatched for NIMA.",Comparative Study,6535.0,217.0,In haploidentical transplantation the mismatched haplotype of the donor can originate from either of the parents We refer to such mismatched haplotypes as noninherited maternal antigens NIMA haplotype or noninherited paternal antigens NIPA haplotype To determine whether exposure to maternal HLA antigens benefits patients undergoing marrow transplantation we analyzed graft failure and graft-versus-host disease GVHD after transplantations from parental or haploidentical sibling donors We studied 269 patients receiving 1 or 2 HLA-A -B -DR antigen-mismatched sibling or parental non-T-cell-depleted marrow transplants for acute myelogenous acute lymphoblastic or chronic myelogenous between 1985 and 1997 that were reported to the International Marrow Transplant Registry Included were 121 45 NIMA-mismatched and 148 55 NIPA-mismatched transplantations Sixty-three 52 of the NIMA-mismatched transplants and 69 47 of the NIPA-mismatched transplants were from haploidentical sibling donors Sibling transplantations mismatched for NIMA had similar rates of graft failure but lower rates of acute GVHD P .02 than NIPA-mismatched sibling transplantations In the first 4 months after transplantation mother-to-child transplantations involved significantly less chronic GVHD than father-to-child transplantations P .02 Treatment-related mortality TRM was significantly higher after parental transplantations P =.009 for mother P =.03 for father than after haploidentical sibling transplantations mismatched for the NIMA Non-T-cell-depleted marrow transplants donated by haploidentical siblings to recipients mismatched for NIPA and transplants donated by parents caused more acute and chronic GVHD and TRM than transplants donated by haploidentical siblings mismatched for NIMA,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 5802, 497, 3, 5095, 4179, 1, 3, 1488, 122, 8838, 29, 361, 1, 3, 2418, 21, 7851, 6, 225, 5095, 5940, 22, 30205, 6039, 1575, 16624, 4179, 15, 30205, 10649, 1575, 30206, 4179, 6, 223, 317, 645, 6, 6039, 1160, 1575, 1141, 7, 479, 581, 497, 21, 311, 1599, 496, 2, 1599, 185, 1204, 34, 1562, 50, 6779, 29, 3418, 15, 5802, 3684, 2344, 21, 656, 8639, 7, 357, 14, 15, 18, 1160, 8, 132, 3436, 448, 5095, 3684, 15, 3418, 220, 102, 31, 4358, 581, 4016, 9, 286, 2194, 286, 1275, 15, 442, 2194, 59, 4675, 2, 2341, 17, 11, 210, 6, 3, 944, 581, 941, 1608, 159, 11, 4141, 512, 16624, 5095, 2, 4647, 614, 30206, 5095, 6779, 1746, 169, 653, 1, 3, 16624, 5095, 4016, 2, 790, 662, 1, 3, 30206, 5095, 4016, 11, 29, 5802, 3684, 2344, 3684, 6779, 5095, 9, 16624, 42, 288, 151, 1, 1599, 496, 84, 280, 151, 1, 286, 1562, 19, 588, 76, 30206, 5095, 3684, 6779, 4, 3, 157, 39, 53, 50, 497, 9733, 6, 2566, 6779, 646, 97, 299, 442, 1562, 76, 17610, 6, 2566, 6779, 19, 588, 24, 139, 282, 5064, 10, 97, 142, 50, 3418, 6779, 19, 2376, 9, 9733, 19, 680, 9, 17610, 76, 50, 5802, 3684, 6779, 5095, 9, 3, 16624, 220, 102, 31, 4358, 581, 4016, 25982, 20, 5802, 2758, 6, 2190, 5095, 9, 30206, 2, 4016, 25982, 20, 2418, 1546, 80, 286, 2, 442, 1562, 2, 5064, 76, 4016, 25982, 20, 5802, 2758, 5095, 9, 16624]",1772.0,11861270,50
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.,Blood,Blood,2002-03-01,"Chronic myelogenous leukemia (CML) is caused by expression of the BCR-ABL tyrosine kinase oncogene, the product of the t(9;22) Philadelphia translocation. Patients with CML in accelerated phase have rapidly progressive disease and are characteristically unresponsive to existing therapies. Imatinib (formerly STI571) is a rationally developed, orally administered inhibitor of the Bcr-Abl kinase. A total of 235 CML patients were enrolled in this study, of whom 181 had a confirmed diagnosis of accelerated phase. Patients were treated with imatinib at 400 or 600 mg/d and were evaluated for hematologic and cytogenetic response, time to progression, survival, and toxicity. Imatinib induced hematologic response in 82% of patients and sustained hematologic responses lasting at least 4 weeks in 69% (complete in 34%). The rate of major cytogenetic response was 24% (complete in 17%). Estimated 12-month progression-free and overall survival rates were 59% and 74%, respectively. Nonhematologic toxicity was usually mild or moderate, and hematologic toxicity was manageable. In comparison to 400 mg, imatinib doses of 600 mg/d led to more cytogenetic responses (28% compared to 16%), longer duration of response (79% compared to 57% at 12 months), time to disease progression (67% compared to 44% at 12 months), and overall survival (78% compared to 65% at 12 months), with no clinically relevant increase in toxicity. Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase. A daily dose of 600 mg is more effective than 400 mg, with similar toxicity.",Clinical Trial,6535.0,922.0,Chronic myelogenous CML is caused by expression of the BCR-ABL tyrosine kinase oncogene the product of the t 9 22 Philadelphia translocation Patients with CML in accelerated phase have rapidly progressive disease and are characteristically unresponsive to existing therapies Imatinib formerly STI571 is a rationally developed orally administered inhibitor of the Bcr-Abl kinase A total of 235 CML patients were enrolled in this study of whom 181 had a confirmed diagnosis of accelerated phase Patients were treated with imatinib at 400 or 600 mg/d and were evaluated for hematologic and cytogenetic response time to progression survival and toxicity Imatinib induced hematologic response in 82 of patients and sustained hematologic responses lasting at least 4 weeks in 69 complete in 34 The rate of major cytogenetic response was 24 complete in 17 Estimated 12-month progression-free and overall survival rates were 59 and 74 respectively Nonhematologic toxicity was usually mild or moderate and hematologic toxicity was manageable In comparison to 400 mg imatinib doses of 600 mg/d led to more cytogenetic responses 28 compared to 16 longer duration of response 79 compared to 57 at 12 months time to disease progression 67 compared to 44 at 12 months and overall survival 78 compared to 65 at 12 months with no clinically relevant increase in toxicity Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase A daily dose of 600 mg is more effective than 400 mg with similar toxicity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 16, 1546, 20, 55, 1, 3, 1062, 1425, 564, 216, 1836, 3, 2821, 1, 3, 102, 83, 350, 3006, 2006, 7, 5, 903, 4, 2241, 124, 47, 1755, 1014, 34, 2, 32, 14079, 7244, 6, 1692, 235, 577, 7350, 5735, 16, 8, 6352, 276, 1428, 468, 230, 1, 3, 1062, 1425, 216, 8, 181, 1, 6465, 903, 7, 11, 346, 4, 26, 45, 1, 953, 5540, 42, 8, 557, 147, 1, 2241, 124, 7, 11, 73, 5, 577, 28, 1524, 15, 2383, 81, 427, 2, 11, 194, 9, 813, 2, 1266, 51, 98, 6, 91, 25, 2, 155, 577, 277, 813, 51, 4, 878, 1, 7, 2, 2275, 813, 253, 3443, 28, 506, 39, 244, 4, 790, 236, 4, 562, 3, 116, 1, 458, 1266, 51, 10, 259, 236, 4, 269, 661, 133, 811, 91, 115, 2, 63, 25, 151, 11, 728, 2, 794, 106, 3534, 155, 10, 2082, 1980, 15, 1163, 2, 813, 155, 10, 2808, 4, 1155, 6, 1524, 81, 577, 415, 1, 2383, 81, 427, 836, 6, 80, 1266, 253, 339, 72, 6, 245, 589, 654, 1, 51, 842, 72, 6, 696, 28, 133, 53, 98, 6, 34, 91, 598, 72, 6, 584, 28, 133, 53, 2, 63, 25, 833, 72, 6, 556, 28, 133, 53, 5, 77, 505, 867, 344, 4, 155, 1428, 468, 577, 16, 35, 323, 2, 149, 421, 24, 9, 7, 5, 903, 4, 2241, 124, 8, 391, 61, 1, 2383, 81, 16, 80, 323, 76, 1524, 81, 5, 288, 155]",1546.0,11877262,164
C-kit expression in pediatric solid tumors: a comparative immunohistochemical study.,The American journal of surgical pathology,Am. J. Surg. Pathol.,2002-04-01,"The stem cell factor/c-kit tyrosine kinase receptor pathway has been shown to be important for tumor growth and progression in several cancers, including mast cell diseases, gastrointestinal stromal tumor, acute myeloid leukemia, small cell lung carcinoma, and Ewing sarcoma. Studies using the oral agent STI-571 (Gleevec, Novartis), an inhibitor of the tyrosine kinases bcr-abl, c-kit, and PDGFR, have shown significant responses in patients with chronic myelogenous leukemia and gastrointestinal stromal tumor. With the aim of identifying additional groups of tumors that may use the stem cell factor/c-kit pathway and secondarily may be responsive to STI-571 treatment, this study surveyed 151 primary tumors from patients treated at St. Jude Children's Research Hospital for immunohistochemical expression of c-kit. Formalin-fixed, paraffin-embedded sections were stained with rabbit polyclonal anti-human c-kit (CD117, Dako) using standard avidin-biotin-peroxidase complex technique, antigen retrieval, and an automated stainer. Strong, diffuse staining for c-kit was seen in a proportion of synovial sarcomas, osteosarcomas, and Ewing sarcomas. Strong, diffuse staining was less common in neuroblastomas, Wilms' tumors, and rhabdomyosarcomas and was negative in alveolar soft part sarcomas and desmoplastic small round cell tumors. Tumors with strong, diffuse staining for c-kit in a pattern similar to gastrointestinal stromal tumor may represent suitable targets for new therapeutic agents.",Journal Article,6504.0,126.0,The stem cell factor/c-kit tyrosine kinase receptor pathway has been shown to be important for tumor growth and progression in several cancers including mast cell diseases stromal tumor acute myeloid small cell carcinoma and Studies using the oral agent STI-571 Gleevec Novartis an inhibitor of the tyrosine kinases bcr-abl c-kit and PDGFR have shown significant responses in patients with chronic myelogenous and stromal tumor With the aim of identifying additional groups of tumors that may use the stem cell factor/c-kit pathway and secondarily may be responsive to STI-571 treatment this study surveyed 151 primary tumors from patients treated at St. Jude Children 's Research Hospital for immunohistochemical expression of c-kit Formalin-fixed paraffin-embedded sections were stained with rabbit polyclonal anti-human c-kit CD117 Dako using standard avidin-biotin-peroxidase complex technique antigen retrieval and an automated stainer Strong diffuse staining for c-kit was seen in a proportion of synovial sarcomas osteosarcomas and sarcomas Strong diffuse staining was less common in neuroblastomas tumors and rhabdomyosarcomas and was negative in alveolar soft part sarcomas and desmoplastic small round cell tumors Tumors with strong diffuse staining for c-kit in a pattern similar to stromal tumor may represent suitable targets for new therapeutic agents,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,"[3, 452, 31, 161, 256, 1164, 564, 216, 153, 308, 71, 85, 443, 6, 40, 305, 9, 30, 129, 2, 91, 4, 392, 163, 141, 5563, 31, 1342, 1126, 30, 286, 533, 302, 31, 134, 2, 94, 75, 3, 518, 420, 10640, 7846, 8569, 7855, 35, 230, 1, 3, 564, 1549, 1062, 1425, 256, 1164, 2, 4103, 47, 443, 93, 253, 4, 7, 5, 442, 2194, 2, 1126, 30, 5, 3, 1130, 1, 1386, 402, 271, 1, 57, 17, 68, 119, 3, 452, 31, 161, 256, 1164, 308, 2, 12974, 68, 40, 2443, 6, 10640, 7846, 24, 26, 45, 3696, 5075, 86, 57, 29, 7, 73, 28, 3062, 4841, 541, 292, 389, 702, 9, 1382, 55, 1, 256, 1164, 3265, 1959, 2487, 2505, 3013, 11, 3386, 5, 11079, 6350, 312, 171, 256, 1164, 6999, 17621, 75, 260, 33198, 12713, 14747, 840, 1312, 448, 8372, 2, 35, 3235, 37118, 1082, 1388, 1029, 9, 256, 1164, 10, 527, 4, 8, 920, 1, 5043, 1479, 11089, 2, 1479, 1082, 1388, 1029, 10, 299, 186, 4, 8915, 57, 2, 15480, 2, 10, 199, 4, 5641, 1214, 760, 1479, 2, 5922, 302, 4436, 31, 57, 57, 5, 1082, 1388, 1029, 9, 256, 1164, 4, 8, 1177, 288, 6, 1126, 30, 68, 1231, 2884, 637, 9, 217, 189, 183]",1365.0,11914627,55
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.,Cancer,Cancer,2002-04-01,"Homoharringtonine (HHT) has antileukemic activity in patients with Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML). Combinations of HHT, interferon-alpha (IFN-alpha), and cytarabine (ara-C) have been studied in various CML phases. The objectives of this study were to evaluate the efficacy and toxicity profiles of a combination regimen of simultaneous HHT and IFN-alpha therapy in patients with chronic-phase CML who were not exposed previously to either agent. Forty-seven patients were treated: 37 patients with early chronic-phase CML (2 patients with clonal evolution) and 10 patients with late chronic-phase CML. Their median age was 62 years (range, 23-73 years). HHT was given at a dose of 2.5 mg/m(2) by continuous intravenous infusion over 24 hours daily for 5 days every month, and IFN-alpha was given daily at a target dose of 5 x 10(6) units/m(2) subcutaneously. Response, survival, and treatment toxicity were analyzed. Overall, the complete hematologic response (CHR) rate was 85%; the cytogenetic response rate was 66%, with major cytogenetic responses (Ph positive in < 35% of metaphases) in 49% of patients and complete cytogenetic responses in 21% of patients. The CHR rate, cytogenetic response rate, and major cytogenetic response rate were 84%, 69%, and 52%, respectively, in patients with early chronic-phase CML. Among the 10 patients with late chronic-phase CML, the CHR rate, cytogenetic response rate, and major cytogenetic response rate were 80%, 50%, and 40%, respectively. Response rates in patients age > 60 years were 84%, 62%, and 49% for CHR, cytogenetic response, and major cytogenetic response. Myelosuppression was frequent but manageable: Anemia with hemoglobin < 8.0 g/dL occurred in 36% of patients, requiring dose adjustments and erythropoietin therapy. Nonhematologic toxicities were mainly fatigue, aches, and gastrointestinal disturbances. Dose reductions with multiple courses were significant and were due to myelosuppression: After 6-24 courses, the median daily IFN-alpha dose was 1 MU/m(2), and the median number of days on HHT per month was 2 days. With a median follow-up of 26 months, the estimated 2-year survival rate was 90% (95% confidence interval, 79-100%). The simultaneous combination of HHT and IFN-alpha is safe and effective, but the dose schedules that actually were delivered were significantly lower than the planned dose schedules. With the availability of signal-transduction inhibitor 571 (imatinib mesylate), studies of combination of HHT and IFN-alpha chemotherapy in patients with CML who have disease that fails to respond to imatinib mesylate and of combinations with imatinib mesylate need to be explored.",Journal Article,6504.0,56.0,Homoharringtonine HHT has antileukemic activity in patients with Philadelphia chromosome Ph positive chronic myelogenous CML Combinations of HHT interferon-alpha IFN-alpha and cytarabine ara-C have been studied in various CML phases The objectives of this study were to evaluate the efficacy and toxicity profiles of a combination regimen of simultaneous HHT and IFN-alpha therapy in patients with chronic-phase CML who were not exposed previously to either agent Forty-seven patients were treated 37 patients with early chronic-phase CML 2 patients with clonal evolution and 10 patients with late chronic-phase CML Their median age was 62 years range 23-73 years HHT was given at a dose of 2.5 mg/m 2 by continuous intravenous infusion over 24 hours daily for 5 days every month and IFN-alpha was given daily at a target dose of 5 x 10 6 units/m 2 subcutaneously Response survival and treatment toxicity were analyzed Overall the complete hematologic response CHR rate was 85 the cytogenetic response rate was 66 with major cytogenetic responses Ph positive in 35 of metaphases in 49 of patients and complete cytogenetic responses in 21 of patients The CHR rate cytogenetic response rate and major cytogenetic response rate were 84 69 and 52 respectively in patients with early chronic-phase CML Among the 10 patients with late chronic-phase CML the CHR rate cytogenetic response rate and major cytogenetic response rate were 80 50 and 40 respectively Response rates in patients age 60 years were 84 62 and 49 for CHR cytogenetic response and major cytogenetic response Myelosuppression was frequent but manageable Anemia with hemoglobin 8.0 g/dL occurred in 36 of patients requiring dose adjustments and erythropoietin therapy Nonhematologic toxicities were mainly fatigue aches and disturbances Dose reductions with multiple courses were significant and were due to myelosuppression After 6-24 courses the median daily IFN-alpha dose was 1 MU/m 2 and the median number of days on HHT per month was 2 days With a median follow-up of 26 months the estimated 2-year survival rate was 90 95 confidence interval 79-100 The simultaneous combination of HHT and IFN-alpha is safe and effective but the dose schedules that actually were delivered were significantly lower than the planned dose schedules With the availability of signal-transduction inhibitor 571 imatinib mesylate studies of combination of HHT and IFN-alpha chemotherapy in patients with CML who have disease that fails to respond to imatinib mesylate and of combinations with imatinib mesylate need to be explored,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[18768, 9249, 71, 4512, 128, 4, 7, 5, 3006, 1170, 2058, 109, 442, 2194, 903, 1247, 1, 9249, 1688, 950, 1256, 950, 2, 1855, 3899, 256, 47, 85, 656, 4, 747, 903, 3523, 3, 2409, 1, 26, 45, 11, 6, 376, 3, 209, 2, 155, 1241, 1, 8, 150, 477, 1, 2824, 9249, 2, 1256, 950, 36, 4, 7, 5, 442, 124, 903, 54, 11, 44, 2234, 373, 6, 361, 420, 1213, 648, 7, 11, 73, 567, 7, 5, 191, 442, 124, 903, 18, 7, 5, 1946, 2554, 2, 79, 7, 5, 807, 442, 124, 903, 136, 52, 89, 10, 744, 60, 184, 382, 803, 60, 9249, 10, 447, 28, 8, 61, 1, 18, 33, 81, 188, 18, 20, 1314, 1262, 904, 252, 259, 1459, 391, 9, 33, 162, 454, 811, 2, 1256, 950, 10, 447, 391, 28, 8, 283, 61, 1, 33, 1006, 79, 49, 2960, 188, 18, 3928, 51, 25, 2, 24, 155, 11, 311, 63, 3, 236, 813, 51, 8158, 116, 10, 772, 3, 1266, 51, 116, 10, 700, 5, 458, 1266, 253, 2058, 109, 4, 465, 1, 10653, 4, 739, 1, 7, 2, 236, 1266, 253, 4, 239, 1, 7, 3, 8158, 116, 1266, 51, 116, 2, 458, 1266, 51, 116, 11, 874, 790, 2, 653, 106, 4, 7, 5, 191, 442, 124, 903, 107, 3, 79, 7, 5, 807, 442, 124, 903, 3, 8158, 116, 1266, 51, 116, 2, 458, 1266, 51, 116, 11, 493, 212, 2, 327, 106, 51, 151, 4, 7, 89, 335, 60, 11, 874, 744, 2, 739, 9, 8158, 1266, 51, 2, 458, 1266, 51, 2858, 10, 908, 84, 2808, 1545, 5, 2222, 66, 13, 499, 1826, 489, 4, 511, 1, 7, 1888, 61, 6017, 2, 6266, 36, 3534, 385, 11, 2615, 613, 30221, 2, 6741, 61, 2153, 5, 232, 1993, 11, 93, 2, 11, 520, 6, 2858, 50, 49, 259, 1993, 3, 52, 391, 1256, 950, 61, 10, 14, 6601, 188, 18, 2, 3, 52, 207, 1, 162, 23, 9249, 379, 811, 10, 18, 162, 5, 8, 52, 166, 126, 1, 432, 53, 3, 661, 18, 111, 25, 116, 10, 424, 48, 307, 268, 842, 394, 3, 2824, 150, 1, 9249, 2, 1256, 950, 16, 1165, 2, 323, 84, 3, 61, 2314, 17, 6742, 11, 1623, 11, 97, 280, 76, 3, 1465, 61, 2314, 5, 3, 2550, 1, 1235, 2761, 230, 7846, 577, 2347, 94, 1, 150, 1, 9249, 2, 1256, 950, 56, 4, 7, 5, 903, 54, 47, 34, 17, 7688, 6, 1892, 6, 577, 2347, 2, 1, 1247, 5, 577, 2347, 594, 6, 40, 1443]",2575.0,11932905,165
Targeted chemotherapy: chronic myelogenous leukemia as a model.,"Journal of molecular medicine (Berlin, Germany)",J. Mol. Med.,2002-01-24,"Many of the therapeutic agents used for cancer chemotherapy today are based on decades-old agents which are highly cytotoxic but are nonselective for cancer cells. The hallmark of chronic myelogenous leukemia (CML) is the Philadelphia chromosome translocation t(9;22), which results in the bcr-abl fusion gene. As an alteration that is nearly universal in CML cells, bcr-abl presents a therapeutic target that is unique to the pathological cells in CML patients. Advances in the understanding of the molecular mechanisms which sustain leukemic cells in CML have enabled the development of selective therapies for this disease. We review here the molecular pathogenesis and current treatment of CML. We also discuss the development of imatinib mesylate, a selective inhibitor of Bcr-Abl which has shown promise in clinical trials with CML. This recent advance in CML therapy represents a novel approach to rational design and development of new anticancer drugs.",Journal Article,6571.0,6.0,Many of the therapeutic agents used for cancer chemotherapy today are based on decades-old agents which are highly cytotoxic but are nonselective for cancer cells The hallmark of chronic myelogenous CML is the Philadelphia chromosome translocation t 9 22 which results in the bcr-abl fusion gene As an alteration that is nearly universal in CML cells bcr-abl presents a therapeutic target that is unique to the pathological cells in CML patients Advances in the understanding of the molecular mechanisms which sustain leukemic cells in CML have enabled the development of selective therapies for this disease We review here the molecular pathogenesis and current treatment of CML We also discuss the development of imatinib mesylate a selective inhibitor of Bcr-Abl which has shown promise in clinical trials with CML This recent advance in CML therapy represents a novel approach to rational design and development of new anticancer drugs,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[445, 1, 3, 189, 183, 95, 9, 12, 56, 5665, 32, 90, 23, 1968, 1095, 183, 92, 32, 561, 759, 84, 32, 19449, 9, 12, 37, 3, 4683, 1, 442, 2194, 903, 16, 3, 3006, 1170, 2006, 102, 83, 350, 92, 99, 4, 3, 1062, 1425, 1212, 145, 22, 35, 2611, 17, 16, 1857, 4967, 4, 903, 37, 1062, 1425, 2740, 8, 189, 283, 17, 16, 991, 6, 3, 1301, 37, 4, 903, 7, 954, 4, 3, 612, 1, 3, 219, 483, 92, 8844, 2015, 37, 4, 903, 47, 4387, 3, 193, 1, 1094, 235, 9, 26, 34, 21, 206, 467, 3, 219, 1384, 2, 291, 24, 1, 903, 21, 120, 1139, 3, 193, 1, 577, 2347, 8, 1094, 230, 1, 1062, 1425, 92, 71, 443, 1783, 4, 38, 143, 5, 903, 26, 435, 3148, 4, 903, 36, 1449, 8, 229, 353, 6, 2696, 771, 2, 193, 1, 217, 1475, 600]",939.0,11976731,203
t(1;3)(p36;p21) is a recurring therapy-related translocation.,"Genes, chromosomes & cancer",Genes Chromosomes Cancer,2002-06-01,"Chromosome bands 1p36 and 3p21 are known to be recurring breakpoints in therapy-related (t-) leukemia. We identified a recurring translocation, t(1;3)(p36;p21), in eight patients with various hematologic malignancies: three patients with ALL, one with chronic myelogenous leukemia (CML) in accelerated phase (AP), two with MDS, and two with AML(M3). Five of the eight patients had a history of chemotherapy, including alkylating agents in three, before the translocation was detected. In two of these five patients, the t(1;3)(p36;p21) emerged only at relapse or in the accelerated phase of CML. The karyotypes of the patients were complex, including -7 and structural abnormalities of 5q, 6q, 7q, 9p, and 11q23. Survival time varied among patients (25 days to more than 16 years). Using FISH with 13 1p35-36 cosmid probes (tel-FB12-CA5-G7-FD2-CB1-ED8-FD9-G32-AE3-G50-AD8-GG4-G43-cen), we delineated the 1p36 breakpoint in two patients with MDS and ALL as lying between FB12 and FD2 (between BAC47P3 and PAC963K15), with a small deletion near the breakpoint in both cases. In the patient with MDS, there was also a deletion at 3p21.3, as detected with the cosmid probe cosNRL9. The results of the present study suggest that t(1;3)(p36;p21) in hematologic diseases is associated with prior exposure to mutagens, including alkylating agents.",Case Reports,6443.0,11.0,Chromosome bands 1p36 and 3p21 are known to be recurring breakpoints in therapy-related t- We identified a recurring translocation t 1 3 p36 p21 in eight patients with various hematologic malignancies three patients with ALL one with chronic myelogenous CML in accelerated phase AP two with MDS and two with AML M3 Five of the eight patients had a history of chemotherapy including alkylating agents in three before the translocation was detected In two of these five patients the t 1 3 p36 p21 emerged only at relapse or in the accelerated phase of CML The karyotypes of the patients were complex including -7 and structural abnormalities of 5q 6q 7q 9p and 11q23 Survival time varied among patients 25 days to more than 16 years Using FISH with 13 1p35-36 cosmid probes tel-FB12-CA5-G7-FD2-CB1-ED8-FD9-G32-AE3-G50-AD8-GG4-G43-cen we delineated the 1p36 breakpoint in two patients with MDS and ALL as lying between FB12 and FD2 between BAC47P3 and PAC963K15 with a small deletion near the breakpoint in both cases In the patient with MDS there was also a deletion at 3p21.3 as detected with the cosmid probe cosNRL9 The results of the present study suggest that t 1 3 p36 p21 in hematologic diseases is associated with prior exposure to mutagens including alkylating agents,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1170, 13759, 12265, 2, 10274, 32, 440, 6, 40, 6385, 7843, 4, 36, 139, 102, 21, 108, 8, 6385, 2006, 102, 14, 27, 27881, 2657, 4, 659, 7, 5, 747, 813, 441, 169, 7, 5, 62, 104, 5, 442, 2194, 903, 4, 2241, 124, 2517, 100, 5, 1223, 2, 100, 5, 329, 9852, 365, 1, 3, 659, 7, 42, 8, 532, 1, 56, 141, 3410, 183, 4, 169, 348, 3, 2006, 10, 530, 4, 100, 1, 46, 365, 7, 3, 102, 14, 27, 27881, 2657, 2054, 158, 28, 429, 15, 4, 3, 2241, 124, 1, 903, 3, 6809, 1, 3, 7, 11, 840, 141, 67, 2, 3281, 1171, 1, 5460, 10961, 9723, 11234, 2, 7975, 25, 98, 2051, 107, 7, 243, 162, 6, 80, 76, 245, 60, 75, 1277, 5, 233, 33222, 511, 37149, 3701, 8573, 42902, 52852, 21973, 42903, 23099, 52853, 52854, 52855, 20168, 52856, 52857, 27882, 52858, 37150, 21, 5610, 3, 12265, 8567, 4, 100, 7, 5, 1223, 2, 62, 22, 18170, 59, 42902, 2, 42903, 59, 52859, 2, 52860, 5, 8, 302, 1528, 1829, 3, 8567, 4, 110, 140, 4, 3, 69, 5, 1223, 125, 10, 120, 8, 1528, 28, 10274, 27, 22, 530, 5, 3, 37149, 2888, 52861, 3, 99, 1, 3, 364, 45, 309, 17, 102, 14, 27, 27881, 2657, 4, 813, 1342, 16, 41, 5, 324, 645, 6, 16212, 141, 3410, 183]",1274.0,11979552,13
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2002-04-30,"An important goal of cancer immunology is the identification of antigens associated with tumor destruction. Vaccination with irradiated tumor cells engineered to secrete granulocyte/macrophage colony-stimulating factor (GM-CSF) generates potent, specific, and long-lasting antitumor immunity in multiple murine tumor models. A phase I clinical trial of this vaccination strategy in patients with advanced melanoma demonstrated the consistent induction of dense CD4(+) and CD8(+) T lymphocyte and plasma cell infiltrates in distant metastases, resulting in extensive tumor destruction, fibrosis, and edema. Antimelanoma antibody and cytotoxic T cell responses were associated with tumor cell death. To characterize the targets of these responses, we screened an autologous cDNA expression library prepared from a densely infiltrated metastasis with postvaccination sera from a long-term responding patient. High-titer IgG antibodies detected ATP6S1, a putative accessory unit of the vacuolar H(+)-ATPase complex. A longitudinal analysis of this patient revealed an association between the vaccine-induced increase in antibodies to ATP6S1 and tumor destruction. Three additional vaccinated melanoma patients and three metastatic non-small cell lung carcinoma patients vaccinated with autologous GM-CSF-secreting tumor cells similarly showed a correlation between humoral responses to ATP6S1 and tumor destruction. Moreover, a chronic myelogenous leukemia patient who experienced a complete remission after CD4(+) donor lymphocyte infusions also developed high-titer antibodies to ATP6S1. Lastly, vaccination with GM-CSF-secreting B16 melanoma cells stimulated high-titer antibodies to ATPS1 in a murine model. Taken together, these findings demonstrate that potent humoral responses to ATP6S1 are associated with immune-mediated destruction of diverse tumors.",Journal Article,6475.0,41.0,An important goal of cancer immunology is the identification of antigens associated with tumor destruction Vaccination with irradiated tumor cells engineered to secrete granulocyte/macrophage colony-stimulating factor GM-CSF generates potent specific and long-lasting antitumor immunity in multiple murine tumor models A phase I clinical trial of this vaccination strategy in patients with advanced demonstrated the consistent induction of dense CD4 and CD8 T lymphocyte and plasma cell infiltrates in distant metastases resulting in extensive tumor destruction fibrosis and edema Antimelanoma antibody and cytotoxic T cell responses were associated with tumor cell death To characterize the targets of these responses we screened an autologous cDNA expression library prepared from a densely infiltrated metastasis with postvaccination sera from a long-term responding patient High-titer IgG antibodies detected ATP6S1 a putative accessory unit of the vacuolar H -ATPase complex A longitudinal analysis of this patient revealed an association between the vaccine-induced increase in antibodies to ATP6S1 and tumor destruction Three additional vaccinated patients and three metastatic cell carcinoma patients vaccinated with autologous GM-CSF-secreting tumor cells similarly showed a correlation between humoral responses to ATP6S1 and tumor destruction Moreover a chronic myelogenous patient who experienced a complete remission after CD4 donor lymphocyte infusions also developed high-titer antibodies to ATP6S1 Lastly vaccination with GM-CSF-secreting B16 cells stimulated high-titer antibodies to ATPS1 in a murine model Taken together these findings demonstrate that potent humoral responses to ATP6S1 are associated with immune-mediated destruction of diverse tumors,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[35, 305, 1326, 1, 12, 6534, 16, 3, 911, 1, 1575, 41, 5, 30, 4572, 1915, 5, 2398, 30, 37, 2794, 6, 6401, 2764, 2674, 1975, 2122, 161, 2147, 1211, 7919, 1157, 112, 2, 319, 3443, 579, 1604, 4, 232, 1471, 30, 274, 8, 124, 70, 38, 160, 1, 26, 1915, 692, 4, 7, 5, 131, 264, 3, 925, 504, 1, 3076, 1440, 2, 968, 102, 1448, 2, 554, 31, 5942, 4, 626, 196, 1113, 4, 1344, 30, 4572, 3000, 2, 3306, 16201, 548, 2, 759, 102, 31, 253, 11, 41, 5, 30, 31, 273, 6, 1507, 3, 637, 1, 46, 253, 21, 2261, 35, 1028, 4212, 55, 4157, 4421, 29, 8, 18775, 8652, 278, 5, 14420, 4210, 29, 8, 319, 337, 3261, 69, 64, 8444, 3630, 890, 530, 18776, 8, 2743, 12082, 2712, 1, 3, 37154, 555, 11401, 840, 8, 2380, 65, 1, 26, 69, 553, 35, 248, 59, 3, 1274, 277, 344, 4, 890, 6, 18776, 2, 30, 4572, 169, 402, 5130, 7, 2, 169, 113, 31, 134, 7, 5130, 5, 1028, 2147, 1211, 5052, 30, 37, 1813, 224, 8, 816, 59, 5498, 253, 6, 18776, 2, 30, 4572, 1393, 8, 442, 2194, 69, 54, 592, 8, 236, 734, 50, 1440, 1488, 1448, 3435, 120, 276, 64, 8444, 890, 6, 18776, 6354, 1915, 5, 2147, 1211, 5052, 5507, 37, 2816, 64, 8444, 890, 6, 52867, 4, 8, 1471, 202, 1633, 1162, 46, 272, 608, 17, 1157, 5498, 253, 6, 18776, 32, 41, 5, 250, 517, 4572, 1, 1867, 57]",1772.0,11983866,56
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.,Blood,Blood,2002-05-01,"Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is highly refractory to therapy. CML is caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, the product of the t(9;22) Philadelphia translocation. Imatinib (Glivec, formerly STI571) is a rationally developed, orally administered inhibitor of the Bcr-Abl tyrosine kinase. A total of 260 patients with CML were enrolled in a phase II trial, of whom 229 had a confirmed diagnosis of CML in blast crisis. Patients were treated with imatinib in daily oral doses of 400 mg or 600 mg. Imatinib induced hematologic responses in 52% of patients and sustained hematologic responses lasting at least 4 weeks in 31% of patients, including complete hematologic responses in 8%. For patients with a sustained response, the estimated median response duration was 10 months. Imatinib induced major cytogenetic responses in 16% of patients, with 7% of the responses being complete. Median survival time was 6.9 months. Nonhematologic adverse reactions were frequent but generally mild or moderate. Episodes of severe cytopenia were also frequent and were attributable to the underlying condition and treatment with imatinib. Drug-related adverse events led to discontinuation of therapy in 5% of patients, most often because of cytopenia, skin disorders, or gastrointestinal reactions. These results demonstrate that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis. Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs.",Clinical Trial,6474.0,1019.0,Blast crisis is the most advanced stage of chronic myelogenous CML and is highly refractory to therapy CML is caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene the product of the t 9 22 Philadelphia translocation Imatinib Glivec formerly STI571 is a rationally developed orally administered inhibitor of the Bcr-Abl tyrosine kinase A total of 260 patients with CML were enrolled in a phase II trial of whom 229 had a confirmed diagnosis of CML in blast crisis Patients were treated with imatinib in daily oral doses of 400 mg or 600 mg. Imatinib induced hematologic responses in 52 of patients and sustained hematologic responses lasting at least 4 weeks in 31 of patients including complete hematologic responses in 8 For patients with a sustained response the estimated median response duration was 10 months Imatinib induced major cytogenetic responses in 16 of patients with 7 of the responses being complete Median survival time was 6.9 months Nonhematologic adverse reactions were frequent but generally mild or moderate Episodes of severe cytopenia were also frequent and were attributable to the underlying condition and treatment with imatinib Drug-related adverse events led to discontinuation of therapy in 5 of patients most often because of cytopenia disorders or reactions These results demonstrate that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[3112, 6540, 16, 3, 96, 131, 82, 1, 442, 2194, 903, 2, 16, 561, 430, 6, 36, 903, 16, 1546, 20, 55, 1, 3, 2897, 1062, 1425, 564, 216, 1836, 3, 2821, 1, 3, 102, 83, 350, 3006, 2006, 577, 33225, 7350, 5735, 16, 8, 6352, 276, 1428, 468, 230, 1, 3, 1062, 1425, 564, 216, 8, 181, 1, 6398, 7, 5, 903, 11, 346, 4, 8, 124, 215, 160, 1, 953, 7584, 42, 8, 557, 147, 1, 903, 4, 3112, 6540, 7, 11, 73, 5, 577, 4, 391, 518, 415, 1, 1524, 81, 15, 2383, 81, 577, 277, 813, 253, 4, 653, 1, 7, 2, 2275, 813, 253, 3443, 28, 506, 39, 244, 4, 456, 1, 7, 141, 236, 813, 253, 4, 66, 9, 7, 5, 8, 2275, 51, 3, 661, 52, 51, 654, 10, 79, 53, 577, 277, 458, 1266, 253, 4, 245, 1, 7, 5, 67, 1, 3, 253, 486, 236, 52, 25, 98, 10, 49, 83, 53, 3534, 290, 2428, 11, 908, 84, 1228, 1980, 15, 1163, 3750, 1, 905, 8165, 11, 120, 908, 2, 11, 2971, 6, 3, 1181, 2850, 2, 24, 5, 577, 234, 139, 290, 281, 836, 6, 2007, 1, 36, 4, 33, 1, 7, 96, 629, 408, 1, 8165, 1997, 15, 2428, 46, 99, 608, 17, 577, 71, 1281, 128, 2, 8, 913, 367, 800, 198, 95, 22, 8, 226, 420, 4, 7, 5, 903, 4, 3112, 6540, 402, 38, 94, 32, 1197, 6, 1645, 3, 209, 2, 1437, 1, 577, 95, 4, 150, 5, 127, 4512, 600]",1611.0,11986204,39
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.,Blood,Blood,2002-05-01,"Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the development and progression of Philadelphia chromosome-positive (Ph(+)) chronic myelogenous leukemia (CML). Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML. Here, we describe the use of imatinib mesylate to treat 75 patients in blast-phase CML (median age, 53 years; 65 with nonlymphoid and 10 with lymphoid blasts), and compare the results with those of a historical control group treated with standard cytarabine-based therapy. Imatinib mesylate was given as oral doses at 300 to 1000 mg per day and was the first salvage therapy for 47 patients. The objective response rate was 52% (39 of 75 patients: 16 had complete and 3 had partial hematologic response; 12 had hematologic improvement; 7 returned to second chronic phase; and 1 had a complete response in extramedullary blastic disease). Response rates were not different between nonlymphoid and lymphoid groups. The cytogenetic response rate was 16% (12 patients: 5 complete, 3 partial [Ph(+) below 35%], and 4 minor [Ph(+), 34% to 90%]). The estimated median overall survival was 6.5 months; the estimated 1-year survival was 22%. Response to therapy (landmark analysis at 8 weeks) was associated with survival prolongation. Compared with standard cytarabine combinations, imatinib mesylate therapy was less toxic and produced a higher response rate (55% versus 29%, P =.001), longer median survival (7 versus 4 months, P =.04), and lower 4-week induction mortality (4% versus 15%, P =.07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML.",Clinical Trial,6474.0,261.0,Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the development and progression of Philadelphia chromosome-positive Ph chronic myelogenous CML Imatinib mesylate STI571 a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor has shown encouraging activity in phase I and II studies of CML Here we describe the use of imatinib mesylate to treat 75 patients in blast-phase CML median age 53 years 65 with nonlymphoid and 10 with lymphoid blasts and compare the results with those of a historical control group treated with standard cytarabine-based therapy Imatinib mesylate was given as oral doses at 300 to 1000 mg per day and was the first salvage therapy for 47 patients The objective response rate was 52 39 of 75 patients 16 had complete and 3 had partial hematologic response 12 had hematologic improvement 7 returned to second chronic phase and 1 had a complete response in extramedullary blastic disease Response rates were not different between nonlymphoid and lymphoid groups The cytogenetic response rate was 16 12 patients 5 complete 3 partial Ph below 35 and 4 minor Ph 34 to 90 The estimated median overall survival was 6.5 months the estimated 1-year survival was 22 Response to therapy landmark analysis at 8 weeks was associated with survival prolongation Compared with standard cytarabine combinations imatinib mesylate therapy was less toxic and produced a higher response rate 55 versus 29 P =.001 longer median survival 7 versus 4 months P =.04 and lower 4-week induction mortality 4 versus 15 P =.07 Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[219, 1171, 1546, 20, 3, 4542, 1062, 1425, 145, 32, 12511, 41, 5, 3, 193, 2, 91, 1, 3006, 1170, 109, 2058, 442, 2194, 903, 577, 2347, 5735, 8, 112, 1062, 1425, 564, 216, 1235, 2761, 230, 71, 443, 2269, 128, 4, 124, 70, 2, 215, 94, 1, 903, 467, 21, 897, 3, 119, 1, 577, 2347, 6, 943, 481, 7, 4, 3112, 124, 903, 52, 89, 699, 60, 556, 5, 20180, 2, 79, 5, 2303, 2438, 2, 932, 3, 99, 5, 135, 1, 8, 2252, 182, 87, 73, 5, 260, 1855, 90, 36, 577, 2347, 10, 447, 22, 518, 415, 28, 2036, 6, 2345, 81, 379, 218, 2, 10, 3, 157, 992, 36, 9, 662, 7, 3, 461, 51, 116, 10, 653, 587, 1, 481, 7, 245, 42, 236, 2, 27, 42, 450, 813, 51, 133, 42, 813, 767, 67, 5157, 6, 419, 442, 124, 2, 14, 42, 8, 236, 51, 4, 5508, 6529, 34, 51, 151, 11, 44, 338, 59, 20180, 2, 2303, 271, 3, 1266, 51, 116, 10, 245, 133, 7, 33, 236, 27, 450, 2058, 2736, 465, 2, 39, 2278, 2058, 562, 6, 424, 3, 661, 52, 63, 25, 10, 49, 33, 53, 3, 661, 14, 111, 25, 10, 350, 51, 6, 36, 3829, 65, 28, 66, 244, 10, 41, 5, 25, 4464, 72, 5, 260, 1855, 1247, 577, 2347, 36, 10, 299, 1812, 2, 1687, 8, 142, 51, 116, 614, 185, 462, 19, 144, 589, 52, 25, 67, 185, 39, 53, 19, 755, 2, 280, 39, 647, 504, 282, 39, 185, 167, 19, 1615, 577, 2347, 16, 694, 486, 650, 4, 150, 5, 127, 600, 6, 401, 3, 356, 9, 3112, 124, 903]",1688.0,11986206,127
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.,Blood,Blood,2002-05-01,"Imatinib mesylate (STI571) is a promising new treatment for chronic myelogenous leukemia (CML). The effect of imatinib mesylate on primitive malignant progenitors in CML has not been evaluated, and it is not clear whether suppression of progenitor growth represents inhibition of increased proliferation, induction of apoptosis, or both. We demonstrated here that in vitro exposure to concentrations of imatinib mesylate usually achieved in patients (1-2 microM) for 96 hours inhibited BCR/ABL-positive primitive progenitors (6-week long-term culture-initiating cells [LTCICs]) as well as committed progenitors (colony-forming cells [CFCs]). No suppression of normal LTCICs and significantly less suppression of normal CFCs were observed. A higher concentration of imatinib mesylate (5 microM) did not significantly increase suppression of CML or normal LTCICs but did increase suppression of CML CFCs, and to a lesser extent, normal CFCs. Analysis of cell division using the fluorescent dye carboxyfluorescein diacetate succinimidyl ester indicated that imatinib mesylate (1-2 microM) inhibits cycling of CML primitive (CD34(+)CD38(-)) and committed (CD34(+)CD38(+)) progenitors to a much greater extent than normal cells. Conversely, treatment with 1 to 2 microM imatinib mesylate did not significantly increase the percentage of cells undergoing apoptosis. Although a higher concentration of imatinib mesylate (5 microM) led to an increase in apoptosis of CML cells, apoptosis also increased in normal samples. In summary, at clinically relevant concentrations, imatinib mesylate selectively suppresses CML primitive progenitors by reversing abnormally increased proliferation but does not significantly increase apoptosis. These results suggest that inhibition of Bcr-Abl tyrosine kinase by imatinib mesylate restores normal hematopoiesis by removing the proliferative advantage of CML progenitors but that elimination of all CML progenitors may not occur.",Comparative Study,6474.0,214.0,Imatinib mesylate STI571 is a promising new treatment for chronic myelogenous CML The effect of imatinib mesylate on primitive malignant progenitors in CML has not been evaluated and it is not clear whether suppression of progenitor growth represents inhibition of increased proliferation induction of apoptosis or both We demonstrated here that in vitro exposure to concentrations of imatinib mesylate usually achieved in patients 1-2 microM for 96 hours inhibited BCR/ABL-positive primitive progenitors 6-week long-term culture-initiating cells LTCICs as well as committed progenitors colony-forming cells CFCs No suppression of normal LTCICs and significantly less suppression of normal CFCs were observed A higher concentration of imatinib mesylate 5 microM did not significantly increase suppression of CML or normal LTCICs but did increase suppression of CML CFCs and to a lesser extent normal CFCs Analysis of cell division using the fluorescent dye carboxyfluorescein diacetate succinimidyl ester indicated that imatinib mesylate 1-2 microM inhibits cycling of CML primitive CD34 CD38 and committed CD34 CD38 progenitors to a much greater extent than normal cells Conversely treatment with 1 to 2 microM imatinib mesylate did not significantly increase the percentage of cells undergoing apoptosis Although a higher concentration of imatinib mesylate 5 microM led to an increase in apoptosis of CML cells apoptosis also increased in normal samples In summary at clinically relevant concentrations imatinib mesylate selectively suppresses CML primitive progenitors by reversing abnormally increased proliferation but does not significantly increase apoptosis These results suggest that inhibition of Bcr-Abl tyrosine kinase by imatinib mesylate restores normal hematopoiesis by removing the proliferative advantage of CML progenitors but that elimination of all CML progenitors may not occur,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 2347, 5735, 16, 8, 721, 217, 24, 9, 442, 2194, 903, 3, 254, 1, 577, 2347, 23, 5594, 393, 4321, 4, 903, 71, 44, 85, 194, 2, 192, 16, 44, 885, 317, 1332, 1, 2520, 129, 1449, 297, 1, 101, 457, 504, 1, 351, 15, 110, 21, 264, 467, 17, 4, 439, 645, 6, 1003, 1, 577, 2347, 2082, 513, 4, 7, 14, 18, 3550, 9, 921, 1459, 879, 1062, 1425, 109, 5594, 4321, 49, 647, 319, 337, 2099, 2637, 37, 37156, 22, 149, 22, 9552, 4321, 1975, 4525, 37, 33227, 77, 1332, 1, 295, 37156, 2, 97, 299, 1332, 1, 295, 33227, 11, 164, 8, 142, 1227, 1, 577, 2347, 33, 3550, 205, 44, 97, 344, 1332, 1, 903, 15, 295, 37156, 84, 205, 344, 1332, 1, 903, 33227, 2, 6, 8, 5191, 1039, 295, 33227, 65, 1, 31, 5750, 75, 3, 2910, 3796, 30236, 24445, 27885, 9617, 1103, 17, 577, 2347, 14, 18, 3550, 1576, 9165, 1, 903, 5594, 2215, 4469, 2, 9552, 2215, 4469, 4321, 6, 8, 1802, 378, 1039, 76, 295, 37, 3154, 24, 5, 14, 6, 18, 3550, 577, 2347, 205, 44, 97, 344, 3, 1150, 1, 37, 479, 351, 242, 8, 142, 1227, 1, 577, 2347, 33, 3550, 836, 6, 35, 344, 4, 351, 1, 903, 37, 351, 120, 101, 4, 295, 347, 4, 1962, 28, 505, 867, 1003, 577, 2347, 2382, 4079, 903, 5594, 4321, 20, 9953, 11749, 101, 457, 84, 1097, 44, 97, 344, 351, 46, 99, 309, 17, 297, 1, 1062, 1425, 564, 216, 20, 577, 2347, 8489, 295, 5114, 20, 9026, 3, 2441, 1874, 1, 903, 4321, 84, 17, 3730, 1, 62, 903, 4321, 68, 44, 1271]",1898.0,11986238,124
Current therapy of chronic myelogenous leukemia.,"Internal medicine (Tokyo, Japan)",Intern. Med.,2002-04-01,"Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder molecularly defined by the BCR-ABL gene and its products. The protein encoded by this chimeric gene is a constitutively activated tyrosine kinase that alters multiple signal transduction pathways inducing malignant transformation. Until recently, treatment options for patients with CML consisted of hydroxyurea, interferon-based therapies or allogeneic stem cell transplantation (alloSCT). Treatment decisions were generally based on the age of the patient and the phase of the disease. Recently, several new therapies have been developed that may change the natural history of CML and patient prognosis. In particular imatinib mesylate (ST1571, Gleevec) an oral Bcr-Abl kinase inhibitor, has demonstrated activity in all phases of CML, and may replace interferon and alloSCT as the initial therapy for this disease. Other agents and therapies with potential value, either alone or in combination, include polyethyleneglycol (PEG) interferon, homoharringtonine, decitabine, oral cytarabine, and growth factor modulation. In this article, we discuss the biological and clinical characteristics of CML, as well as the different therapeutic alternatives for patients with this disorder.",Journal Article,6504.0,14.0,Chronic myelogenous CML is a clonal disorder molecularly defined by the BCR-ABL gene and its products The protein encoded by this chimeric gene is a constitutively activated tyrosine kinase that alters multiple signal transduction pathways inducing malignant transformation Until recently treatment options for patients with CML consisted of hydroxyurea interferon-based therapies or allogeneic stem cell transplantation alloSCT Treatment decisions were generally based on the age of the patient and the phase of the disease Recently several new therapies have been developed that may change the natural history of CML and patient prognosis In particular imatinib mesylate ST1571 Gleevec an oral Bcr-Abl kinase inhibitor has demonstrated activity in all phases of CML and may replace interferon and alloSCT as the initial therapy for this disease Other agents and therapies with potential value either alone or in combination include polyethyleneglycol PEG interferon homoharringtonine decitabine oral cytarabine and growth factor modulation In this article we discuss the biological and clinical characteristics of CML as well as the different therapeutic alternatives for patients with this disorder,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 16, 8, 1946, 2645, 2372, 395, 20, 3, 1062, 1425, 145, 2, 211, 2766, 3, 178, 4587, 20, 26, 2897, 145, 16, 8, 2818, 735, 564, 216, 17, 6745, 232, 1235, 2761, 460, 1958, 393, 1392, 1100, 761, 24, 838, 9, 7, 5, 903, 1695, 1, 5902, 1688, 90, 235, 15, 1063, 452, 31, 497, 7253, 24, 1526, 11, 1228, 90, 23, 3, 89, 1, 3, 69, 2, 3, 124, 1, 3, 34, 761, 392, 217, 235, 47, 85, 276, 17, 68, 707, 3, 1504, 532, 1, 903, 2, 69, 356, 4, 1454, 577, 2347, 52879, 8569, 35, 518, 1062, 1425, 216, 230, 71, 264, 128, 4, 62, 3523, 1, 903, 2, 68, 7195, 1688, 2, 7253, 22, 3, 388, 36, 9, 26, 34, 127, 183, 2, 235, 5, 174, 549, 361, 279, 15, 4, 150, 643, 42912, 3145, 1688, 18768, 3004, 518, 1855, 2, 129, 161, 2356, 4, 26, 946, 21, 1139, 3, 1037, 2, 38, 374, 1, 903, 22, 149, 22, 3, 338, 189, 6295, 9, 7, 5, 26, 2645]",1201.0,11993784,91
Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.,Cancer research,Cancer Res.,2002-06-01,"Chronic myelogenous leukemia (CML) is characterized by a t(9;22) translocation, which results in the expression of chimeric BCR-ABL fusion oncoproteins that are necessary for oncogenesis, unique to the leukemic clones, and represent enticing targets for immunotherapy. As a strategy for the immunotherapy of CML, we constructed a recombinant adeno-associated virus vector encoding the p210(BCR-ABL) b3a2 variant fusion region with flanking sequences (CWRBA) and used it to express the BCR-ABL fusion region within primary human dendritic cells (DCs), the most potent antigen-presenting cells currently known. Peripheral blood mononuclear cells from healthy donors were primed and restimulated in vitro with autologous DCs transduced with purified CWRBA, CWRAP (negative control), or pulsed with a peptide corresponding to the fusion domain (positive control). No specific responses were generated using DCs transduced with CWRAP. In contrast, CWRBA-transduced DCs primed autologous T cells in an antigen-specific, MHC-restricted fashion to levels comparable with the positive control. CWRBA-transduced DCs elicited both cytotoxic CD4+/Th1 and CD8+ responses, although the former were more readily detected in this system. Cytotoxicity against a tumor cell line endogenously expressing the p210(BCR-ABL) b3a2 variant fusion region was also demonstrable. In addition, HLA-DRB5(*)0101+DRA (DR2a) was identified as a new restriction element capable of presenting the b3a2 BCR-ABL fusion region epitope. Thus, the construct developed herein may serve as a candidate vaccine for gene-based antigen-specific immunotherapy of CML and may serve as a paradigm for the use of DCs transduced with recombinant adeno-associated virus vectors encoding multiepitope immunogens for vaccine development.",Journal Article,6443.0,38.0,Chronic myelogenous CML is characterized by a t 9 22 translocation which results in the expression of chimeric BCR-ABL fusion oncoproteins that are necessary for oncogenesis unique to the leukemic clones and represent enticing targets for immunotherapy As a strategy for the immunotherapy of CML we constructed a recombinant adeno-associated virus vector encoding the p210 BCR-ABL b3a2 variant fusion region with flanking sequences CWRBA and used it to express the BCR-ABL fusion region within primary human dendritic cells DCs the most potent antigen-presenting cells currently known Peripheral blood mononuclear cells from healthy donors were primed and restimulated in vitro with autologous DCs transduced with purified CWRBA CWRAP negative control or pulsed with a peptide corresponding to the fusion domain positive control No specific responses were generated using DCs transduced with CWRAP In contrast CWRBA-transduced DCs primed autologous T cells in an antigen-specific MHC-restricted fashion to levels comparable with the positive control CWRBA-transduced DCs elicited both cytotoxic CD4+/Th1 and CD8+ responses although the former were more readily detected in this system Cytotoxicity against a tumor cell line endogenously expressing the p210 BCR-ABL b3a2 variant fusion region was also demonstrable In addition HLA-DRB5 0101+DRA DR2a was identified as a new restriction element capable of presenting the b3a2 BCR-ABL fusion region epitope Thus the construct developed herein may serve as a candidate vaccine for gene-based antigen-specific immunotherapy of CML and may serve as a paradigm for the use of DCs transduced with recombinant adeno-associated virus vectors encoding multiepitope immunogens for vaccine development,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 16, 765, 20, 8, 102, 83, 350, 2006, 92, 99, 4, 3, 55, 1, 2897, 1062, 1425, 1212, 8241, 17, 32, 1493, 9, 4503, 991, 6, 3, 2015, 2749, 2, 1231, 52940, 637, 9, 726, 22, 8, 692, 9, 3, 726, 1, 903, 21, 2776, 8, 2835, 11101, 41, 1450, 3374, 2362, 3, 11538, 1062, 1425, 24460, 1142, 1212, 1053, 5, 12472, 2866, 33239, 2, 95, 192, 6, 1669, 3, 1062, 1425, 1212, 1053, 262, 86, 171, 2464, 37, 3110, 3, 96, 1157, 448, 1656, 37, 694, 440, 672, 315, 3041, 37, 29, 1331, 2344, 11, 7239, 2, 37184, 4, 439, 5, 1028, 3110, 5042, 5, 5963, 33239, 42941, 199, 182, 15, 5695, 5, 8, 1389, 1734, 6, 3, 1212, 1398, 109, 182, 77, 112, 253, 11, 1419, 75, 3110, 5042, 5, 42941, 4, 748, 33239, 5042, 3110, 7239, 1028, 102, 37, 4, 35, 448, 112, 3658, 2016, 3240, 6, 148, 1279, 5, 3, 109, 182, 33239, 5042, 3110, 5179, 110, 759, 1440, 4714, 2, 968, 253, 242, 3, 3623, 11, 80, 3860, 530, 4, 26, 398, 1408, 480, 8, 30, 31, 328, 11748, 1046, 3, 11538, 1062, 1425, 24460, 1142, 1212, 1053, 10, 120, 11411, 4, 352, 1160, 42942, 27902, 37185, 52941, 10, 108, 22, 8, 217, 4575, 4467, 2787, 1, 1656, 3, 24460, 1062, 1425, 1212, 1053, 4430, 631, 3, 3883, 276, 1986, 68, 1833, 22, 8, 1609, 1274, 9, 145, 90, 448, 112, 726, 1, 903, 2, 68, 1833, 22, 8, 2431, 9, 3, 119, 1, 3110, 5042, 5, 2835, 11101, 41, 1450, 5453, 2362, 37186, 24461, 9, 1274, 193]",1738.0,12036931,158
Systemic therapy for advanced soft-tissue sarcomas.,Current oncology reports,Curr Oncol Rep,2002-07-01,"The field of oncology is experiencing a paradigm shift from broad-spectrum cytotoxic therapies to more specific molecularly based targeted therapies. The activity of imatinib mesylate in chronic myelogenous leukemia and gastrointestinal stromal tumors (GIST) has reinforced our faith in translational research and its potential impact on the cure of cancer and improvement in quality of life for patients. This breakthrough has been particularly exciting for the field of sarcoma and for patients with advanced GIST, for whom no other effective therapy was available. Unfortunately, as is becoming increasingly clear, cancer is a very complex problem with multiple mechanisms and pathways that function either independently or interdependently enabling cell survival. We are therefore far away from having solved the problem. Attempts at refining the currently available therapeutic armamentarium to maximize the therapeutic index (dose intensification with growth factor support) must continue in parallel with laboratory-based research identifying critical targets to be inhibited or blocked. Identification of new agents with some activity, such as gemcitabine and ecteinascidin (ET-743), is also of paramount importance.",Journal Article,6413.0,4.0,The field of oncology is experiencing a paradigm shift from broad-spectrum cytotoxic therapies to more specific molecularly based targeted therapies The activity of imatinib mesylate in chronic myelogenous and stromal tumors GIST has reinforced our faith in translational research and its potential impact on the cure of cancer and improvement in quality of life for patients This breakthrough has been particularly exciting for the field of and for patients with advanced GIST for whom no other effective therapy was available Unfortunately as is becoming increasingly clear cancer is a very complex problem with multiple mechanisms and pathways that function either independently or interdependently enabling cell survival We are therefore far away from having solved the problem Attempts at refining the currently available therapeutic armamentarium to maximize the therapeutic index dose intensification with growth factor support must continue in parallel with laboratory-based research identifying critical targets to be inhibited or blocked Identification of new agents with some activity such as gemcitabine and ecteinascidin ET-743 is also of paramount importance,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,"[3, 1067, 1, 413, 16, 2985, 8, 2431, 3024, 29, 2094, 1873, 759, 235, 6, 80, 112, 2372, 90, 238, 235, 3, 128, 1, 577, 2347, 4, 442, 2194, 2, 1126, 57, 1394, 71, 17638, 114, 16646, 4, 2460, 389, 2, 211, 174, 345, 23, 3, 1722, 1, 12, 2, 767, 4, 372, 1, 358, 9, 7, 26, 6022, 71, 85, 823, 4963, 9, 3, 1067, 1, 2, 9, 7, 5, 131, 1394, 9, 953, 77, 127, 323, 36, 10, 390, 3869, 22, 16, 4009, 1635, 885, 12, 16, 8, 923, 840, 2497, 5, 232, 483, 2, 460, 17, 343, 361, 1042, 15, 52951, 5257, 31, 25, 21, 32, 673, 3272, 6565, 29, 1041, 21038, 3, 2497, 4374, 28, 10810, 3, 694, 390, 189, 5543, 6, 4116, 3, 189, 558, 61, 5091, 5, 129, 161, 538, 1642, 1906, 4, 2755, 5, 1624, 90, 389, 1386, 740, 637, 6, 40, 879, 15, 2582, 911, 1, 217, 183, 5, 476, 128, 225, 22, 679, 2, 18784, 2022, 8172, 16, 120, 1, 7640, 1187]",1172.0,12044239,135
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.,Blood,Blood,2002-07-01,"Imatinib mesylate, an Abl kinase inhibitor, produces sustained complete hematologic responses (CHRs) in chronic myelogenous leukemia (CML) patients, but the sequence and timing of morphologic and cytogenetic changes in CML patients during prolonged imatinib mesylate treatment has not been described. In this report, we document sequential hematologic and bone marrow findings in 19 interferon-refractory/interferon-intolerant chronic phase CML patients on imatinib mesylate for at least 14 months. Patients treated at an effective oral dose (300 to 600 mg per day) were followed with peripheral blood (PB) counts, marrow examination, and cytogenetic studies at 0, 2, 5, 8, 11, and 14 months. By 2 months, 17 of 19 patients achieved CHR; 1 reached CHR by 5 months, and 1 at 11 months. Five of 19 patients developed cytopenias requiring treatment interruption and/or dose reduction, but all were able to continue in CHR on study. In contrast to interferon-alfa treatment, imatinib mesylate-treated CML patients achieved not only CHR but complete morphologic marrow response. Normalization of marrow lagged behind PB response; however, by 8 months, all marrows showed normal or reduced cellularity without morphologic evidence of CML. Eighteen of 19 patients continued in CHR and morphologic marrow remission at 14 months; 1 patient relapsed with chronic phase CML. Although hematologic and marrow responses were uniform, cytogenetic responses were variable. Complete cytogenetic responses occurred in 6 patients, with 4 also in remission by fluorescent in situ hybridization and/or reverse-transcription-polymerase chain reaction. Six of 19 had partial and 7 of 19 no cytogenetic response. Several patients acquired additional clonal cytogenetic abnormalities during therapy, a finding with significant implications for prognosis and laboratory monitoring in imatinib mesylate-treated CML patients.",Journal Article,6413.0,92.0,Imatinib mesylate an Abl kinase inhibitor produces sustained complete hematologic responses CHRs in chronic myelogenous CML patients but the sequence and timing of morphologic and cytogenetic changes in CML patients during prolonged imatinib mesylate treatment has not been described In this report we document sequential hematologic and marrow findings in 19 interferon-refractory/interferon-intolerant chronic phase CML patients on imatinib mesylate for at least 14 months Patients treated at an effective oral dose 300 to 600 mg per day were followed with peripheral blood PB counts marrow examination and cytogenetic studies at 0 2 5 8 11 and 14 months By 2 months 17 of 19 patients achieved CHR 1 reached CHR by 5 months and 1 at 11 months Five of 19 patients developed cytopenias requiring treatment interruption and/or dose reduction but all were able to continue in CHR on study In contrast to interferon-alfa treatment imatinib mesylate-treated CML patients achieved not only CHR but complete morphologic marrow response Normalization of marrow lagged behind PB response however by 8 months all marrows showed normal or reduced cellularity without morphologic evidence of CML Eighteen of 19 patients continued in CHR and morphologic marrow remission at 14 months 1 patient relapsed with chronic phase CML Although hematologic and marrow responses were uniform cytogenetic responses were variable Complete cytogenetic responses occurred in 6 patients with 4 also in remission by fluorescent in situ hybridization and/or reverse-transcription-polymerase chain reaction Six of 19 had partial and 7 of 19 no cytogenetic response Several patients acquired additional clonal cytogenetic abnormalities during therapy a finding with significant implications for prognosis and laboratory monitoring in imatinib mesylate-treated CML patients,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 2347, 35, 1425, 216, 230, 4042, 2275, 236, 813, 253, 37211, 4, 442, 2194, 903, 7, 84, 3, 1532, 2, 1972, 1, 2815, 2, 1266, 400, 4, 903, 7, 190, 1069, 577, 2347, 24, 71, 44, 85, 1027, 4, 26, 414, 21, 4753, 1787, 813, 2, 581, 272, 4, 326, 1688, 430, 1688, 4944, 442, 124, 903, 7, 23, 577, 2347, 9, 28, 506, 213, 53, 7, 73, 28, 35, 323, 518, 61, 2036, 6, 2383, 81, 379, 218, 11, 370, 5, 672, 315, 3767, 1911, 581, 1385, 2, 1266, 94, 28, 13, 18, 33, 66, 175, 2, 213, 53, 20, 18, 53, 269, 1, 326, 7, 513, 8158, 14, 1300, 8158, 20, 33, 53, 2, 14, 28, 175, 53, 365, 1, 326, 7, 276, 5635, 1888, 24, 4823, 2, 15, 61, 628, 84, 62, 11, 1665, 6, 1906, 4, 8158, 23, 45, 4, 748, 6, 1688, 4443, 24, 577, 2347, 73, 903, 7, 513, 44, 158, 8158, 84, 236, 2815, 581, 51, 5924, 1, 581, 15501, 5219, 3767, 51, 137, 20, 66, 53, 62, 13800, 224, 295, 15, 405, 6363, 187, 2815, 241, 1, 903, 3195, 1, 326, 7, 1351, 4, 8158, 2, 2815, 581, 734, 28, 213, 53, 14, 69, 591, 5, 442, 124, 903, 242, 813, 2, 581, 253, 11, 3490, 1266, 253, 11, 1347, 236, 1266, 253, 489, 4, 49, 7, 5, 39, 120, 4, 734, 20, 2910, 4, 957, 1554, 2, 15, 1772, 866, 1451, 1260, 1329, 437, 1, 326, 42, 450, 2, 67, 1, 326, 77, 1266, 51, 392, 7, 1294, 402, 1946, 1266, 1171, 190, 36, 8, 1567, 5, 93, 1268, 9, 356, 2, 1624, 1315, 4, 577, 2347, 73, 903, 7]",1840.0,12091333,18
"Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2002-07-01,"DX-8951f is a novel hexacyclic camptothecin-analogue topoisomerase I inhibitor with both in vitro antileukemic activity and myelosuppression as a dose-limiting toxicity in solid tumor Phase I studies. DX-8951f is active in a human acute myeloid leukemia (AML) severe combined immunodeficient mouse model. In a leukemia Phase I study, we investigated the toxicity profile and pharmacokinetics of DX-8951f in patients with primary refractory or relapsed AML or acute lymphocytic leukemia, myelodysplastic syndromes, or chronic myelogenous leukemia in blastic phase (CML-BP). DX-8951f was given as an i.v. infusion over 30 min daily for 5 or 7 days. The starting dose was 0.6 mg/m(2)/day for 5 days (3.0 mg/m(2)/course). Courses were given every 3-4 weeks according to toxicity and antileukemic efficacy. Twenty-five patients (AML, 21 patients; myelodysplastic syndrome, 1 patient; acute lymphocytic leukemia, 2 patients; CML-BP, 1 patient) were treated. Stomatitis was the dose-limiting toxicity, occurring in two of two patients treated at 1.35 mg/m(2)/day for 5 days, two of three treated at 1.2 mg/m(2)/day for 5 days, and one of six treated at 0.9 mg/m(2)/day for 7 days. The recommended Phase II dose was 0.9 mg/m(2)/day for 5 days. The pharmacokinetics of DX-8951 was linear and well fit by a two-compartment model. Phase II studies are warranted to further define the activity of DX-8951f in patients with hematological malignancies.",Clinical Trial,6413.0,24.0,DX-8951f is a novel hexacyclic camptothecin-analogue topoisomerase I inhibitor with both in vitro antileukemic activity and myelosuppression as a dose-limiting toxicity in solid tumor Phase I studies DX-8951f is active in a human acute myeloid AML severe combined immunodeficient mouse model In a Phase I study we investigated the toxicity profile and pharmacokinetics of DX-8951f in patients with primary refractory or relapsed AML or acute lymphocytic syndromes or chronic myelogenous in blastic phase CML-BP DX-8951f was given as an i.v infusion over 30 min daily for 5 or 7 days The starting dose was 0.6 mg/m 2 /day for 5 days 3.0 mg/m 2 /course Courses were given every 3-4 weeks according to toxicity and antileukemic efficacy Twenty-five patients AML 21 patients syndrome 1 patient acute lymphocytic 2 patients CML-BP 1 patient were treated Stomatitis was the dose-limiting toxicity occurring in two of two patients treated at 1.35 mg/m 2 /day for 5 days two of three treated at 1.2 mg/m 2 /day for 5 days and one of six treated at 0.9 mg/m 2 /day for 7 days The recommended Phase II dose was 0.9 mg/m 2 /day for 5 days The pharmacokinetics of DX-8951 was linear and well fit by a two-compartment model Phase II studies are warranted to further define the activity of DX-8951f in patients with hematological malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4946, 16242, 16, 8, 229, 37223, 6968, 4696, 3999, 70, 230, 5, 110, 4, 439, 4512, 128, 2, 2858, 22, 8, 61, 817, 155, 4, 537, 30, 124, 70, 94, 4946, 16242, 16, 544, 4, 8, 171, 286, 533, 329, 905, 397, 5031, 830, 202, 4, 8, 124, 70, 45, 21, 565, 3, 155, 800, 2, 1159, 1, 4946, 16242, 4, 7, 5, 86, 430, 15, 591, 329, 15, 286, 1193, 2040, 15, 442, 2194, 4, 6529, 124, 903, 3044, 4946, 16242, 10, 447, 22, 35, 70, 603, 904, 252, 201, 1538, 391, 9, 33, 15, 67, 162, 3, 1723, 61, 10, 13, 49, 81, 188, 18, 218, 9, 33, 162, 27, 13, 81, 188, 18, 906, 1993, 11, 447, 454, 27, 39, 244, 768, 6, 155, 2, 4512, 209, 737, 365, 7, 329, 239, 7, 681, 14, 69, 286, 1193, 18, 7, 903, 3044, 14, 69, 11, 73, 4486, 10, 3, 61, 817, 155, 1821, 4, 100, 1, 100, 7, 73, 28, 14, 465, 81, 188, 18, 218, 9, 33, 162, 100, 1, 169, 73, 28, 14, 18, 81, 188, 18, 218, 9, 33, 162, 2, 104, 1, 437, 73, 28, 13, 83, 81, 188, 18, 218, 9, 67, 162, 3, 793, 124, 215, 61, 10, 13, 83, 81, 188, 18, 218, 9, 33, 162, 3, 1159, 1, 4946, 24479, 10, 1646, 2, 149, 2975, 20, 8, 100, 3616, 202, 124, 215, 94, 32, 1197, 6, 195, 1107, 3, 128, 1, 4946, 16242, 4, 7, 5, 2890, 441]",1328.0,12114413,117
"Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2002-07-01,"Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML). We treated 237 patients (median age, 50 years; age range, 18-82 years) with Philadelphia chromosome (Ph)-positive accelerated-phase CML with oral imatinib mesylate at daily doses of 400 mg (26 patients) or 600 mg (211 patients) and evaluated response and survival characteristics in univariate and multivariate analyses. Among the 200 patients with accelerated-phase CML for whom follow-up was 3 months or more, rates of complete and partial hematological response were 80% and 10%. Cytogenetic responses were evident in 90 patients [45%; complete response in 47 patients (24%) and partial response (Ph 1-34%) in 21 patients (11%)]. The estimated 18-month survival rate was 73%. The estimated complete hematological response rate at 18 months was 68%; that for cytogenetic response was 82%. In multivariate analyses, a diagnosis-to-treatment interval of 3 years or more, splenomegaly, and peripheral blasts predicted poor major cytogenetic response; age >60 years, marrow basophilia, and clonal evolution predicted poor survival. The 600-mg drug dose was associated with better cytogenetic response and survival in univariate analysis (P < 0.01) but not in multivariate analysis. Landmark analysis showed that achieving a cytogenetic response at 3 months or a major cytogenetic response (Ph < 35%) at 6 months was associated with better long-term survival. Seven of 15 patients who were in a second chronic phase achieved major cytogenetic response. The incidence of severe nonhematological toxic effects was 23%; drug discontinuation for severe toxicity was needed in 3% of patients. Imatinib mesylate was active against Ph-positive, accelerated-phase CML, and the prognostic factors identified in this study could aid in tailoring treatment strategies to specific risk groups.",Clinical Trial,6413.0,96.0,Imatinib mesylate a specific Bcr-Abl tyrosine kinase inhibitor has shown encouraging activity in chronic myelogenous CML We treated 237 patients median age 50 years age range 18-82 years with Philadelphia chromosome Ph -positive accelerated-phase CML with oral imatinib mesylate at daily doses of 400 mg 26 patients or 600 mg 211 patients and evaluated response and survival characteristics in univariate and multivariate analyses Among the 200 patients with accelerated-phase CML for whom follow-up was 3 months or more rates of complete and partial hematological response were 80 and 10 Cytogenetic responses were evident in 90 patients 45 complete response in 47 patients 24 and partial response Ph 1-34 in 21 patients 11 The estimated 18-month survival rate was 73 The estimated complete hematological response rate at 18 months was 68 that for cytogenetic response was 82 In multivariate analyses a diagnosis-to-treatment interval of 3 years or more splenomegaly and peripheral blasts predicted poor major cytogenetic response age 60 years marrow basophilia and clonal evolution predicted poor survival The 600-mg drug dose was associated with better cytogenetic response and survival in univariate analysis P 0.01 but not in multivariate analysis Landmark analysis showed that achieving a cytogenetic response at 3 months or a major cytogenetic response Ph 35 at 6 months was associated with better long-term survival Seven of 15 patients who were in a second chronic phase achieved major cytogenetic response The incidence of severe nonhematological toxic effects was 23 drug discontinuation for severe toxicity was needed in 3 of patients Imatinib mesylate was active against Ph-positive accelerated-phase CML and the prognostic factors identified in this study could aid in tailoring treatment strategies to specific risk groups,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 2347, 8, 112, 1062, 1425, 564, 216, 230, 71, 443, 2269, 128, 4, 442, 2194, 903, 21, 73, 7296, 7, 52, 89, 212, 60, 89, 184, 203, 878, 60, 5, 3006, 1170, 2058, 109, 2241, 124, 903, 5, 518, 577, 2347, 28, 391, 415, 1, 1524, 81, 432, 7, 15, 2383, 81, 5905, 7, 2, 194, 51, 2, 25, 374, 4, 880, 2, 331, 318, 107, 3, 1250, 7, 5, 2241, 124, 903, 9, 953, 166, 126, 10, 27, 53, 15, 80, 151, 1, 236, 2, 450, 2890, 51, 11, 493, 2, 79, 1266, 253, 11, 2853, 4, 424, 7, 512, 236, 51, 4, 662, 7, 259, 2, 450, 51, 2058, 14, 562, 4, 239, 7, 175, 3, 661, 203, 811, 25, 116, 10, 803, 3, 661, 236, 2890, 51, 116, 28, 203, 53, 10, 806, 17, 9, 1266, 51, 10, 878, 4, 331, 318, 8, 147, 6, 24, 268, 1, 27, 60, 15, 80, 6364, 2, 672, 2438, 783, 334, 458, 1266, 51, 89, 335, 60, 581, 26032, 2, 1946, 2554, 783, 334, 25, 3, 2383, 81, 234, 61, 10, 41, 5, 380, 1266, 51, 2, 25, 4, 880, 65, 19, 13, 355, 84, 44, 4, 331, 65, 3829, 65, 224, 17, 1785, 8, 1266, 51, 28, 27, 53, 15, 8, 458, 1266, 51, 2058, 465, 28, 49, 53, 10, 41, 5, 380, 319, 337, 25, 648, 1, 167, 7, 54, 11, 4, 8, 419, 442, 124, 513, 458, 1266, 51, 3, 287, 1, 905, 12494, 1812, 176, 10, 382, 234, 2007, 9, 905, 155, 10, 575, 4, 27, 1, 7, 577, 2347, 10, 544, 480, 2058, 109, 2241, 124, 903, 2, 3, 177, 130, 108, 4, 26, 45, 359, 2427, 4, 7101, 24, 422, 6, 112, 43, 271]",1837.0,12114417,239
Critical role for Gab2 in transformation by BCR/ABL.,Cancer cell,Cancer Cell,2002-06-01,"The BCR/ABL oncogene causes chronic myelogenous leukemia (CML) in humans and a CML-like disease, as well as lymphoid leukemia, in mice. p210 BCR/ABL is an activated tyrosine kinase that phosphorylates itself and several cellular signaling proteins. The autophosphorylation site tyrosine 177 binds the adaptor Grb2 and helps determine the lineage and severity of BCR/ABL disease: Tyr177 mutation (BCR/ABL-Y177F) dramatically impairs myeloid leukemogenesis, while diminishing lymphoid leukemogenesis. The critical signal(s) from Tyr177 has remained unclear. We report that Tyr177 recruits the scaffolding adaptor Gab2 via a Grb2/Gab2 complex. Compared to BCR/ABL-expressing Ba/F3 cells, BCR/ABL-Y177F cells exhibit markedly reduced Gab2 tyrosine phosphorylation and association of phosphatidylinositol-3 kinase (PI3K) and Shp2 with Gab2 and BCR/ABL, and decreased PI3K/Akt and Ras/Erk activation, cell proliferation, and spontaneous migration. Remarkably, bone marrow myeloid progenitors from Gab2 (-/-) mice are resistant to transformation by BCR/ABL, whereas lymphoid transformation is diminished as a consequence of markedly increased apoptosis. BCR/ABL-evoked PI3K/Akt and Ras/Erk activation also are impaired in Gab2 (-/-) primary myeloid and lymphoid cells. Our results identify Gab2 and its associated proteins as key determinants of the lineage and severity of BCR/ABL transformation.",Journal Article,6443.0,262.0,The BCR/ABL oncogene causes chronic myelogenous CML in humans and a CML-like disease as well as lymphoid in mice p210 BCR/ABL is an activated tyrosine kinase that phosphorylates itself and several cellular signaling proteins The autophosphorylation site tyrosine 177 binds the adaptor Grb2 and helps determine the lineage and severity of BCR/ABL disease Tyr177 mutation BCR/ABL-Y177F dramatically impairs myeloid leukemogenesis while diminishing lymphoid leukemogenesis The critical signal s from Tyr177 has remained unclear We report that Tyr177 recruits the scaffolding adaptor Gab2 via a Grb2/Gab2 complex Compared to BCR/ABL-expressing Ba/F3 cells BCR/ABL-Y177F cells exhibit markedly reduced Gab2 tyrosine phosphorylation and association of phosphatidylinositol-3 kinase PI3K and Shp2 with Gab2 and BCR/ABL and decreased PI3K/Akt and Ras/Erk activation cell proliferation and spontaneous migration Remarkably marrow myeloid progenitors from Gab2 -/- mice are resistant to transformation by BCR/ABL whereas lymphoid transformation is diminished as a consequence of markedly increased apoptosis BCR/ABL-evoked PI3K/Akt and Ras/Erk activation also are impaired in Gab2 -/- primary myeloid and lymphoid cells Our results identify Gab2 and its associated proteins as key determinants of the lineage and severity of BCR/ABL transformation,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1062, 1425, 1836, 1626, 442, 2194, 903, 4, 3218, 2, 8, 903, 733, 34, 22, 149, 22, 2303, 4, 399, 11538, 1062, 1425, 16, 35, 735, 564, 216, 17, 12528, 4045, 2, 392, 763, 314, 652, 3, 8146, 606, 564, 4699, 3333, 3, 10171, 10967, 2, 6484, 223, 3, 2542, 2, 1702, 1, 1062, 1425, 34, 37233, 258, 1062, 1425, 42992, 2729, 8312, 533, 5661, 369, 12497, 2303, 5661, 3, 740, 1235, 695, 29, 37233, 71, 958, 1200, 21, 414, 17, 37233, 14063, 3, 16653, 10171, 24484, 847, 8, 10967, 24484, 840, 72, 6, 1062, 1425, 1046, 6669, 6904, 37, 1062, 1425, 42992, 37, 2239, 2195, 405, 24484, 564, 982, 2, 248, 1, 3415, 27, 216, 974, 2, 15508, 5, 24484, 2, 1062, 1425, 2, 340, 974, 649, 2, 1102, 1819, 363, 31, 457, 2, 3280, 1381, 4856, 581, 533, 4321, 29, 24484, 399, 32, 436, 6, 1392, 20, 1062, 1425, 547, 2303, 1392, 16, 2849, 22, 8, 4177, 1, 2195, 101, 351, 1062, 1425, 22008, 974, 649, 2, 1102, 1819, 363, 120, 32, 2364, 4, 24484, 86, 533, 2, 2303, 37, 114, 99, 255, 24484, 2, 211, 41, 652, 22, 825, 3403, 1, 3, 2542, 2, 1702, 1, 1062, 1425, 1392]",1337.0,12124177,23
Targeted alpha particle immunotherapy for myeloid leukemia.,Blood,Blood,2002-08-01,"Unlike beta particle-emitting isotopes, alpha emitters can selectively kill individual cancer cells with a single atomic decay. HuM195, a humanized anti-CD33 monoclonal antibody, specifically targets myeloid leukemia cells and has activity against minimal disease. When labeled with the beta-emitters (131)I and (90)Y, HuM195 can eliminate large leukemic burdens in patients, but it produces prolonged myelosuppression requiring hematopoietic stem cell transplantation at high doses. To enhance the potency of native HuM195 yet avoid the nonspecific cytotoxicity of beta-emitting constructs, the alpha-emitting isotope (213)Bi was conjugated to HuM195. Eighteen patients with relapsed and refractory acute myelogenous leukemia or chronic myelomonocytic leukemia were treated with 10.36 to 37.0 MBq/kg (213)Bi-HuM195. No significant extramedullary toxicity was seen. All 17 evaluable patients developed myelosuppression, with a median time to recovery of 22 days. Nearly all the (213)Bi-HuM195 rapidly localized to and was retained in areas of leukemic involvement, including the bone marrow, liver, and spleen. Absorbed dose ratios between these sites and the whole body were 1000-fold greater than those seen with beta-emitting constructs in this antigen system and patient population. Fourteen (93%) of 15 evaluable patients had reductions in circulating blasts, and 14 (78%) of 18 patients had reductions in the percentage of bone marrow blasts. This study demonstrates the safety, feasibility, and antileukemic effects of (213)Bi-HuM195, and it is the first proof-of-concept for systemic targeted alpha particle immunotherapy in humans.",Clinical Trial,6382.0,352.0,Unlike beta particle-emitting isotopes alpha emitters can selectively kill individual cancer cells with a single atomic decay HuM195 a humanized anti-CD33 monoclonal antibody specifically targets myeloid cells and has activity against minimal disease When labeled with the beta-emitters 131 I and 90 Y HuM195 can eliminate large leukemic burdens in patients but it produces prolonged myelosuppression requiring hematopoietic stem cell transplantation at high doses To enhance the potency of native HuM195 yet avoid the nonspecific cytotoxicity of beta-emitting constructs the alpha-emitting isotope 213 Bi was conjugated to HuM195 Eighteen patients with relapsed and refractory acute myelogenous or chronic myelomonocytic were treated with 10.36 to 37.0 MBq/kg 213 Bi-HuM195 No significant extramedullary toxicity was seen All 17 evaluable patients developed myelosuppression with a median time to recovery of 22 days Nearly all the 213 Bi-HuM195 rapidly localized to and was retained in areas of leukemic involvement including the marrow and spleen Absorbed dose ratios between these sites and the whole body were 1000-fold greater than those seen with beta-emitting constructs in this antigen system and patient population Fourteen 93 of 15 evaluable patients had reductions in circulating blasts and 14 78 of 18 patients had reductions in the percentage of marrow blasts This study demonstrates the safety feasibility and antileukemic effects of 213 Bi-HuM195 and it is the first proof-of-concept for systemic targeted alpha particle immunotherapy in humans,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4246, 1090, 5997, 10394, 16210, 950, 21054, 122, 2382, 5097, 797, 12, 37, 5, 8, 226, 15466, 10960, 16245, 8, 3619, 312, 6353, 848, 548, 1225, 637, 533, 37, 2, 71, 128, 480, 1048, 34, 198, 2841, 5, 3, 1090, 21054, 2229, 70, 2, 424, 2055, 16245, 122, 4964, 375, 2015, 8933, 4, 7, 84, 192, 4042, 1069, 2858, 1888, 1007, 452, 31, 497, 28, 64, 415, 6, 1304, 3, 3593, 1, 4646, 16245, 1145, 3085, 3, 5893, 1408, 1, 1090, 10394, 5500, 3, 950, 10394, 9242, 5833, 3984, 10, 3868, 6, 16245, 3195, 7, 5, 591, 2, 430, 286, 2194, 15, 442, 5451, 11, 73, 5, 79, 511, 6, 567, 13, 5372, 503, 5833, 3984, 16245, 77, 93, 5508, 155, 10, 527, 62, 269, 859, 7, 276, 2858, 5, 8, 52, 98, 6, 1602, 1, 350, 162, 1857, 62, 3, 5833, 3984, 16245, 1755, 909, 6, 2, 10, 3532, 4, 1361, 1, 2015, 799, 141, 3, 581, 2, 4071, 5249, 61, 1137, 59, 46, 633, 2, 3, 902, 642, 11, 2345, 1116, 378, 76, 135, 527, 5, 1090, 10394, 5500, 4, 26, 448, 398, 2, 69, 266, 3225, 966, 1, 167, 859, 7, 42, 2153, 4, 1033, 2438, 2, 213, 833, 1, 203, 7, 42, 2153, 4, 3, 1150, 1, 581, 2438, 26, 45, 1902, 3, 367, 1437, 2, 4512, 176, 1, 5833, 3984, 16245, 2, 192, 16, 3, 157, 3840, 1, 2545, 9, 403, 238, 950, 5997, 726, 4, 3218]",1560.0,12149203,74
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.,Haematologica,Haematologica,2002-08-01,"Early studies have suggested that increasing doses of anthracycline improve outcome in younger patients with acute myelogenous leukemia (AML), but dose escalation has been precluded by the acute and chronic toxicities of these agents. Amifostine is a cytoprotective compound that has been shown to protect against the acute cytotoxicities of anthracyclines in animal models. We report the results of a phase I study of dose escalation of idarubicin with amifostine and high-dose ara-C in patients with relapsed or refractory AML or myelodysplastic syndrome (MDS). The continuous reassessment method was used to predict the probability of toxicity. Five patients were treated at an idarubicin dose of 18 mg/m2/day x 3, three of whom developed grade 3 diarrhea or mucositis. Subsequently, three additional patients were treated at a dose of 15 mg/m2 x 3 days, all of whom experienced grade 3 diarrhea or mucositis. One patient achieved complete remission (CR rate 12.5%, 95% CI 0-0.52%). The addition of amifostine does not allow dose escalation of idarubicin when combined with high-dose ara-C.",Clinical Trial,6382.0,7.0,Early studies have suggested that increasing doses of anthracycline improve outcome in younger patients with acute myelogenous AML but dose escalation has been precluded by the acute and chronic toxicities of these agents Amifostine is a cytoprotective compound that has been shown to protect against the acute cytotoxicities of anthracyclines in animal models We report the results of a phase I study of dose escalation of idarubicin with amifostine and high-dose ara-C in patients with relapsed or refractory AML or syndrome MDS The continuous reassessment method was used to predict the probability of toxicity Five patients were treated at an idarubicin dose of 18 mg/m2/day x 3 three of whom developed grade 3 diarrhea or mucositis Subsequently three additional patients were treated at a dose of 15 mg/m2 x 3 days all of whom experienced grade 3 diarrhea or mucositis One patient achieved complete remission CR rate 12.5 95 CI 0-0.52 The addition of amifostine does not allow dose escalation of idarubicin when combined with high-dose ara-C,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[191, 94, 47, 1148, 17, 602, 415, 1, 2044, 401, 228, 4, 773, 7, 5, 286, 2194, 329, 84, 61, 1125, 71, 85, 8035, 20, 3, 286, 2, 442, 385, 1, 46, 183, 5369, 16, 8, 10677, 2823, 17, 71, 85, 443, 6, 4869, 480, 3, 286, 33273, 1, 3597, 4, 2026, 274, 21, 414, 3, 99, 1, 8, 124, 70, 45, 1, 61, 1125, 1, 5684, 5, 5369, 2, 64, 61, 3899, 256, 4, 7, 5, 591, 15, 430, 329, 15, 681, 1223, 3, 1314, 8756, 596, 10, 95, 6, 678, 3, 1320, 1, 155, 365, 7, 11, 73, 28, 35, 5684, 61, 1, 203, 81, 821, 218, 1006, 27, 169, 1, 953, 276, 88, 27, 1172, 15, 2606, 1611, 169, 402, 7, 11, 73, 28, 8, 61, 1, 167, 81, 821, 1006, 27, 162, 62, 1, 953, 592, 88, 27, 1172, 15, 2606, 104, 69, 513, 236, 734, 684, 116, 133, 33, 48, 58, 13, 13, 653, 3, 352, 1, 5369, 1097, 44, 1700, 61, 1125, 1, 5684, 198, 397, 5, 64, 61, 3899, 256]",1046.0,12161355,24
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.,Cancer,Cancer,2002-05-01,"Chronic myelogenous leukemia (CML) is characterized by a molecular aberration, a fusion BCR-ABL gene encoding for aberrant tyrosine kinase activity, which is crucial in the pathogenesis of CML. In vitro, inhibition of BCR-ABL protein tyrosine kinase activity by a tyrosine kinase inhibitor, Imatinib mesylate (STI571; formerly CGP57148B), successfully suppressed proliferation/survival of the BCR-ABL positive clones. In clinical studies, hematologic and cytogenetic remissions have been achieved in most patients with chronic phase CML; in accelerated and blastic phases of CML, STI571 appeared less effective. In the current study, the authors tested combinations of STI571 and cytarabine and homoharringtonine (HHT), drugs with documented activity in CML. The single agents and their combinations were studied for in vitro effect on proliferation of BCR-ABL positive cell lines KBM5 and KBM7 by 3(4,5-dimethylthiazol-2yl)-2,5 diphenyl-tetrazolium bromide assay and on primary patient-derived BCR-ABL cells by clonogenic assays. The in vitro additive, synergistic, or antagonistic effects of cytarabine and HHT with STI571 were then investigated by computer-assisted analysis using the CalcuSyn software. STI571 consistently suppressed BCR-ABL positive cell proliferation with a dose-effect correlation. In the model system used, STI571/cytarabine and STI571/HHT combinations were more effective in inhibiting KBM5 and KBM7 cell growth than each drug as single agent. These results were also verified in primary CML-derived clonogenic cells in semisolid cultures. In this experimental system, our studies documented additive or synergistic effects with STI571 plus cytarabine or HHT, supporting the future use of STI571 combinations in clinical trials in patients with Philadelphia chromosome-positive leukemias.",Journal Article,6474.0,47.0,"Chronic myelogenous CML is characterized by a molecular aberration a fusion BCR-ABL gene encoding for aberrant tyrosine kinase activity which is crucial in the pathogenesis of CML In vitro inhibition of BCR-ABL protein tyrosine kinase activity by a tyrosine kinase inhibitor Imatinib mesylate STI571 formerly CGP57148B successfully suppressed proliferation/survival of the BCR-ABL positive clones In clinical studies hematologic and cytogenetic remissions have been achieved in most patients with chronic phase CML in accelerated and blastic phases of CML STI571 appeared less effective In the current study the authors tested combinations of STI571 and cytarabine and homoharringtonine HHT drugs with documented activity in CML The single agents and their combinations were studied for in vitro effect on proliferation of BCR-ABL positive cell lines KBM5 and KBM7 by 3 4,5-dimethylthiazol-2yl -2,5 diphenyl-tetrazolium bromide assay and on primary patient-derived BCR-ABL cells by clonogenic assays The in vitro additive synergistic or antagonistic effects of cytarabine and HHT with STI571 were then investigated by computer-assisted analysis using the CalcuSyn software STI571 consistently suppressed BCR-ABL positive cell proliferation with a dose-effect correlation In the model system used STI571/cytarabine and STI571/HHT combinations were more effective in inhibiting KBM5 and KBM7 cell growth than each drug as single agent These results were also verified in primary CML-derived clonogenic cells in semisolid cultures In this experimental system our studies documented additive or synergistic effects with STI571 plus cytarabine or HHT supporting the future use of STI571 combinations in clinical trials in patients with Philadelphia chromosome-positive leukemias",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 16, 765, 20, 8, 219, 7794, 8, 1212, 1062, 1425, 145, 2362, 9, 1898, 564, 216, 128, 92, 16, 2653, 4, 3, 1384, 1, 903, 4, 439, 297, 1, 1062, 1425, 178, 564, 216, 128, 20, 8, 564, 216, 230, 577, 2347, 5735, 7350, 37253, 1878, 1908, 457, 25, 1, 3, 1062, 1425, 109, 2749, 4, 38, 94, 813, 2, 1266, 3166, 47, 85, 513, 4, 96, 7, 5, 442, 124, 903, 4, 2241, 2, 6529, 3523, 1, 903, 5735, 2121, 299, 323, 4, 3, 291, 45, 3, 738, 650, 1247, 1, 5735, 2, 1855, 2, 18768, 9249, 600, 5, 1405, 128, 4, 903, 3, 226, 183, 2, 136, 1247, 11, 656, 9, 4, 439, 254, 23, 457, 1, 1062, 1425, 109, 31, 285, 10822, 2, 18206, 20, 27, 39, 33, 12094, 33277, 18, 33, 22020, 11915, 10168, 719, 2, 23, 86, 69, 526, 1062, 1425, 37, 20, 3798, 1013, 3, 4, 439, 3396, 1806, 15, 9863, 176, 1, 1855, 2, 9249, 5, 5735, 11, 818, 565, 20, 4236, 2927, 65, 75, 3, 30296, 3639, 5735, 2433, 1908, 1062, 1425, 109, 31, 457, 5, 8, 61, 254, 816, 4, 3, 202, 398, 95, 5735, 1855, 2, 5735, 9249, 1247, 11, 80, 323, 4, 2062, 10822, 2, 18206, 31, 129, 76, 296, 234, 22, 226, 420, 46, 99, 11, 120, 4815, 4, 86, 903, 526, 3798, 37, 4, 43013, 3231, 4, 26, 1560, 398, 114, 94, 1405, 3396, 15, 1806, 176, 5, 5735, 349, 1855, 15, 9249, 1912, 3, 508, 119, 1, 5735, 1247, 4, 38, 143, 4, 7, 5, 3006, 1170, 109, 2792]",1773.0,12173333,68
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.,Blood,Blood,2002-09-01,"Twenty-eight adults with chronic myelogenous leukemia (CML) that had relapsed after allogeneic stem cell transplantation (SCT) received imatinib mesylate (400-1000 mg/d). Disease was in chronic phase in 5 patients, accelerated in 15, and blastic in 8 (7 medullary, 1 extramedullary); median time from transplantation to relapse was 9 months (range, 1-137 months). Thirteen patients had undergone salvage donor lymphocyte infusion (DLI) (median time from DLI to imatinib mesylate therapy, 4 months [range, 2-39 months]). The overall response rate was 79% (22 of 28 patients); the complete hematologic response (CHR) rate was 74% (17 of 23 patients), and the cytogenetic response rate was 58% (15 of 26 patients; complete response in 9 [35%] patients). CHR rates were 100% for chronic phase, 83% for accelerated phase, and 43% for blastic phase. The patient with extramedullary blastic disease achieved complete response. Cytogenetic response rates were 63% (12 of 19 patients) for chronic or accelerated phases (complete cytogenetic response in 8) and 43% for blastic phase (3 of 7 patients). At median follow-up of 15 months, 19 patients were alive, 9 with no evidence of disease. The 1-year estimated survival rate was 74%. Five patients had recurrence of grade 3 (3 patients) or grades 1 to 2 (2 patients) graft-versus-host disease (GVHD). Severe granulocytopenia developed in 43% of patients and thrombocytopenia in 27%; both conditions reversed with dose adjustments of imatinib mesylate. We conclude that imatinib mesylate effectively controlled CML that recurred after allogeneic SCT, but it was associated with side effects including myelosuppression and recurrence of severe GVHD.",Clinical Trial,6351.0,146.0,Twenty-eight adults with chronic myelogenous CML that had relapsed after allogeneic stem cell transplantation SCT received imatinib mesylate 400-1000 mg/d Disease was in chronic phase in 5 patients accelerated in 15 and blastic in 8 7 medullary 1 extramedullary median time from transplantation to relapse was 9 months range 1-137 months Thirteen patients had undergone salvage donor lymphocyte infusion DLI median time from DLI to imatinib mesylate therapy 4 months range 2-39 months The overall response rate was 79 22 of 28 patients the complete hematologic response CHR rate was 74 17 of 23 patients and the cytogenetic response rate was 58 15 of 26 patients complete response in 9 35 patients CHR rates were 100 for chronic phase 83 for accelerated phase and 43 for blastic phase The patient with extramedullary blastic disease achieved complete response Cytogenetic response rates were 63 12 of 19 patients for chronic or accelerated phases complete cytogenetic response in 8 and 43 for blastic phase 3 of 7 patients At median follow-up of 15 months 19 patients were alive 9 with no evidence of disease The 1-year estimated survival rate was 74 Five patients had recurrence of grade 3 3 patients or grades 1 to 2 2 patients graft-versus-host disease GVHD Severe granulocytopenia developed in 43 of patients and thrombocytopenia in 27 both conditions reversed with dose adjustments of imatinib mesylate We conclude that imatinib mesylate effectively controlled CML that recurred after allogeneic SCT but it was associated with side effects including myelosuppression and recurrence of severe GVHD,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[737, 659, 857, 5, 442, 2194, 903, 17, 42, 591, 50, 1063, 452, 31, 497, 1988, 103, 577, 2347, 1524, 2345, 81, 427, 34, 10, 4, 442, 124, 4, 33, 7, 2241, 4, 167, 2, 6529, 4, 66, 67, 4564, 14, 5508, 52, 98, 29, 497, 6, 429, 10, 83, 53, 184, 14, 4352, 53, 3170, 7, 42, 1989, 992, 1488, 1448, 904, 4676, 52, 98, 29, 4676, 6, 577, 2347, 36, 39, 53, 184, 18, 587, 53, 3, 63, 51, 116, 10, 842, 350, 1, 339, 7, 3, 236, 813, 51, 8158, 116, 10, 794, 269, 1, 382, 7, 2, 3, 1266, 51, 116, 10, 717, 167, 1, 432, 7, 236, 51, 4, 83, 465, 7, 8158, 151, 11, 394, 9, 442, 124, 852, 9, 2241, 124, 2, 601, 9, 6529, 124, 3, 69, 5, 5508, 6529, 34, 513, 236, 51, 1266, 51, 151, 11, 676, 133, 1, 326, 7, 9, 442, 15, 2241, 3523, 236, 1266, 51, 4, 66, 2, 601, 9, 6529, 124, 27, 1, 67, 7, 28, 52, 166, 126, 1, 167, 53, 326, 7, 11, 1701, 83, 5, 77, 241, 1, 34, 3, 14, 111, 661, 25, 116, 10, 794, 365, 7, 42, 146, 1, 88, 27, 27, 7, 15, 2276, 14, 6, 18, 18, 7, 1599, 185, 1204, 34, 1562, 905, 10552, 276, 4, 601, 1, 7, 2, 1340, 4, 428, 110, 1298, 3682, 5, 61, 6017, 1, 577, 2347, 21, 2060, 17, 577, 2347, 1856, 1149, 903, 17, 3363, 50, 1063, 1988, 84, 192, 10, 41, 5, 1152, 176, 141, 2858, 2, 146, 1, 905, 1562]",1601.0,12176876,164
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.,Blood,Blood,2002-09-01,"The translocation (9;22) gives rise to the p190(Bcr-Abl) and p210(Bcr-Abl) tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph(+)) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We conducted a clinical trial in 56 patients with relapsed or refractory Ph(+) acute lymphoblastic leukemia (ALL; 48 patients) or chronic myelogenous leukemia in lymphoid blast crisis (LyBC; 8 patients). Imatinib was given once daily at 400 mg or 600 mg. Imatinib induced complete hematologic responses (CHRs) and complete marrow responses (marrow-CRs) in 29% of ALL patients (CHR, 19%; marrow-CR, 10%), which were sustained for at least 4 weeks in 6% of patients. Median estimated time to progression and overall survival for ALL patients were 2.2 and 4.9 months, respectively. CHRs were reported for 3 (38%) of the patients with LyBC (one sustained CHR). Grade 3 or 4 treatment-related nonhematologic toxicity was reported for 9% of patients; none of the patients discontinued therapy because of nonhematologic adverse reactions. Grade 4 neutropenia and thrombocytopenia occurred in 54% and 27% of patients, respectively. Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph(+) acute lymphoid leukemia patients, but development of resistance and subsequent disease progression were rapid. Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib.",Clinical Trial,6351.0,463.0,The translocation 9 22 gives rise to the p190 Bcr-Abl and p210 Bcr-Abl tyrosine kinase proteins considered sufficient for leukemic transformation Philadelphia-positive Ph acute patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options Imatinib is an orally administered potent inhibitor of the Bcr-Abl tyrosine kinase We conducted a clinical trial in 56 patients with relapsed or refractory Ph acute lymphoblastic ALL 48 patients or chronic myelogenous in lymphoid blast crisis LyBC 8 patients Imatinib was given once daily at 400 mg or 600 mg. Imatinib induced complete hematologic responses CHRs and complete marrow responses marrow-CRs in 29 of ALL patients CHR 19 marrow-CR 10 which were sustained for at least 4 weeks in 6 of patients Median estimated time to progression and overall survival for ALL patients were 2.2 and 4.9 months respectively CHRs were reported for 3 38 of the patients with LyBC one sustained CHR Grade 3 or 4 treatment-related nonhematologic toxicity was reported for 9 of patients none of the patients discontinued therapy because of nonhematologic adverse reactions Grade 4 neutropenia and thrombocytopenia occurred in 54 and 27 of patients respectively Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph acute lymphoid patients but development of resistance and subsequent disease progression were rapid Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 2006, 83, 350, 7989, 3693, 6, 3, 18813, 1062, 1425, 2, 11538, 1062, 1425, 564, 216, 652, 515, 1952, 9, 2015, 1392, 3006, 109, 2058, 286, 7, 7928, 6, 1892, 6, 388, 504, 36, 47, 8, 334, 356, 5, 1021, 323, 24, 838, 577, 16, 35, 1428, 468, 1157, 230, 1, 3, 1062, 1425, 564, 216, 21, 426, 8, 38, 160, 4, 664, 7, 5, 591, 15, 430, 2058, 286, 1275, 62, 576, 7, 15, 442, 2194, 4, 2303, 3112, 6540, 43026, 66, 7, 577, 10, 447, 1059, 391, 28, 1524, 81, 15, 2383, 81, 577, 277, 236, 813, 253, 37211, 2, 236, 581, 253, 581, 3115, 4, 462, 1, 62, 7, 8158, 326, 581, 684, 79, 92, 11, 2275, 9, 28, 506, 39, 244, 4, 49, 1, 7, 52, 661, 98, 6, 91, 2, 63, 25, 9, 62, 7, 11, 18, 18, 2, 39, 83, 53, 106, 37211, 11, 210, 9, 27, 519, 1, 3, 7, 5, 43026, 104, 2275, 8158, 88, 27, 15, 39, 24, 139, 3534, 155, 10, 210, 9, 83, 1, 7, 1292, 1, 3, 7, 2402, 36, 408, 1, 3534, 290, 2428, 88, 39, 778, 2, 1340, 489, 4, 667, 2, 428, 1, 7, 106, 577, 36, 627, 4, 8, 505, 867, 813, 51, 116, 4, 591, 15, 430, 2058, 286, 2303, 7, 84, 193, 1, 251, 2, 706, 34, 91, 11, 1321, 195, 94, 32, 1197, 6, 412, 3, 176, 1, 577, 4, 150, 5, 127, 183, 2, 6, 1107, 3, 483, 1, 251, 6, 577]",1597.0,12200353,73
Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.,International journal of cancer,Int. J. Cancer,2002-08-01,"Dermatofibrosarcoma protuberans (DFSP) is a rare superficial sarcoma usually affecting the trunk, with significant risk of local recurrence. It is characterized by the presence of ring chromosomes or chromosomal translocations fusing the promoter of the collagen gene COL1A1 to the platelet-derived growth factor beta-chain gene PDGFB, increasing the production of PDGF locally and promoting autocrine or paracrine tumor growth. Fewer than 5% of patients with DFSP develop metastatic sarcoma, with a poor subsequent prognosis. Imatinib (STI-571) was developed as an inhibitor of the PDGF receptor tyrosine kinase and has proven clinical activity against chronic myelogenous leukemia (expressing bcr-abl) and gastrointestinal stromal tumors (expressing c-kit). We describe 2 patients with metastatic and unresectable metastases from DFSP treated with imatinib. After confirmation of negative CD117 status of 2 sarcomas arising from DFSP, patients were given imatinib 400 mg po qd and assessed at regular intervals for their tolerance and response to therapy. One patient had a transient response, then progressed rapidly and died of disease. Another patient showed a partial response to therapy after 2 months, with resolution of superior vena cava syndrome and shrinking of metastatic lung lesions. His response is ongoing after 6 months of therapy. These clinical data confirm findings from models of DFSP and support the use of imatinib in the rare setting of metastatic DFSP. Imatinib may be useful for patients with locally advanced DFSP, when other options for local therapy are limited.",Case Reports,6382.0,209.0,Dermatofibrosarcoma protuberans DFSP is a rare superficial usually affecting the trunk with significant risk of local recurrence It is characterized by the presence of ring chromosomes or chromosomal translocations fusing the promoter of the collagen gene COL1A1 to the platelet-derived growth factor beta-chain gene PDGFB increasing the production of PDGF locally and promoting autocrine or paracrine tumor growth Fewer than 5 of patients with DFSP develop metastatic with a poor subsequent prognosis Imatinib STI-571 was developed as an inhibitor of the PDGF receptor tyrosine kinase and has proven clinical activity against chronic myelogenous expressing bcr-abl and stromal tumors expressing c-kit We describe 2 patients with metastatic and unresectable metastases from DFSP treated with imatinib After confirmation of negative CD117 status of 2 sarcomas arising from DFSP patients were given imatinib 400 mg po qd and assessed at regular intervals for their tolerance and response to therapy One patient had a transient response then progressed rapidly and died of disease Another patient showed a partial response to therapy after 2 months with resolution of superior vena cava syndrome and shrinking of metastatic lesions His response is ongoing after 6 months of therapy These clinical data confirm findings from models of DFSP and support the use of imatinib in the rare setting of metastatic DFSP Imatinib may be useful for patients with locally advanced DFSP when other options for local therapy are limited,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,"[11922, 11923, 6796, 16, 8, 622, 3562, 2082, 2319, 3, 5895, 5, 93, 43, 1, 293, 146, 192, 16, 765, 20, 3, 463, 1, 4091, 3560, 15, 1860, 3262, 20181, 3, 973, 1, 3, 3945, 145, 15149, 6, 3, 1596, 526, 129, 161, 1090, 1260, 145, 10565, 602, 3, 1529, 1, 4546, 795, 2, 2388, 5297, 15, 6012, 30, 129, 1497, 76, 33, 1, 7, 5, 6796, 690, 113, 5, 8, 334, 706, 356, 577, 10640, 7846, 10, 276, 22, 35, 230, 1, 3, 4546, 153, 564, 216, 2, 71, 1930, 38, 128, 480, 442, 2194, 1046, 1062, 1425, 2, 1126, 57, 1046, 256, 1164, 21, 897, 18, 7, 5, 113, 2, 1468, 196, 29, 6796, 73, 5, 577, 50, 3551, 1, 199, 6999, 156, 1, 18, 1479, 2635, 29, 6796, 7, 11, 447, 577, 1524, 81, 4826, 5419, 2, 275, 28, 3316, 1582, 9, 136, 2614, 2, 51, 6, 36, 104, 69, 42, 8, 2473, 51, 818, 1839, 1755, 2, 1016, 1, 34, 1809, 69, 224, 8, 450, 51, 6, 36, 50, 18, 53, 5, 2125, 1, 1123, 6693, 7294, 681, 2, 19494, 1, 113, 406, 3224, 51, 16, 942, 50, 49, 53, 1, 36, 46, 38, 74, 1843, 272, 29, 274, 1, 6796, 2, 538, 3, 119, 1, 577, 4, 3, 622, 546, 1, 113, 6796, 577, 68, 40, 999, 9, 7, 5, 795, 131, 6796, 198, 127, 838, 9, 293, 36, 32, 383]",1518.0,12209598,89
Severe periorbital edema secondary to STI571 (Gleevec).,Cancer,Cancer,2002-08-01,"STI571 (imatinib mesylate; Gleevec) is a selective inhibitor of the bcr-abl, c-kit, and platelet-derived growth factor receptor tyrosine kinases. Mild periorbital edema has been noted as a common side effect in Phase I and II trials of this drug for the treatment of patients with chronic myelogenous leukemia and gastrointestinal stromal tumors. The authors report the case of male patient age 63 years who developed severe periorbital edema after treatment with STI571 for chronic myelogenous leukemia. His edema was severe enough to cause visual obstruction due to lower eyelid festoons that ultimately required surgical debulking. Histopathologic analysis of specimens of the excised upper and lower eyelid tissue revealed dermal dendrocytes that expressed the platelet-derived growth factor receptor and c-kit tyrosine kinases, suggesting a possible role for dermal dendrocytes in the development of this toxic effect.",Case Reports,6382.0,89.0,STI571 imatinib mesylate Gleevec is a selective inhibitor of the bcr-abl c-kit and platelet-derived growth factor receptor tyrosine kinases Mild periorbital edema has been noted as a common side effect in Phase I and II trials of this drug for the treatment of patients with chronic myelogenous and stromal tumors The authors report the case of male patient age 63 years who developed severe periorbital edema after treatment with STI571 for chronic myelogenous His edema was severe enough to cause visual obstruction due to lower eyelid festoons that ultimately required surgical debulking Histopathologic analysis of specimens of the excised upper and lower eyelid tissue revealed dermal dendrocytes that expressed the platelet-derived growth factor receptor and c-kit tyrosine kinases suggesting a possible role for dermal dendrocytes in the development of this toxic effect,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[5735, 577, 2347, 8569, 16, 8, 1094, 230, 1, 3, 1062, 1425, 256, 1164, 2, 1596, 526, 129, 161, 153, 564, 1549, 1980, 20216, 3306, 71, 85, 1051, 22, 8, 186, 1152, 254, 4, 124, 70, 2, 215, 143, 1, 26, 234, 9, 3, 24, 1, 7, 5, 442, 2194, 2, 1126, 57, 3, 738, 414, 3, 473, 1, 1045, 69, 89, 676, 60, 54, 276, 905, 20216, 3306, 50, 24, 5, 5735, 9, 442, 2194, 3224, 3306, 10, 905, 5151, 6, 708, 3046, 3191, 520, 6, 280, 12540, 53111, 17, 2050, 616, 221, 3556, 2630, 65, 1, 623, 1, 3, 5076, 1726, 2, 280, 12540, 246, 553, 6132, 43033, 17, 570, 3, 1596, 526, 129, 161, 153, 2, 256, 1164, 564, 1549, 802, 8, 899, 200, 9, 6132, 43033, 4, 3, 193, 1, 26, 1812, 254]",877.0,12209733,118
"CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells.",Cancer research,Cancer Res.,2002-10-01,"Donor lymphocyte infusion (DLI) reliably induces durable remission in 75-80% of patients with relapsed chronic myelogenous leukemia (CML) after allogeneic hematopoietic stem cell transplantation. To identify immunological targets of the graft-versus-leukemia response (GVL) after DLI, we used CML post-DLI responder sera to screen a CML cDNA expression library. One of the antigens identified in this screen is a M(r) 28,000 protein, termed CML28. CML28 is identical to hRrp46p, a component of the human exosome, a multiprotein complex involved in the 3' processing of RNA. Components of the human exosome include known autoantigens, such as PMScl-100, an autoantibody target in patients with polymyositis, scleroderma, or polymyositis-scleroderma overlap syndrome. Recombinant CML28-GST fusion protein was purified, and used in Western blot and ELISA to demonstrate the development of a high-titer CML28-specific IgG antibody response in a patient with relapsed CML who responded to DLI. Northern blotting demonstrated that CML28 is highly expressed in a variety of hematopoietic and epithelial tumor cell lines, but not in normal hematopoietic tissues or other normal tissue, with the exception of testis. Purified recombinant CML28 was used to generate a CML28-specific murine monoclonal antibody. Western blotting with CML28 monoclonal antibody against whole-cell lysates derived from blood and marrow of normal donors and patients with leukemia revealed high expression of this antigen in tumor but not in normal samples. Because CML28 was highly expressed in epithelial tumor cell lines, anti-CML28 responses were also examined in patients with solid tumors. By ELISA, we found specific serological responses in 10-33% of patients with lung cancer, melanoma, and prostate cancer. Our studies suggest that immunogenicity of CML28 is likely because of overexpression of this antigen in tumor cells. Moreover, given its expression and immunogenicity in a wide variety of malignancies, CML28 merits additional evaluation as a target for antigen-specific immunotherapy.",Journal Article,6321.0,66.0,"Donor lymphocyte infusion DLI reliably induces durable remission in 75-80 of patients with relapsed chronic myelogenous CML after allogeneic hematopoietic stem cell transplantation To identify immunological targets of the graft-versus-leukemia response GVL after DLI we used CML post-DLI responder sera to screen a CML cDNA expression library One of the antigens identified in this screen is a M r 28,000 protein termed CML28 CML28 is identical to hRrp46p a component of the human exosome a multiprotein complex involved in the 3 processing of RNA Components of the human exosome include known autoantigens such as PMScl-100 an autoantibody target in patients with polymyositis scleroderma or polymyositis-scleroderma overlap syndrome Recombinant CML28-GST fusion protein was purified and used in Western blot and ELISA to demonstrate the development of a high-titer CML28-specific IgG antibody response in a patient with relapsed CML who responded to DLI Northern blotting demonstrated that CML28 is highly expressed in a variety of hematopoietic and epithelial tumor cell lines but not in normal hematopoietic tissues or other normal tissue with the exception of Purified recombinant CML28 was used to generate a CML28-specific murine monoclonal antibody Western blotting with CML28 monoclonal antibody against whole-cell lysates derived from blood and marrow of normal donors and patients with revealed high expression of this antigen in tumor but not in normal samples Because CML28 was highly expressed in epithelial tumor cell lines anti-CML28 responses were also examined in patients with solid tumors By ELISA we found specific serological responses in 10-33 of patients with cancer and cancer Our studies suggest that immunogenicity of CML28 is likely because of overexpression of this antigen in tumor cells Moreover given its expression and immunogenicity in a wide variety of malignancies CML28 merits additional evaluation as a target for antigen-specific immunotherapy",0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1488, 1448, 904, 4676, 4092, 1516, 1480, 734, 4, 481, 493, 1, 7, 5, 591, 442, 2194, 903, 50, 1063, 1007, 452, 31, 497, 6, 255, 5073, 637, 1, 3, 1599, 185, 2647, 51, 8149, 50, 4676, 21, 95, 903, 539, 4676, 8735, 4210, 6, 2413, 8, 903, 4212, 55, 4157, 104, 1, 3, 1575, 108, 4, 26, 2413, 16, 8, 188, 668, 339, 984, 178, 4183, 16257, 16257, 16, 3038, 6, 53143, 8, 1249, 1, 3, 171, 11771, 8, 30318, 840, 646, 4, 3, 27, 3325, 1, 893, 1628, 1, 3, 171, 11771, 643, 440, 20227, 225, 22, 53144, 394, 35, 10969, 283, 4, 7, 5, 26038, 11590, 15, 26038, 11590, 4526, 681, 2835, 16257, 5645, 1212, 178, 10, 5963, 2, 95, 4, 1521, 2639, 2, 3664, 6, 608, 3, 193, 1, 8, 64, 8444, 16257, 112, 3630, 548, 51, 4, 8, 69, 5, 591, 903, 54, 2211, 6, 4676, 7088, 3661, 264, 17, 16257, 16, 561, 570, 4, 8, 1362, 1, 1007, 2, 701, 30, 31, 285, 84, 44, 4, 295, 1007, 742, 15, 127, 295, 246, 5, 3, 4188, 1, 5963, 2835, 16257, 10, 95, 6, 2562, 8, 16257, 112, 1471, 848, 548, 1521, 3661, 5, 16257, 848, 548, 480, 902, 31, 8674, 526, 29, 315, 2, 581, 1, 295, 2344, 2, 7, 5, 553, 64, 55, 1, 26, 448, 4, 30, 84, 44, 4, 295, 347, 408, 16257, 10, 561, 570, 4, 701, 30, 31, 285, 312, 16257, 253, 11, 120, 409, 4, 7, 5, 537, 57, 20, 3664, 21, 204, 112, 14132, 253, 4, 79, 466, 1, 7, 5, 12, 2, 12, 114, 94, 309, 17, 4050, 1, 16257, 16, 322, 408, 1, 851, 1, 26, 448, 4, 30, 37, 1393, 447, 211, 55, 2, 4050, 4, 8, 1019, 1362, 1, 441, 16257, 4986, 402, 451, 22, 8, 283, 9, 448, 112, 726]",1982.0,12359762,234
"Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.",Cancer,Cancer,2002-10-01,"Up to 5% of patients with chronic myelogenous leukemia (CML) do not have the Philadelphia (Ph) translocation t(9;22)(q34;q11) or a bcr/abl molecular rearrangement. Although the diagnostic criteria of this entity are still under debate, there is general agreement that patients with Ph negative, bcr/abl negative CML have a severe clinical course that is not affected significantly by current treatment options. A population of 76 patients with bcr/abl negative CML who had received minimal or no previous therapy was characterized carefully with the intent of investigating clinical and hematologic variables and their association with survival by univariate, correlation, and multivariate analyses. A group of 73 patients with Ph negative CML who were not tested for the bcr/abl rearrangement (bcr/abl unknown) was analyzed separately and used for extension of the analysis. In the bcr/abl negative patient population, the median overall survival was 24 months. At the time of the analysis, 38 patients (50%) had died, and blastic transformation preceded death in 31%. Chromosomal abnormalities were found in 30% of the 76 patients, with trisomy 8 the most common abnormality. Complex chromosomal abnormalities were rare, and monosomy 7 was not observed. Survival was not affected significantly by treatment. Multivariate analysis identified older age (> 65 years), anemia (hemoglobin < 10 g/dL), and severe leukocytosis (white blood cells > 50 x 10(9)/L) as variables with independent prognostic significance for poor survival. A prognostic scoring system stratified patients into a low-risk group (53%) and a high-risk group (47%), with median survivals of 38 months and 9 months, respectively. Bcr/abl negative CML is a distinct clinical entity associated with very poor prognosis. Two risk categories are identifiable using a simple scoring system based on age, hemoglobin level, and leukocyte number.",Journal Article,6321.0,47.0,Up to 5 of patients with chronic myelogenous CML do not have the Philadelphia Ph translocation t 9 22 q34 q11 or a bcr/abl molecular rearrangement Although the diagnostic criteria of this entity are still under debate there is general agreement that patients with Ph negative bcr/abl negative CML have a severe clinical course that is not affected significantly by current treatment options A population of 76 patients with bcr/abl negative CML who had received minimal or no previous therapy was characterized carefully with the intent of investigating clinical and hematologic variables and their association with survival by univariate correlation and multivariate analyses A group of 73 patients with Ph negative CML who were not tested for the bcr/abl rearrangement bcr/abl unknown was analyzed separately and used for extension of the analysis In the bcr/abl negative patient population the median overall survival was 24 months At the time of the analysis 38 patients 50 had died and blastic transformation preceded death in 31 Chromosomal abnormalities were found in 30 of the 76 patients with trisomy 8 the most common abnormality Complex chromosomal abnormalities were rare and monosomy 7 was not observed Survival was not affected significantly by treatment Multivariate analysis identified older age 65 years anemia hemoglobin 10 g/dL and severe leukocytosis white blood cells 50 x 10 9 /L as variables with independent prognostic significance for poor survival A prognostic scoring system stratified patients into a low-risk group 53 and a high-risk group 47 with median survivals of 38 months and 9 months respectively Bcr/abl negative CML is a distinct clinical entity associated with very poor prognosis Two risk categories are identifiable using a simple scoring system based on age hemoglobin level and leukocyte number,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[126, 6, 33, 1, 7, 5, 442, 2194, 903, 1022, 44, 47, 3, 3006, 2058, 2006, 102, 83, 350, 16609, 11532, 15, 8, 1062, 1425, 219, 2675, 242, 3, 752, 371, 1, 26, 2983, 32, 1234, 669, 5220, 125, 16, 1083, 2024, 17, 7, 5, 2058, 199, 1062, 1425, 199, 903, 47, 8, 905, 38, 906, 17, 16, 44, 1424, 97, 20, 291, 24, 838, 8, 266, 1, 846, 7, 5, 1062, 1425, 199, 903, 54, 42, 103, 1048, 15, 77, 698, 36, 10, 765, 3900, 5, 3, 1697, 1, 3103, 38, 2, 813, 682, 2, 136, 248, 5, 25, 20, 880, 816, 2, 331, 318, 8, 87, 1, 803, 7, 5, 2058, 199, 903, 54, 11, 44, 650, 9, 3, 1062, 1425, 2675, 1062, 1425, 860, 10, 311, 3582, 2, 95, 9, 2401, 1, 3, 65, 4, 3, 1062, 1425, 199, 69, 266, 3, 52, 63, 25, 10, 259, 53, 28, 3, 98, 1, 3, 65, 519, 7, 212, 42, 1016, 2, 6529, 1392, 6083, 273, 4, 456, 1860, 1171, 11, 204, 4, 201, 1, 3, 846, 7, 5, 6317, 66, 3, 96, 186, 3698, 840, 1860, 1171, 11, 622, 2, 7521, 67, 10, 44, 164, 25, 10, 44, 1424, 97, 20, 24, 331, 65, 108, 434, 89, 556, 60, 1545, 2222, 79, 499, 1826, 2, 905, 7463, 886, 315, 37, 212, 1006, 79, 83, 805, 22, 682, 5, 306, 177, 724, 9, 334, 25, 8, 177, 2504, 398, 1173, 7, 237, 8, 154, 43, 87, 699, 2, 8, 64, 43, 87, 662, 5, 52, 3794, 1, 519, 53, 2, 83, 53, 106, 1062, 1425, 199, 903, 16, 8, 834, 38, 2983, 41, 5, 923, 334, 356, 100, 43, 1996, 32, 6237, 75, 8, 2763, 2504, 398, 90, 23, 89, 2222, 301, 2, 3627, 207]",1837.0,12365015,31
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2002-01-01,"Complete bioavailability of i.v. busulfan (Bu) provides dose assurance by reducing the interdose and interpatient variability in Bu systemic exposure (Bu-SE) associated with the oral formulation. We hypothesized that Bu-SE, represented by the area under the plasma concentration versus time curve (AUC), would correlate with treatment outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myelogenous leukemia (CML). Therefore, we analyzed the risk of death, incidence of regimen-related toxicity, and incidence of acute GVHD (aGVHD) as functions of the per dose i.v. Bu AUC in 36 CML patients who received a HSCT from an HLA-matched family donor after the i.v. BuCy2 regimen. Per-dose Bu AUCs were calculated for each subject using data obtained for doses 1, 5, 9, and 13. Toxicity was evaluated using the modified National Cancer Institute criteria. Because no patient developed veno-occlusive disease, increased serum bilirubin was used to characterize hepatotoxicity. We found that the probabilities of developing gastrointestinal toxicity (P = .01), hepatotoxicity (P < .01), mucositis (P = .09), and aGVHD (P < .01) all increased with increasing AUC. Further, the risk of death was significantly lower for patients having a per-dose AUC between approximately 950 and 1520 microMol-min, whereas the risk increased sharply with either lower or higher AUC values. These data suggest that an optimal Bu therapeutic window, based on per-dose AUC, exists. Given the ability of i.v. Bu to provide a more consistent per-dose AUC, these results should be useful in designing future i.v.V Bu-based treatment protocols for stem cell transplantation.",Clinical Trial,6594.0,164.0,Complete bioavailability of i.v busulfan Bu provides dose assurance by reducing the interdose and interpatient variability in Bu systemic exposure Bu-SE associated with the oral formulation We hypothesized that Bu-SE represented by the area under the plasma concentration versus time curve AUC would correlate with treatment outcome after allogeneic hematopoietic stem cell transplantation HSCT for chronic myelogenous CML Therefore we analyzed the risk of death incidence of regimen-related toxicity and incidence of acute GVHD aGVHD as functions of the per dose i.v Bu AUC in 36 CML patients who received a HSCT from an HLA-matched family donor after the i.v BuCy2 regimen Per-dose Bu AUCs were calculated for each subject using data obtained for doses 1 5 9 and 13 Toxicity was evaluated using the modified National Cancer Institute criteria Because no patient developed veno-occlusive disease increased serum bilirubin was used to characterize hepatotoxicity We found that the probabilities of developing toxicity P .01 hepatotoxicity P .01 mucositis P .09 and aGVHD P .01 all increased with increasing AUC Further the risk of death was significantly lower for patients having a per-dose AUC between approximately 950 and 1520 microMol-min whereas the risk increased sharply with either lower or higher AUC values These data suggest that an optimal Bu therapeutic window based on per-dose AUC exists Given the ability of i.v Bu to provide a more consistent per-dose AUC these results should be useful in designing future i.v.V Bu-based treatment protocols for stem cell transplantation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[236, 5499, 1, 70, 603, 3906, 3667, 777, 61, 8050, 20, 1818, 3, 37284, 2, 7423, 1982, 4, 3667, 403, 645, 3667, 3428, 41, 5, 3, 518, 3583, 21, 1237, 17, 3667, 3428, 3324, 20, 3, 965, 669, 3, 554, 1227, 185, 98, 1496, 1376, 688, 1513, 5, 24, 228, 50, 1063, 1007, 452, 31, 497, 1703, 9, 442, 2194, 903, 673, 21, 311, 3, 43, 1, 273, 287, 1, 477, 139, 155, 2, 287, 1, 286, 1562, 5873, 22, 1681, 1, 3, 379, 61, 70, 603, 3667, 1376, 4, 511, 903, 7, 54, 103, 8, 1703, 29, 35, 1160, 655, 607, 1488, 50, 3, 70, 603, 27967, 477, 379, 61, 3667, 8084, 11, 981, 9, 296, 2974, 75, 74, 683, 9, 415, 14, 33, 83, 2, 233, 155, 10, 194, 75, 3, 1230, 657, 12, 1377, 371, 408, 77, 69, 276, 10273, 8376, 34, 101, 524, 5009, 10, 95, 6, 1507, 6667, 21, 204, 17, 3, 3518, 1, 931, 155, 19, 355, 6667, 19, 355, 2606, 19, 1730, 2, 5873, 19, 355, 62, 101, 5, 602, 1376, 195, 3, 43, 1, 273, 10, 97, 280, 9, 7, 1041, 8, 379, 61, 1376, 59, 705, 14109, 2, 37285, 6297, 1538, 547, 3, 43, 101, 10833, 5, 361, 280, 15, 142, 1376, 1030, 46, 74, 309, 17, 35, 665, 3667, 189, 5421, 90, 23, 379, 61, 1376, 2481, 447, 3, 801, 1, 70, 603, 3667, 6, 377, 8, 80, 925, 379, 61, 1376, 46, 99, 257, 40, 999, 4, 5048, 508, 70, 603, 603, 3667, 90, 24, 2189, 9, 452, 31, 497]",1589.0,12374452,16
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.,Blood,Blood,2002-09-12,"We investigated whether increasing the dose of imatinib mesylate might overcome drug resistance in patients with Philadelphia chromosome-positive (Ph(+)) chronic myelogenous leukemia (CML) whose disease manifests relapse or refractoriness to therapy. Fifty-four patients with Ph(+) CML in chronic phase and with hematologic or cytogenetic resistance or relapse on imatinib mesylate therapy at 400 mg orally daily were treated with a higher dose of 400 mg orally twice daily (800 mg daily, 47 patients; or 600 mg daily increased from 300 mg daily, 7 patients). Among 20 patients treated for hematologic resistance or relapse, 13 (65%) achieved a complete (n = 9) or partial (n = 4) hematologic response, but only 1 had a cytogenetic partial response (Ph reduction from 100% to 10%) and 1 had a minor response (Ph reduction from 100% to 50%). Among 34 patients treated for cytogenetic resistance or relapse, 19 (56%) achieved a complete (n = 6) or partial (n = 7) cytogenetic response. We conclude that higher doses of imatinib mesylate may overcome disease-poor response to conventional doses and that this approach deserves further evaluation as frontline therapy for newly diagnosed CML.",Clinical Trial,6340.0,260.0,We investigated whether increasing the dose of imatinib mesylate might overcome drug resistance in patients with Philadelphia chromosome-positive Ph chronic myelogenous CML whose disease manifests relapse or refractoriness to therapy Fifty-four patients with Ph CML in chronic phase and with hematologic or cytogenetic resistance or relapse on imatinib mesylate therapy at 400 mg orally daily were treated with a higher dose of 400 mg orally twice daily 800 mg daily 47 patients or 600 mg daily increased from 300 mg daily 7 patients Among 20 patients treated for hematologic resistance or relapse 13 65 achieved a complete n 9 or partial n 4 hematologic response but only 1 had a cytogenetic partial response Ph reduction from 100 to 10 and 1 had a minor response Ph reduction from 100 to 50 Among 34 patients treated for cytogenetic resistance or relapse 19 56 achieved a complete n 6 or partial n 7 cytogenetic response We conclude that higher doses of imatinib mesylate may overcome disease-poor response to conventional doses and that this approach deserves further evaluation as frontline therapy for newly diagnosed CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 565, 317, 602, 3, 61, 1, 577, 2347, 822, 1768, 234, 251, 4, 7, 5, 3006, 1170, 109, 2058, 442, 2194, 903, 1310, 34, 15096, 429, 15, 12483, 6, 36, 1461, 294, 7, 5, 2058, 903, 4, 442, 124, 2, 5, 813, 15, 1266, 251, 15, 429, 23, 577, 2347, 36, 28, 1524, 81, 1428, 391, 11, 73, 5, 8, 142, 61, 1, 1524, 81, 1428, 936, 391, 2796, 81, 391, 662, 7, 15, 2383, 81, 391, 101, 29, 2036, 81, 391, 67, 7, 107, 179, 7, 73, 9, 813, 251, 15, 429, 233, 556, 513, 8, 236, 78, 83, 15, 450, 78, 39, 813, 51, 84, 158, 14, 42, 8, 1266, 450, 51, 2058, 628, 29, 394, 6, 79, 2, 14, 42, 8, 2278, 51, 2058, 628, 29, 394, 6, 212, 107, 562, 7, 73, 9, 1266, 251, 15, 429, 326, 664, 513, 8, 236, 78, 49, 15, 450, 78, 67, 1266, 51, 21, 2060, 17, 142, 415, 1, 577, 2347, 68, 1768, 34, 334, 51, 6, 809, 415, 2, 17, 26, 353, 8572, 195, 451, 22, 3171, 36, 9, 732, 265, 903]",1126.0,12393385,35
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.,Blood,Blood,2002-08-29,"Fifty patients with Philadelphia chromosome-positive (Ph(+)) chronic myelogenous leukemia (CML) in early chronic phase received imatinib mesylate, 400 mg orally daily. After a median follow-up of 9 months, 49 patients (98%) achieved a complete hematologic response and 45 patients (90%) achieved a major cytogenetic response, complete in 36 patients (72%). Compared with similar patients who received interferon-alpha with or without hydroxyurea or other interferon-alpha combination regimens, those receiving imatinib mesylate had higher incidences of complete and major (Ph < 35%) cytogenetic responses at 3 months (34% and 74% versus 1%-4% and 9%-24%, respectively), 6 months (52% and 80% versus 3%-7% and 11%-28%, respectively), and 9 months (60% and 77% versus 5%-11% and 14%-30%, respectively; P <.001). Competitive quantitative polymerase chain reaction (QPCR) studies at 9 months showed a median QPCR value (ratio of BCR-ABL/ABL transcripts x 100) of 0.59% overall and of 0.24% (range, 0.001%-29.5%) for complete cytogenetic response.",Clinical Trial,6354.0,135.0,Fifty patients with Philadelphia chromosome-positive Ph chronic myelogenous CML in early chronic phase received imatinib mesylate 400 mg orally daily After a median follow-up of 9 months 49 patients 98 achieved a complete hematologic response and 45 patients 90 achieved a major cytogenetic response complete in 36 patients 72 Compared with similar patients who received interferon-alpha with or without hydroxyurea or other interferon-alpha combination regimens those receiving imatinib mesylate had higher incidences of complete and major Ph 35 cytogenetic responses at 3 months 34 and 74 versus 1 -4 and 9 -24 respectively 6 months 52 and 80 versus 3 -7 and 11 -28 respectively and 9 months 60 and 77 versus 5 -11 and 14 -30 respectively P .001 Competitive quantitative polymerase chain reaction QPCR studies at 9 months showed a median QPCR value ratio of BCR-ABL/ABL transcripts x 100 of 0.59 overall and of 0.24 range 0.001 -29.5 for complete cytogenetic response,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1461, 7, 5, 3006, 1170, 109, 2058, 442, 2194, 903, 4, 191, 442, 124, 103, 577, 2347, 1524, 81, 1428, 391, 50, 8, 52, 166, 126, 1, 83, 53, 739, 7, 1096, 513, 8, 236, 813, 51, 2, 512, 7, 424, 513, 8, 458, 1266, 51, 236, 4, 511, 7, 720, 72, 5, 288, 7, 54, 103, 1688, 950, 5, 15, 187, 5902, 15, 127, 1688, 950, 150, 472, 135, 357, 577, 2347, 42, 142, 3981, 1, 236, 2, 458, 2058, 465, 1266, 253, 28, 27, 53, 562, 2, 794, 185, 14, 39, 2, 83, 259, 106, 49, 53, 653, 2, 493, 185, 27, 67, 2, 175, 339, 106, 2, 83, 53, 335, 2, 849, 185, 33, 175, 2, 213, 201, 106, 19, 144, 6487, 1156, 1451, 1260, 1329, 6162, 94, 28, 83, 53, 224, 8, 52, 6162, 549, 197, 1, 1062, 1425, 1425, 2680, 1006, 394, 1, 13, 728, 63, 2, 1, 13, 259, 184, 13, 144, 462, 33, 9, 236, 1266, 51]",969.0,12393600,261
Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia.,American journal of hematology,Am. J. Hematol.,2002-11-01,"We studied 28 patients with accelerated phase chronic myelogenous leukemia (CML) who were enrolled on the Novartis expanded access study 114. Diagnosis of accelerated phase CML was based on karyotypic evolution (n = 9) and hematologic criteria (n = 18). All patients were begun on 600 mg/day of imatinib mesylate. Dose reductions to 400 mg/day and then 300 mg/day were prescribed for an absolute neutrophil count (ANC) of <0.5/microl or a platelet count of <20,000/microl. Twenty-seven of the 28 patients continued treatment for a median of 34 weeks. Eleven patients developed thrombocytopenia following an average of 8.4 +/- 1.4 weeks of therapy. The onset of thrombocytopenia was associated with disease progression in one patient and a decline in bone marrow megakaryocytes in the other 10. Nine patients recovered to a platelet count of >20,000/microl after an average of 19.7 +/- 1.8 weeks. Patients who developed thrombocytopenia had a longer duration of disease (9.39 vs. 4.35 years; P < 0.01) and were more likely to be diagnosed with accelerated phase CML by hematologic criteria. Hematologic responses in patients with and without thrombocytopenia were comparable; however, 31.3% of patients without thrombocytopenia had a complete cytogenetic response compared to none of those with thrombocytopenia. Grade III-IV thrombocytopenia is common in accelerated phase CML and may be a marker for the inability to achieve cytogenetic response using single agent imatinib mesylate.",Clinical Trial,6290.0,8.0,"We studied 28 patients with accelerated phase chronic myelogenous CML who were enrolled on the Novartis expanded access study 114 Diagnosis of accelerated phase CML was based on karyotypic evolution n 9 and hematologic criteria n 18 All patients were begun on 600 mg/day of imatinib mesylate Dose reductions to 400 mg/day and then 300 mg/day were prescribed for an absolute neutrophil count ANC of 0.5/microl or a platelet count of 20,000/microl Twenty-seven of the 28 patients continued treatment for a median of 34 weeks Eleven patients developed thrombocytopenia following an average of 8.4 +/- 1.4 weeks of therapy The onset of thrombocytopenia was associated with disease progression in one patient and a decline in marrow megakaryocytes in the other 10 Nine patients recovered to a platelet count of 20,000/microl after an average of 19.7 +/- 1.8 weeks Patients who developed thrombocytopenia had a longer duration of disease 9.39 vs. 4.35 years P 0.01 and were more likely to be diagnosed with accelerated phase CML by hematologic criteria Hematologic responses in patients with and without thrombocytopenia were comparable however 31.3 of patients without thrombocytopenia had a complete cytogenetic response compared to none of those with thrombocytopenia Grade III-IV thrombocytopenia is common in accelerated phase CML and may be a marker for the inability to achieve cytogenetic response using single agent imatinib mesylate",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 656, 339, 7, 5, 2241, 124, 442, 2194, 903, 54, 11, 346, 23, 3, 7855, 2064, 1655, 45, 3803, 147, 1, 2241, 124, 903, 10, 90, 23, 9465, 2554, 78, 83, 2, 813, 371, 78, 203, 62, 7, 11, 6973, 23, 2383, 81, 218, 1, 577, 2347, 61, 2153, 6, 1524, 81, 218, 2, 818, 2036, 81, 218, 11, 2746, 9, 35, 1766, 2595, 1276, 6486, 1, 13, 33, 5128, 15, 8, 1596, 1276, 1, 179, 984, 5128, 737, 648, 1, 3, 339, 7, 1351, 24, 9, 8, 52, 1, 562, 244, 2627, 7, 276, 1340, 366, 35, 1011, 1, 66, 39, 14, 39, 244, 1, 36, 3, 1707, 1, 1340, 10, 41, 5, 34, 91, 4, 104, 69, 2, 8, 1858, 4, 581, 15110, 4, 3, 127, 79, 762, 7, 5784, 6, 8, 1596, 1276, 1, 179, 984, 5128, 50, 35, 1011, 1, 326, 67, 14, 66, 244, 7, 54, 276, 1340, 42, 8, 589, 654, 1, 34, 83, 587, 105, 39, 465, 60, 19, 13, 355, 2, 11, 80, 322, 6, 40, 265, 5, 2241, 124, 903, 20, 813, 371, 813, 253, 4, 7, 5, 2, 187, 1340, 11, 1279, 137, 456, 27, 1, 7, 187, 1340, 42, 8, 236, 1266, 51, 72, 6, 1292, 1, 135, 5, 1340, 88, 316, 478, 1340, 16, 186, 4, 2241, 124, 903, 2, 68, 40, 8, 952, 9, 3, 4985, 6, 1359, 1266, 51, 75, 226, 420, 577, 2347]",1436.0,12410573,104
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.,Blood,Blood,2002-10-31,"We investigated the clinical activity of the farnesyl transferase inhibitor R115777 in 22 patients with chronic myelogenous leukemia (CML) in chronic, accelerated, or blastic phase and in 8 patients with myelofibrosis (MF) and 10 patients with multiple myeloma (MM). R115777 was administered at 600 mg orally twice daily for 4 weeks every 6 weeks. Seven patients with CML (6 in chronic phase, 1 in advanced phase) achieved complete or partial hematologic response. Four of them had a minor cytogenetic response. Responses were transient, with a median duration of 9 weeks (range, 3-23 weeks). Two patients discontinued therapy because of toxicity while in complete hematologic response. Two MF patients had a significant decrease in splenomegaly, one had normalization of white blood cell count and differential, and one became transfusion independent. One patient with MM had a reduction in monoclonal protein of 34%. Adverse events included nausea in 22 patients (55%; all grade 2 or lower) and fatigue in 19 (48%; grade 3 or higher in 1). Other grade 3 or 4 toxicities included skin rash (4 patients, 10%), peripheral neuropathy (2 patients, 5%), and liver toxicity (2 patients, 5%). Patients who responded to therapy had significantly higher plasma vascular endothelial growth factor (VEGF) concentrations prior to treatment than nonresponders. Plasma concentrations decreased significantly during therapy among responders. R115777 showed clinical activity in patients with CML and MF. The effect on VEGF needs to be further investigated to determine whether this might be a possible mechanism of action of R115777.",Clinical Trial,6291.0,203.0,We investigated the clinical activity of the farnesyl transferase inhibitor R115777 in 22 patients with chronic myelogenous CML in chronic accelerated or blastic phase and in 8 patients with myelofibrosis MF and 10 patients with multiple MM R115777 was administered at 600 mg orally twice daily for 4 weeks every 6 weeks Seven patients with CML 6 in chronic phase 1 in advanced phase achieved complete or partial hematologic response Four of them had a minor cytogenetic response Responses were transient with a median duration of 9 weeks range 3-23 weeks Two patients discontinued therapy because of toxicity while in complete hematologic response Two MF patients had a significant decrease in splenomegaly one had normalization of white blood cell count and differential and one became transfusion independent One patient with MM had a reduction in monoclonal protein of 34 Adverse events included nausea in 22 patients 55 all grade 2 or lower and fatigue in 19 48 grade 3 or higher in 1 Other grade 3 or 4 toxicities included rash 4 patients 10 peripheral neuropathy 2 patients 5 and toxicity 2 patients 5 Patients who responded to therapy had significantly higher plasma vascular endothelial growth factor VEGF concentrations prior to treatment than nonresponders Plasma concentrations decreased significantly during therapy among responders R115777 showed clinical activity in patients with CML and MF The effect on VEGF needs to be further investigated to determine whether this might be a possible mechanism of action of R115777,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,"[21, 565, 3, 38, 128, 1, 3, 8846, 4402, 230, 9645, 4, 350, 7, 5, 442, 2194, 903, 4, 442, 2241, 15, 6529, 124, 2, 4, 66, 7, 5, 4637, 2966, 2, 79, 7, 5, 232, 321, 9645, 10, 468, 28, 2383, 81, 1428, 936, 391, 9, 39, 244, 454, 49, 244, 648, 7, 5, 903, 49, 4, 442, 124, 14, 4, 131, 124, 513, 236, 15, 450, 813, 51, 294, 1, 1370, 42, 8, 2278, 1266, 51, 253, 11, 2473, 5, 8, 52, 654, 1, 83, 244, 184, 27, 382, 244, 100, 7, 2402, 36, 408, 1, 155, 369, 4, 236, 813, 51, 100, 2966, 7, 42, 8, 93, 775, 4, 6364, 104, 42, 5924, 1, 886, 315, 31, 1276, 2, 1777, 2, 104, 3451, 2785, 306, 104, 69, 5, 321, 42, 8, 628, 4, 848, 178, 1, 562, 290, 281, 159, 1218, 4, 350, 7, 614, 62, 88, 18, 15, 280, 2, 613, 4, 326, 576, 88, 27, 15, 142, 4, 14, 127, 88, 27, 15, 39, 385, 159, 1641, 39, 7, 79, 672, 1751, 18, 7, 33, 2, 155, 18, 7, 33, 7, 54, 2211, 6, 36, 42, 97, 142, 554, 756, 845, 129, 161, 618, 1003, 324, 6, 24, 76, 4498, 554, 1003, 340, 97, 190, 36, 107, 1983, 9645, 224, 38, 128, 4, 7, 5, 903, 2, 2966, 3, 254, 23, 618, 1891, 6, 40, 195, 565, 6, 223, 317, 26, 822, 40, 8, 899, 670, 1, 1578, 1, 9645]",1535.0,12411300,118
Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).,"European journal of cancer (Oxford, England : 1990)",Eur. J. Cancer,2002-09-01,"Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. The concept of GIST and the definition of GIST pathology have evolved greatly over the past 5 years. GIST has been shown to share immunohistochemical, ultrastructural and histogenic similarities with the interstitial cells of Cajal. Both GIST and the interstitial cells of Cajal express KIT, the receptor tyrosine kinase that is the protein product of the c-kit proto-oncogene. KIT is universally phosphorylated in GISTs. Sequencing of c-kit complementary DNA from human GIST cells has demonstrated a high frequency of mutations that lead to constitutive activation of the KIT tyrosine kinase in the absence of stimulation by its physiologic ligand (stem cell factor). This, in turn, causes uncontrolled stimulation of downstream signaling cascades with aberrant cellular proliferation and resistance to apoptosis. Historically, malignant GIST has been highly refractory to conventional cytotoxic therapy. Signal transduction inhibition as cancer therapy was first tested successfully with imatinib mesylate (formerly known as STI571), a selective small-molecule tyrosine kinase inhibitor, with the initial target being blockade of Bcr-Abl, the oncogene with tyrosine kinase activity responsible for the pathogenesis of chronic myelogenous leukemia (CML). Imatinib was subsequently shown to block activity of the KIT tyrosine kinase as well, and in laboratory studies this led to apoptotic death of GIST cells. The first GIST patient to receive imatinib exhibited dramatic benefit despite far-advanced metastatic disease that was previously refractory to all chemotherapy. Subsequently, multicenter clinical trials have been performed to assess the safety, efficacy and biologic activity of imatinib in patients with advanced GIST. The results from these studies have established imatinib as an effective new therapeutic alternative for the majority of patients with advanced GIST, a solid tumor for which no prior chemotherapy has ever shown antitumor efficacy. This work provides proof of concept to the hypothesis that selective inhibition of aberrant signal transduction can provide important anticancer activity, if the proper signaling pathways are identified and blocked.",Journal Article,6351.0,111.0,stromal tumors GISTs are the most common mesenchymal neoplasms of the tract The concept of GIST and the definition of GIST pathology have evolved greatly over the past 5 years GIST has been shown to share immunohistochemical ultrastructural and histogenic similarities with the interstitial cells of Cajal Both GIST and the interstitial cells of Cajal express KIT the receptor tyrosine kinase that is the protein product of the c-kit proto-oncogene KIT is universally phosphorylated in GISTs Sequencing of c-kit complementary DNA from human GIST cells has demonstrated a high frequency of mutations that lead to constitutive activation of the KIT tyrosine kinase in the absence of stimulation by its physiologic ligand stem cell factor This in turn causes uncontrolled stimulation of downstream signaling cascades with aberrant cellular proliferation and resistance to apoptosis Historically malignant GIST has been highly refractory to conventional cytotoxic therapy Signal transduction inhibition as cancer therapy was first tested successfully with imatinib mesylate formerly known as STI571 a selective small-molecule tyrosine kinase inhibitor with the initial target being blockade of Bcr-Abl the oncogene with tyrosine kinase activity responsible for the pathogenesis of chronic myelogenous CML Imatinib was subsequently shown to block activity of the KIT tyrosine kinase as well and in laboratory studies this led to apoptotic death of GIST cells The first GIST patient to receive imatinib exhibited dramatic benefit despite far-advanced metastatic disease that was previously refractory to all chemotherapy Subsequently multicenter clinical trials have been performed to assess the safety efficacy and biologic activity of imatinib in patients with advanced GIST The results from these studies have established imatinib as an effective new therapeutic alternative for the majority of patients with advanced GIST a solid tumor for which no prior chemotherapy has ever shown antitumor efficacy This work provides proof of concept to the hypothesis that selective inhibition of aberrant signal transduction can provide important anticancer activity if the proper signaling pathways are identified and blocked,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[1126, 57, 2508, 32, 3, 96, 186, 1569, 1179, 1, 3, 1696, 3, 2545, 1, 1394, 2, 3, 2470, 1, 1394, 1117, 47, 3937, 3510, 252, 3, 1219, 33, 60, 1394, 71, 85, 443, 6, 4349, 1382, 13755, 2, 53327, 6089, 5, 3, 4543, 37, 1, 18848, 110, 1394, 2, 3, 4543, 37, 1, 18848, 1669, 1164, 3, 153, 564, 216, 17, 16, 3, 178, 2821, 1, 3, 256, 1164, 4976, 1836, 1164, 16, 6813, 2365, 4, 2508, 615, 1, 256, 1164, 3380, 261, 29, 171, 1394, 37, 71, 264, 8, 64, 675, 1, 138, 17, 1122, 6, 3178, 363, 1, 3, 1164, 564, 216, 4, 3, 1127, 1, 2503, 20, 211, 4628, 1232, 452, 31, 161, 26, 4, 3854, 1626, 6180, 2503, 1, 1489, 314, 8036, 5, 1898, 763, 457, 2, 251, 6, 351, 3578, 393, 1394, 71, 85, 561, 430, 6, 809, 759, 36, 1235, 2761, 297, 22, 12, 36, 10, 157, 650, 1878, 5, 577, 2347, 7350, 440, 22, 5735, 8, 1094, 302, 1354, 564, 216, 230, 5, 3, 388, 283, 486, 1189, 1, 1062, 1425, 3, 1836, 5, 564, 216, 128, 2327, 9, 3, 1384, 1, 442, 2194, 903, 577, 10, 1611, 443, 6, 2381, 128, 1, 3, 1164, 564, 216, 22, 149, 2, 4, 1624, 94, 26, 836, 6, 1631, 273, 1, 1394, 37, 3, 157, 1394, 69, 6, 560, 577, 1416, 3079, 247, 550, 3272, 131, 113, 34, 17, 10, 373, 430, 6, 62, 56, 1611, 1570, 38, 143, 47, 85, 173, 6, 423, 3, 367, 209, 2, 1283, 128, 1, 577, 4, 7, 5, 131, 1394, 3, 99, 29, 46, 94, 47, 635, 577, 22, 35, 323, 217, 189, 1091, 9, 3, 686, 1, 7, 5, 131, 1394, 8, 537, 30, 9, 92, 77, 324, 56, 71, 3353, 443, 579, 209, 26, 1357, 777, 3840, 1, 2545, 6, 3, 1492, 17, 1094, 297, 1, 1898, 1235, 2761, 122, 377, 305, 1475, 128, 492, 3, 4576, 314, 460, 32, 108, 2, 2582]",2213.0,12528773,193
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.,Blood,Blood,2003-01-30,"Cytogenetic clonal evolution (CE) is a known poor prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia (Ph-positive CML). However, its prognostic relevance in the era of imatinib therapy is unknown. We investigated the independent prognostic relevance of CE in 498 patients with Ph-positive CML treated with imatinib for chronic or accelerated phases. One hundred twenty-one patients had CE alone (n = 70) or with other accelerated phase criteria (n = 51). Patients were compared in 4 categories: chronic phase (n = 295), CE only (n = 70), accelerated phase without CE (n = 82), and accelerated phase with CE (n = 51). Statistical methods used established methodologies for univariate and multivariate analyses. In chronic and accelerated phases of CML, CE was not associated with significant differences in major or complete cytogenetic response rates, but it was an independent poor prognostic factor for survival by multivariate analyses in both chronic (P =.005) and accelerated phase (P =.03). Multivariate analyses conducted at the 3-month landmark (including the 3-month cytogenetic response) identified the lack of cytogenetic response at 3 months to be a stronger independent poor prognostic factor for survival than CE for both chronic (major cytogenetic response versus other) and accelerated phase (any cytogenetic response versus other). We conclude that cytogenetic CE is not an important factor for achieving major or complete cytogenetic response with imatinib mesylate therapy, but it is an independent poor prognostic factor for survival in both chronic and accelerated phases of CML. The 3-month cytogenetic response to imatinib mesylate refined the prognostic relevance of such studies in patients on imatinib mesylate therapy.",Clinical Trial,6200.0,175.0,Cytogenetic clonal evolution CE is a known poor prognostic factor in Philadelphia chromosome-positive chronic myelogenous Ph-positive CML However its prognostic relevance in the era of imatinib therapy is unknown We investigated the independent prognostic relevance of CE in 498 patients with Ph-positive CML treated with imatinib for chronic or accelerated phases One hundred twenty-one patients had CE alone n 70 or with other accelerated phase criteria n 51 Patients were compared in 4 categories chronic phase n 295 CE only n 70 accelerated phase without CE n 82 and accelerated phase with CE n 51 Statistical methods used established methodologies for univariate and multivariate analyses In chronic and accelerated phases of CML CE was not associated with significant differences in major or complete cytogenetic response rates but it was an independent poor prognostic factor for survival by multivariate analyses in both chronic P =.005 and accelerated phase P =.03 Multivariate analyses conducted at the 3-month landmark including the 3-month cytogenetic response identified the lack of cytogenetic response at 3 months to be a stronger independent poor prognostic factor for survival than CE for both chronic major cytogenetic response versus other and accelerated phase any cytogenetic response versus other We conclude that cytogenetic CE is not an important factor for achieving major or complete cytogenetic response with imatinib mesylate therapy but it is an independent poor prognostic factor for survival in both chronic and accelerated phases of CML The 3-month cytogenetic response to imatinib mesylate refined the prognostic relevance of such studies in patients on imatinib mesylate therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1266, 1946, 2554, 7065, 16, 8, 440, 334, 177, 161, 4, 3006, 1170, 109, 442, 2194, 2058, 109, 903, 137, 211, 177, 2088, 4, 3, 1713, 1, 577, 36, 16, 860, 21, 565, 3, 306, 177, 2088, 1, 7065, 4, 8928, 7, 5, 2058, 109, 903, 73, 5, 577, 9, 442, 15, 2241, 3523, 104, 1128, 737, 104, 7, 42, 7065, 279, 78, 431, 15, 5, 127, 2241, 124, 371, 78, 725, 7, 11, 72, 4, 39, 1996, 442, 124, 78, 7051, 7065, 158, 78, 431, 2241, 124, 187, 7065, 78, 878, 2, 2241, 124, 5, 7065, 78, 725, 1050, 636, 95, 635, 6616, 9, 880, 2, 331, 318, 4, 442, 2, 2241, 3523, 1, 903, 7065, 10, 44, 41, 5, 93, 362, 4, 458, 15, 236, 1266, 51, 151, 84, 192, 10, 35, 306, 334, 177, 161, 9, 25, 20, 331, 318, 4, 110, 442, 19, 1614, 2, 2241, 124, 19, 680, 331, 318, 426, 28, 3, 27, 811, 3829, 141, 3, 27, 811, 1266, 51, 108, 3, 926, 1, 1266, 51, 28, 27, 53, 6, 40, 8, 3355, 306, 334, 177, 161, 9, 25, 76, 7065, 9, 110, 442, 458, 1266, 51, 185, 127, 2, 2241, 124, 500, 1266, 51, 185, 127, 21, 2060, 17, 1266, 7065, 16, 44, 35, 305, 161, 9, 1785, 458, 15, 236, 1266, 51, 5, 577, 2347, 36, 84, 192, 16, 35, 306, 334, 177, 161, 9, 25, 4, 110, 442, 2, 2241, 3523, 1, 903, 3, 27, 811, 1266, 51, 6, 577, 2347, 5332, 3, 177, 2088, 1, 225, 94, 4, 7, 23, 577, 2347, 36]",1712.0,12560227,188
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.,Cancer,Cancer,2003-02-01,"Little is known regarding long-term prognosis among patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) who achieve a complete cytogenetic response (0% Ph-positive cells) after treatment with interferon-alpha. The authors analyzed 512 patients with Ph-positive, early chronic-phase CML who were treated with interferon-based therapies between 1981-1995 for the incidence and durability of complete cytogenetic response, and in relation to long-term prognosis. One hundred forty patients (27%) achieved a complete cytogenetic response. Their 10-year survival rate was 78%. At the time of last follow-up, 44 patients (31%, 9% of the total) were alive, 21 in first and 23 in second durable complete cytogenetic response (median, 127 months; range, 88-191 months); 39 patients had not received any therapy for a median of 50 months (range, 11-139 months). Analysis by reverse transcriptase-polymerase chain reaction in 78 patients during complete cytogenetic response showed 46 who had achieved at least 1 complete molecular response. Five of these 78 patients had died by the time of last follow-up, but only 2 had died of disease-specific causes. Recurrence rates were significantly lower and cytogenetic response durations were significantly longer among patients who achieved at least one complete molecular response. Achieving a complete cytogenetic or molecular response after therapy with interferon-alpha appears to be associated with excellent long-term prognosis. Approximately 10% of patients reportedly can achieve durable complete cytogenetic response, with or without continuation of interferon. This finding emphasizes the potential of long-term event-free survival in CML patients outside the context of allogeneic stem cell transplantation, which may be improved with new therapies such as imatinib mesylate.",Journal Article,6198.0,181.0,Little is known regarding long-term prognosis among patients with Philadelphia chromosome Ph -positive chronic myelogenous CML who achieve a complete cytogenetic response 0 Ph-positive cells after treatment with interferon-alpha The authors analyzed 512 patients with Ph-positive early chronic-phase CML who were treated with interferon-based therapies between 1981-1995 for the incidence and durability of complete cytogenetic response and in relation to long-term prognosis One hundred forty patients 27 achieved a complete cytogenetic response Their 10-year survival rate was 78 At the time of last follow-up 44 patients 31 9 of the total were alive 21 in first and 23 in second durable complete cytogenetic response median 127 months range 88-191 months 39 patients had not received any therapy for a median of 50 months range 11-139 months Analysis by reverse transcriptase-polymerase chain reaction in 78 patients during complete cytogenetic response showed 46 who had achieved at least 1 complete molecular response Five of these 78 patients had died by the time of last follow-up but only 2 had died of disease-specific causes Recurrence rates were significantly lower and cytogenetic response durations were significantly longer among patients who achieved at least one complete molecular response Achieving a complete cytogenetic or molecular response after therapy with interferon-alpha appears to be associated with excellent long-term prognosis Approximately 10 of patients reportedly can achieve durable complete cytogenetic response with or without continuation of interferon This finding emphasizes the potential of long-term event-free survival in CML patients outside the context of allogeneic stem cell transplantation which may be improved with new therapies such as imatinib mesylate,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1215, 16, 440, 666, 319, 337, 356, 107, 7, 5, 3006, 1170, 2058, 109, 442, 2194, 903, 54, 1359, 8, 236, 1266, 51, 13, 2058, 109, 37, 50, 24, 5, 1688, 950, 3, 738, 311, 12287, 7, 5, 2058, 109, 191, 442, 124, 903, 54, 11, 73, 5, 1688, 90, 235, 59, 10264, 2323, 9, 3, 287, 2, 6867, 1, 236, 1266, 51, 2, 4, 2191, 6, 319, 337, 356, 104, 1128, 1213, 7, 428, 513, 8, 236, 1266, 51, 136, 79, 111, 25, 116, 10, 833, 28, 3, 98, 1, 1060, 166, 126, 584, 7, 456, 83, 1, 3, 181, 11, 1701, 239, 4, 157, 2, 382, 4, 419, 1480, 236, 1266, 51, 52, 4080, 53, 184, 889, 6130, 53, 587, 7, 42, 44, 103, 500, 36, 9, 8, 52, 1, 212, 53, 184, 175, 4929, 53, 65, 20, 1772, 4456, 1451, 1260, 1329, 4, 833, 7, 190, 236, 1266, 51, 224, 641, 54, 42, 513, 28, 506, 14, 236, 219, 51, 365, 1, 46, 833, 7, 42, 1016, 20, 3, 98, 1, 1060, 166, 126, 84, 158, 18, 42, 1016, 1, 34, 112, 1626, 146, 151, 11, 97, 280, 2, 1266, 51, 4864, 11, 97, 589, 107, 7, 54, 513, 28, 506, 104, 236, 219, 51, 1785, 8, 236, 1266, 15, 219, 51, 50, 36, 5, 1688, 950, 1233, 6, 40, 41, 5, 1503, 319, 337, 356, 705, 79, 1, 7, 11238, 122, 1359, 1480, 236, 1266, 51, 5, 15, 187, 6870, 1, 1688, 26, 1567, 7519, 3, 174, 1, 319, 337, 774, 115, 25, 4, 903, 7, 2513, 3, 1533, 1, 1063, 452, 31, 497, 92, 68, 40, 231, 5, 217, 235, 225, 22, 577, 2347]",1804.0,12569603,144
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.,Blood,Blood,2003-02-06,"The BCR/ABL tyrosine kinase inhibitor imatinib mesylate (Gleevec, STI571; Novartis, Basel, Switzerland) has shown remarkable efficacy in the treatment of chronic myelogenous leukemia (CML), with a high proportion of patients achieving complete cytogenetic responses (CCRs). However, it is not clear whether remissions will be durable and whether imatinib mesylate can eliminate the malignant primitive progenitors in which the disease arises. We investigated whether residual BCR/ABL+ hematopoietic progenitors were present in patients who achieved CCRs with imatinib mesylate treatment. CD34+ progenitor cells were selected from bone marrow mononuclear cells (MNCs) and analyzed for the presence of the BCR/ABL fusion gene by fluorescence in situ hybridization (FISH). CD34+ cells were also plated in committed progenitor (colony-forming cell, or CFC) and primitive progenitor (long-term bone marrow culture-initiating cell, or LTCIC) cultures and resulting colonies analyzed for the presence of BCR/ABL+ cells by FISH. Using these assays, residual BCR/ABL+ progenitors were detected in all patients studied. Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis demonstrated increased levels of BCR/ABL mRNA in CD34+ cells compared with total MNCs. Evaluation of samples collected at different time points demonstrated persistence of BCR/ABL+ progenitors despite continued treatment with imatinib mesylate. Our results indicate that inhibition of BCR/ABL tyrosine kinase activity by imatinib mesylate does not eliminate malignant primitive progenitors in CML patients. Patients in CCR with imatinib mesylate treatment need to be followed carefully to assess for risk of relapse.",Case Reports,6193.0,432.0,The BCR/ABL tyrosine kinase inhibitor imatinib mesylate Gleevec STI571 Novartis Basel Switzerland has shown remarkable efficacy in the treatment of chronic myelogenous CML with a high proportion of patients achieving complete cytogenetic responses CCRs However it is not clear whether remissions will be durable and whether imatinib mesylate can eliminate the malignant primitive progenitors in which the disease arises We investigated whether residual BCR/ABL+ hematopoietic progenitors were present in patients who achieved CCRs with imatinib mesylate treatment CD34+ progenitor cells were selected from marrow mononuclear cells MNCs and analyzed for the presence of the BCR/ABL fusion gene by fluorescence in situ hybridization FISH CD34+ cells were also plated in committed progenitor colony-forming cell or CFC and primitive progenitor long-term marrow culture-initiating cell or LTCIC cultures and resulting colonies analyzed for the presence of BCR/ABL+ cells by FISH Using these assays residual BCR/ABL+ progenitors were detected in all patients studied Quantitative reverse transcriptase-polymerase chain reaction RT-PCR analysis demonstrated increased levels of BCR/ABL mRNA in CD34+ cells compared with total MNCs Evaluation of samples collected at different time points demonstrated persistence of BCR/ABL+ progenitors despite continued treatment with imatinib mesylate Our results indicate that inhibition of BCR/ABL tyrosine kinase activity by imatinib mesylate does not eliminate malignant primitive progenitors in CML patients Patients in CCR with imatinib mesylate treatment need to be followed carefully to assess for risk of relapse,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1062, 1425, 564, 216, 230, 577, 2347, 8569, 5735, 7855, 21102, 17175, 71, 443, 3813, 209, 4, 3, 24, 1, 442, 2194, 903, 5, 8, 64, 920, 1, 7, 1785, 236, 1266, 253, 24579, 137, 192, 16, 44, 885, 317, 3166, 303, 40, 1480, 2, 317, 577, 2347, 122, 4964, 3, 393, 5594, 4321, 4, 92, 3, 34, 6053, 21, 565, 317, 753, 1062, 1425, 1007, 4321, 11, 364, 4, 7, 54, 513, 24579, 5, 577, 2347, 24, 2215, 2520, 37, 11, 715, 29, 581, 3041, 37, 28012, 2, 311, 9, 3, 463, 1, 3, 1062, 1425, 1212, 145, 20, 1591, 4, 957, 1554, 1277, 2215, 37, 11, 120, 17115, 4, 9552, 2520, 1975, 4525, 31, 15, 43162, 2, 5594, 2520, 319, 337, 581, 2099, 2637, 31, 15, 53364, 3231, 2, 1113, 8633, 311, 9, 3, 463, 1, 1062, 1425, 37, 20, 1277, 75, 46, 1013, 753, 1062, 1425, 4321, 11, 530, 4, 62, 7, 656, 1156, 1772, 4456, 1451, 1260, 1329, 240, 604, 65, 264, 101, 148, 1, 1062, 1425, 956, 4, 2215, 37, 72, 5, 181, 28012, 451, 1, 347, 786, 28, 338, 98, 862, 264, 4108, 1, 1062, 1425, 4321, 550, 1351, 24, 5, 577, 2347, 114, 99, 1008, 17, 297, 1, 1062, 1425, 564, 216, 128, 20, 577, 2347, 1097, 44, 4964, 393, 5594, 4321, 4, 903, 7, 7, 4, 4992, 5, 577, 2347, 24, 594, 6, 40, 370, 3900, 6, 423, 9, 43, 1, 429]",1651.0,12576334,84
Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2003-02-01,"The high remission rates observed in patients with chronic myelogenous leukemia who receive Imatinib mesylate (Gleevec) indicate that targeted therapy for hematological malignancies is achievable. At the same time, progress in cellular biology over the past decade has resulted in a better understanding of the process of malignant transformation, a better classification of subtypes of each disease on the basis of molecular markers, and a better characterization of the molecular targets for drug development. These advances have already spawned the development of such effective agents as monoclonal antibodies and specific enzyme inhibitors. This review attempts to provide a practical introduction to the complex and growing field of targeted therapy in hematological malignancies.",Journal Article,6198.0,32.0,The high remission rates observed in patients with chronic myelogenous who receive Imatinib mesylate Gleevec indicate that targeted therapy for hematological malignancies is achievable At the same time progress in cellular biology over the past decade has resulted in a better understanding of the process of malignant transformation a better classification of subtypes of each disease on the basis of molecular markers and a better characterization of the molecular targets for drug development These advances have already spawned the development of such effective agents as monoclonal antibodies and specific enzyme inhibitors This review attempts to provide a practical introduction to the complex and growing field of targeted therapy in hematological malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 64, 734, 151, 164, 4, 7, 5, 442, 2194, 54, 560, 577, 2347, 8569, 1008, 17, 238, 36, 9, 2890, 441, 16, 6171, 28, 3, 827, 98, 1466, 4, 763, 891, 252, 3, 1219, 2025, 71, 627, 4, 8, 380, 612, 1, 3, 1129, 1, 393, 1392, 8, 380, 947, 1, 814, 1, 296, 34, 23, 3, 877, 1, 219, 525, 2, 8, 380, 2136, 1, 3, 219, 637, 9, 234, 193, 46, 954, 47, 3298, 30366, 3, 193, 1, 225, 323, 183, 22, 848, 890, 2, 112, 1644, 222, 26, 206, 4374, 6, 377, 8, 3320, 2456, 6, 3, 840, 2, 1921, 1067, 1, 238, 36, 4, 2890, 441]",768.0,12576416,246
"Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.",Cancer,Cancer,2003-03-01,"Decitabine is a hypomethylating agent that has activity in patients with leukemia. The authors combined decitabine with busulfan and cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Patients with high-risk acute myeloid leukemia (AML) (n = 12 patients); chronic myelomonocytic leukemia (CMML) (n = 1 patient); acute lymphocytic leukemia (ALL) (n = 1 patient); or late chronic phase, accelerated, or blastic phase chronic myelogenous leukemia (n = 9 patients) were eligible for the study. The treatment plan was comprised of busulfan, 12 mg/kg orally; cyclophosphamide, 100 mg/kg (n = 4 patients) or 120 mg/kg (n = 19 patients); and decitabine, intravenously at 3 dose levels: 400 mg/m(2) (n = 10 patients), 600 mg/m(2) (n = 8 patients), and 800 mg/m(2) (n = 5 patients). Donors were human leukocyte antigen-identical siblings in all cases, and all but one patient received peripheral blood stem cells. Graft-versus-host disease (GVHD) prophylaxis was tacrolimus based in all but one patient. The median time to neutrophil and platelet engraftment was 12.5 days and 17.5 days, respectively. Twenty-one patients were engrafted and achieved disease remission. At a median of 3.3 years posttransplantation, 26% of patients (40% of patients with AML) were alive and disease free. The median survival for the group was 17.2 months, and the disease free survival for the group was 8.9 months. Causes of death were disease recurrence (nine patients), chronic GVHD (four patients), infections (three patients), and acute GVHD (one patient). The 100-day mortality rate was 9%. No decitabine dose-limiting toxicity was documented. The treatment-related mortality rate at 3 years was 35%. Responders were treated at all three decitabine dose levels, and no dose-response correlation was observed. There was a high response rate with low treatment-related mortality, with 26% of patients alive in remission 3.3 years after transplantation.",Clinical Trial,6170.0,35.0,Decitabine is a hypomethylating agent that has activity in patients with The authors combined decitabine with busulfan and cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation Patients with high-risk acute myeloid AML n 12 patients chronic myelomonocytic CMML n 1 patient acute lymphocytic ALL n 1 patient or late chronic phase accelerated or blastic phase chronic myelogenous n 9 patients were eligible for the study The treatment plan was comprised of busulfan 12 mg/kg orally cyclophosphamide 100 mg/kg n 4 patients or 120 mg/kg n 19 patients and decitabine intravenously at 3 dose levels 400 mg/m 2 n 10 patients 600 mg/m 2 n 8 patients and 800 mg/m 2 n 5 patients Donors were human leukocyte antigen-identical siblings in all cases and all but one patient received peripheral blood stem cells Graft-versus-host disease GVHD prophylaxis was tacrolimus based in all but one patient The median time to neutrophil and platelet engraftment was 12.5 days and 17.5 days respectively Twenty-one patients were engrafted and achieved disease remission At a median of 3.3 years posttransplantation 26 of patients 40 of patients with AML were alive and disease free The median survival for the group was 17.2 months and the disease free survival for the group was 8.9 months Causes of death were disease recurrence nine patients chronic GVHD four patients infections three patients and acute GVHD one patient The 100-day mortality rate was 9 No decitabine dose-limiting toxicity was documented The treatment-related mortality rate at 3 years was 35 Responders were treated at all three decitabine dose levels and no dose-response correlation was observed There was a high response rate with low treatment-related mortality with 26 of patients alive in remission 3.3 years after transplantation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3004, 16, 8, 4931, 420, 17, 71, 128, 4, 7, 5, 3, 738, 397, 3004, 5, 3906, 2, 1112, 22, 8, 1933, 477, 324, 6, 1063, 1007, 452, 31, 497, 7, 5, 64, 43, 286, 533, 329, 78, 133, 7, 442, 5451, 3382, 78, 14, 69, 286, 1193, 62, 78, 14, 69, 15, 807, 442, 124, 2241, 15, 6529, 124, 442, 2194, 78, 83, 7, 11, 625, 9, 3, 45, 3, 24, 2242, 10, 2603, 1, 3906, 133, 81, 503, 1428, 1112, 394, 81, 503, 78, 39, 7, 15, 2031, 81, 503, 78, 326, 7, 2, 3004, 1672, 28, 27, 61, 148, 1524, 81, 188, 18, 78, 79, 7, 2383, 81, 188, 18, 78, 66, 7, 2, 2796, 81, 188, 18, 78, 33, 7, 2344, 11, 171, 3627, 448, 3038, 2758, 4, 62, 140, 2, 62, 84, 104, 69, 103, 672, 315, 452, 37, 1599, 185, 1204, 34, 1562, 2049, 10, 5643, 90, 4, 62, 84, 104, 69, 3, 52, 98, 6, 2595, 2, 1596, 2881, 10, 133, 33, 162, 2, 269, 33, 162, 106, 737, 104, 7, 11, 6914, 2, 513, 34, 734, 28, 8, 52, 1, 27, 27, 60, 8046, 432, 1, 7, 327, 1, 7, 5, 329, 11, 1701, 2, 34, 115, 3, 52, 25, 9, 3, 87, 10, 269, 18, 53, 2, 3, 34, 115, 25, 9, 3, 87, 10, 66, 83, 53, 1626, 1, 273, 11, 34, 146, 762, 7, 442, 1562, 294, 7, 1875, 169, 7, 2, 286, 1562, 104, 69, 3, 394, 218, 282, 116, 10, 83, 77, 3004, 61, 817, 155, 10, 1405, 3, 24, 139, 282, 116, 28, 27, 60, 10, 465, 1983, 11, 73, 28, 62, 169, 3004, 61, 148, 2, 77, 61, 51, 816, 10, 164, 125, 10, 8, 64, 51, 116, 5, 154, 24, 139, 282, 5, 432, 1, 7, 1701, 4, 734, 27, 27, 60, 50, 497]",1836.0,12599231,138
Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia.,American journal of ophthalmology,Am. J. Ophthalmol.,2003-03-01,"To report a case of leukemic retinopathy before and after treatment with imatinib mesylate (formerly STI-571) for chronic myelogenous leukemia (CML). Interventional case report. A 58-year-old man diagnosed with stable phase CML (SP-CML) presented with blurry vision. Fundoscopy revealed several flame-shaped hemorrhages in the macular region in both eyes. One month after this initial visit, imatinib therapy was initiated. : The patient noticed improvement in his visual as well as his medical symptoms; on repeat examination 6 months after the initial visit, the retinal hemorrhages had resolved and remained so after 18 months. Imatinib appears to be an effective treatment for SP-CML, and the improvement in visual and medical symptoms in our case report correlates with this.",Case Reports,6170.0,2.0,To report a case of leukemic retinopathy before and after treatment with imatinib mesylate formerly STI-571 for chronic myelogenous CML Interventional case report A 58-year-old man diagnosed with stable phase CML SP-CML presented with blurry vision Fundoscopy revealed several flame-shaped hemorrhages in the macular region in both eyes One month after this initial visit imatinib therapy was initiated The patient noticed improvement in his visual as well as his medical symptoms on repeat examination 6 months after the initial visit the retinal hemorrhages had resolved and remained so after 18 months Imatinib appears to be an effective treatment for SP-CML and the improvement in visual and medical symptoms in our case report correlates with this,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 414, 8, 473, 1, 2015, 12124, 348, 2, 50, 24, 5, 577, 2347, 7350, 10640, 7846, 9, 442, 2194, 903, 6182, 473, 414, 8, 717, 111, 1095, 3628, 265, 5, 585, 124, 903, 4074, 903, 917, 5, 53393, 5859, 53394, 553, 392, 53395, 8902, 13773, 4, 3, 18253, 1053, 4, 110, 3799, 104, 811, 50, 26, 388, 2807, 577, 36, 10, 1917, 3, 69, 16285, 767, 4, 3224, 3046, 22, 149, 22, 3224, 484, 507, 23, 2334, 1385, 49, 53, 50, 3, 388, 2807, 3, 6831, 13773, 42, 3862, 2, 958, 1743, 50, 203, 53, 577, 1233, 6, 40, 35, 323, 24, 9, 4074, 903, 2, 3, 767, 4, 3046, 2, 484, 507, 4, 114, 473, 414, 1871, 5, 26]",752.0,12614767,223
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.,The Journal of clinical investigation,J. Clin. Invest.,2003-03-01,"We have shown that cytotoxic T lymphocytes specific for PR1, an HLA-A2-restricted nonopeptide derived from proteinase 3, kill leukemia cells and may contribute to the elimination of chronic myelogenous leukemia (CML) after treatment with IFN or allogeneic bone marrow transplant. Some patients with persistent disease also have circulating PR1-specific T cells, however, suggesting the likelihood of immune tolerance. Here we show that both high- and low-avidity PR1-specific T cells from the peripheral blood of healthy donors can be identified and selectively expanded in vitro. Although high-avidity PR1-specific T cells killed CML more effectively than low-avidity T cells, only high-avidity T cells underwent apoptosis when stimulated with high PR1 peptide concentration or when exposed to leukemia that overexpressed proteinase 3. No high-avidity PR1-specific T cells could be identified or expanded from newly diagnosed leukemia patients, whereas low-avidity T cells were readily expanded. Circulating high-avidity PR1-specific T cells were identified in IFN-sensitive patients in cytogenetic remission, however. These results provide evidence that CML shapes the host immune response and that leukemia outgrowth may result in part from leukemia-induced selective deletion of high-avidity PR1-specific T cells.",Journal Article,6170.0,173.0,We have shown that cytotoxic T lymphocytes specific for PR1 an HLA-A2-restricted nonopeptide derived from proteinase 3 kill cells and may contribute to the elimination of chronic myelogenous CML after treatment with IFN or allogeneic marrow transplant Some patients with persistent disease also have circulating PR1-specific T cells however suggesting the likelihood of immune tolerance Here we show that both high- and low-avidity PR1-specific T cells from the peripheral blood of healthy donors can be identified and selectively expanded in vitro Although high-avidity PR1-specific T cells killed CML more effectively than low-avidity T cells only high-avidity T cells underwent apoptosis when stimulated with high PR1 peptide concentration or when exposed to that overexpressed proteinase 3 No high-avidity PR1-specific T cells could be identified or expanded from newly diagnosed patients whereas low-avidity T cells were readily expanded Circulating high-avidity PR1-specific T cells were identified in IFN-sensitive patients in cytogenetic remission however These results provide evidence that CML shapes the host immune response and that outgrowth may result in part from leukemia-induced selective deletion of high-avidity PR1-specific T cells,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 47, 443, 17, 759, 102, 1594, 112, 9, 6298, 35, 1160, 4099, 2016, 53397, 526, 29, 10974, 27, 5097, 37, 2, 68, 1248, 6, 3, 3730, 1, 442, 2194, 903, 50, 24, 5, 1256, 15, 1063, 581, 941, 476, 7, 5, 1882, 34, 120, 47, 1033, 6298, 112, 102, 37, 137, 802, 3, 1420, 1, 250, 2614, 467, 21, 514, 17, 110, 64, 2, 154, 6071, 6298, 112, 102, 37, 29, 3, 672, 315, 1, 1331, 2344, 122, 40, 108, 2, 2382, 2064, 4, 439, 242, 64, 6071, 6298, 112, 102, 37, 8239, 903, 80, 1856, 76, 154, 6071, 102, 37, 158, 64, 6071, 102, 37, 208, 351, 198, 2816, 5, 64, 6298, 1389, 1227, 15, 198, 2234, 6, 17, 1711, 10974, 27, 77, 64, 6071, 6298, 112, 102, 37, 359, 40, 108, 15, 2064, 29, 732, 265, 7, 547, 154, 6071, 102, 37, 11, 3860, 2064, 1033, 64, 6071, 6298, 112, 102, 37, 11, 108, 4, 1256, 745, 7, 4, 1266, 734, 137, 46, 99, 377, 241, 17, 903, 14475, 3, 1204, 250, 51, 2, 17, 7201, 68, 757, 4, 760, 29, 2647, 277, 1094, 1528, 1, 64, 6071, 6298, 112, 102, 37]",1251.0,12618518,20
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2003-03-01,"Infection with Varicella-Zoster virus (VZV) is an exceptionally rare complication of chronic myelogenous leukemia (CML) without stem cell transplantation. We report 16 patients with CML who developed VZV infection during imatinib mesylate therapy. From July 1998 until February 2002, 771 patients were included in 11 imatinib mesylate studies for all CML phases in the Departments of Leukemia and Bioimmunotherapy at The University of Texas M. D. Anderson Cancer Center. Sixteen patients developed VZV infection. Charts and follow-up information of were reviewed and analyzed. Sixteen patients (2%) developed a VZV infection [15 episodes of herpes zoster (HZ), 1 varicella]. The baseline characteristics of the 16 patients with infection do not differ significantly from those who did not develop VZV infection, except for time from diagnosis of CML to imatinib (median: 55 versus 25 months, P = 0.0056) and the number of prior therapies (3 versus 1, P < 0.001). All patients received therapy with antiviral agents with good response. Six patients developed postherpetic neuralgia. Our results suggest that imatinib therapy in CML is associated with low incidence of HZ infection. VZV infection is more frequent with longer duration of CML disease and with prior therapy, does not disseminate, responds well to therapy, and does not mandate a recommendation for HZ prophylaxis in such patients.",Journal Article,6170.0,69.0,Infection with Varicella-Zoster virus VZV is an exceptionally rare complication of chronic myelogenous CML without stem cell transplantation We report 16 patients with CML who developed VZV infection during imatinib mesylate therapy From July 1998 until February 2002 771 patients were included in 11 imatinib mesylate studies for all CML phases in the Departments of and Bioimmunotherapy at The University of Texas M. D. Anderson Cancer Center Sixteen patients developed VZV infection Charts and follow-up information of were reviewed and analyzed Sixteen patients 2 developed a VZV infection 15 episodes of herpes zoster HZ 1 varicella The baseline characteristics of the 16 patients with infection do not differ significantly from those who did not develop VZV infection except for time from diagnosis of CML to imatinib median 55 versus 25 months P 0.0056 and the number of prior therapies 3 versus 1 P 0.001 All patients received therapy with antiviral agents with good response Six patients developed postherpetic neuralgia Our results suggest that imatinib therapy in CML is associated with low incidence of HZ infection VZV infection is more frequent with longer duration of CML disease and with prior therapy does not disseminate responds well to therapy and does not mandate a recommendation for HZ prophylaxis in such patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[930, 5, 17098, 11398, 1450, 15871, 16, 35, 13854, 622, 1447, 1, 442, 2194, 903, 187, 452, 31, 497, 21, 414, 245, 7, 5, 903, 54, 276, 15871, 930, 190, 577, 2347, 36, 29, 2066, 1850, 1100, 3010, 1544, 15186, 7, 11, 159, 4, 175, 577, 2347, 94, 9, 62, 903, 3523, 4, 3, 14467, 1, 2, 53414, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 3228, 7, 276, 15871, 930, 4413, 2, 166, 126, 487, 1, 11, 446, 2, 311, 3228, 7, 18, 276, 8, 15871, 930, 167, 3750, 1, 4716, 11398, 16287, 14, 17098, 3, 330, 374, 1, 3, 245, 7, 5, 930, 1022, 44, 1505, 97, 29, 135, 54, 205, 44, 690, 15871, 930, 2187, 9, 98, 29, 147, 1, 903, 6, 577, 52, 614, 185, 243, 53, 19, 13, 23205, 2, 3, 207, 1, 324, 235, 27, 185, 14, 19, 13, 144, 62, 7, 103, 36, 5, 6264, 183, 5, 1178, 51, 437, 7, 276, 53415, 33218, 114, 99, 309, 17, 577, 36, 4, 903, 16, 41, 5, 154, 287, 1, 16287, 930, 15871, 930, 16, 80, 908, 5, 589, 654, 1, 903, 34, 2, 5, 324, 36, 1097, 44, 12785, 7920, 149, 6, 36, 2, 1097, 44, 12493, 8, 3347, 9, 16287, 2049, 4, 225, 7]",1337.0,12631595,7
"Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-03-01,"Troxacitabine has significant single-agent activity. This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan. Patients with refractory acute myeloid leukemia (AML), advanced myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP) were initially randomly assigned to receive troxacitabine 5.0 mg/m(2) by intravenous (IV) infusion over 30 minutes on days 1 to 5 with ara-C 1.0 g/m(2)/d IV [DOSAGE ERROR CORRECTED] over 2 hours on days 1 to 5, idarubicin 12 mg/m(2) by 5 minute IV infusion on days 1 to 3, or topotecan 1.0 mg/m(2) as an continuous IV infusion on days 1 to 5. Doses were then adjusted to define DLT for each combination. Eighty-seven patients (68 AML, eight MDS, 11 CML-BP) were treated. DLTs were hepatic transaminitis, hyperbilirubinemia, and hand foot syndrome (HFS) on the troxacitabine plus ara-C combination. The recommended phase II doses were 6 mg/m(2) once a day for 5 days and 1.0g/m(2) once a day for 5 days, respectively. DLTs were diarrhea, rash, and mucositis on the troxacitabine plus topotecan combination. The recommended phase II doses were 4 mg/m(2) once a day for 5 days and 0.75 mg/m(2) once a day for 5 days, respectively. DLTs were HFS, rash, and mucositis on the troxacitabine plus idarubicin combination. The recommended phase II doses were 4 mg/m(2) once a day for 5 days and 9 mg/m(2) once a day for 3 days, respectively. Among 74 evaluable patients with AML or MDS, 10 (13%) achieved complete remission and four (5%) had hematologic improvement. Two of 11 (18%) evaluable patients with CML-BP returned to chronic phase. Troxacitabine-based combinations had significant antileukemic activity.",Clinical Trial,6170.0,29.0,Troxacitabine has significant single-agent activity This study was conducted to define the dose-limiting toxicities DLTs of its combination with cytarabine ara-C idarubicin or topotecan Patients with refractory acute myeloid AML advanced syndromes MDS or chronic myelogenous in blastic phase CML-BP were initially randomly assigned to receive troxacitabine 5.0 mg/m 2 by intravenous IV infusion over 30 minutes on days 1 to 5 with ara-C 1.0 g/m 2 /d IV DOSAGE ERROR CORRECTED over 2 hours on days 1 to 5 idarubicin 12 mg/m 2 by 5 minute IV infusion on days 1 to 3 or topotecan 1.0 mg/m 2 as an continuous IV infusion on days 1 to 5 Doses were then adjusted to define DLT for each combination Eighty-seven patients 68 AML eight MDS 11 CML-BP were treated DLTs were hepatic transaminitis hyperbilirubinemia and hand foot syndrome HFS on the troxacitabine plus ara-C combination The recommended phase II doses were 6 mg/m 2 once a day for 5 days and 1.0g/m 2 once a day for 5 days respectively DLTs were diarrhea rash and mucositis on the troxacitabine plus topotecan combination The recommended phase II doses were 4 mg/m 2 once a day for 5 days and 0.75 mg/m 2 once a day for 5 days respectively DLTs were HFS rash and mucositis on the troxacitabine plus idarubicin combination The recommended phase II doses were 4 mg/m 2 once a day for 5 days and 9 mg/m 2 once a day for 3 days respectively Among 74 evaluable patients with AML or MDS 10 13 achieved complete remission and four 5 had hematologic improvement Two of 11 18 evaluable patients with CML-BP returned to chronic phase Troxacitabine-based combinations had significant antileukemic activity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[10949, 71, 93, 226, 420, 128, 26, 45, 10, 426, 6, 1107, 3, 61, 817, 385, 2506, 1, 211, 150, 5, 1855, 3899, 256, 5684, 15, 2129, 7, 5, 430, 286, 533, 329, 131, 2040, 1223, 15, 442, 2194, 4, 6529, 124, 903, 3044, 11, 1625, 1108, 896, 6, 560, 10949, 33, 13, 81, 188, 18, 20, 1262, 478, 904, 252, 201, 2511, 23, 162, 14, 6, 33, 5, 3899, 256, 14, 13, 499, 188, 18, 427, 478, 3323, 3444, 3848, 252, 18, 1459, 23, 162, 14, 6, 33, 5684, 133, 81, 188, 18, 20, 33, 3949, 478, 904, 23, 162, 14, 6, 27, 15, 2129, 14, 13, 81, 188, 18, 22, 35, 1314, 478, 904, 23, 162, 14, 6, 33, 415, 11, 818, 586, 6, 1107, 2059, 9, 296, 150, 2207, 648, 7, 806, 329, 659, 1223, 175, 903, 3044, 11, 73, 2506, 11, 939, 8181, 7236, 2, 2833, 4100, 681, 8597, 23, 3, 10949, 349, 3899, 256, 150, 3, 793, 124, 215, 415, 11, 49, 81, 188, 18, 1059, 8, 218, 9, 33, 162, 2, 14, 53429, 188, 18, 1059, 8, 218, 9, 33, 162, 106, 2506, 11, 1172, 1641, 2, 2606, 23, 3, 10949, 349, 2129, 150, 3, 793, 124, 215, 415, 11, 39, 81, 188, 18, 1059, 8, 218, 9, 33, 162, 2, 13, 481, 81, 188, 18, 1059, 8, 218, 9, 33, 162, 106, 2506, 11, 8597, 1641, 2, 2606, 23, 3, 10949, 349, 5684, 150, 3, 793, 124, 215, 415, 11, 39, 81, 188, 18, 1059, 8, 218, 9, 33, 162, 2, 83, 81, 188, 18, 1059, 8, 218, 9, 27, 162, 106, 107, 794, 859, 7, 5, 329, 15, 1223, 79, 233, 513, 236, 734, 2, 294, 33, 42, 813, 767, 100, 1, 175, 203, 859, 7, 5, 903, 3044, 5157, 6, 442, 124, 10949, 90, 1247, 42, 93, 4512, 128]",1649.0,12637470,176
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.,Cancer,Cancer,2003-05-01,"Obtaining a major (Philadelphia chromosome [Ph] of < 35%) or a complete cytogenetic response (Ph of 0%) has been associated with excellent long-term survival. Cytogenetic response may continue to improve with therapy. Because early allogeneic stem cell transplantation (SCT) may be associated with a better outcome, early parameters predicting for subsequent cytogenetic responses would optimize the treatment decision-making. The current study was performed to analyze whether early cytogenetic responses may be predictive of later major or complete cytogenetic responses to imatinib mesylate therapy in patients with Ph-positive chronic myelogenous leukemia (CML). Two hundred sixty-one patients with Ph-positive, chronic-phase CML after failure with interferon therapy who were treated with imatinib mesylate therapy were analyzed. A persistence of 100% Ph-positive cells after > or = 6 months of imatinib mesylate therapy was associated with a major cytogenetic response rate of 9-13% and a complete cytogenetic response rate of 0-4%. However, a minor cytogenetic response after 3-12 months of therapy still was associated with high rates of major (68-83%) or complete (35-54%) cytogenetic response rates. Patients with Ph-positive, chronic-phase CML who have persistent 100% Ph-positive disease after > or = 6 months of imatinib mesylate therapy may be offered allogeneic SCT or considered for alternative investigational therapies.",Journal Article,6109.0,22.0,Obtaining a major Philadelphia chromosome Ph of 35 or a complete cytogenetic response Ph of 0 has been associated with excellent long-term survival Cytogenetic response may continue to improve with therapy Because early allogeneic stem cell transplantation SCT may be associated with a better outcome early parameters predicting for subsequent cytogenetic responses would optimize the treatment decision-making The current study was performed to analyze whether early cytogenetic responses may be predictive of later major or complete cytogenetic responses to imatinib mesylate therapy in patients with Ph-positive chronic myelogenous CML Two hundred sixty-one patients with Ph-positive chronic-phase CML after failure with interferon therapy who were treated with imatinib mesylate therapy were analyzed A persistence of 100 Ph-positive cells after or 6 months of imatinib mesylate therapy was associated with a major cytogenetic response rate of 9-13 and a complete cytogenetic response rate of 0-4 However a minor cytogenetic response after 3-12 months of therapy still was associated with high rates of major 68-83 or complete 35-54 cytogenetic response rates Patients with Ph-positive chronic-phase CML who have persistent 100 Ph-positive disease after or 6 months of imatinib mesylate therapy may be offered allogeneic SCT or considered for alternative investigational therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[5244, 8, 458, 3006, 1170, 2058, 1, 465, 15, 8, 236, 1266, 51, 2058, 1, 13, 71, 85, 41, 5, 1503, 319, 337, 25, 1266, 51, 68, 1906, 6, 401, 5, 36, 408, 191, 1063, 452, 31, 497, 1988, 68, 40, 41, 5, 8, 380, 228, 191, 1038, 1434, 9, 706, 1266, 253, 688, 2465, 3, 24, 948, 1079, 3, 291, 45, 10, 173, 6, 1992, 317, 191, 1266, 253, 68, 40, 464, 1, 1559, 458, 15, 236, 1266, 253, 6, 577, 2347, 36, 4, 7, 5, 2058, 109, 442, 2194, 903, 100, 1128, 1746, 104, 7, 5, 2058, 109, 442, 124, 903, 50, 496, 5, 1688, 36, 54, 11, 73, 5, 577, 2347, 36, 11, 311, 8, 4108, 1, 394, 2058, 109, 37, 50, 15, 49, 53, 1, 577, 2347, 36, 10, 41, 5, 8, 458, 1266, 51, 116, 1, 83, 233, 2, 8, 236, 1266, 51, 116, 1, 13, 39, 137, 8, 2278, 1266, 51, 50, 27, 133, 53, 1, 36, 1234, 10, 41, 5, 64, 151, 1, 458, 806, 852, 15, 236, 465, 667, 1266, 51, 151, 7, 5, 2058, 109, 442, 124, 903, 54, 47, 1882, 394, 2058, 109, 34, 50, 15, 49, 53, 1, 577, 2347, 36, 68, 40, 2216, 1063, 1988, 15, 515, 9, 1091, 3093, 235]",1384.0,12712475,95
Palliative irradiation of the spleen.,American journal of clinical oncology,Am. J. Clin. Oncol.,2003-04-01,"We analyzed the efficacy of splenic irradiation in a population of patients with hematologic diseases. The records of the Radiation Oncology Division, Naval Medical Center San Diego were retrospectively reviewed for all patients treated with splenic irradiation (SI) between January 1, 1990 and March 1, 2001. The charts of 17 patients were identified: 5 patients had chronic myelogenous leukemia, 4 had chronic lymphocytic leukemia, 4 had idiopathic myelofibrosis, 2 had polycythemia vera, and 1 patient each had idiopathic thrombocytopenic purpura and acute myelogenous leukemia. Patient ages ranged from 37 to 88 years. Sixteen of 17 suffered from symptomatic splenomegaly. Twenty-six courses of splenic irradiation were delivered to these 17 patients. Treatment courses generally consisted of two fractions of 50 cGy in the first week, two fractions of 75 cGy the second week, and two fractions of 100 cGy the third week. Blood counts were checked prior to each treatment. Seven of the 17 patients died 1 month or less after SI due to the terminal nature of their disease. Twenty-two of 25 treatment courses for splenomegaly resulted in decreased pain and symptoms. Five patients required two treatment courses for splenomegaly, and one patient required five treatment courses. Three of four patients treated for thrombocytopenia demonstrated improvement, but only one was evaluable for more than 2 weeks due to disease-related mortality. Three of five patients treated for leukocytosis had significant improvement. In general, patients suffered few significant complications from this palliative intervention. Splenic irradiation can effectively palliate symptomatic splenomegaly in patients for whom splenectomy is not an option. Retreatment is possible. Splenic irradiation is less effective in the treatment of thrombocytopenia or leukocytosis.",Journal Article,6139.0,37.0,We analyzed the efficacy of splenic irradiation in a population of patients with hematologic diseases The records of the Radiation Oncology Division Naval Medical Center San Diego were retrospectively reviewed for all patients treated with splenic irradiation SI between January 1 1990 and March 1 2001 The charts of 17 patients were identified 5 patients had chronic myelogenous 4 had chronic lymphocytic 4 had idiopathic myelofibrosis 2 had polycythemia vera and 1 patient each had idiopathic thrombocytopenic purpura and acute myelogenous Patient ages ranged from 37 to 88 years Sixteen of 17 suffered from symptomatic splenomegaly Twenty-six courses of splenic irradiation were delivered to these 17 patients Treatment courses generally consisted of two fractions of 50 cGy in the first week two fractions of 75 cGy the second week and two fractions of 100 cGy the third week Blood counts were checked prior to each treatment Seven of the 17 patients died 1 month or less after SI due to the terminal nature of their disease Twenty-two of 25 treatment courses for splenomegaly resulted in decreased pain and symptoms Five patients required two treatment courses for splenomegaly and one patient required five treatment courses Three of four patients treated for thrombocytopenia demonstrated improvement but only one was evaluable for more than 2 weeks due to disease-related mortality Three of five patients treated for leukocytosis had significant improvement In general patients suffered few significant complications from this palliative intervention Splenic irradiation can effectively palliate symptomatic splenomegaly in patients for whom splenectomy is not an option Retreatment is possible Splenic irradiation is less effective in the treatment of thrombocytopenia or leukocytosis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[21, 311, 3, 209, 1, 5237, 1104, 4, 8, 266, 1, 7, 5, 813, 1342, 3, 1064, 1, 3, 121, 413, 5750, 53501, 484, 574, 6889, 12965, 11, 894, 446, 9, 62, 7, 73, 5, 5237, 1104, 5069, 59, 1024, 14, 2289, 2, 2363, 14, 1758, 3, 4413, 1, 269, 7, 11, 108, 33, 7, 42, 442, 2194, 39, 42, 442, 1193, 39, 42, 7540, 4637, 18, 42, 5755, 5756, 2, 14, 69, 296, 42, 7540, 11908, 14174, 2, 286, 2194, 69, 2165, 1869, 29, 567, 6, 889, 60, 3228, 1, 269, 6388, 29, 1704, 6364, 737, 437, 1993, 1, 5237, 1104, 11, 1623, 6, 46, 269, 7, 24, 1993, 1228, 1695, 1, 100, 1550, 1, 212, 3071, 4, 3, 157, 647, 100, 1550, 1, 481, 3071, 3, 419, 647, 2, 100, 1550, 1, 394, 3071, 3, 1282, 647, 315, 1911, 11, 14749, 324, 6, 296, 24, 648, 1, 3, 269, 7, 1016, 14, 811, 15, 299, 50, 5069, 520, 6, 3, 2158, 2202, 1, 136, 34, 737, 100, 1, 243, 24, 1993, 9, 6364, 627, 4, 340, 559, 2, 507, 365, 7, 616, 100, 24, 1993, 9, 6364, 2, 104, 69, 616, 365, 24, 1993, 169, 1, 294, 7, 73, 9, 1340, 264, 767, 84, 158, 104, 10, 859, 9, 80, 76, 18, 244, 520, 6, 34, 139, 282, 169, 1, 365, 7, 73, 9, 7463, 42, 93, 767, 4, 1083, 7, 6388, 1021, 93, 521, 29, 26, 994, 788, 5237, 1104, 122, 1856, 10982, 1704, 6364, 4, 7, 9, 953, 6569, 16, 44, 35, 1501, 6291, 16, 899, 5237, 1104, 16, 299, 323, 4, 3, 24, 1, 1340, 15, 7463]",1793.0,12714892,163
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.,Annals of internal medicine,Ann. Intern. Med.,2003-05-01,"The Philadelphia chromosome translocation (t(9;22)) results in the molecular juxtaposition of two genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22. BCR-ABL is critical to the pathogenesis of chronic myelogenous leukemia and a subset of acute leukemias. The chimeric Bcr-Abl protein has constitutively elevated tyrosine phosphokinase activity. This abnormal enzymatic activation is critical to the oncogenic potential of Bcr-Abl. Initially, protein kinases were thought to be poor therapeutic targets because of their ubiquitous nature and crucial role in many normal physiologic processes. However, the advent of imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), formerly known as STI571 and CGP57148B, demonstrated that designer kinase inhibitors could be specific. This agent has shown striking activity in chronic myelogenous leukemia. It also inhibits phosphorylation of Kit (stem-cell factor receptor) and platelet-derived growth factor receptor. In addition, it has shown similar impressive responses, with little host toxicity, in gastrointestinal stromal tumors, which harbor activating Kit mutations, and in tumors with activated platelet-derived growth factor receptor. The studies of imatinib mesylate provide proof-of-principle for using aberrant kinases as a therapeutic target and are a model for the promise of molecular therapeutics. This paper reviews the current knowledge on the function of Bcr-Abl and its normal counterparts (Bcr and Abl), as well as the impact of this knowledge on the development of a remarkably successful targeted therapy approach.",Journal Article,6109.0,239.0,The Philadelphia chromosome translocation t 9 22 results in the molecular juxtaposition of two genes BCR and ABL to form an aberrant BCR-ABL gene on chromosome 22 BCR-ABL is critical to the pathogenesis of chronic myelogenous and a subset of acute leukemias The chimeric Bcr-Abl protein has constitutively elevated tyrosine phosphokinase activity This abnormal enzymatic activation is critical to the oncogenic potential of Bcr-Abl Initially protein kinases were thought to be poor therapeutic targets because of their ubiquitous nature and crucial role in many normal physiologic processes However the advent of imatinib mesylate Gleevec Novartis Pharmaceuticals Basel Switzerland formerly known as STI571 and CGP57148B demonstrated that designer kinase inhibitors could be specific This agent has shown striking activity in chronic myelogenous It also inhibits phosphorylation of Kit stem-cell factor receptor and platelet-derived growth factor receptor In addition it has shown similar impressive responses with little host toxicity in stromal tumors which harbor activating Kit mutations and in tumors with activated platelet-derived growth factor receptor The studies of imatinib mesylate provide proof-of-principle for using aberrant kinases as a therapeutic target and are a model for the promise of molecular therapeutics This paper reviews the current knowledge on the function of Bcr-Abl and its normal counterparts Bcr and Abl as well as the impact of this knowledge on the development of a remarkably successful targeted therapy approach,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[3, 3006, 1170, 2006, 102, 83, 350, 99, 4, 3, 219, 20172, 1, 100, 214, 1062, 2, 1425, 6, 1297, 35, 1898, 1062, 1425, 145, 23, 1170, 350, 1062, 1425, 16, 740, 6, 3, 1384, 1, 442, 2194, 2, 8, 697, 1, 286, 2792, 3, 2897, 1062, 1425, 178, 71, 2818, 804, 564, 15562, 128, 26, 1668, 5226, 363, 16, 740, 6, 3, 1302, 174, 1, 1062, 1425, 1625, 178, 1549, 11, 2739, 6, 40, 334, 189, 637, 408, 1, 136, 8577, 2202, 2, 2653, 200, 4, 445, 295, 4628, 1849, 137, 3, 4114, 1, 577, 2347, 8569, 7855, 5888, 21102, 17175, 7350, 440, 22, 5735, 2, 37253, 264, 17, 28052, 216, 222, 359, 40, 112, 26, 420, 71, 443, 5133, 128, 4, 442, 2194, 192, 120, 1576, 982, 1, 1164, 452, 31, 161, 153, 2, 1596, 526, 129, 161, 153, 4, 352, 192, 71, 443, 288, 5790, 253, 5, 1215, 1204, 155, 4, 1126, 57, 92, 2760, 1616, 1164, 138, 2, 4, 57, 5, 735, 1596, 526, 129, 161, 153, 3, 94, 1, 577, 2347, 377, 3840, 1, 4968, 9, 75, 1898, 1549, 22, 8, 189, 283, 2, 32, 8, 202, 9, 3, 1783, 1, 219, 1943, 26, 2817, 2004, 3, 291, 922, 23, 3, 343, 1, 1062, 1425, 2, 211, 295, 3953, 1062, 2, 1425, 22, 149, 22, 3, 345, 1, 26, 922, 23, 3, 193, 1, 8, 4856, 1401, 238, 36, 353]",1549.0,12755554,87
Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2003-05-01,"Multiple myeloma may be cured by myeloablative conditioning and allogeneic blood or marrow transplantation (alloBMT), but this occurs at the expense of high transplant-related mortality. In an endeavor to reduce procedure-related toxicity, this study retrospectively evaluated the safety, tolerability, and efficacy of T cell depletion by counterflow centrifugal elutriation before alloBMT. Fifty-one patients with stage II (6) or III (45) multiple myeloma received alloBMTs using T cell depletion by elutriation. Fifty-three percent (27 of 51) of patients had primary refractory disease at the time of transplantation, 10% (5 of 51) had relapsed disease, and 4% (2 of 51) had refractory relapsed disease. The median age was 49 (range, 32 to 62) years, and the median time from diagnosis to transplantation was 9 (range, 4 to 58) months. Patients had received a median of 1 (range, 1 to 3) regimen and 4 (range, 2 to 16) cycles of chemotherapy. In this population, transplant-related mortality rate was 24% (12 of 51) with 2 patients dying of graft-versus-host disease (GVHD). Thirty-one of 39 evaluable patients have experienced relapse, and the probability of progression-free survival 5 years after alloBMT alone is 16%. Sixteen patients were given donor lymphocyte infusions (DLI) at the time of relapse (n = 11) or for persistent disease 1 year after transplantation (n = 5). Acute or chronic GVHD was seen in 63% (10 of 16) of patients given DLI. Responses were seen in 8 of 16 patients (6 complete response [CR], 2 partial response [PR]) with 6 of 8 responding patients having GVHD. Five recipients of DLI remain in a continuous CR, ranging from 3 to 64 months in duration. Thus, like chronic myelogenous leukemia, allogeneic T cells appear to have potent antimyeloma activity that is critical for achieving a cure. DLI-induced remissions of multiple myeloma can be durable, even in patients with refractory multiple myeloma. Unlike chronic myelogenous leukemia, the antimyeloma effect of allogeneic T cells rarely occurs in the absence of clinically significant GVHD.",Journal Article,6109.0,25.0,Multiple may be cured by myeloablative conditioning and allogeneic blood or marrow transplantation alloBMT but this occurs at the expense of high transplant-related mortality In an endeavor to reduce procedure-related toxicity this study retrospectively evaluated the safety tolerability and efficacy of T cell depletion by counterflow centrifugal elutriation before alloBMT Fifty-one patients with stage II 6 or III 45 multiple received alloBMTs using T cell depletion by elutriation Fifty-three percent 27 of 51 of patients had primary refractory disease at the time of transplantation 10 5 of 51 had relapsed disease and 4 2 of 51 had refractory relapsed disease The median age was 49 range 32 to 62 years and the median time from diagnosis to transplantation was 9 range 4 to 58 months Patients had received a median of 1 range 1 to 3 regimen and 4 range 2 to 16 cycles of chemotherapy In this population transplant-related mortality rate was 24 12 of 51 with 2 patients dying of graft-versus-host disease GVHD Thirty-one of 39 evaluable patients have experienced relapse and the probability of progression-free survival 5 years after alloBMT alone is 16 Sixteen patients were given donor lymphocyte infusions DLI at the time of relapse n 11 or for persistent disease 1 year after transplantation n 5 Acute or chronic GVHD was seen in 63 10 of 16 of patients given DLI Responses were seen in 8 of 16 patients 6 complete response CR 2 partial response PR with 6 of 8 responding patients having GVHD Five recipients of DLI remain in a continuous CR ranging from 3 to 64 months in duration Thus like chronic myelogenous allogeneic T cells appear to have potent antimyeloma activity that is critical for achieving a cure DLI-induced remissions of multiple can be durable even in patients with refractory multiple Unlike chronic myelogenous the antimyeloma effect of allogeneic T cells rarely occurs in the absence of clinically significant GVHD,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[232, 68, 40, 3733, 20, 3246, 1933, 2, 1063, 315, 15, 581, 497, 13051, 84, 26, 1780, 28, 3, 8563, 1, 64, 941, 139, 282, 4, 35, 12131, 6, 969, 1299, 139, 155, 26, 45, 894, 194, 3, 367, 1543, 2, 209, 1, 102, 31, 2286, 20, 53544, 53545, 28055, 348, 13051, 1461, 104, 7, 5, 82, 215, 49, 15, 316, 512, 232, 103, 30418, 75, 102, 31, 2286, 20, 28055, 1461, 169, 714, 428, 1, 725, 1, 7, 42, 86, 430, 34, 28, 3, 98, 1, 497, 79, 33, 1, 725, 42, 591, 34, 2, 39, 18, 1, 725, 42, 430, 591, 34, 3, 52, 89, 10, 739, 184, 531, 6, 744, 60, 2, 3, 52, 98, 29, 147, 6, 497, 10, 83, 184, 39, 6, 717, 53, 7, 42, 103, 8, 52, 1, 14, 184, 14, 6, 27, 477, 2, 39, 184, 18, 6, 245, 410, 1, 56, 4, 26, 266, 941, 139, 282, 116, 10, 259, 133, 1, 725, 5, 18, 7, 4536, 1, 1599, 185, 1204, 34, 1562, 977, 104, 1, 587, 859, 7, 47, 592, 429, 2, 3, 1320, 1, 91, 115, 25, 33, 60, 50, 13051, 279, 16, 245, 3228, 7, 11, 447, 1488, 1448, 3435, 4676, 28, 3, 98, 1, 429, 78, 175, 15, 9, 1882, 34, 14, 111, 50, 497, 78, 33, 286, 15, 442, 1562, 10, 527, 4, 676, 79, 1, 245, 1, 7, 447, 4676, 253, 11, 527, 4, 66, 1, 245, 7, 49, 236, 51, 684, 18, 450, 51, 998, 5, 49, 1, 66, 3261, 7, 1041, 1562, 365, 2190, 1, 4676, 918, 4, 8, 1314, 684, 2223, 29, 27, 6, 660, 53, 4, 654, 631, 733, 442, 2194, 1063, 102, 37, 1322, 6, 47, 1157, 9115, 128, 17, 16, 740, 9, 1785, 8, 1722, 4676, 277, 3166, 1, 232, 122, 40, 1480, 871, 4, 7, 5, 430, 232, 4246, 442, 2194, 3, 9115, 254, 1, 1063, 102, 37, 2416, 1780, 4, 3, 1127, 1, 505, 93, 1562]",1944.0,12766881,186
Molecular mechanisms of transformation by the BCR-ABL oncogene.,Seminars in hematology,Semin. Hematol.,2003-04-01,"The BCR-ABL oncogene is generated by the Philadelphia chromosome (Ph) translocation, fusing the BCR gene to the ABL gene. The BCR-ABL fusion protein has elevated ABL tyrosine kinase activity that is critical for transformation of hematopoietic cells. Chronic myelogenous leukemia (CML) cells transformed by BCR-ABL show reduced growth factor requirements and apoptosis, as well as enhanced viability and altered adhesion. The elevated ABL kinase activity leads to chronic activation of signaling pathways that are required for all aspects of transformation. Progression of the disease from chronic phase to blast crisis correlates with additional cytogenetic alterations that are likely to contribute to the failure of traditional therapy. This review describes molecular mechanisms that are thought to be important for transformation by the BCR-ABL oncoprotein and points at pathways for targeted drug development in the treatment of CML.",Journal Article,6139.0,142.0,The BCR-ABL oncogene is generated by the Philadelphia chromosome Ph translocation fusing the BCR gene to the ABL gene The BCR-ABL fusion protein has elevated ABL tyrosine kinase activity that is critical for transformation of hematopoietic cells Chronic myelogenous CML cells transformed by BCR-ABL show reduced growth factor requirements and apoptosis as well as enhanced viability and altered adhesion The elevated ABL kinase activity leads to chronic activation of signaling pathways that are required for all aspects of transformation Progression of the disease from chronic phase to blast crisis correlates with additional cytogenetic alterations that are likely to contribute to the failure of traditional therapy This review describes molecular mechanisms that are thought to be important for transformation by the BCR-ABL oncoprotein and points at pathways for targeted drug development in the treatment of CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1062, 1425, 1836, 16, 1419, 20, 3, 3006, 1170, 2058, 2006, 20181, 3, 1062, 145, 6, 3, 1425, 145, 3, 1062, 1425, 1212, 178, 71, 804, 1425, 564, 216, 128, 17, 16, 740, 9, 1392, 1, 1007, 37, 442, 2194, 903, 37, 2423, 20, 1062, 1425, 514, 405, 129, 161, 4230, 2, 351, 22, 149, 22, 651, 2120, 2, 1495, 2128, 3, 804, 1425, 216, 128, 1940, 6, 442, 363, 1, 314, 460, 17, 32, 616, 9, 62, 2695, 1, 1392, 91, 1, 3, 34, 29, 442, 124, 6, 3112, 6540, 1871, 5, 402, 1266, 593, 17, 32, 322, 6, 1248, 6, 3, 496, 1, 1847, 36, 26, 206, 2677, 219, 483, 17, 32, 2739, 6, 40, 305, 9, 1392, 20, 3, 1062, 1425, 6159, 2, 862, 28, 460, 9, 238, 234, 193, 4, 3, 24, 1, 903]",918.0,12783368,128
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.,Cancer,Cancer,2003-06-01,"To evaluate the activity and toxicity of weekly Schering 54301, a polyethylene glycol formulation of interferon- alpha-2b (PEG-IFN-alpha-2b), with cytosine arabinoside (ara-C) in patients with chronic myelogenous leukemia (CML). Seventy-six patients with Philadelphia chromosome (Ph)-positive early chronic-phase CML were treated with the combination of PEG-IFN-alpha-2b and ara-C (10 mg daily subcutaneously [s.c.]). The starting dose of PEG-IFN-alpha-2b was 6 microg/kg s.c. weekly in the first 24 patients but was reduced to 4.5 microg/kg in the next 52 patients. Overall, 73% of patients had a complete hematologic response, 35% of patients had a major cytogenetic response (Ph < 35%), and 21% of patients had a complete cytogenetic response (Ph = 0%). With a median follow-up of 19 months, the estimated 2-year survival rate was 89%. Therapy was discontinued in 24% of patients due to Grade III-IV toxicity. Frequent severe side effects that required dose reductions included neutropenia (49%), fatigue (43%), and neurologic toxicity (17%). The median PEG-IFN-alpha-2b and ara-C doses delivered were 3 microg/kg weekly and 7.5 mg daily, respectively, at 12 months of therapy. The activity and toxicity profiles of this combination was similar to those observed in historical patients treated with IFN-alpha and cytarabine. The combination of PEG-IFN-alpha-2b and ara-C is active but has significant toxicity in patients with chronic-phase CML at the dose schedule used. The recommended dose of PEG-IFN-alpha-2b in future combination studies is 3 microg/kg or less.",Clinical Trial,6078.0,9.0,To evaluate the activity and toxicity of weekly Schering 54301 a polyethylene glycol formulation of interferon- alpha-2b PEG-IFN-alpha-2b with cytosine arabinoside ara-C in patients with chronic myelogenous CML Seventy-six patients with Philadelphia chromosome Ph -positive early chronic-phase CML were treated with the combination of PEG-IFN-alpha-2b and ara-C 10 mg daily subcutaneously s.c. The starting dose of PEG-IFN-alpha-2b was 6 microg/kg s.c. weekly in the first 24 patients but was reduced to 4.5 microg/kg in the next 52 patients Overall 73 of patients had a complete hematologic response 35 of patients had a major cytogenetic response Ph 35 and 21 of patients had a complete cytogenetic response Ph 0 With a median follow-up of 19 months the estimated 2-year survival rate was 89 Therapy was discontinued in 24 of patients due to Grade III-IV toxicity Frequent severe side effects that required dose reductions included neutropenia 49 fatigue 43 and neurologic toxicity 17 The median PEG-IFN-alpha-2b and ara-C doses delivered were 3 microg/kg weekly and 7.5 mg daily respectively at 12 months of therapy The activity and toxicity profiles of this combination was similar to those observed in historical patients treated with IFN-alpha and cytarabine The combination of PEG-IFN-alpha-2b and ara-C is active but has significant toxicity in patients with chronic-phase CML at the dose schedule used The recommended dose of PEG-IFN-alpha-2b in future combination studies is 3 microg/kg or less,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 3, 128, 2, 155, 1, 709, 26175, 53557, 8, 12997, 10809, 3583, 1, 1688, 950, 3381, 3145, 1256, 950, 3381, 5, 6903, 11563, 3899, 256, 4, 7, 5, 442, 2194, 903, 2073, 437, 7, 5, 3006, 1170, 2058, 109, 191, 442, 124, 903, 11, 73, 5, 3, 150, 1, 3145, 1256, 950, 3381, 2, 3899, 256, 79, 81, 391, 3928, 695, 256, 3, 1723, 61, 1, 3145, 1256, 950, 3381, 10, 49, 2440, 503, 695, 256, 709, 4, 3, 157, 259, 7, 84, 10, 405, 6, 39, 33, 2440, 503, 4, 3, 1305, 653, 7, 63, 803, 1, 7, 42, 8, 236, 813, 51, 465, 1, 7, 42, 8, 458, 1266, 51, 2058, 465, 2, 239, 1, 7, 42, 8, 236, 1266, 51, 2058, 13, 5, 8, 52, 166, 126, 1, 326, 53, 3, 661, 18, 111, 25, 116, 10, 887, 36, 10, 2402, 4, 259, 1, 7, 520, 6, 88, 316, 478, 155, 908, 905, 1152, 176, 17, 616, 61, 2153, 159, 778, 739, 613, 601, 2, 2543, 155, 269, 3, 52, 3145, 1256, 950, 3381, 2, 3899, 256, 415, 1623, 11, 27, 2440, 503, 709, 2, 67, 33, 81, 391, 106, 28, 133, 53, 1, 36, 3, 128, 2, 155, 1241, 1, 26, 150, 10, 288, 6, 135, 164, 4, 2252, 7, 73, 5, 1256, 950, 2, 1855, 3, 150, 1, 3145, 1256, 950, 3381, 2, 3899, 256, 16, 544, 84, 71, 93, 155, 4, 7, 5, 442, 124, 903, 28, 3, 61, 1055, 95, 3, 793, 61, 1, 3145, 1256, 950, 3381, 4, 508, 150, 94, 16, 27, 2440, 503, 15, 299]",1504.0,12784336,163
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.,Cancer,Cancer,2003-08-01,"General and site-specific DNA methylation is associated with tumor progression and resistance in several cancers, including chronic myelogenous leukemia (CML). Decitabine is a hypomethylating agent that has shown encouraging preliminary anti-CML activity. This study evaluated the activity and toxicity of decitabine in different phases of CML. One hundred and thirty patients with CML were treated: 123 with Philadelphia chromosome (Ph)-positive CML (64 blastic, 51 accelerated, 8 chronic) and 7 with Ph-negative CML. Decitabine was given at 100 mg/m(2) over 6 hours every 12 hours x 5 days (1000 mg/m(2) per course) in the first 13 patients, 75 mg/m(2) in the subsequent 33 patients, and 50 mg/m(2) in the remaining 84 patients. A total of 552 courses were given to the 130 patients. Only four patients (3%) died during the first course from myelosuppressive complications (three patients) or progressive disease (one patient). Of 64 patients in the CML blastic phase, 18 patients (28%) achieved objective responses. Of these 18 patients, 6 achieved complete hematologic responses (CHR), 2 achieved partial hematologic responses (PHR), 7 achieved hematologic improvements (HI), and 3 returned to the second chronic phase (second CP). Five patients (8%) had cytogenetic responses. Among 51 patients in the accelerated phase, 28 patients (55%) achieved objective responses (12 CHR, 10 PHR, 3 HI, and 3 second CP). Seven patients (14%) had cytogenetic responses. Among eight patients treated in the chronic phase, five (63%) had objective responses. Of seven patients treated for Ph-negative CML, four (57%) had objective responses. There was no evidence of a dose-response effect. The estimated 3-year survival rate was less than 5% in the blastic phase and 27% in the accelerated phase. The only significant toxicity reported was severe myelosuppression, which was delayed, prolonged, and dose dependent. With decitabine 50-75 mg/m(2), the median time to granulocyte recovery above 0.5 x 10(9)/L was about 4 weeks. Myelosuppression-associated complications included febrile episodes in 37% and documented infections in 34%. Decitabine appears to have significant anti-CML activity. Future studies should evaluate lower-dose, longer-exposure decitabine schedules alone in imatinib-resistant CML, as well as combinations of decitabine and imatinib in different CML phases.",Journal Article,6017.0,185.0,General and site-specific DNA methylation is associated with tumor progression and resistance in several cancers including chronic myelogenous CML Decitabine is a hypomethylating agent that has shown encouraging preliminary anti-CML activity This study evaluated the activity and toxicity of decitabine in different phases of CML One hundred and thirty patients with CML were treated 123 with Philadelphia chromosome Ph -positive CML 64 blastic 51 accelerated 8 chronic and 7 with Ph-negative CML Decitabine was given at 100 mg/m 2 over 6 hours every 12 hours x 5 days 1000 mg/m 2 per course in the first 13 patients 75 mg/m 2 in the subsequent 33 patients and 50 mg/m 2 in the remaining 84 patients A total of 552 courses were given to the 130 patients Only four patients 3 died during the first course from myelosuppressive complications three patients or progressive disease one patient Of 64 patients in the CML blastic phase 18 patients 28 achieved objective responses Of these 18 patients 6 achieved complete hematologic responses CHR 2 achieved partial hematologic responses PHR 7 achieved hematologic improvements HI and 3 returned to the second chronic phase second CP Five patients 8 had cytogenetic responses Among 51 patients in the accelerated phase 28 patients 55 achieved objective responses 12 CHR 10 PHR 3 HI and 3 second CP Seven patients 14 had cytogenetic responses Among eight patients treated in the chronic phase five 63 had objective responses Of seven patients treated for Ph-negative CML four 57 had objective responses There was no evidence of a dose-response effect The estimated 3-year survival rate was less than 5 in the blastic phase and 27 in the accelerated phase The only significant toxicity reported was severe myelosuppression which was delayed prolonged and dose dependent With decitabine 50-75 mg/m 2 the median time to granulocyte recovery above 0.5 x 10 9 /L was about 4 weeks Myelosuppression-associated complications included febrile episodes in 37 and documented infections in 34 Decitabine appears to have significant anti-CML activity Future studies should evaluate lower-dose longer-exposure decitabine schedules alone in imatinib-resistant CML as well as combinations of decitabine and imatinib in different CML phases,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1083, 2, 606, 112, 261, 569, 16, 41, 5, 30, 91, 2, 251, 4, 392, 163, 141, 442, 2194, 903, 3004, 16, 8, 4931, 420, 17, 71, 443, 2269, 1676, 312, 903, 128, 26, 45, 194, 3, 128, 2, 155, 1, 3004, 4, 338, 3523, 1, 903, 104, 1128, 2, 977, 7, 5, 903, 11, 73, 2698, 5, 3006, 1170, 2058, 109, 903, 660, 6529, 725, 2241, 66, 442, 2, 67, 5, 2058, 199, 903, 3004, 10, 447, 28, 394, 81, 188, 18, 252, 49, 1459, 454, 133, 1459, 1006, 33, 162, 2345, 81, 188, 18, 379, 906, 4, 3, 157, 233, 7, 481, 81, 188, 18, 4, 3, 706, 466, 7, 2, 212, 81, 188, 18, 4, 3, 1844, 874, 7, 8, 181, 1, 10097, 1993, 11, 447, 6, 3, 3431, 7, 158, 294, 7, 27, 1016, 190, 3, 157, 906, 29, 11109, 521, 169, 7, 15, 1014, 34, 104, 69, 1, 660, 7, 4, 3, 903, 6529, 124, 203, 7, 339, 513, 461, 253, 1, 46, 203, 7, 49, 513, 236, 813, 253, 8158, 18, 513, 450, 813, 253, 43313, 67, 513, 813, 1474, 5910, 2, 27, 5157, 6, 3, 419, 442, 124, 419, 2541, 365, 7, 66, 42, 1266, 253, 107, 725, 7, 4, 3, 2241, 124, 339, 7, 614, 513, 461, 253, 133, 8158, 79, 43313, 27, 5910, 2, 27, 419, 2541, 648, 7, 213, 42, 1266, 253, 107, 659, 7, 73, 4, 3, 442, 124, 365, 676, 42, 461, 253, 1, 648, 7, 73, 9, 2058, 199, 903, 294, 696, 42, 461, 253, 125, 10, 77, 241, 1, 8, 61, 51, 254, 3, 661, 27, 111, 25, 116, 10, 299, 76, 33, 4, 3, 6529, 124, 2, 428, 4, 3, 2241, 124, 3, 158, 93, 155, 210, 10, 905, 2858, 92, 10, 1612, 1069, 2, 61, 470, 5, 3004, 212, 481, 81, 188, 18, 3, 52, 98, 6, 2764, 1602, 2090, 13, 33, 1006, 79, 83, 805, 10, 545, 39, 244, 2858, 41, 521, 159, 2498, 3750, 4, 567, 2, 1405, 1875, 4, 562, 3004, 1233, 6, 47, 93, 312, 903, 128, 508, 94, 257, 376, 280, 61, 589, 645, 3004, 2314, 279, 4, 577, 436, 903, 22, 149, 22, 1247, 1, 3004, 2, 577, 4, 338, 903, 3523]",2267.0,12879469,260
"Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.",Cancer,Cancer,2003-08-01,"Tyrosine kinases, such as c-KIT, c-ABL, and platelet-derived growth factor-beta (PDGFR-beta), are important regulators of cell growth. Highly potent and selective inhibitors of tyrosine kinases are being investigated as alternatives to standard chemotherapy. One such inhibitor, imatinib mesylate, is being used to treat gastrointestinal stromal tumors and chronic myelogenous leukemia. Ovarian carcinomas frequently develop resistance to conventional chemotherapeutic agents. Immunohistochemical expression of c-ABL, PDGFR-beta, and c-KIT was evaluated in ovarian carcinomas to determine whether treatment with imatinib mesylate might be feasible. The expression of c-ABL, c-KIT, and PDGFR-beta in tumors was evaluated by immunohistochemical analysis of 52 ovarian serous carcinomas, including 21 low-grade (well differentiated) and 31 high-grade (poorly differentiated) tumors. Fourteen normal ovaries were also evaluated. In normal ovarian surface epithelium, c-ABL was expressed universally. PDGFR-beta was expressed in the majority (93%) of samples of normal ovarian epithelium, whereas the c-KIT protein was undetectable in normal ovarian surface epithelium. Overall, c-ABL was expressed in 71% of serous carcinomas. c-ABL was expressed more frequently in the low-grade serous carcinomas (81%) compared with the high-grade serous carcinomas (65%). PDGFR-beta expression was observed in 81% of serous carcinomas overall and was observed more frequently in higher-grade tumors. c-KIT immunohistochemical staining was absent in low-grade tumors but was present in 26% of high-grade serous carcinomas. The majority of ovarian serous carcinomas express one or more of the kinases targeted by the tyrosine kinase inhibitor, imatinib mesylate, suggesting the potential usefulness of this drug in the treatment of ovarian carcinoma.",Journal Article,6017.0,97.0,Tyrosine kinases such as c-KIT c-ABL and platelet-derived growth factor-beta PDGFR-beta are important regulators of cell growth Highly potent and selective inhibitors of tyrosine kinases are being investigated as alternatives to standard chemotherapy One such inhibitor imatinib mesylate is being used to treat stromal tumors and chronic myelogenous carcinomas frequently develop resistance to conventional chemotherapeutic agents Immunohistochemical expression of c-ABL PDGFR-beta and c-KIT was evaluated in carcinomas to determine whether treatment with imatinib mesylate might be feasible The expression of c-ABL c-KIT and PDGFR-beta in tumors was evaluated by immunohistochemical analysis of 52 serous carcinomas including 21 low-grade well differentiated and 31 high-grade poorly differentiated tumors Fourteen normal ovaries were also evaluated In normal surface epithelium c-ABL was expressed universally PDGFR-beta was expressed in the majority 93 of samples of normal epithelium whereas the c-KIT protein was undetectable in normal surface epithelium Overall c-ABL was expressed in 71 of serous carcinomas c-ABL was expressed more frequently in the low-grade serous carcinomas 81 compared with the high-grade serous carcinomas 65 PDGFR-beta expression was observed in 81 of serous carcinomas overall and was observed more frequently in higher-grade tumors c-KIT immunohistochemical staining was absent in low-grade tumors but was present in 26 of high-grade serous carcinomas The majority of serous carcinomas express one or more of the kinases targeted by the tyrosine kinase inhibitor imatinib mesylate suggesting the potential usefulness of this drug in the treatment of carcinoma,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[564, 1549, 225, 22, 256, 1164, 256, 1425, 2, 1596, 526, 129, 161, 1090, 4103, 1090, 32, 305, 3196, 1, 31, 129, 561, 1157, 2, 1094, 222, 1, 564, 1549, 32, 486, 565, 22, 6295, 6, 260, 56, 104, 225, 230, 577, 2347, 16, 486, 95, 6, 943, 1126, 57, 2, 442, 2194, 826, 746, 690, 251, 6, 809, 1573, 183, 1382, 55, 1, 256, 1425, 4103, 1090, 2, 256, 1164, 10, 194, 4, 826, 6, 223, 317, 24, 5, 577, 2347, 822, 40, 1313, 3, 55, 1, 256, 1425, 256, 1164, 2, 4103, 1090, 4, 57, 10, 194, 20, 1382, 65, 1, 653, 1744, 826, 141, 239, 154, 88, 149, 1442, 2, 456, 64, 88, 1240, 1442, 57, 3225, 295, 7262, 11, 120, 194, 4, 295, 1255, 2781, 256, 1425, 10, 570, 6813, 4103, 1090, 10, 570, 4, 3, 686, 966, 1, 347, 1, 295, 2781, 547, 3, 256, 1164, 178, 10, 3920, 4, 295, 1255, 2781, 63, 256, 1425, 10, 570, 4, 792, 1, 1744, 826, 256, 1425, 10, 570, 80, 746, 4, 3, 154, 88, 1744, 826, 865, 72, 5, 3, 64, 88, 1744, 826, 556, 4103, 1090, 55, 10, 164, 4, 865, 1, 1744, 826, 63, 2, 10, 164, 80, 746, 4, 142, 88, 57, 256, 1164, 1382, 1029, 10, 3269, 4, 154, 88, 57, 84, 10, 364, 4, 432, 1, 64, 88, 1744, 826, 3, 686, 1, 1744, 826, 1669, 104, 15, 80, 1, 3, 1549, 238, 20, 3, 564, 216, 230, 577, 2347, 802, 3, 174, 5235, 1, 26, 234, 4, 3, 24, 1, 134]",1692.0,12910520,80
"Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.",Leukemia research,Leuk. Res.,2003-12-01,"A phase II study of troxacitabine, a non-natural dioxolane nucleoside L-enantiomer, was conducted in patients with chronic myelogenous leukemia in blastic phase (CML-BP). Patients were untreated for BP, or treated with imatinib mesylate (IM) as sole prior therapy for BP. Troxacitabine was given as an intravenous infusion over 30 min daily for 5 days at a dose of 8.0 mg/m(2) per day. Thirty-one patients, 29 (93%) of whom had failed prior IM therapy, received 51 courses of therapy. Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML.",Clinical Trial,5895.0,20.0,A phase II study of troxacitabine a non-natural dioxolane nucleoside L-enantiomer was conducted in patients with chronic myelogenous in blastic phase CML-BP Patients were untreated for BP or treated with imatinib mesylate IM as sole prior therapy for BP Troxacitabine was given as an intravenous infusion over 30 min daily for 5 days at a dose of 8.0 mg/m 2 per day Thirty-one patients 29 93 of whom had failed prior IM therapy received 51 courses of therapy Grade 3 or 4 toxicities included stomatitis 4 hand-foot syndrome 18 and rash 12 Four patients 13 responded Troxacitabine-based combinations merit study in IM-resistant CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[8, 124, 215, 45, 1, 10949, 8, 220, 1504, 42835, 4032, 805, 30314, 10, 426, 4, 7, 5, 442, 2194, 4, 6529, 124, 903, 3044, 7, 11, 1278, 9, 3044, 15, 73, 5, 577, 2347, 2820, 22, 4991, 324, 36, 9, 3044, 10949, 10, 447, 22, 35, 1262, 904, 252, 201, 1538, 391, 9, 33, 162, 28, 8, 61, 1, 66, 13, 81, 188, 18, 379, 218, 977, 104, 7, 462, 966, 1, 953, 42, 1551, 324, 2820, 36, 103, 725, 1993, 1, 36, 88, 27, 15, 39, 385, 159, 4486, 39, 2833, 4100, 681, 203, 2, 1641, 133, 294, 7, 233, 2211, 10949, 90, 1247, 7062, 45, 4, 2820, 436, 903]",630.0,12921945,32
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.,Haematologica,Haematologica,2003-08-01,"Imatinib mesylate (IM) is the choice treatment for Bcr/Abl-positive malignancies. Emergence of resistance to IM warrants the exploration of novel well-tolerated anticancer agents. We intended to evaluate the effect of PS-341 on proliferation, survival, and cellular events in Bcr/Abl-positive cells sensitive and resistant to IM, and to investigate the effect of PS-341 and IM in conjunction. Bcr/Abl-positive cell lines sensitive (p210Bcr/Abl KBM5, p210Bcr/Abl KBM7, and p190Bcr/Abl Z-119) or resistant (KBM5-R) to IM were treated with PS-341 alone or in combination with IM. The effect on cell growth was determined using the MTT assay. Cell-cycle analysis was performed by propidium iodide staining. Apoptosis was evaluated by measurement of sub-G1 DNA content, annexin V binding, and caspase 3 activity assays. Levels of apoptotic proteins, P-IkBalpha, Bcr/Abl, and phosphorylated Bcr/Abl were determined by western blotting. NF-kappaB activity was evaluated by electromobility gel shift assays. PS-341 exerted growth inhibition effects in IM-sensitive and -resistant cells. This phenomenon correlated with accumulation of cells in the G2/M phase of cell cycle; transient downregulation of NFkappaB DNA binding activity; downregulation of Bcl-xL; activation of caspase 3, induction of apoptosis; inhibition of expression and phosphorylation of Bcr/Abl. Sequential combination of PS-341 followed by IM demonstrated a synergistic pro-apoptotic effect in IM-sensitive cells; concomitant exposure was antagonistic. PS-341 suppresses growth and induces apoptosis in Bcr/Abl-positive cells sensitive and resistant to IM. The use of PS-341 should be explored in patients with chronic myelogenous leukemia resistant to IM. Trials of combinations of PS-341 and IM require cautious design.",Journal Article,6017.0,72.0,Imatinib mesylate IM is the choice treatment for Bcr/Abl-positive malignancies Emergence of resistance to IM warrants the exploration of novel well-tolerated anticancer agents We intended to evaluate the effect of PS-341 on proliferation survival and cellular events in Bcr/Abl-positive cells sensitive and resistant to IM and to investigate the effect of PS-341 and IM in conjunction Bcr/Abl-positive cell lines sensitive p210Bcr/Abl KBM5 p210Bcr/Abl KBM7 and p190Bcr/Abl Z-119 or resistant KBM5-R to IM were treated with PS-341 alone or in combination with IM The effect on cell growth was determined using the MTT assay Cell-cycle analysis was performed by propidium iodide staining Apoptosis was evaluated by measurement of sub-G1 DNA content annexin V binding and caspase 3 activity assays Levels of apoptotic proteins P-IkBalpha Bcr/Abl and phosphorylated Bcr/Abl were determined by western blotting NF-kappaB activity was evaluated by electromobility gel shift assays PS-341 exerted growth inhibition effects in IM-sensitive and -resistant cells This phenomenon correlated with accumulation of cells in the G2/M phase of cell cycle transient downregulation of NFkappaB DNA binding activity downregulation of Bcl-xL activation of caspase 3 induction of apoptosis inhibition of expression and phosphorylation of Bcr/Abl Sequential combination of PS-341 followed by IM demonstrated a synergistic pro-apoptotic effect in IM-sensitive cells concomitant exposure was antagonistic PS-341 suppresses growth and induces apoptosis in Bcr/Abl-positive cells sensitive and resistant to IM The use of PS-341 should be explored in patients with chronic myelogenous resistant to IM Trials of combinations of PS-341 and IM require cautious design,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 2347, 2820, 16, 3, 1866, 24, 9, 1062, 1425, 109, 441, 3397, 1, 251, 6, 2820, 2782, 3, 3370, 1, 229, 149, 421, 1475, 183, 21, 4081, 6, 376, 3, 254, 1, 1511, 4065, 23, 457, 25, 2, 763, 281, 4, 1062, 1425, 109, 37, 745, 2, 436, 6, 2820, 2, 6, 963, 3, 254, 1, 1511, 4065, 2, 2820, 4, 3357, 1062, 1425, 109, 31, 285, 745, 37526, 1425, 10822, 37526, 1425, 18206, 2, 43024, 1425, 3905, 4299, 15, 436, 10822, 668, 6, 2820, 11, 73, 5, 1511, 4065, 279, 15, 4, 150, 5, 2820, 3, 254, 23, 31, 129, 10, 509, 75, 3, 4988, 719, 31, 417, 65, 10, 173, 20, 10839, 8456, 1029, 351, 10, 194, 20, 2204, 1, 551, 3344, 261, 2457, 4850, 603, 791, 2, 1469, 27, 128, 1013, 148, 1, 1631, 652, 19, 53703, 1062, 1425, 2, 2365, 1062, 1425, 11, 509, 20, 1521, 3661, 1365, 2119, 128, 10, 194, 20, 28011, 5916, 3024, 1013, 1511, 4065, 8753, 129, 297, 176, 4, 2820, 745, 2, 436, 37, 26, 3936, 438, 5, 1835, 1, 37, 4, 3, 3774, 188, 124, 1, 31, 417, 2473, 2475, 1, 6469, 261, 791, 128, 2475, 1, 1044, 3870, 363, 1, 1469, 27, 504, 1, 351, 297, 1, 55, 2, 982, 1, 1062, 1425, 1787, 150, 1, 1511, 4065, 370, 20, 2820, 264, 8, 1806, 1805, 1631, 254, 4, 2820, 745, 37, 1781, 645, 10, 9863, 1511, 4065, 4079, 129, 2, 1516, 351, 4, 1062, 1425, 109, 37, 745, 2, 436, 6, 2820, 3, 119, 1, 1511, 4065, 257, 40, 1443, 4, 7, 5, 442, 2194, 436, 6, 2820, 143, 1, 1247, 1, 1511, 4065, 2, 2820, 1353, 17741, 771]",1737.0,12935973,2
"Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.",Cancer,Cancer,2003-09-01,"Before the discovery of imatinib mesylate, a Bcr-Abl selective tyrosine kinase inhibitor, three agents, interferon-alpha (IFN-alpha), cytarabine (ara-C), and homoharringtonine (HHT), had demonstrated activity against Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) as single agents and in couplet combinations. The goals of the current study were to evaluate the efficacy of the triple combination regimen with IFN-alpha, ara-C, and HHT in newly diagnosed Ph-positive CML and to assess the impact of the added sequential therapy with imatinib on overall prognosis. Ninety patients with Ph-positive CML in early chronic phase received the triple regimen. Therapy consisted of 5 million units (MU)/m(2) IFN-alpha subcutaneously (s.c. daily, ara-C 10 mg s.c. daily, and HHT 2.5 mg/m(2) by continuous infusion over 24 hours daily x 5 every month. After a median duration of 16.5 months of therapy, 78 patients had their therapy changed to 400 mg orally administered imatinib daily. With the triple regimen, 85 patients (94%) achieved complete hematologic response and 67 patients (74%) had a cytogenetic response (Ph suppression to < or = 90%) which was complete (Ph 0%) in 20 patients (22%) and major in 42 patients (46%). Myelosuppression was significant, resulting in considerable reductions in the dose schedules. After 12 months of therapy, the median IFN-alpha dose was 1.6 MU/m(2) daily, the median ara-C dose was 1.85 mg daily, and the median number of HHT days was 2 every month. Only three patients developed blastic phase while receiving the triple regimen. With the change to imatinib therapy, currently 57 patients (63%) are in complete cytogenetic response and 69 patients (76%) in major cytogenetic response. With a median follow-up time of 46 months for the total study group, the estimated 5-year survival rate was 88%, and only 8 patients (9%) to date have developed blastic phase. The sequence of IFN-alpha, ara-C, and HHT followed by imatinib (imposed by the discovery of the latter drug) resulted in an estimated 5-year survival rate of 88%. This finding suggests that imatinib combination regimens may improve the prognosis in CML.",Clinical Trial,5986.0,56.0,Before the discovery of imatinib mesylate a Bcr-Abl selective tyrosine kinase inhibitor three agents interferon-alpha IFN-alpha cytarabine ara-C and homoharringtonine HHT had demonstrated activity against Philadelphia chromosome Ph -positive chronic myelogenous CML as single agents and in couplet combinations The goals of the current study were to evaluate the efficacy of the triple combination regimen with IFN-alpha ara-C and HHT in newly diagnosed Ph-positive CML and to assess the impact of the added sequential therapy with imatinib on overall prognosis Ninety patients with Ph-positive CML in early chronic phase received the triple regimen Therapy consisted of 5 million units MU /m 2 IFN-alpha subcutaneously s.c. daily ara-C 10 mg s.c. daily and HHT 2.5 mg/m 2 by continuous infusion over 24 hours daily x 5 every month After a median duration of 16.5 months of therapy 78 patients had their therapy changed to 400 mg orally administered imatinib daily With the triple regimen 85 patients 94 achieved complete hematologic response and 67 patients 74 had a cytogenetic response Ph suppression to or 90 which was complete Ph 0 in 20 patients 22 and major in 42 patients 46 Myelosuppression was significant resulting in considerable reductions in the dose schedules After 12 months of therapy the median IFN-alpha dose was 1.6 MU/m 2 daily the median ara-C dose was 1.85 mg daily and the median number of HHT days was 2 every month Only three patients developed blastic phase while receiving the triple regimen With the change to imatinib therapy currently 57 patients 63 are in complete cytogenetic response and 69 patients 76 in major cytogenetic response With a median follow-up time of 46 months for the total study group the estimated 5-year survival rate was 88 and only 8 patients 9 to date have developed blastic phase The sequence of IFN-alpha ara-C and HHT followed by imatinib imposed by the discovery of the latter drug resulted in an estimated 5-year survival rate of 88 This finding suggests that imatinib combination regimens may improve the prognosis in CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[348, 3, 1574, 1, 577, 2347, 8, 1062, 1425, 1094, 564, 216, 230, 169, 183, 1688, 950, 1256, 950, 1855, 3899, 256, 2, 18768, 9249, 42, 264, 128, 480, 3006, 1170, 2058, 109, 442, 2194, 903, 22, 226, 183, 2, 4, 33499, 1247, 3, 2802, 1, 3, 291, 45, 11, 6, 376, 3, 209, 1, 3, 1500, 150, 477, 5, 1256, 950, 3899, 256, 2, 9249, 4, 732, 265, 2058, 109, 903, 2, 6, 423, 3, 345, 1, 3, 1953, 1787, 36, 5, 577, 23, 63, 356, 2493, 7, 5, 2058, 109, 903, 4, 191, 442, 124, 103, 3, 1500, 477, 36, 1695, 1, 33, 3346, 2960, 6601, 188, 18, 1256, 950, 3928, 695, 256, 391, 3899, 256, 79, 81, 695, 256, 391, 2, 9249, 18, 33, 81, 188, 18, 20, 1314, 904, 252, 259, 1459, 391, 1006, 33, 454, 811, 50, 8, 52, 654, 1, 245, 33, 53, 1, 36, 833, 7, 42, 136, 36, 2368, 6, 1524, 81, 1428, 468, 577, 391, 5, 3, 1500, 477, 772, 7, 960, 513, 236, 813, 51, 2, 598, 7, 794, 42, 8, 1266, 51, 2058, 1332, 6, 15, 424, 92, 10, 236, 2058, 13, 4, 179, 7, 350, 2, 458, 4, 595, 7, 641, 2858, 10, 93, 1113, 4, 2658, 2153, 4, 3, 61, 2314, 50, 133, 53, 1, 36, 3, 52, 1256, 950, 61, 10, 14, 49, 6601, 188, 18, 391, 3, 52, 3899, 256, 61, 10, 14, 772, 81, 391, 2, 3, 52, 207, 1, 9249, 162, 10, 18, 454, 811, 158, 169, 7, 276, 6529, 124, 369, 357, 3, 1500, 477, 5, 3, 707, 6, 577, 36, 694, 696, 7, 676, 32, 4, 236, 1266, 51, 2, 790, 7, 846, 4, 458, 1266, 51, 5, 8, 52, 166, 126, 98, 1, 641, 53, 9, 3, 181, 45, 87, 3, 661, 33, 111, 25, 116, 10, 889, 2, 158, 66, 7, 83, 6, 1244, 47, 276, 6529, 124, 3, 1532, 1, 1256, 950, 3899, 256, 2, 9249, 370, 20, 577, 15933, 20, 3, 1574, 1, 3, 3286, 234, 627, 4, 35, 661, 33, 111, 25, 116, 1, 889, 26, 1567, 844, 17, 577, 150, 472, 68, 401, 3, 356, 4, 903]",2082.0,12942553,175
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.,Cancer,Cancer,2003-09-01,"Older age is a consistent poor prognostic factor in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). Whether this is related to an intrinsic worse disease biology or to inadequate drug delivery or excessive treatment-associated toxicity is unknown. The availability of imatinib mesylate, a selective, Bcr-Abl-targeted therapy that is administered orally with minimal side effects, may clarify whether older age would remain an adverse factor (thus, implying a different age-related CML biology). Seven hundred forty-seven patients in different phases of Ph-positive CML who were treated with imatinib from 1999 until the time of last follow-up were evaluated. Among them, 187 patients had newly diagnosed, early chronic phase CML; 351 patients had chronic phase CML after interferon alpha (IFN) failure; 133 patients had accelerated phase CML; and 76 patients had blastic phase CML. The imatinib daily dose varied from 400 mg to 800 mg orally, according to the protocol design. Patients were categorized into a group of older patients (age 60 years or older) or younger patients (age younger than 60 years). Their characteristics, responses to therapy, and survival were compared by univariate and multivariate analyses. One hundred eighty-seven patients had newly diagnosed CML, and 49 patients (26%) were in the older age group. Older patients had similar cytogenetic response rates and survival compared with younger patients. Among 351 patients with late chronic phase CML after IFN failure, 120 patients (34%) were in the older age group. Although the older patients had a lower incidence of achievement of complete cytogenetic response (Ph, 0%) by univariate analysis (56% vs. 44%; P = 0.05), age was not found to be an independent poor prognostic factor in the multivariate analysis. Similarly, older age was not an adverse poor prognostic factor for survival. Forty-two of 133 patients (32%) with accelerated phase CML were older. The incidence of any cytogenetic response was lower in older patients (53% vs. 33%; P = 0.04), but age was not significant in the multivariate analysis. Older patients also had a trend toward worse survival (P = 0.09) that was not significant in the multivariate analysis. Twenty-eight of 76 patients (37%) evaluated in blastic phase were older. Older age was not a significant prognostic factor either for achieving response or for survival. With imatinib therapy, older age appears to have lost much of its prognostic relevance. This suggests that the previous poor prognosis observed with older age was related to treatment-associated factors (e.g., toxicity with allogeneic transplantation or with IFN therapy) rather than to an intrinsic, different disease biology of CML in older patients.",Journal Article,5986.0,74.0,Older age is a consistent poor prognostic factor in patients with Philadelphia chromosome Ph -positive chronic myelogenous CML Whether this is related to an intrinsic worse disease biology or to inadequate drug delivery or excessive treatment-associated toxicity is unknown The availability of imatinib mesylate a selective Bcr-Abl-targeted therapy that is administered orally with minimal side effects may clarify whether older age would remain an adverse factor thus implying a different age-related CML biology Seven hundred forty-seven patients in different phases of Ph-positive CML who were treated with imatinib from 1999 until the time of last follow-up were evaluated Among them 187 patients had newly diagnosed early chronic phase CML 351 patients had chronic phase CML after interferon alpha IFN failure 133 patients had accelerated phase CML and 76 patients had blastic phase CML The imatinib daily dose varied from 400 mg to 800 mg orally according to the protocol design Patients were categorized into a group of older patients age 60 years or older or younger patients age younger than 60 years Their characteristics responses to therapy and survival were compared by univariate and multivariate analyses One hundred eighty-seven patients had newly diagnosed CML and 49 patients 26 were in the older age group Older patients had similar cytogenetic response rates and survival compared with younger patients Among 351 patients with late chronic phase CML after IFN failure 120 patients 34 were in the older age group Although the older patients had a lower incidence of achievement of complete cytogenetic response Ph 0 by univariate analysis 56 vs. 44 P 0.05 age was not found to be an independent poor prognostic factor in the multivariate analysis Similarly older age was not an adverse poor prognostic factor for survival Forty-two of 133 patients 32 with accelerated phase CML were older The incidence of any cytogenetic response was lower in older patients 53 vs. 33 P 0.04 but age was not significant in the multivariate analysis Older patients also had a trend toward worse survival P 0.09 that was not significant in the multivariate analysis Twenty-eight of 76 patients 37 evaluated in blastic phase were older Older age was not a significant prognostic factor either for achieving response or for survival With imatinib therapy older age appears to have lost much of its prognostic relevance This suggests that the previous poor prognosis observed with older age was related to treatment-associated factors e.g. toxicity with allogeneic transplantation or with IFN therapy rather than to an intrinsic different disease biology of CML in older patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[434, 89, 16, 8, 925, 334, 177, 161, 4, 7, 5, 3006, 1170, 2058, 109, 442, 2194, 903, 317, 26, 16, 139, 6, 35, 2354, 639, 34, 891, 15, 6, 3358, 234, 989, 15, 4529, 24, 41, 155, 16, 860, 3, 2550, 1, 577, 2347, 8, 1094, 1062, 1425, 238, 36, 17, 16, 468, 1428, 5, 1048, 1152, 176, 68, 3968, 317, 434, 89, 688, 918, 35, 290, 161, 631, 7885, 8, 338, 89, 139, 903, 891, 648, 1128, 1213, 648, 7, 4, 338, 3523, 1, 2058, 109, 903, 54, 11, 73, 5, 577, 29, 2043, 1100, 3, 98, 1, 1060, 166, 126, 11, 194, 107, 1370, 5568, 7, 42, 732, 265, 191, 442, 124, 903, 7270, 7, 42, 442, 124, 903, 50, 1688, 950, 1256, 496, 5026, 7, 42, 2241, 124, 903, 2, 846, 7, 42, 6529, 124, 903, 3, 577, 391, 61, 2051, 29, 1524, 81, 6, 2796, 81, 1428, 768, 6, 3, 1182, 771, 7, 11, 2320, 237, 8, 87, 1, 434, 7, 89, 335, 60, 15, 434, 15, 773, 7, 89, 773, 76, 335, 60, 136, 374, 253, 6, 36, 2, 25, 11, 72, 20, 880, 2, 331, 318, 104, 1128, 2207, 648, 7, 42, 732, 265, 903, 2, 739, 7, 432, 11, 4, 3, 434, 89, 87, 434, 7, 42, 288, 1266, 51, 151, 2, 25, 72, 5, 773, 7, 107, 7270, 7, 5, 807, 442, 124, 903, 50, 1256, 496, 2031, 7, 562, 11, 4, 3, 434, 89, 87, 242, 3, 434, 7, 42, 8, 280, 287, 1, 5088, 1, 236, 1266, 51, 2058, 13, 20, 880, 65, 664, 105, 584, 19, 13, 474, 89, 10, 44, 204, 6, 40, 35, 306, 334, 177, 161, 4, 3, 331, 65, 1813, 434, 89, 10, 44, 35, 290, 334, 177, 161, 9, 25, 1213, 100, 1, 5026, 7, 531, 5, 2241, 124, 903, 11, 434, 3, 287, 1, 500, 1266, 51, 10, 280, 4, 434, 7, 699, 105, 466, 19, 13, 755, 84, 89, 10, 44, 93, 4, 3, 331, 65, 434, 7, 120, 42, 8, 853, 1317, 639, 25, 19, 13, 1730, 17, 10, 44, 93, 4, 3, 331, 65, 737, 659, 1, 846, 7, 567, 194, 4, 6529, 124, 11, 434, 434, 89, 10, 44, 8, 93, 177, 161, 361, 9, 1785, 51, 15, 9, 25, 5, 577, 36, 434, 89, 1233, 6, 47, 3009, 1802, 1, 211, 177, 2088, 26, 844, 17, 3, 698, 334, 356, 164, 5, 434, 89, 10, 139, 6, 24, 41, 130, 563, 499, 155, 5, 1063, 497, 15, 5, 1256, 36, 1832, 76, 6, 35, 2354, 338, 34, 891, 1, 903, 4, 434, 7]",2677.0,12973833,247
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.,Blood,Blood,2003-09-22,"A tumor-specific, bcr-abl-derived fusion peptide vaccine can be safely administered to patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific T-cell immune response. In the present phase 2 trial, 14 patients with CML in chronic phase were vaccinated with 6 fusion peptides mixed with Quillaja saponaria (QS-21). No significant toxic effects were observed. In 14 of 14 patients, delayed-type hypersensitivity (DTH) and/or CD4 proliferative responses developed after beginning vaccinations, and 11 of 14 patients showed interferon-gamma (IFN-gamma) release by CD4 enzyme-linked immunospot (ELISPOT) at one or more time points. These responses were CD4(+)CD45RO(+). A peptide-specific CD8(+) interferon-gamma ELISPOT was found in 4 patients. Four patients in hematologic remission had a decrease in Philadelphia chromosome (Ph) percentage (3 concurrently receiving interferon-alpha and 1 on imatinib mesylate), and 3 patients in molecular relapse after allogenic transplantation became transiently polymerase chain reaction (PCR) negative after vaccination; 2 of these patients received concurrent donor lymphocyte infusion (DLI). All 5 patients on IFN-alpha ultimately reached a complete cytogenetic remission. In conclusion, a tumor-specific bcr-abl breakpoint peptide-derived vaccine can be safely administered and can reliably elicit measurable peptide-specific CD4 immune responses, including in patients after bone marrow transplantation, on interferon, or on imatinib mesylate. A relationship between the clinical responses and vaccination cannot be determined from this trial.",Clinical Trial,5965.0,158.0,A tumor-specific bcr-abl-derived fusion peptide vaccine can be safely administered to patients with chronic myelogenous CML and can elicit a bcr-abl peptide-specific T-cell immune response In the present phase 2 trial 14 patients with CML in chronic phase were vaccinated with 6 fusion peptides mixed with Quillaja saponaria QS-21 No significant toxic effects were observed In 14 of 14 patients delayed-type hypersensitivity DTH and/or CD4 proliferative responses developed after beginning vaccinations and 11 of 14 patients showed interferon-gamma IFN-gamma release by CD4 enzyme-linked immunospot ELISPOT at one or more time points These responses were CD4 CD45RO A peptide-specific CD8 interferon-gamma ELISPOT was found in 4 patients Four patients in hematologic remission had a decrease in Philadelphia chromosome Ph percentage 3 concurrently receiving interferon-alpha and 1 on imatinib mesylate and 3 patients in molecular relapse after allogenic transplantation became transiently polymerase chain reaction PCR negative after vaccination 2 of these patients received concurrent donor lymphocyte infusion DLI All 5 patients on IFN-alpha ultimately reached a complete cytogenetic remission In conclusion a tumor-specific bcr-abl breakpoint peptide-derived vaccine can be safely administered and can reliably elicit measurable peptide-specific CD4 immune responses including in patients after marrow transplantation on interferon or on imatinib mesylate A relationship between the clinical responses and vaccination can not be determined from this trial,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8, 30, 112, 1062, 1425, 526, 1212, 1389, 1274, 122, 40, 2268, 468, 6, 7, 5, 442, 2194, 903, 2, 122, 5487, 8, 1062, 1425, 1389, 112, 102, 31, 250, 51, 4, 3, 364, 124, 18, 160, 213, 7, 5, 903, 4, 442, 124, 11, 5130, 5, 49, 1212, 2491, 1739, 5, 53752, 53753, 9347, 239, 77, 93, 1812, 176, 11, 164, 4, 213, 1, 213, 7, 1612, 267, 4034, 10283, 2, 15, 1440, 2441, 253, 276, 50, 2948, 7318, 2, 175, 1, 213, 7, 224, 1688, 1705, 1256, 1705, 2008, 20, 1440, 1644, 1199, 11244, 7662, 28, 104, 15, 80, 98, 862, 46, 253, 11, 1440, 11469, 8, 1389, 112, 968, 1688, 1705, 7662, 10, 204, 4, 39, 7, 294, 7, 4, 813, 734, 42, 8, 775, 4, 3006, 1170, 2058, 1150, 27, 3294, 357, 1688, 950, 2, 14, 23, 577, 2347, 2, 27, 7, 4, 219, 429, 50, 15122, 497, 3451, 9235, 1451, 1260, 1329, 604, 199, 50, 1915, 18, 1, 46, 7, 103, 750, 1488, 1448, 904, 4676, 62, 33, 7, 23, 1256, 950, 2050, 1300, 8, 236, 1266, 734, 4, 1221, 8, 30, 112, 1062, 1425, 8567, 1389, 526, 1274, 122, 40, 2268, 468, 2, 122, 4092, 5487, 1884, 1389, 112, 1440, 250, 253, 141, 4, 7, 50, 581, 497, 23, 1688, 15, 23, 577, 2347, 8, 858, 59, 3, 38, 253, 2, 1915, 122, 44, 40, 509, 29, 26, 160]",1558.0,14504104,169
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.,Cancer,Cancer,2003-10-01,"The effect on prognosis of adding imatinib mesylate to the treatment of patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) has not been explored fully. The objective of the current study was to evaluate the benefit of adding imatinib to the treatment sequence of patients with early chronic phase Ph-positive CML who received interferon alpha (IFN)-based regimens as frontline therapy. A total of 201 patients with early chronic phase Ph-positive CML who were treated on our 3 recent frontline IFN-based programs and were impacted early by the availability of sequential therapy with imatinib were analyzed. Their outcome was compared with that of a historical control group of 293 patients treated from 1982 until 1990 who were treated with IFN programs for early chronic phase CML and who did not have the opportunity of early access to imatinib (because it was not available during that period). Multivariate analysis was used to evaluate the independent effect of imatinib therapy on survival. Of 201 patients who were treated, 159 patients (79%) had their regimen changed sequentially to imatinib after a median duration of 14 months of IFN therapy. Of 139 patients who continued evaluation at our institution, 101 patients (73%; 64% of the total group) achieved a complete cytogenetic response, and 20 of 80 patients analyzed (25%; 10% of the total group) had no disease according to molecular studies (quantitative polymerase chain reaction studies). The estimated 5-year survival rate for the total study group of 201 patients was 86%. Survival of this group was significantly superior to the historic control group of IFN-treated patients who did not have the benefit of imatinib (P = 0.03). The trend also was observed within defined CML risk groups. Imatinib therapy was confirmed as an independent, significant, favorable prognostic factor for survival by multivariate analysis, after accounting for the independent prognostic effect of pretreatment prognostic factors (P = 0.005). The current analysis is the first to indicate the independent, favorable effect of imatinib on the survival of patients with Ph-positive CML.",Comparative Study,5956.0,18.0,The effect on prognosis of adding imatinib mesylate to the treatment of patients with Philadelphia chromosome Ph -positive chronic myelogenous CML has not been explored fully The objective of the current study was to evaluate the benefit of adding imatinib to the treatment sequence of patients with early chronic phase Ph-positive CML who received interferon alpha IFN -based regimens as frontline therapy A total of 201 patients with early chronic phase Ph-positive CML who were treated on our 3 recent frontline IFN-based programs and were impacted early by the availability of sequential therapy with imatinib were analyzed Their outcome was compared with that of a historical control group of 293 patients treated from 1982 until 1990 who were treated with IFN programs for early chronic phase CML and who did not have the opportunity of early access to imatinib because it was not available during that period Multivariate analysis was used to evaluate the independent effect of imatinib therapy on survival Of 201 patients who were treated 159 patients 79 had their regimen changed sequentially to imatinib after a median duration of 14 months of IFN therapy Of 139 patients who continued evaluation at our institution 101 patients 73 64 of the total group achieved a complete cytogenetic response and 20 of 80 patients analyzed 25 10 of the total group had no disease according to molecular studies quantitative polymerase chain reaction studies The estimated 5-year survival rate for the total study group of 201 patients was 86 Survival of this group was significantly superior to the historic control group of IFN-treated patients who did not have the benefit of imatinib P 0.03 The trend also was observed within defined CML risk groups Imatinib therapy was confirmed as an independent significant favorable prognostic factor for survival by multivariate analysis after accounting for the independent prognostic effect of pretreatment prognostic factors P 0.005 The current analysis is the first to indicate the independent favorable effect of imatinib on the survival of patients with Ph-positive CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 254, 23, 356, 1, 2726, 577, 2347, 6, 3, 24, 1, 7, 5, 3006, 1170, 2058, 109, 442, 2194, 903, 71, 44, 85, 1443, 1910, 3, 461, 1, 3, 291, 45, 10, 6, 376, 3, 247, 1, 2726, 577, 6, 3, 24, 1532, 1, 7, 5, 191, 442, 124, 2058, 109, 903, 54, 103, 1688, 950, 1256, 90, 472, 22, 3171, 36, 8, 181, 1, 4766, 7, 5, 191, 442, 124, 2058, 109, 903, 54, 11, 73, 23, 114, 27, 435, 3171, 1256, 90, 2251, 2, 11, 4619, 191, 20, 3, 2550, 1, 1787, 36, 5, 577, 11, 311, 136, 228, 10, 72, 5, 17, 1, 8, 2252, 182, 87, 1, 7541, 7, 73, 29, 6652, 1100, 2289, 54, 11, 73, 5, 1256, 2251, 9, 191, 442, 124, 903, 2, 54, 205, 44, 47, 3, 2666, 1, 191, 1655, 6, 577, 408, 192, 10, 44, 390, 190, 17, 727, 331, 65, 10, 95, 6, 376, 3, 306, 254, 1, 577, 36, 23, 25, 1, 4766, 7, 54, 11, 73, 5917, 7, 842, 42, 136, 477, 2368, 5455, 6, 577, 50, 8, 52, 654, 1, 213, 53, 1, 1256, 36, 1, 4929, 7, 54, 1351, 451, 28, 114, 731, 2338, 7, 803, 660, 1, 3, 181, 87, 513, 8, 236, 1266, 51, 2, 179, 1, 493, 7, 311, 243, 79, 1, 3, 181, 87, 42, 77, 34, 768, 6, 219, 94, 1156, 1451, 1260, 1329, 94, 3, 661, 33, 111, 25, 116, 9, 3, 181, 45, 87, 1, 4766, 7, 10, 868, 25, 1, 26, 87, 10, 97, 1123, 6, 3, 6875, 182, 87, 1, 1256, 73, 7, 54, 205, 44, 47, 3, 247, 1, 577, 19, 13, 680, 3, 853, 120, 10, 164, 262, 395, 903, 43, 271, 577, 36, 10, 557, 22, 35, 306, 93, 913, 177, 161, 9, 25, 20, 331, 65, 50, 3116, 9, 3, 306, 177, 254, 1, 1194, 177, 130, 19, 13, 1614, 3, 291, 65, 16, 3, 157, 6, 1008, 3, 306, 913, 254, 1, 577, 23, 3, 25, 1, 7, 5, 2058, 109, 903]",2113.0,14508830,253
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.,Cancer,Cancer,2003-11-01,"Anecdotal cases of chromosomal abnormalities in Philadelphia chromosome (Ph)-negative metaphases have been reported in patients with chronic myelogenous leukemia (CML) in the chronic phase during treatment with interferon and, more recently, with imatinib. This phenomenon is different from true clonal evolution in that the additional cytogenetic abnormality occurs in Ph-negative cells. The authors analyzed their experience with 342 patients with CML in chronic phase treated with imatinib to investigate the frequency and significance of this event. After a median follow-up of 30 months (range, 16-35 months), 21 patients (6%; 95% confidence interval, 0.04, 0.09) developed 25 chromosomal abnormalities in Ph-negative cells. Thirteen (54%) of these abnormalities were seen in 2 or more metaphases. The median time from the start of treatment with imatinib to the appearance of the abnormalities was 6 months (range, 3-22 months). The most common cytogenetic abnormality detected was trisomy 8 (33%). Twenty of 21 patients (95%) achieved a major (Ph < 35%) cytogenetic response (complete cytogenetic response in 13-62%). After a median follow-up of 22 months (range, 4-33 months), all 21 patients were alive, 20 of them in chronic phase and in complete hematologic response. None of the patients showed features of myelodysplasia. Cytogenetic abnormalities occur in Ph-negative cells in a fraction of patients with CML in chronic phase treated with imatinib. With a short follow-up, no clear clinical consequences can be identified.",Journal Article,5925.0,107.0,Anecdotal cases of chromosomal abnormalities in Philadelphia chromosome Ph -negative metaphases have been reported in patients with chronic myelogenous CML in the chronic phase during treatment with interferon and more recently with imatinib This phenomenon is different from true clonal evolution in that the additional cytogenetic abnormality occurs in Ph-negative cells The authors analyzed their experience with 342 patients with CML in chronic phase treated with imatinib to investigate the frequency and significance of this event After a median follow-up of 30 months range 16-35 months 21 patients 6 95 confidence interval 0.04 0.09 developed 25 chromosomal abnormalities in Ph-negative cells Thirteen 54 of these abnormalities were seen in 2 or more metaphases The median time from the start of treatment with imatinib to the appearance of the abnormalities was 6 months range 3-22 months The most common cytogenetic abnormality detected was trisomy 8 33 Twenty of 21 patients 95 achieved a major Ph 35 cytogenetic response complete cytogenetic response in 13-62 After a median follow-up of 22 months range 4-33 months all 21 patients were alive 20 of them in chronic phase and in complete hematologic response None of the patients showed features of myelodysplasia Cytogenetic abnormalities occur in Ph-negative cells in a fraction of patients with CML in chronic phase treated with imatinib With a short follow-up no clear clinical consequences can be identified,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[9244, 140, 1, 1860, 1171, 4, 3006, 1170, 2058, 199, 10653, 47, 85, 210, 4, 7, 5, 442, 2194, 903, 4, 3, 442, 124, 190, 24, 5, 1688, 2, 80, 761, 5, 577, 26, 3936, 16, 338, 29, 2501, 1946, 2554, 4, 17, 3, 402, 1266, 3698, 1780, 4, 2058, 199, 37, 3, 738, 311, 136, 730, 5, 8906, 7, 5, 903, 4, 442, 124, 73, 5, 577, 6, 963, 3, 675, 2, 724, 1, 26, 774, 50, 8, 52, 166, 126, 1, 201, 53, 184, 245, 465, 53, 239, 7, 49, 48, 307, 268, 13, 755, 13, 1730, 276, 243, 1860, 1171, 4, 2058, 199, 37, 3170, 667, 1, 46, 1171, 11, 527, 4, 18, 15, 80, 10653, 3, 52, 98, 29, 3, 2435, 1, 24, 5, 577, 6, 3, 3592, 1, 3, 1171, 10, 49, 53, 184, 27, 350, 53, 3, 96, 186, 1266, 3698, 530, 10, 6317, 66, 466, 737, 1, 239, 7, 48, 513, 8, 458, 2058, 465, 1266, 51, 236, 1266, 51, 4, 233, 744, 50, 8, 52, 166, 126, 1, 350, 53, 184, 39, 466, 53, 62, 239, 7, 11, 1701, 179, 1, 1370, 4, 442, 124, 2, 4, 236, 813, 51, 1292, 1, 3, 7, 224, 404, 1, 6128, 1266, 1171, 1271, 4, 2058, 199, 37, 4, 8, 1509, 1, 7, 5, 903, 4, 442, 124, 73, 5, 577, 5, 8, 978, 166, 126, 77, 885, 38, 3255, 122, 40, 108]",1473.0,14584073,20
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.,Blood,Blood,2003-11-06,"Decitabine (5-aza-2'-deoxycytidine) inhibits DNA methylation and has dual effects on neoplastic cells, including the reactivation of silenced genes and differentiation at low doses and cytotoxicity at high doses. We evaluated, in a phase 1 study, low-dose prolonged exposure schedules of decitabine in relapsed/refractory leukemias. Patient cohorts received decitabine at 5, 10, 15, or 20 mg/m2 intravenously over one hour daily, 5 days a week for 2 consecutive weeks, doses 5- to approximately 30-fold lower than the maximum tolerated dose (MTD). There were 2 groups that also received 15 mg/m2 daily for 15 or 20 days. A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect. Responses were seen at all dose levels. However, the dose of 15 mg/m2 for 10 days appeared to induce the most responses (11 of 17 or 65%), with fewer responses seen when the dose was escalated or prolonged (2 of 19 or 11%). There was no correlation between P15 methylation at baseline or after therapy and response to decitabine. We conclude that decitabine is effective in myeloid malignancies, and low doses are as or more effective than higher doses.",Clinical Trial,5920.0,643.0,Decitabine 5-aza-2'-deoxycytidine inhibits DNA methylation and has dual effects on neoplastic cells including the reactivation of silenced genes and differentiation at low doses and cytotoxicity at high doses We evaluated in a phase 1 study low-dose prolonged exposure schedules of decitabine in relapsed/refractory leukemias Patient cohorts received decitabine at 5 10 15 or 20 mg/m2 intravenously over one hour daily 5 days a week for 2 consecutive weeks doses 5- to approximately 30-fold lower than the maximum tolerated dose MTD There were 2 groups that also received 15 mg/m2 daily for 15 or 20 days A total of 50 patients were treated 44 with acute myelogenous AML /myelodysplasia MDS 5 with chronic myelogenous CML and 1 with acute lymphocytic ALL and the drug was well tolerated at all dose levels with myelosuppression being the major side effect Responses were seen at all dose levels However the dose of 15 mg/m2 for 10 days appeared to induce the most responses 11 of 17 or 65 with fewer responses seen when the dose was escalated or prolonged 2 of 19 or 11 There was no correlation between P15 methylation at baseline or after therapy and response to decitabine We conclude that decitabine is effective in myeloid malignancies and low doses are as or more effective than higher doses,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3004, 33, 3924, 6135, 6750, 1576, 261, 569, 2, 71, 1828, 176, 23, 2000, 37, 141, 3, 3834, 1, 5442, 214, 2, 910, 28, 154, 415, 2, 1408, 28, 64, 415, 21, 194, 4, 8, 124, 14, 45, 154, 61, 1069, 645, 2314, 1, 3004, 4, 591, 430, 2792, 69, 736, 103, 3004, 28, 33, 79, 167, 15, 179, 81, 821, 1672, 252, 104, 2583, 391, 33, 162, 8, 647, 9, 18, 935, 244, 415, 33, 6, 705, 201, 1116, 280, 76, 3, 689, 421, 61, 961, 125, 11, 18, 271, 17, 120, 103, 167, 81, 821, 391, 9, 167, 15, 179, 162, 8, 181, 1, 212, 7, 11, 73, 584, 5, 286, 2194, 329, 6128, 1223, 33, 5, 442, 2194, 903, 2, 14, 5, 286, 1193, 62, 2, 3, 234, 10, 149, 421, 28, 62, 61, 148, 5, 2858, 486, 3, 458, 1152, 254, 253, 11, 527, 28, 62, 61, 148, 137, 3, 61, 1, 167, 81, 821, 9, 79, 162, 2121, 6, 1290, 3, 96, 253, 175, 1, 269, 15, 556, 5, 1497, 253, 527, 198, 3, 61, 10, 2842, 15, 1069, 18, 1, 326, 15, 175, 125, 10, 77, 816, 59, 8840, 569, 28, 330, 15, 50, 36, 2, 51, 6, 3004, 21, 2060, 17, 3004, 16, 323, 4, 533, 441, 2, 154, 415, 32, 22, 15, 80, 323, 76, 142, 415]",1296.0,14604977,114
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.,Seminars in oncology,Semin. Oncol.,2003-10-01,"Modulation of the signaling pathways that are aberrant in cancer cells has the potential to provide an effective nontoxic approach to patient management in a broad range of cancers. This quest has taken a major leap forward with the demonstration that STI-571 (imatinib mesylate) induces clinical and molecular remissions in the majority of patients with interferon-refractory chronic myelogenous leukemia and gastrointestinal stromal tumors through inhibition of the Bcr/Abl fusion protein required for the initiation and progression of chronic myelogenous leukemia and inhibition of a mutant, activated c-kit present in gastrointestinal stromal tumors. Support for the concept of targeting products of fusion genes found in specific cancers was first provided by the efficacy of all-trans retinoic acid in acute promyelocytic leukemia where the RARalpha all-trans retinoic acid target is the target of multiple different chromosomal rearrangements. In breast cancer, trastuzumab, which alters the function of the HER2 proto-oncogene overexpressed in a portion of breast cancers, provides an additional example of targeting specific molecular aberrations present in cancer cells. Although the target for these signal transduction modulators is functional in normal cells, acceptable therapeutic indices sufficient to prevent tumor growth without unacceptable toxicities have been observed. Whether STI-571 and other signal transduction modulators also target the stroma, and specifically the neovasculature, in addition to the tumor remains an open question. The presence of the target in the cancer cells or in the surrounding stroma appears to be required but not sufficient for the action of molecular therapeutics. Thus, linking molecular diagnostics to identify patients where the target is amplified or activated and driving the pathophysiology of the patients' tumor to effective molecular therapeutics will be necessary to translate these concepts into approaches that will alter the outcome for breast cancer patients. This review will focus on the phosphatidylinositol 3-kinase pathway and novel molecules targeting this pathway to illustrate the questions and challenges underlying the implementation of molecular therapeutics in breast cancer.",Journal Article,5956.0,46.0,Modulation of the signaling pathways that are aberrant in cancer cells has the potential to provide an effective nontoxic approach to patient management in a broad range of cancers This quest has taken a major leap forward with the demonstration that STI-571 imatinib mesylate induces clinical and molecular remissions in the majority of patients with interferon-refractory chronic myelogenous and stromal tumors through inhibition of the Bcr/Abl fusion protein required for the initiation and progression of chronic myelogenous and inhibition of a mutant activated c-kit present in stromal tumors Support for the concept of targeting products of fusion genes found in specific cancers was first provided by the efficacy of all-trans retinoic acid in acute promyelocytic where the RARalpha all-trans retinoic acid target is the target of multiple different chromosomal rearrangements In cancer trastuzumab which alters the function of the HER2 proto-oncogene overexpressed in a portion of cancers provides an additional example of targeting specific molecular aberrations present in cancer cells Although the target for these signal transduction modulators is functional in normal cells acceptable therapeutic indices sufficient to prevent tumor growth without unacceptable toxicities have been observed Whether STI-571 and other signal transduction modulators also target the stroma and specifically the neovasculature in addition to the tumor remains an open question The presence of the target in the cancer cells or in the surrounding stroma appears to be required but not sufficient for the action of molecular therapeutics Thus linking molecular diagnostics to identify patients where the target is amplified or activated and driving the pathophysiology of the patients tumor to effective molecular therapeutics will be necessary to translate these concepts into approaches that will alter the outcome for cancer patients This review will focus on the phosphatidylinositol 3-kinase pathway and novel molecules targeting this pathway to illustrate the questions and challenges underlying the implementation of molecular therapeutics in cancer,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[2356, 1, 3, 314, 460, 17, 32, 1898, 4, 12, 37, 71, 3, 174, 6, 377, 35, 323, 10535, 353, 6, 69, 284, 4, 8, 2094, 184, 1, 163, 26, 19439, 71, 1633, 8, 458, 33552, 4674, 5, 3, 6533, 17, 10640, 7846, 577, 2347, 1516, 38, 2, 219, 3166, 4, 3, 686, 1, 7, 5, 1688, 430, 442, 2194, 2, 1126, 57, 298, 297, 1, 3, 1062, 1425, 1212, 178, 616, 9, 3, 1118, 2, 91, 1, 442, 2194, 2, 297, 1, 8, 620, 735, 256, 1164, 364, 4, 1126, 57, 538, 9, 3, 2545, 1, 529, 2766, 1, 1212, 214, 204, 4, 112, 163, 10, 157, 1052, 20, 3, 209, 1, 62, 3437, 3887, 971, 4, 286, 4300, 1257, 3, 10412, 62, 3437, 3887, 971, 283, 16, 3, 283, 1, 232, 338, 1860, 2072, 4, 12, 769, 92, 6745, 3, 343, 1, 3, 354, 4976, 1836, 1711, 4, 8, 3206, 1, 163, 777, 35, 402, 2685, 1, 529, 112, 219, 2152, 364, 4, 12, 37, 242, 3, 283, 9, 46, 1235, 2761, 5014, 16, 583, 4, 295, 37, 1595, 189, 3824, 1952, 6, 1682, 30, 129, 187, 3215, 385, 47, 85, 164, 317, 10640, 7846, 2, 127, 1235, 2761, 5014, 120, 283, 3, 2477, 2, 1225, 3, 12136, 4, 352, 6, 3, 30, 469, 35, 1020, 2840, 3, 463, 1, 3, 283, 4, 3, 12, 37, 15, 4, 3, 2976, 2477, 1233, 6, 40, 616, 84, 44, 1952, 9, 3, 1578, 1, 219, 1943, 631, 5806, 219, 5197, 6, 255, 7, 1257, 3, 283, 16, 2429, 15, 735, 2, 4057, 3, 4320, 1, 3, 7, 30, 6, 323, 219, 1943, 303, 40, 1493, 6, 4509, 46, 5101, 237, 611, 17, 303, 2688, 3, 228, 9, 12, 7, 26, 206, 303, 1222, 23, 3, 3415, 27, 216, 308, 2, 229, 1598, 529, 26, 308, 6, 4746, 3, 1937, 2, 1427, 1181, 3, 2393, 1, 219, 1943, 4, 12]",2147.0,14613030,42
Resistance to imatinib (Glivec): update on clinical mechanisms.,Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy,Drug Resist. Updat.,2003-10-01,"Imatinib mesylate, an orally administered 2-phenylaminopyrimidine derivative that inhibits BCR/ABL tyrosine kinase activity, has shown great promise in the treatment of chronic myelogenous leukemia (CML). This small molecule, tyrosine kinase inhibitor, has also been shown to be effective against metastatic gastrointestinal stromal tumors (GISTs) expressing the stem cell factor (SCF) receptor kit. However, the threat of resistance in patients has prompted investigators to uncover the mechanisms whereby malignant cells develop resistance to imatinib, and has also led to the establishment of strategies designed to over-ride imatinib resistance. Here, we provide a comprehensive overview of the effectiveness of imatinib in the treatment of chronic, accelerated and blast crisis-phase CML, Philadelphia chromosome-positive (Ph+) acute lymphoid leukemia (ALL) and metastatic GIST. Established mechanisms of resistance to imatinib are discussed, as are novel therapeutic approaches to improving drug responsiveness by reversing development of imatinib resistance in patients.",Journal Article,5956.0,77.0,Imatinib mesylate an orally administered 2-phenylaminopyrimidine derivative that inhibits BCR/ABL tyrosine kinase activity has shown great promise in the treatment of chronic myelogenous CML This small molecule tyrosine kinase inhibitor has also been shown to be effective against metastatic stromal tumors GISTs expressing the stem cell factor SCF receptor kit However the threat of resistance in patients has prompted investigators to uncover the mechanisms whereby malignant cells develop resistance to imatinib and has also led to the establishment of strategies designed to over-ride imatinib resistance Here we provide a comprehensive overview of the effectiveness of imatinib in the treatment of chronic accelerated and blast crisis-phase CML Philadelphia chromosome-positive Ph+ acute lymphoid ALL and metastatic GIST Established mechanisms of resistance to imatinib are discussed as are novel therapeutic approaches to improving drug responsiveness by reversing development of imatinib resistance in patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[577, 2347, 35, 1428, 468, 18, 53883, 4819, 17, 1576, 1062, 1425, 564, 216, 128, 71, 443, 2797, 1783, 4, 3, 24, 1, 442, 2194, 903, 26, 302, 1354, 564, 216, 230, 71, 120, 85, 443, 6, 40, 323, 480, 113, 1126, 57, 2508, 1046, 3, 452, 31, 161, 8447, 153, 1164, 137, 3, 10965, 1, 251, 4, 7, 71, 4140, 2394, 6, 6281, 3, 483, 6131, 393, 37, 690, 251, 6, 577, 2, 71, 120, 836, 6, 3, 5346, 1, 422, 1114, 6, 252, 37586, 577, 251, 467, 21, 377, 8, 949, 2901, 1, 3, 1236, 1, 577, 4, 3, 24, 1, 442, 2241, 2, 3112, 6540, 124, 903, 3006, 1170, 109, 2058, 286, 2303, 62, 2, 113, 1394, 635, 483, 1, 251, 6, 577, 32, 1588, 22, 32, 229, 189, 611, 6, 1673, 234, 3642, 20, 9953, 193, 1, 577, 251, 4, 7]",1017.0,14643293,0
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.,Cancer,Cancer,2003-12-01,"The International Randomized study of Interferon-alpha plus cytarabine (IFN-alpha plus ara-C) versus STI571 (imatinib mesylate) [IRIS trial] in patients with newly diagnosed Philadelphia chromosome (Ph)-positive, chronic-phase chronic myelogenous leukemia (CML) has not shown (to date) a survival advantage for imatinib. This was most likely because approximately 90% of patients receiving IFN-alpha plus ara-C changed to imatinib therapy after a median of 8 months into therapy. The authors analyzed the results with imatinib therapy in patients with newly diagnosed Ph-positive CML in chronic phase and compared their outcome with patients who received IFN-alpha regimens. A total of 187 patients with Ph-positive CML in early chronic phase treated with imatinib were compared with a historic group of 650 similar patients treated with IFN-alpha regimens from 1982 until 1997. Patients who received imatinib were significantly older and had significantly more bone marrow basophilia and less leukocytosis. The complete cytogenetic response (Ph 0%) rates were better with imatinib (81% vs. 32%; P < 0.001), as were the survival rates (30-month estimated survival rates 98% vs. 88%; P = 0.01). A multivariate analysis of the total study group of 837 patients identified imatinib therapy to be a significant independent favorable prognostic factor for survival (P = 0.01). The current study is the first to indicate the survival advantage of imatinib compared with IFN-alpha, the previous standard of care, in patients with early chronic-phase CML.",Comparative Study,5895.0,93.0,The International Randomized study of Interferon-alpha plus cytarabine IFN-alpha plus ara-C versus STI571 imatinib mesylate IRIS trial in patients with newly diagnosed Philadelphia chromosome Ph -positive chronic-phase chronic myelogenous CML has not shown to date a survival advantage for imatinib This was most likely because approximately 90 of patients receiving IFN-alpha plus ara-C changed to imatinib therapy after a median of 8 months into therapy The authors analyzed the results with imatinib therapy in patients with newly diagnosed Ph-positive CML in chronic phase and compared their outcome with patients who received IFN-alpha regimens A total of 187 patients with Ph-positive CML in early chronic phase treated with imatinib were compared with a historic group of 650 similar patients treated with IFN-alpha regimens from 1982 until 1997 Patients who received imatinib were significantly older and had significantly more marrow basophilia and less leukocytosis The complete cytogenetic response Ph 0 rates were better with imatinib 81 vs. 32 P 0.001 as were the survival rates 30-month estimated survival rates 98 vs. 88 P 0.01 A multivariate analysis of the total study group of 837 patients identified imatinib therapy to be a significant independent favorable prognostic factor for survival P 0.01 The current study is the first to indicate the survival advantage of imatinib compared with IFN-alpha the previous standard of care in patients with early chronic-phase CML,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 944, 384, 45, 1, 1688, 950, 349, 1855, 1256, 950, 349, 3899, 256, 185, 5735, 577, 2347, 15950, 160, 4, 7, 5, 732, 265, 3006, 1170, 2058, 109, 442, 124, 442, 2194, 903, 71, 44, 443, 6, 1244, 8, 25, 1874, 9, 577, 26, 10, 96, 322, 408, 705, 424, 1, 7, 357, 1256, 950, 349, 3899, 256, 2368, 6, 577, 36, 50, 8, 52, 1, 66, 53, 237, 36, 3, 738, 311, 3, 99, 5, 577, 36, 4, 7, 5, 732, 265, 2058, 109, 903, 4, 442, 124, 2, 72, 136, 228, 5, 7, 54, 103, 1256, 950, 472, 8, 181, 1, 5568, 7, 5, 2058, 109, 903, 4, 191, 442, 124, 73, 5, 577, 11, 72, 5, 8, 6875, 87, 1, 8642, 288, 7, 73, 5, 1256, 950, 472, 29, 6652, 1100, 2341, 7, 54, 103, 577, 11, 97, 434, 2, 42, 97, 80, 581, 26032, 2, 299, 7463, 3, 236, 1266, 51, 2058, 13, 151, 11, 380, 5, 577, 865, 105, 531, 19, 13, 144, 22, 11, 3, 25, 151, 201, 811, 661, 25, 151, 1096, 105, 889, 19, 13, 355, 8, 331, 65, 1, 3, 181, 45, 87, 1, 17243, 7, 108, 577, 36, 6, 40, 8, 93, 306, 913, 177, 161, 9, 25, 19, 13, 355, 3, 291, 45, 16, 3, 157, 6, 1008, 3, 25, 1874, 1, 577, 72, 5, 1256, 950, 3, 698, 260, 1, 165, 4, 7, 5, 191, 442, 124, 903]",1488.0,14669283,4
Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.,Cancer,Cancer,2003-12-01,"Initial treatment for adult patients with Philadelphia chromosome-positive (Ph[+]) chronic myelogenous leukemia (CML) now includes imatinib mesylate. However, to our knowledge, there are few data regarding imatinib safety, efficacy, and response monitoring in patients age < 18 years. In the current series, the authors report 5 consecutive patients ages 20 months to 12 years with Ph+ leukemia who were treated with imatinib and evaluated for a response using cytogenetics, fluorescent in situ hybridization (FISH), and real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) on serial bone marrow aspirations. Doses of imatinib were escalated as tolerated from a starting dose of 400 mg/m2 (patients with a body surface area [BSA] < 1 m2) or 400 mg/day (patients with a BSA > 1 m2). After the initiation of imatinib therapy, all 4 patients with CML were found to have no detectable Ph chromosome by cytogenetics (median of 198 days of imatinib therapy; range, 138-346 days), FISH (median of 285 days of imatinib therapy; range, 138-366 days), and real-time RT-PCR (median of 287 days of imatinib therapy; range, 224-366 days). One patient with Ph+ acute mixed lineage leukemia achieved a morphologic disease remission with standard chemotherapy, but within 10 months had increasing Ph positivity in consecutive bone marrow aspirations. Imatinib was added to the intensive leukemia therapy, and within 26 days there were no detectable Ph+ cells in the bone marrow. Mild thrombocytopenia was noted in two patients and transient mild hepatic toxicity was noted in one patient. Imatinib mesylate was found to be effective in inducing undetectable residual disease in a small cohort of pediatric patients with Ph+ leukemia. Further studies of the use of imatinib in childhood Ph+ malignancies are needed.",Case Reports,5895.0,33.0,Initial treatment for adult patients with Philadelphia chromosome-positive Ph chronic myelogenous CML now includes imatinib mesylate However to our knowledge there are few data regarding imatinib safety efficacy and response monitoring in patients age 18 years In the current series the authors report 5 consecutive patients ages 20 months to 12 years with Ph+ who were treated with imatinib and evaluated for a response using cytogenetics fluorescent in situ hybridization FISH and real-time quantitative reverse transcriptase-polymerase chain reaction RT-PCR on serial marrow aspirations Doses of imatinib were escalated as tolerated from a starting dose of 400 mg/m2 patients with a body surface area BSA 1 m2 or 400 mg/day patients with a BSA 1 m2 After the initiation of imatinib therapy all 4 patients with CML were found to have no detectable Ph chromosome by cytogenetics median of 198 days of imatinib therapy range 138-346 days FISH median of 285 days of imatinib therapy range 138-366 days and real-time RT-PCR median of 287 days of imatinib therapy range 224-366 days One patient with Ph+ acute mixed lineage achieved a morphologic disease remission with standard chemotherapy but within 10 months had increasing Ph positivity in consecutive marrow aspirations Imatinib was added to the intensive therapy and within 26 days there were no detectable Ph+ cells in the marrow Mild thrombocytopenia was noted in two patients and transient mild hepatic toxicity was noted in one patient Imatinib mesylate was found to be effective in inducing undetectable residual disease in a small cohort of pediatric patients with Ph+ Further studies of the use of imatinib in childhood Ph+ malignancies are needed,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[388, 24, 9, 780, 7, 5, 3006, 1170, 109, 2058, 442, 2194, 903, 1134, 1920, 577, 2347, 137, 6, 114, 922, 125, 32, 1021, 74, 666, 577, 367, 209, 2, 51, 1315, 4, 7, 89, 203, 60, 4, 3, 291, 988, 3, 738, 414, 33, 935, 7, 2165, 179, 53, 6, 133, 60, 5, 2058, 54, 11, 73, 5, 577, 2, 194, 9, 8, 51, 75, 2510, 2910, 4, 957, 1554, 1277, 2, 1589, 98, 1156, 1772, 4456, 1451, 1260, 1329, 240, 604, 23, 2108, 581, 16666, 415, 1, 577, 11, 2842, 22, 421, 29, 8, 1723, 61, 1, 1524, 81, 821, 7, 5, 8, 642, 1255, 965, 8321, 14, 821, 15, 1524, 81, 218, 7, 5, 8, 8321, 14, 821, 50, 3, 1118, 1, 577, 36, 62, 39, 7, 5, 903, 11, 204, 6, 47, 77, 2083, 2058, 1170, 20, 2510, 52, 1, 6189, 162, 1, 577, 36, 184, 4478, 9184, 162, 1277, 52, 1, 8121, 162, 1, 577, 36, 184, 4478, 9797, 162, 2, 1589, 98, 240, 604, 52, 1, 8488, 162, 1, 577, 36, 184, 5908, 9797, 162, 104, 69, 5, 2058, 286, 1739, 2542, 513, 8, 2815, 34, 734, 5, 260, 56, 84, 262, 79, 53, 42, 602, 2058, 1887, 4, 935, 581, 16666, 577, 10, 1953, 6, 3, 1686, 36, 2, 262, 432, 162, 125, 11, 77, 2083, 2058, 37, 4, 3, 581, 1980, 1340, 10, 1051, 4, 100, 7, 2, 2473, 1980, 939, 155, 10, 1051, 4, 104, 69, 577, 2347, 10, 204, 6, 40, 323, 4, 1958, 3920, 753, 34, 4, 8, 302, 180, 1, 815, 7, 5, 2058, 195, 94, 1, 3, 119, 1, 577, 4, 864, 2058, 441, 32, 575]",1708.0,14669284,187
Evolving role of pegylated interferons in metastatic renal cell carcinoma.,Expert review of anticancer therapy,Expert Rev Anticancer Ther,2003-12-01,"Interferon (IFN)-alpha has demonstrated antitumor activity in a variety of solid and hematologic malignancies, including metastatic renal cell carcinoma. Pegylation, the process of combining a polyethylene glycol moiety to a biologic protein, substantially changes the pharmacokinetic profile of a drug, resulting in prolongation in half-life, increased area under the curve and, in some cases, improved efficacy. Pegylated IFN-alpha has been evaluated in chronic hepatitis C, chronic myelogenous leukemia and most recently in metastatic renal cell carcinoma. Registrational studies of pegylated IFN-alpha2a (PEGASYS) and pegylated IFN-alpha2b (PEG Intron) in patients with hepatitis C demonstrated greater efficacy with similar safety and tolerability to nonpegylated IFNs, with the advantage of less frequent administration. Studies evaluating these agents in the treatment of metastatic renal cell carcinoma and other cancers are ongoing.",Journal Article,5895.0,18.0,Interferon IFN -alpha has demonstrated antitumor activity in a variety of solid and hematologic malignancies including metastatic cell carcinoma Pegylation the process of combining a polyethylene glycol moiety to a biologic protein substantially changes the pharmacokinetic profile of a drug resulting in prolongation in half-life increased area under the curve and in some cases improved efficacy Pegylated IFN-alpha has been evaluated in chronic hepatitis C chronic myelogenous and most recently in metastatic cell carcinoma Registrational studies of pegylated IFN-alpha2a PEGASYS and pegylated IFN-alpha2b PEG Intron in patients with hepatitis C demonstrated greater efficacy with similar safety and tolerability to nonpegylated IFNs with the advantage of less frequent administration Studies evaluating these agents in the treatment of metastatic cell carcinoma and other cancers are ongoing,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1688, 1256, 950, 71, 264, 579, 128, 4, 8, 1362, 1, 537, 2, 813, 441, 141, 113, 31, 134, 24665, 3, 1129, 1, 1525, 8, 12997, 10809, 10461, 6, 8, 1283, 178, 2109, 400, 3, 1456, 800, 1, 8, 234, 1113, 4, 4464, 4, 1303, 358, 101, 965, 669, 3, 1496, 2, 4, 476, 140, 231, 209, 4424, 1256, 950, 71, 85, 194, 4, 442, 3002, 256, 442, 2194, 2, 96, 761, 4, 113, 31, 134, 30519, 94, 1, 4424, 1256, 33579, 53923, 2, 4424, 1256, 15150, 3145, 6259, 4, 7, 5, 3002, 256, 264, 378, 209, 5, 288, 367, 2, 1543, 6, 19495, 11808, 5, 3, 1874, 1, 299, 908, 634, 94, 1435, 46, 183, 4, 3, 24, 1, 113, 31, 134, 2, 127, 163, 32, 942]",895.0,14686704,201
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.,Cancer,Cancer,2004-01-01,"Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression > or = Grade 3, requiring interruption of therapy and/or dose reductions. The significance of myelosuppression for response to imatinib is unknown. The authors analyzed 143 patients with late chronic-phase CML who were treated with imatinib after failing interferon. Univariate and multivariate analyses were performed to determine patient characteristics that were correlated with myelosuppression response and the association between myelosuppression and cytogenetic response. Neutropenia > or = Grade 3 (according to National Cancer Institute Common Toxicity Criteria) occurred in 64 patients (45%), and thrombocytopenia > or = Grade 3 occurred in 31 patients (22%). Any myelosuppression > or = Grade 3 was associated with a lower rate of major (P = 0.04) or complete (P = 0.01) cytogenetic responses. This was more pronounced with myelosuppression that lasted > 2 weeks. The major cytogenetic response rate was 58% with Grade > or = 3 myelosuppression compared with a rate of 75% without Grade > or =3 myelosuppression (P = 0.03); the complete cytogenetic response rates were 36% and 63%, respectively (P = 0.001). In a multivariate analysis, pretreatment platelet count, imatinib dose reductions, and duration of myelosuppression were associated significantly with response. Myelosuppression is an independent adverse factor for achieving cytogenetic response with imatinib in patients with CML. Intervention with hematopoietic growth factors in patients with CML who are treated with imatinib should be investigated.",Clinical Trial,5864.0,86.0,Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous CML During therapy with imatinib up to 45 of patients with CML reportedly experience myelosuppression or Grade 3 requiring interruption of therapy and/or dose reductions The significance of myelosuppression for response to imatinib is unknown The authors analyzed 143 patients with late chronic-phase CML who were treated with imatinib after failing interferon Univariate and multivariate analyses were performed to determine patient characteristics that were correlated with myelosuppression response and the association between myelosuppression and cytogenetic response Neutropenia or Grade 3 according to National Cancer Institute Common Toxicity Criteria occurred in 64 patients 45 and thrombocytopenia or Grade 3 occurred in 31 patients 22 Any myelosuppression or Grade 3 was associated with a lower rate of major P 0.04 or complete P 0.01 cytogenetic responses This was more pronounced with myelosuppression that lasted 2 weeks The major cytogenetic response rate was 58 with Grade or 3 myelosuppression compared with a rate of 75 without Grade or =3 myelosuppression P 0.03 the complete cytogenetic response rates were 36 and 63 respectively P 0.001 In a multivariate analysis pretreatment platelet count imatinib dose reductions and duration of myelosuppression were associated significantly with response Myelosuppression is an independent adverse factor for achieving cytogenetic response with imatinib in patients with CML Intervention with hematopoietic growth factors in patients with CML who are treated with imatinib should be investigated,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 2347, 1516, 64, 151, 1, 813, 2, 1266, 51, 4, 7, 5, 442, 2194, 903, 190, 36, 5, 577, 126, 6, 512, 1, 7, 5, 903, 11238, 730, 2858, 15, 88, 27, 1888, 4823, 1, 36, 2, 15, 61, 2153, 3, 724, 1, 2858, 9, 51, 6, 577, 16, 860, 3, 738, 311, 4400, 7, 5, 807, 442, 124, 903, 54, 11, 73, 5, 577, 50, 7928, 1688, 880, 2, 331, 318, 11, 173, 6, 223, 69, 374, 17, 11, 438, 5, 2858, 51, 2, 3, 248, 59, 2858, 2, 1266, 51, 778, 15, 88, 27, 768, 6, 657, 12, 1377, 186, 155, 371, 489, 4, 660, 7, 512, 2, 1340, 15, 88, 27, 489, 4, 456, 7, 350, 500, 2858, 15, 88, 27, 10, 41, 5, 8, 280, 116, 1, 458, 19, 13, 755, 15, 236, 19, 13, 355, 1266, 253, 26, 10, 80, 3517, 5, 2858, 17, 6854, 18, 244, 3, 458, 1266, 51, 116, 10, 717, 5, 88, 15, 27, 2858, 72, 5, 8, 116, 1, 481, 187, 88, 15, 27, 2858, 19, 13, 680, 3, 236, 1266, 51, 151, 11, 511, 2, 676, 106, 19, 13, 144, 4, 8, 331, 65, 1194, 1596, 1276, 577, 61, 2153, 2, 654, 1, 2858, 11, 41, 97, 5, 51, 2858, 16, 35, 306, 290, 161, 9, 1785, 1266, 51, 5, 577, 4, 7, 5, 903, 788, 5, 1007, 129, 130, 4, 7, 5, 903, 54, 32, 73, 5, 577, 257, 40, 565]",1668.0,14692031,12
"Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2004-01-01,"The purpose of this research was to compare the survival of patients with Philadelphia chromosome (Ph) -positive chronic myelogenous leukemia (CML) post-IFN-alpha failure treated with imatinib to historical experiences with standards of care or other therapies. The outcome of 261 patients with Ph-positive chronic phase CML post-IFN failure treated with imatinib was compared with 204 historical control patients treated for a similar disease status with existing therapies. A subset of 147 patients in late chronic phase CML and 100% Ph-positive status treated with imatinib was compared with 95 patients in a similar disease status treated with IFN. Multivariate analyses were conducted to assess the independent prognostic effect of therapy (imatinib versus other) on survival. In the first analysis involving 261 patients on imatinib plus 204 historical patients, the complete cytogenetic response rates were 62% and 19%, respectively (P < 0.001). A multivariate analysis identified pretreatment peripheral blasts and thrombocytosis to be independent poor prognostic factors for survival. Imatinib therapy (versus others) was a significant independent favorable prognostic factor for survival (hazard ratio, 0.17; P < 0.0001). In the second analysis involving the subset of 147 patients receiving imatinib plus 95 historical patients treated with IFN regimens, the complete cytogenetic response rates were 41% and 7%, respectively (P < 0.001). A multivariate analysis selected pretreatment anemia and peripheral blasts to be significant independent poor prognostic factors for survival. Imatinib therapy (versus IFN) was an independent favorable prognostic factor for survival (hazard ratio, 0.20; P < 0.0001). Three-month and 6-month landmark analyses showed that patients in all cytogenetic response categories (major, minor, and none) after imatinib therapy had survival outcomes better than the historical control population. Within each cytogenetic response category, survival was also better with imatinib than with other therapies. This analysis provides evidence for a survival advantage with imatinib versus other therapies in chronic-phase CML post-IFN failure, and for a survival advantage with imatinib versus IFN in late chronic-phase CML.",Comparative Study,5864.0,53.0,The purpose of this research was to compare the survival of patients with Philadelphia chromosome Ph -positive chronic myelogenous CML post-IFN-alpha failure treated with imatinib to historical experiences with standards of care or other therapies The outcome of 261 patients with Ph-positive chronic phase CML post-IFN failure treated with imatinib was compared with 204 historical control patients treated for a similar disease status with existing therapies A subset of 147 patients in late chronic phase CML and 100 Ph-positive status treated with imatinib was compared with 95 patients in a similar disease status treated with IFN Multivariate analyses were conducted to assess the independent prognostic effect of therapy imatinib versus other on survival In the first analysis involving 261 patients on imatinib plus 204 historical patients the complete cytogenetic response rates were 62 and 19 respectively P 0.001 A multivariate analysis identified pretreatment peripheral blasts and thrombocytosis to be independent poor prognostic factors for survival Imatinib therapy versus others was a significant independent favorable prognostic factor for survival hazard ratio 0.17 P 0.0001 In the second analysis involving the subset of 147 patients receiving imatinib plus 95 historical patients treated with IFN regimens the complete cytogenetic response rates were 41 and 7 respectively P 0.001 A multivariate analysis selected pretreatment anemia and peripheral blasts to be significant independent poor prognostic factors for survival Imatinib therapy versus IFN was an independent favorable prognostic factor for survival hazard ratio 0.20 P 0.0001 Three-month and 6-month landmark analyses showed that patients in all cytogenetic response categories major minor and none after imatinib therapy had survival outcomes better than the historical control population Within each cytogenetic response category survival was also better with imatinib than with other therapies This analysis provides evidence for a survival advantage with imatinib versus other therapies in chronic-phase CML post-IFN failure and for a survival advantage with imatinib versus IFN in late chronic-phase CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 743, 1, 26, 389, 10, 6, 932, 3, 25, 1, 7, 5, 3006, 1170, 2058, 109, 442, 2194, 903, 539, 1256, 950, 496, 73, 5, 577, 6, 2252, 4031, 5, 3371, 1, 165, 15, 127, 235, 3, 228, 1, 7007, 7, 5, 2058, 109, 442, 124, 903, 539, 1256, 496, 73, 5, 577, 10, 72, 5, 5996, 2252, 182, 7, 73, 9, 8, 288, 34, 156, 5, 1692, 235, 8, 697, 1, 4961, 7, 4, 807, 442, 124, 903, 2, 394, 2058, 109, 156, 73, 5, 577, 10, 72, 5, 48, 7, 4, 8, 288, 34, 156, 73, 5, 1256, 331, 318, 11, 426, 6, 423, 3, 306, 177, 254, 1, 36, 577, 185, 127, 23, 25, 4, 3, 157, 65, 1267, 7007, 7, 23, 577, 349, 5996, 2252, 7, 3, 236, 1266, 51, 151, 11, 744, 2, 326, 106, 19, 13, 144, 8, 331, 65, 108, 1194, 672, 2438, 2, 7589, 6, 40, 306, 334, 177, 130, 9, 25, 577, 36, 185, 1749, 10, 8, 93, 306, 913, 177, 161, 9, 25, 360, 197, 13, 269, 19, 13, 488, 4, 3, 419, 65, 1267, 3, 697, 1, 4961, 7, 357, 577, 349, 48, 2252, 7, 73, 5, 1256, 472, 3, 236, 1266, 51, 151, 11, 605, 2, 67, 106, 19, 13, 144, 8, 331, 65, 715, 1194, 1545, 2, 672, 2438, 6, 40, 93, 306, 334, 177, 130, 9, 25, 577, 36, 185, 1256, 10, 35, 306, 913, 177, 161, 9, 25, 360, 197, 13, 179, 19, 13, 488, 169, 811, 2, 49, 811, 3829, 318, 224, 17, 7, 4, 62, 1266, 51, 1996, 458, 2278, 2, 1292, 50, 577, 36, 42, 25, 123, 380, 76, 3, 2252, 182, 266, 262, 296, 1266, 51, 2169, 25, 10, 120, 380, 5, 577, 76, 5, 127, 235, 26, 65, 777, 241, 9, 8, 25, 1874, 5, 577, 185, 127, 235, 4, 442, 124, 903, 539, 1256, 496, 2, 9, 8, 25, 1874, 5, 577, 185, 1256, 4, 807, 442, 124, 903]",2190.0,14734453,17
Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.,Leukemia & lymphoma,Leuk. Lymphoma,2003-11-01,"A tyrosine kinase inhibitor, STI571, has been demonstrated to be effective for the treatment of chronic myelogenous leukemia (CML). STI571 inhibits tyrosine kinase activity of ABL and induces apoptosis of CML cells. However, drug resistance develops commonly in patients with blast phase CML, and has become a significant therapeutic problem. We examined the effects of aminopeptidase inhibitors on CML cell line (K562) and a STI571-resistant subline of K562. Ubenimex and the more potent aminopeptidase inhibitor, actinonin, inhibited proliferation of both K562 cells and STI571-resistant K562 cells and also induced their apoptosis in dose- and time-dependent manners. Ubenimex and actinonin induced the activation of caspase-3, and the induction of apoptosis was inhibited by pan-caspase inhibitor, indicating this apoptosis is caspase-dependent. We found that serine phosphorylation of both MAPK and glycogen synthase kinase-3beta were suppressed by aminopeptidase inhibitors in parent K562 and STI571-resistant K562 cells. The expression level of cyclin D1 protein was also reduced by ubenimex and actinonin in both cell lines. These results indicated STI571-resistance does not confer the cross-resistance to aminopeptidase inhibitors in K562 cells and revealed the new findings of aminopeptidase inhibitor-induced intracellular signaling pathways.",Comparative Study,5925.0,26.0,A tyrosine kinase inhibitor STI571 has been demonstrated to be effective for the treatment of chronic myelogenous CML STI571 inhibits tyrosine kinase activity of ABL and induces apoptosis of CML cells However drug resistance develops commonly in patients with blast phase CML and has become a significant therapeutic problem We examined the effects of aminopeptidase inhibitors on CML cell line K562 and a STI571-resistant subline of K562 Ubenimex and the more potent aminopeptidase inhibitor actinonin inhibited proliferation of both K562 cells and STI571-resistant K562 cells and also induced their apoptosis in dose- and time-dependent manners Ubenimex and actinonin induced the activation of caspase-3 and the induction of apoptosis was inhibited by pan-caspase inhibitor indicating this apoptosis is caspase-dependent We found that serine phosphorylation of both MAPK and glycogen synthase kinase-3beta were suppressed by aminopeptidase inhibitors in parent K562 and STI571-resistant K562 cells The expression level of cyclin D1 protein was also reduced by ubenimex and actinonin in both cell lines These results indicated STI571-resistance does not confer the cross-resistance to aminopeptidase inhibitors in K562 cells and revealed the new findings of aminopeptidase inhibitor-induced intracellular signaling pathways,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8, 564, 216, 230, 5735, 71, 85, 264, 6, 40, 323, 9, 3, 24, 1, 442, 2194, 903, 5735, 1576, 564, 216, 128, 1, 1425, 2, 1516, 351, 1, 903, 37, 137, 234, 251, 4734, 841, 4, 7, 5, 3112, 124, 903, 2, 71, 1417, 8, 93, 189, 2497, 21, 409, 3, 176, 1, 18319, 222, 23, 903, 31, 328, 5208, 2, 8, 5735, 436, 28178, 1, 5208, 37619, 2, 3, 80, 1157, 18319, 230, 26257, 879, 457, 1, 110, 5208, 37, 2, 5735, 436, 5208, 37, 2, 120, 277, 136, 351, 4, 61, 2, 98, 470, 18948, 37619, 2, 26257, 277, 3, 363, 1, 1469, 27, 2, 3, 504, 1, 351, 10, 879, 20, 3055, 1469, 230, 1716, 26, 351, 16, 1469, 470, 21, 204, 17, 3734, 982, 1, 110, 1748, 2, 9482, 3522, 216, 12586, 11, 1908, 20, 18319, 222, 4, 3841, 5208, 2, 5735, 436, 5208, 37, 3, 55, 301, 1, 1226, 2146, 178, 10, 120, 405, 20, 37619, 2, 26257, 4, 110, 31, 285, 46, 99, 1103, 5735, 251, 1097, 44, 2913, 3, 1383, 251, 6, 18319, 222, 4, 5208, 37, 2, 553, 3, 217, 272, 1, 18319, 230, 277, 2087, 314, 460]",1324.0,14738154,15
Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma.,Cancer research,Cancer Res.,2004-02-01,"Multiple isoforms (TAG-1, TAG-2a, TAG-2b, and TAG-2c) of a novel cancer/testis antigen gene have been identified and are expressed in 84-88% of melanoma cell lines tested. The tumor antigen (TAG) genes are also expressed in K562, a myelogenous leukemia cell line, and they have homology to two chronic myelogenous leukemia-derived clones and a hepatocellular carcinoma clone in the human expressed sequence tags (EST) database, thus indicating that their expression is not restricted to melanomas. In contrast to the fact that many cancer/testis antigens are poorly immunogenic, the TAG-derived peptide, RLSNRLLLR, is recognized by HLA-A3-restricted, melanoma-specific CTLs that were obtained from a melanoma patient with spontaneous reactivity to the peptide. Unlike most cancer/testis antigen genes which are located on the X chromosome, the TAG genes are located on chromosome 5. The genes have the additional unusual features of being coded for in an open reading frame that is initiated by one of three nonstandard initiation codons, and the sequence coding the RLSNRLLLR peptide crosses an exon-exon boundary. The properties of the TAG antigens indicate that they are excellent vaccine candidates for the treatment of melanoma and perhaps other cancers.",Journal Article,5833.0,17.0,Multiple isoforms TAG-1 TAG-2a TAG-2b and TAG-2c of a novel cancer/testis antigen gene have been identified and are expressed in 84-88 of cell lines tested The tumor antigen TAG genes are also expressed in K562 a myelogenous cell line and they have homology to two chronic myelogenous leukemia-derived clones and a carcinoma clone in the human expressed sequence tags EST database thus indicating that their expression is not restricted to melanomas In contrast to the fact that many cancer/testis antigens are poorly immunogenic the TAG-derived peptide RLSNRLLLR is recognized by HLA-A3-restricted melanoma-specific CTLs that were obtained from a patient with spontaneous reactivity to the peptide Unlike most cancer/testis antigen genes which are located on the X chromosome the TAG genes are located on chromosome 5 The genes have the additional unusual features of being coded for in an open reading frame that is initiated by one of three nonstandard initiation codons and the sequence coding the RLSNRLLLR peptide crosses an exon-exon boundary The properties of the TAG antigens indicate that they are excellent vaccine candidates for the treatment of and perhaps other cancers,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[232, 3913, 7479, 14, 7479, 4707, 7479, 3381, 2, 7479, 11779, 1, 8, 229, 12, 7697, 448, 145, 47, 85, 108, 2, 32, 570, 4, 874, 889, 1, 31, 285, 650, 3, 30, 448, 7479, 214, 32, 120, 570, 4, 5208, 8, 2194, 31, 328, 2, 491, 47, 7984, 6, 100, 442, 2194, 2647, 526, 2749, 2, 8, 134, 3910, 4, 3, 171, 570, 1532, 13059, 13807, 609, 631, 1716, 17, 136, 55, 16, 44, 2016, 6, 1965, 4, 748, 6, 3, 1991, 17, 445, 12, 7697, 1575, 32, 1240, 4190, 3, 7479, 526, 1389, 43510, 16, 1904, 20, 1160, 7024, 2016, 4128, 112, 5416, 17, 11, 683, 29, 8, 69, 5, 3280, 4601, 6, 3, 1389, 4246, 96, 12, 7697, 448, 214, 92, 32, 2308, 23, 3, 1006, 1170, 3, 7479, 214, 32, 2308, 23, 1170, 33, 3, 214, 47, 3, 402, 4015, 404, 1, 486, 8259, 9, 4, 35, 1020, 7299, 5331, 17, 16, 1917, 20, 104, 1, 169, 18798, 1118, 9107, 2, 3, 1532, 3097, 3, 43510, 1389, 17716, 35, 1725, 1725, 8920, 3, 1571, 1, 3, 7479, 1575, 1008, 17, 491, 32, 1503, 1274, 1931, 9, 3, 24, 1, 2, 4434, 127, 163]",1183.0,14871852,249
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2004-02-19,"Abnormal protein tyrosine kinases (PTKs) cause many human leukemias. For example, BCR/ABL causes chronic myelogenous leukemia (CML), whereas FLT3 mutations contribute to the pathogenesis of acute myelogenous leukemia. The ABL inhibitor Imatinib (Gleevec, STI571) has remarkable efficacy for treating chronic phase CML, and FLT3 inhibitors (e.g., PKC412) show similar promise in preclinical studies. However, resistance to PTK inhibitors is a major emerging problem that may limit long-term therapeutic efficacy. Development of rational combination therapies will probably be required to effect cures of these and other neoplastic disorders. Here, we report that the mTOR inhibitor rapamycin synergizes with Imatinib against BCR/ABL-transformed myeloid and lymphoid cells and increases survival in a murine CML model. Rapamycin/Imatinib combinations also inhibit Imatinib-resistant mutants of BCR/ABL, and rapamycin plus PKC412 synergistically inhibits cells expressing PKC412-sensitive or -resistant leukemogenic FLT3 mutants. Biochemical analyses raise the possibility that inhibition of 4E-BP1 phosphorylation may be particularly important for the synergistic effects of PTK inhibitor/rapamycin combinations. Addition of a mitogen-activated protein kinase kinase inhibitor to rapamycin or rapamycin plus PTK inhibitor further increases efficacy. Our results suggest that simultaneous targeting of more than one signaling pathway required by leukemogenic PTKs may improve the treatment of primary and relapsed CML and/or acute myelogenous leukemia caused by FLT3 mutations. Similar strategies may be useful for treating solid tumors associated with mutant and/or overexpressed PTKs.",Journal Article,5815.0,222.0,Abnormal protein tyrosine kinases PTKs cause many human leukemias For example BCR/ABL causes chronic myelogenous CML whereas FLT3 mutations contribute to the pathogenesis of acute myelogenous The ABL inhibitor Imatinib Gleevec STI571 has remarkable efficacy for treating chronic phase CML and FLT3 inhibitors e.g. PKC412 show similar promise in preclinical studies However resistance to PTK inhibitors is a major emerging problem that may limit long-term therapeutic efficacy Development of rational combination therapies will probably be required to effect cures of these and other neoplastic disorders Here we report that the mTOR inhibitor rapamycin synergizes with Imatinib against BCR/ABL-transformed myeloid and lymphoid cells and increases survival in a murine CML model Rapamycin/Imatinib combinations also inhibit Imatinib-resistant mutants of BCR/ABL and rapamycin plus PKC412 synergistically inhibits cells expressing PKC412-sensitive or -resistant leukemogenic FLT3 mutants Biochemical analyses raise the possibility that inhibition of 4E-BP1 phosphorylation may be particularly important for the synergistic effects of PTK inhibitor/rapamycin combinations Addition of a mitogen-activated protein kinase kinase inhibitor to rapamycin or rapamycin plus PTK inhibitor further increases efficacy Our results suggest that simultaneous targeting of more than one signaling pathway required by leukemogenic PTKs may improve the treatment of primary and relapsed CML and/or acute myelogenous caused by FLT3 mutations Similar strategies may be useful for treating solid tumors associated with mutant and/or overexpressed PTKs,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1668, 178, 564, 1549, 30553, 708, 445, 171, 2792, 9, 2685, 1062, 1425, 1626, 442, 2194, 903, 547, 1224, 138, 1248, 6, 3, 1384, 1, 286, 2194, 3, 1425, 230, 577, 8569, 5735, 71, 3813, 209, 9, 1367, 442, 124, 903, 2, 1224, 222, 563, 499, 7154, 514, 288, 1783, 4, 693, 94, 137, 251, 6, 20351, 222, 16, 8, 458, 1478, 2497, 17, 68, 2385, 319, 337, 189, 209, 193, 1, 2696, 150, 235, 303, 4061, 40, 616, 6, 254, 9154, 1, 46, 2, 127, 2000, 1997, 467, 21, 414, 17, 3, 873, 230, 1620, 10824, 5, 577, 480, 1062, 1425, 2423, 533, 2, 2303, 37, 2, 1106, 25, 4, 8, 1471, 903, 202, 1620, 577, 1247, 120, 1433, 577, 436, 3423, 1, 1062, 1425, 2, 1620, 349, 7154, 4240, 1576, 37, 1046, 7154, 745, 15, 436, 13519, 1224, 3423, 1487, 318, 5008, 3, 2526, 17, 297, 1, 6726, 7949, 982, 68, 40, 823, 305, 9, 3, 1806, 176, 1, 20351, 230, 1620, 1247, 352, 1, 8, 2625, 735, 178, 216, 216, 230, 6, 1620, 15, 1620, 349, 20351, 230, 195, 1106, 209, 114, 99, 309, 17, 2824, 529, 1, 80, 76, 104, 314, 308, 616, 20, 13519, 30553, 68, 401, 3, 24, 1, 86, 2, 591, 903, 2, 15, 286, 2194, 1546, 20, 1224, 138, 288, 422, 68, 40, 999, 9, 1367, 537, 57, 41, 5, 620, 2, 15, 1711, 30553]",1629.0,14976243,21
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.,Blood,Blood,2004-03-23,"Interactions between the cyclin-dependent kinase (CDK) inhibitor flavopiridol and the proteasome inhibitor bortezomib were examined in Bcr/Abl(+) human leukemia cells. Coexposure of K562 or LAMA84 cells to subtoxic concentration of flavopiridol (150-200 nM) and bortezomib (5-8 nM) resulted in a synergistic increase in mitochondrial dysfunction and apoptosis. These events were associated with a marked diminution in nuclear factor kappaB (NF-kappaB)/DNA binding activity; enhanced phosphorylation of SEK1/MKK4 (stress-activated protein kinase/extracellular signal-related kinase 1/mitogen-activated protein kinase kinase 4), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK); down-regulation of Bcr/Abl; and a marked reduction in signal transducer and activator of transcription 3 (STAT3) and STAT5 activity. In imatinib mesylate-resistant K562 cells displaying increased Bcr/Abl expression, bortezomib/flavopiridol treatment markedly increased apoptosis in association with down-regulation of Bcr/Abl and BclxL, and diminished phosphorylation of Lyn, Hck, CrkL, and Akt. Parallel studies were performed in imatinib mesylate-resistant LAMA84 cells exhibiting reduced expression of Bcr/Abl but a marked increase in expression/activation of Lyn and Hck. Flavopiridol/bortezomib effectively induced apoptosis in these cells in association with Lyn and Hck inactivation. The capacity of flavopiridol to promote bortezomib-mediated Bcr/Abl down-regulation and apoptosis was mimicked by the positive transcription elongation factor-b (P-TEFb) inhibitor DRB (5,6-dichloro 1-beta-d-ribofuranosylbenzinida-sole). Finally, the bortezomib/flavopiridol regimen also potently induced apoptosis in Bcr/Abl(-) human leukemia cells. Collectively, these findings suggest that a strategy combining flavopiridol and bortezomib warrants further examination in chronic myelogenous leukemia and related hematologic malignancies.",Journal Article,5782.0,102.0,"Interactions between the cyclin-dependent kinase CDK inhibitor flavopiridol and the proteasome inhibitor bortezomib were examined in Bcr/Abl human cells Coexposure of K562 or LAMA84 cells to subtoxic concentration of flavopiridol 150-200 nM and bortezomib 5-8 nM resulted in a synergistic increase in mitochondrial dysfunction and apoptosis These events were associated with a marked diminution in nuclear factor kappaB NF-kappaB /DNA binding activity enhanced phosphorylation of SEK1/MKK4 stress-activated protein kinase/extracellular signal-related kinase 1/mitogen-activated protein kinase kinase 4 c-Jun N-terminal kinase JNK and p38 mitogen-activated protein kinase MAPK down-regulation of Bcr/Abl and a marked reduction in signal transducer and activator of transcription 3 STAT3 and STAT5 activity In imatinib mesylate-resistant K562 cells displaying increased Bcr/Abl expression bortezomib/flavopiridol treatment markedly increased apoptosis in association with down-regulation of Bcr/Abl and BclxL and diminished phosphorylation of Lyn Hck CrkL and Akt Parallel studies were performed in imatinib mesylate-resistant LAMA84 cells exhibiting reduced expression of Bcr/Abl but a marked increase in expression/activation of Lyn and Hck Flavopiridol/bortezomib effectively induced apoptosis in these cells in association with Lyn and Hck inactivation The capacity of flavopiridol to promote bortezomib-mediated Bcr/Abl down-regulation and apoptosis was mimicked by the positive transcription elongation factor-b P-TEFb inhibitor DRB 5,6-dichloro 1-beta-d-ribofuranosylbenzinida-sole Finally the bortezomib/flavopiridol regimen also potently induced apoptosis in Bcr/Abl human cells Collectively these findings suggest that a strategy combining flavopiridol and bortezomib warrants further examination in chronic myelogenous and related hematologic malignancies",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1286, 59, 3, 1226, 470, 216, 3954, 230, 3030, 2, 3, 1694, 230, 819, 11, 409, 4, 1062, 1425, 171, 37, 21094, 1, 5208, 15, 33628, 37, 6, 23172, 1227, 1, 3030, 1577, 1250, 2878, 2, 819, 33, 66, 2878, 627, 4, 8, 1806, 344, 4, 2019, 1527, 2, 351, 46, 281, 11, 41, 5, 8, 2003, 20255, 4, 928, 161, 2119, 1365, 2119, 261, 791, 128, 651, 982, 1, 37658, 13903, 1531, 735, 178, 216, 1976, 1235, 139, 216, 14, 2625, 735, 178, 216, 216, 39, 256, 4578, 78, 2158, 216, 3958, 2, 3970, 2625, 735, 178, 216, 1748, 1328, 863, 1, 1062, 1425, 2, 8, 2003, 628, 4, 1235, 5182, 2, 3393, 1, 866, 27, 1439, 2, 5517, 128, 4, 577, 2347, 436, 5208, 37, 6609, 101, 1062, 1425, 55, 819, 3030, 24, 2195, 101, 351, 4, 248, 5, 1328, 863, 1, 1062, 1425, 2, 26276, 2, 2849, 982, 1, 8309, 17252, 13765, 2, 649, 2755, 94, 11, 173, 4, 577, 2347, 436, 33628, 37, 4801, 405, 55, 1, 1062, 1425, 84, 8, 2003, 344, 4, 55, 363, 1, 8309, 2, 17252, 3030, 819, 1856, 277, 351, 4, 46, 37, 4, 248, 5, 8309, 2, 17252, 2297, 3, 2162, 1, 3030, 6, 1617, 819, 517, 1062, 1425, 1328, 863, 2, 351, 10, 11102, 20, 3, 109, 866, 12359, 161, 132, 19, 30565, 230, 43544, 33, 49, 43545, 14, 1090, 427, 54062, 4991, 1368, 3, 819, 3030, 477, 120, 4684, 277, 351, 4, 1062, 1425, 171, 37, 2535, 46, 272, 309, 17, 8, 692, 1525, 3030, 2, 819, 2782, 195, 1385, 4, 442, 2194, 2, 139, 813, 441]",1864.0,15039284,150
"Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.",Cancer,Cancer,2004-04-01,"OSI-211 is a low-clearance, unilamellar liposomal formulation of a water-soluble camptothecin analogue, lurtotecan. OSI-211 has significant activity in severe combined immunodeficient mouse models of human leukemia. This study was conducted to define the dose-limiting toxicities (DLT) and pharmacokinetics of OSI-211 in patients with refractory myeloid leukemias. Patients with refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP) were eligible. OSI-211 was given as an intravenous infusion over 30 minutes daily for 3 days. The starting dose was 1.5 mg/m2 per day (4.5 mg/m2 per course). The dose was escalated by 50% until Grade 2 toxicity was observed and then by 30-35% until the DLT was defined. Serial plasma and urine samples were collected, and drug levels were determined by high-performance liquid chromatography with fluorescence detection. Twenty patients (18 patients [90%] with AML, and 1 patient each [5%] with MDS and CML-BP) were treated. Mucositis and diarrhea were considered to be the DLTs. The maximum tolerated dose was 3.7 mg/m2 per day. Fourteen of 18 evaluable patients (78%) with AML or MDS achieved transient bone marrow aplasia. The mean systemic clearance of lurtotecan in plasma was 0.946 +/- 1.53 L/hour/m2. Urinary recovery of lurtotecan was 6.66% +/- 5.26% (range, 1.05-18.4%). Liposomal encapsulation of lurtotecan altered its metabolism significantly. There was no evident correlation between exposure, as measured by plasma pharmacokinetics of lurtotecan, and clinical response or toxicities. OSI-211 merits further study in hematologic malignancies.",Clinical Trial,5773.0,34.0,OSI-211 is a low-clearance unilamellar liposomal formulation of a water-soluble camptothecin analogue lurtotecan OSI-211 has significant activity in severe combined immunodeficient mouse models of human This study was conducted to define the dose-limiting toxicities DLT and pharmacokinetics of OSI-211 in patients with refractory myeloid leukemias Patients with refractory acute myeloid AML syndrome MDS or chronic myelogenous in blastic phase CML-BP were eligible OSI-211 was given as an intravenous infusion over 30 minutes daily for 3 days The starting dose was 1.5 mg/m2 per day 4.5 mg/m2 per course The dose was escalated by 50 until Grade 2 toxicity was observed and then by 30-35 until the DLT was defined Serial plasma and urine samples were collected and drug levels were determined by high-performance liquid chromatography with fluorescence detection Twenty patients 18 patients 90 with AML and 1 patient each 5 with MDS and CML-BP were treated Mucositis and diarrhea were considered to be the DLTs The maximum tolerated dose was 3.7 mg/m2 per day Fourteen of 18 evaluable patients 78 with AML or MDS achieved transient marrow aplasia The mean systemic clearance of lurtotecan in plasma was 0.946 +/- 1.53 L/hour/m2 Urinary recovery of lurtotecan was 6.66 +/- 5.26 range 1.05-18.4 Liposomal encapsulation of lurtotecan altered its metabolism significantly There was no evident correlation between exposure as measured by plasma pharmacokinetics of lurtotecan and clinical response or toxicities OSI-211 merits further study in hematologic malignancies,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6186, 5905, 16, 8, 154, 1960, 43548, 3275, 3583, 1, 8, 4388, 2968, 6968, 4696, 30568, 6186, 5905, 71, 93, 128, 4, 905, 397, 5031, 830, 274, 1, 171, 26, 45, 10, 426, 6, 1107, 3, 61, 817, 385, 2059, 2, 1159, 1, 6186, 5905, 4, 7, 5, 430, 533, 2792, 7, 5, 430, 286, 533, 329, 681, 1223, 15, 442, 2194, 4, 6529, 124, 903, 3044, 11, 625, 6186, 5905, 10, 447, 22, 35, 1262, 904, 252, 201, 2511, 391, 9, 27, 162, 3, 1723, 61, 10, 14, 33, 81, 821, 379, 218, 39, 33, 81, 821, 379, 906, 3, 61, 10, 2842, 20, 212, 1100, 88, 18, 155, 10, 164, 2, 818, 20, 201, 465, 1100, 3, 2059, 10, 395, 2108, 554, 2, 2646, 347, 11, 786, 2, 234, 148, 11, 509, 20, 64, 528, 3165, 5140, 5, 1591, 638, 737, 7, 203, 7, 424, 5, 329, 2, 14, 69, 296, 33, 5, 1223, 2, 903, 3044, 11, 73, 2606, 2, 1172, 11, 515, 6, 40, 3, 2506, 3, 689, 421, 61, 10, 27, 67, 81, 821, 379, 218, 3225, 1, 203, 859, 7, 833, 5, 329, 15, 1223, 513, 2473, 581, 12307, 3, 313, 403, 1960, 1, 30568, 4, 554, 10, 13, 17787, 14, 699, 805, 2583, 821, 1660, 1602, 1, 30568, 10, 49, 700, 33, 432, 184, 14, 474, 203, 39, 3275, 12784, 1, 30568, 1495, 211, 1600, 97, 125, 10, 77, 2853, 816, 59, 645, 22, 644, 20, 554, 1159, 1, 30568, 2, 38, 51, 15, 385, 6186, 5905, 4986, 195, 45, 4, 813, 441]",1563.0,15042679,2
Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.,The Journal of biological chemistry,J. Biol. Chem.,2004-03-31,"Imatinib mesylate (STI571), a specific inhibitor of the BCR-ABL tyrosine kinase, exhibits potent antileukemic effects in vitro and in vivo. Despite the well established role of STI571 in the treatment of chronic myelogenous leukemia, the precise mechanisms by which inhibition of BCR-ABL tyrosine kinase activity results in generation of antileukemic responses remain unknown. In the present study we provide evidence that treatment of CML-derived BCR-ABL-expressing leukemia cells with STI571 results in activation of the p38 mitogen-activated protein (MAP) kinase signaling pathway. Our data indicate that STI571 induces phosphorylation of the p38 and activation of its kinase domain, in KT-1 cells and other BCR-ABL-expressing cell lines. We also identify the kinases MAP kinase-activated protein kinase-2 and Msk1 as two downstream effectors of p38, activated during inhibition of BCR-ABL activity by STI571. Importantly, pharmacological inhibition of p38 reverses the growth inhibitory effects of STI571 on primary leukemic colony-forming unit granulocyte/macrophage progenitors from patients with CML. Altogether, our data establish that activation of the p38 MAP kinase signaling cascade plays an important role in the generation of the effects of STI571 on BCR-ABL-expressing cells. They also suggest that, in addition to activation of mitogenic pathways, BCR-ABL promotes leukemogenesis by suppressing the function of growth inhibitory signaling cascades.",Journal Article,5774.0,55.0,Imatinib mesylate STI571 a specific inhibitor of the BCR-ABL tyrosine kinase exhibits potent antileukemic effects in vitro and in vivo Despite the well established role of STI571 in the treatment of chronic myelogenous the precise mechanisms by which inhibition of BCR-ABL tyrosine kinase activity results in generation of antileukemic responses remain unknown In the present study we provide evidence that treatment of CML-derived BCR-ABL-expressing cells with STI571 results in activation of the p38 mitogen-activated protein MAP kinase signaling pathway Our data indicate that STI571 induces phosphorylation of the p38 and activation of its kinase domain in KT-1 cells and other BCR-ABL-expressing cell lines We also identify the kinases MAP kinase-activated protein kinase-2 and Msk1 as two downstream effectors of p38 activated during inhibition of BCR-ABL activity by STI571 Importantly pharmacological inhibition of p38 reverses the growth inhibitory effects of STI571 on primary leukemic colony-forming unit granulocyte/macrophage progenitors from patients with CML Altogether our data establish that activation of the p38 MAP kinase signaling cascade plays an important role in the generation of the effects of STI571 on BCR-ABL-expressing cells They also suggest that in addition to activation of mitogenic pathways BCR-ABL promotes leukemogenesis by suppressing the function of growth inhibitory signaling cascades,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 2347, 5735, 8, 112, 230, 1, 3, 1062, 1425, 564, 216, 4273, 1157, 4512, 176, 4, 439, 2, 4, 386, 550, 3, 149, 635, 200, 1, 5735, 4, 3, 24, 1, 442, 2194, 3, 3260, 483, 20, 92, 297, 1, 1062, 1425, 564, 216, 128, 99, 4, 914, 1, 4512, 253, 918, 860, 4, 3, 364, 45, 21, 377, 241, 17, 24, 1, 903, 526, 1062, 1425, 1046, 37, 5, 5735, 99, 4, 363, 1, 3, 3970, 2625, 735, 178, 3771, 216, 314, 308, 114, 74, 1008, 17, 5735, 1516, 982, 1, 3, 3970, 2, 363, 1, 211, 216, 1398, 4, 24697, 14, 37, 2, 127, 1062, 1425, 1046, 31, 285, 21, 120, 255, 3, 1549, 3771, 216, 735, 178, 216, 18, 2, 20365, 22, 100, 1489, 4926, 1, 3970, 735, 190, 297, 1, 1062, 1425, 128, 20, 5735, 1859, 3419, 297, 1, 3970, 10984, 3, 129, 1810, 176, 1, 5735, 23, 86, 2015, 1975, 4525, 2712, 2764, 2674, 4321, 29, 7, 5, 903, 6767, 114, 74, 1811, 17, 363, 1, 3, 3970, 3771, 216, 314, 4678, 1698, 35, 305, 200, 4, 3, 914, 1, 3, 176, 1, 5735, 23, 1062, 1425, 1046, 37, 491, 120, 309, 17, 4, 352, 6, 363, 1, 8233, 460, 1062, 1425, 2148, 5661, 20, 4669, 3, 343, 1, 129, 1810, 314, 8036]",1425.0,15056660,140
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.,Blood,Blood,2003-12-24,"Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia (CML). However, most patients treated with 400 mg imatinib daily have variable levels of residual molecular disease. We treated 114 patients with newly diagnosed chronic phase CML with 400 mg imatinib twice daily. Overall, 109 patients (96%) had a major cytogenetic response (Philadelphia chromosome [Ph] < 35%), and 103 (90%) had a complete response (Ph 0%). With a median follow-up of 15 months, no patient has progressed to accelerated or blastic phase. The estimated 2-year survival rate was 94%. By quantitative polymerase chain reaction (QPCR) studies, 71 (63%) of 112 patients showed BCR-ABL/ABL percentage ratios decrease to less than 0.05%, and 31 (28%) to undetectable levels. Compared with standard-dose imatinib, high-dose imatinib was associated with significantly better complete cytogenetic response (P =.0005), major molecular response (QPRC < 0.05%; P =.00001), and complete molecular response (undetectable BCR-ABL; P =.001). High-dose imatinib was well tolerated but resulted in more frequent myelosuppression; 82% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induced higher rates of complete cytogenetic response and of molecular response in patients with newly diagnosed chronic phase CML.",Journal Article,5872.0,348.0,Imatinib mesylate STI571 is effective in chronic phase chronic myelogenous CML However most patients treated with 400 mg imatinib daily have variable levels of residual molecular disease We treated 114 patients with newly diagnosed chronic phase CML with 400 mg imatinib twice daily Overall 109 patients 96 had a major cytogenetic response Philadelphia chromosome Ph 35 and 103 90 had a complete response Ph 0 With a median follow-up of 15 months no patient has progressed to accelerated or blastic phase The estimated 2-year survival rate was 94 By quantitative polymerase chain reaction QPCR studies 71 63 of 112 patients showed BCR-ABL/ABL percentage ratios decrease to less than 0.05 and 31 28 to undetectable levels Compared with standard-dose imatinib high-dose imatinib was associated with significantly better complete cytogenetic response P =.0005 major molecular response QPRC 0.05 P =.00001 and complete molecular response undetectable BCR-ABL P =.001 High-dose imatinib was well tolerated but resulted in more frequent myelosuppression 82 of patients continue to receive 600 mg or more of imatinib daily In conclusion high-dose imatinib induced higher rates of complete cytogenetic response and of molecular response in patients with newly diagnosed chronic phase CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 2347, 5735, 16, 323, 4, 442, 124, 442, 2194, 903, 137, 96, 7, 73, 5, 1524, 81, 577, 391, 47, 1347, 148, 1, 753, 219, 34, 21, 73, 3803, 7, 5, 732, 265, 442, 124, 903, 5, 1524, 81, 577, 936, 391, 63, 3486, 7, 921, 42, 8, 458, 1266, 51, 3006, 1170, 2058, 465, 2, 3283, 424, 42, 8, 236, 51, 2058, 13, 5, 8, 52, 166, 126, 1, 167, 53, 77, 69, 71, 1839, 6, 2241, 15, 6529, 124, 3, 661, 18, 111, 25, 116, 10, 960, 20, 1156, 1451, 1260, 1329, 6162, 94, 792, 676, 1, 3726, 7, 224, 1062, 1425, 1425, 1150, 1137, 775, 6, 299, 76, 13, 474, 2, 456, 339, 6, 3920, 148, 72, 5, 260, 61, 577, 64, 61, 577, 10, 41, 5, 97, 380, 236, 1266, 51, 19, 4252, 458, 219, 51, 54107, 13, 474, 19, 7868, 2, 236, 219, 51, 3920, 1062, 1425, 19, 144, 64, 61, 577, 10, 149, 421, 84, 627, 4, 80, 908, 2858, 878, 1, 7, 1906, 6, 560, 2383, 81, 15, 80, 1, 577, 391, 4, 1221, 64, 61, 577, 277, 142, 151, 1, 236, 1266, 51, 2, 1, 219, 51, 4, 7, 5, 732, 265, 442, 124, 903]",1279.0,15070658,38
The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia.,Cancer,Cancer,2004-05-01,"Although central nervous system (CNS) prophylaxis in patients with leukemia has reduced the incidence of CNS disease recurrence, it still is reported to occur in approximately 5-10% of cases, resulting in a median survival of 6 months. Craniospinal irradiation (CSI) has been shown to improve survival in children who develop a CNS recurrence of acute lymphocytic leukemia (ALL). However, to the authors' knowledge, the role of CSI in adults with a CNS recurrence of leukemia is unknown. A retrospective review of adult patients treated with CSI for a CNS recurrence of leukemia identified 16 patients treated between 1986 and 2001. The median age of the patients was 34 years (range, 16-58 years). The diagnoses included seven patients with acute myelogenous leukemia (AML), eight patients with ALL, and one patient with chronic myelogenous leukemia in blast crisis. All patients had achieved a complete disease remission prior to the CNS recurrence. Eleven patients had an isolated CNS recurrence and 5 patients had concurrent disease identified in the blood/bone marrow. The median dose of radiation was 24 grays (Gy) (range, 18-34.5 Gy) to the cranium and 18 Gy (range, 15-30 Gy) to the spine. The median fraction size was 1.8 Gy (range, 1.5-2.0 Gy) to the cranium and 1.5 Gy (range, 1.5-2.0 Gy) to the spine. Fifteen patients were also treated with intrathecal chemotherapy. One patient failed to complete radiation treatment because of disease progression. Thirteen patients achieved a complete response in the cerebrospinal fluid (CSF). The median time to disease progression was 3 months from the first day of CSI and 7 months from CNS recurrence. The median survival was 4 months and 9 months, respectively. No CNS recurrences occurred, but there were 11 bone marrow failures, 2 patients without recurrence at > 5 years, and 3 deaths without a documented site of failure. Thirteen patients had no evidence of disease in the CSF until their death or the time of last follow-up. CSI with or without intrathecal chemotherapy appears to be effective at eliminating leukemia in the craniospinal axis. However, the eradication of disease in the CNS was not found to be effective at preventing disease recurrence in the bone marrow, and despite improved control of disease in the CNS, adult patients with a CNS recurrence still had a poor prognosis. Furthermore, the rapidly fatal course of disease prevented an assessment of the durability of CNS response to irradiation.",Journal Article,5743.0,26.0,Although central nervous system CNS prophylaxis in patients with has reduced the incidence of CNS disease recurrence it still is reported to occur in approximately 5-10 of cases resulting in a median survival of 6 months Craniospinal irradiation CSI has been shown to improve survival in children who develop a CNS recurrence of acute lymphocytic ALL However to the authors knowledge the role of CSI in adults with a CNS recurrence of is unknown A retrospective review of adult patients treated with CSI for a CNS recurrence of identified 16 patients treated between 1986 and 2001 The median age of the patients was 34 years range 16-58 years The diagnoses included seven patients with acute myelogenous AML eight patients with ALL and one patient with chronic myelogenous in blast crisis All patients had achieved a complete disease remission prior to the CNS recurrence Eleven patients had an isolated CNS recurrence and 5 patients had concurrent disease identified in the blood/bone marrow The median dose of radiation was 24 grays Gy range 18-34.5 Gy to the cranium and 18 Gy range 15-30 Gy to the spine The median fraction size was 1.8 Gy range 1.5-2.0 Gy to the cranium and 1.5 Gy range 1.5-2.0 Gy to the spine Fifteen patients were also treated with intrathecal chemotherapy One patient failed to complete radiation treatment because of disease progression Thirteen patients achieved a complete response in the cerebrospinal fluid CSF The median time to disease progression was 3 months from the first day of CSI and 7 months from CNS recurrence The median survival was 4 months and 9 months respectively No CNS recurrences occurred but there were 11 marrow failures 2 patients without recurrence at 5 years and 3 deaths without a documented site of failure Thirteen patients had no evidence of disease in the CSF until their death or the time of last follow-up CSI with or without intrathecal chemotherapy appears to be effective at eliminating in the craniospinal axis However the eradication of disease in the CNS was not found to be effective at preventing disease recurrence in the marrow and despite improved control of disease in the CNS adult patients with a CNS recurrence still had a poor prognosis Furthermore the rapidly fatal course of disease prevented an assessment of the durability of CNS response to irradiation,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[242, 854, 1880, 398, 1025, 2049, 4, 7, 5, 71, 405, 3, 287, 1, 1025, 34, 146, 192, 1234, 16, 210, 6, 1271, 4, 705, 33, 79, 1, 140, 1113, 4, 8, 52, 25, 1, 49, 53, 5748, 1104, 4293, 71, 85, 443, 6, 401, 25, 4, 541, 54, 690, 8, 1025, 146, 1, 286, 1193, 62, 137, 6, 3, 738, 922, 3, 200, 1, 4293, 4, 857, 5, 8, 1025, 146, 1, 16, 860, 8, 459, 206, 1, 780, 7, 73, 5, 4293, 9, 8, 1025, 146, 1, 108, 245, 7, 73, 59, 3751, 2, 1758, 3, 52, 89, 1, 3, 7, 10, 562, 60, 184, 245, 717, 60, 3, 2403, 159, 648, 7, 5, 286, 2194, 329, 659, 7, 5, 62, 2, 104, 69, 5, 442, 2194, 4, 3112, 6540, 62, 7, 42, 513, 8, 236, 34, 734, 324, 6, 3, 1025, 146, 2627, 7, 42, 35, 1355, 1025, 146, 2, 33, 7, 42, 750, 34, 108, 4, 3, 315, 3417, 581, 3, 52, 61, 1, 121, 10, 259, 9864, 381, 184, 203, 562, 33, 381, 6, 3, 37683, 2, 203, 381, 184, 167, 201, 381, 6, 3, 2342, 3, 52, 1509, 444, 10, 14, 66, 381, 184, 14, 33, 18, 13, 381, 6, 3, 37683, 2, 14, 33, 381, 184, 14, 33, 18, 13, 381, 6, 3, 2342, 3057, 7, 11, 120, 73, 5, 5126, 56, 104, 69, 1551, 6, 236, 121, 24, 408, 1, 34, 91, 3170, 7, 513, 8, 236, 51, 4, 3, 5156, 2357, 1211, 3, 52, 98, 6, 34, 91, 10, 27, 53, 29, 3, 157, 218, 1, 4293, 2, 67, 53, 29, 1025, 146, 3, 52, 25, 10, 39, 53, 2, 83, 53, 106, 77, 1025, 1593, 489, 84, 125, 11, 175, 581, 3368, 18, 7, 187, 146, 28, 33, 60, 2, 27, 1043, 187, 8, 1405, 606, 1, 496, 3170, 7, 42, 77, 241, 1, 34, 4, 3, 1211, 1100, 136, 273, 15, 3, 98, 1, 1060, 166, 126, 4293, 5, 15, 187, 5126, 56, 1233, 6, 40, 323, 28, 6923, 4, 3, 5748, 2310, 137, 3, 5173, 1, 34, 4, 3, 1025, 10, 44, 204, 6, 40, 323, 28, 3017, 34, 146, 4, 3, 581, 2, 550, 231, 182, 1, 34, 4, 3, 1025, 780, 7, 5, 8, 1025, 146, 1234, 42, 8, 334, 356, 798, 3, 1755, 3034, 906, 1, 34, 3902, 35, 455, 1, 3, 6867, 1, 1025, 51, 6, 1104]",2336.0,15139061,32
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.,Cancer,Cancer,2004-06-01,"Imatinib mesylate administration has become standard treatment for patients with chronic myelogenous leukemia (CML). Although the safety profile of imatinib is favorable, Grade > or = 3 neutropenia (according to the National Cancer Institute Common Toxicity Criteria) occurs in 35-45% of patients with CML in chronic phase who receive standard-dose imatinib. Myelosuppression results in treatment interruptions, which may compromise responses to imatinib. The authors investigated the ability of granulocyte-colony-stimulating factor (filgrastim) to reverse imatinib-associated neutropenia, thereby allowing for more continuous imatinib administration. Thirteen patients with chronic-phase CML and Grade > or = 3, imatinib-induced neutropenia were treated with filgrastim. Treatment with filgrastim was initiated after a median of 22 months from the start of imatinib. Eleven patients received filgrastim 5 microg/kg 1-3 times weekly, and 2 patients received filgrastim 5 microg/kg daily; doses were titrated to maintain an absolute neutrophil count (ANC) > or = 10(9)/L. Seven of 11 patients (64%) who began treatment with an ANC < 1.5 x 10(9)/L had responses (i.e., their ANC improved to > or = 2 x 10(9)/L within 21 days); the other 4 patients experienced slower recovery but were able to continue receiving imatinib uninterrupted. Before filgrastim administration was initiated, patients did not receive imatinib (due to neutropenia-related treatment interruptions) for an average of 21% of the total time since the start of imatinib. This figure decreased to 6% after the start of filgrastim treatment (P = 0.0008). Before filgrastim treatment was initiated, only one patient had achieved a major (partial) cytogenetic response. After the start of filgrastim treatment, five patients had major cytogenetic responses (including two complete responses). The authors concluded that filgrastim may overcome imatinib-associated neutropenia and allow improved delivery of imatinib. Some patients may experience improvements in their responses to therapy as a result.",Evaluation Study,5712.0,51.0,Imatinib mesylate administration has become standard treatment for patients with chronic myelogenous CML Although the safety profile of imatinib is favorable Grade or 3 neutropenia according to the National Cancer Institute Common Toxicity Criteria occurs in 35-45 of patients with CML in chronic phase who receive standard-dose imatinib Myelosuppression results in treatment interruptions which may compromise responses to imatinib The authors investigated the ability of granulocyte-colony-stimulating factor filgrastim to reverse imatinib-associated neutropenia thereby allowing for more continuous imatinib administration Thirteen patients with chronic-phase CML and Grade or 3 imatinib-induced neutropenia were treated with filgrastim Treatment with filgrastim was initiated after a median of 22 months from the start of imatinib Eleven patients received filgrastim 5 microg/kg 1-3 times weekly and 2 patients received filgrastim 5 microg/kg daily doses were titrated to maintain an absolute neutrophil count ANC or 10 9 /L Seven of 11 patients 64 who began treatment with an ANC 1.5 x 10 9 /L had responses i.e. their ANC improved to or 2 x 10 9 /L within 21 days the other 4 patients experienced slower recovery but were able to continue receiving imatinib uninterrupted Before filgrastim administration was initiated patients did not receive imatinib due to neutropenia-related treatment interruptions for an average of 21 of the total time since the start of imatinib This figure decreased to 6 after the start of filgrastim treatment P 0.0008 Before filgrastim treatment was initiated only one patient had achieved a major partial cytogenetic response After the start of filgrastim treatment five patients had major cytogenetic responses including two complete responses The authors concluded that filgrastim may overcome imatinib-associated neutropenia and allow improved delivery of imatinib Some patients may experience improvements in their responses to therapy as a result,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 2347, 634, 71, 1417, 260, 24, 9, 7, 5, 442, 2194, 903, 242, 3, 367, 800, 1, 577, 16, 913, 88, 15, 27, 778, 768, 6, 3, 657, 12, 1377, 186, 155, 371, 1780, 4, 465, 512, 1, 7, 5, 903, 4, 442, 124, 54, 560, 260, 61, 577, 2858, 99, 4, 24, 7406, 92, 68, 4665, 253, 6, 577, 3, 738, 565, 3, 801, 1, 2764, 1975, 2122, 161, 5552, 6, 1772, 577, 41, 778, 2267, 2952, 9, 80, 1314, 577, 634, 3170, 7, 5, 442, 124, 903, 2, 88, 15, 27, 577, 277, 778, 11, 73, 5, 5552, 24, 5, 5552, 10, 1917, 50, 8, 52, 1, 350, 53, 29, 3, 2435, 1, 577, 2627, 7, 103, 5552, 33, 2440, 503, 14, 27, 1072, 709, 2, 18, 7, 103, 5552, 33, 2440, 503, 391, 415, 11, 15875, 6, 3040, 35, 1766, 2595, 1276, 6486, 15, 79, 83, 805, 648, 1, 175, 7, 660, 54, 4603, 24, 5, 35, 6486, 14, 33, 1006, 79, 83, 805, 42, 253, 70, 563, 136, 6486, 231, 6, 15, 18, 1006, 79, 83, 805, 262, 239, 162, 3, 127, 39, 7, 592, 6715, 1602, 84, 11, 1665, 6, 1906, 357, 577, 22029, 348, 5552, 634, 10, 1917, 7, 205, 44, 560, 577, 520, 6, 778, 139, 24, 7406, 9, 35, 1011, 1, 239, 1, 3, 181, 98, 1192, 3, 2435, 1, 577, 26, 15170, 340, 6, 49, 50, 3, 2435, 1, 5552, 24, 19, 13, 7044, 348, 5552, 24, 10, 1917, 158, 104, 69, 42, 513, 8, 458, 450, 1266, 51, 50, 3, 2435, 1, 5552, 24, 365, 7, 42, 458, 1266, 253, 141, 100, 236, 253, 3, 738, 4724, 17, 5552, 68, 1768, 577, 41, 778, 2, 1700, 231, 989, 1, 577, 476, 7, 68, 730, 1474, 4, 136, 253, 6, 36, 22, 8, 757]",1987.0,15197801,80
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.,Blood,Blood,2004-06-15,"We reviewed 261 patients with chronicphase chronic myelogenous leukemia (CML) after interferon-alpha (IFN-alpha) failure treated with imatinib mesylate 400 mg daily. With a median follow-up time of 45 months, the major cytogenetic response rate was 73% and the complete cytogenetic response rate 63%. The estimated 4-year survival rate was 86%. Multivariate analysis for survival identified hematologic resistance to IFN-alpha (P =.01), splenomegaly (P =.03), and lack of any cytogenetic response after 3 months of therapy (P =.01) to have independent poor prognostic significance. Patients could be divided into good (no adverse factors), intermediate (1 adverse factor), and poor-risk groups (2 or 3 adverse factors; 12% of patients) with estimated 4-year survival rates of 96%, 86%, and 49%, respectively (P <.00001). The 4-year cumulative major molecular response (quantitative reverse transcriptase-polymerase chain reaction [Q-PCR] = BCR-ABL/ABL less than 0.05%) rate was 43% and complete molecular response rate (BCR-ABL undetectable) 26%. Compared with a historical group of 251 similar patients treated with nonimatinib therapies, imatinib mesylate was associated with a better 4-year survival rate (86% versus 43%; P <.0001); the survival advantage was confirmed by multivariate analysis (hazard ratio, 0.19; P <.0001).",Journal Article,5698.0,147.0,We reviewed 261 patients with chronicphase chronic myelogenous CML after interferon-alpha IFN-alpha failure treated with imatinib mesylate 400 mg daily With a median follow-up time of 45 months the major cytogenetic response rate was 73 and the complete cytogenetic response rate 63 The estimated 4-year survival rate was 86 Multivariate analysis for survival identified hematologic resistance to IFN-alpha P =.01 splenomegaly P =.03 and lack of any cytogenetic response after 3 months of therapy P =.01 to have independent poor prognostic significance Patients could be divided into good no adverse factors intermediate 1 adverse factor and poor-risk groups 2 or 3 adverse factors 12 of patients with estimated 4-year survival rates of 96 86 and 49 respectively P .00001 The 4-year cumulative major molecular response quantitative reverse transcriptase-polymerase chain reaction Q-PCR BCR-ABL/ABL less than 0.05 rate was 43 and complete molecular response rate BCR-ABL undetectable 26 Compared with a historical group of 251 similar patients treated with nonimatinib therapies imatinib mesylate was associated with a better 4-year survival rate 86 versus 43 P .0001 the survival advantage was confirmed by multivariate analysis hazard ratio 0.19 P .0001,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 446, 7007, 7, 5, 54216, 442, 2194, 903, 50, 1688, 950, 1256, 950, 496, 73, 5, 577, 2347, 1524, 81, 391, 5, 8, 52, 166, 126, 98, 1, 512, 53, 3, 458, 1266, 51, 116, 10, 803, 2, 3, 236, 1266, 51, 116, 676, 3, 661, 39, 111, 25, 116, 10, 868, 331, 65, 9, 25, 108, 813, 251, 6, 1256, 950, 19, 355, 6364, 19, 680, 2, 926, 1, 500, 1266, 51, 50, 27, 53, 1, 36, 19, 355, 6, 47, 306, 334, 177, 724, 7, 359, 40, 2176, 237, 1178, 77, 290, 130, 919, 14, 290, 161, 2, 334, 43, 271, 18, 15, 27, 290, 130, 133, 1, 7, 5, 661, 39, 111, 25, 151, 1, 921, 868, 2, 739, 106, 19, 7868, 3, 39, 111, 967, 458, 219, 51, 1156, 1772, 4456, 1451, 1260, 1329, 4170, 604, 1062, 1425, 1425, 299, 76, 13, 474, 116, 10, 601, 2, 236, 219, 51, 116, 1062, 1425, 3920, 432, 72, 5, 8, 2252, 87, 1, 7288, 288, 7, 73, 5, 54217, 235, 577, 2347, 10, 41, 5, 8, 380, 39, 111, 25, 116, 868, 185, 601, 19, 488, 3, 25, 1874, 10, 557, 20, 331, 65, 360, 197, 13, 326, 19, 488]",1254.0,15198956,50
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.,International journal of oncology,Int. J. Oncol.,2004-07-01,"Secondary cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) have been associated with an inferior outcome in reported series of largely chemotherapy-treated patients. To date, no study has specifically focused on the prognostic significance of secondary karyotypic abnormalities, detected at the time of diagnosis, in interferon (IFN)-alpha treated patients. We compared the outcome of 29 newly diagnosed Ph+ CML patients with additional abnormalities to that of 234 sole Ph+ patients, treated on CALGB protocols with IFN-alpha alone or together with IFN-gamma or low-dose cytarabine. Complete and partial cytogenetic responses were achieved in 20 and 19% of sole Ph+ patients, compared to 23 and 18%, respectively, of patients with additional abnormalities (P=1.00). None of 4 patients with 'high-risk' secondary abnormalities [+8, +Ph and i(17)(q10)], for whom follow-up cytogenetic samples were available, achieved a cytogenetic response. With a median follow-up of 11.3 years, the median overall survival (OS) was 6.0 years for sole Ph+ patients compared to 7.5 years for patients with additional abnormalities (P=0.70), with corresponding 8-year OS of 36 and 38%, respectively. On multivariable analysis, only age (P<0.001) and white blood cell count (P=0.02) were associated with outcome. We conclude that, with the possible exception of +8, +Ph and i(17)(q10), additional chromosomal abnormalities at diagnosis are not associated with inferior outcome in Ph+ CML patients treated with IFN-alpha-based therapy.",Clinical Trial,5682.0,19.0,Secondary cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive Ph+ chronic myelogenous CML have been associated with an inferior outcome in reported series of largely chemotherapy-treated patients To date no study has specifically focused on the prognostic significance of secondary karyotypic abnormalities detected at the time of diagnosis in interferon IFN -alpha treated patients We compared the outcome of 29 newly diagnosed Ph+ CML patients with additional abnormalities to that of 234 sole Ph+ patients treated on CALGB protocols with IFN-alpha alone or together with IFN-gamma or low-dose cytarabine Complete and partial cytogenetic responses were achieved in 20 and 19 of sole Ph+ patients compared to 23 and 18 respectively of patients with additional abnormalities P=1.00 None of 4 patients with 'high-risk secondary abnormalities +8 +Ph and i 17 q10 for whom follow-up cytogenetic samples were available achieved a cytogenetic response With a median follow-up of 11.3 years the median overall survival OS was 6.0 years for sole Ph+ patients compared to 7.5 years for patients with additional abnormalities P=0.70 with corresponding 8-year OS of 36 and 38 respectively On multivariable analysis only age P 0.001 and white blood cell count P=0.02 were associated with outcome We conclude that with the possible exception of +8 +Ph and i 17 q10 additional chromosomal abnormalities at diagnosis are not associated with inferior outcome in Ph+ CML patients treated with IFN-alpha-based therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[568, 1266, 1171, 28, 147, 1, 3006, 1170, 109, 2058, 442, 2194, 903, 47, 85, 41, 5, 35, 1663, 228, 4, 210, 988, 1, 1733, 56, 73, 7, 6, 1244, 77, 45, 71, 1225, 1649, 23, 3, 177, 724, 1, 568, 9465, 1171, 530, 28, 3, 98, 1, 147, 4, 1688, 1256, 950, 73, 7, 21, 72, 3, 228, 1, 462, 732, 265, 2058, 903, 7, 5, 402, 1171, 6, 17, 1, 8049, 4991, 2058, 7, 73, 23, 4077, 2189, 5, 1256, 950, 279, 15, 1162, 5, 1256, 1705, 15, 154, 61, 1855, 236, 2, 450, 1266, 253, 11, 513, 4, 179, 2, 326, 1, 4991, 2058, 7, 72, 6, 382, 2, 203, 106, 1, 7, 5, 402, 1171, 19, 14, 2038, 1292, 1, 39, 7, 5, 24717, 43, 568, 1171, 66, 2058, 2, 70, 269, 19649, 9, 953, 166, 126, 1266, 347, 11, 390, 513, 8, 1266, 51, 5, 8, 52, 166, 126, 1, 175, 27, 60, 3, 52, 63, 25, 118, 10, 49, 13, 60, 9, 4991, 2058, 7, 72, 6, 67, 33, 60, 9, 7, 5, 402, 1171, 19, 13, 431, 5, 1734, 66, 111, 118, 1, 511, 2, 519, 106, 23, 658, 65, 158, 89, 19, 13, 144, 2, 886, 315, 31, 1276, 19, 13, 588, 11, 41, 5, 228, 21, 2060, 17, 5, 3, 899, 4188, 1, 66, 2058, 2, 70, 269, 19649, 402, 1860, 1171, 28, 147, 32, 44, 41, 5, 1663, 228, 4, 2058, 903, 7, 73, 5, 1256, 950, 90, 36]",1523.0,15201999,60
Heat shock protein-based cancer vaccines.,Expert review of vaccines,Expert Rev Vaccines,2004-08-01,"Heat shock proteins (HSPs) exist ubiquitously across all species and function as chaperones stabilizing and delivering peptides. Tumor-derived HSP-peptide complex has been known to induce immunity against the original tumor in preclinical studies. HSP-based vaccines work across tumor types and bypass the need for identifying the responsible peptide(s) for inducing immunity. These vaccines are tumor- and patient-specific in that they capture the tumor cells' fingerprints. HSP-based vaccines have been studied in early phase clinical trials, mostly using HSP glycoprotein 96, for various types of malignancies including melanoma, renal cell carcinoma, gastric cancer, pancreatic cancer, low-grade lymphoma, colorectal cancer and chronic myelogenous leukemia. All showed minimal toxicity and potential efficacy. Phase III studies for melanoma and renal cell carcinoma are ongoing. HSP-based vaccines are a novel vaccine preparation with a promising role in cancer management. Further studies to determine the administering strategy and specific indication are warranted.",Journal Article,5651.0,50.0,Heat shock proteins HSPs exist ubiquitously across all species and function as chaperones stabilizing and delivering peptides Tumor-derived HSP-peptide complex has been known to induce immunity against the original tumor in preclinical studies HSP-based vaccines work across tumor types and bypass the need for identifying the responsible peptide s for inducing immunity These vaccines are tumor- and patient-specific in that they capture the tumor cells fingerprints HSP-based vaccines have been studied in early phase clinical trials mostly using HSP glycoprotein 96 for various types of malignancies including cell carcinoma cancer cancer low-grade cancer and chronic myelogenous All showed minimal toxicity and potential efficacy Phase III studies for and cell carcinoma are ongoing HSP-based vaccines are a novel vaccine preparation with a promising role in cancer management Further studies to determine the administering strategy and specific indication are warranted,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,"[3545, 3971, 652, 13504, 1923, 11156, 716, 62, 2915, 2, 343, 22, 14847, 9116, 2, 4790, 2491, 30, 526, 7921, 1389, 840, 71, 85, 440, 6, 1290, 1604, 480, 3, 2279, 30, 4, 693, 94, 7921, 90, 1842, 1357, 716, 30, 630, 2, 5481, 3, 594, 9, 1386, 3, 2327, 1389, 695, 9, 1958, 1604, 46, 1842, 32, 30, 2, 69, 112, 4, 17, 491, 2891, 3, 30, 37, 24712, 7921, 90, 1842, 47, 85, 656, 4, 191, 124, 38, 143, 2754, 75, 7921, 4455, 921, 9, 747, 630, 1, 441, 141, 31, 134, 12, 12, 154, 88, 12, 2, 442, 2194, 62, 224, 1048, 155, 2, 174, 209, 124, 316, 94, 9, 2, 31, 134, 32, 942, 7921, 90, 1842, 32, 8, 229, 1274, 4824, 5, 8, 721, 200, 4, 12, 284, 195, 94, 6, 223, 3, 5776, 692, 2, 112, 3607, 32, 1197]",974.0,15270645,155
Investigational strategies in chronic myelogenous leukemia.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2004-06-01,"Imatinib is the cornerstone of therapy in chronic myelogenous leukemia (CML) and a model for the development of novel agents directed at specific targets. The results of imatinib therapy continue to improve with approaches such as higher doses of imatinib and, possibly, with combinations of imatinib and interferon-alpha with or without cytarabine. There are multiple targets with agents directed to them that may prove to be synergistic with imatinib. These approaches are attractive, particularly when dealing with imatinib resistant CML, to prevent resistance and improve the probability of cure. The continued understanding of the biology of CML and mechanisms of resistance to imatinib and the ability to develop target-specific therapies should lead to the increased probability of cure for most patients who have CML.",Journal Article,5712.0,8.0,Imatinib is the cornerstone of therapy in chronic myelogenous CML and a model for the development of novel agents directed at specific targets The results of imatinib therapy continue to improve with approaches such as higher doses of imatinib and possibly with combinations of imatinib and interferon-alpha with or without cytarabine There are multiple targets with agents directed to them that may prove to be synergistic with imatinib These approaches are attractive particularly when dealing with imatinib resistant CML to prevent resistance and improve the probability of cure The continued understanding of the biology of CML and mechanisms of resistance to imatinib and the ability to develop target-specific therapies should lead to the increased probability of cure for most patients who have CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 16, 3, 7019, 1, 36, 4, 442, 2194, 903, 2, 8, 202, 9, 3, 193, 1, 229, 183, 1166, 28, 112, 637, 3, 99, 1, 577, 36, 1906, 6, 401, 5, 611, 225, 22, 142, 415, 1, 577, 2, 2150, 5, 1247, 1, 577, 2, 1688, 950, 5, 15, 187, 1855, 125, 32, 232, 637, 5, 183, 1166, 6, 1370, 17, 68, 4361, 6, 40, 1806, 5, 577, 46, 611, 32, 3059, 823, 198, 12607, 5, 577, 436, 903, 6, 1682, 251, 2, 401, 3, 1320, 1, 1722, 3, 1351, 612, 1, 3, 891, 1, 903, 2, 483, 1, 251, 6, 577, 2, 3, 801, 6, 690, 283, 112, 235, 257, 1122, 6, 3, 101, 1320, 1, 1722, 9, 96, 7, 54, 47, 903]",805.0,15271396,100
Immunity to chronic myelogenous leukemia.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2004-06-01,"Given the high rate of cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia (CML), logical future treatment strategies will include combinations of tyrosine kinase inhibitors and immunotherapies such as vaccines. Increased understanding of highly specific immune responses will lead to novel and improved immunotherapy strategies for CML patients. Such advances can be expected to revolutionize the field much in the same way that imatinib mesylate and other targeted small molecules have revolutionized our conception of traditional chemotherapy. This article begins with a brief discussion of why CML may represent a model disease for immunotherapy-based strategies. Laboratory evidence of the immunoresponsiveness of CML is discussed and used to highlight the principles for understanding tumor immunity. Finally,the authors discuss how advances in the understanding of the molecular and cellular nature of immunity are being translated into new therapeutic strategies for the treatment of CML.",Journal Article,5712.0,9.0,Given the high rate of cytogenetic responses to imatinib mesylate in chronic myelogenous CML logical future treatment strategies will include combinations of tyrosine kinase inhibitors and immunotherapies such as vaccines Increased understanding of highly specific immune responses will lead to novel and improved immunotherapy strategies for CML patients Such advances can be expected to revolutionize the field much in the same way that imatinib mesylate and other targeted small molecules have revolutionized our conception of traditional chemotherapy This article begins with a brief discussion of why CML may represent a model disease for immunotherapy-based strategies Laboratory evidence of the immunoresponsiveness of CML is discussed and used to highlight the principles for understanding tumor immunity Finally the authors discuss how advances in the understanding of the molecular and cellular nature of immunity are being translated into new therapeutic strategies for the treatment of CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[447, 3, 64, 116, 1, 1266, 253, 6, 577, 2347, 4, 442, 2194, 903, 10405, 508, 24, 422, 303, 643, 1247, 1, 564, 216, 222, 2, 2811, 225, 22, 1842, 101, 612, 1, 561, 112, 250, 253, 303, 1122, 6, 229, 2, 231, 726, 422, 9, 903, 7, 225, 954, 122, 40, 1336, 6, 15630, 3, 1067, 1802, 4, 3, 827, 2255, 17, 577, 2347, 2, 127, 238, 302, 1598, 47, 5746, 114, 17273, 1, 1847, 56, 26, 946, 12811, 5, 8, 3190, 2488, 1, 5283, 903, 68, 1231, 8, 202, 34, 9, 726, 90, 422, 1624, 241, 1, 3, 43666, 1, 903, 16, 1588, 2, 95, 6, 1817, 3, 4650, 9, 612, 30, 1604, 1368, 3, 738, 1139, 832, 954, 4, 3, 612, 1, 3, 219, 2, 763, 2202, 1, 1604, 32, 486, 5136, 237, 217, 189, 422, 9, 3, 24, 1, 903]",1001.0,15271403,110
Accelerated and blastic phases of chronic myelogenous leukemia.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2004-06-01,"Chronic myelogenous leukemia (CML) may have a biphasic or triphasic course, whereby patients who were initially diagnosed in the chronic phase (CP) develop more aggressive disease, frequently pass through an intermediate or accelerated phase (AP), and finally evolve into an acute leukemia like blastic phase (BP). A slowing in the rate of development of AP or BP has accompanied successive improvements in therapy for patients who have CP CML. Variable diagnostic criteria for AP and BP are used in the literature, rendering comparisons difficult. The management of patients in AP or BP consistently has been less effective than the management of those inCP for all modalities of therapy. This article reviews the current diagnostic criteria, therapeutic strategies, outcomes, and investigational therapies for AP and BP CML.",Journal Article,5712.0,32.0,Chronic myelogenous CML may have a biphasic or triphasic course whereby patients who were initially diagnosed in the chronic phase CP develop more aggressive disease frequently pass through an intermediate or accelerated phase AP and finally evolve into an acute like blastic phase BP A slowing in the rate of development of AP or BP has accompanied successive improvements in therapy for patients who have CP CML Variable diagnostic criteria for AP and BP are used in the literature rendering comparisons difficult The management of patients in AP or BP consistently has been less effective than the management of those inCP for all modalities of therapy This article reviews the current diagnostic criteria therapeutic strategies outcomes and investigational therapies for AP and BP CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 68, 47, 8, 7739, 15, 26315, 906, 6131, 7, 54, 11, 1625, 265, 4, 3, 442, 124, 2541, 690, 80, 571, 34, 746, 10152, 298, 35, 919, 15, 2241, 124, 2517, 2, 1368, 4800, 237, 35, 286, 733, 6529, 124, 3044, 8, 16279, 4, 3, 116, 1, 193, 1, 2517, 15, 3044, 71, 2756, 6808, 1474, 4, 36, 9, 7, 54, 47, 2541, 903, 1347, 752, 371, 9, 2517, 2, 3044, 32, 95, 4, 3, 789, 9535, 2213, 1740, 3, 284, 1, 7, 4, 2517, 15, 3044, 2433, 71, 85, 299, 323, 76, 3, 284, 1, 135, 54285, 9, 62, 1558, 1, 36, 26, 946, 2004, 3, 291, 752, 371, 189, 422, 123, 2, 3093, 235, 9, 2517, 2, 3044, 903]",788.0,15271404,258
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2004-08-01,"Over the last several years, donor lymphocyte infusions have become the standard approach for patients with chronic myelogenous leukemia (CML) who relapse after allogeneic stem cell transplantation (SCT). Recent reports indicate that imatinib mesylate (Gleevec) can induce remissions in these patients as well. Less is known about the extent and durability of these responses. We studied 15 patients treated with imatinib for recurrent CML after SCT, 10 patients with stable phase CML (SP-CML), 1 with accelerated phase (AP-CML), and 4 with blast phase (BP-CML). The dose of imatinib was 600 mg (n = 10) or 400 mg (n = 5) daily. Patients were followed for hematological, cytogenetic, and molecular response. A susbset of responders was followed for changes in donor-derived hematopoietic chimerism. Of the 10 patients with SP-CML, all achieved a hematological response. Within 3 months, five of these patients had achieved a complete cytogenetic response (CCR). By six months, 9 of 10 patients had achieved CCR. The BCR-ABL transcript could not be detected by reverse transcription-PCR in 7 of these 9 patients. Patients who achieved CCR showed evidence of conversion to complete donor chimerism. No patient developed graft-versus-host disease. With a median follow up of 25 months, all patients are alive and 9 of 10 patients remain in CCR. Only one of the 5 patients with AP/BP-CML achieved a complete cytogenetic response. We find that imatinib is well tolerated in patients with SP-CML who relapse after SCT. Responses were rapid, durable, and associated with conversion to full donor chimerism without graft-versus-host disease. Imantinib was far less effective in patients who relapsed with AP/BP-CML. Imatinib should be evaluated as either an alternative or as an adjunct to donor lymphocyte infusions for patients with SP-CML who relapse after SCT.",Journal Article,5651.0,65.0,Over the last several years donor lymphocyte infusions have become the standard approach for patients with chronic myelogenous CML who relapse after allogeneic stem cell transplantation SCT Recent reports indicate that imatinib mesylate Gleevec can induce remissions in these patients as well Less is known about the extent and durability of these responses We studied 15 patients treated with imatinib for recurrent CML after SCT 10 patients with stable phase CML SP-CML 1 with accelerated phase AP-CML and 4 with blast phase BP-CML The dose of imatinib was 600 mg n 10 or 400 mg n 5 daily Patients were followed for hematological cytogenetic and molecular response A susbset of responders was followed for changes in donor-derived hematopoietic chimerism Of the 10 patients with SP-CML all achieved a hematological response Within 3 months five of these patients had achieved a complete cytogenetic response CCR By six months 9 of 10 patients had achieved CCR The BCR-ABL transcript could not be detected by reverse transcription-PCR in 7 of these 9 patients Patients who achieved CCR showed evidence of conversion to complete donor chimerism No patient developed graft-versus-host disease With a median follow up of 25 months all patients are alive and 9 of 10 patients remain in CCR Only one of the 5 patients with AP/BP-CML achieved a complete cytogenetic response We find that imatinib is well tolerated in patients with SP-CML who relapse after SCT Responses were rapid durable and associated with conversion to full donor chimerism without graft-versus-host disease Imantinib was far less effective in patients who relapsed with AP/BP-CML Imatinib should be evaluated as either an alternative or as an adjunct to donor lymphocyte infusions for patients with SP-CML who relapse after SCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[252, 3, 1060, 392, 60, 1488, 1448, 3435, 47, 1417, 3, 260, 353, 9, 7, 5, 442, 2194, 903, 54, 429, 50, 1063, 452, 31, 497, 1988, 435, 1198, 1008, 17, 577, 2347, 8569, 122, 1290, 3166, 4, 46, 7, 22, 149, 299, 16, 440, 545, 3, 1039, 2, 6867, 1, 46, 253, 21, 656, 167, 7, 73, 5, 577, 9, 387, 903, 50, 1988, 79, 7, 5, 585, 124, 903, 4074, 903, 14, 5, 2241, 124, 2517, 903, 2, 39, 5, 3112, 124, 3044, 903, 3, 61, 1, 577, 10, 2383, 81, 78, 79, 15, 1524, 81, 78, 33, 391, 7, 11, 370, 9, 2890, 1266, 2, 219, 51, 8, 54299, 1, 1983, 10, 370, 9, 400, 4, 1488, 526, 1007, 6047, 1, 3, 79, 7, 5, 4074, 903, 62, 513, 8, 2890, 51, 262, 27, 53, 365, 1, 46, 7, 42, 513, 8, 236, 1266, 51, 4992, 20, 437, 53, 83, 1, 79, 7, 42, 513, 4992, 3, 1062, 1425, 3268, 359, 44, 40, 530, 20, 1772, 866, 604, 4, 67, 1, 46, 83, 7, 7, 54, 513, 4992, 224, 241, 1, 3111, 6, 236, 1488, 6047, 77, 69, 276, 1599, 185, 1204, 34, 5, 8, 52, 166, 126, 1, 243, 53, 62, 7, 32, 1701, 2, 83, 1, 79, 7, 918, 4, 4992, 158, 104, 1, 3, 33, 7, 5, 2517, 3044, 903, 513, 8, 236, 1266, 51, 21, 2469, 17, 577, 16, 149, 421, 4, 7, 5, 4074, 903, 54, 429, 50, 1988, 253, 11, 1321, 1480, 2, 41, 5, 3111, 6, 1647, 1488, 6047, 187, 1599, 185, 1204, 34, 54300, 10, 3272, 299, 323, 4, 7, 54, 591, 5, 2517, 3044, 903, 577, 257, 40, 194, 22, 361, 35, 1091, 15, 22, 35, 5471, 6, 1488, 1448, 3435, 9, 7, 5, 4074, 903, 54, 429, 50, 1988]",1794.0,15297408,23
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.,The New England journal of medicine,N. Engl. J. Med.,2004-08-01,"The progression of chronic myelogenous leukemia (CML) to blast crisis is supported by self-renewing leukemic stem cells. In normal mouse hematopoietic stem cells, the process of self-renewal involves the beta-catenin-signaling pathway. We investigated whether leukemic stem cells in CML also use the beta-catenin pathway for self-renewal. We used fluorescence-activated cell sorting to isolate hematopoietic stem cells, common myeloid progenitors, granulocyte-macrophage progenitors, and megakaryocyte-erythroid progenitors from marrow during several phases of CML and from normal marrow. BCR-ABL, beta-catenin, and LEF-1 transcripts were compared by means of a quantitative reverse-transcriptase-polymerase-chain-reaction assay in normal and CML hematopoietic stem cells and granulocyte-macrophage progenitors. Confocal fluorescence microscopy and a lymphoid enhancer factor/T-cell factor reporter assay were used to detect nuclear beta-catenin in these cells. In vitro replating assays were used to identify self-renewing cells as candidate leukemic stem cells, and the dependence of self-renewal on beta-catenin activation was tested by lentiviral transduction of hematopoietic progenitors with axin, an inhibitor of the beta-catenin pathway. The granulocyte-macrophage progenitor pool from patients with CML in blast crisis and imatinib-resistant CML was expanded, expressed BCR-ABL, and had elevated levels of nuclear beta-catenin as compared with the levels in progenitors from normal marrow. Unlike normal granulocyte-macrophage progenitors, CML granulocyte-macrophage progenitors formed self-renewing, replatable myeloid colonies, and in vitro self-renewal capacity was reduced by enforced expression of axin. Activation of beta-catenin in CML granulocyte-macrophage progenitors appears to enhance the self-renewal activity and leukemic potential of these cells.",Journal Article,5651.0,1180.0,The progression of chronic myelogenous CML to blast crisis is supported by self-renewing leukemic stem cells In normal mouse hematopoietic stem cells the process of self-renewal involves the beta-catenin-signaling pathway We investigated whether leukemic stem cells in CML also use the beta-catenin pathway for self-renewal We used fluorescence-activated cell sorting to isolate hematopoietic stem cells common myeloid progenitors granulocyte-macrophage progenitors and megakaryocyte-erythroid progenitors from marrow during several phases of CML and from normal marrow BCR-ABL beta-catenin and LEF-1 transcripts were compared by means of a quantitative reverse-transcriptase-polymerase-chain-reaction assay in normal and CML hematopoietic stem cells and granulocyte-macrophage progenitors Confocal fluorescence microscopy and a lymphoid enhancer factor/T-cell factor reporter assay were used to detect nuclear beta-catenin in these cells In vitro replating assays were used to identify self-renewing cells as candidate leukemic stem cells and the dependence of self-renewal on beta-catenin activation was tested by lentiviral transduction of hematopoietic progenitors with axin an inhibitor of the beta-catenin pathway The granulocyte-macrophage progenitor pool from patients with CML in blast crisis and imatinib-resistant CML was expanded expressed BCR-ABL and had elevated levels of nuclear beta-catenin as compared with the levels in progenitors from normal marrow Unlike normal granulocyte-macrophage progenitors CML granulocyte-macrophage progenitors formed self-renewing replatable myeloid colonies and in vitro self-renewal capacity was reduced by enforced expression of axin Activation of beta-catenin in CML granulocyte-macrophage progenitors appears to enhance the self-renewal activity and leukemic potential of these cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 91, 1, 442, 2194, 903, 6, 3112, 6540, 16, 2708, 20, 1074, 13350, 2015, 452, 37, 4, 295, 830, 1007, 452, 37, 3, 1129, 1, 1074, 4495, 2921, 3, 1090, 1778, 314, 308, 21, 565, 317, 2015, 452, 37, 4, 903, 120, 119, 3, 1090, 1778, 308, 9, 1074, 4495, 21, 95, 1591, 735, 31, 6751, 6, 7910, 1007, 452, 37, 186, 533, 4321, 2764, 2674, 4321, 2, 21987, 7839, 4321, 29, 581, 190, 392, 3523, 1, 903, 2, 29, 295, 581, 1062, 1425, 1090, 1778, 2, 14136, 14, 2680, 11, 72, 20, 2263, 1, 8, 1156, 1772, 4456, 1451, 1260, 1329, 719, 4, 295, 2, 903, 1007, 452, 37, 2, 2764, 2674, 4321, 6541, 1591, 3804, 2, 8, 2303, 4239, 161, 102, 31, 161, 3674, 719, 11, 95, 6, 1426, 928, 1090, 1778, 4, 46, 37, 4, 439, 33251, 1013, 11, 95, 6, 255, 1074, 13350, 37, 22, 1609, 2015, 452, 37, 2, 3, 3721, 1, 1074, 4495, 23, 1090, 1778, 363, 10, 650, 20, 7823, 2761, 1, 1007, 4321, 5, 37746, 35, 230, 1, 3, 1090, 1778, 308, 3, 2764, 2674, 2520, 6545, 29, 7, 5, 903, 4, 3112, 6540, 2, 577, 436, 903, 10, 2064, 570, 1062, 1425, 2, 42, 804, 148, 1, 928, 1090, 1778, 22, 72, 5, 3, 148, 4, 4321, 29, 295, 581, 4246, 295, 2764, 2674, 4321, 903, 2764, 2674, 4321, 3516, 1074, 13350, 54311, 533, 8633, 2, 4, 439, 1074, 4495, 2162, 10, 405, 20, 7807, 55, 1, 37746, 363, 1, 1090, 1778, 4, 903, 2764, 2674, 4321, 1233, 6, 1304, 3, 1074, 4495, 128, 2, 2015, 174, 1, 46, 37]",1836.0,15306667,82
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.,Blood,Blood,2004-09-02,"The BCR-ABL kinase inhibitor imatinib mesylate induces complete cytogenetic response (CCR) in a high proportion of chronic myelogenous leukemia (CML) patients. However, patients in CCR usually demonstrate evidence of residual BCR-ABL-positive progenitors. The mechanisms underlying persistence of small numbers of malignant progenitors in imatinib-sensitive patients are unclear. BCR-ABL kinase domain mutations affecting drug binding can lead to secondary resistance to imatinib. We show here that kinase mutations could be detected in CD34+ cells isolated from CML patients in CCR on imatinib. Most mutations seen have not been reported in previous clinical studies. Interestingly, several of the involved amino acid positions have been implicated in an in vitro mutagenesis screen. These BCR-ABL mutations were associated with varying levels of imatinib resistance. Two of 5 patients in whom mutations were detected on initial evaluation have relapsed. In addition, 4 patients in whom mutations were not initially detected, but with rising BCR-ABL mRNA levels on quantitative polymerase chain reaction (Q-PCR) analysis, had mutations detected on follow-up evaluation. We conclude that BCR-ABL kinase mutations can be detected in CD34+ cells from CML patients in CCR on imatinib, may contribute to persistence of small populations of malignant progenitors, and could be a potential source of relapse.",Journal Article,5619.0,172.0,The BCR-ABL kinase inhibitor imatinib mesylate induces complete cytogenetic response CCR in a high proportion of chronic myelogenous CML patients However patients in CCR usually demonstrate evidence of residual BCR-ABL-positive progenitors The mechanisms underlying persistence of small numbers of malignant progenitors in imatinib-sensitive patients are unclear BCR-ABL kinase domain mutations affecting drug binding can lead to secondary resistance to imatinib We show here that kinase mutations could be detected in CD34+ cells isolated from CML patients in CCR on imatinib Most mutations seen have not been reported in previous clinical studies Interestingly several of the involved amino acid positions have been implicated in an in vitro mutagenesis screen These BCR-ABL mutations were associated with varying levels of imatinib resistance Two of 5 patients in whom mutations were detected on initial evaluation have relapsed In addition 4 patients in whom mutations were not initially detected but with rising BCR-ABL mRNA levels on quantitative polymerase chain reaction Q-PCR analysis had mutations detected on follow-up evaluation We conclude that BCR-ABL kinase mutations can be detected in CD34+ cells from CML patients in CCR on imatinib may contribute to persistence of small populations of malignant progenitors and could be a potential source of relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1062, 1425, 216, 230, 577, 2347, 1516, 236, 1266, 51, 4992, 4, 8, 64, 920, 1, 442, 2194, 903, 7, 137, 7, 4, 4992, 2082, 608, 241, 1, 753, 1062, 1425, 109, 4321, 3, 483, 1181, 4108, 1, 302, 1870, 1, 393, 4321, 4, 577, 745, 7, 32, 1200, 1062, 1425, 216, 1398, 138, 2319, 234, 791, 122, 1122, 6, 568, 251, 6, 577, 21, 514, 467, 17, 216, 138, 359, 40, 530, 4, 2215, 37, 1355, 29, 903, 7, 4, 4992, 23, 577, 96, 138, 527, 47, 44, 85, 210, 4, 698, 38, 94, 2873, 392, 1, 3, 646, 3078, 971, 7134, 47, 85, 1771, 4, 35, 4, 439, 8595, 2413, 46, 1062, 1425, 138, 11, 41, 5, 2990, 148, 1, 577, 251, 100, 1, 33, 7, 4, 953, 138, 11, 530, 23, 388, 451, 47, 591, 4, 352, 39, 7, 4, 953, 138, 11, 44, 1625, 530, 84, 5, 3699, 1062, 1425, 956, 148, 23, 1156, 1451, 1260, 1329, 4170, 604, 65, 42, 138, 530, 23, 166, 126, 451, 21, 2060, 17, 1062, 1425, 216, 138, 122, 40, 530, 4, 2215, 37, 29, 903, 7, 4, 4992, 23, 577, 68, 1248, 6, 4108, 1, 302, 1184, 1, 393, 4321, 2, 359, 40, 8, 174, 2353, 1, 429]",1369.0,15345592,198
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.,Blood,Blood,2004-09-09,"Tyrosine kinases phosphorylate proteins on tyrosine residues, producing a biologic signal that influences many aspects of cellular function including cell growth, proliferation, differentiation, and death. Constitutive or unregulated activity through mutation or overexpression of these enzymes is a common pathologic feature in many acute and chronic leukemias. Inhibition of tyrosine kinases represents a strategy to disrupt signaling pathways that promote neoplastic growth and survival in hematologic malignancies and likely in other neoplasias as well. This review focuses on tyrosine kinases that have been implicated in the pathogenesis of hematologic diseases other than chronic myelogenous leukemia and discusses the evidence for the use of small molecules to target these kinases.",Journal Article,5612.0,49.0,Tyrosine kinases phosphorylate proteins on tyrosine residues producing a biologic signal that influences many aspects of cellular function including cell growth proliferation differentiation and death Constitutive or unregulated activity through mutation or overexpression of these enzymes is a common pathologic feature in many acute and chronic leukemias Inhibition of tyrosine kinases represents a strategy to disrupt signaling pathways that promote neoplastic growth and survival in hematologic malignancies and likely in other neoplasias as well This review focuses on tyrosine kinases that have been implicated in the pathogenesis of hematologic diseases other than chronic myelogenous and discusses the evidence for the use of small molecules to target these kinases,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[564, 1549, 14099, 652, 23, 564, 6418, 3787, 8, 1283, 1235, 17, 3859, 445, 2695, 1, 763, 343, 141, 31, 129, 457, 910, 2, 273, 3178, 15, 17770, 128, 298, 258, 15, 851, 1, 46, 3039, 16, 8, 186, 510, 2705, 4, 445, 286, 2, 442, 2792, 297, 1, 564, 1549, 1449, 8, 692, 6, 6619, 314, 460, 17, 1617, 2000, 129, 2, 25, 4, 813, 441, 2, 322, 4, 127, 8235, 22, 149, 26, 206, 3026, 23, 564, 1549, 17, 47, 85, 1771, 4, 3, 1384, 1, 813, 1342, 127, 76, 442, 2194, 2, 2759, 3, 241, 9, 3, 119, 1, 302, 1598, 6, 283, 46, 1549]",773.0,15358622,149
Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.,Leukemia & lymphoma,Leuk. Lymphoma,2004-08-01,"We report two patients with Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML) in myeloid blastic phase that developed central nervous system disease while on imatinib mesylate therapy. Patient 1 presented with CML in myeloid blastic phase and responded to imatinib, cytarabine, and idarubicin-based treatment achieving complete cytogenetic remission in the marrow, but developed myeloid blasts in his cerebrospinal fluid (CSF) during treatment. Patient 2 developed CML myeloid blastic phase after initially being in hematologic and cytogenetic remission with imatinib treatment. He represented with an extramedullary mass at the base of his skull and CSF involvement. Both patients were treated with intrathecal chemotherapy and received craniospinal irradiation to clear the spinal fluid of disease. Both patients have undergone related allogeneic stem cell transplant and are in complete hematologic remission; one is in complete cytogenetic remission, the other is too early to evaluate. Central nervous system involvement with myeloid blasts is previously unreported for patients with CML in blastic phase on imatinib and warrants cautious observation and vigilance in these patients.",Case Reports,5651.0,23.0,We report two patients with Philadelphia Ph chromosome positive chronic myelogenous CML in myeloid blastic phase that developed central nervous system disease while on imatinib mesylate therapy Patient 1 presented with CML in myeloid blastic phase and responded to imatinib cytarabine and idarubicin-based treatment achieving complete cytogenetic remission in the marrow but developed myeloid blasts in his cerebrospinal fluid CSF during treatment Patient 2 developed CML myeloid blastic phase after initially being in hematologic and cytogenetic remission with imatinib treatment He represented with an extramedullary mass at the base of his skull and CSF involvement Both patients were treated with intrathecal chemotherapy and received craniospinal irradiation to clear the spinal fluid of disease Both patients have undergone related allogeneic stem cell transplant and are in complete hematologic remission one is in complete cytogenetic remission the other is too early to evaluate Central nervous system involvement with myeloid blasts is previously unreported for patients with CML in blastic phase on imatinib and warrants cautious observation and vigilance in these patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 414, 100, 7, 5, 3006, 2058, 1170, 109, 442, 2194, 903, 4, 533, 6529, 124, 17, 276, 854, 1880, 398, 34, 369, 23, 577, 2347, 36, 69, 14, 917, 5, 903, 4, 533, 6529, 124, 2, 2211, 6, 577, 1855, 2, 5684, 90, 24, 1785, 236, 1266, 734, 4, 3, 581, 84, 276, 533, 2438, 4, 3224, 5156, 2357, 1211, 190, 24, 69, 18, 276, 903, 533, 6529, 124, 50, 1625, 486, 4, 813, 2, 1266, 734, 5, 577, 24, 3174, 3324, 5, 35, 5508, 782, 28, 3, 1782, 1, 3224, 5054, 2, 1211, 799, 110, 7, 11, 73, 5, 5126, 56, 2, 103, 5748, 1104, 6, 885, 3, 1499, 2357, 1, 34, 110, 7, 47, 1989, 139, 1063, 452, 31, 941, 2, 32, 4, 236, 813, 734, 104, 16, 4, 236, 1266, 734, 3, 127, 16, 5044, 191, 6, 376, 854, 1880, 398, 799, 5, 533, 2438, 16, 373, 10046, 9, 7, 5, 903, 4, 6529, 124, 23, 577, 2, 2782, 17741, 1664, 2, 13264, 4, 46, 7]",1184.0,15370215,191
Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.,Gynecologic oncology,Gynecol. Oncol.,2004-10-01,"Imatinib mesylate is a tyrosine kinase inhibitor that specifically targets c-Kit, Abl, and platelet-derived growth factor receptor (PDGFR). It has been shown to be an effective treatment for patients with chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). These cancers are characterized by activating mutations of the Abl and c-Kit tyrosine kinases, respectively. To determine whether imatinib mesylate could be a potentially useful agent in the treatment of endometrial cancer, we assessed the expressions of Abl, c-Kit, and PDGFR in both primary and recurrent endometrial carcinoma. We performed immunohistochemical analysis on formalin-fixed, paraffin-embedded sections from 63 patients: 33 with endometrioid endometrial carcinoma (EEC), 11 with uterine papillary serous carcinoma (UPSC), 12 with recurrent EEC, and seven with recurrent UPSC. The sections were stained with commercially available antibodies for Abl, PDGFR, and c-Kit. The sections were also stained for phosphorylated Abl and phosphorylated PDGFR. Among the primary EEC, 28/33 (85%) stained positively for Abl and 30/33 (91%) were positive for PDGFR. Of the primary UPSC, 8/11 (73%) were positive for Abl. In addition, 8/11 (73%) of the primary UPSC tumors were positive for PDGFR. Neither the primary EEC (0/33) nor the primary UPSC (0/11) expressed c-Kit. Of the recurrent EEC tumors, 11/12 (92%) were positive for Abl expression, 12/12 (100%) were positive for PDGFR, and 2/8 (25%) were positive for c-Kit. Of the recurrent UPSC, 6/7 (86%) were positive for Abl, 7/7 (100%) were positive for PDGFR, and 2/4 (50%) for c-Kit. In addition, the majority of primary and recurrent tumors were positive for phosphorylated Abl (primary EEC, 91%; primary UPSC, 64%; recurrent EEC, 83%; recurrent UPSC, 86%), and phosphorylated PDGFR (primary EEC, 46%; primary UPSC, 40%; recurrent EEC, 58%; recurrent UPSC, 100%). Within the EEC primary tumors, the differences in kinase expression by grade of tumor were not significant except for PDGFR kinase; the lower grade tumors (1 and 2) had more PDGFR expression than the grade 3 tumors (P < 0.05). The majority of primary and recurrent EEC, as well as primary and recurrent UPSC express Abl and PDGFR. This preclinical data suggest that imatinib mesylate may be useful in the treatment of patients with endometrial carcinoma.",Journal Article,5590.0,27.0,Imatinib mesylate is a tyrosine kinase inhibitor that specifically targets c-Kit Abl and platelet-derived growth factor receptor PDGFR It has been shown to be an effective treatment for patients with chronic myelogenous CML and stromal tumors GIST These cancers are characterized by activating mutations of the Abl and c-Kit tyrosine kinases respectively To determine whether imatinib mesylate could be a potentially useful agent in the treatment of cancer we assessed the expressions of Abl c-Kit and PDGFR in both primary and recurrent carcinoma We performed immunohistochemical analysis on formalin-fixed paraffin-embedded sections from 63 patients 33 with endometrioid carcinoma EEC 11 with papillary serous carcinoma UPSC 12 with recurrent EEC and seven with recurrent UPSC The sections were stained with commercially available antibodies for Abl PDGFR and c-Kit The sections were also stained for phosphorylated Abl and phosphorylated PDGFR Among the primary EEC 28/33 85 stained positively for Abl and 30/33 91 were positive for PDGFR Of the primary UPSC 8/11 73 were positive for Abl In addition 8/11 73 of the primary UPSC tumors were positive for PDGFR Neither the primary EEC 0/33 nor the primary UPSC 0/11 expressed c-Kit Of the recurrent EEC tumors 11/12 92 were positive for Abl expression 12/12 100 were positive for PDGFR and 2/8 25 were positive for c-Kit Of the recurrent UPSC 6/7 86 were positive for Abl 7/7 100 were positive for PDGFR and 2/4 50 for c-Kit In addition the majority of primary and recurrent tumors were positive for phosphorylated Abl primary EEC 91 primary UPSC 64 recurrent EEC 83 recurrent UPSC 86 and phosphorylated PDGFR primary EEC 46 primary UPSC 40 recurrent EEC 58 recurrent UPSC 100 Within the EEC primary tumors the differences in kinase expression by grade of tumor were not significant except for PDGFR kinase the lower grade tumors 1 and 2 had more PDGFR expression than the grade 3 tumors P 0.05 The majority of primary and recurrent EEC as well as primary and recurrent UPSC express Abl and PDGFR This preclinical data suggest that imatinib mesylate may be useful in the treatment of patients with carcinoma,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,"[577, 2347, 16, 8, 564, 216, 230, 17, 1225, 637, 256, 1164, 1425, 2, 1596, 526, 129, 161, 153, 4103, 192, 71, 85, 443, 6, 40, 35, 323, 24, 9, 7, 5, 442, 2194, 903, 2, 1126, 57, 1394, 46, 163, 32, 765, 20, 1616, 138, 1, 3, 1425, 2, 256, 1164, 564, 1549, 106, 6, 223, 317, 577, 2347, 359, 40, 8, 751, 999, 420, 4, 3, 24, 1, 12, 21, 275, 3, 4249, 1, 1425, 256, 1164, 2, 4103, 4, 110, 86, 2, 387, 134, 21, 173, 1382, 65, 23, 3265, 1959, 2487, 2505, 3013, 29, 676, 7, 466, 5, 3151, 134, 9599, 175, 5, 1796, 1744, 134, 5676, 133, 5, 387, 9599, 2, 648, 5, 387, 5676, 3, 3013, 11, 3386, 5, 5262, 390, 890, 9, 1425, 4103, 2, 256, 1164, 3, 3013, 11, 120, 3386, 9, 2365, 1425, 2, 2365, 4103, 107, 3, 86, 9599, 339, 466, 772, 3386, 2375, 9, 1425, 2, 201, 466, 970, 11, 109, 9, 4103, 1, 3, 86, 5676, 66, 175, 803, 11, 109, 9, 1425, 4, 352, 66, 175, 803, 1, 3, 86, 5676, 57, 11, 109, 9, 4103, 2174, 3, 86, 9599, 13, 466, 2110, 3, 86, 5676, 13, 175, 570, 256, 1164, 1, 3, 387, 9599, 57, 175, 133, 937, 11, 109, 9, 1425, 55, 133, 133, 394, 11, 109, 9, 4103, 2, 18, 66, 243, 11, 109, 9, 256, 1164, 1, 3, 387, 5676, 49, 67, 868, 11, 109, 9, 1425, 67, 67, 394, 11, 109, 9, 4103, 2, 18, 39, 212, 9, 256, 1164, 4, 352, 3, 686, 1, 86, 2, 387, 57, 11, 109, 9, 2365, 1425, 86, 9599, 970, 86, 5676, 660, 387, 9599, 852, 387, 5676, 868, 2, 2365, 4103, 86, 9599, 641, 86, 5676, 327, 387, 9599, 717, 387, 5676, 394, 262, 3, 9599, 86, 57, 3, 362, 4, 216, 55, 20, 88, 1, 30, 11, 44, 93, 2187, 9, 4103, 216, 3, 280, 88, 57, 14, 2, 18, 42, 80, 4103, 55, 76, 3, 88, 27, 57, 19, 13, 474, 3, 686, 1, 86, 2, 387, 9599, 22, 149, 22, 86, 2, 387, 5676, 1669, 1425, 2, 4103, 26, 693, 74, 309, 17, 577, 2347, 68, 40, 999, 4, 3, 24, 1, 7, 5, 134]",2159.0,15385107,68
Hematopoietic stem cell transplantation among patients with leukemia of all ages in Texas.,Cancer,Cancer,2004-11-01,"Hematopoietic stem cell transplantation (HSCT) is an effective but expensive medical procedure to which some ethnic minorities, the elderly, and those without insurance have been shown to have limited access. The purpose of the current study was to determine whether socioeconomic factors were associated with HSCT usage rates in patients with leukemia. The authors identified 6574 patients with acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, or other leukemias from the 1999 Texas Hospital Inpatient Discharge Public Use Data File. Of these patients, 1604 received an autologous or allogeneic HSCT. The authors assessed patients' ethnicity, payer status, age, gender, and comorbid medical conditions. Logistic regression was used to control for patient characteristics and to evaluate associations among payer status, ethnicity, and HSCT use. P < or = 0.05 indicated statistical significance. Patients who self-paid had the highest rate of HSCT use in all age groups (32%; P < or = 0.01) and in the adult group (36%; P = 0.11). Elderly patients with Medicare had a low rate of HSCT use (17%; P = 0.13). Logistic regression showed no statistically significant associations between payer status or ethnicity and HSCT use. However, elderly women were significantly less likely to undergo HSCT than elderly men (odds ratio, 0.34; P < or = 0.01). The lack of statistically significant differences in HSCT use among adult patients with leukemia was surprising because previous studies had shown differences in HSCT by ethnicity and insurance.",Comparative Study,5559.0,12.0,Hematopoietic stem cell transplantation HSCT is an effective but expensive medical procedure to which some ethnic minorities the elderly and those without insurance have been shown to have limited access The purpose of the current study was to determine whether socioeconomic factors were associated with HSCT usage rates in patients with The authors identified 6574 patients with acute lymphocytic chronic lymphocytic acute myelogenous chronic myelogenous or other leukemias from the 1999 Texas Hospital Inpatient Discharge Public Use Data File Of these patients 1604 received an autologous or allogeneic HSCT The authors assessed patients ethnicity payer status age gender and comorbid medical conditions Logistic regression was used to control for patient characteristics and to evaluate associations among payer status ethnicity and HSCT use P or 0.05 indicated statistical significance Patients who self-paid had the highest rate of HSCT use in all age groups 32 P or 0.01 and in the adult group 36 P 0.11 Elderly patients with Medicare had a low rate of HSCT use 17 P 0.13 Logistic regression showed no statistically significant associations between payer status or ethnicity and HSCT use However elderly women were significantly less likely to undergo HSCT than elderly men odds ratio 0.34 P or 0.01 The lack of statistically significant differences in HSCT use among adult patients with was surprising because previous studies had shown differences in HSCT by ethnicity and insurance,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1007, 452, 31, 497, 1703, 16, 35, 323, 84, 6038, 484, 1299, 6, 92, 476, 2871, 6727, 3, 1216, 2, 135, 187, 1935, 47, 85, 443, 6, 47, 383, 1655, 3, 743, 1, 3, 291, 45, 10, 6, 223, 317, 3331, 130, 11, 41, 5, 1703, 5015, 151, 4, 7, 5, 3, 738, 108, 54405, 7, 5, 286, 1193, 442, 1193, 286, 2194, 442, 2194, 15, 127, 2792, 29, 3, 2043, 2738, 702, 2420, 2993, 3067, 119, 74, 12339, 1, 46, 7, 54406, 103, 35, 1028, 15, 1063, 1703, 3, 738, 275, 7, 2091, 7433, 156, 89, 1632, 2, 3952, 484, 1298, 812, 320, 10, 95, 6, 182, 9, 69, 374, 2, 6, 376, 685, 107, 7433, 156, 2091, 2, 1703, 119, 19, 15, 13, 474, 1103, 1050, 724, 7, 54, 1074, 8328, 42, 3, 1076, 116, 1, 1703, 119, 4, 62, 89, 271, 531, 19, 15, 13, 355, 2, 4, 3, 780, 87, 511, 19, 13, 175, 1216, 7, 5, 1378, 42, 8, 154, 116, 1, 1703, 119, 269, 19, 13, 233, 812, 320, 224, 77, 712, 93, 685, 59, 7433, 156, 15, 2091, 2, 1703, 119, 137, 1216, 117, 11, 97, 299, 322, 6, 1251, 1703, 76, 1216, 325, 610, 197, 13, 562, 19, 15, 13, 355, 3, 926, 1, 712, 93, 362, 4, 1703, 119, 107, 780, 7, 5, 10, 14157, 408, 698, 94, 42, 443, 362, 4, 1703, 20, 2091, 2, 1935]",1491.0,15484218,24
Targeted therapies for cancer 2004.,American journal of clinical pathology,Am. J. Clin. Pathol.,2004-10-01,"The regulatory agency approvals in the United States and Europe of imatinib mesylate (Gleevec) for patients with bcr/abl-positive chronic myelogenous leukemia, cetuximab (Erbitux) for patients with epidermal growth factor receptor overexpressing metastatic colorectal cancer, the antiangiogenesis agent bevacizumab (Avastin), and the proteasome inhibitor bortezomib (Velcade)--and the considerable public interest in new anticancer drugs that take advantage of specific genetic defects that render the malignant cells more likely to respond to specific treatment--are driving a new era of integrated diagnostics and therapeutics. The recent discovery of a drug response predicting activating mutation in the epidermal growth factor receptor gene for patients with non-small cell lung cancer treated with gefitinib (Iressa) has intensified this interest. In this review, the history of targeted anticancer therapies is highlighted, with focus on the development of molecular diagnostics for hematologic malignancies and the emergence of trastuzumab (Herceptin), an antibody-based targeted therapy for HER-2/neu overexpressing metastatic breast cancer: The potential of pharmacogenomic strategies and the use of high-density genomic microarrays to classify and select therapy for cancer are briefly considered. This review also considers the widely held view that, in the next 5 to 10 years, the clinical application of molecular diagnostics will further revolutionize the drug discovery and development process; customize the selection, dosing, route of administration of existing and new therapeutic agents; and truly personalize medical care for cancer patients.",Journal Article,5590.0,229.0,The regulatory agency approvals in the United States and Europe of imatinib mesylate Gleevec for patients with bcr/abl-positive chronic myelogenous cetuximab Erbitux for patients with epidermal growth factor receptor overexpressing metastatic cancer the antiangiogenesis agent bevacizumab Avastin and the proteasome inhibitor bortezomib Velcade -- and the considerable public interest in new anticancer drugs that take advantage of specific genetic defects that render the malignant cells more likely to respond to specific treatment -- are driving a new era of integrated diagnostics and therapeutics The recent discovery of a drug response predicting activating mutation in the epidermal growth factor receptor gene for patients with cell cancer treated with gefitinib Iressa has intensified this interest In this review the history of targeted anticancer therapies is highlighted with focus on the development of molecular diagnostics for hematologic malignancies and the emergence of trastuzumab Herceptin an antibody-based targeted therapy for HER-2/neu overexpressing metastatic cancer The potential of pharmacogenomic strategies and the use of high-density genomic microarrays to classify and select therapy for cancer are briefly considered This review also considers the widely held view that in the next 5 to 10 years the clinical application of molecular diagnostics will further revolutionize the drug discovery and development process customize the selection dosing route of administration of existing and new therapeutic agents and truly personalize medical care for cancer patients,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1253, 8613, 6802, 4, 3, 1088, 907, 2, 3934, 1, 577, 2347, 8569, 9, 7, 5, 1062, 1425, 109, 442, 2194, 1175, 13018, 9, 7, 5, 829, 129, 161, 153, 2810, 113, 12, 3, 7351, 420, 599, 11262, 2, 3, 1694, 230, 819, 11296, 2, 3, 2658, 3067, 1333, 4, 217, 1475, 600, 17, 3585, 1874, 1, 112, 336, 2945, 17, 7873, 3, 393, 37, 80, 322, 6, 1892, 6, 112, 24, 32, 4057, 8, 217, 1713, 1, 2102, 5197, 2, 1943, 3, 435, 1574, 1, 8, 234, 51, 1434, 1616, 258, 4, 3, 829, 129, 161, 153, 145, 9, 7, 5, 31, 12, 73, 5, 1372, 8630, 71, 7311, 26, 1333, 4, 26, 206, 3, 532, 1, 238, 1475, 235, 16, 3681, 5, 1222, 23, 3, 193, 1, 219, 5197, 9, 813, 441, 2, 3, 3397, 1, 769, 8723, 35, 548, 90, 238, 36, 9, 1084, 18, 1637, 2810, 113, 12, 3, 174, 1, 6971, 422, 2, 3, 119, 1, 64, 1263, 572, 2774, 6, 4896, 2, 1717, 36, 9, 12, 32, 6277, 515, 26, 206, 120, 9961, 3, 1792, 4033, 3811, 17, 4, 3, 1305, 33, 6, 79, 60, 3, 38, 1581, 1, 219, 5197, 303, 195, 15630, 3, 234, 1574, 2, 193, 1129, 22144, 3, 881, 1280, 5841, 1, 634, 1, 1692, 2, 217, 189, 183, 2, 7260, 8346, 484, 165, 9, 12, 7]",1596.0,15487459,151
"A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2004-10-01,"A novel regimen designed to maximize antileukemia activity of carboplatin through inhibiting repair of platinum-DNA adducts was conducted in poor prognosis, acute leukemia patients. Patients received fludarabine (10 to 15 mg/m(2) x 5 days), carboplatin (area under the curve 10 to 12 by continuous infusion over 5 days), followed by escalated doses of topotecan infused over 72 hours (fludarabine, carboplatin, topotecan regimen). Twenty-eight patients had acute myelogenous leukemia (7 untreated secondary acute myelogenous leukemia, 11 in first relapse, and 10 in second relapse or refractory), 1 patient had refractory/relapsed acute lymphoblastic leukemia, and 2 patients had untreated chronic myelogenous leukemia blast crisis. Six patients had failed an autologous stem cell transplant. Patients ranged from 19 to 76 (median 54) years. Measurement of platinum-DNA adducts were done in serial bone marrow specimens. Fifteen of 31 patients achieved bone marrow aplasia. Clinical responses included 2 complete response, 4 complete response with persistent thrombocytopenia, and 2 partial response. Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days. Grade 3 or greater infections occurred in all of the patients, and there were 2 infection-related deaths. The nonhematologic toxicity profile was acceptable. Five patients subsequently received allografts without early transplant-related mortality. Maximum tolerated dose of fludarabine, carboplatin, topotecan regimen was fludarabine 15 mg/m(2) x 5, carboplatin area under the curve 12, and topotecan 2.55 mg/m(2) over 72 hours. An increase in bone marrow, platinum-DNA adduct formation between the end of carboplatin infusion and 48 hours after the infusion correlated with bone marrow response. Fludarabine, carboplatin, topotecan regimen is a promising treatment based on potential pharmacodynamic interactions, which merits additional study in poor prognosis, acute leukemia patients.",Clinical Trial,5590.0,24.0,"A novel regimen designed to maximize antileukemia activity of carboplatin through inhibiting repair of platinum-DNA adducts was conducted in poor prognosis acute patients Patients received fludarabine 10 to 15 mg/m 2 x 5 days carboplatin area under the curve 10 to 12 by continuous infusion over 5 days followed by escalated doses of topotecan infused over 72 hours fludarabine carboplatin topotecan regimen Twenty-eight patients had acute myelogenous 7 untreated secondary acute myelogenous 11 in first relapse and 10 in second relapse or refractory 1 patient had refractory/relapsed acute lymphoblastic and 2 patients had untreated chronic myelogenous blast crisis Six patients had failed an autologous stem cell transplant Patients ranged from 19 to 76 median 54 years Measurement of platinum-DNA adducts were done in serial marrow specimens Fifteen of 31 patients achieved marrow aplasia Clinical responses included 2 complete response 4 complete response with persistent thrombocytopenia and 2 partial response Prolonged myelosuppression was observed with median time to blood neutrophils /=200/microl of 28 0 to 43 days and time to platelets /=20,000/microl untransfused of 40 24 to 120 days Grade 3 or greater infections occurred in all of the patients and there were 2 infection-related deaths The nonhematologic toxicity profile was acceptable Five patients subsequently received allografts without early transplant-related mortality Maximum tolerated dose of fludarabine carboplatin topotecan regimen was fludarabine 15 mg/m 2 x 5 carboplatin area under the curve 12 and topotecan 2.55 mg/m 2 over 72 hours An increase in marrow platinum-DNA adduct formation between the end of carboplatin infusion and 48 hours after the infusion correlated with marrow response Fludarabine carboplatin topotecan regimen is a promising treatment based on potential pharmacodynamic interactions which merits additional study in poor prognosis acute patients",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[8, 229, 477, 1114, 6, 4116, 9169, 128, 1, 927, 298, 2062, 972, 1, 828, 261, 9722, 10, 426, 4, 334, 356, 286, 7, 7, 103, 2027, 79, 6, 167, 81, 188, 18, 1006, 33, 162, 927, 965, 669, 3, 1496, 79, 6, 133, 20, 1314, 904, 252, 33, 162, 370, 20, 2842, 415, 1, 2129, 4524, 252, 720, 1459, 2027, 927, 2129, 477, 737, 659, 7, 42, 286, 2194, 67, 1278, 568, 286, 2194, 175, 4, 157, 429, 2, 79, 4, 419, 429, 15, 430, 14, 69, 42, 430, 591, 286, 1275, 2, 18, 7, 42, 1278, 442, 2194, 3112, 6540, 437, 7, 42, 1551, 35, 1028, 452, 31, 941, 7, 1869, 29, 326, 6, 846, 52, 667, 60, 2204, 1, 828, 261, 9722, 11, 1822, 4, 2108, 581, 623, 3057, 1, 456, 7, 513, 581, 12307, 38, 253, 159, 18, 236, 51, 39, 236, 51, 5, 1882, 1340, 2, 18, 450, 51, 1069, 2858, 10, 164, 5, 52, 98, 6, 315, 5700, 1250, 5128, 1, 339, 13, 6, 601, 162, 2, 98, 6, 4407, 179, 984, 5128, 37795, 1, 327, 259, 6, 2031, 162, 88, 27, 15, 378, 1875, 489, 4, 62, 1, 3, 7, 2, 125, 11, 18, 930, 139, 1043, 3, 3534, 155, 800, 10, 1595, 365, 7, 1611, 103, 10586, 187, 191, 941, 139, 282, 689, 421, 61, 1, 2027, 927, 2129, 477, 10, 2027, 167, 81, 188, 18, 1006, 33, 927, 965, 669, 3, 1496, 133, 2, 2129, 18, 614, 81, 188, 18, 252, 720, 1459, 35, 344, 4, 581, 828, 261, 13038, 1264, 59, 3, 396, 1, 927, 904, 2, 576, 1459, 50, 3, 904, 438, 5, 581, 51, 2027, 927, 2129, 477, 16, 8, 721, 24, 90, 23, 174, 2424, 1286, 92, 4986, 402, 45, 4, 334, 356, 286, 7]",1950.0,15501959,26
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2004-12-01,"Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, has activity in hematologic malignancies, but the dose required to achieve the proposed biologic end point, inhibition of farnesylation, is unknown. The impact on post-translational farnesylation was assessed in 42 patients with refractory hematologic malignancies and bone marrow involvement. Tipifarnib was taken orally for 21 days of a 28-day cycle. For cycle 1, patients were randomly assigned to one of four dose levels: 100 mg bid, 200 mg bid, 300 mg bid, and 600 mg bid. In cycle 1, peripheral blood and bone marrow mononuclear cells were analyzed for inhibition of HDJ2 prenylation by Western blot analysis at baseline and on day 21. Twenty-three patients were assessable for analysis of HDJ2 prenylation before and after therapy. Inhibition of farnesylation was noted at all dose levels, although the highest level of inhibition was noted at the 300-mg-bid dose. The inhibition of farnesylation in the peripheral blood correlated with the inhibition in the bone marrow (r = 0.62). Of the 26 patients assessable for clinical activity after cycle 1, three patients had a significant decrease in total blasts count (acute myeloid leukemia in two patients, and chronic myelogenous leukemia in one patient). The inhibition of farnesylation was greater in the three responders than the nonresponders (P = .03). Farnesylation as measured by HDJ2 analysis was inhibited at all dose levels administered. Clinical activity may correlate with the degree of farnesylation inhibition, rather than dose of tipifarnib, and escalation beyond 300 mg bid might not result in additional clinical activity.",Clinical Trial,5529.0,,Tipifarnib an orally bioavailable inhibitor of farnesyl transferase has activity in hematologic malignancies but the dose required to achieve the proposed biologic end point inhibition of farnesylation is unknown The impact on post-translational farnesylation was assessed in 42 patients with refractory hematologic malignancies and marrow involvement Tipifarnib was taken orally for 21 days of a 28-day cycle For cycle 1 patients were randomly assigned to one of four dose levels 100 mg bid 200 mg bid 300 mg bid and 600 mg bid In cycle 1 peripheral blood and marrow mononuclear cells were analyzed for inhibition of HDJ2 prenylation by Western blot analysis at baseline and on day 21 Twenty-three patients were assessable for analysis of HDJ2 prenylation before and after therapy Inhibition of farnesylation was noted at all dose levels although the highest level of inhibition was noted at the 300-mg-bid dose The inhibition of farnesylation in the peripheral blood correlated with the inhibition in the marrow r 0.62 Of the 26 patients assessable for clinical activity after cycle 1 three patients had a significant decrease in total blasts count acute myeloid in two patients and chronic myelogenous in one patient The inhibition of farnesylation was greater in the three responders than the nonresponders P .03 Farnesylation as measured by HDJ2 analysis was inhibited at all dose levels administered Clinical activity may correlate with the degree of farnesylation inhibition rather than dose of tipifarnib and escalation beyond 300 mg bid might not result in additional clinical activity,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4781, 35, 1428, 6582, 230, 1, 8846, 4402, 71, 128, 4, 813, 441, 84, 3, 61, 616, 6, 1359, 3, 1587, 1283, 396, 741, 297, 1, 11905, 16, 860, 3, 345, 23, 539, 2460, 11905, 10, 275, 4, 595, 7, 5, 430, 813, 441, 2, 581, 799, 4781, 10, 1633, 1428, 9, 239, 162, 1, 8, 339, 218, 417, 9, 417, 14, 7, 11, 1108, 896, 6, 104, 1, 294, 61, 148, 394, 81, 2793, 1250, 81, 2793, 2036, 81, 2793, 2, 2383, 81, 2793, 4, 417, 14, 672, 315, 2, 581, 3041, 37, 11, 311, 9, 297, 1, 33727, 17719, 20, 1521, 2639, 65, 28, 330, 2, 23, 218, 239, 737, 169, 7, 11, 3120, 9, 65, 1, 33727, 17719, 348, 2, 50, 36, 297, 1, 11905, 10, 1051, 28, 62, 61, 148, 242, 3, 1076, 301, 1, 297, 10, 1051, 28, 3, 2036, 81, 2793, 61, 3, 297, 1, 11905, 4, 3, 672, 315, 438, 5, 3, 297, 4, 3, 581, 668, 13, 744, 1, 3, 432, 7, 3120, 9, 38, 128, 50, 417, 14, 169, 7, 42, 8, 93, 775, 4, 181, 2438, 1276, 286, 533, 4, 100, 7, 2, 442, 2194, 4, 104, 69, 3, 297, 1, 11905, 10, 378, 4, 3, 169, 1983, 76, 3, 4498, 19, 680, 11905, 22, 644, 20, 33727, 65, 10, 879, 28, 62, 61, 148, 468, 38, 128, 68, 1513, 5, 3, 1444, 1, 11905, 297, 1832, 76, 61, 1, 4781, 2, 1125, 1654, 2036, 81, 2793, 822, 44, 757, 4, 402, 38, 128]",1594.0,15570084,86
"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.",Cancer cell,Cancer Cell,2005-02-01,"The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 <30 nM), which is significantly more potent than imatinib, and active against a number of imatinib-resistant Bcr-Abl mutants. Crystallographic analysis of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl. Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models. AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.",Journal Article,5467.0,1151.0,The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous CML and Philadelphia chromosome-positive Ph+ acute lymphoblastic ALL We describe a novel selective inhibitor of Bcr-Abl AMN107 IC50 30 nM which is significantly more potent than imatinib and active against a number of imatinib-resistant Bcr-Abl mutants Crystallographic analysis of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl Consistent with its in vitro and pharmacokinetic profile AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells and prolonged survival in imatinib-resistant CML mouse models AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1062, 1425, 564, 216, 1836, 1626, 442, 2194, 903, 2, 3006, 1170, 109, 2058, 286, 1275, 62, 21, 897, 8, 229, 1094, 230, 1, 1062, 1425, 12189, 5211, 201, 2878, 92, 16, 97, 80, 1157, 76, 577, 2, 544, 480, 8, 207, 1, 577, 436, 1062, 1425, 3423, 33712, 65, 1, 1425, 12189, 3817, 777, 8, 3281, 6603, 9, 3, 1777, 128, 1, 12189, 2, 577, 480, 577, 436, 1062, 1425, 925, 5, 211, 4, 439, 2, 1456, 800, 12189, 1069, 25, 1, 399, 2651, 5, 1062, 1425, 2423, 1007, 31, 285, 15, 86, 581, 37, 2, 1069, 25, 4, 577, 436, 903, 830, 274, 12189, 16, 8, 721, 217, 230, 9, 3, 36, 1, 903, 2, 2058, 62]",795.0,15710326,60
Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.,Blood,Blood,2005-03-24,"The precise mechanisms by which imatinib mesylate (STI571) and interferon alpha (IFNalpha) exhibit antileukemic effects are not known. We examined the effects of IFNs or imatinib mesylate on signaling pathways regulating initiation of mRNA translation in BCR-ABL-expressing cells. Treatment of IFN-sensitive KT-1 cells with IFNalpha resulted in phosphorylation/activation of mammalian target of rapamycin (mTOR) and downstream activation of p70 S6 kinase. The IFN-activated p70 S6 kinase was found to regulate phosphorylation of S6 ribosomal protein, which regulates translation of mRNAs with oligopyrimidine tracts in the 5'-untranslated region. In addition, IFNalpha treatment resulted in an mTOR- and/or phosphatidyl-inositol 3'(PI 3') kinase-dependent phosphorylation of 4E-BP1 repressor of mRNA translation on sites that are required for its deactivation and dissociation from the eukaryotic initiation factor-4E (eIF4E) complex. In contrast to the effects of IFNs, imatinib mesylate suppressed p70 S6 kinase activity, consistent with inhibition of BCR-ABL-mediated activation of the mTOR/p70 S6 kinase pathway. Moreover, the mTOR inhibitor rapamycin enhanced the suppressive effects of imatinib mesylate on primary leukemic granulocyte macrophage-colony-forming unit (CFU-GM) progenitors from patients with chronic myelogenous leukemia (CML). Taken altogether, our data demonstrate that IFNs and imatinib mesylate differentially regulate PI 3' kinase/mTOR-dependent signaling cascades in BCR-ABL-transformed cells, consistent with distinct effects of these agents on pathways regulating mRNA translation. They also support the concept that combined use of imatinib mesylate with mTOR inhibitors may be an appropriate future therapeutic strategy for the treatment of CML.",Journal Article,5416.0,55.0,The precise mechanisms by which imatinib mesylate STI571 and interferon alpha IFNalpha exhibit antileukemic effects are not known We examined the effects of IFNs or imatinib mesylate on signaling pathways regulating initiation of mRNA translation in BCR-ABL-expressing cells Treatment of IFN-sensitive KT-1 cells with IFNalpha resulted in phosphorylation/activation of mammalian target of rapamycin mTOR and downstream activation of p70 S6 kinase The IFN-activated p70 S6 kinase was found to regulate phosphorylation of S6 ribosomal protein which regulates translation of mRNAs with oligopyrimidine tracts in the 5'-untranslated region In addition IFNalpha treatment resulted in an mTOR- and/or phosphatidyl-inositol 3 PI 3 kinase-dependent phosphorylation of 4E-BP1 repressor of mRNA translation on sites that are required for its deactivation and dissociation from the eukaryotic initiation factor-4E eIF4E complex In contrast to the effects of IFNs imatinib mesylate suppressed p70 S6 kinase activity consistent with inhibition of BCR-ABL-mediated activation of the mTOR/p70 S6 kinase pathway Moreover the mTOR inhibitor rapamycin enhanced the suppressive effects of imatinib mesylate on primary leukemic granulocyte macrophage-colony-forming unit CFU-GM progenitors from patients with chronic myelogenous CML Taken altogether our data demonstrate that IFNs and imatinib mesylate differentially regulate PI 3 kinase/mTOR-dependent signaling cascades in BCR-ABL-transformed cells consistent with distinct effects of these agents on pathways regulating mRNA translation They also support the concept that combined use of imatinib mesylate with mTOR inhibitors may be an appropriate future therapeutic strategy for the treatment of CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 3260, 483, 20, 92, 577, 2347, 5735, 2, 1688, 950, 10947, 2239, 4512, 176, 32, 44, 440, 21, 409, 3, 176, 1, 11808, 15, 577, 2347, 23, 314, 460, 2681, 1118, 1, 956, 2691, 4, 1062, 1425, 1046, 37, 24, 1, 1256, 745, 24697, 14, 37, 5, 10947, 627, 4, 982, 363, 1, 2359, 283, 1, 1620, 873, 2, 1489, 363, 1, 9036, 4977, 216, 3, 1256, 735, 9036, 4977, 216, 10, 204, 6, 2288, 982, 1, 4977, 8194, 178, 92, 2468, 2691, 1, 7503, 5, 43735, 10950, 4, 3, 7344, 7379, 1053, 4, 352, 10947, 24, 627, 4, 35, 873, 2, 15, 15628, 13816, 27, 2928, 27, 216, 470, 982, 1, 6726, 7949, 7434, 1, 956, 2691, 23, 633, 17, 32, 616, 9, 211, 30663, 2, 10443, 29, 3, 8374, 1118, 161, 6726, 6916, 840, 4, 748, 6, 3, 176, 1, 11808, 577, 2347, 1908, 9036, 4977, 216, 128, 925, 5, 297, 1, 1062, 1425, 517, 363, 1, 3, 873, 9036, 4977, 216, 308, 1393, 3, 873, 230, 1620, 651, 3, 3707, 176, 1, 577, 2347, 23, 86, 2015, 2764, 2674, 1975, 4525, 2712, 10388, 2147, 4321, 29, 7, 5, 442, 2194, 903, 1633, 6767, 114, 74, 608, 17, 11808, 2, 577, 2347, 2478, 2288, 2928, 27, 216, 873, 470, 314, 8036, 4, 1062, 1425, 2423, 37, 925, 5, 834, 176, 1, 46, 183, 23, 460, 2681, 956, 2691, 491, 120, 538, 3, 2545, 17, 397, 119, 1, 577, 2347, 5, 873, 222, 68, 40, 35, 870, 508, 189, 692, 9, 3, 24, 1, 903]",1735.0,15790787,18
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.,Cancer,Cancer,2005-05-01,"The effect of imatinib mesylate on survival in the accelerated phase of chronic myelogenous leukemia (CML) is unknown. The objectives of this study were to update the long-term experience with imatinib in patients who had accelerated-phase CML and to compare outcomes with historic experience. The outcomes of 176 patients who received treatment with imatinib were reviewed and compared with the outcomes of 213 historic control patients with accelerated-phase CML who received treatment with interferon-alpha or with other modalities. With imatinib, the complete hematologic response rate was 82% versus a rate < or = 50% for others, and the complete cytogenetic response rate was 43% versus rates of 0-6% for others. The estimated 4-year survival rates were 53% with imatinib, 42% with interferon-alpha, and 0-21% for others. A multivariate analysis of the total population of 389 patients indicated that imatinib therapy (vs. other therapies) was an independent, favorable prognostic factor for survival (P < 0.0001; hazard rate, 0.62). A subset analysis that included only patients who were treated with imatinib and interferon-alpha (276 patients) also identified imatinib as an independent favorable prognostic factor (P < 0.0001; hazard rate, 0.65). The 3-month cytogenetic response to imatinib was associated with significantly different survival outcomes (P < 0.0001). A multivariate analysis that included pretreatment characteristics and 3-month cytogenetic response among 150 patients who received imatinib and were alive at 3 months identified only 2 adverse independent prognostic factors: lack of a cytogenetic response at 3 months (P < 0.001) and anemia (hemoglobin < 10 g/dL; P = 0.003). Patients who had neither factor (41%) had an estimated 4-year survival rate of 88%; in the other patients, the 4-year survival rate was < or = 60%. This may have implications in relation to subsequent therapy, because, according to the outcomes of patients who underwent allogeneic transplantation in accelerated phase at the authors' institution and from literature reports, the estimates of 5-year survival were 25-30%. The current results suggest that imatinib improved survival compared with other therapies in patients with accelerated-phase CML.",Comparative Study,5378.0,58.0,The effect of imatinib mesylate on survival in the accelerated phase of chronic myelogenous CML is unknown The objectives of this study were to update the long-term experience with imatinib in patients who had accelerated-phase CML and to compare outcomes with historic experience The outcomes of 176 patients who received treatment with imatinib were reviewed and compared with the outcomes of 213 historic control patients with accelerated-phase CML who received treatment with interferon-alpha or with other modalities With imatinib the complete hematologic response rate was 82 versus a rate or 50 for others and the complete cytogenetic response rate was 43 versus rates of 0-6 for others The estimated 4-year survival rates were 53 with imatinib 42 with interferon-alpha and 0-21 for others A multivariate analysis of the total population of 389 patients indicated that imatinib therapy vs. other therapies was an independent favorable prognostic factor for survival P 0.0001 hazard rate 0.62 A subset analysis that included only patients who were treated with imatinib and interferon-alpha 276 patients also identified imatinib as an independent favorable prognostic factor P 0.0001 hazard rate 0.65 The 3-month cytogenetic response to imatinib was associated with significantly different survival outcomes P 0.0001 A multivariate analysis that included pretreatment characteristics and 3-month cytogenetic response among 150 patients who received imatinib and were alive at 3 months identified only 2 adverse independent prognostic factors lack of a cytogenetic response at 3 months P 0.001 and anemia hemoglobin 10 g/dL P 0.003 Patients who had neither factor 41 had an estimated 4-year survival rate of 88 in the other patients the 4-year survival rate was or 60 This may have implications in relation to subsequent therapy because according to the outcomes of patients who underwent allogeneic transplantation in accelerated phase at the authors institution and from literature reports the estimates of 5-year survival were 25-30 The current results suggest that imatinib improved survival compared with other therapies in patients with accelerated-phase CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 254, 1, 577, 2347, 23, 25, 4, 3, 2241, 124, 1, 442, 2194, 903, 16, 860, 3, 2409, 1, 26, 45, 11, 6, 2991, 3, 319, 337, 730, 5, 577, 4, 7, 54, 42, 2241, 124, 903, 2, 6, 932, 123, 5, 6875, 730, 3, 123, 1, 5800, 7, 54, 103, 24, 5, 577, 11, 446, 2, 72, 5, 3, 123, 1, 5833, 6875, 182, 7, 5, 2241, 124, 903, 54, 103, 24, 5, 1688, 950, 15, 5, 127, 1558, 5, 577, 3, 236, 813, 51, 116, 10, 878, 185, 8, 116, 15, 212, 9, 1749, 2, 3, 236, 1266, 51, 116, 10, 601, 185, 151, 1, 13, 49, 9, 1749, 3, 661, 39, 111, 25, 151, 11, 699, 5, 577, 595, 5, 1688, 950, 2, 13, 239, 9, 1749, 8, 331, 65, 1, 3, 181, 266, 1, 9182, 7, 1103, 17, 577, 36, 105, 127, 235, 10, 35, 306, 913, 177, 161, 9, 25, 19, 13, 488, 360, 116, 13, 744, 8, 697, 65, 17, 159, 158, 7, 54, 11, 73, 5, 577, 2, 1688, 950, 7976, 7, 120, 108, 577, 22, 35, 306, 913, 177, 161, 19, 13, 488, 360, 116, 13, 556, 3, 27, 811, 1266, 51, 6, 577, 10, 41, 5, 97, 338, 25, 123, 19, 13, 488, 8, 331, 65, 17, 159, 1194, 374, 2, 27, 811, 1266, 51, 107, 1577, 7, 54, 103, 577, 2, 11, 1701, 28, 27, 53, 108, 158, 18, 290, 306, 177, 130, 926, 1, 8, 1266, 51, 28, 27, 53, 19, 13, 144, 2, 1545, 2222, 79, 499, 1826, 19, 13, 1421, 7, 54, 42, 2174, 161, 605, 42, 35, 661, 39, 111, 25, 116, 1, 889, 4, 3, 127, 7, 3, 39, 111, 25, 116, 10, 15, 335, 26, 68, 47, 1268, 4, 2191, 6, 706, 36, 408, 768, 6, 3, 123, 1, 7, 54, 208, 1063, 497, 4, 2241, 124, 28, 3, 738, 731, 2, 29, 789, 1198, 3, 1423, 1, 33, 111, 25, 11, 243, 201, 3, 291, 99, 309, 17, 577, 231, 25, 72, 5, 127, 235, 4, 7, 5, 2241, 124, 903]",2169.0,15830345,60
Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells.,Experimental hematology,Exp. Hematol.,2005-05-01,"The mechanisms by which interferon alpha (IFN-alpha) induces antileukemic responses in chronic myelogenous leukemia (CML) cells are not known. We examined whether a member of the protein kinase C (PKC) family of proteins, PKC-delta, is activated during treatment of BCR-ABL cells with IFN-alpha and participates in the induction of interferon responses. Immunoblots and immune complex kinase assays were performed to study the phosphorylation and activation of PKC-delta in response to IFN-alpha in CML-derived cell lines. The effects of pharmacological inhibition of PKC-delta on the suppressive effects of IFN-alpha on leukemic CFU-GM progenitors from CML patients were assessed by clonogenic assays in methylcellulose. IFN-alpha treatment of the sensitive CML-derived KT-1 cell line resulted in phosphorylation of PKC-delta and activation of its kinase domain. Such phosphorylation/activation of PKC-delta was required for phosphorylation of Stat1 on serine 727, as inhibition of PKC-delta activity blocked the IFN-alpha-dependent serine phosphorylation of Stat1 and IFN-alpha-inducible gene transcription. IFN-alpha treatment strongly inhibited leukemic CFU-GM progenitor colony formation from bone marrow or peripheral blood of patients with CML, and such inhibition was reversed by concomitant treatment of the cells with the PKC-delta pharmacologic inhibitor rottlerin. Taken altogether, our data demonstrate that PKC-delta plays a critical role in Type I IFN signaling in BCR-ABL expressing cells, acting as a serine kinase for Stat1, to regulate transcriptional activation of interferon-regulated genes and induction of antileukemic responses.",Journal Article,5378.0,30.0,The mechanisms by which interferon alpha IFN-alpha induces antileukemic responses in chronic myelogenous CML cells are not known We examined whether a member of the protein kinase C PKC family of proteins PKC-delta is activated during treatment of BCR-ABL cells with IFN-alpha and participates in the induction of interferon responses Immunoblots and immune complex kinase assays were performed to study the phosphorylation and activation of PKC-delta in response to IFN-alpha in CML-derived cell lines The effects of pharmacological inhibition of PKC-delta on the suppressive effects of IFN-alpha on leukemic CFU-GM progenitors from CML patients were assessed by clonogenic assays in methylcellulose IFN-alpha treatment of the sensitive CML-derived KT-1 cell line resulted in phosphorylation of PKC-delta and activation of its kinase domain Such phosphorylation/activation of PKC-delta was required for phosphorylation of Stat1 on serine 727 as inhibition of PKC-delta activity blocked the IFN-alpha-dependent serine phosphorylation of Stat1 and IFN-alpha-inducible gene transcription IFN-alpha treatment strongly inhibited leukemic CFU-GM progenitor colony formation from marrow or peripheral blood of patients with CML and such inhibition was reversed by concomitant treatment of the cells with the PKC-delta pharmacologic inhibitor rottlerin Taken altogether our data demonstrate that PKC-delta plays a critical role in Type I IFN signaling in BCR-ABL expressing cells acting as a serine kinase for Stat1 to regulate transcriptional activation of interferon-regulated genes and induction of antileukemic responses,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 483, 20, 92, 1688, 950, 1256, 950, 1516, 4512, 253, 4, 442, 2194, 903, 37, 32, 44, 440, 21, 409, 317, 8, 2693, 1, 3, 178, 216, 256, 4644, 607, 1, 652, 4644, 4305, 16, 735, 190, 24, 1, 1062, 1425, 37, 5, 1256, 950, 2, 11931, 4, 3, 504, 1, 1688, 253, 13867, 2, 250, 840, 216, 1013, 11, 173, 6, 45, 3, 982, 2, 363, 1, 4644, 4305, 4, 51, 6, 1256, 950, 4, 903, 526, 31, 285, 3, 176, 1, 3419, 297, 1, 4644, 4305, 23, 3, 3707, 176, 1, 1256, 950, 23, 2015, 10388, 2147, 4321, 29, 903, 7, 11, 275, 20, 3798, 1013, 4, 24816, 1256, 950, 24, 1, 3, 745, 903, 526, 24697, 14, 31, 328, 627, 4, 982, 1, 4644, 4305, 2, 363, 1, 211, 216, 1398, 225, 982, 363, 1, 4644, 4305, 10, 616, 9, 982, 1, 5793, 23, 3734, 14093, 22, 297, 1, 4644, 4305, 128, 2582, 3, 1256, 950, 470, 3734, 982, 1, 5793, 2, 1256, 950, 2877, 145, 866, 1256, 950, 24, 1327, 879, 2015, 10388, 2147, 2520, 1975, 1264, 29, 581, 15, 672, 315, 1, 7, 5, 903, 2, 225, 297, 10, 3682, 20, 1781, 24, 1, 3, 37, 5, 3, 4644, 4305, 2788, 230, 30761, 1633, 6767, 114, 74, 608, 17, 4644, 4305, 1698, 8, 740, 200, 4, 267, 70, 1256, 314, 4, 1062, 1425, 1046, 37, 5375, 22, 8, 3734, 216, 9, 5793, 6, 2288, 1431, 363, 1, 1688, 1065, 214, 2, 504, 1, 4512, 253]",1617.0,15850832,37
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2005-05-01,"To determine the clinical significance of molecular response and relapse among patients with chronic myelogenous leukemia (CML) treated with imatinib. We analyzed the results of quantitative PCR in 280 patients with CML in chronic phase who achieved complete cytogenetic remission with imatinib (117 after IFN-alpha failure and 163 previously untreated). Median follow-up was 31 months (range, 3-52 months). Median BCR-ABL/ABL ratio before the start of therapy was 39.44 (range, 0.252-170.53). A major molecular response (BCR-ABL/ABL ratio <0.05%) was achieved in 174 (62%), and transcripts became undetectable (complete molecular response) in 95 (34%). By multivariate analysis, only treatment with high-dose imatinib (P = 0.02) was associated with achievement of a major molecular response. Nine of 166 (5%) patients who achieved a major molecular response lost their cytogenetic remission, compared with 25 of 68 (37%) among those who did not achieve this response (P < 0.0001). Patients achieving a major molecular response 12 months after the start of therapy had significantly better complete cytogenetic remission duration than others. A >1-log reduction in transcript levels after 3 months of therapy predicted for an improved probability of achieving a major molecular response at 24 months. Increasing levels of BCR-ABL transcripts predicted for a loss of cytogenetic remission only among patients who did not achieve a major molecular response. Achieving a major molecular response, particularly within the first year of therapy, is predictive of a durable cytogenetic remission and may be the future goal of therapy in CML.",Clinical Trial,5378.0,240.0,To determine the clinical significance of molecular response and relapse among patients with chronic myelogenous CML treated with imatinib We analyzed the results of quantitative PCR in 280 patients with CML in chronic phase who achieved complete cytogenetic remission with imatinib 117 after IFN-alpha failure and 163 previously untreated Median follow-up was 31 months range 3-52 months Median BCR-ABL/ABL ratio before the start of therapy was 39.44 range 0.252-170.53 A major molecular response BCR-ABL/ABL ratio 0.05 was achieved in 174 62 and transcripts became undetectable complete molecular response in 95 34 By multivariate analysis only treatment with high-dose imatinib P 0.02 was associated with achievement of a major molecular response Nine of 166 5 patients who achieved a major molecular response lost their cytogenetic remission compared with 25 of 68 37 among those who did not achieve this response P 0.0001 Patients achieving a major molecular response 12 months after the start of therapy had significantly better complete cytogenetic remission duration than others A 1-log reduction in transcript levels after 3 months of therapy predicted for an improved probability of achieving a major molecular response at 24 months Increasing levels of BCR-ABL transcripts predicted for a loss of cytogenetic remission only among patients who did not achieve a major molecular response Achieving a major molecular response particularly within the first year of therapy is predictive of a durable cytogenetic remission and may be the future goal of therapy in CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 223, 3, 38, 724, 1, 219, 51, 2, 429, 107, 7, 5, 442, 2194, 903, 73, 5, 577, 21, 311, 3, 99, 1, 1156, 604, 4, 5775, 7, 5, 903, 4, 442, 124, 54, 513, 236, 1266, 734, 5, 577, 3843, 50, 1256, 950, 496, 2, 5409, 373, 1278, 52, 166, 126, 10, 456, 53, 184, 27, 653, 53, 52, 1062, 1425, 1425, 197, 348, 3, 2435, 1, 36, 10, 587, 584, 184, 13, 6951, 5248, 699, 8, 458, 219, 51, 1062, 1425, 1425, 197, 13, 474, 10, 513, 4, 5811, 744, 2, 2680, 3451, 3920, 236, 219, 51, 4, 48, 562, 20, 331, 65, 158, 24, 5, 64, 61, 577, 19, 13, 588, 10, 41, 5, 5088, 1, 8, 458, 219, 51, 762, 1, 5812, 33, 7, 54, 513, 8, 458, 219, 51, 3009, 136, 1266, 734, 72, 5, 243, 1, 806, 567, 107, 135, 54, 205, 44, 1359, 26, 51, 19, 13, 488, 7, 1785, 8, 458, 219, 51, 133, 53, 50, 3, 2435, 1, 36, 42, 97, 380, 236, 1266, 734, 654, 76, 1749, 8, 14, 1066, 628, 4, 3268, 148, 50, 27, 53, 1, 36, 783, 9, 35, 231, 1320, 1, 1785, 8, 458, 219, 51, 28, 259, 53, 602, 148, 1, 1062, 1425, 2680, 783, 9, 8, 407, 1, 1266, 734, 158, 107, 7, 54, 205, 44, 1359, 8, 458, 219, 51, 1785, 8, 458, 219, 51, 823, 262, 3, 157, 111, 1, 36, 16, 464, 1, 8, 1480, 1266, 734, 2, 68, 40, 3, 508, 1326, 1, 36, 4, 903]",1573.0,15867244,147
"Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors.",Nuclear medicine and biology,Nucl. Med. Biol.,2005-05-01,"The pyridopyrimidinones are a potent class of inhibitors of c-Abl kinase and Bcr-Abl kinase, the causative fusion protein in chronic myelogenous leukemia and Src family kinases. A novel method for routine, high-yield no-carrier-added synthesis of [(124)I]-, [(125)I]- and [(131)I]-6-(2,6-dichlorophenyl)-2-(4-iodophenylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one has been developed. The 4'-trimethylstannyl- or 4'-tri-n-butylstannyl-pyridopyrimidinone precursors were prepared from the aryl bromide via a palladium-mediated coupling with hexaalkylditin (dioxane/microwave irradiation/10 min at 160 degrees C). The radioiodination of 4'-stannylpyridopyrimidinones was found to optimally occur via an iododestannylation with Na(124)I, Na(125)I or Na(131)I in the presence of an oxidant [30% H(2)O(2)/HOAc (1:3)/10 min] in 79-87% radiochemical yield with >99% radiochemical purity. The total radiosynthesis time was 30 min. The 4-iodophenylpyridopyrimidinone 2 inhibited recombinant Abl kinase activity with an IC(50) of 2.0 nM. Cell proliferation of K562 and A431 cells was inhibited with an IC(50) of 2.0 and 20 nM, respectively. Rapid cellular uptake and equilibrium were observed within 10-15 min using [(131)I]-4-iodophenylpyridopyrimidinone 6c in K562 and A431 cells and demonstrated a 2.8-fold uptake selectivity for the Bcr-Abl-expressing K562 cells at 60 min. These results suggest that pyridopyrimidinone radiotracers may be useful in imaging Abl-, Bcr-Abl- or Src-expressing malignancies.",Comparative Study,5378.0,16.0,"The pyridopyrimidinones are a potent class of inhibitors of c-Abl kinase and Bcr-Abl kinase the causative fusion protein in chronic myelogenous and Src family kinases A novel method for routine high-yield no-carrier-added synthesis of 124 I 125 I and 131 I -6- 2,6-dichlorophenyl -2- 4-iodophenylamino -8-methyl-8H-pyrido 2,3-d pyrimidin-7-one has been developed The 4'-trimethylstannyl- or 4'-tri-n-butylstannyl-pyridopyrimidinone precursors were prepared from the aryl bromide via a palladium-mediated coupling with hexaalkylditin dioxane/microwave irradiation/10 min at 160 degrees C The radioiodination of 4'-stannylpyridopyrimidinones was found to optimally occur via an iododestannylation with Na 124 I Na 125 I or Na 131 I in the presence of an oxidant 30 H 2 O 2 /HOAc 1:3 /10 min in 79-87 radiochemical yield with 99 radiochemical purity The total radiosynthesis time was 30 min The 4-iodophenylpyridopyrimidinone 2 inhibited recombinant Abl kinase activity with an IC 50 of 2.0 nM Cell proliferation of K562 and A431 cells was inhibited with an IC 50 of 2.0 and 20 nM respectively Rapid cellular uptake and equilibrium were observed within 10-15 min using 131 I -4-iodophenylpyridopyrimidinone 6c in K562 and A431 cells and demonstrated a 2.8-fold uptake selectivity for the Bcr-Abl-expressing K562 cells at 60 min These results suggest that pyridopyrimidinone radiotracers may be useful in imaging Abl- Bcr-Abl- or Src-expressing malignancies",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 54796, 32, 8, 1157, 1040, 1, 222, 1, 256, 1425, 216, 2, 1062, 1425, 216, 3, 8088, 1212, 178, 4, 442, 2194, 2, 2023, 607, 1549, 8, 229, 596, 9, 1311, 64, 2309, 77, 4715, 1953, 2525, 1, 2834, 70, 1731, 70, 2, 2229, 70, 49, 18, 49, 54797, 18, 39, 43958, 66, 5228, 37912, 54798, 18, 27, 427, 54799, 67, 104, 71, 85, 276, 3, 14401, 54800, 15, 14401, 11181, 78, 54801, 43959, 4881, 11, 4421, 29, 3, 20285, 10168, 847, 8, 22221, 517, 13506, 5, 54802, 54803, 11182, 1104, 79, 1538, 28, 3457, 4133, 256, 3, 37913, 1, 14401, 54804, 10, 204, 6, 5074, 1271, 847, 35, 54805, 5, 5328, 2834, 70, 5328, 1731, 70, 15, 5328, 2229, 70, 4, 3, 463, 1, 35, 13322, 201, 555, 18, 1990, 18, 54806, 14, 27, 79, 1538, 4, 842, 912, 20992, 2309, 5, 1058, 20992, 12963, 3, 181, 54807, 98, 10, 201, 1538, 3, 39, 43960, 18, 879, 2835, 1425, 216, 128, 5, 35, 2340, 212, 1, 18, 13, 2878, 31, 457, 1, 5208, 2, 10527, 37, 10, 879, 5, 35, 2340, 212, 1, 18, 13, 2, 179, 2878, 106, 1321, 763, 1135, 2, 11614, 11, 164, 262, 79, 167, 1538, 75, 2229, 70, 39, 43960, 54808, 4, 5208, 2, 10527, 37, 2, 264, 8, 18, 66, 1116, 1135, 6072, 9, 3, 1062, 1425, 1046, 5208, 37, 28, 335, 1538, 46, 99, 309, 17, 43959, 13626, 68, 40, 999, 4, 270, 1425, 1062, 1425, 15, 2023, 1046, 441]",1453.0,15878500,0
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-05-09,"To determine the activity of decitabine, a DNA methylation inhibitor, in imatinib-refractory or intolerant chronic myelogenous leukemia. Thirty-five patients were enrolled in this phase II study (12 in chronic phase, 17 in accelerated phase, and six in blastic phase). Decitabine was administered at 15 mg/m2 intravenously over 1 hour daily, 5 days a week for 2 weeks. DNA methylation was measured using a LINE1 bisulfite/pyrosequencing assay. Complete hematologic responses were seen in 12 patients (34%) and partial hematologic responses in seven patients (20%), for an overall hematologic response rate of 54% (83% in chronic phase, 41% in accelerated phase, and 34% in blastic phase). Major cytogenetic responses were observed in six patients (17%), and minor cytogenetic responses were seen in 10 patients (29%) for an overall cytogenetic response rate of 46%. Median response duration was 3.5 months (range, 2 to 13+ months). Myelosuppression was the major adverse effect, with neutropenic fever in 28 (23%) of 124 courses of therapy. LINE1 methylation decreased from 71.3% +/- 1.4% (mean +/- standard error of the mean) to 60.7% +/- 1.4% after 1 week, 50.9% +/- 2.4% after 2 weeks, and returned to 66.5% +/- 2.7% at recovery of counts (median, 46 days). LINE1 methylation at the end of week 1 did not correlate with subsequent responses. However, at day 12, the absolute decrease in methylation was 14.5% +/- 3.0% versus 26.8% +/- 2.7% in responders versus nonresponders (P = .007). Decitabine induces hypomethylation and has clinical activity in imatinib refractory chronic myelogenous leukemia. We hypothesize that the inverse correlation between hypomethylation 2 weeks after therapy and response is due to a cell death mechanism of response, whereby resistant cells can withstand more hypomethylation.",Clinical Trial,5370.0,238.0,To determine the activity of decitabine a DNA methylation inhibitor in imatinib-refractory or intolerant chronic myelogenous Thirty-five patients were enrolled in this phase II study 12 in chronic phase 17 in accelerated phase and six in blastic phase Decitabine was administered at 15 mg/m2 intravenously over 1 hour daily 5 days a week for 2 weeks DNA methylation was measured using a LINE1 bisulfite/pyrosequencing assay Complete hematologic responses were seen in 12 patients 34 and partial hematologic responses in seven patients 20 for an overall hematologic response rate of 54 83 in chronic phase 41 in accelerated phase and 34 in blastic phase Major cytogenetic responses were observed in six patients 17 and minor cytogenetic responses were seen in 10 patients 29 for an overall cytogenetic response rate of 46 Median response duration was 3.5 months range 2 to 13+ months Myelosuppression was the major adverse effect with neutropenic fever in 28 23 of 124 courses of therapy LINE1 methylation decreased from 71.3 +/- 1.4 mean +/- standard error of the mean to 60.7 +/- 1.4 after 1 week 50.9 +/- 2.4 after 2 weeks and returned to 66.5 +/- 2.7 at recovery of counts median 46 days LINE1 methylation at the end of week 1 did not correlate with subsequent responses However at day 12 the absolute decrease in methylation was 14.5 +/- 3.0 versus 26.8 +/- 2.7 in responders versus nonresponders P .007 Decitabine induces hypomethylation and has clinical activity in imatinib refractory chronic myelogenous We hypothesize that the inverse correlation between hypomethylation 2 weeks after therapy and response is due to a cell death mechanism of response whereby resistant cells can withstand more hypomethylation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 223, 3, 128, 1, 3004, 8, 261, 569, 230, 4, 577, 430, 15, 4944, 442, 2194, 977, 365, 7, 11, 346, 4, 26, 124, 215, 45, 133, 4, 442, 124, 269, 4, 2241, 124, 2, 437, 4, 6529, 124, 3004, 10, 468, 28, 167, 81, 821, 1672, 252, 14, 2583, 391, 33, 162, 8, 647, 9, 18, 244, 261, 569, 10, 644, 75, 8, 17845, 6181, 6031, 719, 236, 813, 253, 11, 527, 4, 133, 7, 562, 2, 450, 813, 253, 4, 648, 7, 179, 9, 35, 63, 813, 51, 116, 1, 667, 852, 4, 442, 124, 605, 4, 2241, 124, 2, 562, 4, 6529, 124, 458, 1266, 253, 11, 164, 4, 437, 7, 269, 2, 2278, 1266, 253, 11, 527, 4, 79, 7, 462, 9, 35, 63, 1266, 51, 116, 1, 641, 52, 51, 654, 10, 27, 33, 53, 184, 18, 6, 233, 53, 2858, 10, 3, 458, 290, 254, 5, 3659, 2775, 4, 339, 382, 1, 2834, 1993, 1, 36, 17845, 569, 340, 29, 792, 27, 14, 39, 313, 260, 3444, 1, 3, 313, 6, 335, 67, 14, 39, 50, 14, 647, 212, 83, 18, 39, 50, 18, 244, 2, 5157, 6, 700, 33, 18, 67, 28, 1602, 1, 1911, 52, 641, 162, 17845, 569, 28, 3, 396, 1, 647, 14, 205, 44, 1513, 5, 706, 253, 137, 28, 218, 133, 3, 1766, 775, 4, 569, 10, 213, 33, 27, 13, 185, 432, 66, 18, 67, 4, 1983, 185, 4498, 19, 1999, 3004, 1516, 4441, 2, 71, 38, 128, 4, 577, 430, 442, 2194, 21, 4919, 17, 3, 2931, 816, 59, 4441, 18, 244, 50, 36, 2, 51, 16, 520, 6, 8, 31, 273, 670, 1, 51, 6131, 436, 37, 122, 21330, 80, 4441]",1718.0,15883410,118
Imatinib resistance in gastrointestinal stromal tumors.,Current oncology reports,Curr Oncol Rep,2005-07-01,"Conventional chemotherapeutic drugs are ineffective in treatment of gastrointestinal stromal tumors (GISTs). Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. Unfortunately, imatinib resistance has emerged. The reported mechanism of imatinib resistance in GISTs involves missense mutation in the kinase domain of KIT, including Thr670Ile, Tyr823Asp, and Val654Ala. The established mechanisms and potential mechanisms of imatinib resistance in GISTs, the imaging studies indicative of early development of imatinib resistance, and the management of imatinib-resistant GISTs are discussed.",Journal Article,5317.0,39.0,Conventional chemotherapeutic drugs are ineffective in treatment of stromal tumors GISTs Imatinib STI571 Gleevec Glivec Novartis Pharmaceuticals East Hanover NJ a selective inhibitor of KIT ABL BCR-ABL PDGFRA and PDGFRB represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous and GISTs Unfortunately imatinib resistance has emerged The reported mechanism of imatinib resistance in GISTs involves missense mutation in the kinase domain of KIT including Thr670Ile Tyr823Asp and Val654Ala The established mechanisms and potential mechanisms of imatinib resistance in GISTs the imaging studies indicative of early development of imatinib resistance and the management of imatinib-resistant GISTs are discussed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[809, 1573, 600, 32, 3957, 4, 24, 1, 1126, 57, 2508, 577, 5735, 8569, 33225, 7855, 5888, 6633, 33861, 12754, 8, 1094, 230, 1, 1164, 1425, 1062, 1425, 4006, 2, 10231, 1449, 8, 217, 2431, 1, 238, 12, 36, 2, 71, 5746, 3, 24, 1, 7, 5, 442, 2194, 2, 2508, 3869, 577, 251, 71, 2054, 3, 210, 670, 1, 577, 251, 4, 2508, 2921, 4007, 258, 4, 3, 216, 1398, 1, 1164, 141, 54860, 54861, 2, 43705, 3, 635, 483, 2, 174, 483, 1, 577, 251, 4, 2508, 3, 270, 94, 5572, 1, 191, 193, 1, 577, 251, 2, 3, 284, 1, 577, 436, 2508, 32, 1588]",776.0,15946589,230
Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2005-06-01,"Donor lymphocyte infusion (DLI) reliably induces durable remission in 75% to 80% of patients with relapsed chronic myelogenous leukemia (CML) following allogeneic bone marrow transplantation. We previously reported the identification of a high titer-specific immunoglobulin G response against two novel leukemia-associated antigens, CML28 and CML66, which correlated with immune-induced remission. The present studies characterize expression of CML28 and CML66 in primary hematopoietic tissues. Specific monoclonal antibodies to CML28 and CML66 were developed and used to detect antigen expression in leukemia cell lines and primary leukemia tissue on Western blot and immunohistochemistry. Expression patterns were confirmed by antigen-specific real-time PCR. Both CML28 and CML66 were highly expressed in leukemic blasts from patients with acute myelogenous leukemia and CML blast crisis but barely detectable in normal bone marrow, normal peripheral blood, or leukemic cells from patients with stable-phase CML. In contrast, purified CD34+ progenitors from normal individuals and patients with stable-phase CML expressed high levels of CML28 and CML66 transcript and protein. Immunohistochemical staining for CML66 confirmed rare staining of myeloid precursors in normal marrow and diffuse staining of myeloblastic cells in acute myelogenous leukemia and blast crisis CML marrows. The expression patterns of CML28 and CML66 are strikingly similar and suggest that antigen expression may play a role in shaping the post-DLI antibody repertoire. The CD34+ restricted pattern of expression of CML28 and CML66 is particularly relevant in light of the notion that DLI likely exerts its curative effect by targeting antigens present in self-renewing malignant progenitor populations in CML.",Journal Article,5347.0,35.0,Donor lymphocyte infusion DLI reliably induces durable remission in 75 to 80 of patients with relapsed chronic myelogenous CML following allogeneic marrow transplantation We previously reported the identification of a high titer-specific immunoglobulin G response against two novel leukemia-associated antigens CML28 and CML66 which correlated with immune-induced remission The present studies characterize expression of CML28 and CML66 in primary hematopoietic tissues Specific monoclonal antibodies to CML28 and CML66 were developed and used to detect antigen expression in cell lines and primary tissue on Western blot and immunohistochemistry Expression patterns were confirmed by antigen-specific real-time PCR Both CML28 and CML66 were highly expressed in leukemic blasts from patients with acute myelogenous and CML blast crisis but barely detectable in normal marrow normal peripheral blood or leukemic cells from patients with stable-phase CML In contrast purified CD34+ progenitors from normal individuals and patients with stable-phase CML expressed high levels of CML28 and CML66 transcript and protein Immunohistochemical staining for CML66 confirmed rare staining of myeloid precursors in normal marrow and diffuse staining of myeloblastic cells in acute myelogenous and blast crisis CML marrows The expression patterns of CML28 and CML66 are strikingly similar and suggest that antigen expression may play a role in shaping the post-DLI antibody repertoire The CD34+ restricted pattern of expression of CML28 and CML66 is particularly relevant in light of the notion that DLI likely exerts its curative effect by targeting antigens present in self-renewing malignant progenitor populations in CML,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1488, 1448, 904, 4676, 4092, 1516, 1480, 734, 4, 481, 6, 493, 1, 7, 5, 591, 442, 2194, 903, 366, 1063, 581, 497, 21, 373, 210, 3, 911, 1, 8, 64, 8444, 112, 2593, 499, 51, 480, 100, 229, 2647, 41, 1575, 16257, 2, 12826, 92, 438, 5, 250, 277, 734, 3, 364, 94, 1507, 55, 1, 16257, 2, 12826, 4, 86, 1007, 742, 112, 848, 890, 6, 16257, 2, 12826, 11, 276, 2, 95, 6, 1426, 448, 55, 4, 31, 285, 2, 86, 246, 23, 1521, 2639, 2, 888, 55, 764, 11, 557, 20, 448, 112, 1589, 98, 604, 110, 16257, 2, 12826, 11, 561, 570, 4, 2015, 2438, 29, 7, 5, 286, 2194, 2, 903, 3112, 6540, 84, 18335, 2083, 4, 295, 581, 295, 672, 315, 15, 2015, 37, 29, 7, 5, 585, 124, 903, 4, 748, 5963, 2215, 4321, 29, 295, 869, 2, 7, 5, 585, 124, 903, 570, 64, 148, 1, 16257, 2, 12826, 3268, 2, 178, 1382, 1029, 9, 12826, 557, 622, 1029, 1, 533, 4881, 4, 295, 581, 2, 1388, 1029, 1, 21049, 37, 4, 286, 2194, 2, 3112, 6540, 903, 13800, 3, 55, 764, 1, 16257, 2, 12826, 32, 6787, 288, 2, 309, 17, 448, 55, 68, 1343, 8, 200, 4, 14917, 3, 539, 4676, 548, 5306, 3, 2215, 2016, 1177, 1, 55, 1, 16257, 2, 12826, 16, 823, 867, 4, 1691, 1, 3, 6691, 17, 4676, 322, 5685, 211, 1075, 254, 20, 529, 1575, 364, 4, 1074, 13350, 393, 2520, 1184, 4, 903]",1711.0,15958636,212
"Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.",Cancer,Cancer,2005-08-01,"Myelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML). Its significance in the recent era of effective therapy with imatinib mesylate is unknown. The current study evaluated the significance of the degree of pretreatment myelofibrosis on response and survival with imatinib therapy in patients with newly diagnosed CML. The study group comprised 198 patients with newly diagnosed Philadelphia chromosome-positive, chronic-phase CML treated with imatinib mesylate therapy. They were analyzed for the prognostic significance of bone marrow reticulin fibrosis. Severe reticulin (Grade 3-4) fibrosis was observed in 75 patients (38%): Grade 3 in 46 (23%) patients and Grade 4 in 29 (15%) patients. There was a trend towards a lower incidence of a complete cytogenetic response in patients with Grade 4 reticulin fibrosis (76% vs. 89%; P = 0.07), and a significantly worse survival (estimated 3-year survival rate of 87% vs. 97%; P = 0.04). Although the prognostic significance of severe reticulin fibrosis in patients with newly diagnosed CML receiving imatinib therapy was better, 15% of patients with Grade 4 reticulin fibrosis still had a worse outcome.",Journal Article,5286.0,14.0,Myelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous CML Its significance in the recent era of effective therapy with imatinib mesylate is unknown The current study evaluated the significance of the degree of pretreatment myelofibrosis on response and survival with imatinib therapy in patients with newly diagnosed CML The study group comprised 198 patients with newly diagnosed Philadelphia chromosome-positive chronic-phase CML treated with imatinib mesylate therapy They were analyzed for the prognostic significance of marrow reticulin fibrosis Severe reticulin Grade 3-4 fibrosis was observed in 75 patients 38 Grade 3 in 46 23 patients and Grade 4 in 29 15 patients There was a trend towards a lower incidence of a complete cytogenetic response in patients with Grade 4 reticulin fibrosis 76 vs. 89 P 0.07 and a significantly worse survival estimated 3-year survival rate of 87 vs. 97 P 0.04 Although the prognostic significance of severe reticulin fibrosis in patients with newly diagnosed CML receiving imatinib therapy was better 15 of patients with Grade 4 reticulin fibrosis still had a worse outcome,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4637, 16, 41, 3578, 5, 8, 334, 356, 4, 7, 5, 442, 2194, 903, 211, 724, 4, 3, 435, 1713, 1, 323, 36, 5, 577, 2347, 16, 860, 3, 291, 45, 194, 3, 724, 1, 3, 1444, 1, 1194, 4637, 23, 51, 2, 25, 5, 577, 36, 4, 7, 5, 732, 265, 903, 3, 45, 87, 2603, 6189, 7, 5, 732, 265, 3006, 1170, 109, 442, 124, 903, 73, 5, 577, 2347, 36, 491, 11, 311, 9, 3, 177, 724, 1, 581, 19464, 3000, 905, 19464, 88, 27, 39, 3000, 10, 164, 4, 481, 7, 519, 88, 27, 4, 641, 382, 7, 2, 88, 39, 4, 462, 167, 7, 125, 10, 8, 853, 3113, 8, 280, 287, 1, 8, 236, 1266, 51, 4, 7, 5, 88, 39, 19464, 3000, 846, 105, 887, 19, 13, 1615, 2, 8, 97, 639, 25, 661, 27, 111, 25, 116, 1, 912, 105, 1015, 19, 13, 755, 242, 3, 177, 724, 1, 905, 19464, 3000, 4, 7, 5, 732, 265, 903, 357, 577, 36, 10, 380, 167, 1, 7, 5, 88, 39, 19464, 3000, 1234, 42, 8, 639, 228]",1159.0,15971197,220
The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo.,Cancer research,Cancer Res.,2005-07-01,"MYC is frequently overexpressed in human cancers, but the downstream events contributing to tumorigenesis remain incompletely understood. MYC encodes an oncogenic transcription factor, of which target genes presumably contribute to cellular transformation. Although Myc regulates about 15% of genes and combinations of target genes are likely required for tumorigenesis, we studied in depth the expression of the Myc target gene, JPO1/CDCA7, in human cancers and its ability to provoke tumorigenesis in transgenic mice. JPO1/CDCA7 is frequently overexpressed in human cancers, and in particular, its expression is highly elevated in chronic myelogenous leukemia blast crisis as compared with the chronic phase. In murine lymphoid tissues, ectopic human JPO1/CDCA7 expression resulted in a 2-fold increased risk of lymphoid malignancies at 1 year. The transgene, which was driven by the H2-K promoter, exhibited leaky expression in nonlymphoid tissues such as kidney. We observed a significant increased incidence of transgenic animal solid tumors, which were not seen in littermate controls. These observations suggest that JPO1/CDCA7 may contribute to Myc-mediated tumorigenesis.",Journal Article,5317.0,33.0,MYC is frequently overexpressed in human cancers but the downstream events contributing to tumorigenesis remain incompletely understood MYC encodes an oncogenic transcription factor of which target genes presumably contribute to cellular transformation Although Myc regulates about 15 of genes and combinations of target genes are likely required for tumorigenesis we studied in depth the expression of the Myc target gene JPO1/CDCA7 in human cancers and its ability to provoke tumorigenesis in transgenic mice JPO1/CDCA7 is frequently overexpressed in human cancers and in particular its expression is highly elevated in chronic myelogenous blast crisis as compared with the chronic phase In murine lymphoid tissues ectopic human JPO1/CDCA7 expression resulted in a 2-fold increased risk of lymphoid malignancies at 1 year The transgene which was driven by the H2-K promoter exhibited leaky expression in nonlymphoid tissues such as We observed a significant increased incidence of transgenic animal solid tumors which were not seen in littermate controls These observations suggest that JPO1/CDCA7 may contribute to Myc-mediated tumorigenesis,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1371, 16, 746, 1711, 4, 171, 163, 84, 3, 1489, 281, 3156, 6, 1565, 918, 5252, 1784, 1371, 4322, 35, 1302, 866, 161, 1, 92, 283, 214, 8682, 1248, 6, 763, 1392, 242, 1371, 2468, 545, 167, 1, 214, 2, 1247, 1, 283, 214, 32, 322, 616, 9, 1565, 21, 656, 4, 2436, 3, 55, 1, 3, 1371, 283, 145, 33917, 30800, 4, 171, 163, 2, 211, 801, 6, 20282, 1565, 4, 2862, 399, 33917, 30800, 16, 746, 1711, 4, 171, 163, 2, 4, 1454, 211, 55, 16, 561, 804, 4, 442, 2194, 3112, 6540, 22, 72, 5, 3, 442, 124, 4, 1471, 2303, 742, 3647, 171, 33917, 30800, 55, 627, 4, 8, 18, 1116, 101, 43, 1, 2303, 441, 28, 14, 111, 3, 6632, 92, 10, 1621, 20, 3, 16237, 1634, 973, 1416, 28430, 55, 4, 20180, 742, 225, 22, 21, 164, 8, 93, 101, 287, 1, 2862, 2026, 537, 57, 92, 11, 44, 527, 4, 28316, 535, 46, 2172, 309, 17, 33917, 30800, 68, 1248, 6, 1371, 517, 1565]",1144.0,15994934,244
"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2005-07-01,"Resistance to or intolerance of imatinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) has encouraged the development of more potent Bcr-Abl inhibitors. AMN107 is a novel, orally bioavailable ATP-competitive inhibitor of Bcr-Abl. The effects of AMN107 were compared with those of imatinib on imatinib-sensitive (KBM5 and KBM7) and imatinib-resistant CML cell lines (KBM5-STI571R1.0 and KBM7-STI571R1.0). Compared with the antiproliferative activity of imatinib, AMN107 was 43 times more potent in KBM5 (IC50 of 11.3 versus 480.5 nmol/L) and 60 times more potent in KBM7 (IC50 of 4.3 versus 259.0 nmol/L) cells. IC50 for AMN107 and imatinib were 2,418.3 and 6,361.4 nmol/L, respectively, in KBM5-STI571R1.0, and 97.2 and 2,497.3 nmol/L, respectively, in KBM7-STI571R1.0 cells. AMN107 inhibited autophosphorylation of Bcr-Abl kinase more effectively than imatinib in all cell lines. They had similar effects on cell cycle progression and apoptotic response in these cell lines. Among severe combined immunodeficient mice bearing KBM5 cells, mean survival times of groups treated with 10, 20, and 30 mg/kg/d of AMN107, starting day 20 after leukemic cell grafting and continuing for 20 days, were 144%, 159%, and 182%, respectively, compared with controls. These results strongly support investigation of the clinical efficacy of AMN107 in patients with CML.",Comparative Study,5317.0,175.0,"Resistance to or intolerance of imatinib in patients with Philadelphia chromosome-positive chronic myelogenous CML has encouraged the development of more potent Bcr-Abl inhibitors AMN107 is a novel orally bioavailable ATP-competitive inhibitor of Bcr-Abl The effects of AMN107 were compared with those of imatinib on imatinib-sensitive KBM5 and KBM7 and imatinib-resistant CML cell lines KBM5-STI571R1.0 and KBM7-STI571R1.0 Compared with the antiproliferative activity of imatinib AMN107 was 43 times more potent in KBM5 IC50 of 11.3 versus 480.5 nmol/L and 60 times more potent in KBM7 IC50 of 4.3 versus 259.0 nmol/L cells IC50 for AMN107 and imatinib were 2,418.3 and 6,361.4 nmol/L respectively in KBM5-STI571R1.0 and 97.2 and 2,497.3 nmol/L respectively in KBM7-STI571R1.0 cells AMN107 inhibited autophosphorylation of Bcr-Abl kinase more effectively than imatinib in all cell lines They had similar effects on cell cycle progression and apoptotic response in these cell lines Among severe combined immunodeficient mice bearing KBM5 cells mean survival times of groups treated with 10 20 and 30 mg/kg/d of AMN107 starting day 20 after leukemic cell grafting and continuing for 20 days were 144 159 and 182 respectively compared with controls These results strongly support investigation of the clinical efficacy of AMN107 in patients with CML",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[251, 6, 15, 5266, 1, 577, 4, 7, 5, 3006, 1170, 109, 442, 2194, 903, 71, 5865, 3, 193, 1, 80, 1157, 1062, 1425, 222, 12189, 16, 8, 229, 1428, 6582, 3918, 6487, 230, 1, 1062, 1425, 3, 176, 1, 12189, 11, 72, 5, 135, 1, 577, 23, 577, 745, 10822, 2, 18206, 2, 577, 436, 903, 31, 285, 10822, 33919, 13, 2, 18206, 33919, 13, 72, 5, 3, 3669, 128, 1, 577, 12189, 10, 601, 1072, 80, 1157, 4, 10822, 5211, 1, 175, 27, 185, 9108, 33, 4694, 805, 2, 335, 1072, 80, 1157, 4, 18206, 5211, 1, 39, 27, 185, 7696, 13, 4694, 805, 37, 5211, 9, 12189, 2, 577, 11, 18, 10387, 27, 2, 49, 9234, 39, 4694, 805, 106, 4, 10822, 33919, 13, 2, 1015, 18, 2, 18, 11178, 27, 4694, 805, 106, 4, 18206, 33919, 13, 37, 12189, 879, 8146, 1, 1062, 1425, 216, 80, 1856, 76, 577, 4, 62, 31, 285, 491, 42, 288, 176, 23, 31, 417, 91, 2, 1631, 51, 4, 46, 31, 285, 107, 905, 397, 5031, 399, 1894, 10822, 37, 313, 25, 1072, 1, 271, 73, 5, 79, 179, 2, 201, 81, 503, 427, 1, 12189, 1723, 218, 179, 50, 2015, 31, 13074, 2, 4346, 9, 179, 162, 11, 4415, 5917, 2, 5160, 106, 72, 5, 535, 46, 99, 1327, 538, 940, 1, 3, 38, 209, 1, 12189, 4, 7, 5, 903]",1347.0,16000593,42
Decitabine in chronic leukemias.,Seminars in hematology,Semin. Hematol.,2005-07-01,"5-Aza-2'-deoxycitidine (decitabine, Dacogen, Bloomington, MN) is a cytosine analogue that promotes hypomethylation of DNA and has documented efficacy in myeloid malignancies. Indeed, promising clinical results have been observed in acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS). Aberrant methylation has also been found in chronic leukemias, providing a rationale for investigating the use of decitabine in these diseases. There is clear evidence of molecular (hypomethylation) as well as hematologic and cytogenetic responses to decitabine in chronic myelogenous leukemia of all phases, including in patients resistant to imatinib mesylate. Clinical trials of decitabine in chronic lymphocytic leukemia are ongoing. There are many unanswered questions regarding optimizing this treatment for chronic leukemias, but successful proof-of-concept studies for hypomethylating agents move us closer to approaches that may have a significant impact on patient outcomes.",Journal Article,5317.0,15.0,5-Aza-2'-deoxycitidine decitabine Dacogen Bloomington MN is a cytosine analogue that promotes hypomethylation of DNA and has documented efficacy in myeloid malignancies Indeed promising clinical results have been observed in acute myeloid AML and the syndromes MDS Aberrant methylation has also been found in chronic leukemias providing a rationale for investigating the use of decitabine in these diseases There is clear evidence of molecular hypomethylation as well as hematologic and cytogenetic responses to decitabine in chronic myelogenous of all phases including in patients resistant to imatinib mesylate Clinical trials of decitabine in chronic lymphocytic are ongoing There are many unanswered questions regarding optimizing this treatment for chronic leukemias but successful proof-of-concept studies for hypomethylating agents move us closer to approaches that may have a significant impact on patient outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[33, 3924, 6135, 44028, 3004, 33559, 37971, 4691, 16, 8, 6903, 4696, 17, 2148, 4441, 1, 261, 2, 71, 1405, 209, 4, 533, 441, 4462, 721, 38, 99, 47, 85, 164, 4, 286, 533, 329, 2, 3, 2040, 1223, 1898, 569, 71, 120, 85, 204, 4, 442, 2792, 1736, 8, 1728, 9, 3103, 3, 119, 1, 3004, 4, 46, 1342, 125, 16, 885, 241, 1, 219, 4441, 22, 149, 22, 813, 2, 1266, 253, 6, 3004, 4, 442, 2194, 1, 62, 3523, 141, 4, 7, 436, 6, 577, 2347, 38, 143, 1, 3004, 4, 442, 1193, 32, 942, 125, 32, 445, 7550, 1937, 666, 4336, 26, 24, 9, 442, 2792, 84, 1401, 3840, 1, 2545, 94, 9, 4931, 183, 6759, 843, 6576, 6, 611, 17, 68, 47, 8, 93, 345, 23, 69, 123]",922.0,16015505,43
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.,Leukemia & lymphoma,Leuk. Lymphoma,2005-07-01,One hundred and ten patients with Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML) post-interferon-a failure treated with imatinib mesylate therapy were analyzed for the prognostic significance of marrow reticulin stain-measured fibrosis. The median time from diagnosis was 31 months. Severe reticulin (grade 3 - 4) fibrosis was observed in 67 patients (61%). Patients with severe marrow fibrosis had similar complete cytogenetic response rates with imatinib (67 vs. 58%; P = 0.45) compared with those with mild?-?moderate fibrosis. The estimated 4 year survival rates (80 vs. 88%; P = 0.27) and failure-free survival rates (69 vs. 77%; P = 0.34) were also not different. We conclude that the previously established poor prognostic significance of marrow fibrosis in CML is less relevant with imatinib therapy.,Journal Article,5317.0,19.0,One hundred and ten patients with Philadelphia chromosome Ph -positive chronic phase chronic myelogenous CML post-interferon-a failure treated with imatinib mesylate therapy were analyzed for the prognostic significance of marrow reticulin stain-measured fibrosis The median time from diagnosis was 31 months Severe reticulin grade 3 4 fibrosis was observed in 67 patients 61 Patients with severe marrow fibrosis had similar complete cytogenetic response rates with imatinib 67 vs. 58 P 0.45 compared with those with mild moderate fibrosis The estimated 4 year survival rates 80 vs. 88 P 0.27 and failure-free survival rates 69 vs. 77 P 0.34 were also not different We conclude that the previously established poor prognostic significance of marrow fibrosis in CML is less relevant with imatinib therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[104, 1128, 2, 1618, 7, 5, 3006, 1170, 2058, 109, 442, 124, 442, 2194, 903, 539, 1688, 8, 496, 73, 5, 577, 2347, 36, 11, 311, 9, 3, 177, 724, 1, 581, 19464, 8763, 644, 3000, 3, 52, 98, 29, 147, 10, 456, 53, 905, 19464, 88, 27, 39, 3000, 10, 164, 4, 598, 7, 713, 7, 5, 905, 581, 3000, 42, 288, 236, 1266, 51, 151, 5, 577, 598, 105, 717, 19, 13, 512, 72, 5, 135, 5, 1980, 1163, 3000, 3, 661, 39, 111, 25, 151, 493, 105, 889, 19, 13, 428, 2, 496, 115, 25, 151, 790, 105, 849, 19, 13, 562, 11, 120, 44, 338, 21, 2060, 17, 3, 373, 635, 334, 177, 724, 1, 581, 3000, 4, 903, 16, 299, 867, 5, 577, 36]",803.0,16019549,247
"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.",Blood,Blood,2005-07-21,"An activating 1849G>T mutation of JAK2 (Janus kinase 2) tyrosine kinase was recently described in chronic myeloproliferative disorders (MPDs). Its role in other hematologic neoplasms is unclear. We developed a quantitative pyrosequencing assay and analyzed 374 samples of hematologic neoplasms. The mutation was frequent in polycythemia vera (PV) (86%) and myelofibrosis (95%) but less prevalent in acute myeloid leukemia (AML) with an antecedent PV or myelofibrosis (5 [36%] of 14 patients). JAK2 mutation was also detected in 3 (19%) of 16 patients with Philadelphia-chromosome (Ph)-negative chronic myelogenous leukemia (CML), 2 (18%) of 11 patients with megakaryocytic AML, 7 (13%) of 52 patients with chronic myelomonocytic leukemia, and 1 (1%) of 68 patients with myelodysplastic syndromes. No mutation was found in Ph(+)CML (99 patients), AML M0-M6 (28 patients), or acute lymphoblastic leukemia (20 patients). We conclude that the JAK2 1849G>T mutation is common in Ph(-) MPD but not critical for transformation to the acute phase of these diseases and that it is generally rare in aggressive leukemias.",Journal Article,5297.0,302.0,An activating 1849G T mutation of JAK2 Janus kinase 2 tyrosine kinase was recently described in chronic disorders MPDs Its role in other hematologic neoplasms is unclear We developed a quantitative pyrosequencing assay and analyzed 374 samples of hematologic neoplasms The mutation was frequent in polycythemia vera PV 86 and myelofibrosis 95 but less prevalent in acute myeloid AML with an antecedent PV or myelofibrosis 5 36 of 14 patients JAK2 mutation was also detected in 3 19 of 16 patients with Philadelphia-chromosome Ph -negative chronic myelogenous CML 2 18 of 11 patients with megakaryocytic AML 7 13 of 52 patients with chronic myelomonocytic and 1 1 of 68 patients with syndromes No mutation was found in Ph CML 99 patients AML M0-M6 28 patients or acute lymphoblastic 20 patients We conclude that the JAK2 1849G T mutation is common in Ph MPD but not critical for transformation to the acute phase of these diseases and that it is generally rare in aggressive leukemias,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[35, 1616, 44054, 102, 258, 1, 2509, 6191, 216, 18, 564, 216, 10, 761, 1027, 4, 442, 1997, 24840, 211, 200, 4, 127, 813, 1179, 16, 1200, 21, 276, 8, 1156, 6031, 719, 2, 311, 10349, 347, 1, 813, 1179, 3, 258, 10, 908, 4, 5755, 5756, 3328, 868, 2, 4637, 48, 84, 299, 2485, 4, 286, 533, 329, 5, 35, 8775, 3328, 15, 4637, 33, 511, 1, 213, 7, 2509, 258, 10, 120, 530, 4, 27, 326, 1, 245, 7, 5, 3006, 1170, 2058, 199, 442, 2194, 903, 18, 203, 1, 175, 7, 5, 14385, 329, 67, 233, 1, 653, 7, 5, 442, 5451, 2, 14, 14, 1, 806, 7, 5, 2040, 77, 258, 10, 204, 4, 2058, 903, 1058, 7, 329, 4591, 30814, 339, 7, 15, 286, 1275, 179, 7, 21, 2060, 17, 3, 2509, 44054, 102, 258, 16, 186, 4, 2058, 7712, 84, 44, 740, 9, 1392, 6, 3, 286, 124, 1, 46, 1342, 2, 17, 192, 16, 1228, 622, 4, 571, 2792]",983.0,16037387,2
"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.",Blood,Blood,2005-08-04,"Activating mutations in tyrosine kinases have been identified in hematopoietic and nonhematopoietic malignancies. Recently, we and others identified a single recurrent somatic activating mutation (JAK2V617F) in the Janus kinase 2 (JAK2) tyrosine kinase in the myeloproliferative disorders (MPDs) polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. We used direct sequence analysis to determine if the JAK2V617F mutation was present in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML)/atypical chronic myelogenous leukemia (aCML), myelodysplastic syndrome (MDS), B-lineage acute lymphoblastic leukemia (ALL), T-cell ALL, and chronic lymphocytic leukemia (CLL). Analysis of 222 patients with AML identified JAK2V617F mutations in 4 patients with AML, 3 of whom had a preceding MPD. JAK2V617F mutations were identified in 9 (7.8%) of 116 CMML/a CML samples, and in 2 (4.2%) of 48 MDS samples. We did not identify the JAK2V617F disease allele in B-lineage ALL (n = 83), T-cell ALL (n = 93), or CLL (n = 45). These data indicate that the JAK2V617F allele is present in acute and chronic myeloid malignancies but not in lymphoid malignancies.",Clinical Trial,5283.0,292.0,Activating mutations in tyrosine kinases have been identified in hematopoietic and nonhematopoietic malignancies Recently we and others identified a single recurrent somatic activating mutation JAK2V617F in the Janus kinase 2 JAK2 tyrosine kinase in the disorders MPDs polycythemia vera essential thrombocythemia and myeloid metaplasia with myelofibrosis We used direct sequence analysis to determine if the JAK2V617F mutation was present in acute myeloid AML chronic myelomonocytic CMML /atypical chronic myelogenous aCML syndrome MDS B-lineage acute lymphoblastic ALL T-cell ALL and chronic lymphocytic CLL Analysis of 222 patients with AML identified JAK2V617F mutations in 4 patients with AML 3 of whom had a preceding MPD JAK2V617F mutations were identified in 9 7.8 of 116 CMML/a CML samples and in 2 4.2 of 48 MDS samples We did not identify the JAK2V617F disease allele in B-lineage ALL n 83 T-cell ALL n 93 or CLL n 45 These data indicate that the JAK2V617F allele is present in acute and chronic myeloid malignancies but not in lymphoid malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[1616, 138, 4, 564, 1549, 47, 85, 108, 4, 1007, 2, 19463, 441, 761, 21, 2, 1749, 108, 8, 226, 387, 1119, 1616, 258, 9061, 4, 3, 6191, 216, 18, 2509, 564, 216, 4, 3, 1997, 24840, 5755, 5756, 1452, 8962, 2, 533, 6054, 5, 4637, 21, 95, 1196, 1532, 65, 6, 223, 492, 3, 9061, 258, 10, 364, 4, 286, 533, 329, 442, 5451, 3382, 1973, 442, 2194, 21345, 681, 1223, 132, 2542, 286, 1275, 62, 102, 31, 62, 2, 442, 1193, 552, 65, 1, 5647, 7, 5, 329, 108, 9061, 138, 4, 39, 7, 5, 329, 27, 1, 953, 42, 8, 5892, 7712, 9061, 138, 11, 108, 4, 83, 67, 66, 1, 3790, 3382, 8, 903, 347, 2, 4, 18, 39, 18, 1, 576, 1223, 347, 21, 205, 44, 255, 3, 9061, 34, 1254, 4, 132, 2542, 62, 78, 852, 102, 31, 62, 78, 966, 15, 552, 78, 512, 46, 74, 1008, 17, 3, 9061, 1254, 16, 364, 4, 286, 2, 442, 533, 441, 84, 44, 4, 2303, 441]",1059.0,16081687,3
Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation.,Blood,Blood,2005-10-20,"Granulocyte colony-stimulating factor (G-CSF) is often administered after hematopoietic-cell transplantation (HCT) to accelerate neutrophil recovery, but it is unclear what impact G-CSF has on long-term transplantation outcomes. We analyzed within the database of the Center for International Blood and Marrow Transplant Research the impact of giving posttransplantation G-CSF on the outcomes of allogeneic HCT for acute myelogenous leukemia and chronic myelogenous leukemia in 2719 patients who underwent transplantation between 1995 and 2000. These included 1435 recipients of HLA-identical sibling bone marrow (BM), 609 recipients of HLA-identical peripheral-blood stem cells (PBSCs), and 675 recipients of unrelated donor BM transplants. Outcomes were compared between patients receiving or not receiving G-CSF within 7 days of HCT according to graft type. Median follow-up was more than 30 months (range, 2-87 months). G-CSF shortened the posttransplantation neutropenic period, but did not affect days +30 and +100 treatment-related mortality (TRM). Probabilities of acute and chronic graft-versus-host disease (GVHD), leukemia-free survival (LFS), and overall survival were similar whether or not G-CSF was given. Multivariate analyses confirmed that giving G-CSF did not affect the risk of GVHD, TRM, LFS, or survival. In conclusion, results of this study found no long-term benefit or disadvantage of giving G-CSF after transplantation to promote hematopoietic recovery.",Journal Article,5206.0,60.0,Granulocyte colony-stimulating factor G-CSF is often administered after hematopoietic-cell transplantation HCT to accelerate neutrophil recovery but it is unclear what impact G-CSF has on long-term transplantation outcomes We analyzed within the database of the Center for International Blood and Marrow Transplant Research the impact of giving posttransplantation G-CSF on the outcomes of allogeneic HCT for acute myelogenous and chronic myelogenous in 2719 patients who underwent transplantation between 1995 and 2000 These included 1435 recipients of HLA-identical sibling marrow BM 609 recipients of HLA-identical peripheral-blood stem cells PBSCs and 675 recipients of unrelated donor BM transplants Outcomes were compared between patients receiving or not receiving G-CSF within 7 days of HCT according to graft type Median follow-up was more than 30 months range 2-87 months G-CSF shortened the posttransplantation neutropenic period but did not affect days +30 and +100 treatment-related mortality TRM Probabilities of acute and chronic graft-versus-host disease GVHD leukemia-free survival LFS and overall survival were similar whether or not G-CSF was given Multivariate analyses confirmed that giving G-CSF did not affect the risk of GVHD TRM LFS or survival In conclusion results of this study found no long-term benefit or disadvantage of giving G-CSF after transplantation to promote hematopoietic recovery,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2764, 1975, 2122, 161, 499, 1211, 16, 629, 468, 50, 1007, 31, 497, 1085, 6, 5792, 2595, 1602, 84, 192, 16, 1200, 2067, 345, 499, 1211, 71, 23, 319, 337, 497, 123, 21, 311, 262, 3, 609, 1, 3, 574, 9, 944, 315, 2, 581, 941, 389, 3, 345, 1, 7375, 8046, 499, 1211, 23, 3, 123, 1, 1063, 1085, 9, 286, 2194, 2, 442, 2194, 4, 44136, 7, 54, 208, 497, 59, 2323, 2, 1081, 46, 159, 30862, 2190, 1, 1160, 3038, 3684, 581, 1246, 11954, 2190, 1, 1160, 3038, 672, 315, 452, 37, 13620, 2, 9908, 2190, 1, 2092, 1488, 1246, 4016, 123, 11, 72, 59, 7, 357, 15, 44, 357, 499, 1211, 262, 67, 162, 1, 1085, 768, 6, 1599, 267, 52, 166, 126, 10, 80, 76, 201, 53, 184, 18, 912, 53, 499, 1211, 6151, 3, 8046, 3659, 727, 84, 205, 44, 1158, 162, 201, 2, 394, 24, 139, 282, 5064, 3518, 1, 286, 2, 442, 1599, 185, 1204, 34, 1562, 2647, 115, 25, 5674, 2, 63, 25, 11, 288, 317, 15, 44, 499, 1211, 10, 447, 331, 318, 557, 17, 7375, 499, 1211, 205, 44, 1158, 3, 43, 1, 1562, 5064, 5674, 15, 25, 4, 1221, 99, 1, 26, 45, 204, 77, 319, 337, 247, 15, 14144, 1, 7375, 499, 1211, 50, 497, 6, 1617, 1007, 1602]",1420.0,16239431,227
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.,Blood,Blood,2005-11-15,"The BCR/ABL kinase has been targeted for the treatment of chronic myelogenous leukemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML and Ph+ acute lymphoblastic leukemia (ALL) are often resistant. In particular, mutation of the T315 residue in the bcr/abl activation loop renders cells highly resistant to imatinib and to second-generation kinase inhibitors such as BMS-354825 or AMN107. Adaphostin is a tyrphostin that was originally intended to inhibit the BCR/ABL kinase by competing with its peptide substrates. Recent findings have in addition implicated reactive oxygen species (ROS) in the cytotoxic mechanism of adaphostin. In view of this unique mode of action, we examined the effects of adaphostin on numerous imatinib-resistant leukemia models, including imatinib-resistant CML and Ph+ ALL cell lines, cells harboring point mutations in BCR/ABL, and specimens from imatinib-resistant CML patients, using assays for intracellular ROS, apoptosis, and clonogenicity. Every model of imatinib resistance examined remained fully sensitive to adaphostin-induced cell death. Collectively, these data suggest that ROS generation by adaphostin overcomes even the most potent imatinib resistance in CML and Ph+ ALL.",Journal Article,5180.0,58.0,The BCR/ABL kinase has been targeted for the treatment of chronic myelogenous CML by imatinib mesylate While imatinib has been extremely effective for chronic phase CML blast crisis CML and Ph+ acute lymphoblastic ALL are often resistant In particular mutation of the T315 residue in the bcr/abl activation loop renders cells highly resistant to imatinib and to second-generation kinase inhibitors such as BMS-354825 or AMN107 Adaphostin is a tyrphostin that was originally intended to inhibit the BCR/ABL kinase by competing with its peptide substrates Recent findings have in addition implicated reactive oxygen species ROS in the cytotoxic mechanism of adaphostin In view of this unique mode of action we examined the effects of adaphostin on numerous imatinib-resistant models including imatinib-resistant CML and Ph+ ALL cell lines cells harboring point mutations in BCR/ABL and specimens from imatinib-resistant CML patients using assays for intracellular ROS apoptosis and clonogenicity Every model of imatinib resistance examined remained fully sensitive to adaphostin-induced cell death Collectively these data suggest that ROS generation by adaphostin overcomes even the most potent imatinib resistance in CML and Ph+ ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1062, 1425, 216, 71, 85, 238, 9, 3, 24, 1, 442, 2194, 903, 20, 577, 2347, 369, 577, 71, 85, 2938, 323, 9, 442, 124, 903, 3112, 6540, 903, 2, 2058, 286, 1275, 62, 32, 629, 436, 4, 1454, 258, 1, 3, 21359, 7840, 4, 3, 1062, 1425, 363, 4432, 8080, 37, 561, 436, 6, 577, 2, 6, 419, 914, 216, 222, 225, 22, 3502, 23350, 15, 12189, 10028, 16, 8, 25963, 17, 10, 5045, 4081, 6, 1433, 3, 1062, 1425, 216, 20, 2573, 5, 211, 1389, 6063, 435, 272, 47, 4, 352, 1771, 2163, 2848, 2915, 2609, 4, 3, 759, 670, 1, 10028, 4, 3811, 1, 26, 991, 4530, 1, 1578, 21, 409, 3, 176, 1, 10028, 23, 2331, 577, 436, 274, 141, 577, 436, 903, 2, 2058, 62, 31, 285, 37, 2105, 741, 138, 4, 1062, 1425, 2, 623, 29, 577, 436, 903, 7, 75, 1013, 9, 2087, 2609, 351, 2, 9880, 454, 202, 1, 577, 251, 409, 958, 1910, 745, 6, 10028, 277, 31, 273, 2535, 46, 74, 309, 17, 2609, 914, 20, 10028, 8510, 871, 3, 96, 1157, 577, 251, 4, 903, 2, 2058, 62]",1231.0,16291594,202
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.,Current molecular medicine,Curr. Mol. Med.,2005-11-01,"Imatinib mesylate is a major advance in the therapy of patients with chronic myelogenous leukemia (CML). Imatinib mesylate binds to the inactive conformation of BCR-ABL tyrosine kinase suppressing the Philadelphia chromosome positive clone in CML. Clinical studies have yielded impressive results in all phases of CML. With higher rates of complete cytogenetic response with imatinib, molecular monitoring of disease is now advisable in assessing response and determining prognosis. Emergence of resistance to imatinib may be manifest at the hematologic, cytogenetic, or molecular levels in patients who remain in chronic phase, or may be evidenced by the development of more advanced CML phases. Resistance and eventual clinical failure of imatinib occurs in most patients with blastic phase disease. Resistance may occur at the level of Bcr-Abl, with reduction or loss of imatinib effectiveness as a kinase inhibitor, or, despite retention of its inhibitory ability, with changes in the ability to deliver an effective dose at the cellular level, and/or, the leukemia becoming less dependent on Bcr-Abl. The various mechanisms underlying these differing, non-mutually exclusive, mechanisms of resistance must be understood to develop corresponding therapeutic remedies. We review the current data on imatinib in CML, the criteria for diagnosis of imatinib resistance, and the mechanisms that underlie such resistance in CML.",Journal Article,5194.0,30.0,Imatinib mesylate is a major advance in the therapy of patients with chronic myelogenous CML Imatinib mesylate binds to the inactive conformation of BCR-ABL tyrosine kinase suppressing the Philadelphia chromosome positive clone in CML Clinical studies have yielded impressive results in all phases of CML With higher rates of complete cytogenetic response with imatinib molecular monitoring of disease is now advisable in assessing response and determining prognosis Emergence of resistance to imatinib may be manifest at the hematologic cytogenetic or molecular levels in patients who remain in chronic phase or may be evidenced by the development of more advanced CML phases Resistance and eventual clinical failure of imatinib occurs in most patients with blastic phase disease Resistance may occur at the level of Bcr-Abl with reduction or loss of imatinib effectiveness as a kinase inhibitor or despite retention of its inhibitory ability with changes in the ability to deliver an effective dose at the cellular level and/or the becoming less dependent on Bcr-Abl The various mechanisms underlying these differing non-mutually exclusive mechanisms of resistance must be understood to develop corresponding therapeutic remedies We review the current data on imatinib in CML the criteria for diagnosis of imatinib resistance and the mechanisms that underlie such resistance in CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 2347, 16, 8, 458, 3148, 4, 3, 36, 1, 7, 5, 442, 2194, 903, 577, 2347, 3333, 6, 3, 5002, 7788, 1, 1062, 1425, 564, 216, 4669, 3, 3006, 1170, 109, 3910, 4, 903, 38, 94, 47, 2178, 5790, 99, 4, 62, 3523, 1, 903, 5, 142, 151, 1, 236, 1266, 51, 5, 577, 219, 1315, 1, 34, 16, 1134, 19443, 4, 1977, 51, 2, 2196, 356, 3397, 1, 251, 6, 577, 68, 40, 7633, 28, 3, 813, 1266, 15, 219, 148, 4, 7, 54, 918, 4, 442, 124, 15, 68, 40, 4728, 20, 3, 193, 1, 80, 131, 903, 3523, 251, 2, 6956, 38, 496, 1, 577, 1780, 4, 96, 7, 5, 6529, 124, 34, 251, 68, 1271, 28, 3, 301, 1, 1062, 1425, 5, 628, 15, 407, 1, 577, 1236, 22, 8, 216, 230, 15, 550, 3947, 1, 211, 1810, 801, 5, 400, 4, 3, 801, 6, 3392, 35, 323, 61, 28, 3, 763, 301, 2, 15, 3, 4009, 299, 470, 23, 1062, 1425, 3, 747, 483, 1181, 46, 5276, 220, 5575, 4804, 483, 1, 251, 1642, 40, 1784, 6, 690, 1734, 189, 25973, 21, 206, 3, 291, 74, 23, 577, 4, 903, 3, 371, 9, 147, 1, 577, 251, 2, 3, 483, 17, 5875, 225, 251, 4, 903]",1383.0,16305488,56
"Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.",Cancer,Cancer,2006-01-01,"Lonafarnib (SCH66336) is a nonpeptidomimetic farnesyl transferase inhibitor that has demonstrated significant preclinical activity against chronic myelogenous leukemia (CML) cells and in CML animal models. In the current study, the efficacy of lonafarnib was investigated in patients with CML in the chronic or accelerated phase that was resistant or intolerant to imatinib. Thirteen patients with CML in the chronic (n = 6 patients) or accelerated (n = 7 patients) phase were treated with lonafarnib at a dose of 200 mg orally twice daily. Ten patients had failed therapy with imatinib and 3 patients were intolerant to imatinib. The median age of the patients was 62 years (range, 38-80 yrs) and the median time from the diagnosis of CML to therapy with lonafarnib was 5 years (range, 0.3-13 yrs). In addition to imatinib mesylate, all patients had received prior therapy with interferon-alpha and seven patients had received other treatments. The median duration of therapy with lonafarnib was 8 weeks (range, 2-41 wks). Two patients responded. One patient in the accelerated phase of CML returned to the chronic phase, a response that lasted for 3 months. Another patient with chronic phase disease had lowering of the leukocyte count without the need for hydroxyurea and normalization of the differential count that lasted for 5 months. The most common adverse event was diarrhea, which was noted in 11 patients (84%) (Grade > or = 3 in 4 patients; 31%; toxicity was graded according to the National Cancer Institute Common Toxicity Criteria [version 2.0]). Therapy was discontinued in one patient because of diarrhea not responding to dose adjustments. Single-agent lonafarnib appears to have clinical activity in a small proportion of patients with CML refractory to imatinib.",Clinical Trial,5133.0,54.0,Lonafarnib SCH66336 is a nonpeptidomimetic farnesyl transferase inhibitor that has demonstrated significant preclinical activity against chronic myelogenous CML cells and in CML animal models In the current study the efficacy of lonafarnib was investigated in patients with CML in the chronic or accelerated phase that was resistant or intolerant to imatinib Thirteen patients with CML in the chronic n 6 patients or accelerated n 7 patients phase were treated with lonafarnib at a dose of 200 mg orally twice daily Ten patients had failed therapy with imatinib and 3 patients were intolerant to imatinib The median age of the patients was 62 years range 38-80 yrs and the median time from the diagnosis of CML to therapy with lonafarnib was 5 years range 0.3-13 yrs In addition to imatinib mesylate all patients had received prior therapy with interferon-alpha and seven patients had received other treatments The median duration of therapy with lonafarnib was 8 weeks range 2-41 wks Two patients responded One patient in the accelerated phase of CML returned to the chronic phase a response that lasted for 3 months Another patient with chronic phase disease had lowering of the leukocyte count without the need for hydroxyurea and normalization of the differential count that lasted for 5 months The most common adverse event was diarrhea which was noted in 11 patients 84 Grade or 3 in 4 patients 31 toxicity was graded according to the National Cancer Institute Common Toxicity Criteria version 2.0 Therapy was discontinued in one patient because of diarrhea not responding to dose adjustments Single-agent lonafarnib appears to have clinical activity in a small proportion of patients with CML refractory to imatinib,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[9388, 16022, 16, 8, 33400, 8846, 4402, 230, 17, 71, 264, 93, 693, 128, 480, 442, 2194, 903, 37, 2, 4, 903, 2026, 274, 4, 3, 291, 45, 3, 209, 1, 9388, 10, 565, 4, 7, 5, 903, 4, 3, 442, 15, 2241, 124, 17, 10, 436, 15, 4944, 6, 577, 3170, 7, 5, 903, 4, 3, 442, 78, 49, 7, 15, 2241, 78, 67, 7, 124, 11, 73, 5, 9388, 28, 8, 61, 1, 1250, 81, 1428, 936, 391, 1618, 7, 42, 1551, 36, 5, 577, 2, 27, 7, 11, 4944, 6, 577, 3, 52, 89, 1, 3, 7, 10, 744, 60, 184, 519, 493, 10345, 2, 3, 52, 98, 29, 3, 147, 1, 903, 6, 36, 5, 9388, 10, 33, 60, 184, 13, 27, 233, 10345, 4, 352, 6, 577, 2347, 62, 7, 42, 103, 324, 36, 5, 1688, 950, 2, 648, 7, 42, 103, 127, 640, 3, 52, 654, 1, 36, 5, 9388, 10, 66, 244, 184, 18, 605, 16820, 100, 7, 2211, 104, 69, 4, 3, 2241, 124, 1, 903, 5157, 6, 3, 442, 124, 8, 51, 17, 6854, 9, 27, 53, 1809, 69, 5, 442, 124, 34, 42, 8326, 1, 3, 3627, 1276, 187, 3, 594, 9, 5902, 2, 5924, 1, 3, 1777, 1276, 17, 6854, 9, 33, 53, 3, 96, 186, 290, 774, 10, 1172, 92, 10, 1051, 4, 175, 7, 874, 88, 15, 27, 4, 39, 7, 456, 155, 10, 3468, 768, 6, 3, 657, 12, 1377, 186, 155, 371, 2256, 18, 13, 36, 10, 2402, 4, 104, 69, 408, 1, 1172, 44, 3261, 6, 61, 6017, 226, 420, 9388, 1233, 6, 47, 38, 128, 4, 8, 302, 920, 1, 7, 5, 903, 430, 6, 577]",1722.0,16342165,33
Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts.,"Diagnostic molecular pathology : the American journal of surgical pathology, part B",Diagn. Mol. Pathol.,2006-03-01,"Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder that is characterized by the presence of a reciprocal translocation between chromosomes 9 and 22 and results in the formation of the Philadelphia (Ph1) chromosome and is present in most of CML patients. The Ph1 chromosome forms a chimeric gene that encodes an abnormal P210 mRNA transcript in most CML patients. Surveillance for minimal residual disease by detection of BCR/ABL transcripts is currently done mostly by quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR). Quantitation of BCR/ABL transcripts can monitor tumor load and the outcome of therapy. Absolute quantification determines the input copy number of the transcript of interest, usually by plotting the amount of PCR product onto a standard curve based on serial dilutions of the same product cloned in plasmids. Relative quantification describes the change in expression of the target gene in the patient sample relative to that of a control transcript by using the 2-DeltaDeltaCt calculation. The results of real-time RT-PCR for BCR/ABL transcripts are often analyzed by using plasmid DNA standard curves. In the present study, 79 BCR/ABL transcript-positive samples from CML patients who were being monitored for minimal residual disease by real-time quantitative RT-PCR were studied to determine whether the 2-DeltaDeltaCt approach was equivalent to the plasmid standard curve method. BCR/ABL P210 transcripts were quantitated using both the plasmid standard curve method and the 2-DeltaDeltaCt calculation. The comparison of both methods revealed a highly significant and linear correlation between the plasmid standard curve method and the 2-DeltaDeltaCt calculation (R2=0.98, P<0.0001). Furthermore, there was a reduction of preparation time, contamination risk, and reagent usage. The 2-DeltaDeltaCt calculation is a convenient alternative method to derive accurate quantitative information from real time PCR assays.",Journal Article,5074.0,193.0,Chronic myelogenous CML is a clonal disorder that is characterized by the presence of a reciprocal translocation between chromosomes 9 and 22 and results in the formation of the Philadelphia Ph1 chromosome and is present in most of CML patients The Ph1 chromosome forms a chimeric gene that encodes an abnormal P210 mRNA transcript in most CML patients Surveillance for minimal residual disease by detection of BCR/ABL transcripts is currently done mostly by quantitative real-time reverse transcriptase polymerase chain reaction RT-PCR Quantitation of BCR/ABL transcripts can monitor tumor load and the outcome of therapy Absolute quantification determines the input copy number of the transcript of interest usually by plotting the amount of PCR product onto a standard curve based on serial dilutions of the same product cloned in plasmids Relative quantification describes the change in expression of the target gene in the patient sample relative to that of a control transcript by using the 2-DeltaDeltaCt calculation The results of real-time RT-PCR for BCR/ABL transcripts are often analyzed by using plasmid DNA standard curves In the present study 79 BCR/ABL transcript-positive samples from CML patients who were being monitored for minimal residual disease by real-time quantitative RT-PCR were studied to determine whether the 2-DeltaDeltaCt approach was equivalent to the plasmid standard curve method BCR/ABL P210 transcripts were quantitated using both the plasmid standard curve method and the 2-DeltaDeltaCt calculation The comparison of both methods revealed a highly significant and linear correlation between the plasmid standard curve method and the 2-DeltaDeltaCt calculation R2=0.98 P 0.0001 Furthermore there was a reduction of preparation time contamination risk and reagent usage The 2-DeltaDeltaCt calculation is a convenient alternative method to derive accurate quantitative information from real time PCR assays,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 16, 8, 1946, 2645, 17, 16, 765, 20, 3, 463, 1, 8, 8020, 2006, 59, 3560, 83, 2, 350, 2, 99, 4, 3, 1264, 1, 3, 3006, 21381, 1170, 2, 16, 364, 4, 96, 1, 903, 7, 3, 21381, 1170, 2377, 8, 2897, 145, 17, 4322, 35, 1668, 11538, 956, 3268, 4, 96, 903, 7, 617, 9, 1048, 753, 34, 20, 638, 1, 1062, 1425, 2680, 16, 694, 1822, 2754, 20, 1156, 1589, 98, 1772, 4456, 1451, 1260, 1329, 240, 604, 7887, 1, 1062, 1425, 2680, 122, 3334, 30, 3800, 2, 3, 228, 1, 36, 1766, 4752, 9476, 3, 5772, 1337, 207, 1, 3, 3268, 1, 1333, 2082, 20, 38128, 3, 3108, 1, 604, 2821, 3301, 8, 260, 1496, 90, 23, 2108, 17686, 1, 3, 827, 2821, 8560, 4, 12473, 580, 4752, 2677, 3, 707, 4, 55, 1, 3, 283, 145, 4, 3, 69, 1000, 580, 6, 17, 1, 8, 182, 3268, 20, 75, 3, 18, 24434, 6333, 3, 99, 1, 1589, 98, 240, 604, 9, 1062, 1425, 2680, 32, 629, 311, 20, 75, 6007, 261, 260, 2400, 4, 3, 364, 45, 842, 1062, 1425, 3268, 109, 347, 29, 903, 7, 54, 11, 486, 2909, 9, 1048, 753, 34, 20, 1589, 98, 1156, 240, 604, 11, 656, 6, 223, 317, 3, 18, 24434, 353, 10, 2017, 6, 3, 6007, 260, 1496, 596, 1062, 1425, 11538, 2680, 11, 11773, 75, 110, 3, 6007, 260, 1496, 596, 2, 3, 18, 24434, 6333, 3, 1155, 1, 110, 636, 553, 8, 561, 93, 2, 1646, 816, 59, 3, 6007, 260, 1496, 596, 2, 3, 18, 24434, 6333, 4332, 13, 1096, 19, 13, 488, 798, 125, 10, 8, 628, 1, 4824, 98, 9866, 43, 2, 10989, 5015, 3, 18, 24434, 6333, 16, 8, 7048, 1091, 596, 6, 3823, 1481, 1156, 487, 29, 1589, 98, 604, 1013]",1941.0,16531770,150
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.,International journal of oncology,Int. J. Oncol.,2006-05-01,"Molecular monitoring of the BCR-ABL transcript in chronic myelogenous leukemia (CML) using quantitative RT-PCR provides clinicians with important diagnostic and prognostic information. To determine whether molecular detection and monitoring of CML is comparable using peripheral blood (PB) and bone marrow (BM) aspirate samples, we performed a prospective study using quantitative real-time RT-PCR (QRT-PCR) of paired PB and BM samples from 41 patients with CML entered onto a single Cancer and Leukemia Group B (CALGB) treatment study. QRT-PCR analysis of PB and BM samples was performed prior to initiation of, and during, treatment with homoharringtonine and cytarabine on a CALGB study for previously untreated CML. Statistical analyses demonstrated good agreement of PB and BM pre-treatment samples. However, using the Bland-Altman statistical method that measures true agreement between PB and BM values, we found that there was only modest agreement of BCR-ABL measurements in PB and BM for samples obtained during treatment. PB values obtained during treatment tended to be lower than the corresponding BM values [average difference = -0.37 (p<0.001) in 36 paired samples] and the 95% limits of agreement ranged from -1.23 to 0.48. Nevertheless, our study demonstrates that BM and PB QRT-PCR values followed a similar trend during treatment (Spearman correlation coefficient, 0.83; 95% CI, 0.70, 0.96). Our data suggest that, quantitatively, PB and BM measurements of BCR-ABL are frequently disparate. Since BM values tended to be higher than PB values, BM sampling provides the most accurate assessment of minimal residual disease (MRD). Based on these results, we caution against interchanging BM with PB sampling for MRD monitoring during treatment of CML since this may lead to misinterpretation of treatment results.",Journal Article,5013.0,23.0,Molecular monitoring of the BCR-ABL transcript in chronic myelogenous CML using quantitative RT-PCR provides clinicians with important diagnostic and prognostic information To determine whether molecular detection and monitoring of CML is comparable using peripheral blood PB and marrow BM aspirate samples we performed a prospective study using quantitative real-time RT-PCR QRT-PCR of paired PB and BM samples from 41 patients with CML entered onto a single Cancer and Group B CALGB treatment study QRT-PCR analysis of PB and BM samples was performed prior to initiation of and during treatment with homoharringtonine and cytarabine on a CALGB study for previously untreated CML Statistical analyses demonstrated good agreement of PB and BM pre-treatment samples However using the Bland-Altman statistical method that measures true agreement between PB and BM values we found that there was only modest agreement of BCR-ABL measurements in PB and BM for samples obtained during treatment PB values obtained during treatment tended to be lower than the corresponding BM values average difference -0.37 p 0.001 in 36 paired samples and the 95 limits of agreement ranged from -1.23 to 0.48 Nevertheless our study demonstrates that BM and PB QRT-PCR values followed a similar trend during treatment Spearman correlation coefficient 0.83 95 CI 0.70 0.96 Our data suggest that quantitatively PB and BM measurements of BCR-ABL are frequently disparate Since BM values tended to be higher than PB values BM sampling provides the most accurate assessment of minimal residual disease MRD Based on these results we caution against interchanging BM with PB sampling for MRD monitoring during treatment of CML since this may lead to misinterpretation of treatment results,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[219, 1315, 1, 3, 1062, 1425, 3268, 4, 442, 2194, 903, 75, 1156, 240, 604, 777, 1490, 5, 305, 752, 2, 177, 487, 6, 223, 317, 219, 638, 2, 1315, 1, 903, 16, 1279, 75, 672, 315, 3767, 2, 581, 1246, 8022, 347, 21, 173, 8, 482, 45, 75, 1156, 1589, 98, 240, 604, 5822, 604, 1, 2355, 3767, 2, 1246, 347, 29, 605, 7, 5, 903, 2836, 3301, 8, 226, 12, 2, 87, 132, 4077, 24, 45, 5822, 604, 65, 1, 3767, 2, 1246, 347, 10, 173, 324, 6, 1118, 1, 2, 190, 24, 5, 18768, 2, 1855, 23, 8, 4077, 45, 9, 373, 1278, 903, 1050, 318, 264, 1178, 2024, 1, 3767, 2, 1246, 671, 24, 347, 137, 75, 3, 11150, 15322, 1050, 596, 17, 1018, 2501, 2024, 59, 3767, 2, 1246, 1030, 21, 204, 17, 125, 10, 158, 1721, 2024, 1, 1062, 1425, 1685, 4, 3767, 2, 1246, 9, 347, 683, 190, 24, 3767, 1030, 683, 190, 24, 3886, 6, 40, 280, 76, 3, 1734, 1246, 1030, 1011, 523, 13, 567, 19, 13, 144, 4, 511, 2355, 347, 2, 3, 48, 3526, 1, 2024, 1869, 29, 14, 382, 6, 13, 576, 3873, 114, 45, 1902, 17, 1246, 2, 3767, 5822, 604, 1030, 370, 8, 288, 853, 190, 24, 5061, 816, 3200, 13, 852, 48, 58, 13, 431, 13, 921, 114, 74, 309, 17, 5889, 3767, 2, 1246, 1685, 1, 1062, 1425, 32, 746, 7985, 1192, 1246, 1030, 3886, 6, 40, 142, 76, 3767, 1030, 1246, 2874, 777, 3, 96, 1481, 455, 1, 1048, 753, 34, 2029, 90, 23, 46, 99, 21, 5526, 480, 55397, 1246, 5, 3767, 2874, 9, 2029, 1315, 190, 24, 1, 903, 1192, 26, 68, 1122, 6, 22357, 1, 24, 99]",1760.0,16596225,2
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.,Blood,Blood,2006-04-20,"In the multinational IRIS study comparing imatinib with interferon plus cytarabine (IFN/Ara-C) in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CP CML), imatinib demonstrated significantly higher rates of complete cytogenetic responses (CCyRs) and improved progression-free survival (PFS). However, because of a high early crossover rate to imatinib, survival benefit was not assessable. Here, we report the result of a study comparing long-term outcome of patients included in 2 prospective randomized trials: 551 patients assigned to imatinib in the IRIS trial from 2000 to 2001 and 325 patients who received the combination IFN/Ara-C in the CML91 trial between 1991 and 1996 before imatinib was available. With a follow-up of 42 months for both groups of patients, estimated CCyR, survival free of transformation, and overall survival were significantly higher with imatinib compared with IFN/Ara-C (P < .001, P = .004, and P < .001, respectively). Improved overall survival was also confirmed within different Sokal prognostic risk groups. Of interest, among all patients who achieved major cytogenetic response or CCyR at 12 months, the survival rate was similar irrespective of their treatment. In conclusion, within the limitation of this historical comparison, there is a survival advantage from first-line therapy with imatinib over IFN/Ara-C.",Comparative Study,5024.0,180.0,In the multinational IRIS study comparing imatinib with interferon plus cytarabine IFN/Ara-C in patients with newly diagnosed chronic-phase chronic myelogenous CP CML imatinib demonstrated significantly higher rates of complete cytogenetic responses CCyRs and improved progression-free survival PFS However because of a high early crossover rate to imatinib survival benefit was not assessable Here we report the result of a study comparing long-term outcome of patients included in 2 prospective randomized trials 551 patients assigned to imatinib in the IRIS trial from 2000 to 2001 and 325 patients who received the combination IFN/Ara-C in the CML91 trial between 1991 and 1996 before imatinib was available With a follow-up of 42 months for both groups of patients estimated CCyR survival free of transformation and overall survival were significantly higher with imatinib compared with IFN/Ara-C P .001 P .004 and P .001 respectively Improved overall survival was also confirmed within different Sokal prognostic risk groups Of interest among all patients who achieved major cytogenetic response or CCyR at 12 months the survival rate was similar irrespective of their treatment In conclusion within the limitation of this historical comparison there is a survival advantage from first-line therapy with imatinib over IFN/Ara-C,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 3, 8243, 15950, 45, 1430, 577, 5, 1688, 349, 1855, 1256, 3899, 256, 4, 7, 5, 732, 265, 442, 124, 442, 2194, 2541, 903, 577, 264, 97, 142, 151, 1, 236, 1266, 253, 55430, 2, 231, 91, 115, 25, 300, 137, 408, 1, 8, 64, 191, 5265, 116, 6, 577, 25, 247, 10, 44, 3120, 467, 21, 414, 3, 757, 1, 8, 45, 1430, 319, 337, 228, 1, 7, 159, 4, 18, 482, 384, 143, 11248, 7, 896, 6, 577, 4, 3, 15950, 160, 29, 1081, 6, 1758, 2, 7139, 7, 54, 103, 3, 150, 1256, 3899, 256, 4, 3, 55431, 160, 59, 3372, 2, 2648, 348, 577, 10, 390, 5, 8, 166, 126, 1, 595, 53, 9, 110, 271, 1, 7, 661, 6412, 25, 115, 1, 1392, 2, 63, 25, 11, 97, 142, 5, 577, 72, 5, 1256, 3899, 256, 19, 144, 19, 1520, 2, 19, 144, 106, 231, 63, 25, 10, 120, 557, 262, 338, 18354, 177, 43, 271, 1, 1333, 107, 62, 7, 54, 513, 458, 1266, 51, 15, 6412, 28, 133, 53, 3, 25, 116, 10, 288, 3500, 1, 136, 24, 4, 1221, 262, 3, 5039, 1, 26, 2252, 1155, 125, 16, 8, 25, 1874, 29, 157, 328, 36, 5, 577, 252, 1256, 3899, 256]",1333.0,16627756,45
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.,Blood,Blood,2006-04-27,"IL-2 plays a critical role in the maintenance of CD4+CD25+ FOXP3(+) regulatory T cells (Tregs) in vivo. We examined the effects of IL-2 signaling in human Tregs. In vitro, IL-2 selectively up-regulated the expression of FOXP3 in purified CD4+CD25+ T cells but not in CD4+CD25- cells. This regulation involved the binding of STAT3 and STAT5 proteins to a highly conserved STAT-binding site located in the first intron of the FOXP3 gene. We also examined the effects of low-dose IL-2 treatment in 12 patients with metastatic cancer and 9 patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation. Overall, IL-2 treatment resulted in a 1.9 median fold increase in the frequency of CD4+CD25+ cells in peripheral blood as well as a 9.7 median fold increase in FOXP3 expression in CD3+ T cells. CD56+CD3- natural killer (NK) cells also expanded during IL-2 therapy but did not express FOXP3. In vitro treatment of NK cells with 5-aza-2'-deoxycytidine restored the IL-2 signaling pathway leading to FOXP3 expression, suggesting that this gene was constitutively repressed by DNA methylation in these cells. Our findings support the clinical evaluation of low-dose IL-2 to selectively modulate CD4+CD25+ Tregs and increase expression of FOXP3 in vivo.",Journal Article,5017.0,463.0,IL-2 plays a critical role in the maintenance of CD4+CD25+ FOXP3 regulatory T cells Tregs in vivo We examined the effects of IL-2 signaling in human Tregs In vitro IL-2 selectively up-regulated the expression of FOXP3 in purified CD4+CD25+ T cells but not in CD4+CD25- cells This regulation involved the binding of STAT3 and STAT5 proteins to a highly conserved STAT-binding site located in the first intron of the FOXP3 gene We also examined the effects of low-dose IL-2 treatment in 12 patients with metastatic cancer and 9 patients with chronic myelogenous after allogeneic hematopoietic stem cell transplantation Overall IL-2 treatment resulted in a 1.9 median fold increase in the frequency of CD4+CD25+ cells in peripheral blood as well as a 9.7 median fold increase in FOXP3 expression in CD3+ T cells CD56+CD3- natural killer NK cells also expanded during IL-2 therapy but did not express FOXP3 In vitro treatment of NK cells with 5-aza-2'-deoxycytidine restored the IL-2 signaling pathway leading to FOXP3 expression suggesting that this gene was constitutively repressed by DNA methylation in these cells Our findings support the clinical evaluation of low-dose IL-2 to selectively modulate CD4+CD25+ Tregs and increase expression of FOXP3 in vivo,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[501, 18, 1698, 8, 740, 200, 4, 3, 1146, 1, 1440, 4531, 3548, 1253, 102, 37, 3975, 4, 386, 21, 409, 3, 176, 1, 501, 18, 314, 4, 171, 3975, 4, 439, 501, 18, 2382, 126, 1065, 3, 55, 1, 3548, 4, 5963, 1440, 4531, 102, 37, 84, 44, 4, 1440, 4531, 37, 26, 863, 646, 3, 791, 1, 1439, 2, 5517, 652, 6, 8, 561, 5547, 4168, 791, 606, 2308, 4, 3, 157, 6259, 1, 3, 3548, 145, 21, 120, 409, 3, 176, 1, 154, 61, 501, 18, 24, 4, 133, 7, 5, 113, 12, 2, 83, 7, 5, 442, 2194, 50, 1063, 1007, 452, 31, 497, 63, 501, 18, 24, 627, 4, 8, 14, 83, 52, 1116, 344, 4, 3, 675, 1, 1440, 4531, 37, 4, 672, 315, 22, 149, 22, 8, 83, 67, 52, 1116, 344, 4, 3548, 55, 4, 3117, 102, 37, 5803, 3117, 1504, 3458, 1765, 37, 120, 2064, 190, 501, 18, 36, 84, 205, 44, 1669, 3548, 4, 439, 24, 1, 1765, 37, 5, 33, 3924, 6135, 6750, 4138, 3, 501, 18, 314, 308, 1049, 6, 3548, 55, 802, 17, 26, 145, 10, 2818, 6654, 20, 261, 569, 4, 46, 37, 114, 272, 538, 3, 38, 451, 1, 154, 61, 501, 18, 6, 2382, 3319, 1440, 4531, 3975, 2, 344, 55, 1, 3548, 4, 386]",1257.0,16645171,84
Altered bone and mineral metabolism in patients receiving imatinib mesylate.,The New England journal of medicine,N. Engl. J. Med.,2006-05-01,"Imatinib mesylate inhibits several tyrosine kinases, including BCR-ABL, the C-KIT receptor, and the platelet-derived growth factor receptors alpha and beta, all of which are associated with disease. We observed that hypophosphatemia developed in some patients with either chronic myelogenous leukemia or gastrointestinal stromal tumors who were receiving imatinib. We identified 16 patients who had low serum phosphate levels and 8 patients who had normal serum phosphate levels, all of whom were receiving imatinib. We performed the following biochemical measurements: whole-blood levels of ionized calcium, plasma levels of intact parathyroid hormone, and serum levels of total calcium, phosphate, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, magnesium, and markers of bone formation (bone alkaline phosphatase and osteocalcin) and bone resorption (N-telopeptide of collagen cross-links); urinalysis; and phosphate, calcium, and creatinine levels in ""spot"" urine specimens. Patients in the low-phosphate group (median serum phosphate level, 2.0 mg per deciliter [0.6 mmol per liter]; normal level, >2.5 mg per deciliter [0.8 mmol per liter]) had elevated parathyroid hormone levels and low-to-normal serum calcium levels, were younger, and were receiving a higher dose of imatinib than patients in the normal-phosphate group (median level, 3.2 mg per deciliter [1.0 mmol per liter]). Both groups had high levels of phosphate excreted in the urine and markedly decreased serum levels of osteocalcin and N-telopeptide of collagen cross-links. Hypophosphatemia, with associated changes in bone and mineral metabolism, develops in a proportion of patients taking imatinib for either chronic myelogenous leukemia or gastrointestinal stromal tumors. The drug may inhibit bone remodeling (formation and resorption), even in patients with normal serum phosphate levels.",Journal Article,5013.0,217.0,"Imatinib mesylate inhibits several tyrosine kinases including BCR-ABL the C-KIT receptor and the platelet-derived growth factor receptors alpha and beta all of which are associated with disease We observed that hypophosphatemia developed in some patients with either chronic myelogenous or stromal tumors who were receiving imatinib We identified 16 patients who had low serum phosphate levels and 8 patients who had normal serum phosphate levels all of whom were receiving imatinib We performed the following biochemical measurements whole-blood levels of ionized calcium plasma levels of intact hormone and serum levels of total calcium phosphate 25-hydroxyvitamin D 1,25-dihydroxyvitamin D magnesium and markers of formation alkaline phosphatase and osteocalcin and resorption N-telopeptide of collagen cross-links urinalysis and phosphate calcium and creatinine levels in `` spot '' urine specimens Patients in the low-phosphate group median serum phosphate level 2.0 mg per deciliter 0.6 mmol per liter normal level 2.5 mg per deciliter 0.8 mmol per liter had elevated hormone levels and low-to-normal serum calcium levels were younger and were receiving a higher dose of imatinib than patients in the normal-phosphate group median level 3.2 mg per deciliter 1.0 mmol per liter Both groups had high levels of phosphate excreted in the urine and markedly decreased serum levels of osteocalcin and N-telopeptide of collagen cross-links Hypophosphatemia with associated changes in and mineral metabolism develops in a proportion of patients taking imatinib for either chronic myelogenous or stromal tumors The drug may inhibit remodeling formation and resorption even in patients with normal serum phosphate levels",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[577, 2347, 1576, 392, 564, 1549, 141, 1062, 1425, 3, 256, 1164, 153, 2, 3, 1596, 526, 129, 161, 1186, 950, 2, 1090, 62, 1, 92, 32, 41, 5, 34, 21, 164, 17, 8021, 276, 4, 476, 7, 5, 361, 442, 2194, 15, 1126, 57, 54, 11, 357, 577, 21, 108, 245, 7, 54, 42, 154, 524, 4849, 148, 2, 66, 7, 54, 42, 295, 524, 4849, 148, 62, 1, 953, 11, 357, 577, 21, 173, 3, 366, 1487, 1685, 902, 315, 148, 1, 44339, 3299, 554, 148, 1, 2964, 785, 2, 524, 148, 1, 181, 3299, 4849, 243, 9761, 427, 14, 243, 11430, 427, 8089, 2, 525, 1, 1264, 5355, 2577, 2, 15282, 2, 8143, 78, 9466, 1, 3945, 1383, 6491, 24923, 2, 4849, 3299, 2, 3177, 148, 4, 6901, 522, 2646, 623, 7, 4, 3, 154, 4849, 87, 52, 524, 4849, 301, 18, 13, 81, 379, 21949, 13, 49, 10645, 379, 15460, 295, 301, 18, 33, 81, 379, 21949, 13, 66, 10645, 379, 15460, 42, 804, 785, 148, 2, 154, 6, 295, 524, 3299, 148, 11, 773, 2, 11, 357, 8, 142, 61, 1, 577, 76, 7, 4, 3, 295, 4849, 87, 52, 301, 27, 18, 81, 379, 21949, 14, 13, 10645, 379, 15460, 110, 271, 42, 64, 148, 1, 4849, 14119, 4, 3, 2646, 2, 2195, 340, 524, 148, 1, 15282, 2, 78, 9466, 1, 3945, 1383, 6491, 8021, 5, 41, 400, 4, 2, 5033, 1600, 4734, 4, 8, 920, 1, 7, 2727, 577, 9, 361, 442, 2194, 15, 1126, 57, 3, 234, 68, 1433, 4429, 1264, 2, 8143, 871, 4, 7, 5, 295, 524, 4849, 148]",1716.0,16687713,19
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.,Cancer research,Cancer Res.,2006-05-01,"5-Aza-2'-deoxycytidine (decitabine) is postulated to have clinical activity in myeloid leukemias via its ability to inhibit DNA methylation. To study this, we examined DNA methylation in patients with leukemia treated with decitabine. Five days after the treatment, total genomic 5-methylcytosine/cytosine decreased on average by 14% (from 4.3% to 3.7%), whereas methylation of repetitive DNA elements showed a mean decrease of 9% and 16% for Alu and long interspersed nucleotide elements, respectively. Methylation decreased linearly with increasing doses between 5 and 20 mg/m(2)/d (r = 0.88; P = 0.05) but showed a plateau above that. Hypomethylation correlated with response in patients with acute myelogenous leukemia treated with low doses (5-20 mg/m(2)/d), but patients with chronic myelogenous leukemia treated with high doses (100-180 mg/m(2)/d) showed no such correlation. Aberrant methylation of p15 (>10%) was found in 27% of patients, and 80% of these showed a decrease by at least one third, but this did not correlate with response. The imprinted gene H19 showed little change in methylation after decitabine. In conclusion, we show dose-dependent hypomethylation after decitabine at low doses. Increasing the dose, which has been shown previously to result in a reduced response rate, was not accompanied by further hypomethylation.",Journal Article,5013.0,214.0,5-Aza-2'-deoxycytidine decitabine is postulated to have clinical activity in myeloid leukemias via its ability to inhibit DNA methylation To study this we examined DNA methylation in patients with treated with decitabine Five days after the treatment total genomic 5-methylcytosine/cytosine decreased on average by 14 from 4.3 to 3.7 whereas methylation of repetitive DNA elements showed a mean decrease of 9 and 16 for Alu and long interspersed nucleotide elements respectively Methylation decreased linearly with increasing doses between 5 and 20 mg/m 2 /d r 0.88 P 0.05 but showed a plateau above that Hypomethylation correlated with response in patients with acute myelogenous treated with low doses 5-20 mg/m 2 /d but patients with chronic myelogenous treated with high doses 100-180 mg/m 2 /d showed no such correlation Aberrant methylation of p15 10 was found in 27 of patients and 80 of these showed a decrease by at least one third but this did not correlate with response The imprinted gene H19 showed little change in methylation after decitabine In conclusion we show dose-dependent hypomethylation after decitabine at low doses Increasing the dose which has been shown previously to result in a reduced response rate was not accompanied by further hypomethylation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[33, 3924, 6135, 6750, 3004, 16, 6507, 6, 47, 38, 128, 4, 533, 2792, 847, 211, 801, 6, 1433, 261, 569, 6, 45, 26, 21, 409, 261, 569, 4, 7, 5, 73, 5, 3004, 365, 162, 50, 3, 24, 181, 572, 33, 14943, 6903, 340, 23, 1011, 20, 213, 29, 39, 27, 6, 27, 67, 547, 569, 1, 9246, 261, 2531, 224, 8, 313, 775, 1, 83, 2, 245, 9, 15265, 2, 319, 11038, 1579, 2531, 106, 569, 340, 9853, 5, 602, 415, 59, 33, 2, 179, 81, 188, 18, 427, 668, 13, 889, 19, 13, 474, 84, 224, 8, 6133, 2090, 17, 4441, 438, 5, 51, 4, 7, 5, 286, 2194, 73, 5, 154, 415, 33, 179, 81, 188, 18, 427, 84, 7, 5, 442, 2194, 73, 5, 64, 415, 394, 3172, 81, 188, 18, 427, 224, 77, 225, 816, 1898, 569, 1, 8840, 79, 10, 204, 4, 428, 1, 7, 2, 493, 1, 46, 224, 8, 775, 20, 28, 506, 104, 1282, 84, 26, 205, 44, 1513, 5, 51, 3, 9268, 145, 8947, 224, 1215, 707, 4, 569, 50, 3004, 4, 1221, 21, 514, 61, 470, 4441, 50, 3004, 28, 154, 415, 602, 3, 61, 92, 71, 85, 443, 373, 6, 757, 4, 8, 405, 51, 116, 10, 44, 2756, 20, 195, 4441]",1276.0,16707479,42
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.,Blood,Blood,2006-05-18,"A survival benefit for imatinib mesylate versus interferon-alpha therapy could not be demonstrated in the randomized study in newly diagnosed Philadelphia chromosome (Ph)-positive chronic-phase chronic myelogenous leukemia (CML) due to the high rate of crossover (90%) from interferon-alpha to imatinib mesylate within a year of study entry. We compared survival in 279 patients with newly diagnosed CML treated with imatinib mesylate at our institution (2000-2004) to 650 patients treated with interferon-alpha (1982-1997). The complete cytogenetic response rates were 87% with imatinib mesylate and 28% with interferon-alpha (P < .001). The estimated 3-year survival rates were 96% with imatinib mesylate and 81% with interferon-alpha (P < .01). Survival rates with imatinib mesylate were significantly better than with interferon-alpha within each of the CML prognostic risks groups. By multivariate analysis, imatinib mesylate therapy was identified as an independent favorable prognostic factor, after accounting for the impact of pretreatment factors (hazard ratio, 0.44; P < .01). By landmark analysis at 12 months, survival within each cytogenetic response category was similar with imatinib mesylate or interferon-alpha, suggesting that the survival benefit of imatinib mesylate (versus interferon-alpha in newly diagnosed CML) is through improving cytogenetic response.",Clinical Trial,4996.0,181.0,A survival benefit for imatinib mesylate versus interferon-alpha therapy could not be demonstrated in the randomized study in newly diagnosed Philadelphia chromosome Ph -positive chronic-phase chronic myelogenous CML due to the high rate of crossover 90 from interferon-alpha to imatinib mesylate within a year of study entry We compared survival in 279 patients with newly diagnosed CML treated with imatinib mesylate at our institution 2000-2004 to 650 patients treated with interferon-alpha 1982-1997 The complete cytogenetic response rates were 87 with imatinib mesylate and 28 with interferon-alpha P .001 The estimated 3-year survival rates were 96 with imatinib mesylate and 81 with interferon-alpha P .01 Survival rates with imatinib mesylate were significantly better than with interferon-alpha within each of the CML prognostic risks groups By multivariate analysis imatinib mesylate therapy was identified as an independent favorable prognostic factor after accounting for the impact of pretreatment factors hazard ratio 0.44 P .01 By landmark analysis at 12 months survival within each cytogenetic response category was similar with imatinib mesylate or interferon-alpha suggesting that the survival benefit of imatinib mesylate versus interferon-alpha in newly diagnosed CML is through improving cytogenetic response,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8, 25, 247, 9, 577, 2347, 185, 1688, 950, 36, 359, 44, 40, 264, 4, 3, 384, 45, 4, 732, 265, 3006, 1170, 2058, 109, 442, 124, 442, 2194, 903, 520, 6, 3, 64, 116, 1, 5265, 424, 29, 1688, 950, 6, 577, 2347, 262, 8, 111, 1, 45, 3001, 21, 72, 25, 4, 8562, 7, 5, 732, 265, 903, 73, 5, 577, 2347, 28, 114, 731, 1081, 1131, 6, 8642, 7, 73, 5, 1688, 950, 6652, 2341, 3, 236, 1266, 51, 151, 11, 912, 5, 577, 2347, 2, 339, 5, 1688, 950, 19, 144, 3, 661, 27, 111, 25, 151, 11, 921, 5, 577, 2347, 2, 865, 5, 1688, 950, 19, 355, 25, 151, 5, 577, 2347, 11, 97, 380, 76, 5, 1688, 950, 262, 296, 1, 3, 903, 177, 1098, 271, 20, 331, 65, 577, 2347, 36, 10, 108, 22, 35, 306, 913, 177, 161, 50, 3116, 9, 3, 345, 1, 1194, 130, 360, 197, 13, 584, 19, 355, 20, 3829, 65, 28, 133, 53, 25, 262, 296, 1266, 51, 2169, 10, 288, 5, 577, 2347, 15, 1688, 950, 802, 17, 3, 25, 247, 1, 577, 2347, 185, 1688, 950, 4, 732, 265, 903, 16, 298, 1673, 1266, 51]",1329.0,16709931,33
Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide.,The Journal of biological chemistry,J. Biol. Chem.,2006-06-08,"Arsenic trioxide (As2O3) is a potent inducer of apoptosis of leukemic cells in vitro and in vivo, but the precise mechanisms by which it mediates such effects are not well defined. We provide evidence that As2O3 induces activation of the mitogen- and stress-activated kinase 1 (MSK1) and downstream phosphorylation of its substrate, histone H3, in leukemia cell lines. Such activation requires upstream engagement of p38 MAPK, as demonstrated by experiments using pharmacological inhibitors of p38 or p38alpha knock-out cells. Arsenic-induced apoptosis was enhanced in cells in which MSK1 expression was decreased using small interfering RNA and in Msk1 knock-out mouse embryonic fibroblasts, suggesting that this kinase is activated in a negative feedback regulatory manner to regulate As2O3 responses. Consistent with this, pharmacological inhibition of MSK1 enhanced the suppressive effects of As2O3 on the growth of primary leukemic progenitors from chronic myelogenous leukemia patients. Altogether, these findings indicate an important role for MSK1 downstream of p38 in the regulation of As2O3 responses.",Journal Article,4975.0,45.0,Arsenic trioxide As2O3 is a potent inducer of apoptosis of leukemic cells in vitro and in vivo but the precise mechanisms by which it mediates such effects are not well defined We provide evidence that As2O3 induces activation of the mitogen- and stress-activated kinase 1 MSK1 and downstream phosphorylation of its substrate histone H3 in cell lines Such activation requires upstream engagement of p38 MAPK as demonstrated by experiments using pharmacological inhibitors of p38 or p38alpha knock-out cells Arsenic-induced apoptosis was enhanced in cells in which MSK1 expression was decreased using small interfering RNA and in Msk1 knock-out mouse embryonic fibroblasts suggesting that this kinase is activated in a negative feedback regulatory manner to regulate As2O3 responses Consistent with this pharmacological inhibition of MSK1 enhanced the suppressive effects of As2O3 on the growth of primary leukemic progenitors from chronic myelogenous patients Altogether these findings indicate an important role for MSK1 downstream of p38 in the regulation of As2O3 responses,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3217, 4574, 18209, 16, 8, 1157, 9567, 1, 351, 1, 2015, 37, 4, 439, 2, 4, 386, 84, 3, 3260, 483, 20, 92, 192, 3961, 225, 176, 32, 44, 149, 395, 21, 377, 241, 17, 18209, 1516, 363, 1, 3, 2625, 2, 1531, 735, 216, 14, 20365, 2, 1489, 982, 1, 211, 4235, 1508, 3739, 4, 31, 285, 225, 363, 1706, 3988, 5103, 1, 3970, 1748, 22, 264, 20, 2332, 75, 3419, 222, 1, 3970, 15, 34103, 6252, 1205, 37, 3217, 277, 351, 10, 651, 4, 37, 4, 92, 20365, 55, 10, 340, 75, 302, 3449, 893, 2, 4, 20365, 6252, 1205, 830, 5390, 3921, 802, 17, 26, 216, 16, 735, 4, 8, 199, 3983, 1253, 1708, 6, 2288, 18209, 253, 925, 5, 26, 3419, 297, 1, 20365, 651, 3, 3707, 176, 1, 18209, 23, 3, 129, 1, 86, 2015, 4321, 29, 442, 2194, 7, 6767, 46, 272, 1008, 35, 305, 200, 9, 20365, 1489, 1, 3970, 4, 3, 863, 1, 18209, 253]",1076.0,16762916,153
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.,The New England journal of medicine,N. Engl. J. Med.,2006-06-01,"The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-positive (Ph-positive) leukemias, but relapse occurs, mainly as a result of the outgrowth of leukemic subclones with imatinib-resistant BCR-ABL mutations. We evaluated dasatinib, a BCR-ABL inhibitor that targets most imatinib-resistant BCR-ABL mutations, in patients with chronic myelogenous leukemia (CML) or Ph-positive acute lymphoblastic leukemia (ALL). Patients with various phases of CML or with Ph-positive ALL who could not tolerate or were resistant to imatinib were enrolled in a phase 1 dose-escalation study. Dasatinib (15 to 240 mg per day) was administered orally in four-week treatment cycles, once or twice daily. A complete hematologic response was achieved in 37 of 40 patients with chronic-phase CML, and major hematologic responses were seen in 31 of 44 patients with accelerated-phase CML, CML with blast crisis, or Ph-positive ALL. In these two phases, the rates of major cytogenetic response were 45 percent and 25 percent, respectively. Responses were maintained in 95 percent of patients with chronic-phase disease and in 82 percent of patients with accelerated-phase disease, with a median follow-up more than 12 months and 5 months, respectively. Nearly all patients with lymphoid blast crisis and Ph-positive ALL had a relapse within six months. Responses occurred among all BCR-ABL genotypes, with the exception of the T315I mutation, which confers resistance to both dasatinib and imatinib in vitro. Myelosuppression was common but not dose-limiting. Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib. (ClinicalTrials.gov number, NCT00064233 [ClinicalTrials.gov].).","Clinical Trial, Phase I",4982.0,1321.0,The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-positive Ph-positive leukemias but relapse occurs mainly as a result of the outgrowth of leukemic subclones with imatinib-resistant BCR-ABL mutations We evaluated dasatinib a BCR-ABL inhibitor that targets most imatinib-resistant BCR-ABL mutations in patients with chronic myelogenous CML or Ph-positive acute lymphoblastic ALL Patients with various phases of CML or with Ph-positive ALL who could not tolerate or were resistant to imatinib were enrolled in a phase 1 dose-escalation study Dasatinib 15 to 240 mg per day was administered orally in four-week treatment cycles once or twice daily A complete hematologic response was achieved in 37 of 40 patients with chronic-phase CML and major hematologic responses were seen in 31 of 44 patients with accelerated-phase CML CML with blast crisis or Ph-positive ALL In these two phases the rates of major cytogenetic response were 45 percent and 25 percent respectively Responses were maintained in 95 percent of patients with chronic-phase disease and in 82 percent of patients with accelerated-phase disease with a median follow-up more than 12 months and 5 months respectively Nearly all patients with lymphoid blast crisis and Ph-positive ALL had a relapse within six months Responses occurred among all BCR-ABL genotypes with the exception of the T315I mutation which confers resistance to both dasatinib and imatinib in vitro Myelosuppression was common but not dose-limiting Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who can not tolerate or are resistant to imatinib ClinicalTrials.gov number NCT00064233 ClinicalTrials.gov,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1062, 1425, 564, 216, 230, 577, 16, 323, 4, 3006, 1170, 109, 2058, 109, 2792, 84, 429, 1780, 2615, 22, 8, 757, 1, 3, 7201, 1, 2015, 8881, 5, 577, 436, 1062, 1425, 138, 21, 194, 1674, 8, 1062, 1425, 230, 17, 637, 96, 577, 436, 1062, 1425, 138, 4, 7, 5, 442, 2194, 903, 15, 2058, 109, 286, 1275, 62, 7, 5, 747, 3523, 1, 903, 15, 5, 2058, 109, 62, 54, 359, 44, 5010, 15, 11, 436, 6, 577, 11, 346, 4, 8, 124, 14, 61, 1125, 45, 1674, 167, 6, 4263, 81, 379, 218, 10, 468, 1428, 4, 294, 647, 24, 410, 1059, 15, 936, 391, 8, 236, 813, 51, 10, 513, 4, 567, 1, 327, 7, 5, 442, 124, 903, 2, 458, 813, 253, 11, 527, 4, 456, 1, 584, 7, 5, 2241, 124, 903, 903, 5, 3112, 6540, 15, 2058, 109, 62, 4, 46, 100, 3523, 3, 151, 1, 458, 1266, 51, 11, 512, 714, 2, 243, 714, 106, 253, 11, 1955, 4, 48, 714, 1, 7, 5, 442, 124, 34, 2, 4, 878, 714, 1, 7, 5, 2241, 124, 34, 5, 8, 52, 166, 126, 80, 76, 133, 53, 2, 33, 53, 106, 1857, 62, 7, 5, 2303, 3112, 6540, 2, 2058, 109, 62, 42, 8, 429, 262, 437, 53, 253, 489, 107, 62, 1062, 1425, 2071, 5, 3, 4188, 1, 3, 6184, 258, 92, 4020, 251, 6, 110, 1674, 2, 577, 4, 439, 2858, 10, 186, 84, 44, 61, 817, 1674, 1516, 813, 2, 1266, 253, 4, 7, 5, 903, 15, 2058, 109, 62, 54, 122, 44, 5010, 15, 32, 436, 6, 577, 1252, 1239, 207, 55566, 1252, 1239]",1720.0,16775234,55
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.,The New England journal of medicine,N. Engl. J. Med.,2006-06-01,"Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor, is more potent than imatinib against CML cells by a factor of 20 to 50. In a phase 1 dose-escalation study, we assigned 119 patients with imatinib-resistant CML or acute lymphoblastic leukemia (ALL) to receive nilotinib orally at doses of 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, and 1200 mg once daily and at 400 mg and 600 mg twice daily. Common adverse events were myelosuppression, transient indirect hyperbilirubinemia, and rashes. Of 33 patients with the blastic phase of disease, 13 had a hematologic response and 9 had a cytogenetic response; of 46 patients with the accelerated phase, 33 had a hematologic response and 22 had a cytogenetic response; 11 of 12 patients with the chronic phase had a complete hematologic remission. Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML. (ClinicalTrials.gov number, NCT00109707 [ClinicalTrials.gov].).","Clinical Trial, Phase I",4982.0,1041.0,Resistance to imatinib mesylate can occur in chronic myelogenous CML Preclinical in vitro studies have shown that nilotinib AMN107 a new BCR-ABL tyrosine kinase inhibitor is more potent than imatinib against CML cells by a factor of 20 to 50 In a phase 1 dose-escalation study we assigned 119 patients with imatinib-resistant CML or acute lymphoblastic ALL to receive nilotinib orally at doses of 50 mg 100 mg 200 mg 400 mg 600 mg 800 mg and 1200 mg once daily and at 400 mg and 600 mg twice daily Common adverse events were myelosuppression transient indirect hyperbilirubinemia and rashes Of 33 patients with the blastic phase of disease 13 had a hematologic response and 9 had a cytogenetic response of 46 patients with the accelerated phase 33 had a hematologic response and 22 had a cytogenetic response 11 of 12 patients with the chronic phase had a complete hematologic remission Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML ClinicalTrials.gov number NCT00109707 ClinicalTrials.gov,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[251, 6, 577, 2347, 122, 1271, 4, 442, 2194, 903, 693, 4, 439, 94, 47, 443, 17, 2638, 12189, 8, 217, 1062, 1425, 564, 216, 230, 16, 80, 1157, 76, 577, 480, 903, 37, 20, 8, 161, 1, 179, 6, 212, 4, 8, 124, 14, 61, 1125, 45, 21, 896, 4299, 7, 5, 577, 436, 903, 15, 286, 1275, 62, 6, 560, 2638, 1428, 28, 415, 1, 212, 81, 394, 81, 1250, 81, 1524, 81, 2383, 81, 2796, 81, 2, 6847, 81, 1059, 391, 2, 28, 1524, 81, 2, 2383, 81, 936, 391, 186, 290, 281, 11, 2858, 2473, 6110, 7236, 2, 11775, 1, 466, 7, 5, 3, 6529, 124, 1, 34, 233, 42, 8, 813, 51, 2, 83, 42, 8, 1266, 51, 1, 641, 7, 5, 3, 2241, 124, 466, 42, 8, 813, 51, 2, 350, 42, 8, 1266, 51, 175, 1, 133, 7, 5, 3, 442, 124, 42, 8, 236, 813, 734, 2638, 71, 8, 1352, 913, 367, 800, 2, 16, 544, 4, 577, 436, 903, 1252, 1239, 207, 38200, 1252, 1239]",1035.0,16775235,9
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.,Blood,Blood,2006-06-29,"During therapy with imatinib, some patients with chronic myeloid leukemia (CML) develop chromosomal abnormalities in Philadelphia chromosome (Ph)-negative cells. These abnormalities are frequently transient and their clinical consequence is unclear. Although some reports have suggested that the abnormalities might be associated with secondary myelodysplastic syndrome (MDS), the diagnosis has not always been established using standard criteria. We report 3 cases of patients treated with imatinib for CML who were subsequently found to have chromosomal abnormalities in Ph-negative cells. One of them developed acute myelogenous leukemia (AML) and the other 2 developed high-risk MDS that rapidly transformed to AML. These cases were identified in a total study group of 1701 patients. Although these occurrences are rare, the findings highlight the need for close monitoring of patients with CML treated with imatinib.",Case Reports,4954.0,123.0,During therapy with imatinib some patients with chronic myeloid CML develop chromosomal abnormalities in Philadelphia chromosome Ph -negative cells These abnormalities are frequently transient and their clinical consequence is unclear Although some reports have suggested that the abnormalities might be associated with secondary syndrome MDS the diagnosis has not always been established using standard criteria We report 3 cases of patients treated with imatinib for CML who were subsequently found to have chromosomal abnormalities in Ph-negative cells One of them developed acute myelogenous AML and the other 2 developed high-risk MDS that rapidly transformed to AML These cases were identified in a total study group of 1701 patients Although these occurrences are rare the findings highlight the need for close monitoring of patients with CML treated with imatinib,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[190, 36, 5, 577, 476, 7, 5, 442, 533, 903, 690, 1860, 1171, 4, 3006, 1170, 2058, 199, 37, 46, 1171, 32, 746, 2473, 2, 136, 38, 4177, 16, 1200, 242, 476, 1198, 47, 1148, 17, 3, 1171, 822, 40, 41, 5, 568, 681, 1223, 3, 147, 71, 44, 3763, 85, 635, 75, 260, 371, 21, 414, 27, 140, 1, 7, 73, 5, 577, 9, 903, 54, 11, 1611, 204, 6, 47, 1860, 1171, 4, 2058, 199, 37, 104, 1, 1370, 276, 286, 2194, 329, 2, 3, 127, 18, 276, 64, 43, 1223, 17, 1755, 2423, 6, 329, 46, 140, 11, 108, 4, 8, 181, 45, 87, 1, 38208, 7, 242, 46, 8781, 32, 622, 3, 272, 1817, 3, 594, 9, 2336, 1315, 1, 7, 5, 903, 73, 5, 577]",871.0,16809614,7
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.,Seminars in thrombosis and hemostasis,Semin. Thromb. Hemost.,2006-06-01,"The conventional management of patients with high-risk Philadelphia chromosome-negative (Ph-negative) myeloproliferative disorders (MPDs) revolves around the administration of cytoreductive agents such as hydroxyurea, anagrelide, and recombinant human interferon alpha (IFN-alpha). IFN-alpha has shown significant activity in the treatment of chronic myelogenous leukemia (CML) and Ph-negative MDPs. However, the response rates of IFN-alpha therapy frequently have been hampered by high dropout rates due to side effects and inconvenient dosing schedules. Pegylated (PEG) IFN-alpha is formulated by covalently attaching polymers of ethylene glycol of large molecular weight to the native IFN-alpha molecule. Such chemical modification increases serum half-life, decreases renal excretion, and results in prolonged patient exposure to PEG-IFN-alpha, thus allowing for weekly administration while maintaining acceptable toxicity, tolerability, and activity profiles. The lack of adequate therapies for patients with MPDs and the superior pharmacokinetic and pharmacodynamic profile of PEG-IFN-alpha relative to standard IFN-alpha has prompted the investigation of the activity and safety of PEG-IFN-alpha in patients with essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis. We summarize the available data on the use of PEG-IFN-alpha in patients with Ph-negative MPDs.",Journal Article,4982.0,20.0,The conventional management of patients with high-risk Philadelphia chromosome-negative Ph-negative disorders MPDs revolves around the administration of cytoreductive agents such as hydroxyurea anagrelide and recombinant human interferon alpha IFN-alpha IFN-alpha has shown significant activity in the treatment of chronic myelogenous CML and Ph-negative MDPs However the response rates of IFN-alpha therapy frequently have been hampered by high dropout rates due to side effects and inconvenient dosing schedules Pegylated PEG IFN-alpha is formulated by covalently attaching polymers of ethylene glycol of large molecular weight to the native IFN-alpha molecule Such chemical modification increases serum half-life decreases excretion and results in prolonged patient exposure to PEG-IFN-alpha thus allowing for weekly administration while maintaining acceptable toxicity tolerability and activity profiles The lack of adequate therapies for patients with MPDs and the superior pharmacokinetic and pharmacodynamic profile of PEG-IFN-alpha relative to standard IFN-alpha has prompted the investigation of the activity and safety of PEG-IFN-alpha in patients with essential thrombocythemia polycythemia vera and idiopathic myelofibrosis We summarize the available data on the use of PEG-IFN-alpha in patients with Ph-negative MPDs,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 809, 284, 1, 7, 5, 64, 43, 3006, 1170, 199, 2058, 199, 1997, 24840, 30909, 3337, 3, 634, 1, 2604, 183, 225, 22, 5902, 24940, 2, 2835, 171, 1688, 950, 1256, 950, 1256, 950, 71, 443, 93, 128, 4, 3, 24, 1, 442, 2194, 903, 2, 2058, 199, 55612, 137, 3, 51, 151, 1, 1256, 950, 36, 746, 47, 85, 6786, 20, 64, 13929, 151, 520, 6, 1152, 176, 2, 23338, 1280, 2314, 4424, 3145, 1256, 950, 16, 7495, 20, 10732, 24941, 8101, 1, 16179, 10809, 1, 375, 219, 924, 6, 3, 4646, 1256, 950, 1354, 225, 3743, 2437, 1106, 524, 1303, 358, 2140, 8294, 2, 99, 4, 1069, 69, 645, 6, 3145, 1256, 950, 631, 2952, 9, 709, 634, 369, 3284, 1595, 155, 1543, 2, 128, 1241, 3, 926, 1, 1658, 235, 9, 7, 5, 24840, 2, 3, 1123, 1456, 2, 2424, 800, 1, 3145, 1256, 950, 580, 6, 260, 1256, 950, 71, 4140, 3, 940, 1, 3, 128, 2, 367, 1, 3145, 1256, 950, 4, 7, 5, 1452, 8962, 5755, 5756, 2, 7540, 4637, 21, 2479, 3, 390, 74, 23, 3, 119, 1, 3145, 1256, 950, 4, 7, 5, 2058, 199, 24840]",1329.0,16810616,6
Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.,Cancer research,Cancer Res.,2006-07-01,"Arsenic trioxide (As(2)O(3)) induces differentiation and apoptosis of leukemic cells in vitro and in vivo, but the precise mechanisms that mediate such effects are not known. In the present study, we provide evidence that the kinases MAPK kinase 3 (Mkk3) and Mkk6 are activated during treatment of leukemic cell lines with As(2)O(3) to regulate downstream engagement of the p38 mitogen-activated protein kinase. Using cells with targeted disruption of both the Mkk3 and Mkk6 genes, we show that As(2)O(3)-dependent activation of p38 is defective in the absence of Mkk3 and Mkk6, establishing that these kinases are essential for As(2)O(3)-dependent engagement of the p38 pathway. Pharmacologic inhibition of p38 enhances As(2)O(3)-dependent activation of the c-jun NH(2)-terminal kinase (JNK) and subsequent induction of apoptosis of chronic myelogenous leukemia (CML)- or acute promyelocytic leukemia (APL)-derived cell lines. In addition, in APL blasts, inhibition of p38 enhances myeloid cell differentiation in response to As(2)O(3), as well as suppression of Bcl-2 expression and loss of mitochondrial membrane potential. Similarly, induction of As(2)O(3)-dependent apoptosis is enhanced in mouse embryonic fibroblasts (MEF) with targeted disruption of both the Mkk3 and Mkk6 genes, establishing a key role for this pathway in the regulation of As(2)O(3)-induced apoptosis. In other studies, we show that the small-molecule p38 inhibitors SD-282 and SCIO-469 potentiate As(2)O(3)-mediated suppression of myeloid leukemic progenitor growth from CML patients, indicating a critical regulatory role for p38 in the induction of antileukemic responses. Altogether, our data indicate that the Mkk3/6-p38 signaling cascade is activated in a negative regulatory feedback manner to control induction of As(2)O(3)-mediated antileukemic effects.",Journal Article,4952.0,67.0,Arsenic trioxide As 2 O 3 induces differentiation and apoptosis of leukemic cells in vitro and in vivo but the precise mechanisms that mediate such effects are not known In the present study we provide evidence that the kinases MAPK kinase 3 Mkk3 and Mkk6 are activated during treatment of leukemic cell lines with As 2 O 3 to regulate downstream engagement of the p38 mitogen-activated protein kinase Using cells with targeted disruption of both the Mkk3 and Mkk6 genes we show that As 2 O 3 -dependent activation of p38 is defective in the absence of Mkk3 and Mkk6 establishing that these kinases are essential for As 2 O 3 -dependent engagement of the p38 pathway Pharmacologic inhibition of p38 enhances As 2 O 3 -dependent activation of the c-jun NH 2 -terminal kinase JNK and subsequent induction of apoptosis of chronic myelogenous CML or acute promyelocytic APL -derived cell lines In addition in APL blasts inhibition of p38 enhances myeloid cell differentiation in response to As 2 O 3 as well as suppression of Bcl-2 expression and loss of mitochondrial membrane potential Similarly induction of As 2 O 3 -dependent apoptosis is enhanced in mouse embryonic fibroblasts MEF with targeted disruption of both the Mkk3 and Mkk6 genes establishing a key role for this pathway in the regulation of As 2 O 3 -induced apoptosis In other studies we show that the small-molecule p38 inhibitors SD-282 and SCIO-469 potentiate As 2 O 3 -mediated suppression of myeloid leukemic progenitor growth from CML patients indicating a critical regulatory role for p38 in the induction of antileukemic responses Altogether our data indicate that the Mkk3/6-p38 signaling cascade is activated in a negative regulatory feedback manner to control induction of As 2 O 3 -mediated antileukemic effects,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3217, 4574, 22, 18, 1990, 27, 1516, 910, 2, 351, 1, 2015, 37, 4, 439, 2, 4, 386, 84, 3, 3260, 483, 17, 3367, 225, 176, 32, 44, 440, 4, 3, 364, 45, 21, 377, 241, 17, 3, 1549, 1748, 216, 27, 28554, 2, 30967, 32, 735, 190, 24, 1, 2015, 31, 285, 5, 22, 18, 1990, 27, 6, 2288, 1489, 5103, 1, 3, 3970, 2625, 735, 178, 216, 75, 37, 5, 238, 3220, 1, 110, 3, 28554, 2, 30967, 214, 21, 514, 17, 22, 18, 1990, 27, 470, 363, 1, 3970, 16, 4552, 4, 3, 1127, 1, 28554, 2, 30967, 4431, 17, 46, 1549, 32, 1452, 9, 22, 18, 1990, 27, 470, 5103, 1, 3, 3970, 308, 2788, 297, 1, 3970, 2519, 22, 18, 1990, 27, 470, 363, 1, 3, 256, 4578, 6260, 18, 2158, 216, 3958, 2, 706, 504, 1, 351, 1, 442, 2194, 903, 15, 286, 4300, 2578, 526, 31, 285, 4, 352, 4, 2578, 2438, 297, 1, 3970, 2519, 533, 31, 910, 4, 51, 6, 22, 18, 1990, 27, 22, 149, 22, 1332, 1, 1044, 18, 55, 2, 407, 1, 2019, 1905, 174, 1813, 504, 1, 22, 18, 1990, 27, 470, 351, 16, 651, 4, 830, 5390, 3921, 16051, 5, 238, 3220, 1, 110, 3, 28554, 2, 30967, 214, 4431, 8, 825, 200, 9, 26, 308, 4, 3, 863, 1, 22, 18, 1990, 27, 277, 351, 4, 127, 94, 21, 514, 17, 3, 302, 1354, 3970, 222, 1270, 8219, 2, 28296, 9747, 6428, 22, 18, 1990, 27, 517, 1332, 1, 533, 2015, 2520, 129, 29, 903, 7, 1716, 8, 740, 1253, 200, 9, 3970, 4, 3, 504, 1, 4512, 253, 6767, 114, 74, 1008, 17, 3, 28554, 49, 3970, 314, 4678, 16, 735, 4, 8, 199, 1253, 3983, 1708, 6, 182, 504, 1, 22, 18, 1990, 27, 517, 4512, 176]",1786.0,16818652,69
Reversible peripartum cardiomyopathy in a patient with prior exposure to interferon.,American journal of therapeutics,Am J Ther,,"Peripartum cardiomyopathy creates complications for 1 in 3000 to 4000 pregnant women in the US. As this rare condition is associated with a high mortality rate (50% to 85%), it has been investigated to define the possible associated causes. Several factors including hypertension, nutritional and dietary discrepancies, and, recently, myocarditis are being implicated, but the mechanism of cardiac injury is yet to be discovered. Here we present an interesting case of possible interferon-induced reversible peripartum cardiomyopathy. The patient, with a diagnosis of chronic myelogenous leukemia, had been given interferon for 6 years. The therapy was discontinued when she became pregnant, and later she presented with symptoms of heart failure 6 weeks after her c-section. Interferon is an immunomodulating agent and used as an antiviral and an anticancer agent. Interferon-related dilated cardiomyopathy has been described as a rare side effect of the drug, the mechanism of which is unknown. There is compelling data supporting the fact that both peripartum cardiomyopathy and interferon-related cardiomyopathy are autoimmune disorders; so it is suggested that interferon therapy given in the past can have an additive effect in causing dilated cardiomyopathy. It is therefore advisable to follow closely those pregnant patients; who received interferon therapy in the past, for symptoms of cardiac failure, as there can be synergistic action between interferon and pregnancy causing dilated cardiomyopathy.",Case Reports,,0.0,Peripartum cardiomyopathy creates complications for 1 in 3000 to 4000 pregnant women in the US As this rare condition is associated with a high mortality rate 50 to 85 it has been investigated to define the possible associated causes Several factors including hypertension nutritional and dietary discrepancies and recently myocarditis are being implicated but the mechanism of injury is yet to be discovered Here we present an interesting case of possible interferon-induced reversible peripartum cardiomyopathy The patient with a diagnosis of chronic myelogenous had been given interferon for 6 years The therapy was discontinued when she became pregnant and later she presented with symptoms of failure 6 weeks after her c-section Interferon is an immunomodulating agent and used as an antiviral and an anticancer agent Interferon-related dilated cardiomyopathy has been described as a rare side effect of the drug the mechanism of which is unknown There is compelling data supporting the fact that both peripartum cardiomyopathy and interferon-related cardiomyopathy are autoimmune disorders so it is suggested that interferon therapy given in the past can have an additive effect in causing dilated cardiomyopathy It is therefore advisable to follow closely those pregnant patients who received interferon therapy in the past for symptoms of failure as there can be synergistic action between interferon and pregnancy causing dilated cardiomyopathy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,"[21399, 6460, 9803, 521, 9, 14, 4, 11264, 6, 10660, 6086, 117, 4, 3, 843, 22, 26, 622, 2850, 16, 41, 5, 8, 64, 282, 116, 212, 6, 772, 192, 71, 85, 565, 6, 1107, 3, 899, 41, 1626, 392, 130, 141, 1824, 5082, 2, 2013, 7631, 2, 761, 15329, 32, 486, 1771, 84, 3, 670, 1, 2730, 16, 1145, 6, 40, 2747, 467, 21, 364, 35, 6597, 473, 1, 899, 1688, 277, 2786, 21399, 6460, 3, 69, 5, 8, 147, 1, 442, 2194, 42, 85, 447, 1688, 9, 49, 60, 3, 36, 10, 2402, 198, 3109, 3451, 6086, 2, 1559, 3109, 917, 5, 507, 1, 496, 49, 244, 50, 1084, 256, 2917, 1688, 16, 35, 13861, 420, 2, 95, 22, 35, 6264, 2, 35, 1475, 420, 1688, 139, 11536, 6460, 71, 85, 1027, 22, 8, 622, 1152, 254, 1, 3, 234, 3, 670, 1, 92, 16, 860, 125, 16, 6051, 74, 1912, 3, 1991, 17, 110, 21399, 6460, 2, 1688, 139, 6460, 32, 3445, 1997, 1743, 192, 16, 1148, 17, 1688, 36, 447, 4, 3, 1219, 122, 47, 35, 3396, 254, 4, 3440, 11536, 6460, 192, 16, 673, 19443, 6, 166, 3210, 135, 6086, 7, 54, 103, 1688, 36, 4, 3, 1219, 9, 507, 1, 496, 22, 125, 122, 40, 1806, 1578, 59, 1688, 2, 2290, 3440, 11536, 6460]",1453.0,16858174,134
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2006-08-01,"Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-inducing antiepileptic drugs (EIAED) or not taking EIAED. Phase II: To determine the therapeutic efficacy of imatinib. Phase I component used an interpatient dose escalation scheme. End points of the phase II component were 6-month progression-free survival and response. Fifty patients enrolled in the phase I component (27 EIAED and 23 non-EIAED). The maximum tolerated dose for non-EIAED patients was 800 mg/d. Dose-limiting toxicities were neutropenia, rash, and elevated alanine aminotransferase. EIAED patients received up to 1,200 mg/d imatinib without developing dose-limiting toxicity. Plasma exposure of imatinib was reduced by approximately 68% in EIAED patients compared with non-EIAED patients. Fifty-five non-EIAED patients (34 glioblastoma multiforme and 21 anaplastic glioma) enrolled in the phase II component. Patients initially received 800 mg/d imatinib; 15 anaplastic glioma patients received 600 mg/d after hemorrhages were observed. There were 2 partial response and 6 stable disease among glioblastoma multiforme patients and 0 partial response and 5 stable disease among anaplastic glioma patients. Six-month progression-free survival was 3% for glioblastoma multiforme and 10% for anaplastic glioma patients. Five phase II patients developed intratumoral hemorrhages. Single-agent imatinib has minimal activity in malignant gliomas. CYP3A4 inducers, such as EIAEDs, substantially decreased plasma exposure of imatinib and should be avoided in patients receiving imatinib for chronic myelogenous leukemia and gastrointestinal stromal tumors. The evaluation of the activity of combination regimens incorporating imatinib is under way in phase II trials.","Clinical Trial, Phase I",4921.0,312.0,"Phase I To determine the maximum tolerated doses toxicities and pharmacokinetics of imatinib mesylate Gleevec in patients with malignant gliomas taking enzyme-inducing antiepileptic drugs EIAED or not taking EIAED Phase II To determine the therapeutic efficacy of imatinib Phase I component used an interpatient dose escalation scheme End points of the phase II component were 6-month progression-free survival and response Fifty patients enrolled in the phase I component 27 EIAED and 23 non-EIAED The maximum tolerated dose for non-EIAED patients was 800 mg/d Dose-limiting toxicities were neutropenia rash and elevated alanine aminotransferase EIAED patients received up to 1,200 mg/d imatinib without developing dose-limiting toxicity Plasma exposure of imatinib was reduced by approximately 68 in EIAED patients compared with non-EIAED patients Fifty-five non-EIAED patients 34 glioblastoma multiforme and 21 anaplastic glioma enrolled in the phase II component Patients initially received 800 mg/d imatinib 15 anaplastic glioma patients received 600 mg/d after hemorrhages were observed There were 2 partial response and 6 stable disease among glioblastoma multiforme patients and 0 partial response and 5 stable disease among anaplastic glioma patients Six-month progression-free survival was 3 for glioblastoma multiforme and 10 for anaplastic glioma patients Five phase II patients developed intratumoral hemorrhages Single-agent imatinib has minimal activity in malignant gliomas CYP3A4 inducers such as EIAEDs substantially decreased plasma exposure of imatinib and should be avoided in patients receiving imatinib for chronic myelogenous and stromal tumors The evaluation of the activity of combination regimens incorporating imatinib is under way in phase II trials",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[124, 70, 6, 223, 3, 689, 421, 415, 385, 2, 1159, 1, 577, 2347, 8569, 4, 7, 5, 393, 1287, 2727, 1644, 1958, 8164, 600, 10002, 15, 44, 2727, 10002, 124, 215, 6, 223, 3, 189, 209, 1, 577, 124, 70, 1249, 95, 35, 7423, 61, 1125, 4633, 396, 862, 1, 3, 124, 215, 1249, 11, 49, 811, 91, 115, 25, 2, 51, 1461, 7, 346, 4, 3, 124, 70, 1249, 428, 10002, 2, 382, 220, 10002, 3, 689, 421, 61, 9, 220, 10002, 7, 10, 2796, 81, 427, 61, 817, 385, 11, 778, 1641, 2, 804, 5411, 4597, 10002, 7, 103, 126, 6, 14, 1250, 81, 427, 577, 187, 931, 61, 817, 155, 554, 645, 1, 577, 10, 405, 20, 705, 806, 4, 10002, 7, 72, 5, 220, 10002, 7, 1461, 365, 220, 10002, 7, 562, 996, 3238, 2, 239, 1841, 945, 346, 4, 3, 124, 215, 1249, 7, 1625, 103, 2796, 81, 427, 577, 167, 1841, 945, 7, 103, 2383, 81, 427, 50, 13773, 11, 164, 125, 11, 18, 450, 51, 2, 49, 585, 34, 107, 996, 3238, 7, 2, 13, 450, 51, 2, 33, 585, 34, 107, 1841, 945, 7, 437, 811, 91, 115, 25, 10, 27, 9, 996, 3238, 2, 79, 9, 1841, 945, 7, 365, 124, 215, 7, 276, 2074, 13773, 226, 420, 577, 71, 1048, 128, 4, 393, 1287, 6208, 12780, 225, 22, 6059, 2109, 340, 554, 645, 1, 577, 2, 257, 40, 5617, 4, 7, 357, 577, 9, 442, 2194, 2, 1126, 57, 3, 451, 1, 3, 128, 1, 150, 472, 2570, 577, 16, 669, 2255, 4, 124, 215, 143]",1778.0,16914578,125
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2006-09-01,"Everolimus (RAD001, Novartis), an oral derivative of rapamycin, inhibits the mammalian target of rapamycin (mTOR), which regulates many aspects of cell growth and division. A phase I/II study was done to determine safety and efficacy of everolimus in patients with relapsed or refractory hematologic malignancies. Two dose levels (5 and 10 mg orally once daily continuously) were evaluated in the phase I portion of this study to determine the maximum tolerated dose of everolimus to be used in the phase II study. Twenty-seven patients (9 acute myelogenous leukemia, 5 myelodysplastic syndrome, 6 B-chronic lymphocytic leukemia, 4 mantle cell lymphoma, 1 myelofibrosis, 1 natural killer cell/T-cell leukemia, and 1 T-cell prolymphocytic leukemia) received everolimus. No dose-limiting toxicities were observed. Grade 3 potentially drug-related toxicities included hyperglycemia (22%), hypophosphatemia (7%), fatigue (7%), anorexia (4%), and diarrhea (4%). One patient developed a cutaneous leukocytoclastic vasculitis requiring a skin graft. One patient with refractory anemia with excess blasts achieved a major platelet response of over 3-month duration. A second patient with refractory anemia with excess blasts showed a minor platelet response of 25-day duration. Phosphorylation of downstream targets of mTOR, eukaryotic initiation factor 4E-binding protein 1, and/or, p70 S6 kinase, was inhibited in six of nine patient samples, including those from the patient with a major platelet response. Everolimus is well tolerated at a daily dose of 10 mg daily and may have activity in patients with myelodysplastic syndrome. Studies of everolimus in combination with therapeutic agents directed against other components of the phosphatidylinositol 3-kinase/Akt/mTOR pathway are warranted.","Clinical Trial, Phase I",4890.0,262.0,Everolimus RAD001 Novartis an oral derivative of rapamycin inhibits the mammalian target of rapamycin mTOR which regulates many aspects of cell growth and division A phase I/II study was done to determine safety and efficacy of everolimus in patients with relapsed or refractory hematologic malignancies Two dose levels 5 and 10 mg orally once daily continuously were evaluated in the phase I portion of this study to determine the maximum tolerated dose of everolimus to be used in the phase II study Twenty-seven patients 9 acute myelogenous 5 syndrome 6 B-chronic lymphocytic 4 mantle cell 1 myelofibrosis 1 natural killer cell/T-cell and 1 T-cell prolymphocytic received everolimus No dose-limiting toxicities were observed Grade 3 potentially drug-related toxicities included hyperglycemia 22 hypophosphatemia 7 fatigue 7 anorexia 4 and diarrhea 4 One patient developed a cutaneous leukocytoclastic vasculitis requiring a graft One patient with refractory anemia with excess blasts achieved a major platelet response of over 3-month duration A second patient with refractory anemia with excess blasts showed a minor platelet response of 25-day duration Phosphorylation of downstream targets of mTOR eukaryotic initiation factor 4E-binding protein 1 and/or p70 S6 kinase was inhibited in six of nine patient samples including those from the patient with a major platelet response Everolimus is well tolerated at a daily dose of 10 mg daily and may have activity in patients with syndrome Studies of everolimus in combination with therapeutic agents directed against other components of the phosphatidylinositol 3-kinase/Akt/mTOR pathway are warranted,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[1400, 7027, 7855, 35, 518, 4819, 1, 1620, 1576, 3, 2359, 283, 1, 1620, 873, 92, 2468, 445, 2695, 1, 31, 129, 2, 5750, 8, 124, 70, 215, 45, 10, 1822, 6, 223, 367, 2, 209, 1, 1400, 4, 7, 5, 591, 15, 430, 813, 441, 100, 61, 148, 33, 2, 79, 81, 1428, 1059, 391, 4285, 11, 194, 4, 3, 124, 70, 3206, 1, 26, 45, 6, 223, 3, 689, 421, 61, 1, 1400, 6, 40, 95, 4, 3, 124, 215, 45, 737, 648, 7, 83, 286, 2194, 33, 681, 49, 132, 442, 1193, 39, 2757, 31, 14, 4637, 14, 1504, 3458, 31, 102, 31, 2, 14, 102, 31, 14779, 103, 1400, 77, 61, 817, 385, 11, 164, 88, 27, 751, 234, 139, 385, 159, 3992, 350, 8021, 67, 613, 67, 3373, 39, 2, 1172, 39, 104, 69, 276, 8, 1486, 38242, 18850, 1888, 8, 1599, 104, 69, 5, 430, 1545, 5, 2612, 2438, 513, 8, 458, 1596, 51, 1, 252, 27, 811, 654, 8, 419, 69, 5, 430, 1545, 5, 2612, 2438, 224, 8, 2278, 1596, 51, 1, 243, 218, 654, 982, 1, 1489, 637, 1, 873, 8374, 1118, 161, 6726, 791, 178, 14, 2, 15, 9036, 4977, 216, 10, 879, 4, 437, 1, 762, 69, 347, 141, 135, 29, 3, 69, 5, 8, 458, 1596, 51, 1400, 16, 149, 421, 28, 8, 391, 61, 1, 79, 81, 391, 2, 68, 47, 128, 4, 7, 5, 681, 94, 1, 1400, 4, 150, 5, 189, 183, 1166, 480, 127, 1628, 1, 3, 3415, 27, 216, 649, 873, 308, 32, 1197]",1654.0,16951235,136
An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions.,"Journal of immunology (Baltimore, Md. : 1950)",J. Immunol.,2006-10-01,"Self-tumor Ags that elicit antitumor immune responses in responses to IFN-alpha stimulation remain poorly defined. We screened a human testis cDNA library with sera from three polycythemia vera patients who responded to IFN-alpha and identified a novel Ag, MPD6. MPD6 belongs to the group of cryptic Ags without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3'-untranslated region of myotrophin mRNA. MPD6 elicits IgG Ab responses in a subset of polycythemia vera patients, as well as patients with chronic myelogenous leukemia and prostate cancer, suggesting that it is broadly immunogenic. The expression of myotrophin-MPD6 transcripts was up-regulated in some tumor cells, but only slightly increased in K562 cells in response to IFN-alpha treatment. By using bicistronic reporter constructs, we showed that the translation of MPD6 was mediated by a novel internal ribosome entry site (IRES) upstream of the MPD6 reading frame. Furthermore, the MPD6-IRES-mediated translation, but not myotrophin-MPD6 transcription, was significantly up-regulated in response to IFN-alpha stimulation. These findings demonstrate that a novel IRES-mediated mechanism may be responsible for the translation of unconventional self-Ag MPD6 in responsive to IFN-alpha stimulation. The eliciting antitumor immune response against unconventional Ag MPD6 in patients with myeloproliferative diseases suggests MPD6 as a potential target of novel immunotherapy.",Journal Article,4860.0,16.0,Self-tumor Ags that elicit antitumor immune responses in responses to IFN-alpha stimulation remain poorly defined We screened a human cDNA library with sera from three polycythemia vera patients who responded to IFN-alpha and identified a novel Ag MPD6 MPD6 belongs to the group of cryptic Ags without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3'-untranslated region of myotrophin mRNA MPD6 elicits IgG Ab responses in a subset of polycythemia vera patients as well as patients with chronic myelogenous and cancer suggesting that it is broadly immunogenic The expression of myotrophin-MPD6 transcripts was up-regulated in some tumor cells but only slightly increased in K562 cells in response to IFN-alpha treatment By using bicistronic reporter constructs we showed that the translation of MPD6 was mediated by a novel internal ribosome entry site IRES upstream of the MPD6 reading frame Furthermore the MPD6-IRES-mediated translation but not myotrophin-MPD6 transcription was significantly up-regulated in response to IFN-alpha stimulation These findings demonstrate that a novel IRES-mediated mechanism may be responsible for the translation of unconventional self-Ag MPD6 in responsive to IFN-alpha stimulation The eliciting antitumor immune response against unconventional Ag MPD6 in patients with diseases suggests MPD6 as a potential target of novel immunotherapy,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1074, 30, 6596, 17, 5487, 579, 250, 253, 4, 253, 6, 1256, 950, 2503, 918, 1240, 395, 21, 2261, 8, 171, 4212, 4157, 5, 4210, 29, 169, 5755, 5756, 7, 54, 2211, 6, 1256, 950, 2, 108, 8, 229, 2741, 21406, 21406, 14815, 6, 3, 87, 1, 10294, 6596, 187, 809, 572, 2772, 2, 16, 4587, 20, 8, 10294, 1020, 7299, 5331, 2308, 4, 3, 5435, 7379, 1053, 1, 38251, 956, 21406, 8748, 3630, 5094, 253, 4, 8, 697, 1, 5755, 5756, 7, 22, 149, 22, 7, 5, 442, 2194, 2, 12, 802, 17, 192, 16, 5482, 4190, 3, 55, 1, 38251, 21406, 2680, 10, 126, 1065, 4, 476, 30, 37, 84, 158, 3223, 101, 4, 5208, 37, 4, 51, 6, 1256, 950, 24, 20, 75, 31006, 3674, 5500, 21, 224, 17, 3, 2691, 1, 21406, 10, 517, 20, 8, 229, 2329, 16346, 3001, 606, 22362, 3988, 1, 3, 21406, 7299, 5331, 798, 3, 21406, 22362, 517, 2691, 84, 44, 38251, 21406, 866, 10, 97, 126, 1065, 4, 51, 6, 1256, 950, 2503, 46, 272, 608, 17, 8, 229, 22362, 517, 670, 68, 40, 2327, 9, 3, 2691, 1, 18146, 1074, 2741, 21406, 4, 2443, 6, 1256, 950, 2503, 3, 10299, 579, 250, 51, 480, 18146, 2741, 21406, 4, 7, 5, 1342, 844, 21406, 22, 8, 174, 283, 1, 229, 726]",1421.0,16982933,234
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.,Blood,Blood,2006-10-26,"Drug resistance resulting from emergence of imatinib-resistant BCR-ABL point mutations is a significant problem in advanced-stage chronic myelogenous leukemia (CML). The BCR-ABL inhibitor, nilotinib (AMN107), is significantly more potent against BCR-ABL than imatinib, and is active against many imatinib-resistant BCR-ABL mutants. Phase 1/2 clinical trials show that nilotinib can induce remissions in patients who have previously failed imatinib, indicating that sequential therapy with these 2 agents has clinical value. However, simultaneous, rather than sequential, administration of 2 BCR-ABL kinase inhibitors is attractive for many reasons, including the theoretical possibility that this could reduce emergence of drug-resistant clones. Here, we show that exposure of a variety of BCR-ABL+ cell lines to imatinib and nilotinib results in additive or synergistic cytotoxicity, including testing of a large panel of cells expressing BCR-ABL point mutations causing resistance to imatinib in patients. Further, using a highly quantifiable bioluminescent in vivo model, drug combinations were at least additive in antileukemic activity, compared with each drug alone. These results suggest that despite binding to the same site in the same target kinase, the combination of imatinib and nilotinib is highly efficacious in these models, indicating that clinical testing of combinations of BCR-ABL kinase inhibitors is warranted.",Journal Article,4835.0,74.0,Drug resistance resulting from emergence of imatinib-resistant BCR-ABL point mutations is a significant problem in advanced-stage chronic myelogenous CML The BCR-ABL inhibitor nilotinib AMN107 is significantly more potent against BCR-ABL than imatinib and is active against many imatinib-resistant BCR-ABL mutants Phase 1/2 clinical trials show that nilotinib can induce remissions in patients who have previously failed imatinib indicating that sequential therapy with these 2 agents has clinical value However simultaneous rather than sequential administration of 2 BCR-ABL kinase inhibitors is attractive for many reasons including the theoretical possibility that this could reduce emergence of drug-resistant clones Here we show that exposure of a variety of BCR-ABL+ cell lines to imatinib and nilotinib results in additive or synergistic cytotoxicity including testing of a large panel of cells expressing BCR-ABL point mutations causing resistance to imatinib in patients Further using a highly quantifiable bioluminescent in vivo model drug combinations were at least additive in antileukemic activity compared with each drug alone These results suggest that despite binding to the same site in the same target kinase the combination of imatinib and nilotinib is highly efficacious in these models indicating that clinical testing of combinations of BCR-ABL kinase inhibitors is warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[234, 251, 1113, 29, 3397, 1, 577, 436, 1062, 1425, 741, 138, 16, 8, 93, 2497, 4, 131, 82, 442, 2194, 903, 3, 1062, 1425, 230, 2638, 12189, 16, 97, 80, 1157, 480, 1062, 1425, 76, 577, 2, 16, 544, 480, 445, 577, 436, 1062, 1425, 3423, 124, 14, 18, 38, 143, 514, 17, 2638, 122, 1290, 3166, 4, 7, 54, 47, 373, 1551, 577, 1716, 17, 1787, 36, 5, 46, 18, 183, 71, 38, 549, 137, 2824, 1832, 76, 1787, 634, 1, 18, 1062, 1425, 216, 222, 16, 3059, 9, 445, 2325, 141, 3, 7060, 2526, 17, 26, 359, 969, 3397, 1, 234, 436, 2749, 467, 21, 514, 17, 645, 1, 8, 1362, 1, 1062, 1425, 31, 285, 6, 577, 2, 2638, 99, 4, 3396, 15, 1806, 1408, 141, 471, 1, 8, 375, 993, 1, 37, 1046, 1062, 1425, 741, 138, 3440, 251, 6, 577, 4, 7, 195, 75, 8, 561, 11639, 12571, 4, 386, 202, 234, 1247, 11, 28, 506, 3396, 4, 4512, 128, 72, 5, 296, 234, 279, 46, 99, 309, 17, 550, 791, 6, 3, 827, 606, 4, 3, 827, 283, 216, 3, 150, 1, 577, 2, 2638, 16, 561, 3289, 4, 46, 274, 1716, 17, 38, 471, 1, 1247, 1, 1062, 1425, 216, 222, 16, 1197]",1397.0,17068153,145
Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.,Molecular cancer therapeutics,Mol. Cancer Ther.,2006-11-01,"Arsenic trioxide (As(2)O(3)) exhibits important antitumor activities in vitro and in vivo, but the precise mechanisms by which it induces its effects are not known. We provide evidence that during treatment of BCR-ABL-expressing cells with As(2)O(3), there is activation of a cellular pathway involving the p70 S6 kinase (p70S6K). Our data show that p70S6K is rapidly phosphorylated on Thr(421) and Ser(424) and is activated in an As(2)O(3)-inducible manner. The mammalian target of rapamycin (mTOR) is also phosphorylated/activated in an As(2)O(3)-inducible manner, and its activity is required for downstream engagement of p70S6K. p70S6K subsequently phosphorylates the S6 ribosomal protein on Ser(235)/Ser(236) and Ser(240)/Ser(244) to promote initiation of mRNA translation. Treatment of chronic myelogenous leukemia-derived cell lines with As(2)O(3) also results in phosphorylation of the 4E-BP1 repressor of mRNA translation on Thr(37)/Thr(46) and Thr(70), sites required for its deactivation and its dissociation from the eukaryotic initiation factor 4E complex to allow cap-dependent mRNA translation. In studies to determine the functional relevance of this pathway, we found that inhibition of mTOR and downstream cascades enhances induction of apoptosis by As(2)O(3). Consistent with this, the mTOR inhibitor rapamycin strongly potentiated As(2)O(3)-mediated suppression of primitive leukemic progenitors from the bone marrow of chronic myelogenous leukemia patients. Altogether, our data show that the mTOR/p70S6K pathway is activated in a negative feedback regulatory manner in response to As(2)O(3) in BCR-ABL-transformed cells and plays a key regulatory role in the induction of anti-leukemic responses.",Journal Article,4829.0,24.0,Arsenic trioxide As 2 O 3 exhibits important antitumor activities in vitro and in vivo but the precise mechanisms by which it induces its effects are not known We provide evidence that during treatment of BCR-ABL-expressing cells with As 2 O 3 there is activation of a cellular pathway involving the p70 S6 kinase p70S6K Our data show that p70S6K is rapidly phosphorylated on Thr 421 and Ser 424 and is activated in an As 2 O 3 -inducible manner The mammalian target of rapamycin mTOR is also phosphorylated/activated in an As 2 O 3 -inducible manner and its activity is required for downstream engagement of p70S6K p70S6K subsequently phosphorylates the S6 ribosomal protein on Ser 235 /Ser 236 and Ser 240 /Ser 244 to promote initiation of mRNA translation Treatment of chronic myelogenous leukemia-derived cell lines with As 2 O 3 also results in phosphorylation of the 4E-BP1 repressor of mRNA translation on Thr 37 /Thr 46 and Thr 70 sites required for its deactivation and its dissociation from the eukaryotic initiation factor 4E complex to allow cap-dependent mRNA translation In studies to determine the functional relevance of this pathway we found that inhibition of mTOR and downstream cascades enhances induction of apoptosis by As 2 O 3 Consistent with this the mTOR inhibitor rapamycin strongly potentiated As 2 O 3 -mediated suppression of primitive leukemic progenitors from the marrow of chronic myelogenous patients Altogether our data show that the mTOR/p70S6K pathway is activated in a negative feedback regulatory manner in response to As 2 O 3 in BCR-ABL-transformed cells and plays a key regulatory role in the induction of anti-leukemic responses,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3217, 4574, 22, 18, 1990, 27, 4273, 305, 579, 2042, 4, 439, 2, 4, 386, 84, 3, 3260, 483, 20, 92, 192, 1516, 211, 176, 32, 44, 440, 21, 377, 241, 17, 190, 24, 1, 1062, 1425, 1046, 37, 5, 22, 18, 1990, 27, 125, 16, 363, 1, 8, 763, 308, 1267, 3, 9036, 4977, 216, 8066, 114, 74, 514, 17, 8066, 16, 1755, 2365, 23, 11105, 9664, 2, 6963, 12364, 2, 16, 735, 4, 35, 22, 18, 1990, 27, 2877, 1708, 3, 2359, 283, 1, 1620, 873, 16, 120, 2365, 735, 4, 35, 22, 18, 1990, 27, 2877, 1708, 2, 211, 128, 16, 616, 9, 1489, 5103, 1, 8066, 8066, 1611, 12528, 3, 4977, 8194, 178, 23, 6963, 6465, 6963, 6383, 2, 6963, 4263, 6963, 6567, 6, 1617, 1118, 1, 956, 2691, 24, 1, 442, 2194, 2647, 526, 31, 285, 5, 22, 18, 1990, 27, 120, 99, 4, 982, 1, 3, 6726, 7949, 7434, 1, 956, 2691, 23, 11105, 567, 11105, 641, 2, 11105, 431, 633, 616, 9, 211, 30663, 2, 211, 10443, 29, 3, 8374, 1118, 161, 6726, 840, 6, 1700, 3204, 470, 956, 2691, 4, 94, 6, 223, 3, 583, 2088, 1, 26, 308, 21, 204, 17, 297, 1, 873, 2, 1489, 8036, 2519, 504, 1, 351, 20, 22, 18, 1990, 27, 925, 5, 26, 3, 873, 230, 1620, 1327, 6707, 22, 18, 1990, 27, 517, 1332, 1, 5594, 2015, 4321, 29, 3, 581, 1, 442, 2194, 7, 6767, 114, 74, 514, 17, 3, 873, 8066, 308, 16, 735, 4, 8, 199, 3983, 1253, 1708, 4, 51, 6, 22, 18, 1990, 27, 4, 1062, 1425, 2423, 37, 2, 1698, 8, 825, 1253, 200, 4, 3, 504, 1, 312, 2015, 253]",1671.0,17121928,43
"Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2006-12-08,"A MESSAGE FROM ASCO's PRESIDENT For the second consecutive year, the American Society of Clinical Oncology (ASCO) is publishing Clinical Cancer Advances: Major Research Advances in Cancer Treatment, Prevention, and Screening, an annual review of the most significant cancer research presented or published over the past year. ASCO developed this report to demonstrate the enormous progress being made on the front lines of cancer research today. The report is intended to give all those with an interest in cancer care-the general public, cancer patients and physicians, policymakers, oncologists, and other medical professionals-an accessible summary of the year's most important cancer research advances. These pages report on new targeted therapies that are improving survival and response rates in hard-to-treat cancers such as kidney cancer, HER-2-positive breast cancer, head and neck cancer, and chronic myelogenous leukemia; the FDA's approval of the world's first preventive vaccine for human papillomavirus (HPV), which has the potential to dramatically reduce the global burden of cervical cancer; and advances in the fast-growing field of personalized medicine, including a new lung cancer test that could help physicians better target treatments and predict prognosis. These advances are only part of the landscape. Survival rates are on the rise, the number of cancer deaths in the United States began declining for the first time since 1930, and new research is showing that the rates of certain common cancers, such as those of the breast and colon, have stabilized, and may have even begun to decline. However, cancer research still faces a number of major obstacles. At a time of extraordinary scientific potential, declining federal funding of cancer research threatens to stall or even reverse recent progress. Such funding cuts have already led to fewer clinical trials, fewer talented young physicians entering the field, and a growing bottleneck of basic science discoveries waiting to be ""translated"" into useful therapies and diagnostics. In addition to highlighting the major research advances over the past year, this report also identifies key barriers to accelerating the pace of cancer research and outlines ASCO's recommendations for overcoming them. Despite these and other challenges, there is much good news on the front lines of cancer research. This report demonstrates the essential role of clinical cancer research in finding new and better ways to treat, diagnose, and prevent a group of diseases that strike half of men and one-third of women in the United States.",Journal Article,4792.0,94.0,A MESSAGE FROM ASCO 's PRESIDENT For the second consecutive year the American Society of Clinical Oncology ASCO is publishing Clinical Cancer Advances Major Research Advances in Cancer Treatment Prevention and Screening an annual review of the most significant cancer research presented or published over the past year ASCO developed this report to demonstrate the enormous progress being made on the front lines of cancer research today The report is intended to give all those with an interest in cancer care-the general public cancer patients and physicians policymakers oncologists and other medical professionals-an accessible summary of the year 's most important cancer research advances These pages report on new targeted therapies that are improving survival and response rates in hard-to-treat cancers such as cancer HER-2-positive cancer head and cancer and chronic myelogenous the FDA 's approval of the world 's first preventive vaccine for human papillomavirus HPV which has the potential to dramatically reduce the global burden of cancer and advances in the fast-growing field of personalized medicine including a new cancer test that could help physicians better target treatments and predict prognosis These advances are only part of the landscape Survival rates are on the rise the number of cancer deaths in the United States began declining for the first time since 1930 and new research is showing that the rates of certain common cancers such as those of the and have stabilized and may have even begun to decline However cancer research still faces a number of major obstacles At a time of extraordinary scientific potential declining federal funding of cancer research threatens to stall or even reverse recent progress Such funding cuts have already led to fewer clinical trials fewer talented young physicians entering the field and a growing bottleneck of basic science discoveries waiting to be `` translated '' into useful therapies and diagnostics In addition to highlighting the major research advances over the past year this report also identifies key barriers to accelerating the pace of cancer research and outlines ASCO 's recommendations for overcoming them Despite these and other challenges there is much good news on the front lines of cancer research This report demonstrates the essential role of clinical cancer research in finding new and better ways to treat diagnose and prevent a group of diseases that strike half of men and one-third of women in the United States,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8, 10035, 29, 2697, 292, 15703, 9, 3, 419, 935, 111, 3, 597, 1174, 1, 38, 413, 2697, 16, 31038, 38, 12, 954, 458, 389, 954, 4, 12, 24, 1070, 2, 453, 35, 2114, 206, 1, 3, 96, 93, 12, 389, 917, 15, 983, 252, 3, 1219, 111, 2697, 276, 26, 414, 6, 608, 3, 8790, 1466, 486, 1229, 23, 3, 3007, 285, 1, 12, 389, 5665, 3, 414, 16, 4081, 6, 4978, 62, 135, 5, 35, 1333, 4, 12, 165, 3, 1083, 3067, 12, 7, 2, 1261, 16862, 1339, 2, 127, 484, 3409, 35, 5981, 1962, 1, 3, 111, 292, 96, 305, 12, 389, 954, 46, 14961, 414, 23, 217, 238, 235, 17, 32, 1673, 25, 2, 51, 151, 4, 9327, 6, 943, 163, 225, 22, 12, 1084, 18, 109, 12, 718, 2, 12, 2, 442, 2194, 3, 2078, 292, 1814, 1, 3, 1956, 292, 157, 3494, 1274, 9, 171, 3242, 933, 92, 71, 3, 174, 6, 2729, 969, 3, 1648, 892, 1, 12, 2, 954, 4, 3, 5830, 1921, 1067, 1, 2175, 1807, 141, 8, 217, 12, 412, 17, 359, 987, 1261, 380, 283, 640, 2, 678, 356, 46, 954, 32, 158, 760, 1, 3, 2801, 25, 151, 32, 23, 3, 3693, 3, 207, 1, 12, 1043, 4, 3, 1088, 907, 4603, 6896, 9, 3, 157, 98, 1192, 30582, 2, 217, 389, 16, 2069, 17, 3, 151, 1, 1840, 186, 163, 225, 22, 135, 1, 3, 2, 47, 7368, 2, 68, 47, 871, 6973, 6, 1858, 137, 12, 389, 1234, 19786, 8, 207, 1, 458, 7140, 28, 8, 98, 1, 17915, 3138, 174, 6896, 8536, 5468, 1, 12, 389, 24738, 6, 38315, 15, 871, 1772, 435, 1466, 225, 5468, 28471, 47, 3298, 836, 6, 1497, 38, 143, 1497, 38316, 1169, 1261, 7653, 3, 1067, 2, 8, 1921, 26563, 1, 2795, 3797, 5012, 7598, 6, 40, 5136, 522, 237, 999, 235, 2, 5197, 4, 352, 6, 4051, 3, 458, 389, 954, 252, 3, 1219, 111, 26, 414, 120, 2953, 825, 2160, 6, 13387, 3, 7265, 1, 12, 389, 2, 6510, 2697, 292, 883, 9, 5344, 1370, 550, 46, 2, 127, 1427, 125, 16, 1802, 1178, 8793, 23, 3, 3007, 285, 1, 12, 389, 26, 414, 1902, 3, 1452, 200, 1, 38, 12, 389, 4, 1567, 217, 2, 380, 4245, 6, 943, 6073, 2, 1682, 8, 87, 1, 1342, 17, 38317, 1303, 1, 325, 2, 104, 1282, 1, 117, 4, 3, 1088, 907]",2513.0,17158528,56
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.,Molecular cancer therapeutics,Mol. Cancer Ther.,2006-12-01,"The chemokine receptor CXCR4 mediates the migration of hematopoietic cells to the stroma-derived factor 1alpha (SDF-1alpha)-producing bone marrow microenvironment. Using peptide-based CXCR4 inhibitors derived from the chemokine viral macrophage inflammatory protein II, we tested the hypothesis that the inhibition of CXCR4 increases sensitivity to chemotherapy by interfering with stromal/leukemia cell interactions. First, leukemic cells expressing varying amounts of surface CXCR4 were examined for their chemotactic response to SDF-1alpha or stromal cells, alone or in the presence of different CXCR4 inhibitors. Results showed that the polypeptide RCP168 had the strongest antagonistic effect on the SDF-1alpha- or stromal cell-induced chemotaxis of leukemic cells. Furthermore, RCP168 blocked the binding of anti-CXCR4 monoclonal antibody 12G5 to surface CXCR4 in a concentration-dependent manner and inhibited SDF-1alpha-induced AKT and extracellular signal-regulated kinase phosphorylation. Finally, RCP168 significantly enhanced chemotherapy-induced apoptosis in stroma-cocultured Jurkat, primary chronic lymphocytic leukemia, and in a subset of acute myelogenous leukemia cells harboring Flt3 mutation. Equivalent results were obtained with the small-molecule CXCR4 inhibitor AMD3465. Our data therefore suggest that the SDF-1alpha/CXCR4 interaction contributes to the resistance of leukemia cells to chemotherapy-induced apoptosis. Disruption of these interactions by the peptide CXCR4 inhibitor RCP168 represents a novel strategy for targeting leukemic cells within the bone marrow microenvironment.",Journal Article,4799.0,141.0,The chemokine receptor CXCR4 mediates the migration of hematopoietic cells to the stroma-derived factor 1alpha SDF-1alpha -producing marrow microenvironment Using peptide-based CXCR4 inhibitors derived from the chemokine viral macrophage inflammatory protein II we tested the hypothesis that the inhibition of CXCR4 increases sensitivity to chemotherapy by interfering with stromal/leukemia cell interactions First leukemic cells expressing varying amounts of surface CXCR4 were examined for their chemotactic response to SDF-1alpha or stromal cells alone or in the presence of different CXCR4 inhibitors Results showed that the polypeptide RCP168 had the strongest antagonistic effect on the SDF-1alpha- or stromal cell-induced chemotaxis of leukemic cells Furthermore RCP168 blocked the binding of anti-CXCR4 monoclonal antibody 12G5 to surface CXCR4 in a concentration-dependent manner and inhibited SDF-1alpha-induced AKT and extracellular signal-regulated kinase phosphorylation Finally RCP168 significantly enhanced chemotherapy-induced apoptosis in stroma-cocultured Jurkat primary chronic lymphocytic and in a subset of acute myelogenous cells harboring Flt3 mutation Equivalent results were obtained with the small-molecule CXCR4 inhibitor AMD3465 Our data therefore suggest that the SDF-1alpha/CXCR4 interaction contributes to the resistance of cells to chemotherapy-induced apoptosis Disruption of these interactions by the peptide CXCR4 inhibitor RCP168 represents a novel strategy for targeting leukemic cells within the marrow microenvironment,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,"[3, 3596, 153, 2318, 3961, 3, 1381, 1, 1007, 37, 6, 3, 2477, 526, 161, 5018, 5524, 5018, 3787, 581, 995, 75, 1389, 90, 2318, 222, 526, 29, 3, 3596, 1667, 2674, 1291, 178, 215, 21, 650, 3, 1492, 17, 3, 297, 1, 2318, 1106, 485, 6, 56, 20, 3449, 5, 1126, 2647, 31, 1286, 157, 2015, 37, 1046, 2990, 4939, 1, 1255, 2318, 11, 409, 9, 136, 15279, 51, 6, 5524, 5018, 15, 1126, 37, 279, 15, 4, 3, 463, 1, 338, 2318, 222, 99, 224, 17, 3, 8720, 34192, 42, 3, 3311, 9863, 254, 23, 3, 5524, 5018, 15, 1126, 31, 277, 12561, 1, 2015, 37, 798, 34192, 2582, 3, 791, 1, 312, 2318, 848, 548, 55947, 6, 1255, 2318, 4, 8, 1227, 470, 1708, 2, 879, 5524, 5018, 277, 649, 2, 1976, 1235, 1065, 216, 982, 1368, 34192, 97, 651, 56, 277, 351, 4, 2477, 11444, 8433, 86, 442, 1193, 2, 4, 8, 697, 1, 286, 2194, 37, 2105, 1224, 258, 2017, 99, 11, 683, 5, 3, 302, 1354, 2318, 230, 20532, 114, 74, 673, 309, 17, 3, 5524, 5018, 2318, 915, 2444, 6, 3, 251, 1, 37, 6, 56, 277, 351, 3220, 1, 46, 1286, 20, 3, 1389, 2318, 230, 34192, 1449, 8, 229, 692, 9, 529, 2015, 37, 262, 3, 581, 995]",1557.0,17172414,254
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.,Cancer,Cancer,2007-03-01,"Resistance to imatinib is a frequent clinical problem in advanced phase chronic myelogenous leukemia (CML). A Phase II study was performed on low-dose decitabine, a DNA methyltransferase inhibitor, in combination with imatinib in patients with CML in accelerated phase (AP) and myeloid blastic phase (BP). Patients received decitabine 15 mg/m(2) intravenously daily, 5 days a week for 2 weeks, and imatinib 600 mg orally daily. Global DNA methylation was measured by long interspersed nucleotide element (LINE) bisulfite/pyrosequencing. Twenty-eight patients were enrolled (25 with imatinib resistance; 18 in AP, 10 in BP). A total of 91 cycles (median, 2.5 cycles per patient) was administered. Complete hematologic responses, partial hematologic responses, and hematologic improvement were observed in 9 (32%), 1 (4%), and 2 (7%) patients. Major and minor cytogenetic responses were observed in 5 (18%) and 3 (11%) patients. The hematologic response rate was higher in patients without BCR-ABL kinase mutations (10 of 19, 53%) than in those with mutations (1 of 7, 14%). Median duration of hematologic response was 18 (range, 4 to 107+) weeks. Myelosuppression was the major adverse effect, with neutropenic fever in 9 patients (32%). LINE methylation decreased from 71.6% +/- 0.9% (mean +/- standard error of the mean) to 60.4% +/- 2.0% on Day 5, 60.5% +/- 1.8% on Day 12, and returned to 68.8% +/- 1.4% at peripheral blood recovery. A decrease in LINE methylation tended to be greater in nonresponders than in responders on Days 5 and 12. Combination therapy with decitabine and imatinib is well tolerated and active in advanced phase CML without BCR-ABL kinase mutations.","Clinical Trial, Phase II",4709.0,100.0,Resistance to imatinib is a frequent clinical problem in advanced phase chronic myelogenous CML A Phase II study was performed on low-dose decitabine a DNA methyltransferase inhibitor in combination with imatinib in patients with CML in accelerated phase AP and myeloid blastic phase BP Patients received decitabine 15 mg/m 2 intravenously daily 5 days a week for 2 weeks and imatinib 600 mg orally daily Global DNA methylation was measured by long interspersed nucleotide element LINE bisulfite/pyrosequencing Twenty-eight patients were enrolled 25 with imatinib resistance 18 in AP 10 in BP A total of 91 cycles median 2.5 cycles per patient was administered Complete hematologic responses partial hematologic responses and hematologic improvement were observed in 9 32 1 4 and 2 7 patients Major and minor cytogenetic responses were observed in 5 18 and 3 11 patients The hematologic response rate was higher in patients without BCR-ABL kinase mutations 10 of 19 53 than in those with mutations 1 of 7 14 Median duration of hematologic response was 18 range 4 to 107+ weeks Myelosuppression was the major adverse effect with neutropenic fever in 9 patients 32 LINE methylation decreased from 71.6 +/- 0.9 mean +/- standard error of the mean to 60.4 +/- 2.0 on Day 5 60.5 +/- 1.8 on Day 12 and returned to 68.8 +/- 1.4 at peripheral blood recovery A decrease in LINE methylation tended to be greater in nonresponders than in responders on Days 5 and 12 Combination therapy with decitabine and imatinib is well tolerated and active in advanced phase CML without BCR-ABL kinase mutations,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[251, 6, 577, 16, 8, 908, 38, 2497, 4, 131, 124, 442, 2194, 903, 8, 124, 215, 45, 10, 173, 23, 154, 61, 3004, 8, 261, 3747, 230, 4, 150, 5, 577, 4, 7, 5, 903, 4, 2241, 124, 2517, 2, 533, 6529, 124, 3044, 7, 103, 3004, 167, 81, 188, 18, 1672, 391, 33, 162, 8, 647, 9, 18, 244, 2, 577, 2383, 81, 1428, 391, 1648, 261, 569, 10, 644, 20, 319, 11038, 1579, 4467, 328, 6181, 6031, 737, 659, 7, 11, 346, 243, 5, 577, 251, 203, 4, 2517, 79, 4, 3044, 8, 181, 1, 970, 410, 52, 18, 33, 410, 379, 69, 10, 468, 236, 813, 253, 450, 813, 253, 2, 813, 767, 11, 164, 4, 83, 531, 14, 39, 2, 18, 67, 7, 458, 2, 2278, 1266, 253, 11, 164, 4, 33, 203, 2, 27, 175, 7, 3, 813, 51, 116, 10, 142, 4, 7, 187, 1062, 1425, 216, 138, 79, 1, 326, 699, 76, 4, 135, 5, 138, 14, 1, 67, 213, 52, 654, 1, 813, 51, 10, 203, 184, 39, 6, 3650, 244, 2858, 10, 3, 458, 290, 254, 5, 3659, 2775, 4, 83, 7, 531, 328, 569, 340, 29, 792, 49, 13, 83, 313, 260, 3444, 1, 3, 313, 6, 335, 39, 18, 13, 23, 218, 33, 335, 33, 14, 66, 23, 218, 133, 2, 5157, 6, 806, 66, 14, 39, 28, 672, 315, 1602, 8, 775, 4, 328, 569, 3886, 6, 40, 378, 4, 4498, 76, 4, 1983, 23, 162, 33, 2, 133, 150, 36, 5, 3004, 2, 577, 16, 149, 421, 2, 544, 4, 131, 124, 903, 187, 1062, 1425, 216, 138]",1587.0,17236224,46
"Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2007-02-01,"Results of allogeneic hematopoietic stem cell transplantation (HCT) to treat advanced leukemia or myelodysplastic syndrome (MDS) remain poor due to excessive relapse and transplant-related mortality. To improve transplant outcome in this patient population, 43 patients (median age, 46.1 years) with high-risk or advanced lymphoid (n = 5) or myeloid malignancy (n = 38) were prospectively enrolled on a pilot trial of cytoreduction with intravenous busulfan and melphalan followed by an unmodified HLA-A, -B, and -DRbeta1-matched related (n = 18) or unrelated (n = 25) HCT. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and methotrexate. Thirty-four patients had > or = 5% blasts at the time of HCT; 12 of these had > 20% blasts. Seventeen patients had unfavorable cytogenetics, 8 patients underwent transplantation for secondary MDS or acute myelogenous leukemia, and 4 patients had relapsed after a previous allogeneic transplantation. Although mucositis was the most significant regimen-related toxicity, requiring the addition of folinic acid rescue and failure to receive all 4 doses of methotrexate in 23 patients, the nonrelapse mortality at 30 and 100 days was low at 0% and 16%, respectively. The cumulative incidence of grade II-IV acute GVHD was 24%, and that of extensive chronic GVHD was 7%. With a minimum follow-up of 18 months, the estimated 3-year overall survival is 37% and the estimated disease-free survival (DFS) is 33%. For 18 patients with MDS (< or = RAEB-2) or high-risk myeloproliferative disorder, the estimated 3 year DFS is 61%. These data demonstrate the curative potential of this regimen in patients with high-risk myeloid malignancies.",Clinical Trial,4737.0,22.0,Results of allogeneic hematopoietic stem cell transplantation HCT to treat advanced or syndrome MDS remain poor due to excessive relapse and transplant-related mortality To improve transplant outcome in this patient population 43 patients median age 46.1 years with high-risk or advanced lymphoid n 5 or myeloid malignancy n 38 were prospectively enrolled on a pilot trial of cytoreduction with intravenous busulfan and melphalan followed by an unmodified HLA-A -B and -DRbeta1-matched related n 18 or unrelated n 25 HCT Graft-versus-host disease GVHD prophylaxis consisted of tacrolimus and methotrexate Thirty-four patients had or 5 blasts at the time of HCT 12 of these had 20 blasts Seventeen patients had unfavorable cytogenetics 8 patients underwent transplantation for secondary MDS or acute myelogenous and 4 patients had relapsed after a previous allogeneic transplantation Although mucositis was the most significant regimen-related toxicity requiring the addition of folinic acid rescue and failure to receive all 4 doses of methotrexate in 23 patients the nonrelapse mortality at 30 and 100 days was low at 0 and 16 respectively The cumulative incidence of grade II-IV acute GVHD was 24 and that of extensive chronic GVHD was 7 With a minimum follow-up of 18 months the estimated 3-year overall survival is 37 and the estimated disease-free survival DFS is 33 For 18 patients with MDS or RAEB-2 or high-risk disorder the estimated 3 year DFS is 61 These data demonstrate the curative potential of this regimen in patients with high-risk myeloid malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[99, 1, 1063, 1007, 452, 31, 497, 1085, 6, 943, 131, 15, 681, 1223, 918, 334, 520, 6, 4529, 429, 2, 941, 139, 282, 6, 401, 941, 228, 4, 26, 69, 266, 601, 7, 52, 89, 641, 14, 60, 5, 64, 43, 15, 131, 2303, 78, 33, 15, 533, 710, 78, 519, 11, 1143, 346, 23, 8, 2281, 160, 1, 2844, 5, 1262, 3906, 2, 2370, 370, 20, 35, 10424, 1160, 8, 132, 2, 30379, 655, 139, 78, 203, 15, 2092, 78, 243, 1085, 1599, 185, 1204, 34, 1562, 2049, 1695, 1, 5643, 2, 2116, 977, 294, 7, 42, 15, 33, 2438, 28, 3, 98, 1, 1085, 133, 1, 46, 42, 179, 2438, 3591, 7, 42, 2483, 2510, 66, 7, 208, 497, 9, 568, 1223, 15, 286, 2194, 2, 39, 7, 42, 591, 50, 8, 698, 1063, 497, 242, 2606, 10, 3, 96, 93, 477, 139, 155, 1888, 3, 352, 1, 12175, 971, 4256, 2, 496, 6, 560, 62, 39, 415, 1, 2116, 4, 382, 7, 3, 4640, 282, 28, 201, 2, 394, 162, 10, 154, 28, 13, 2, 245, 106, 3, 967, 287, 1, 88, 215, 478, 286, 1562, 10, 259, 2, 17, 1, 1344, 442, 1562, 10, 67, 5, 8, 2499, 166, 126, 1, 203, 53, 3, 661, 27, 111, 63, 25, 16, 567, 2, 3, 661, 34, 115, 25, 1010, 16, 466, 9, 203, 7, 5, 1223, 15, 20273, 18, 15, 64, 43, 2645, 3, 661, 27, 111, 1010, 16, 713, 46, 74, 608, 3, 1075, 174, 1, 26, 477, 4, 7, 5, 64, 43, 533, 441]",1569.0,17241929,241
Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment.,Cancer research,Cancer Res.,2007-02-01,"The BCR/ABL tyrosine kinase inhibitor imatinib mesylate is highly effective in the treatment of chronic myelogenous leukemia (CML) but fails to eliminate all leukemia cells. Residual leukemia stem and progenitor cells persist in imatinib-responsive patients and may be a potential source of relapse. Previous studies indicate that imatinib preferentially targets dividing cells, and nondividing progenitor cells are resistant to imatinib-mediated apoptosis. We investigated whether growth factor stimulation of progenitor proliferation could reduce the number of residual nondividing cells remaining after imatinib treatment. CML and normal CD34(+) cells were labeled with 5-(and 6-)-carboxyfluorescein diacetate succinimidyl ester (CFSE) to track cell division and cultured in low or high concentrations of growth factor to determine effects of growth factor stimulation on nondividing cells. High growth factor concentrations significantly enhanced CML proliferation with or without imatinib treatment and significantly reduced the number of viable, nondividing CFSE bright cells remaining after imatinib exposure. Stimulation with high growth factor before imatinib treatment further reduced the number of residual nondividing CML CD34(+) cells. Importantly, clinically achievable concentrations of granulocyte macrophage colony-stimulating factor alone or in combination with granulocyte colony-stimulating factor also significantly reduced nondividing CML CD34(+) cells. These results support the potential efficacy of growth factor stimulation in reducing the residual leukemia progenitor population in imatinib-treated patients.",Journal Article,4737.0,66.0,The BCR/ABL tyrosine kinase inhibitor imatinib mesylate is highly effective in the treatment of chronic myelogenous CML but fails to eliminate all cells Residual stem and progenitor cells persist in imatinib-responsive patients and may be a potential source of relapse Previous studies indicate that imatinib preferentially targets dividing cells and nondividing progenitor cells are resistant to imatinib-mediated apoptosis We investigated whether growth factor stimulation of progenitor proliferation could reduce the number of residual nondividing cells remaining after imatinib treatment CML and normal CD34 cells were labeled with 5- and 6- -carboxyfluorescein diacetate succinimidyl ester CFSE to track cell division and cultured in low or high concentrations of growth factor to determine effects of growth factor stimulation on nondividing cells High growth factor concentrations significantly enhanced CML proliferation with or without imatinib treatment and significantly reduced the number of viable nondividing CFSE bright cells remaining after imatinib exposure Stimulation with high growth factor before imatinib treatment further reduced the number of residual nondividing CML CD34 cells Importantly clinically achievable concentrations of granulocyte macrophage colony-stimulating factor alone or in combination with granulocyte colony-stimulating factor also significantly reduced nondividing CML CD34 cells These results support the potential efficacy of growth factor stimulation in reducing the residual progenitor population in imatinib-treated patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1062, 1425, 564, 216, 230, 577, 2347, 16, 561, 323, 4, 3, 24, 1, 442, 2194, 903, 84, 7688, 6, 4964, 62, 37, 753, 452, 2, 2520, 37, 5589, 4, 577, 2443, 7, 2, 68, 40, 8, 174, 2353, 1, 429, 698, 94, 1008, 17, 577, 3509, 637, 9515, 37, 2, 24986, 2520, 37, 32, 436, 6, 577, 517, 351, 21, 565, 317, 129, 161, 2503, 1, 2520, 457, 359, 969, 3, 207, 1, 753, 24986, 37, 1844, 50, 577, 24, 903, 2, 295, 2215, 37, 11, 2841, 5, 33, 2, 49, 30236, 24445, 27885, 9617, 24987, 6, 7446, 31, 5750, 2, 3197, 4, 154, 15, 64, 1003, 1, 129, 161, 6, 223, 176, 1, 129, 161, 2503, 23, 24986, 37, 64, 129, 161, 1003, 97, 651, 903, 457, 5, 15, 187, 577, 24, 2, 97, 405, 3, 207, 1, 2663, 24986, 24987, 9676, 37, 1844, 50, 577, 645, 2503, 5, 64, 129, 161, 348, 577, 24, 195, 405, 3, 207, 1, 753, 24986, 903, 2215, 37, 1859, 505, 6171, 1003, 1, 2764, 2674, 1975, 2122, 161, 279, 15, 4, 150, 5, 2764, 1975, 2122, 161, 120, 97, 405, 24986, 903, 2215, 37, 46, 99, 538, 3, 174, 209, 1, 129, 161, 2503, 4, 1818, 3, 753, 2520, 266, 4, 577, 73, 7]",1574.0,17283145,106
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.,Seminars in hematology,Semin. Hematol.,2007-01-01,"The advent of tyrosine kinase inhibitors (TKIs) has ushered in a new era in the management of chronic myelogenous leukemia (CML). Imatinib, the first TKI to be approved for the treatment of CML and the current standard first-line therapy, has significantly improved the prognosis of patients with CML. Nevertheless, a minority of patients in chronic-phase CML and even more patients with advanced-phase disease demonstrate resistance to imatinib or develop resistance during treatment. In 40% to 50% of cases, this is attributed to the development of mutations that impair the ability of imatinib to bind to and inhibit the constitutively active Bcr-Abl kinase. Consequently, researchers have developed novel, more potent TKIs that can overcome not only Bcr-Abl-dependent mechanisms of resistance, but also those that are Bcr-Abl-independent. These include: dasatinib, a potent dual Bcr-Abl and Src inhibitor; nilotinib, a selective, potent Bcr-Abl inhibitor; bosutinib (SKI-606) and INNO-406 (NS-187), which are both Src-Abl inhibitors; and others. Combination therapy is also being explored concurrently using agents that affect a variety of oncogenic pathways and immune modulation. Herein, we review some of these strategies, particularly those for which clinical data are currently available.",Journal Article,4768.0,25.0,The advent of tyrosine kinase inhibitors TKIs has ushered in a new era in the management of chronic myelogenous CML Imatinib the first TKI to be approved for the treatment of CML and the current standard first-line therapy has significantly improved the prognosis of patients with CML Nevertheless a minority of patients in chronic-phase CML and even more patients with advanced-phase disease demonstrate resistance to imatinib or develop resistance during treatment In 40 to 50 of cases this is attributed to the development of mutations that impair the ability of imatinib to bind to and inhibit the constitutively active Bcr-Abl kinase Consequently researchers have developed novel more potent TKIs that can overcome not only Bcr-Abl-dependent mechanisms of resistance but also those that are Bcr-Abl-independent These include dasatinib a potent dual Bcr-Abl and Src inhibitor nilotinib a selective potent Bcr-Abl inhibitor bosutinib SKI-606 and INNO-406 NS-187 which are both Src-Abl inhibitors and others Combination therapy is also being explored concurrently using agents that affect a variety of oncogenic pathways and immune modulation Herein we review some of these strategies particularly those for which clinical data are currently available,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 4114, 1, 564, 216, 222, 1671, 71, 14250, 4, 8, 217, 1713, 4, 3, 284, 1, 442, 2194, 903, 577, 3, 157, 1379, 6, 40, 850, 9, 3, 24, 1, 903, 2, 3, 291, 260, 157, 328, 36, 71, 97, 231, 3, 356, 1, 7, 5, 903, 3873, 8, 2652, 1, 7, 4, 442, 124, 903, 2, 871, 80, 7, 5, 131, 124, 34, 608, 251, 6, 577, 15, 690, 251, 190, 24, 4, 327, 6, 212, 1, 140, 26, 16, 3073, 6, 3, 193, 1, 138, 17, 6267, 3, 801, 1, 577, 6, 4060, 6, 2, 1433, 3, 2818, 544, 1062, 1425, 216, 3244, 4211, 47, 276, 229, 80, 1157, 1671, 17, 122, 1768, 44, 158, 1062, 1425, 470, 483, 1, 251, 84, 120, 135, 17, 32, 1062, 1425, 306, 46, 643, 1674, 8, 1157, 1828, 1062, 1425, 2, 2023, 230, 2638, 8, 1094, 1157, 1062, 1425, 230, 5936, 13314, 14495, 2, 23580, 8522, 4044, 5568, 92, 32, 110, 2023, 1425, 222, 2, 1749, 150, 36, 16, 120, 486, 1443, 3294, 75, 183, 17, 1158, 8, 1362, 1, 1302, 460, 2, 250, 2356, 1986, 21, 206, 476, 1, 46, 422, 823, 135, 9, 92, 38, 74, 32, 694, 390]",1253.0,17292738,215
Important therapeutic targets in chronic myelogenous leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2007-02-01,"Review the state-of-art knowledge of the biology and therapy of chronic myelogenous leukemia (CML). A review of the literature was undertaken to summarize current information on the pathophysiology of CML and to update data of imatinib mesylate therapy, mechanisms of resistance, and in vitro and clinical data with the new tyrosine kinase inhibitors. Imatinib, which targets the ABL kinase activity of BCR-ABL, has prolonged survival in CML. Despite the efficacy of imatinib, some patients in chronic phase and more in advanced phases of CML develop resistance, frequently as a result of BCR-ABL tyrosine kinase domain mutants that impair imatinib binding but retain enzymatic activity. New tyrosine kinase inhibitors inhibit BCR-ABL more potently than imatinib and maintain activity against an array of imatinib-resistant BCR-ABL mutants. The IC(50) values of nilotinib and dasatinib are at least 10- to 100-fold lower for BCR-ABL compared with imatinib. Phase I-II trials of nilotinib and dasatinib showed high activity in imatinib-resistant CML and Philadelphia chromosome-positive ALL. Dasatinib also inhibits members of the Src family of kinases (SFKs); nilotinib does not. Whether SFKs have a critical role in imatinib resistance or BCR-ABL-mediated oncogenesis is unresolved. Agents that target signals downstream of BCR-ABL (e.g. Ras/Raf and phosphatidylinositol 3-kinase) are under investigation. Understanding the pathophysiology of CML and mechanisms of resistance has produced effective targeted strategies for imatinib-resistant CML.",Journal Article,4737.0,83.0,Review the state-of-art knowledge of the biology and therapy of chronic myelogenous CML A review of the literature was undertaken to summarize current information on the pathophysiology of CML and to update data of imatinib mesylate therapy mechanisms of resistance and in vitro and clinical data with the new tyrosine kinase inhibitors Imatinib which targets the ABL kinase activity of BCR-ABL has prolonged survival in CML Despite the efficacy of imatinib some patients in chronic phase and more in advanced phases of CML develop resistance frequently as a result of BCR-ABL tyrosine kinase domain mutants that impair imatinib binding but retain enzymatic activity New tyrosine kinase inhibitors inhibit BCR-ABL more potently than imatinib and maintain activity against an array of imatinib-resistant BCR-ABL mutants The IC 50 values of nilotinib and dasatinib are at least 10- to 100-fold lower for BCR-ABL compared with imatinib Phase I-II trials of nilotinib and dasatinib showed high activity in imatinib-resistant CML and Philadelphia chromosome-positive ALL Dasatinib also inhibits members of the Src family of kinases SFKs nilotinib does not Whether SFKs have a critical role in imatinib resistance or BCR-ABL-mediated oncogenesis is unresolved Agents that target signals downstream of BCR-ABL e.g Ras/Raf and phosphatidylinositol 3-kinase are under investigation Understanding the pathophysiology of CML and mechanisms of resistance has produced effective targeted strategies for imatinib-resistant CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[206, 3, 1309, 1, 4363, 922, 1, 3, 891, 2, 36, 1, 442, 2194, 903, 8, 206, 1, 3, 789, 10, 2789, 6, 2479, 291, 487, 23, 3, 4320, 1, 903, 2, 6, 2991, 74, 1, 577, 2347, 36, 483, 1, 251, 2, 4, 439, 2, 38, 74, 5, 3, 217, 564, 216, 222, 577, 92, 637, 3, 1425, 216, 128, 1, 1062, 1425, 71, 1069, 25, 4, 903, 550, 3, 209, 1, 577, 476, 7, 4, 442, 124, 2, 80, 4, 131, 3523, 1, 903, 690, 251, 746, 22, 8, 757, 1, 1062, 1425, 564, 216, 1398, 3423, 17, 6267, 577, 791, 84, 6630, 5226, 128, 217, 564, 216, 222, 1433, 1062, 1425, 80, 4684, 76, 577, 2, 3040, 128, 480, 35, 1926, 1, 577, 436, 1062, 1425, 3423, 3, 2340, 212, 1030, 1, 2638, 2, 1674, 32, 28, 506, 79, 6, 394, 1116, 280, 9, 1062, 1425, 72, 5, 577, 124, 70, 215, 143, 1, 2638, 2, 1674, 224, 64, 128, 4, 577, 436, 903, 2, 3006, 1170, 109, 62, 1674, 120, 1576, 1684, 1, 3, 2023, 607, 1, 1549, 13982, 2638, 1097, 44, 317, 13982, 47, 8, 740, 200, 4, 577, 251, 15, 1062, 1425, 517, 4503, 16, 9420, 183, 17, 283, 2312, 1489, 1, 1062, 1425, 563, 499, 1102, 2212, 2, 3415, 27, 216, 32, 669, 940, 612, 3, 4320, 1, 903, 2, 483, 1, 251, 71, 1687, 323, 238, 422, 9, 577, 436, 903]",1512.0,17317816,179
"A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.",Leukemia & lymphoma,Leuk. Lymphoma,2007-02-01,"Imatinib is the single most effective agent in chronic myelogenous leukemia (CML) in blast phase (BP), inducing hematologic responses in 30 - 50% of patients. However, only a few of these are complete (CHR) and durable. Imatinib is synergistic with idarubicin and cytarabine. We administered imatinib 600 mg/day, cytarabine 10 mg/day subcutaneous, and idarubicin 12 mg/m2 intravenous every 14 days in 19 patients with CML in myeloid BP. Fourteen patients (74%) achieved a hematologic response: CHR in 9 (47%) (3 with complete and 1 with minor cytogenetic responses) and return to chronic phase (RTC) in 5 (26%). Median duration of response was 10 weeks (range, 2 - 89). Six patients received allogeneic stem cell transplantation: 4 CHR, 1 chronic phase and 1 BP. Median survival was 5 months (range, 2 - 20 months). This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP.",Journal Article,4737.0,38.0,Imatinib is the single most effective agent in chronic myelogenous CML in blast phase BP inducing hematologic responses in 30 50 of patients However only a few of these are complete CHR and durable Imatinib is synergistic with idarubicin and cytarabine We administered imatinib 600 mg/day cytarabine 10 mg/day subcutaneous and idarubicin 12 mg/m2 intravenous every 14 days in 19 patients with CML in myeloid BP Fourteen patients 74 achieved a hematologic response CHR in 9 47 3 with complete and 1 with minor cytogenetic responses and return to chronic phase RTC in 5 26 Median duration of response was 10 weeks range 2 89 Six patients received allogeneic stem cell transplantation 4 CHR 1 chronic phase and 1 BP Median survival was 5 months range 2 20 months This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 16, 3, 226, 96, 323, 420, 4, 442, 2194, 903, 4, 3112, 124, 3044, 1958, 813, 253, 4, 201, 212, 1, 7, 137, 158, 8, 1021, 1, 46, 32, 236, 8158, 2, 1480, 577, 16, 1806, 5, 5684, 2, 1855, 21, 468, 577, 2383, 81, 218, 1855, 79, 81, 218, 2529, 2, 5684, 133, 81, 821, 1262, 454, 213, 162, 4, 326, 7, 5, 903, 4, 533, 3044, 3225, 7, 794, 513, 8, 813, 51, 8158, 4, 83, 662, 27, 5, 236, 2, 14, 5, 2278, 1266, 253, 2, 4656, 6, 442, 124, 56098, 4, 33, 432, 52, 654, 1, 51, 10, 79, 244, 184, 18, 887, 437, 7, 103, 1063, 452, 31, 497, 39, 8158, 14, 442, 124, 2, 14, 3044, 52, 25, 10, 33, 53, 184, 18, 179, 53, 26, 2379, 477, 16, 323, 2, 149, 421, 2, 4434, 1123, 6, 226, 420, 577, 9, 7, 4, 533, 3044]",888.0,17325887,148
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.,Cancer,Cancer,2007-04-01,"The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented. The outcome of 420 patients with CML post-imatinib failure (resistance-recurrence in 374; toxicities in 46) were reviewed in relation to survival, overall, and by different therapies. The estimated 3-year survival rates were 72% in 88 patients who progressed in chronic phase, 30% in 130 patients who progressed in accelerated phase, 7% in 156 patients who progressed in blastic phase, and 75% in 37 patients in chronic phase with imatinib intolerance. Survival in chronic phase was better when subsequent therapy was nilotinib or dasatinib vs allogeneic stem cell transplant vs others (estimated 2-year survival rates 100% vs 72% vs 67%; P = .01), but not in accelerated-blastic phase. Prognosis post-imatinib failure in chronic phase is reasonable; it is poor if the CML phase post-imatinib failure is accelerated or blastic.",Journal Article,4678.0,70.0,The prognosis of patients with chronic myelogenous CML after failure of imatinib mesylate therapy is not well documented The outcome of 420 patients with CML post-imatinib failure resistance-recurrence in 374 toxicities in 46 were reviewed in relation to survival overall and by different therapies The estimated 3-year survival rates were 72 in 88 patients who progressed in chronic phase 30 in 130 patients who progressed in accelerated phase 7 in 156 patients who progressed in blastic phase and 75 in 37 patients in chronic phase with imatinib intolerance Survival in chronic phase was better when subsequent therapy was nilotinib or dasatinib vs allogeneic stem cell transplant vs others estimated 2-year survival rates 100 vs 72 vs 67 P .01 but not in accelerated-blastic phase Prognosis post-imatinib failure in chronic phase is reasonable it is poor if the CML phase post-imatinib failure is accelerated or blastic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 356, 1, 7, 5, 442, 2194, 903, 50, 496, 1, 577, 2347, 36, 16, 44, 149, 1405, 3, 228, 1, 5401, 7, 5, 903, 539, 577, 496, 251, 146, 4, 10349, 385, 4, 641, 11, 446, 4, 2191, 6, 25, 63, 2, 20, 338, 235, 3, 661, 27, 111, 25, 151, 11, 720, 4, 889, 7, 54, 1839, 4, 442, 124, 201, 4, 3431, 7, 54, 1839, 4, 2241, 124, 67, 4, 5693, 7, 54, 1839, 4, 6529, 124, 2, 481, 4, 567, 7, 4, 442, 124, 5, 577, 5266, 25, 4, 442, 124, 10, 380, 198, 706, 36, 10, 2638, 15, 1674, 105, 1063, 452, 31, 941, 105, 1749, 661, 18, 111, 25, 151, 394, 105, 720, 105, 598, 19, 355, 84, 44, 4, 2241, 6529, 124, 356, 539, 577, 496, 4, 442, 124, 16, 3203, 192, 16, 334, 492, 3, 903, 124, 539, 577, 496, 16, 2241, 15, 6529]",922.0,17342766,264
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.,Clinical lymphoma & myeloma,Clin Lymphoma Myeloma,2007-03-01,"Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome. This arises from a balanced translocation between chromosomes 9 and 22, creating the bcr-abl fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation, which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy. After imatinib treatment, > 90% of patients had a complete hematologic response, and 70%-80% had a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging and exhibit a major change in the natural history of the disease. The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance. The outlook today for patients with CML is much brighter than that of a few years ago.",Journal Article,4709.0,5.0,Chronic myelogenous CML is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome This arises from a balanced translocation between chromosomes 9 and 22 creating the bcr-abl fusion gene It is often stated that the only proven curative option is allogeneic stem cell transplantation which is indicated for only a limited subset of patients The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy After imatinib treatment 90 of patients had a complete hematologic response and 70 -80 had a complete cytogenetic response With 5 years of follow-up the data are very encouraging and exhibit a major change in the natural history of the disease The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance The outlook today for patients with CML is much brighter than that of a few years ago,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 16, 8, 1014, 2, 629, 3034, 1007, 2131, 765, 20, 3, 463, 1, 3, 3006, 1170, 26, 6053, 29, 8, 4115, 2006, 59, 3560, 83, 2, 350, 6147, 3, 1062, 1425, 1212, 145, 192, 16, 629, 8245, 17, 3, 158, 1930, 1075, 1501, 16, 1063, 452, 31, 497, 92, 16, 1103, 9, 158, 8, 383, 697, 1, 7, 3, 1062, 1425, 564, 216, 230, 577, 3324, 8, 458, 3148, 252, 809, 903, 36, 50, 577, 24, 424, 1, 7, 42, 8, 236, 813, 51, 2, 431, 493, 42, 8, 236, 1266, 51, 5, 33, 60, 1, 166, 126, 3, 74, 32, 923, 2269, 2, 2239, 8, 458, 707, 4, 3, 1504, 532, 1, 3, 34, 3, 612, 1, 476, 1, 3, 483, 1, 251, 6, 577, 71, 836, 6, 8, 1321, 193, 1, 217, 183, 17, 822, 1768, 26, 251, 3, 8628, 5665, 9, 7, 5, 903, 16, 1802, 28658, 76, 17, 1, 8, 1021, 60, 5028]",983.0,17382013,98
Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date.,Clinical lymphoma & myeloma,Clin Lymphoma Myeloma,2007-03-01,"Allogeneic hematopoietic stem cell transplantation with an human leukocyte antigen-matched related or unrelated donor has been the curative treatment of choice for young patients with chronic phase chronic myelogenous leukemia. The introduction of imatinib, a selective inhibitor of the Bcr-Abl protein kinase, as well as a new generation of other tyrosine kinase inhibitors that are effective in obtaining major and complete cytogenetic responses with minimal toxicity, has resulted in significant changes in the standard approach for newly diagnosed patients. In this article, we will address the role of allogeneic transplantation in the context of imatinib and other tyrosine kinase inhibitors.",Journal Article,4709.0,7.0,Allogeneic hematopoietic stem cell transplantation with an human leukocyte antigen-matched related or unrelated donor has been the curative treatment of choice for young patients with chronic phase chronic myelogenous The introduction of imatinib a selective inhibitor of the Bcr-Abl protein kinase as well as a new generation of other tyrosine kinase inhibitors that are effective in obtaining major and complete cytogenetic responses with minimal toxicity has resulted in significant changes in the standard approach for newly diagnosed patients In this article we will address the role of allogeneic transplantation in the context of imatinib and other tyrosine kinase inhibitors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 1007, 452, 31, 497, 5, 35, 171, 3627, 448, 655, 139, 15, 2092, 1488, 71, 85, 3, 1075, 24, 1, 1866, 9, 1169, 7, 5, 442, 124, 442, 2194, 3, 2456, 1, 577, 8, 1094, 230, 1, 3, 1062, 1425, 178, 216, 22, 149, 22, 8, 217, 914, 1, 127, 564, 216, 222, 17, 32, 323, 4, 5244, 458, 2, 236, 1266, 253, 5, 1048, 155, 71, 627, 4, 93, 400, 4, 3, 260, 353, 9, 732, 265, 7, 4, 26, 946, 21, 303, 1539, 3, 200, 1, 1063, 497, 4, 3, 1533, 1, 577, 2, 127, 564, 216, 222]",682.0,17382018,7
Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors.,Leukemia research,Leuk. Res.,2007-04-02,"Acquired imatinib resistance in chronic myelogenous leukemia (CML) can be the consequence of mutations in the kinase domain of BCR-ABL or increased protein levels. However, as in other malignancies, acquired resistance to cytostatic drugs is a common reason for treatment failure or disease progression. As a model for drug resistance, we developed a CML cell line resistant to cyclophosphamide (CP). Using oligonucleotide arrays, we examined changes in global gene expression. Selected genes were also examined by real-time PCR and flow cytometry. Neither the parent nor the resistant lines had mutations in their ATP binding domain. Filtering genes with a low-base line expression, a total of 239 genes showed significant changes (162 up- and 77 down-regulated) in the resistant clone. Most of the up-regulated genes were associated with metabolism, signal transduction, or encoded enzymes. The gene for aldehyde dehydrogenase 1 was over-expressed more than 2000-fold in the resistant clone. BCR-ABL was expressed in both cell lines to a comparable extent. When exposed to the tyrosine kinase inhibitors imatinib and nilotinib, both lines were sensitive. In conclusion, we found multiple genetic changes in a CML cell line resistant to CP related to metabolism, signal transduction or apoptosis. Despite these changes, the resistant cells retained sensitivity to tyrosine kinase inhibitors.",Comparative Study,4677.0,10.0,Acquired imatinib resistance in chronic myelogenous CML can be the consequence of mutations in the kinase domain of BCR-ABL or increased protein levels However as in other malignancies acquired resistance to cytostatic drugs is a common reason for treatment failure or disease progression As a model for drug resistance we developed a CML cell line resistant to cyclophosphamide CP Using oligonucleotide arrays we examined changes in global gene expression Selected genes were also examined by real-time PCR and flow cytometry Neither the parent nor the resistant lines had mutations in their ATP binding domain Filtering genes with a low-base line expression a total of 239 genes showed significant changes 162 up- and 77 down-regulated in the resistant clone Most of the up-regulated genes were associated with metabolism signal transduction or encoded enzymes The gene for aldehyde dehydrogenase 1 was over-expressed more than 2000-fold in the resistant clone BCR-ABL was expressed in both cell lines to a comparable extent When exposed to the tyrosine kinase inhibitors imatinib and nilotinib both lines were sensitive In conclusion we found multiple genetic changes in a CML cell line resistant to CP related to metabolism signal transduction or apoptosis Despite these changes the resistant cells retained sensitivity to tyrosine kinase inhibitors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1294, 577, 251, 4, 442, 2194, 903, 122, 40, 3, 4177, 1, 138, 4, 3, 216, 1398, 1, 1062, 1425, 15, 101, 178, 148, 137, 22, 4, 127, 441, 1294, 251, 6, 8154, 600, 16, 8, 186, 3852, 9, 24, 496, 15, 34, 91, 22, 8, 202, 9, 234, 251, 21, 276, 8, 903, 31, 328, 436, 6, 1112, 2541, 75, 4727, 3923, 21, 409, 400, 4, 1648, 145, 55, 715, 214, 11, 120, 409, 20, 1589, 98, 604, 2, 1412, 1914, 2174, 3, 3841, 2110, 3, 436, 285, 42, 138, 4, 136, 3918, 791, 1398, 15234, 214, 5, 8, 154, 1782, 328, 55, 8, 181, 1, 7141, 214, 224, 93, 400, 5441, 126, 2, 849, 1328, 1065, 4, 3, 436, 3910, 96, 1, 3, 126, 1065, 214, 11, 41, 5, 1600, 1235, 2761, 15, 4587, 3039, 3, 145, 9, 10657, 2374, 14, 10, 252, 570, 80, 76, 1081, 1116, 4, 3, 436, 3910, 1062, 1425, 10, 570, 4, 110, 31, 285, 6, 8, 1279, 1039, 198, 2234, 6, 3, 564, 216, 222, 577, 2, 2638, 110, 285, 11, 745, 4, 1221, 21, 204, 232, 336, 400, 4, 8, 903, 31, 328, 436, 6, 2541, 139, 6, 1600, 1235, 2761, 15, 351, 550, 46, 400, 3, 436, 37, 3532, 485, 6, 564, 216, 222]",1353.0,17403535,14
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.,Molecular pharmacology,Mol. Pharmacol.,2007-06-26,"The effects of the multikinase inhibitor sorafenib (BAY 43-9006), an agent shown previously to induce apoptosis in human leukemia cells through inhibition of myeloid cell leukemia-1 (Mcl-1) translation, have been examined in Bcr/Abl(+) leukemia cells resistant to imatinib mesylate (IM). When administered at pharmacologically relevant concentrations (10-15 microM), sorafenib potently induced apoptosis in imatinib mesylate-resistant cells expressing high levels of Bcr/Abl, cells exhibiting a Bcr/Abl-independent, Lyn-dependent form of resistance, and CD34(+) cells obtained from imatinib-resistant patients. In addition, Ba/F3 cells expressing mutations rendering them resistant to IM (e.g., E255K, M351T) or to IM, dasatinib, and nilotinib (T315I) remained fully sensitive to sorafenib. Induction of apoptosis by sorafenib was associated with rapid and pronounced down-regulation of Mcl-1 and diminished signal transducer and activator of transcription (STAT) 5 phosphorylation and reporter activity but only very modest and delayed inactivation of the Bcr/Abl downstream target Crkl. Moreover, transfection with a constitutively active STAT5 construct partially but significantly protected cells from sorafenib lethality. Ba/F3 cells expressing Bcr/Abl mutations were as sensitive to sorafenib-induced Mcl-1 down-regulation and dephosphorylation of STAT5 and eukaryotic initiation factor 4E as wild-type cells. Finally, stable knockdown of Bcl-2-interacting mediator of cell death (Bim) with short hairpin RNA in K562 cells significantly diminished sorafenib lethality, arguing strongly for a functional role of this proapoptotic Bcl-2 family member in the lethality of this agent. Together, these findings suggest that sorafenib effectively induces apoptosis in highly imatinib-resistant chronic myelogenous leukemia cells, most likely by inhibiting or down-regulating targets (i.e., STAT5 and Mcl-1) downstream or independent of Bcr/Abl.",Journal Article,4592.0,57.0,The effects of the multikinase inhibitor sorafenib BAY 43-9006 an agent shown previously to induce apoptosis in human cells through inhibition of myeloid cell leukemia-1 Mcl-1 translation have been examined in Bcr/Abl cells resistant to imatinib mesylate IM When administered at pharmacologically relevant concentrations 10-15 microM sorafenib potently induced apoptosis in imatinib mesylate-resistant cells expressing high levels of Bcr/Abl cells exhibiting a Bcr/Abl-independent Lyn-dependent form of resistance and CD34 cells obtained from imatinib-resistant patients In addition Ba/F3 cells expressing mutations rendering them resistant to IM e.g. E255K M351T or to IM dasatinib and nilotinib T315I remained fully sensitive to sorafenib Induction of apoptosis by sorafenib was associated with rapid and pronounced down-regulation of Mcl-1 and diminished signal transducer and activator of transcription STAT 5 phosphorylation and reporter activity but only very modest and delayed inactivation of the Bcr/Abl downstream target Crkl Moreover transfection with a constitutively active STAT5 construct partially but significantly protected cells from sorafenib lethality Ba/F3 cells expressing Bcr/Abl mutations were as sensitive to sorafenib-induced Mcl-1 down-regulation and dephosphorylation of STAT5 and eukaryotic initiation factor 4E as wild-type cells Finally stable knockdown of Bcl-2-interacting mediator of cell death Bim with short hairpin RNA in K562 cells significantly diminished sorafenib lethality arguing strongly for a functional role of this proapoptotic Bcl-2 family member in the lethality of this agent Together these findings suggest that sorafenib effectively induces apoptosis in highly imatinib-resistant chronic myelogenous cells most likely by inhibiting or down-regulating targets i.e. STAT5 and Mcl-1 downstream or independent of Bcr/Abl,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 176, 1, 3, 6524, 230, 1034, 7444, 601, 12387, 35, 420, 443, 373, 6, 1290, 351, 4, 171, 37, 298, 297, 1, 533, 31, 2647, 14, 1308, 14, 2691, 47, 85, 409, 4, 1062, 1425, 37, 436, 6, 577, 2347, 2820, 198, 468, 28, 7854, 867, 1003, 79, 167, 3550, 1034, 4684, 277, 351, 4, 577, 2347, 436, 37, 1046, 64, 148, 1, 1062, 1425, 37, 4801, 8, 1062, 1425, 306, 8309, 470, 1297, 1, 251, 2, 2215, 37, 683, 29, 577, 436, 7, 4, 352, 6669, 6904, 37, 1046, 138, 9535, 1370, 436, 6, 2820, 563, 499, 16677, 30931, 15, 6, 2820, 1674, 2, 2638, 6184, 958, 1910, 745, 6, 1034, 504, 1, 351, 20, 1034, 10, 41, 5, 1321, 2, 3517, 1328, 863, 1, 1308, 14, 2, 2849, 1235, 5182, 2, 3393, 1, 866, 4168, 33, 982, 2, 3674, 128, 84, 158, 923, 1721, 2, 1612, 2297, 1, 3, 1062, 1425, 1489, 283, 13765, 1393, 3789, 5, 8, 2818, 544, 5517, 3883, 2995, 84, 97, 5541, 37, 29, 1034, 3266, 6669, 6904, 37, 1046, 1062, 1425, 138, 11, 22, 745, 6, 1034, 277, 1308, 14, 1328, 863, 2, 7849, 1, 5517, 2, 8374, 1118, 161, 6726, 22, 955, 267, 37, 1368, 585, 1563, 1, 1044, 18, 5505, 3810, 1, 31, 273, 3595, 5, 978, 5957, 893, 4, 5208, 37, 97, 2849, 1034, 3266, 13009, 1327, 9, 8, 583, 200, 1, 26, 4118, 1044, 18, 607, 2693, 4, 3, 3266, 1, 26, 420, 1162, 46, 272, 309, 17, 1034, 1856, 1516, 351, 4, 561, 577, 436, 442, 2194, 37, 96, 322, 20, 2062, 15, 1328, 2681, 637, 70, 563, 5517, 2, 1308, 14, 1489, 15, 306, 1, 1062, 1425]",1868.0,17595328,60
Ras as a therapeutic target in hematologic malignancies.,Expert opinion on emerging drugs,Expert Opin Emerg Drugs,2007-05-01,"The RAS gene product is normally a membrane-localized G protein (N-Ras, K-Ras and H-Ras) of 21 kDa classically described as a molecular off/on switch. It is inactive when bound to guanosine diphosphate and active when bound to GTP. When mutated, the gene produces an abnormal protein resistant to GTP hydrolysis by GTPase, resulting in a constitutively active GTP-bound protein that stimulates a critical network of signal transduction pathways that lead to cellular proliferation, survival and differentiation. At least three downstream effector pathways have been described, including Raf/MEK/ERK, PI3K/AKT and RalGDS, but they are not completely understood. Ras pathways are also important downstream effectors of several receptor tyrosine kinases localized in the cell membrane, most notably the BCR-ABL fusion protein seen in patients with Philadelphia chromosome positive chronic myelogenous leukemia. An important consideration in designing strategies to block Ras stimulatory effect is that Ras proteins are synthesized in the cytosol, but require post-translational modifications and attachment to anchor proteins or membrane binding sites in the cell membrane to be biologically active. Farnesyl transferase inhibitors (FTIs) are probably the best-studied class of Ras inhibitors in hematologic malignancies. They block the enzyme farnesyl-transferase (FTase), which is essential for post-translational modification. However, it has been observed that the Ras proteins also can be geranylgeranylated in the presence of FTIs, thus allowing membrane localization and activation, which limits their effectiveness. It is now hypothesized that their mechanism of action may be through FTase inhibition involving other signal transduction pathways. S-trans, trans-farnesylthiosalicylic acid, which was first designed as a prenylated protein methyltransferase inhibitor, has shown in vitro activity against all activated Ras proteins by dislodging them from their membrane-anchoring sites. Here, Ras biology, its signaling pathways and its implications as a therapeutic target in hematologic malignancies are reviewed.",Journal Article,4648.0,28.0,The RAS gene product is normally a membrane-localized G protein N-Ras K-Ras and H-Ras of 21 kDa classically described as a molecular off/on switch It is inactive when bound to guanosine diphosphate and active when bound to GTP When mutated the gene produces an abnormal protein resistant to GTP hydrolysis by GTPase resulting in a constitutively active GTP-bound protein that stimulates a critical network of signal transduction pathways that lead to cellular proliferation survival and differentiation At least three downstream effector pathways have been described including Raf/MEK/ERK PI3K/AKT and RalGDS but they are not completely understood Ras pathways are also important downstream effectors of several receptor tyrosine kinases localized in the cell membrane most notably the BCR-ABL fusion protein seen in patients with Philadelphia chromosome positive chronic myelogenous An important consideration in designing strategies to block Ras stimulatory effect is that Ras proteins are synthesized in the cytosol but require post-translational modifications and attachment to anchor proteins or membrane binding sites in the cell membrane to be biologically active Farnesyl transferase inhibitors FTIs are probably the best-studied class of Ras inhibitors in hematologic malignancies They block the enzyme farnesyl-transferase FTase which is essential for post-translational modification However it has been observed that the Ras proteins also can be geranylgeranylated in the presence of FTIs thus allowing membrane localization and activation which limits their effectiveness It is now hypothesized that their mechanism of action may be through FTase inhibition involving other signal transduction pathways S-trans trans-farnesylthiosalicylic acid which was first designed as a prenylated protein methyltransferase inhibitor has shown in vitro activity against all activated Ras proteins by dislodging them from their membrane-anchoring sites Here Ras biology its signaling pathways and its implications as a therapeutic target in hematologic malignancies are reviewed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1102, 145, 2821, 16, 6150, 8, 1905, 909, 499, 178, 78, 1102, 1634, 1102, 2, 555, 1102, 1, 239, 6362, 9260, 1027, 22, 8, 219, 1889, 23, 5096, 192, 16, 5002, 198, 2951, 6, 14478, 8762, 2, 544, 198, 2951, 6, 9969, 198, 1185, 3, 145, 4042, 35, 1668, 178, 436, 6, 9969, 15205, 20, 9189, 1113, 4, 8, 2818, 544, 9969, 2951, 178, 17, 6200, 8, 740, 1801, 1, 1235, 2761, 460, 17, 1122, 6, 763, 457, 25, 2, 910, 28, 506, 169, 1489, 2070, 460, 47, 85, 1027, 141, 2212, 1693, 1819, 974, 649, 2, 56365, 84, 491, 32, 44, 2500, 1784, 1102, 460, 32, 120, 305, 1489, 4926, 1, 392, 153, 564, 1549, 909, 4, 3, 31, 1905, 96, 2552, 3, 1062, 1425, 1212, 178, 527, 4, 7, 5, 3006, 1170, 109, 442, 2194, 35, 305, 2415, 4, 5048, 422, 6, 2381, 1102, 6708, 254, 16, 17, 1102, 652, 32, 5134, 4, 3, 11107, 84, 1353, 539, 2460, 2916, 2, 9364, 6, 15192, 652, 15, 1905, 791, 633, 4, 3, 31, 1905, 6, 40, 2665, 544, 8846, 4402, 222, 8576, 32, 4061, 3, 824, 656, 1040, 1, 1102, 222, 4, 813, 441, 491, 2381, 3, 1644, 8846, 4402, 14104, 92, 16, 1452, 9, 539, 2460, 2437, 137, 192, 71, 85, 164, 17, 3, 1102, 652, 120, 122, 40, 44763, 4, 3, 463, 1, 8576, 631, 2952, 1905, 2145, 2, 363, 92, 3526, 136, 1236, 192, 16, 1134, 1237, 17, 136, 670, 1, 1578, 68, 40, 298, 14104, 297, 1267, 127, 1235, 2761, 460, 695, 3437, 3437, 33909, 971, 92, 10, 157, 1114, 22, 8, 43506, 178, 3747, 230, 71, 443, 4, 439, 128, 480, 62, 735, 1102, 652, 20, 37672, 1370, 29, 136, 1905, 26610, 633, 467, 1102, 891, 211, 314, 460, 2, 211, 1268, 22, 8, 189, 283, 4, 813, 441, 32, 446]",2076.0,17604501,137
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2007-07-01,"Interactions between the multikinase inhibitor sorafenib (Bay 43-9006) and the histone deacetylase inhibitor vorinostat were examined in chronic myelogenous leukemia (CML) cells sensitive and resistant to imatinib mesylate. K562, LAMA 84, and primary CML patient-derived CD34(+) mononuclear cells were exposed to vorinostat followed by sorafenib, after which effects on cell viability and various survival signaling pathways were monitored by flow cytometry, clonogenic assays, and Western blotting. Real-time reverse transcription-PCR was used to monitor gene expression, and the functional contribution of p21(CIP1) and Mcl-1 down-regulation were determined in cells transfected with corresponding constructs. Pretreatment (24 h) with vorinostat followed by sorafenib optimally induced mitochondrial injury and cell death in Bcr/Abl(+) cells (e.g., K562 and LAMA 84). Similar results were obtained in imatinib mesylate-resistant cells expressing activated Lyn as well as in primary CD34(+) bone marrow cells obtained from CML patients. This regimen also markedly inhibited CML cell colony formation. Combined but not individual treatment of CML cells with vorinostat and sorafenib triggered pronounced mitochondrial dysfunction (i.e., cytochrome c, Smac, and AIF release), caspase activation, poly(ADP-ribose) polymerase cleavage, and down-regulation of Mcl-1. Sorafenib also blocked vorinostat-mediated induction of p21(CIP1). Down-regulation of Mcl-1 was caspase and transcription independent, whereas p21(CIP1) down-regulation was partially caspase and transcription dependent. Enforced expression of p21(CIP1) and particularly Mcl-1 significantly attenuated vorinostat/sorafenib-mediated lethality. These findings suggest that combined treatment with vorinostat and sorafenib synergistically induces apoptosis in CML cells through a process that involves Mcl-1 down-regulation and inhibition of p21(CIP1) induction.",Journal Article,4587.0,59.0,Interactions between the multikinase inhibitor sorafenib Bay 43-9006 and the histone deacetylase inhibitor vorinostat were examined in chronic myelogenous CML cells sensitive and resistant to imatinib mesylate K562 LAMA 84 and primary CML patient-derived CD34 mononuclear cells were exposed to vorinostat followed by sorafenib after which effects on cell viability and various survival signaling pathways were monitored by flow cytometry clonogenic assays and Western blotting Real-time reverse transcription-PCR was used to monitor gene expression and the functional contribution of p21 CIP1 and Mcl-1 down-regulation were determined in cells transfected with corresponding constructs Pretreatment 24 h with vorinostat followed by sorafenib optimally induced mitochondrial injury and cell death in Bcr/Abl cells e.g. K562 and LAMA 84 Similar results were obtained in imatinib mesylate-resistant cells expressing activated Lyn as well as in primary CD34 marrow cells obtained from CML patients This regimen also markedly inhibited CML cell colony formation Combined but not individual treatment of CML cells with vorinostat and sorafenib triggered pronounced mitochondrial dysfunction i.e. cytochrome c Smac and AIF release caspase activation poly ADP-ribose polymerase cleavage and down-regulation of Mcl-1 Sorafenib also blocked vorinostat-mediated induction of p21 CIP1 Down-regulation of Mcl-1 was caspase and transcription independent whereas p21 CIP1 down-regulation was partially caspase and transcription dependent Enforced expression of p21 CIP1 and particularly Mcl-1 significantly attenuated vorinostat/sorafenib-mediated lethality These findings suggest that combined treatment with vorinostat and sorafenib synergistically induces apoptosis in CML cells through a process that involves Mcl-1 down-regulation and inhibition of p21 CIP1 induction,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1286, 59, 3, 6524, 230, 1034, 7444, 601, 12387, 2, 3, 1508, 2732, 230, 2371, 11, 409, 4, 442, 2194, 903, 37, 745, 2, 436, 6, 577, 2347, 5208, 21071, 874, 2, 86, 903, 69, 526, 2215, 3041, 37, 11, 2234, 6, 2371, 370, 20, 1034, 50, 92, 176, 23, 31, 2120, 2, 747, 25, 314, 460, 11, 2909, 20, 1412, 1914, 3798, 1013, 2, 1521, 3661, 1589, 98, 1772, 866, 604, 10, 95, 6, 3334, 145, 55, 2, 3, 583, 2925, 1, 2657, 6927, 2, 1308, 14, 1328, 863, 11, 509, 4, 37, 3245, 5, 1734, 5500, 1194, 259, 555, 5, 2371, 370, 20, 1034, 5074, 277, 2019, 2730, 2, 31, 273, 4, 1062, 1425, 37, 563, 499, 5208, 2, 21071, 874, 288, 99, 11, 683, 4, 577, 2347, 436, 37, 1046, 735, 8309, 22, 149, 22, 4, 86, 2215, 581, 37, 683, 29, 903, 7, 26, 477, 120, 2195, 879, 903, 31, 1975, 1264, 397, 84, 44, 797, 24, 1, 903, 37, 5, 2371, 2, 1034, 4173, 3517, 2019, 1527, 70, 563, 4155, 256, 9251, 2, 10092, 2008, 1469, 363, 2699, 3638, 3507, 1451, 3155, 2, 1328, 863, 1, 1308, 14, 1034, 120, 2582, 2371, 517, 504, 1, 2657, 6927, 1328, 863, 1, 1308, 14, 10, 1469, 2, 866, 306, 547, 2657, 6927, 1328, 863, 10, 2995, 1469, 2, 866, 470, 7807, 55, 1, 2657, 6927, 2, 823, 1308, 14, 97, 2656, 2371, 1034, 517, 3266, 46, 272, 309, 17, 397, 24, 5, 2371, 2, 1034, 4240, 1516, 351, 4, 903, 37, 298, 8, 1129, 17, 2921, 1308, 14, 1328, 863, 2, 297, 1, 2657, 6927, 504]",1857.0,17634558,121
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.,The Journal of clinical investigation,J. Clin. Invest.,2007-09-01,"Molecularly targeted kinase inhibitor cancer therapies are currently administered sequentially rather than simultaneously. We addressed the potential long-term impact of this strategy in patients with chronic myelogenous leukemia (CML), which is driven by the fusion oncogene BCR-ABL. Analysis of BCR-ABL genotypes in CML patients who relapsed after sequential treatment with the ABL inhibitors imatinib and dasatinib revealed evolving resistant BCR-ABL kinase domain mutations in all cases. Twelve patients relapsed with the pan-resistant T315I mutation, whereas 6 patients developed novel BCR-ABL mutations predicted to retain sensitivity to imatinib based on in vitro studies. Three of these patients were retreated with imatinib (or the chemically related compound nilotinib) and responded; however, selection for compound mutants (2 or 3 BCR-ABL mutations in the same molecule) can substantially limit the potential effectiveness of retreating patients with inhibitors that have previously failed. Furthermore, drug-resistant mutations, when compounded, can increase oncogenic potency relative to the component mutants in transformation assays. The Aurora kinase inhibitor VX-680, currently under clinical evaluation based on its activity against the T315I mutation, is also effective against the other commonly detected dasatinib-resistant mutation in our analysis, V299L. Our findings demonstrate the potential hazards of sequential kinase inhibitor therapy and suggest a role for a combination of ABL kinase inhibitors, perhaps including VX-680, to prevent the outgrowth of cells harboring drug-resistant BCR-ABL mutations.",Journal Article,4525.0,290.0,Molecularly targeted kinase inhibitor cancer therapies are currently administered sequentially rather than simultaneously We addressed the potential long-term impact of this strategy in patients with chronic myelogenous CML which is driven by the fusion oncogene BCR-ABL Analysis of BCR-ABL genotypes in CML patients who relapsed after sequential treatment with the ABL inhibitors imatinib and dasatinib revealed evolving resistant BCR-ABL kinase domain mutations in all cases Twelve patients relapsed with the pan-resistant T315I mutation whereas 6 patients developed novel BCR-ABL mutations predicted to retain sensitivity to imatinib based on in vitro studies Three of these patients were retreated with imatinib or the chemically related compound nilotinib and responded however selection for compound mutants 2 or 3 BCR-ABL mutations in the same molecule can substantially limit the potential effectiveness of retreating patients with inhibitors that have previously failed Furthermore drug-resistant mutations when compounded can increase oncogenic potency relative to the component mutants in transformation assays The Aurora kinase inhibitor VX-680 currently under clinical evaluation based on its activity against the T315I mutation is also effective against the other commonly detected dasatinib-resistant mutation in our analysis V299L Our findings demonstrate the potential hazards of sequential kinase inhibitor therapy and suggest a role for a combination of ABL kinase inhibitors perhaps including VX-680 to prevent the outgrowth of cells harboring drug-resistant BCR-ABL mutations,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2372, 238, 216, 230, 12, 235, 32, 694, 468, 5455, 1832, 76, 3074, 21, 2814, 3, 174, 319, 337, 345, 1, 26, 692, 4, 7, 5, 442, 2194, 903, 92, 16, 1621, 20, 3, 1212, 1836, 1062, 1425, 65, 1, 1062, 1425, 2071, 4, 903, 7, 54, 591, 50, 1787, 24, 5, 3, 1425, 222, 577, 2, 1674, 553, 3276, 436, 1062, 1425, 216, 1398, 138, 4, 62, 140, 2544, 7, 591, 5, 3, 3055, 436, 6184, 258, 547, 49, 7, 276, 229, 1062, 1425, 138, 783, 6, 6630, 485, 6, 577, 90, 23, 4, 439, 94, 169, 1, 46, 7, 11, 11088, 5, 577, 15, 3, 9343, 139, 2823, 2638, 2, 2211, 137, 881, 9, 2823, 3423, 18, 15, 27, 1062, 1425, 138, 4, 3, 827, 1354, 122, 2109, 2385, 3, 174, 1236, 1, 44823, 7, 5, 222, 17, 47, 373, 1551, 798, 234, 436, 138, 198, 18416, 122, 344, 1302, 3593, 580, 6, 3, 1249, 3423, 4, 1392, 1013, 3, 4095, 216, 230, 9009, 9297, 694, 669, 38, 451, 90, 23, 211, 128, 480, 3, 6184, 258, 16, 120, 323, 480, 3, 127, 841, 530, 1674, 436, 258, 4, 114, 65, 44824, 114, 272, 608, 3, 174, 1017, 1, 1787, 216, 230, 36, 2, 309, 8, 200, 9, 8, 150, 1, 1425, 216, 222, 4434, 141, 9009, 9297, 6, 1682, 3, 7201, 1, 37, 2105, 234, 436, 1062, 1425, 138]",1596.0,17710227,215
"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.",The Journal of clinical investigation,J. Clin. Invest.,2007-09-01,"Blast crisis chronic myelogenous leukemia (CML-BC) and Philadelphia chromosome-positive (Ph1-positive) acute lymphocytic leukemia (ALL) are 2 fatal BCR/ABL-driven leukemias against which Abl kinase inhibitors fail to induce a long-term response. We recently reported that functional loss of protein phosphatase 2A (PP2A) activity is important for CML blastic transformation. We assessed the therapeutic potential of the PP2A activator FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride), an immunomodulator in Phase III trials for patients with multiple sclerosis or undergoing organ transplantation, in CML-BC and Ph1 ALL patient cells and in in vitro and in vivo models of these BCR/ABL+ leukemias. Our data indicate that FTY720 induces apoptosis and impairs clonogenicity of imatinib/dasatinib-sensitive and -resistant p210/p190(BCR/ABL) myeloid and lymphoid cell lines and CML-BC(CD34+) and Ph1 ALL(CD34+/CD19+) progenitors but not of normal CD34+ and CD34+/CD19+ bone marrow cells. Furthermore, pharmacologic doses of FTY720 remarkably suppress in vivo p210/p190(BCR/ABL)-driven [including p210/p190(BCR/ABL)(T315I)] leukemogenesis without exerting any toxicity. Altogether, these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients.",Journal Article,4525.0,271.0,"Blast crisis chronic myelogenous CML-BC and Philadelphia chromosome-positive Ph1-positive acute lymphocytic ALL are 2 fatal BCR/ABL-driven leukemias against which Abl kinase inhibitors fail to induce a long-term response We recently reported that functional loss of protein phosphatase 2A PP2A activity is important for CML blastic transformation We assessed the therapeutic potential of the PP2A activator FTY720 2-amino-2- 2- 4-octylphenyl ethyl -1,3-propanediol hydrochloride an immunomodulator in Phase III trials for patients with multiple sclerosis or undergoing organ transplantation in CML-BC and Ph1 ALL patient cells and in in vitro and in vivo models of these BCR/ABL+ leukemias Our data indicate that FTY720 induces apoptosis and impairs clonogenicity of imatinib/dasatinib-sensitive and -resistant p210/p190 BCR/ABL myeloid and lymphoid cell lines and CML-BC CD34+ and Ph1 ALL CD34+/CD19+ progenitors but not of normal CD34+ and CD34+/CD19+ marrow cells Furthermore pharmacologic doses of FTY720 remarkably suppress in vivo p210/p190 BCR/ABL -driven including p210/p190 BCR/ABL T315I leukemogenesis without exerting any toxicity Altogether these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients",0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3112, 6540, 442, 2194, 903, 1402, 2, 3006, 1170, 109, 21381, 109, 286, 1193, 62, 32, 18, 3034, 1062, 1425, 1621, 2792, 480, 92, 1425, 216, 222, 4373, 6, 1290, 8, 319, 337, 51, 21, 761, 210, 17, 583, 407, 1, 178, 2577, 4707, 7890, 128, 16, 305, 9, 903, 6529, 1392, 21, 275, 3, 189, 174, 1, 3, 7890, 3393, 6340, 18, 3078, 18, 18, 39, 56484, 10559, 14, 27, 56485, 12268, 35, 21196, 4, 124, 316, 143, 9, 7, 5, 232, 7426, 15, 479, 1259, 497, 4, 903, 1402, 2, 21381, 62, 69, 37, 2, 4, 4, 439, 2, 4, 386, 274, 1, 46, 1062, 1425, 2792, 114, 74, 1008, 17, 6340, 1516, 351, 2, 8312, 9880, 1, 577, 1674, 745, 2, 436, 11538, 18813, 1062, 1425, 533, 2, 2303, 31, 285, 2, 903, 1402, 2215, 2, 21381, 62, 2215, 3158, 4321, 84, 44, 1, 295, 2215, 2, 2215, 3158, 581, 37, 798, 2788, 415, 1, 6340, 4856, 3134, 4, 386, 11538, 18813, 1062, 1425, 1621, 141, 11538, 18813, 1062, 1425, 6184, 5661, 187, 17648, 500, 155, 6767, 46, 99, 1817, 3, 189, 2088, 1, 31159, 7890, 30, 1245, 128, 4, 21381, 2792, 2, 1327, 538, 3, 2456, 1, 3, 7890, 3393, 6340, 4, 3, 24, 1, 903, 1402, 2, 21381, 62, 7]",1377.0,17717597,79
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.,Cancer,Cancer,2007-11-01,"The tolerability and efficacy of the combination of tipifarnib, an orally bioavailable nonpeptidomimetic farnesyl transferase inhibitor, and imatinib was investigated in patients with chronic myelogenous leukemia in chronic phase who had failed imatinib. Twenty-six patients (13 [50%] with Abl kinase domain mutations) were treated. The initial dose level was tipifarnib at a dose of 300 mg twice daily and imatinib at a dose of 300 mg daily. Therapy was escalated following a '3 + 3' phase 1 design and the maximum tolerated dose was defined as tipifarnib at a dose of 400 mg twice daily and imatinib at a dose of 400 mg daily. Therapy was administered for a median of 26 weeks (range, 3-150 weeks). Adverse events included diarrhea in 21 patients (81%) and nausea in 18 patients (69%), but were generally grade 2 or less (using the revised National Cancer Institute Common Toxicity Criteria). Grade 3-4 neutropenia and thrombocytopenia occurred in 11 patients (42%) and 8 patients (31%), respectively. Sixteen patients discontinued therapy (5 due to toxicity and 11 due to lack of response or disease progression). Hematologic responses were attained by 17 (68%) of 25 assessable patients. Nine patients (36%) also achieved a cytogenetic response (3 complete responses, 4 partial responses, and 2 minimal responses), including 4 patients harboring mutant Bcr-Abl tyrosine kinases. One patient bearing the highly imatinib-resistant T315I mutant achieved a partial cytogenetic response. The median response duration was 3 months (range, 2-30+ months). The combination of tipifarnib and imatinib is well tolerated and has activity against several Abl kinase domain mutants. Combinations of tipifarnib with more potent tyrosine kinase inhibitors warrant further investigation.","Clinical Trial, Phase I",4464.0,29.0,The tolerability and efficacy of the combination of tipifarnib an orally bioavailable nonpeptidomimetic farnesyl transferase inhibitor and imatinib was investigated in patients with chronic myelogenous in chronic phase who had failed imatinib Twenty-six patients 13 50 with Abl kinase domain mutations were treated The initial dose level was tipifarnib at a dose of 300 mg twice daily and imatinib at a dose of 300 mg daily Therapy was escalated following a 3 3 phase 1 design and the maximum tolerated dose was defined as tipifarnib at a dose of 400 mg twice daily and imatinib at a dose of 400 mg daily Therapy was administered for a median of 26 weeks range 3-150 weeks Adverse events included diarrhea in 21 patients 81 and nausea in 18 patients 69 but were generally grade 2 or less using the revised National Cancer Institute Common Toxicity Criteria Grade 3-4 neutropenia and thrombocytopenia occurred in 11 patients 42 and 8 patients 31 respectively Sixteen patients discontinued therapy 5 due to toxicity and 11 due to lack of response or disease progression Hematologic responses were attained by 17 68 of 25 assessable patients Nine patients 36 also achieved a cytogenetic response 3 complete responses 4 partial responses and 2 minimal responses including 4 patients harboring mutant Bcr-Abl tyrosine kinases One patient bearing the highly imatinib-resistant T315I mutant achieved a partial cytogenetic response The median response duration was 3 months range 2-30+ months The combination of tipifarnib and imatinib is well tolerated and has activity against several Abl kinase domain mutants Combinations of tipifarnib with more potent tyrosine kinase inhibitors warrant further investigation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1543, 2, 209, 1, 3, 150, 1, 4781, 35, 1428, 6582, 33400, 8846, 4402, 230, 2, 577, 10, 565, 4, 7, 5, 442, 2194, 4, 442, 124, 54, 42, 1551, 577, 737, 437, 7, 233, 212, 5, 1425, 216, 1398, 138, 11, 73, 3, 388, 61, 301, 10, 4781, 28, 8, 61, 1, 2036, 81, 936, 391, 2, 577, 28, 8, 61, 1, 2036, 81, 391, 36, 10, 2842, 366, 8, 27, 27, 124, 14, 771, 2, 3, 689, 421, 61, 10, 395, 22, 4781, 28, 8, 61, 1, 1524, 81, 936, 391, 2, 577, 28, 8, 61, 1, 1524, 81, 391, 36, 10, 468, 9, 8, 52, 1, 432, 244, 184, 27, 1577, 244, 290, 281, 159, 1172, 4, 239, 7, 865, 2, 1218, 4, 203, 7, 790, 84, 11, 1228, 88, 18, 15, 299, 75, 3, 4218, 657, 12, 1377, 186, 155, 371, 88, 27, 39, 778, 2, 1340, 489, 4, 175, 7, 595, 2, 66, 7, 456, 106, 3228, 7, 2402, 36, 33, 520, 6, 155, 2, 175, 520, 6, 926, 1, 51, 15, 34, 91, 813, 253, 11, 5105, 20, 269, 806, 1, 243, 3120, 7, 762, 7, 511, 120, 513, 8, 1266, 51, 27, 236, 253, 39, 450, 253, 2, 18, 1048, 253, 141, 39, 7, 2105, 620, 1062, 1425, 564, 1549, 104, 69, 1894, 3, 561, 577, 436, 6184, 620, 513, 8, 450, 1266, 51, 3, 52, 51, 654, 10, 27, 53, 184, 18, 201, 53, 3, 150, 1, 4781, 2, 577, 16, 149, 421, 2, 71, 128, 480, 392, 1425, 216, 1398, 3423, 1247, 1, 4781, 5, 80, 1157, 564, 216, 222, 2946, 195, 940]",1705.0,17849425,66
"Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae.",Neuroradiology,Neuroradiology,2007-10-09,"During the past three decades, improvements in the treatment of childhood leukemia have resulted in high cure rates, particularly for acute lymphoblastic leukemia (ALL). Unfortunately, successful therapy has come with a price, as significant morbidity can result from neurological affects which harm the brain and spinal cord. The expectation and hope is that chemotherapy, as a primary means of CNS therapy, will result in acceptable disease control with less CNS morbidity than has been observed with combinations of chemotherapy and radiotherapy over the past several decades. In this review we discuss the poignant, historical aspects of CNS leukemia therapy, outline current methods of systemic and CNS leukemia therapy, and present imaging findings we have encountered in childhood leukemia patients with a variety of acute neurological conditions. A major objective of our research is to understand the neuroimaging correlates of acute and chronic effects of cancer and therapy. Specific features related to CNS leukemia and associated short-term toxicities, both disease- and therapy-related, are emphasized in this review with the specific neuroimaging findings. Specific CNS findings are similarly important when treating acute myelogenous leukemia (AML), and details of leukemic involvement and toxicities are also presented in this entity. Despite contemporary treatment approaches which favor the use of chemotherapy (including intrathecal therapy) over radiotherapy in the treatment of CNS leukemia, children still occasionally experience morbid neurotoxicity. Standard neuroimaging is sufficient to identify a variety of neurotoxic sequelae in children, and often suggest specific etiologies. Specific neuroimaging findings frequently indicate a need to alter antileukemia therapy. It is important to appreciate that intrathecal and high doses of systemic chemotherapy are not innocuous and are associated with acute, specific, recognizable, and often serious neurological consequences.",Journal Article,4487.0,38.0,During the past three decades improvements in the treatment of childhood have resulted in high cure rates particularly for acute lymphoblastic ALL Unfortunately successful therapy has come with a price as significant morbidity can result from neurological affects which harm the brain and spinal cord The expectation and hope is that chemotherapy as a primary means of CNS therapy will result in acceptable disease control with less CNS morbidity than has been observed with combinations of chemotherapy and radiotherapy over the past several decades In this review we discuss the poignant historical aspects of CNS therapy outline current methods of systemic and CNS therapy and present imaging findings we have encountered in childhood patients with a variety of acute neurological conditions A major objective of our research is to understand the neuroimaging correlates of acute and chronic effects of cancer and therapy Specific features related to CNS and associated short-term toxicities both disease- and therapy-related are emphasized in this review with the specific neuroimaging findings Specific CNS findings are similarly important when treating acute myelogenous AML and details of leukemic involvement and toxicities are also presented in this entity Despite contemporary treatment approaches which favor the use of chemotherapy including intrathecal therapy over radiotherapy in the treatment of CNS children still occasionally experience morbid neurotoxicity Standard neuroimaging is sufficient to identify a variety of neurotoxic sequelae in children and often suggest specific etiologies Specific neuroimaging findings frequently indicate a need to alter antileukemia therapy It is important to appreciate that intrathecal and high doses of systemic chemotherapy are not innocuous and are associated with acute specific recognizable and often serious neurological consequences,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[190, 3, 1219, 169, 1968, 1474, 4, 3, 24, 1, 864, 47, 627, 4, 64, 1722, 151, 823, 9, 286, 1275, 62, 3869, 1401, 36, 71, 6235, 5, 8, 8816, 22, 93, 787, 122, 757, 29, 3622, 2561, 92, 7158, 3, 342, 2, 1499, 1885, 3, 9988, 2, 3045, 16, 17, 56, 22, 8, 86, 2263, 1, 1025, 36, 303, 757, 4, 1595, 34, 182, 5, 299, 1025, 787, 76, 71, 85, 164, 5, 1247, 1, 56, 2, 310, 252, 3, 1219, 392, 1968, 4, 26, 206, 21, 1139, 3, 56604, 2252, 2695, 1, 1025, 36, 5277, 291, 636, 1, 403, 2, 1025, 36, 2, 364, 270, 272, 21, 47, 3903, 4, 864, 7, 5, 8, 1362, 1, 286, 3622, 1298, 8, 458, 461, 1, 114, 389, 16, 6, 1640, 3, 7468, 1871, 1, 286, 2, 442, 176, 1, 12, 2, 36, 112, 404, 139, 6, 1025, 2, 41, 978, 337, 385, 110, 34, 2, 36, 139, 32, 8585, 4, 26, 206, 5, 3, 112, 7468, 272, 112, 1025, 272, 32, 1813, 305, 198, 1367, 286, 2194, 329, 2, 3791, 1, 2015, 799, 2, 385, 32, 120, 917, 4, 26, 2983, 550, 2667, 24, 611, 92, 4283, 3, 119, 1, 56, 141, 5126, 36, 252, 310, 4, 3, 24, 1, 1025, 541, 1234, 6319, 730, 8188, 3561, 260, 7468, 16, 1952, 6, 255, 8, 1362, 1, 11148, 4156, 4, 541, 2, 629, 309, 112, 8523, 112, 7468, 272, 746, 1008, 8, 594, 6, 2688, 9169, 36, 192, 16, 305, 6, 19754, 17, 5126, 2, 64, 415, 1, 403, 56, 32, 44, 33576, 2, 32, 41, 5, 286, 112, 13908, 2, 629, 1762, 3622, 3255]",1895.0,17924103,200
"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.",Blood,Blood,2007-11-29,"Patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia (CML-AP) have very limited therapeutic options. Nilotinib is a highly selective BCR-ABL tyrosine kinase inhibitor. This phase 2 trial was designed to characterize the efficacy and safety of nilotinib (400 mg twice daily) in this patient population with hematologic response (HR) as primary efficacy endpoint. A total of 119 patients were enrolled and had a median duration of treatment of 202 days (range, 2-611 days). An HR was observed in 56 patients (47%; 95% confidence interval [CI], 38%-56%). Major cytogenetic response (MCyR) was observed in 35 patients (29%; 95% CI, 21%-39%). The median duration of HR has not been reached. Overall survival rate among the 119 patients after 12 months of follow-up was 79% (95% CI, 70%-87%). Nonhematologic adverse events were mostly mild to moderate. Severe peripheral edema and pleural effusions were not observed. The most common grade 3 or higher hematologic adverse events were thrombocytopenia (35%) and neutropenia (21%). Grade 3 or higher bilirubin and lipase elevations occurred in 9% and 18% of patients, respectively, resulting in treatment discontinuation in one patient. In conclusion, nilotinib is an effective and well-tolerated treatment in imatinib-resistant and -intolerant CML-AP. This trial is registered at www.clinicaltrials.gov as NCT00384228.","Clinical Trial, Phase II",4436.0,245.0,Patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous CML-AP have very limited therapeutic options Nilotinib is a highly selective BCR-ABL tyrosine kinase inhibitor This phase 2 trial was designed to characterize the efficacy and safety of nilotinib 400 mg twice daily in this patient population with hematologic response HR as primary efficacy endpoint A total of 119 patients were enrolled and had a median duration of treatment of 202 days range 2-611 days An HR was observed in 56 patients 47 95 confidence interval CI 38 -56 Major cytogenetic response MCyR was observed in 35 patients 29 95 CI 21 -39 The median duration of HR has not been reached Overall survival rate among the 119 patients after 12 months of follow-up was 79 95 CI 70 -87 Nonhematologic adverse events were mostly mild to moderate Severe peripheral edema and pleural effusions were not observed The most common grade 3 or higher hematologic adverse events were thrombocytopenia 35 and neutropenia 21 Grade 3 or higher bilirubin and lipase elevations occurred in 9 and 18 of patients respectively resulting in treatment discontinuation in one patient In conclusion nilotinib is an effective and well-tolerated treatment in imatinib-resistant and -intolerant CML-AP This trial is registered at www.clinicaltrials.gov as NCT00384228,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 5, 577, 436, 15, 4944, 2241, 124, 442, 2194, 903, 2517, 47, 923, 383, 189, 838, 2638, 16, 8, 561, 1094, 1062, 1425, 564, 216, 230, 26, 124, 18, 160, 10, 1114, 6, 1507, 3, 209, 2, 367, 1, 2638, 1524, 81, 936, 391, 4, 26, 69, 266, 5, 813, 51, 168, 22, 86, 209, 1138, 8, 181, 1, 4299, 7, 11, 346, 2, 42, 8, 52, 654, 1, 24, 1, 5918, 162, 184, 18, 10711, 162, 35, 168, 10, 164, 4, 664, 7, 662, 48, 307, 268, 58, 519, 664, 458, 1266, 51, 10240, 10, 164, 4, 465, 7, 462, 48, 58, 239, 587, 3, 52, 654, 1, 168, 71, 44, 85, 1300, 63, 25, 116, 107, 3, 4299, 7, 50, 133, 53, 1, 166, 126, 10, 842, 48, 58, 431, 912, 3534, 290, 281, 11, 2754, 1980, 6, 1163, 905, 672, 3306, 2, 2164, 5154, 11, 44, 164, 3, 96, 186, 88, 27, 15, 142, 813, 290, 281, 11, 1340, 465, 2, 778, 239, 88, 27, 15, 142, 5009, 2, 7272, 4712, 489, 4, 83, 2, 203, 1, 7, 106, 1113, 4, 24, 2007, 4, 104, 69, 4, 1221, 2638, 16, 35, 323, 2, 149, 421, 24, 4, 577, 436, 2, 4944, 903, 2517, 26, 160, 16, 1653, 28, 3064, 1252, 1239, 22, 56705]",1336.0,18048643,59
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.,Molecular cancer therapeutics,Mol. Cancer Ther.,2008-01-01,"Chronic myelogenous leukemia (CML) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of CML cells to bone marrow stroma. The overexpression of p210Bcr-Abl was reported to down-regulate CXCR4 expression, and this is associated with the cell migration defects in CML. We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells. In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased CXCR4 expression and migration. This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or IFN-alpha. Imatinib induced G0-G1 cell cycle block in CML cells, which was further enhanced in a mesenchymal stem cell (MSC) coculture system. MSC coculture protected KBM-5 cells from imatinib-induced cell death. These antiapoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by inhibitor of integrin-linked kinase QLT0267. Altogether, these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells.",Journal Article,4403.0,134.0,Chronic myelogenous CML is driven by constitutively activated Bcr-Abl tyrosine kinase which causes the defective adhesion of CML cells to marrow stroma The overexpression of p210Bcr-Abl was reported to down-regulate CXCR4 expression and this is associated with the cell migration defects in CML We proposed that tyrosine kinase inhibitors imatinib or INNO-406 may restore CXCR4 expression and cause the migration of CML cells to marrow microenvironment niches which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells In KBM5 and K562 cells imatinib INNO-406 or IFN-alpha increased CXCR4 expression and migration This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or IFN-alpha Imatinib induced G0-G1 cell cycle block in CML cells which was further enhanced in a mesenchymal stem cell MSC coculture system MSC coculture protected KBM-5 cells from imatinib-induced cell death These antiapoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by inhibitor of integrin-linked kinase QLT0267 Altogether these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration of CML cells to marrow stroma causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 16, 1621, 20, 2818, 735, 1062, 1425, 564, 216, 92, 1626, 3, 4552, 2128, 1, 903, 37, 6, 581, 2477, 3, 851, 1, 37526, 1425, 10, 210, 6, 1328, 2288, 2318, 55, 2, 26, 16, 41, 5, 3, 31, 1381, 2945, 4, 903, 21, 1587, 17, 564, 216, 222, 577, 15, 23580, 8522, 68, 6075, 2318, 55, 2, 708, 3, 1381, 1, 903, 37, 6, 581, 995, 8005, 92, 4, 3854, 99, 4, 3405, 1, 2477, 517, 3782, 1, 903, 2520, 37, 4, 10822, 2, 5208, 37, 577, 23580, 8522, 15, 1256, 950, 101, 2318, 55, 2, 1381, 26, 344, 4, 2318, 148, 23, 903, 2520, 37, 10, 6269, 204, 4, 347, 29, 903, 7, 73, 5, 577, 15, 1256, 950, 577, 277, 8588, 3344, 31, 417, 2381, 4, 903, 37, 92, 10, 195, 651, 4, 8, 1569, 452, 31, 4150, 7604, 398, 4150, 7604, 5541, 44409, 33, 37, 29, 577, 277, 31, 273, 46, 4176, 176, 11, 3728, 20, 3, 2318, 3137, 20532, 15, 20, 230, 1, 2876, 1199, 216, 16836, 6767, 46, 272, 309, 17, 3, 126, 863, 1, 2318, 20, 577, 2148, 1381, 1, 903, 37, 6, 581, 2477, 3440, 3, 8588, 3344, 31, 417, 1854, 2, 3665, 8397, 3, 25, 1, 6735, 903, 2520, 37]",1338.0,18202009,198
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2008-02-01,"Allogeneic hematopoietic cell transplantation (HCT) is the only curative strategy for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD). We report the results of 148 patients (median age = 59 years old) with de novo MDS (n = 40), acute myelogenous leukemia (AML) after antecedent MDS/MPD (n = 49), treatment-related MDS (t-MDS) (n = 25), MPD (n = 27), and chronic myelomonocytic leukemia (CMML) (n = 7) who underwent allogeneic HCT using a conditioning regimen of low-dose total body irradiation (TBI) alone (200 cGy) on day 0 (n = 5) or with the addition of fludarabine (Flu) 30 mg/m(2)/day on days -4 to -2 (n = 143). Postgrafting immunosuppression consisted of cyclosporine and mycophenolate mofetil (MMF). Seventy-five patients (51%) received an allograft from a matched related donor (MRD), and 73 patients (49%) were recipients of unrelated donor (URD) grafts. There was no significant difference in the incidence of acute (gr II-IV) and chronic extensive graft-versus-host disease (aGVHD, cGVHD) between the recipients of related and unrelated donor grafts. By day +28, 75% of patients demonstrated mixed T cell chimerism. Graft rejection was seen in 15% of patients. With a median follow-up of 47 (range: 6-89) months, the 3-year relapse-free survival (RFS) and overall survival (OS) are both 27% for all patients, with a relapse incidence of 41%. The 3-year RFS for the patients with de novo MDS, AML after antecedent MDS/MPD, t-MDS, MPD, and CMML were 22%, 20%, 29%, 37%, and 43%, respectively, and the 3-year OS was 20%, 23%, 27%, 43%, and 43%, respectively. The 3-year nonrelapse mortality (NRM) was 32%. Factors associated with a lower risk of relapse were the development of extensive cGVHD and having a low risk or intermediate-1 risk International Prognostic Score for the de novo MDS patients. Nonmyeloablative HCT confers remissions in patients who otherwise were not eligible for conventional HCT but for whom relapse is the leading cause of treatment failure.",Clinical Trial,4372.0,106.0,Allogeneic hematopoietic cell transplantation HCT is the only curative strategy for patients with syndrome MDS and disorders MPD We report the results of 148 patients median age 59 years old with de novo MDS n 40 acute myelogenous AML after antecedent MDS/MPD n 49 treatment-related MDS t-MDS n 25 MPD n 27 and chronic myelomonocytic CMML n 7 who underwent allogeneic HCT using a conditioning regimen of low-dose total body irradiation TBI alone 200 cGy on day 0 n 5 or with the addition of fludarabine Flu 30 mg/m 2 /day on days -4 to -2 n 143 Postgrafting immunosuppression consisted of cyclosporine and mycophenolate mofetil MMF Seventy-five patients 51 received an allograft from a matched related donor MRD and 73 patients 49 were recipients of unrelated donor URD grafts There was no significant difference in the incidence of acute gr II-IV and chronic extensive graft-versus-host disease aGVHD cGVHD between the recipients of related and unrelated donor grafts By day +28 75 of patients demonstrated mixed T cell chimerism Graft rejection was seen in 15 of patients With a median follow-up of 47 range 6-89 months the 3-year relapse-free survival RFS and overall survival OS are both 27 for all patients with a relapse incidence of 41 The 3-year RFS for the patients with de novo MDS AML after antecedent MDS/MPD t-MDS MPD and CMML were 22 20 29 37 and 43 respectively and the 3-year OS was 20 23 27 43 and 43 respectively The 3-year nonrelapse mortality NRM was 32 Factors associated with a lower risk of relapse were the development of extensive cGVHD and having a low risk or intermediate-1 risk International Prognostic Score for the de novo MDS patients Nonmyeloablative HCT confers remissions in patients who otherwise were not eligible for conventional HCT but for whom relapse is the leading cause of treatment failure,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 1007, 31, 497, 1085, 16, 3, 158, 1075, 692, 9, 7, 5, 681, 1223, 2, 1997, 7712, 21, 414, 3, 99, 1, 4647, 7, 52, 89, 728, 60, 1095, 5, 1566, 2018, 1223, 78, 327, 286, 2194, 329, 50, 8775, 1223, 7712, 78, 739, 24, 139, 1223, 102, 1223, 78, 243, 7712, 78, 428, 2, 442, 5451, 3382, 78, 67, 54, 208, 1063, 1085, 75, 8, 1933, 477, 1, 154, 61, 181, 642, 1104, 4889, 279, 1250, 3071, 23, 218, 13, 78, 33, 15, 5, 3, 352, 1, 2027, 5119, 201, 81, 188, 18, 218, 23, 162, 39, 6, 18, 78, 4400, 28085, 3646, 1695, 1, 9112, 2, 11902, 13246, 9889, 2073, 365, 7, 725, 103, 35, 9568, 29, 8, 655, 139, 1488, 2029, 2, 803, 7, 739, 11, 2190, 1, 2092, 1488, 5847, 4713, 125, 10, 77, 93, 523, 4, 3, 287, 1, 286, 3845, 215, 478, 2, 442, 1344, 1599, 185, 1204, 34, 5873, 6670, 59, 3, 2190, 1, 139, 2, 2092, 1488, 4713, 20, 218, 339, 481, 1, 7, 264, 1739, 102, 31, 6047, 1599, 4772, 10, 527, 4, 167, 1, 7, 5, 8, 52, 166, 126, 1, 662, 184, 49, 887, 53, 3, 27, 111, 429, 115, 25, 1272, 2, 63, 25, 118, 32, 110, 428, 9, 62, 7, 5, 8, 429, 287, 1, 605, 3, 27, 111, 1272, 9, 3, 7, 5, 1566, 2018, 1223, 329, 50, 8775, 1223, 7712, 102, 1223, 7712, 2, 3382, 11, 350, 179, 462, 567, 2, 601, 106, 2, 3, 27, 111, 118, 10, 179, 382, 428, 601, 2, 601, 106, 3, 27, 111, 4640, 282, 4296, 10, 531, 130, 41, 5, 8, 280, 43, 1, 429, 11, 3, 193, 1, 1344, 6670, 2, 1041, 8, 154, 43, 15, 919, 14, 43, 944, 177, 368, 9, 3, 1566, 2018, 1223, 7, 6094, 1085, 4020, 3166, 4, 7, 54, 2632, 11, 44, 625, 9, 809, 1085, 84, 9, 953, 429, 16, 3, 1049, 708, 1, 24, 496]",1834.0,18215785,213
Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2008-03-01,"The lower morbidity and mortality of reduced-intensity conditioning (RIC) regimens have allowed allogeneic hematopoietic cell transplantation (HCT) in older patients. Unrelated umbilical cord blood (UCB) has been investigated as an alternative stem cell source to suitably HLA matched related (MRD) and adult volunteer unrelated donors. We hypothesized that RIC HCT using UCB would be safe and efficacious in older patients, and compared the treatment-related mortality (TRM) and overall survival (OS) of RIC HCT in patients older than 55 years using either MRD (n = 47) or, in patients with no 5 of 6 or 6 of 6 HLA compatible related donors, UCB (n = 43). RIC regimen consisted of total-body irradiation (TBI; 200 cGy) and either cyclophosphamide and fludarabine (n = 69), or busulfan and fludarabine (n = 16) or busulfan and cladribine (n = 5). The median age of MRD and UCB cohorts was 58 (range, 55-70) and 59 (range, 55-69) years, respectively. acute myelogenous leukemia/myelodysplastic syndrome (AML/MDS) (50%) was the most common diagnosis. All MRD grafts were 6 of 6 HLA matched to the recipient. Among patients undergoing UCB HCT, 88% received 2 UCB units to optimize cell dose and 93% received 1-2 HLA mismatched grafts. The median follow-up for survivors was 27 (range: 12-61) months. The 3-year probabilities of progression-free survival (PFS; 30% versus 34%, P = .98) and OS (43% versus 34%, P = .57) were similar for recipients of MRD and UCB. The cumulative incidence of grade II-IV acute graft-versus-host (aGVHD) disease (42% versus 49%, P = .20) and TRM at 180-days (23% versus 28%, P = .36) were comparable. However, UCB recipients had a lower incidence of chronic graft-versus-host disease (cGVHD) at 1 year (40% versus 17%, P = .02). On multivariate analysis, graft type had no impact on TRM or survival, and the HCT comorbidity index score was the only factor independently predictive for these endpoints. Our study supports the use of HLA mismatched UCB as an alternative graft source for older patients who need a transplant but do not have an MRD. The use of RIC and UCB extends the availability of transplant therapy to older patients previously excluded on the basis of age and lack of a suitable MRD. A careful review of existing comorbidities is necessary when considering older patients for HCT.",Clinical Trial,4343.0,96.0,The lower morbidity and mortality of reduced-intensity conditioning RIC regimens have allowed allogeneic hematopoietic cell transplantation HCT in older patients Unrelated umbilical cord blood UCB has been investigated as an alternative stem cell source to suitably HLA matched related MRD and adult volunteer unrelated donors We hypothesized that RIC HCT using UCB would be safe and efficacious in older patients and compared the treatment-related mortality TRM and overall survival OS of RIC HCT in patients older than 55 years using either MRD n 47 or in patients with no 5 of 6 or 6 of 6 HLA compatible related donors UCB n 43 RIC regimen consisted of total-body irradiation TBI 200 cGy and either cyclophosphamide and fludarabine n 69 or busulfan and fludarabine n 16 or busulfan and cladribine n 5 The median age of MRD and UCB cohorts was 58 range 55-70 and 59 range 55-69 years respectively acute myelogenous leukemia/myelodysplastic syndrome AML/MDS 50 was the most common diagnosis All MRD grafts were 6 of 6 HLA matched to the recipient Among patients undergoing UCB HCT 88 received 2 UCB units to optimize cell dose and 93 received 1-2 HLA mismatched grafts The median follow-up for survivors was 27 range 12-61 months The 3-year probabilities of progression-free survival PFS 30 versus 34 P .98 and OS 43 versus 34 P .57 were similar for recipients of MRD and UCB The cumulative incidence of grade II-IV acute graft-versus-host aGVHD disease 42 versus 49 P .20 and TRM at 180-days 23 versus 28 P .36 were comparable However UCB recipients had a lower incidence of chronic graft-versus-host disease cGVHD at 1 year 40 versus 17 P .02 On multivariate analysis graft type had no impact on TRM or survival and the HCT comorbidity index score was the only factor independently predictive for these endpoints Our study supports the use of HLA mismatched UCB as an alternative graft source for older patients who need a transplant but do not have an MRD The use of RIC and UCB extends the availability of transplant therapy to older patients previously excluded on the basis of age and lack of a suitable MRD A careful review of existing comorbidities is necessary when considering older patients for HCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 280, 787, 2, 282, 1, 405, 837, 1933, 3365, 472, 47, 2313, 1063, 1007, 31, 497, 1085, 4, 434, 7, 2092, 5998, 1885, 315, 4056, 71, 85, 565, 22, 35, 1091, 452, 31, 2353, 6, 33526, 1160, 655, 139, 2029, 2, 780, 15536, 2092, 2344, 21, 1237, 17, 3365, 1085, 75, 4056, 688, 40, 1165, 2, 3289, 4, 434, 7, 2, 72, 3, 24, 139, 282, 5064, 2, 63, 25, 118, 1, 3365, 1085, 4, 7, 434, 76, 614, 60, 75, 361, 2029, 78, 662, 15, 4, 7, 5, 77, 33, 1, 49, 15, 49, 1, 49, 1160, 7293, 139, 2344, 4056, 78, 601, 3365, 477, 1695, 1, 181, 642, 1104, 4889, 1250, 3071, 2, 361, 1112, 2, 2027, 78, 790, 15, 3906, 2, 2027, 78, 245, 15, 3906, 2, 8251, 78, 33, 3, 52, 89, 1, 2029, 2, 4056, 736, 10, 717, 184, 614, 431, 2, 728, 184, 614, 790, 60, 106, 286, 2194, 2647, 10589, 681, 329, 1223, 212, 10, 3, 96, 186, 147, 62, 2029, 4713, 11, 49, 1, 49, 1160, 655, 6, 3, 5783, 107, 7, 479, 4056, 1085, 889, 103, 18, 4056, 2960, 6, 2465, 31, 61, 2, 966, 103, 14, 18, 1160, 5095, 4713, 3, 52, 166, 126, 9, 332, 10, 428, 184, 133, 713, 53, 3, 27, 111, 3518, 1, 91, 115, 25, 300, 201, 185, 562, 19, 1096, 2, 118, 601, 185, 562, 19, 696, 11, 288, 9, 2190, 1, 2029, 2, 4056, 3, 967, 287, 1, 88, 215, 478, 286, 1599, 185, 1204, 5873, 34, 595, 185, 739, 19, 179, 2, 5064, 28, 3172, 162, 382, 185, 339, 19, 511, 11, 1279, 137, 4056, 2190, 42, 8, 280, 287, 1, 442, 1599, 185, 1204, 34, 6670, 28, 14, 111, 327, 185, 269, 19, 588, 23, 331, 65, 1599, 267, 42, 77, 345, 23, 5064, 15, 25, 2, 3, 1085, 1879, 558, 368, 10, 3, 158, 161, 1042, 464, 9, 46, 1387, 114, 45, 2304, 3, 119, 1, 1160, 5095, 4056, 22, 35, 1091, 1599, 2353, 9, 434, 7, 54, 594, 8, 941, 84, 1022, 44, 47, 35, 2029, 3, 119, 1, 3365, 2, 4056, 8464, 3, 2550, 1, 941, 36, 6, 434, 7, 373, 1800, 23, 3, 877, 1, 89, 2, 926, 1, 8, 2884, 2029, 8, 3465, 206, 1, 1692, 1909, 16, 1493, 198, 3075, 434, 7, 9, 1085]",2210.0,18275894,265
Altered gene expression in busulfan-resistant human myeloid leukemia.,Leukemia research,Leuk. Res.,2008-03-12,"Busulfan (Bu) resistance is a major obstacle to hematopoietic stem cell transplantation (HSCT) of patients with chronic or acute myelogenous leukemia (CML or AML). We used gene expression analysis to identify cellular factors underlying Bu resistance. Two Bu-resistant leukemia cell lines were established, characterized and analyzed for differentially expressed genes. The CML B5/Bu250(6) cells are 4.5-fold more resistant to Bu than their parental B5 cells. The AML KBM3/Bu250(6) cells are 4.0-fold more Bu-resistant than KBM3 parental cells. Both resistant sublines evade Bu-mediated G2-arrest and apoptosis with altered regulations of CHK2 and CDC2 proteins, constitutively up-regulated anti-apoptotic genes (BCL-X(L), BCL2, BCL2L10, BAG3 and IAP2/BIRC3) and down-regulated pro-apoptotic genes (BIK, BNIP3, and LTBR). Bu-induced apoptosis is partly mediated by activation of caspases; use of the inhibitor Z-VAD-FMK completely abrogated PARP1 cleavage and reduced apoptosis by approximately 50%. Furthermore, Bu resistance in these cells may be attributed in part to up-regulation of HSP90 protein and activation of STAT3. The inhibition of HSP90 with geldanamycin attenuated phosphorylated STAT3 and made B5/Bu250(6) and KBM3/Bu250(6) more Bu-sensitive. The analysis of cells derived from patients classified as either clinically resistant or sensitive to high-dose Bu-based chemotherapy indicated alterations in gene expression that were analogous to those observed in the in vitro model cell lines, confirming the potential clinical relevance of this model for Bu resistance.",Journal Article,4332.0,40.0,Busulfan Bu resistance is a major obstacle to hematopoietic stem cell transplantation HSCT of patients with chronic or acute myelogenous CML or AML We used gene expression analysis to identify cellular factors underlying Bu resistance Two Bu-resistant cell lines were established characterized and analyzed for differentially expressed genes The CML B5/Bu250 6 cells are 4.5-fold more resistant to Bu than their parental B5 cells The AML KBM3/Bu250 6 cells are 4.0-fold more Bu-resistant than KBM3 parental cells Both resistant sublines evade Bu-mediated G2-arrest and apoptosis with altered regulations of CHK2 and CDC2 proteins constitutively up-regulated anti-apoptotic genes BCL-X L BCL2 BCL2L10 BAG3 and IAP2/BIRC3 and down-regulated pro-apoptotic genes BIK BNIP3 and LTBR Bu-induced apoptosis is partly mediated by activation of caspases use of the inhibitor Z-VAD-FMK completely abrogated PARP1 cleavage and reduced apoptosis by approximately 50 Furthermore Bu resistance in these cells may be attributed in part to up-regulation of HSP90 protein and activation of STAT3 The inhibition of HSP90 with geldanamycin attenuated phosphorylated STAT3 and made B5/Bu250 6 and KBM3/Bu250 6 more Bu-sensitive The analysis of cells derived from patients classified as either clinically resistant or sensitive to high-dose Bu-based chemotherapy indicated alterations in gene expression that were analogous to those observed in the in vitro model cell lines confirming the potential clinical relevance of this model for Bu resistance,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3906, 3667, 251, 16, 8, 458, 7414, 6, 1007, 452, 31, 497, 1703, 1, 7, 5, 442, 15, 286, 2194, 903, 15, 329, 21, 95, 145, 55, 65, 6, 255, 763, 130, 1181, 3667, 251, 100, 3667, 436, 31, 285, 11, 635, 765, 2, 311, 9, 2478, 570, 214, 3, 903, 28617, 21503, 49, 37, 32, 39, 33, 1116, 80, 436, 6, 3667, 76, 136, 3418, 28617, 37, 3, 329, 25070, 21503, 49, 37, 32, 39, 13, 1116, 80, 3667, 436, 76, 25070, 3418, 37, 110, 436, 12538, 6636, 3667, 517, 3774, 1854, 2, 351, 5, 1495, 13608, 1, 14253, 2, 8747, 652, 2818, 126, 1065, 312, 1631, 214, 1044, 1006, 805, 3214, 56929, 56930, 2, 34058, 31246, 2, 1328, 1065, 1805, 1631, 214, 17319, 38668, 2, 44815, 3667, 277, 351, 16, 5180, 517, 20, 363, 1, 7629, 119, 1, 3, 230, 3905, 10167, 10281, 2500, 3728, 6033, 3155, 2, 405, 351, 20, 705, 212, 798, 3667, 251, 4, 46, 37, 68, 40, 3073, 4, 760, 6, 126, 863, 1, 2515, 178, 2, 363, 1, 1439, 3, 297, 1, 2515, 5, 10260, 2656, 2365, 1439, 2, 1229, 28617, 21503, 49, 2, 25070, 21503, 49, 80, 3667, 745, 3, 65, 1, 37, 526, 29, 7, 1373, 22, 361, 505, 436, 15, 745, 6, 64, 61, 3667, 90, 56, 1103, 593, 4, 145, 55, 17, 11, 8579, 6, 135, 164, 4, 3, 4, 439, 202, 31, 285, 5030, 3, 174, 38, 2088, 1, 26, 202, 9, 3667, 251]",1528.0,18339423,86
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.,Seminars in oncology,Semin. Oncol.,2008-02-01,"The treatment of chronic myelogenous leukemia (CML) has been revolutionized by the development of the small-molecule tyrosine kinase inhibitor imatinib. The primary target for this drug is the oncogenic BCR-ABL kinase. Five-year survival rates for patients in chronic phase CML is now greater than 80%. Patients who have advanced beyond the chronic phase to the accelerated phase or blast crisis, however, have not faired as well. Progression occurs for a variety of reasons, including late diagnosis, slow response to imatinib, and the development of imatinib-resistant clones. Imatinib resistance has, in part, been addressed with the introduction of the new BCR-ABL inhibitors, namely dasatinib and nilotinib. These drugs have shown efficacy in CML patients with wild-type BCR-ABL and some BCR-ABL mutants that are imatinib-resistant. Unfortunately, some BCR-ABL mutations remain resistant to these therapies and will require the development of alternative treatments, and other mechanisms of imatinib resistance besides BCR-ABL mutation exist. In the future, genetic and pharmacologic tests may allow the clinician to predict response to imatinib. More aggressive therapies are being considered for high-risk patients, including increased dosage of the current tyrosine kinase inhibitors, along with combination therapies. Aggressive therapy holds promise, as the data suggest that responses are improved. Unfortunately, toxicities are also increased, and thus a balance must be found to ensure safety and compliance. This is especially important for young CML patients, who hopefully will remain in remission for decades. Polymerase chain reaction analysis has become of primary importance as a means of assessing disease burden, and given the idiosyncrasies of this technique, standards must be established to allow results to be compared across different institutions. Additionally, the nature of advanced disease is being explored. Intriguingly, genetic analysis of transformed blasts from patients in blast crisis has identified numerous members of the Wnt/B-catenin pathway and JunB as being activated. Increased activity of these pathways correlates with poor response and eventual disease progression. In addition to these data, evidence is emerging associating survival of the quiescent blast cell with Wnt activity, leading to the hope that Wnt inhibitors will increase the likelihood of eradicating these cells. Other areas such as microRNA profiling and DNA methylation patterns are likely to provide important information.",Journal Article,4372.0,27.0,The treatment of chronic myelogenous CML has been revolutionized by the development of the small-molecule tyrosine kinase inhibitor imatinib The primary target for this drug is the oncogenic BCR-ABL kinase Five-year survival rates for patients in chronic phase CML is now greater than 80 Patients who have advanced beyond the chronic phase to the accelerated phase or blast crisis however have not faired as well Progression occurs for a variety of reasons including late diagnosis slow response to imatinib and the development of imatinib-resistant clones Imatinib resistance has in part been addressed with the introduction of the new BCR-ABL inhibitors namely dasatinib and nilotinib These drugs have shown efficacy in CML patients with wild-type BCR-ABL and some BCR-ABL mutants that are imatinib-resistant Unfortunately some BCR-ABL mutations remain resistant to these therapies and will require the development of alternative treatments and other mechanisms of imatinib resistance besides BCR-ABL mutation exist In the future genetic and pharmacologic tests may allow the clinician to predict response to imatinib More aggressive therapies are being considered for high-risk patients including increased dosage of the current tyrosine kinase inhibitors along with combination therapies Aggressive therapy holds promise as the data suggest that responses are improved Unfortunately toxicities are also increased and thus a balance must be found to ensure safety and compliance This is especially important for young CML patients who hopefully will remain in remission for decades Polymerase chain reaction analysis has become of primary importance as a means of assessing disease burden and given the idiosyncrasies of this technique standards must be established to allow results to be compared across different institutions Additionally the nature of advanced disease is being explored Intriguingly genetic analysis of transformed blasts from patients in blast crisis has identified numerous members of the Wnt/B-catenin pathway and JunB as being activated Increased activity of these pathways correlates with poor response and eventual disease progression In addition to these data evidence is emerging associating survival of the quiescent blast cell with Wnt activity leading to the hope that Wnt inhibitors will increase the likelihood of eradicating these cells Other areas such as microRNA profiling and DNA methylation patterns are likely to provide important information,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 24, 1, 442, 2194, 903, 71, 85, 5746, 20, 3, 193, 1, 3, 302, 1354, 564, 216, 230, 577, 3, 86, 283, 9, 26, 234, 16, 3, 1302, 1062, 1425, 216, 365, 111, 25, 151, 9, 7, 4, 442, 124, 903, 16, 1134, 378, 76, 493, 7, 54, 47, 131, 1654, 3, 442, 124, 6, 3, 2241, 124, 15, 3112, 6540, 137, 47, 44, 33195, 22, 149, 91, 1780, 9, 8, 1362, 1, 2325, 141, 807, 147, 3645, 51, 6, 577, 2, 3, 193, 1, 577, 436, 2749, 577, 251, 71, 4, 760, 85, 2814, 5, 3, 2456, 1, 3, 217, 1062, 1425, 222, 5046, 1674, 2, 2638, 46, 600, 47, 443, 209, 4, 903, 7, 5, 955, 267, 1062, 1425, 2, 476, 1062, 1425, 3423, 17, 32, 577, 436, 3869, 476, 1062, 1425, 138, 918, 436, 6, 46, 235, 2, 303, 1353, 3, 193, 1, 1091, 640, 2, 127, 483, 1, 577, 251, 7301, 1062, 1425, 258, 1923, 4, 3, 508, 336, 2, 2788, 895, 68, 1700, 3, 3744, 6, 678, 51, 6, 577, 80, 571, 235, 32, 486, 515, 9, 64, 43, 7, 141, 101, 3323, 1, 3, 291, 564, 216, 222, 1510, 5, 150, 235, 571, 36, 5253, 1783, 22, 3, 74, 309, 17, 253, 32, 231, 3869, 385, 32, 120, 101, 2, 631, 8, 3459, 1642, 40, 204, 6, 3478, 367, 2, 3336, 26, 16, 1093, 305, 9, 1169, 903, 7, 54, 7464, 303, 918, 4, 734, 9, 1968, 1451, 1260, 1329, 65, 71, 1417, 1, 86, 1187, 22, 8, 2263, 1, 1977, 34, 892, 2, 447, 3, 56937, 1, 26, 1312, 3371, 1642, 40, 635, 6, 1700, 99, 6, 40, 72, 716, 338, 1764, 1724, 3, 2202, 1, 131, 34, 16, 486, 1443, 11550, 336, 65, 1, 2423, 2438, 29, 7, 4, 3112, 6540, 71, 108, 2331, 1684, 1, 3, 2112, 132, 1778, 308, 2, 12868, 22, 486, 735, 101, 128, 1, 46, 460, 1871, 5, 334, 51, 2, 6956, 34, 91, 4, 352, 6, 46, 74, 241, 16, 1478, 12373, 25, 1, 3, 6735, 3112, 31, 5, 2112, 128, 1049, 6, 3, 3045, 17, 2112, 222, 303, 344, 3, 1420, 1, 11001, 46, 37, 127, 1361, 225, 22, 3213, 1080, 2, 261, 569, 764, 32, 322, 6, 377, 305, 487]",2485.0,18346528,66
"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2008-05-01,"Deforolimus (AP23573), a novel non-prodrug rapamycin analogue, inhibits the mammalian target of rapamycin, a downstream effector of the phosphatidylinositol 3-kinase/Akt and nutrient-sensing pathways. A phase 2 trial was conducted to determine the efficacy and safety of single-agent deforolimus in patients with relapsed or refractory hematologic malignancies. Eligible patients were assigned to one of five disease-specific, parallel cohorts and given 12.5 mg deforolimus as a 30-minute infusion once daily for 5 days every 2 weeks. A Simon two-stage design was used for each cohort. Safety, pharmacokinetics, pharmacodynamics, and antitumor response were assessed. Fifty-five patients received deforolimus as follows: cohort 1 23 acute myelogenous leukemia, two myelodysplastic syndrome and one chronic myelogenous leukemia in nonlymphoid blast phase; cohort 2, one acute lymphocytic leukemia; cohort 3, nine agnogenic myeloid metaplasia; cohort 4, eight chronic lymphocytic leukemia; cohort 5, nine mantle cell lymphoma and two T-cell leukemia/lymphoma. Most patients were heavily pretreated. Of the 52 evaluable patients, partial responses were noted in five (10%), two of seven agnogenic myeloid metaplasia and three of nine mantle cell lymphoma. Hematologic improvement/stable disease was observed in 21 (40%). Common treatment-related adverse events, which were generally mild and reversible, were mouth sores, fatigue, nausea, and thrombocytopenia. Decreased levels of phosphorylated 4E-BP1 in 9 of 11 acute myelogenous leukemia/myelodysplastic syndrome patients after therapy showed mammalian target of rapamycin inhibition by deforolimus. Deforolimus was well-tolerated in patients with heavily pretreated hematologic malignancies, and antitumor activity was observed. Further investigation of deforolimus alone and in combination with other therapeutic agents is warranted in patients with selected hematologic malignancies.","Clinical Trial, Phase II",4282.0,192.0,Deforolimus AP23573 a novel non-prodrug rapamycin analogue inhibits the mammalian target of rapamycin a downstream effector of the phosphatidylinositol 3-kinase/Akt and nutrient-sensing pathways A phase 2 trial was conducted to determine the efficacy and safety of single-agent deforolimus in patients with relapsed or refractory hematologic malignancies Eligible patients were assigned to one of five disease-specific parallel cohorts and given 12.5 mg deforolimus as a 30-minute infusion once daily for 5 days every 2 weeks A Simon two-stage design was used for each cohort Safety pharmacokinetics pharmacodynamics and antitumor response were assessed Fifty-five patients received deforolimus as follows cohort 1 23 acute myelogenous two syndrome and one chronic myelogenous in nonlymphoid blast phase cohort 2 one acute lymphocytic cohort 3 nine agnogenic myeloid metaplasia cohort 4 eight chronic lymphocytic cohort 5 nine mantle cell and two T-cell leukemia/lymphoma Most patients were heavily pretreated Of the 52 evaluable patients partial responses were noted in five 10 two of seven agnogenic myeloid metaplasia and three of nine mantle cell Hematologic improvement/stable disease was observed in 21 40 Common treatment-related adverse events which were generally mild and reversible were mouth sores fatigue nausea and thrombocytopenia Decreased levels of phosphorylated 4E-BP1 in 9 of 11 acute myelogenous leukemia/myelodysplastic syndrome patients after therapy showed mammalian target of rapamycin inhibition by deforolimus Deforolimus was well-tolerated in patients with heavily pretreated hematologic malignancies and antitumor activity was observed Further investigation of deforolimus alone and in combination with other therapeutic agents is warranted in patients with selected hematologic malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[19848, 24680, 8, 229, 220, 5227, 1620, 4696, 1576, 3, 2359, 283, 1, 1620, 8, 1489, 2070, 1, 3, 3415, 27, 216, 649, 2, 8749, 8350, 460, 8, 124, 18, 160, 10, 426, 6, 223, 3, 209, 2, 367, 1, 226, 420, 19848, 4, 7, 5, 591, 15, 430, 813, 441, 625, 7, 11, 896, 6, 104, 1, 365, 34, 112, 2755, 736, 2, 447, 133, 33, 81, 19848, 22, 8, 201, 3949, 904, 1059, 391, 9, 33, 162, 454, 18, 244, 8, 7385, 100, 82, 771, 10, 95, 9, 296, 180, 367, 1159, 3587, 2, 579, 51, 11, 275, 1461, 365, 7, 103, 19848, 22, 2962, 180, 14, 382, 286, 2194, 100, 681, 2, 104, 442, 2194, 4, 20180, 3112, 124, 180, 18, 104, 286, 1193, 180, 27, 762, 26059, 533, 6054, 180, 39, 659, 442, 1193, 180, 33, 762, 2757, 31, 2, 100, 102, 31, 2647, 4763, 96, 7, 11, 2447, 2193, 1, 3, 653, 859, 7, 450, 253, 11, 1051, 4, 365, 79, 100, 1, 648, 26059, 533, 6054, 2, 169, 1, 762, 2757, 31, 813, 767, 585, 34, 10, 164, 4, 239, 327, 186, 24, 139, 290, 281, 92, 11, 1228, 1980, 2, 2786, 11, 5831, 45115, 613, 1218, 2, 1340, 340, 148, 1, 2365, 6726, 7949, 4, 83, 1, 175, 286, 2194, 2647, 10589, 681, 7, 50, 36, 224, 2359, 283, 1, 1620, 297, 20, 19848, 19848, 10, 149, 421, 4, 7, 5, 2447, 2193, 813, 441, 2, 579, 128, 10, 164, 195, 940, 1, 19848, 279, 2, 4, 150, 5, 127, 189, 183, 16, 1197, 4, 7, 5, 715, 813, 441]",1820.0,18451242,45
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.,Blood,Blood,2008-05-27,"Interactions between the dual Bcr/Abl and aurora kinase inhibitor MK-0457 and the histone deacetylase inhibitor vorinostat were examined in Bcr/Abl(+) leukemia cells, including those resistant to imatinib mesylate (IM), particularly those with the T315I mutation. Coadministration of vorinostat dramatically increased MK-0457 lethality in K562 and LAMA84 cells. Notably, the MK-0457/vorinostat regimen was highly active against primary CD34(+) chronic myelogenous leukemia (CML) cells and Ba/F3 cells bearing various Bcr/Abl mutations (ie, T315I, E255K, and M351T), as well as IM-resistant K562 cells exhibiting Bcr/Abl-independent, Lyn-dependent resistance. These events were associated with inactivation and down-regulation of wild-type (wt) and mutated Bcr/Abl (particularly T315I). Moreover, treatment with MK-0457 resulted in accumulation of cells with 4N or more DNA content, whereas coadministration of vorinostat markedly enhanced aurora kinase inhibition by MK-0457, and preferentially killed polyploid cells. Furthermore, vorinostat also interacted with a selective inhibitor of aurora kinase A and B to potentiate apoptosis without modifying Bcr/Abl activity. Finally, vorinostat markedly induced Bim expression, while blockade of Bim induction by siRNA dramatically diminished the capacity of this agent to potentiate MK-0457 lethality. Together, these findings indicate that vorinostat strikingly increases MK-0457 activity against IM-sensitive and -resistant CML cells through inactivation of Bcr/Abl and aurora kinases, as well as by induction of Bim.",Journal Article,4256.0,44.0,Interactions between the dual Bcr/Abl and aurora kinase inhibitor MK-0457 and the histone deacetylase inhibitor vorinostat were examined in Bcr/Abl cells including those resistant to imatinib mesylate IM particularly those with the T315I mutation Coadministration of vorinostat dramatically increased MK-0457 lethality in K562 and LAMA84 cells Notably the MK-0457/vorinostat regimen was highly active against primary CD34 chronic myelogenous CML cells and Ba/F3 cells bearing various Bcr/Abl mutations ie T315I E255K and M351T as well as IM-resistant K562 cells exhibiting Bcr/Abl-independent Lyn-dependent resistance These events were associated with inactivation and down-regulation of wild-type wt and mutated Bcr/Abl particularly T315I Moreover treatment with MK-0457 resulted in accumulation of cells with 4N or more DNA content whereas coadministration of vorinostat markedly enhanced aurora kinase inhibition by MK-0457 and preferentially killed polyploid cells Furthermore vorinostat also interacted with a selective inhibitor of aurora kinase A and B to potentiate apoptosis without modifying Bcr/Abl activity Finally vorinostat markedly induced Bim expression while blockade of Bim induction by siRNA dramatically diminished the capacity of this agent to potentiate MK-0457 lethality Together these findings indicate that vorinostat strikingly increases MK-0457 activity against IM-sensitive and -resistant CML cells through inactivation of Bcr/Abl and aurora kinases as well as by induction of Bim,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1286, 59, 3, 1828, 1062, 1425, 2, 4095, 216, 230, 3558, 14996, 2, 3, 1508, 2732, 230, 2371, 11, 409, 4, 1062, 1425, 37, 141, 135, 436, 6, 577, 2347, 2820, 823, 135, 5, 3, 6184, 258, 5777, 1, 2371, 2729, 101, 3558, 14996, 3266, 4, 5208, 2, 33628, 37, 2552, 3, 3558, 14996, 2371, 477, 10, 561, 544, 480, 86, 2215, 442, 2194, 903, 37, 2, 6669, 6904, 37, 1894, 747, 1062, 1425, 138, 2523, 6184, 16677, 2, 30931, 22, 149, 22, 2820, 436, 5208, 37, 4801, 1062, 1425, 306, 8309, 470, 251, 46, 281, 11, 41, 5, 2297, 2, 1328, 863, 1, 955, 267, 1820, 2, 1185, 1062, 1425, 823, 6184, 1393, 24, 5, 3558, 14996, 627, 4, 1835, 1, 37, 5, 22181, 15, 80, 261, 2457, 547, 5777, 1, 2371, 2195, 651, 4095, 216, 297, 20, 3558, 14996, 2, 3509, 8239, 28574, 37, 798, 2371, 120, 7940, 5, 8, 1094, 230, 1, 4095, 216, 8, 2, 132, 6, 6428, 351, 187, 4898, 1062, 1425, 128, 1368, 2371, 2195, 277, 3595, 55, 369, 1189, 1, 3595, 504, 20, 1919, 2729, 2849, 3, 2162, 1, 26, 420, 6, 6428, 3558, 14996, 3266, 1162, 46, 272, 1008, 17, 2371, 6787, 1106, 3558, 14996, 128, 480, 2820, 745, 2, 436, 903, 37, 298, 2297, 1, 1062, 1425, 2, 4095, 1549, 22, 149, 22, 20, 504, 1, 3595]",1508.0,18505786,15
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-06-09,"Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy and safety with dasatinib 70 mg twice daily in chronic-phase (CP) chronic myelogenous leukemia (CML) after imatinib treatment failure. In phase I, responses occurred with once-daily administration despite only intermittent BCR-ABL inhibition. Once-daily treatment resulted in less toxicity, suggesting that toxicity results from continuous inhibition of unintended targets. Here, a dose- and schedule-optimization study is reported. In this open-label phase III trial, 670 patients with imatinib-resistant or -intolerant CP-CML were randomly assigned 1:1:1:1 between four dasatinib treatment groups: 100 mg once daily, 50 mg twice daily, 140 mg once daily, or 70 mg twice daily. With minimum follow-up of 6 months (median treatment duration, 8 months; range, < 1 to 15 months), marked and comparable hematologic (complete, 86% to 92%) and cytogenetic (major, 54% to 59%; complete, 41% to 45%) response rates were observed across the four groups. Time to and duration of cytogenetic response were similar, as was progression-free survival (8% to 11% of patients experienced disease progression or died). Compared with the approved 70-mg twice-daily regimen, dasatinib 100 mg once daily resulted in significantly lower rates of pleural effusion (all grades, 7% v 16%; P = .024) and grade 3 to 4 thrombocytopenia (22% v 37%; P = .004), and fewer patients required dose interruption (51% v 68%), reduction (30% v 55%), or discontinuation (16% v 23%). Dasatinib 100 mg once daily retains the efficacy of 70 mg twice daily with less toxicity. Intermittent target inhibition with tyrosine kinase inhibitors may preserve efficacy and reduce adverse events.","Clinical Trial, Phase III",4243.0,392.0,Dasatinib is a BCR-ABL inhibitor 325-fold more potent than imatinib against unmutated BCR-ABL in vitro Phase II studies have demonstrated efficacy and safety with dasatinib 70 mg twice daily in chronic-phase CP chronic myelogenous CML after imatinib treatment failure In phase I responses occurred with once-daily administration despite only intermittent BCR-ABL inhibition Once-daily treatment resulted in less toxicity suggesting that toxicity results from continuous inhibition of unintended targets Here a dose- and schedule-optimization study is reported In this open-label phase III trial 670 patients with imatinib-resistant or -intolerant CP-CML were randomly assigned 1:1:1:1 between four dasatinib treatment groups 100 mg once daily 50 mg twice daily 140 mg once daily or 70 mg twice daily With minimum follow-up of 6 months median treatment duration 8 months range 1 to 15 months marked and comparable hematologic complete 86 to 92 and cytogenetic major 54 to 59 complete 41 to 45 response rates were observed across the four groups Time to and duration of cytogenetic response were similar as was progression-free survival 8 to 11 of patients experienced disease progression or died Compared with the approved 70-mg twice-daily regimen dasatinib 100 mg once daily resulted in significantly lower rates of pleural effusion all grades 7 v 16 P .024 and grade 3 to 4 thrombocytopenia 22 v 37 P .004 and fewer patients required dose interruption 51 v 68 reduction 30 v 55 or discontinuation 16 v 23 Dasatinib 100 mg once daily retains the efficacy of 70 mg twice daily with less toxicity Intermittent target inhibition with tyrosine kinase inhibitors may preserve efficacy and reduce adverse events,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1674, 16, 8, 1062, 1425, 230, 7139, 1116, 80, 1157, 76, 577, 480, 7216, 1062, 1425, 4, 439, 124, 215, 94, 47, 264, 209, 2, 367, 5, 1674, 431, 81, 936, 391, 4, 442, 124, 2541, 442, 2194, 903, 50, 577, 24, 496, 4, 124, 70, 253, 489, 5, 1059, 391, 634, 550, 158, 4102, 1062, 1425, 297, 1059, 391, 24, 627, 4, 299, 155, 802, 17, 155, 99, 29, 1314, 297, 1, 18348, 637, 467, 8, 61, 2, 1055, 3980, 45, 16, 210, 4, 26, 1020, 1756, 124, 316, 160, 10335, 7, 5, 577, 436, 15, 4944, 2541, 903, 11, 1108, 896, 14, 14, 14, 14, 59, 294, 1674, 24, 271, 394, 81, 1059, 391, 212, 81, 936, 391, 3304, 81, 1059, 391, 15, 431, 81, 936, 391, 5, 2499, 166, 126, 1, 49, 53, 52, 24, 654, 66, 53, 184, 14, 6, 167, 53, 2003, 2, 1279, 813, 236, 868, 6, 937, 2, 1266, 458, 667, 6, 728, 236, 605, 6, 512, 51, 151, 11, 164, 716, 3, 294, 271, 98, 6, 2, 654, 1, 1266, 51, 11, 288, 22, 10, 91, 115, 25, 66, 6, 175, 1, 7, 592, 34, 91, 15, 1016, 72, 5, 3, 850, 431, 81, 936, 391, 477, 1674, 394, 81, 1059, 391, 627, 4, 97, 280, 151, 1, 2164, 4433, 62, 2276, 67, 603, 245, 19, 4247, 2, 88, 27, 6, 39, 1340, 350, 603, 567, 19, 1520, 2, 1497, 7, 616, 61, 4823, 725, 603, 806, 628, 201, 603, 614, 15, 2007, 245, 603, 382, 1674, 394, 81, 1059, 391, 10785, 3, 209, 1, 431, 81, 936, 391, 5, 299, 155, 4102, 283, 297, 5, 564, 216, 222, 68, 6783, 209, 2, 969, 290, 281]",1706.0,18541900,151
Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-06-01,"Osteonecrosis (ON) is a potentially serious complication of therapy in survivors of childhood cancer. Our goals were to describe the incidence of ON and identify patient and treatment characteristics associated with elevated risk. The rate of self-reported ON was determined for 9,261 patients enrolled onto the Childhood Cancer Survivor Study, a cohort of 5-year survivors of childhood cancer diagnosed from 1970 to 1986, and compared with the rate in a random sample of 2,872 siblings of survivors. Survivors with positive responses were reinterviewed to confirm the diagnosis. Fifty-two cancer survivors reported ON in 78 joints, yielding 20-year cumulative incidence of 0.43% and a rate ratio (RR) of 6.2 (95% CI, 2.3 to 17.2) compared with siblings, adjusted for age and sex; 44% developed ON in a previous radiation field. The RR was greatest among survivors of stem-cell transplantation for acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), and chronic myelogenous leukemia (RR = 26.9, 66.5, and 93.1, respectively). Nontransplantation patients with ALL (RR = 6.5; 95% CI, 2.2 to 19.4), AML (RR = 11.2; 95% CI, 2.1 to 61.2), and bone sarcoma (RR = 7.3; 95% CI, 2.0 to 26.2) were at higher risk for ON. Older age at diagnosis, shorter elapsed time, older treatment era, exposure to dexamethasone (+/- prednisone), and gonadal and nongonadal radiation were independently associated with ON. ON among long-term survivors of childhood cancer is rare. However, compared with siblings, childhood cancer survivors have a significantly increased relative rate of ON, particularly those who were older at diagnosis and who received dexamethasone or radiation therapy. Future studies are needed to better delineate our findings, particularly the increased risk after gonadal radiation.",Journal Article,4251.0,80.0,"Osteonecrosis ON is a potentially serious complication of therapy in survivors of childhood cancer Our goals were to describe the incidence of ON and identify patient and treatment characteristics associated with elevated risk The rate of self-reported ON was determined for 9,261 patients enrolled onto the Childhood Cancer Survivor Study a cohort of 5-year survivors of childhood cancer diagnosed from 1970 to 1986 and compared with the rate in a random sample of 2,872 siblings of survivors Survivors with positive responses were reinterviewed to confirm the diagnosis Fifty-two cancer survivors reported ON in 78 joints yielding 20-year cumulative incidence of 0.43 and a rate ratio RR of 6.2 95 CI 2.3 to 17.2 compared with siblings adjusted for age and sex 44 developed ON in a previous radiation field The RR was greatest among survivors of stem-cell transplantation for acute lymphoblastic ALL acute myelogenous AML and chronic myelogenous RR 26.9 66.5 and 93.1 respectively Nontransplantation patients with ALL RR 6.5 95 CI 2.2 to 19.4 AML RR 11.2 95 CI 2.1 to 61.2 and RR 7.3 95 CI 2.0 to 26.2 were at higher risk for ON Older age at diagnosis shorter elapsed time older treatment era exposure to dexamethasone +/- prednisone and gonadal and nongonadal radiation were independently associated with ON ON among long-term survivors of childhood cancer is rare However compared with siblings childhood cancer survivors have a significantly increased relative rate of ON particularly those who were older at diagnosis and who received dexamethasone or radiation therapy Future studies are needed to better delineate our findings particularly the increased risk after gonadal radiation",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,"[5404, 23, 16, 8, 751, 1762, 1447, 1, 36, 4, 332, 1, 864, 12, 114, 2802, 11, 6, 897, 3, 287, 1, 23, 2, 255, 69, 2, 24, 374, 41, 5, 804, 43, 3, 116, 1, 1074, 210, 23, 10, 509, 9, 83, 7007, 7, 346, 3301, 3, 864, 12, 2628, 45, 8, 180, 1, 33, 111, 332, 1, 864, 12, 265, 29, 4868, 6, 3751, 2, 72, 5, 3, 116, 4, 8, 2324, 1000, 1, 18, 17900, 2758, 1, 332, 332, 5, 109, 253, 11, 57178, 6, 1843, 3, 147, 1461, 100, 12, 332, 210, 23, 4, 833, 16854, 4949, 179, 111, 967, 287, 1, 13, 601, 2, 8, 116, 197, 861, 1, 49, 18, 48, 58, 18, 27, 6, 269, 18, 72, 5, 2758, 586, 9, 89, 2, 1035, 584, 276, 23, 4, 8, 698, 121, 1067, 3, 861, 10, 2199, 107, 332, 1, 452, 31, 497, 9, 286, 1275, 62, 286, 2194, 329, 2, 442, 2194, 861, 432, 83, 700, 33, 2, 966, 14, 106, 22487, 7, 5, 62, 861, 49, 33, 48, 58, 18, 18, 6, 326, 39, 329, 861, 175, 18, 48, 58, 18, 14, 6, 713, 18, 2, 861, 67, 27, 48, 58, 18, 13, 6, 432, 18, 11, 28, 142, 43, 9, 23, 434, 89, 28, 147, 985, 10670, 98, 434, 24, 1713, 645, 6, 1217, 1979, 2, 7999, 2, 38753, 121, 11, 1042, 41, 5, 23, 23, 107, 319, 337, 332, 1, 864, 12, 16, 622, 137, 72, 5, 2758, 864, 12, 332, 47, 8, 97, 101, 580, 116, 1, 23, 823, 135, 54, 11, 434, 28, 147, 2, 54, 103, 1217, 15, 121, 36, 508, 94, 32, 575, 6, 380, 5092, 114, 272, 823, 3, 101, 43, 50, 7999, 121]",1690.0,18565890,11
Activation of NK cells by extracellular heat shock protein 70 through induction of NKG2D ligands on dendritic cells.,Cancer immunity,Cancer Immun.,2008-07-10,"We have previously reported that heat shock protein 70 (HSP70) vaccination induced natural killer (NK) cell activity in patients with chronic myelogenous leukemia (CML). In this study, HSP70 of both autologous and allogeneic origin was found to stimulate IFN-gamma production from peripheral blood mononuclear cells of CML patients, as well as of normal subjects. Further investigations demonstrated that the activity of HSP70 was dependent on both NK cells and dendritic cells (DCs). HSP70 did not induce significant IFN-gamma production from either NK cells or DCs alone. Mechanistically, we found that HSP70-mediated DC-NK cell crosstalk required cell-cell contact, which could be inhibited completely by neutralizing antibody against NK activating receptor NKG2D. The significance of NKG2D was further corroborated by the finding that HSP70 induced the expression of an NKG2D ligand, the MHC class I chain-related protein A (MICA), on DCs; HSP70-augmented IFN-gamma release was abrogated by antibody against MICA. Thus extracellular HSP70, released during either stress or inflammatory cell death, may serve as a critical link between NK and DCs in mounting immune responses against infections, cancers and self-antigens.",Journal Article,4212.0,31.0,We have previously reported that heat shock protein 70 HSP70 vaccination induced natural killer NK cell activity in patients with chronic myelogenous CML In this study HSP70 of both autologous and allogeneic origin was found to stimulate IFN-gamma production from peripheral blood mononuclear cells of CML patients as well as of normal subjects Further investigations demonstrated that the activity of HSP70 was dependent on both NK cells and dendritic cells DCs HSP70 did not induce significant IFN-gamma production from either NK cells or DCs alone Mechanistically we found that HSP70-mediated DC-NK cell crosstalk required cell-cell contact which could be inhibited completely by neutralizing antibody against NK activating receptor NKG2D The significance of NKG2D was further corroborated by the finding that HSP70 induced the expression of an NKG2D ligand the MHC class I chain-related protein A MICA on DCs HSP70-augmented IFN-gamma release was abrogated by antibody against MICA Thus extracellular HSP70 released during either stress or inflammatory cell death may serve as a critical link between NK and DCs in mounting immune responses against infections cancers and self-antigens,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 47, 373, 210, 17, 3545, 3971, 178, 431, 6126, 1915, 277, 1504, 3458, 1765, 31, 128, 4, 7, 5, 442, 2194, 903, 4, 26, 45, 6126, 1, 110, 1028, 2, 1063, 1938, 10, 204, 6, 4223, 1256, 1705, 1529, 29, 672, 315, 3041, 37, 1, 903, 7, 22, 149, 22, 1, 295, 976, 195, 2492, 264, 17, 3, 128, 1, 6126, 10, 470, 23, 110, 1765, 37, 2, 2464, 37, 3110, 6126, 205, 44, 1290, 93, 1256, 1705, 1529, 29, 361, 1765, 37, 15, 3110, 279, 4187, 21, 204, 17, 6126, 517, 2321, 1765, 31, 8119, 616, 31, 31, 4393, 92, 359, 40, 879, 2500, 20, 5788, 548, 480, 1765, 1616, 153, 6677, 3, 724, 1, 6677, 10, 195, 10049, 20, 3, 1567, 17, 6126, 277, 3, 55, 1, 35, 6677, 1232, 3, 3658, 1040, 70, 1260, 139, 178, 8, 6804, 23, 3110, 6126, 4277, 1256, 1705, 2008, 10, 3728, 20, 548, 480, 6804, 631, 1976, 6126, 5394, 190, 361, 1531, 15, 1291, 31, 273, 68, 1833, 22, 8, 740, 3460, 59, 1765, 2, 3110, 4, 9183, 250, 253, 480, 1875, 163, 2, 1074, 1575]",1189.0,18613644,216
Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.,Molecular and cellular biology,Mol. Cell. Biol.,2008-08-11,"Dysregulated mRNA translation is implicated in the pathogenesis of many human cancers including chronic myelogenous leukemia (CML). Because our prior work has specifically implicated translation initiation in CML, we tested compounds that could modulate translation initiation and polysomal mRNA assembly. Here, we evaluated the activity of one such compound, CGP57380, against CML cells and explored its mechanisms of action. First, using polysomal mRNA profiles, we found that imatinib and CGP57380 could independently, and cooperatively, impair polysomal mRNA loading. Imatinib and CGP57380 also synergistically inhibited the growth of Ba/F3-Bcr-Abl and K562 cells via impaired cell cycle entry and increased apoptosis. Mechanistically, CGP57380 inhibited efficient polysomal assembly via two processes. First, it enhanced imatinib-mediated inhibition of eukaryotic initiation factor 4F induction, and second, it independently impaired phosphorylation of ribosomal protein S6 on the preinitiation complex. We also identified multiple substrates of the mTOR, Rsk, and Mnk kinases as targets of CGP57380. Finally, we found a novel negative-feedback loop to the mitogen-activated protein kinase/Mnk pathway that is triggered by CGP57380 and demonstrated that an interruption of the loop further increased the activity of the combination against imatinib-sensitive and -resistant CML cells. Together, this work supports the inhibition of translation initiation as a therapeutic strategy for treating cancers fueled by dysregulated translation.",Journal Article,4180.0,45.0,Dysregulated mRNA translation is implicated in the pathogenesis of many human cancers including chronic myelogenous CML Because our prior work has specifically implicated translation initiation in CML we tested compounds that could modulate translation initiation and polysomal mRNA assembly Here we evaluated the activity of one such compound CGP57380 against CML cells and explored its mechanisms of action First using polysomal mRNA profiles we found that imatinib and CGP57380 could independently and cooperatively impair polysomal mRNA loading Imatinib and CGP57380 also synergistically inhibited the growth of Ba/F3-Bcr-Abl and K562 cells via impaired cell cycle entry and increased apoptosis Mechanistically CGP57380 inhibited efficient polysomal assembly via two processes First it enhanced imatinib-mediated inhibition of eukaryotic initiation factor 4F induction and second it independently impaired phosphorylation of ribosomal protein S6 on the preinitiation complex We also identified multiple substrates of the mTOR Rsk and Mnk kinases as targets of CGP57380 Finally we found a novel negative-feedback loop to the mitogen-activated protein kinase/Mnk pathway that is triggered by CGP57380 and demonstrated that an interruption of the loop further increased the activity of the combination against imatinib-sensitive and -resistant CML cells Together this work supports the inhibition of translation initiation as a therapeutic strategy for treating cancers fueled by dysregulated translation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4288, 956, 2691, 16, 1771, 4, 3, 1384, 1, 445, 171, 163, 141, 442, 2194, 903, 408, 114, 324, 1357, 71, 1225, 1771, 2691, 1118, 4, 903, 21, 650, 2411, 17, 359, 3319, 2691, 1118, 2, 31335, 956, 7210, 467, 21, 194, 3, 128, 1, 104, 225, 2823, 28828, 480, 903, 37, 2, 1443, 211, 483, 1, 1578, 157, 75, 31335, 956, 1241, 21, 204, 17, 577, 2, 28828, 359, 1042, 2, 13799, 6267, 31335, 956, 4717, 577, 2, 28828, 120, 4240, 879, 3, 129, 1, 6669, 6904, 1062, 1425, 2, 5208, 37, 847, 2364, 31, 417, 3001, 2, 101, 351, 4187, 28828, 879, 2547, 31335, 7210, 847, 100, 1849, 157, 192, 651, 577, 517, 297, 1, 8374, 1118, 161, 20423, 504, 2, 419, 192, 1042, 2364, 982, 1, 8194, 178, 4977, 23, 3, 57280, 840, 21, 120, 108, 232, 6063, 1, 3, 873, 33750, 2, 14313, 1549, 22, 637, 1, 28828, 1368, 21, 204, 8, 229, 199, 3983, 4432, 6, 3, 2625, 735, 178, 216, 14313, 308, 17, 16, 4173, 20, 28828, 2, 264, 17, 35, 4823, 1, 3, 4432, 195, 101, 3, 128, 1, 3, 150, 480, 577, 745, 2, 436, 903, 37, 1162, 26, 1357, 2304, 3, 297, 1, 2691, 1118, 22, 8, 189, 692, 9, 1367, 163, 14767, 20, 4288, 2691]",1505.0,18694961,226
Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2008-09-01,"For more than 20 years the National Marrow Donor Program has facilitated unrelated donor hematopoietic cell transplants for adult recipients. In this time period, the volunteer donor pool has expanded to nearly 12 million adult donors worldwide, improvements have occurred in the understanding and technology of HLA matching, there have been many changes in clinical practice and supportive care, and the more common graft source has shifted from bone marrow (BM) to peripheral blood stem cells (PBSCs). The percentage of older patients who are receiving unrelated donor transplants is increasing; currently over 1 in 10 adult transplant recipients is over the age of 60 years. Chronic myelogenous leukemia (CML) was previously the most common diagnosis for unrelated donor transplantation, but it now comprises less than 10% of transplants for adult recipients. Transplants for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and myelodysplastic syndromes (MDS) all outnumber CML. Treatment-related mortality (TRM) has declined significantly over the years, particularly in association with myeloablative transplant preparative regimens. Correspondingly, survival within each disease category has improved. Particularly gratifying are the results in severe aplastic anemia (AA) where 2-year survival has doubled in just 10 years.",Historical Article,4159.0,91.0,For more than 20 years the National Marrow Donor Program has facilitated unrelated donor hematopoietic cell transplants for adult recipients In this time period the volunteer donor pool has expanded to nearly 12 million adult donors worldwide improvements have occurred in the understanding and technology of HLA matching there have been many changes in clinical practice and supportive care and the more common graft source has shifted from marrow BM to peripheral blood stem cells PBSCs The percentage of older patients who are receiving unrelated donor transplants is increasing currently over 1 in 10 adult transplant recipients is over the age of 60 years Chronic myelogenous CML was previously the most common diagnosis for unrelated donor transplantation but it now comprises less than 10 of transplants for adult recipients Transplants for acute myelogenous AML acute lymphoblastic ALL NHL and syndromes MDS all outnumber CML Treatment-related mortality TRM has declined significantly over the years particularly in association with myeloablative transplant preparative regimens Correspondingly survival within each disease category has improved Particularly gratifying are the results in severe aplastic anemia AA where 2-year survival has doubled in just 10 years,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9, 80, 76, 179, 60, 3, 657, 581, 1488, 1243, 71, 4667, 2092, 1488, 1007, 31, 4016, 9, 780, 2190, 4, 26, 98, 727, 3, 15536, 1488, 6545, 71, 2064, 6, 1857, 133, 3346, 780, 2344, 2358, 1474, 47, 489, 4, 3, 612, 2, 2033, 1, 1160, 2616, 125, 47, 85, 445, 400, 4, 38, 758, 2, 1877, 165, 2, 3, 80, 186, 1599, 2353, 71, 7289, 29, 581, 1246, 6, 672, 315, 452, 37, 13620, 3, 1150, 1, 434, 7, 54, 32, 357, 2092, 1488, 4016, 16, 602, 694, 252, 14, 4, 79, 780, 941, 2190, 16, 252, 3, 89, 1, 335, 60, 442, 2194, 903, 10, 373, 3, 96, 186, 147, 9, 2092, 1488, 497, 84, 192, 1134, 6704, 299, 76, 79, 1, 4016, 9, 780, 2190, 4016, 9, 286, 2194, 329, 286, 1275, 62, 1176, 2, 2040, 1223, 62, 31036, 903, 24, 139, 282, 5064, 71, 3054, 97, 252, 3, 60, 823, 4, 248, 5, 3246, 941, 6085, 472, 11599, 25, 262, 296, 34, 2169, 71, 231, 823, 34530, 32, 3, 99, 4, 905, 16315, 1545, 1519, 1257, 18, 111, 25, 71, 8431, 4, 4673, 79, 60]",1273.0,18721775,197
Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.,"Cell cycle (Georgetown, Tex.)",Cell Cycle,2008-11-02,"Ceramide is a sphingolipid that activates stress kinases such as p38 and c-JUN N-Terminal Kinase (JNK). Though Chronic Myelogenous Leukemia (CML) derived K562 cells resist killing by short chain C2-ceramide, we report here that longer chain C6-ceramide promotes apoptosis in these cells. C6-ceramide induces cleavage of Caspase-8 and Caspase-9, but only Caspase-8 is required for apoptosis. The sphingolipid killed CML derived KBM5 cells and, to a lesser extent, imatinib-resistant KBM5-STI cells suggesting that BCR-ABL can not completely block C6-ceramide-induced apoptosis but the kinase may regulate the process. BCR-ABL is known to suppress Protein Phosphatase 2A (PP2A) in CML cells. While C6-ceramide can activate PP2A in acute leukemia cells, the sphingolipid did not activate the phosphatase in K562 cells. C6-ceramide did not activate p38 kinase but did promote JNK activation and phosphorylation of JUN. Inhibition of JNK by pharmacological agent protected K562 cells from C6-ceramide suggesting that JNK plays an essential role in C6-ceramide mediated apoptosis. Furthermore, the sphingolipid promoted MCL-1 phosphorylation by a mechanism that, at least in part, involves JNK. The findings presented here suggest that Caspase-8, JNK, and perhaps MCL-1 may play important roles in regulating cell death and may represent new targets for therapeutic strategies for CML.",Journal Article,4097.0,44.0,Ceramide is a sphingolipid that activates stress kinases such as p38 and c-JUN N-Terminal Kinase JNK Though Chronic Myelogenous CML derived K562 cells resist killing by short chain C2-ceramide we report here that longer chain C6-ceramide promotes apoptosis in these cells C6-ceramide induces cleavage of Caspase-8 and Caspase-9 but only Caspase-8 is required for apoptosis The sphingolipid killed CML derived KBM5 cells and to a lesser extent imatinib-resistant KBM5-STI cells suggesting that BCR-ABL can not completely block C6-ceramide-induced apoptosis but the kinase may regulate the process BCR-ABL is known to suppress Protein Phosphatase 2A PP2A in CML cells While C6-ceramide can activate PP2A in acute cells the sphingolipid did not activate the phosphatase in K562 cells C6-ceramide did not activate p38 kinase but did promote JNK activation and phosphorylation of JUN Inhibition of JNK by pharmacological agent protected K562 cells from C6-ceramide suggesting that JNK plays an essential role in C6-ceramide mediated apoptosis Furthermore the sphingolipid promoted MCL-1 phosphorylation by a mechanism that at least in part involves JNK The findings presented here suggest that Caspase-8 JNK and perhaps MCL-1 may play important roles in regulating cell death and may represent new targets for therapeutic strategies for CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6307, 16, 8, 12918, 17, 3932, 1531, 1549, 225, 22, 3970, 2, 256, 4578, 78, 2158, 216, 3958, 2471, 442, 2194, 903, 526, 5208, 37, 13010, 3003, 20, 978, 1260, 6706, 6307, 21, 414, 467, 17, 589, 1260, 12267, 6307, 2148, 351, 4, 46, 37, 12267, 6307, 1516, 3155, 1, 1469, 66, 2, 1469, 83, 84, 158, 1469, 66, 16, 616, 9, 351, 3, 12918, 8239, 903, 526, 10822, 37, 2, 6, 8, 5191, 1039, 577, 436, 10822, 10640, 37, 802, 17, 1062, 1425, 122, 44, 2500, 2381, 12267, 6307, 277, 351, 84, 3, 216, 68, 2288, 3, 1129, 1062, 1425, 16, 440, 6, 3134, 178, 2577, 4707, 7890, 4, 903, 37, 369, 12267, 6307, 122, 2977, 7890, 4, 286, 37, 3, 12918, 205, 44, 2977, 3, 2577, 4, 5208, 37, 12267, 6307, 205, 44, 2977, 3970, 216, 84, 205, 1617, 3958, 363, 2, 982, 1, 4578, 297, 1, 3958, 20, 3419, 420, 5541, 5208, 37, 29, 12267, 6307, 802, 17, 3958, 1698, 35, 1452, 200, 4, 12267, 6307, 517, 351, 798, 3, 12918, 2992, 1308, 14, 982, 20, 8, 670, 17, 28, 506, 4, 760, 2921, 3958, 3, 272, 917, 467, 309, 17, 1469, 66, 3958, 2, 4434, 1308, 14, 68, 1343, 305, 1790, 4, 2681, 31, 273, 2, 68, 1231, 217, 637, 9, 189, 422, 9, 903]",1335.0,18948750,215
Following the cytokine signaling pathway to leukemogenesis: a chronology.,The Journal of clinical investigation,J. Clin. Invest.,2008-11-01,"Studies over the past 50 years revealing the molecular events that promote normal T lymphocyte cycle competence and progression led to a detailed understanding of how cytokines function to regulate normal hematopoietic cell proliferation. During that same period, the molecular and genetic changes introduced by the Philadelphia chromosome in chronic myelogenous leukemia were unraveled, and these have led to an understanding of how mutations that constitutively activate normal cytokine signaling pathways can cause unregulated cell proliferation and malignant transformation. Based on the paradigm established by these data, it is inescapable that going forward, investigators will operate under the hypothesis that transformation of additional cells and tissues will have a similar pathogenesis.",Journal Article,4098.0,8.0,Studies over the past 50 years revealing the molecular events that promote normal T lymphocyte cycle competence and progression led to a detailed understanding of how cytokines function to regulate normal hematopoietic cell proliferation During that same period the molecular and genetic changes introduced by the Philadelphia chromosome in chronic myelogenous were unraveled and these have led to an understanding of how mutations that constitutively activate normal cytokine signaling pathways can cause unregulated cell proliferation and malignant transformation Based on the paradigm established by these data it is inescapable that going forward investigators will operate under the hypothesis that transformation of additional cells and tissues will have a similar pathogenesis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[94, 252, 3, 1219, 212, 60, 6475, 3, 219, 281, 17, 1617, 295, 102, 1448, 417, 11573, 2, 91, 836, 6, 8, 2455, 612, 1, 832, 1886, 343, 6, 2288, 295, 1007, 31, 457, 190, 17, 827, 727, 3, 219, 2, 336, 400, 3955, 20, 3, 3006, 1170, 4, 442, 2194, 11, 20632, 2, 46, 47, 836, 6, 35, 612, 1, 832, 138, 17, 2818, 2977, 295, 1675, 314, 460, 122, 708, 17770, 31, 457, 2, 393, 1392, 90, 23, 3, 2431, 635, 20, 46, 74, 192, 16, 45311, 17, 11587, 4674, 2394, 303, 15680, 669, 3, 1492, 17, 1392, 1, 402, 37, 2, 742, 303, 47, 8, 288, 1384]",783.0,18982163,169
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2009-01-01,"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment of choice for patients with chronic myelogenous leukemia (CML) who have failed or are intolerant to tyrosine kinase inhibitors (TKI). Myeloablative conditioning regimens have been associated with high treatment-related mortality (TRM) rate in such patients, and reduced-intensity conditioning (RIC) regimens are often preferred but have high rates of disease recurrence and graft-versus-host-disease (GVHD). We report our experience with nine CML patients (four chronic phase and five with accelerated phase or blast crisis) who failed TKI and underwent allo-HSCT using an alemtuzumab-based RIC regimen. The conditioning regimen was well tolerated and induced engraftment in all patients, and complete cytogenetic remission (CCyR) in eight of nine. Four patients, all with a history of accelerated phase or blast crisis, died. Four of the five remaining patients had a cytogenetic relapse a median of 10 months after transplantation. Donor lymphocyte infusion (DLI), TKI or both induced a CCyR in all cases. With a median follow-up of 47 months, five patients, including all those transplanted in first or second chronic phase, are alive and in remission. Allo-HSCT with an alemtuzumab-based conditioning regimen induces remission in patients with CML that have failed TKI therapy and has a low incidence of GVHD. Disease recurrence is frequent but responds to DLI. In some cases, restoration of susceptibility to TKI was observed. Outcomes may improve with the routine administration of post-transplant TKI.",Journal Article,4037.0,10.0,Allogeneic hematopoietic stem cell transplantation allo-HSCT is the treatment of choice for patients with chronic myelogenous CML who have failed or are intolerant to tyrosine kinase inhibitors TKI Myeloablative conditioning regimens have been associated with high treatment-related mortality TRM rate in such patients and reduced-intensity conditioning RIC regimens are often preferred but have high rates of disease recurrence and graft-versus-host-disease GVHD We report our experience with nine CML patients four chronic phase and five with accelerated phase or blast crisis who failed TKI and underwent allo-HSCT using an alemtuzumab-based RIC regimen The conditioning regimen was well tolerated and induced engraftment in all patients and complete cytogenetic remission CCyR in eight of nine Four patients all with a history of accelerated phase or blast crisis died Four of the five remaining patients had a cytogenetic relapse a median of 10 months after transplantation Donor lymphocyte infusion DLI TKI or both induced a CCyR in all cases With a median follow-up of 47 months five patients including all those transplanted in first or second chronic phase are alive and in remission Allo-HSCT with an alemtuzumab-based conditioning regimen induces remission in patients with CML that have failed TKI therapy and has a low incidence of GVHD Disease recurrence is frequent but responds to DLI In some cases restoration of susceptibility to TKI was observed Outcomes may improve with the routine administration of post-transplant TKI,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 1007, 452, 31, 497, 2564, 1703, 16, 3, 24, 1, 1866, 9, 7, 5, 442, 2194, 903, 54, 47, 1551, 15, 32, 4944, 6, 564, 216, 222, 1379, 3246, 1933, 472, 47, 85, 41, 5, 64, 24, 139, 282, 5064, 116, 4, 225, 7, 2, 405, 837, 1933, 3365, 472, 32, 629, 2514, 84, 47, 64, 151, 1, 34, 146, 2, 1599, 185, 1204, 34, 1562, 21, 414, 114, 730, 5, 762, 903, 7, 294, 442, 124, 2, 365, 5, 2241, 124, 15, 3112, 6540, 54, 1551, 1379, 2, 208, 2564, 1703, 75, 35, 3579, 90, 3365, 477, 3, 1933, 477, 10, 149, 421, 2, 277, 2881, 4, 62, 7, 2, 236, 1266, 734, 6412, 4, 659, 1, 762, 294, 7, 62, 5, 8, 532, 1, 2241, 124, 15, 3112, 6540, 1016, 294, 1, 3, 365, 1844, 7, 42, 8, 1266, 429, 8, 52, 1, 79, 53, 50, 497, 1488, 1448, 904, 4676, 1379, 15, 110, 277, 8, 6412, 4, 62, 140, 5, 8, 52, 166, 126, 1, 662, 53, 365, 7, 141, 62, 135, 4600, 4, 157, 15, 419, 442, 124, 32, 1701, 2, 4, 734, 2564, 1703, 5, 35, 3579, 90, 1933, 477, 1516, 734, 4, 7, 5, 903, 17, 47, 1551, 1379, 36, 2, 71, 8, 154, 287, 1, 1562, 34, 146, 16, 908, 84, 7920, 6, 4676, 4, 476, 140, 5194, 1, 1432, 6, 1379, 10, 164, 123, 68, 401, 5, 3, 1311, 634, 1, 539, 941, 1379]",1540.0,19142796,75
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?,Mayo Clinic proceedings,Mayo Clin. Proc.,2009-02-01,"Treatment responses to imatinib vary among patients with chronic myeloid leukemia (CML), and definitions of treatment failure and suboptimal response have been published. This article discusses monitoring and treatment of patients with CML after failure of or suboptimal response to imatinib therapy. We reviewed articles listed on PubMed from January 1, 2002, to July 31, 2008, and abstracts from the 2007 Annual Meeting of the American Society of Hematology. Search terms used were chronic myeloid/myelogenous leukemia, imatinib, and BCR-ABL. To enable early recognition of suboptimal responses, patients should be frequently monitored according to published guidelines, including cytogenetic analysis every 6 months until a complete response is achieved and molecular monitoring every 3 months from the start of therapy or monthly if an increasing BCR-ABL1 transcript level is detected. Mutational analysis of BCR-ABL1 may assist with treatment selection. A recent survey suggests that a notable proportion of physicians do not follow treatment guidelines and that broader communication is required. Recent recommendations state that, in patients whose response to imatinib at 400 mg/d is suboptimal, the dose should be increased, whereas alternative therapies, such as dasatinib, nilotinib, and allogeneic stem cell transplant (in eligible patients), and imatinib dose escalation should be considered after imatinib failure. However, clinical data are lacking to confirm this sequence of treatments, and introducing alternative therapies at an earlier stage of treatment, for example, after a suboptimal response, may produce better long-term outcomes in a higher proportion of patients. Patient and disease characteristics should be carefully considered to optimize treatment strategy for CML.",Journal Article,4006.0,38.0,Treatment responses to imatinib vary among patients with chronic myeloid CML and definitions of treatment failure and suboptimal response have been published This article discusses monitoring and treatment of patients with CML after failure of or suboptimal response to imatinib therapy We reviewed articles listed on PubMed from January 1 2002 to July 31 2008 and abstracts from the 2007 Annual Meeting of the American Society of Hematology Search terms used were chronic myeloid/myelogenous imatinib and BCR-ABL To enable early recognition of suboptimal responses patients should be frequently monitored according to published guidelines including cytogenetic analysis every 6 months until a complete response is achieved and molecular monitoring every 3 months from the start of therapy or monthly if an increasing BCR-ABL1 transcript level is detected Mutational analysis of BCR-ABL1 may assist with treatment selection A recent survey suggests that a notable proportion of physicians do not follow treatment guidelines and that broader communication is required Recent recommendations state that in patients whose response to imatinib at 400 mg/d is suboptimal the dose should be increased whereas alternative therapies such as dasatinib nilotinib and allogeneic stem cell transplant in eligible patients and imatinib dose escalation should be considered after imatinib failure However clinical data are lacking to confirm this sequence of treatments and introducing alternative therapies at an earlier stage of treatment for example after a suboptimal response may produce better long-term outcomes in a higher proportion of patients Patient and disease characteristics should be carefully considered to optimize treatment strategy for CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[24, 253, 6, 577, 2825, 107, 7, 5, 442, 533, 903, 2, 3833, 1, 24, 496, 2, 3291, 51, 47, 85, 983, 26, 946, 2759, 1315, 2, 24, 1, 7, 5, 903, 50, 496, 1, 15, 3291, 51, 6, 577, 36, 21, 446, 2384, 8754, 23, 3161, 29, 1024, 14, 1544, 6, 2066, 456, 1375, 2, 5159, 29, 3, 1307, 2114, 2238, 1, 3, 597, 1174, 1, 6216, 1901, 1794, 95, 11, 442, 533, 2194, 577, 2, 1062, 1425, 6, 3047, 191, 2335, 1, 3291, 253, 7, 257, 40, 746, 2909, 768, 6, 983, 677, 141, 1266, 65, 454, 49, 53, 1100, 8, 236, 51, 16, 513, 2, 219, 1315, 454, 27, 53, 29, 3, 2435, 1, 36, 15, 3889, 492, 35, 602, 1062, 3557, 3268, 301, 16, 530, 1619, 65, 1, 1062, 3557, 68, 3425, 5, 24, 881, 8, 435, 1407, 844, 17, 8, 4090, 920, 1, 1261, 1022, 44, 166, 24, 677, 2, 17, 5410, 2063, 16, 616, 435, 883, 1309, 17, 4, 7, 1310, 51, 6, 577, 28, 1524, 81, 427, 16, 3291, 3, 61, 257, 40, 101, 547, 1091, 235, 225, 22, 1674, 2638, 2, 1063, 452, 31, 941, 4, 625, 7, 2, 577, 61, 1125, 257, 40, 515, 50, 577, 496, 137, 38, 74, 32, 1941, 6, 1843, 26, 1532, 1, 640, 2, 11165, 1091, 235, 28, 35, 1677, 82, 1, 24, 9, 2685, 50, 8, 3291, 51, 68, 2410, 380, 319, 337, 123, 4, 8, 142, 920, 1, 7, 69, 2, 34, 374, 257, 40, 3900, 515, 6, 2465, 24, 692, 9, 903]",1745.0,19181650,22
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2009-02-17,"Vorinostat [suberoylanilide hydroxamic acid (SAHA)] is a potent histone deacetylase inhibitor with promising clinical efficacy as an anticancer agent. In this preclinical study, we evaluated combining cytosine arabinoside [1-beta-D-arabinofuranosylcytosine (ara-C)] and/or etoposide with vorinostat for use in the treatment of acute leukemias. Cell survival was examined in vitro in HL-60 human myeloid leukemia cells and K562 myeloid blast crisis chronic myelogenous leukemia cells, using the 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt and/or fluorescein diacetate/propidium iodide assays. Drug interactions were analyzed by the combination index method (CalcuSyn) and by a novel statistical method that we developed (SynStat). Cell cycle phase distribution was measured by flow cytometry. Cytotoxic antagonism resulted when vorinostat was combined concomitantly with ara-C; however, when vorinostat was given first followed by a drug-free interval before ara-C treatment, this sequential combination was mostly synergistic. Etoposide combined with vorinostat was additive to synergistic, and the synergism became more pronounced when etoposide was given after vorinostat. Cell cycle analyses revealed that the sequence-dependent interaction of vorinostat and ara-C or etoposide reflected the arrest of cells in G1 or G2 phase during vorinostat treatment and recovery into S phase after removal of vorinostat. These findings using two independent methods to assess drug combination effects provide a preclinical rationale for phase I trials of the sequential combination of vorinostat followed by ara-C and etoposide in patients with advanced or refractory leukemias. CalcuSyn findings were concordant with those of SynStat, validating the use of the latter in analyzing drug interactions.",Comparative Study,3990.0,46.0,"Vorinostat suberoylanilide hydroxamic acid SAHA is a potent histone deacetylase inhibitor with promising clinical efficacy as an anticancer agent In this preclinical study we evaluated combining cytosine arabinoside 1-beta-D-arabinofuranosylcytosine ara-C and/or etoposide with vorinostat for use in the treatment of acute leukemias Cell survival was examined in vitro in HL-60 human myeloid cells and K562 myeloid blast crisis chronic myelogenous cells using the 2,3-bis 2-methoxy-4-nitro-5-sulfophenyl -2H-tetrazolium-5-carboxanilide inner salt and/or fluorescein diacetate/propidium iodide assays Drug interactions were analyzed by the combination index method CalcuSyn and by a novel statistical method that we developed SynStat Cell cycle phase distribution was measured by flow cytometry Cytotoxic antagonism resulted when vorinostat was combined concomitantly with ara-C however when vorinostat was given first followed by a drug-free interval before ara-C treatment this sequential combination was mostly synergistic Etoposide combined with vorinostat was additive to synergistic and the synergism became more pronounced when etoposide was given after vorinostat Cell cycle analyses revealed that the sequence-dependent interaction of vorinostat and ara-C or etoposide reflected the arrest of cells in G1 or G2 phase during vorinostat treatment and recovery into S phase after removal of vorinostat These findings using two independent methods to assess drug combination effects provide a preclinical rationale for phase I trials of the sequential combination of vorinostat followed by ara-C and etoposide in patients with advanced or refractory leukemias CalcuSyn findings were concordant with those of SynStat validating the use of the latter in analyzing drug interactions",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2371, 9258, 8856, 971, 5484, 16, 8, 1157, 1508, 2732, 230, 5, 721, 38, 209, 22, 35, 1475, 420, 4, 26, 693, 45, 21, 194, 1525, 6903, 11563, 14, 1090, 427, 21019, 3899, 256, 2, 15, 1934, 5, 2371, 9, 119, 4, 3, 24, 1, 286, 2792, 31, 25, 10, 409, 4, 439, 4, 1718, 335, 171, 533, 37, 2, 5208, 533, 3112, 6540, 442, 2194, 37, 75, 3, 18, 27, 7200, 18, 26436, 39, 18962, 33, 26437, 17328, 11915, 33, 44111, 7938, 11818, 2, 15, 14425, 24445, 10839, 8456, 1013, 234, 1286, 11, 311, 20, 3, 150, 558, 596, 30296, 2, 20, 8, 229, 1050, 596, 17, 21, 276, 45438, 31, 417, 124, 1395, 10, 644, 20, 1412, 1914, 759, 7537, 627, 198, 2371, 10, 397, 6485, 5, 3899, 256, 137, 198, 2371, 10, 447, 157, 370, 20, 8, 234, 115, 268, 348, 3899, 256, 24, 26, 1787, 150, 10, 2754, 1806, 1934, 397, 5, 2371, 10, 3396, 6, 1806, 2, 3, 6494, 3451, 80, 3517, 198, 1934, 10, 447, 50, 2371, 31, 417, 318, 553, 17, 3, 1532, 470, 915, 1, 2371, 2, 3899, 256, 15, 1934, 4686, 3, 1854, 1, 37, 4, 3344, 15, 3774, 124, 190, 2371, 24, 2, 1602, 237, 695, 124, 50, 2829, 1, 2371, 46, 272, 75, 100, 306, 636, 6, 423, 234, 150, 176, 377, 8, 693, 1728, 9, 124, 70, 143, 1, 3, 1787, 150, 1, 2371, 370, 20, 3899, 256, 2, 1934, 4, 7, 5, 131, 15, 430, 2792, 30296, 272, 11, 3610, 5, 135, 1, 45438, 6897, 3, 119, 1, 3, 3286, 4, 4449, 234, 1286]",1783.0,19223502,241
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).,Neuro-oncology,Neuro-oncology,2009-12-01,"Platelet-derived growth factor (PDGF) and its receptors (PDGFR) are frequently coexpressed in meningiomas, potentially contributing to their pathogenesis. The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas. Patients were stratified into benign (WHO grade I) meningiomas or atypical (WHO grade II) and malignant (WHO grade III) meningiomas. The primary end point was 6-month progression-free survival (6M-PFS). Patients requiring enzyme-inducing antiepileptic drugs were ineligible. Patients received imatinib at a dose of 600 mg/day for the first 4-week cycle and then gradually increased to 800 mg/day for subsequent cycles, if there were no unacceptable toxicities. Plasma concentrations of imatinib and its active metabolite, CGP74588, were assessed. Twenty-three heavily pretreated patients were enrolled into the study (13 benign, 5 atypical, and 5 malignant meningiomas), of whom 22 were eligible. The study was closed prematurely due to slow accrual. Tissue was available only from a minority of patients, but in these specimens there was uniform distribution of PDGFR, the drug target. Imatinib was generally well tolerated. Of 19 patients evaluable for response, 10 progressed at the first scan, and 9 were stable. There were no complete or partial responses. Overall median PFS was 2 months (range, 0.7-34 months); 6M-PFS was 29.4%. For benign meningiomas, median PFS was 3 months (range, 1.1-34 months); 6M-PFS was 45%. For atypical and malignant meningiomas, median PFS was 2 months (range, 0.7-3.7 months); 6M-PFS was 0%. Cycle 1 trough concentrations of imatinib and CGP74588 were 2,129 +/- 1,600 ng/ml and 517 +/- 326 ng/ml, respectively. Single-agent imatinib was well tolerated but had no significant activity in recurrent meningiomas. Trough plasma concentrations of imatinib exceeded those associated with imatinib activity in chronic myelogenous leukemia.","Clinical Trial, Phase II",3703.0,82.0,"Platelet-derived growth factor PDGF and its receptors PDGFR are frequently coexpressed in meningiomas potentially contributing to their pathogenesis The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate Gleevec a PDGFR inhibitor in patients with recurrent meningiomas Patients were stratified into benign WHO grade I meningiomas or atypical WHO grade II and malignant WHO grade III meningiomas The primary end point was 6-month progression-free survival 6M-PFS Patients requiring enzyme-inducing antiepileptic drugs were ineligible Patients received imatinib at a dose of 600 mg/day for the first 4-week cycle and then gradually increased to 800 mg/day for subsequent cycles if there were no unacceptable toxicities Plasma concentrations of imatinib and its active metabolite CGP74588 were assessed Twenty-three heavily pretreated patients were enrolled into the study 13 benign 5 atypical and 5 malignant meningiomas of whom 22 were eligible The study was closed prematurely due to slow accrual Tissue was available only from a minority of patients but in these specimens there was uniform distribution of PDGFR the drug target Imatinib was generally well tolerated Of 19 patients evaluable for response 10 progressed at the first scan and 9 were stable There were no complete or partial responses Overall median PFS was 2 months range 0.7-34 months 6M-PFS was 29.4 For benign meningiomas median PFS was 3 months range 1.1-34 months 6M-PFS was 45 For atypical and malignant meningiomas median PFS was 2 months range 0.7-3.7 months 6M-PFS was 0 Cycle 1 trough concentrations of imatinib and CGP74588 were 2,129 +/- 1,600 ng/ml and 517 +/- 326 ng/ml respectively Single-agent imatinib was well tolerated but had no significant activity in recurrent meningiomas Trough plasma concentrations of imatinib exceeded those associated with imatinib activity in chronic myelogenous",0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1596, 526, 129, 161, 4546, 2, 211, 1186, 4103, 32, 746, 10185, 4, 3718, 751, 3156, 6, 136, 1384, 3, 2669, 597, 342, 30, 2404, 426, 8, 124, 215, 45, 6, 376, 3, 189, 174, 1, 577, 2347, 8569, 8, 4103, 230, 4, 7, 5, 387, 3718, 7, 11, 1173, 237, 1002, 54, 88, 70, 3718, 15, 1973, 54, 88, 215, 2, 393, 54, 88, 316, 3718, 3, 86, 396, 741, 10, 49, 811, 91, 115, 25, 19188, 300, 7, 1888, 1644, 1958, 8164, 600, 11, 3773, 7, 103, 577, 28, 8, 61, 1, 2383, 81, 218, 9, 3, 157, 39, 647, 417, 2, 818, 8092, 101, 6, 2796, 81, 218, 9, 706, 410, 492, 125, 11, 77, 3215, 385, 554, 1003, 1, 577, 2, 211, 544, 3379, 31223, 11, 275, 737, 169, 2447, 2193, 7, 11, 346, 237, 3, 45, 233, 1002, 33, 1973, 2, 33, 393, 3718, 1, 953, 350, 11, 625, 3, 45, 10, 3745, 9771, 520, 6, 3645, 2262, 246, 10, 390, 158, 29, 8, 2652, 1, 7, 84, 4, 46, 623, 125, 10, 3490, 1395, 1, 4103, 3, 234, 283, 577, 10, 1228, 149, 421, 1, 326, 7, 859, 9, 51, 79, 1839, 28, 3, 157, 1657, 2, 83, 11, 585, 125, 11, 77, 236, 15, 450, 253, 63, 52, 300, 10, 18, 53, 184, 13, 67, 562, 53, 19188, 300, 10, 462, 39, 9, 1002, 3718, 52, 300, 10, 27, 53, 184, 14, 14, 562, 53, 19188, 300, 10, 512, 9, 1973, 2, 393, 3718, 52, 300, 10, 18, 53, 184, 13, 67, 27, 67, 53, 19188, 300, 10, 13, 417, 14, 6000, 1003, 1, 577, 2, 31223, 11, 18, 4649, 14, 2383, 997, 542, 2, 11100, 9588, 997, 542, 106, 226, 420, 577, 10, 149, 421, 84, 42, 77, 93, 128, 4, 387, 3718, 6000, 554, 1003, 1, 577, 4726, 135, 41, 5, 577, 128, 4, 442, 2194]",1946.0,19293394,54
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2009-05-01,"The purpose of this study was to determine the effect of alemtuzumab on treatment-related mortality (TRM), relapse, overall survival (OS), and disease-free survival (DSF) in patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) undergoing reduced intensity conditioning (RIC). We compared the outcome of 95 patients treated at the University of Chicago with fludarabine melphalan (Flu + Mel) + alemtuzumab conditioning and 59 patients treated at the M.D. Anderson Cancer Center with Flu + Mel conditioning. Both groups had similar patient and donor characteristics. There were no significant differences in TRM, relapse, survival, and DFS between the 2 groups. The incidence of acute graft-versus-host disease (aGVHD) grade II-IV (relative risk [RR] 5.5, P < .01) and chronic GVHD (cGVHD) (RR 6.6, P < .01) were significantly lower in patients receiving alemtuzumab. The addition of alemtuzumab to an RIC regimen dramatically reduces the incidence of aGVHD and cGVHD in patients with AML and MDS undergoing allogeneic transplantation. TRM, relapse risk, OS and DFS are not affected.",Controlled Clinical Trial,3917.0,39.0,The purpose of this study was to determine the effect of alemtuzumab on treatment-related mortality TRM relapse overall survival OS and disease-free survival DSF in patients with acute myelogenous AML and syndromes MDS undergoing reduced intensity conditioning RIC We compared the outcome of 95 patients treated at the University of Chicago with fludarabine melphalan Flu Mel alemtuzumab conditioning and 59 patients treated at the M.D Anderson Cancer Center with Flu Mel conditioning Both groups had similar patient and donor characteristics There were no significant differences in TRM relapse survival and DFS between the 2 groups The incidence of acute graft-versus-host disease aGVHD grade II-IV relative risk RR 5.5 P .01 and chronic GVHD cGVHD RR 6.6 P .01 were significantly lower in patients receiving alemtuzumab The addition of alemtuzumab to an RIC regimen dramatically reduces the incidence of aGVHD and cGVHD in patients with AML and MDS undergoing allogeneic transplantation TRM relapse risk OS and DFS are not affected,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 223, 3, 254, 1, 3579, 23, 24, 139, 282, 5064, 429, 63, 25, 118, 2, 34, 115, 25, 16510, 4, 7, 5, 286, 2194, 329, 2, 2040, 1223, 479, 405, 837, 1933, 3365, 21, 72, 3, 228, 1, 48, 7, 73, 28, 3, 1652, 1, 9344, 5, 2027, 2370, 5119, 7383, 3579, 1933, 2, 728, 7, 73, 28, 3, 188, 427, 1929, 12, 574, 5, 5119, 7383, 1933, 110, 271, 42, 288, 69, 2, 1488, 374, 125, 11, 77, 93, 362, 4, 5064, 429, 25, 2, 1010, 59, 3, 18, 271, 3, 287, 1, 286, 1599, 185, 1204, 34, 5873, 88, 215, 478, 580, 43, 861, 33, 33, 19, 355, 2, 442, 1562, 6670, 861, 49, 49, 19, 355, 11, 97, 280, 4, 7, 357, 3579, 3, 352, 1, 3579, 6, 35, 3365, 477, 2729, 2389, 3, 287, 1, 5873, 2, 6670, 4, 7, 5, 329, 2, 1223, 479, 1063, 497, 5064, 429, 43, 118, 2, 1010, 32, 44, 1424]",1034.0,19361753,240
Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia.,Leukemia research,Leuk. Res.,2009-05-05,"JUNB inactivation in transgenic mice results in a myeloproliferative disorder that closely resembles human chronic myelogenous leukemia (CML). It has been reported that downregulation of JUNB expression is a universal phenomenon in patients with CML due aberrant DNA methylation of its promoter. Based on this, we studied methylation and gene expression levels of JUNB in CML. We analyzed the methylation status of the JUNB gene in 6 cell lines and in 102 patients with CML using several bisulfite PCR assays. JUNB expression was analyzed using real-time PCR and gene expression profiling. JUNB methylation was not observed in any of the cell lines studied, and only in 3% of patients with CML. Despite the lack of JUNB methylation, JUNB was expressed at low levels both in CML cell lines (median dCT -6.86; range -5.87 to -9.61), and in patients with CML in blastic phase (BP) (median dCT -3.95; range -1.48 to -6.29) (p = 0.002). Finally, we evaluated JUNB expression in 82 additional patients with CML by gene expression arrays. We found that JUNB was significantly downregulated in advanced phase CML in contrast to chronic phase CML (median log ratio difference in expression = 0.53). Overall, our results indicate that JUNB expression is downregulated in advanced phase CML through a mechanism independent from DNA methylation.",Journal Article,3913.0,13.0,JUNB inactivation in transgenic mice results in a disorder that closely resembles human chronic myelogenous CML It has been reported that downregulation of JUNB expression is a universal phenomenon in patients with CML due aberrant DNA methylation of its promoter Based on this we studied methylation and gene expression levels of JUNB in CML We analyzed the methylation status of the JUNB gene in 6 cell lines and in 102 patients with CML using several bisulfite PCR assays JUNB expression was analyzed using real-time PCR and gene expression profiling JUNB methylation was not observed in any of the cell lines studied and only in 3 of patients with CML Despite the lack of JUNB methylation JUNB was expressed at low levels both in CML cell lines median dCT -6.86 range -5.87 to -9.61 and in patients with CML in blastic phase BP median dCT -3.95 range -1.48 to -6.29 p 0.002 Finally we evaluated JUNB expression in 82 additional patients with CML by gene expression arrays We found that JUNB was significantly downregulated in advanced phase CML in contrast to chronic phase CML median log ratio difference in expression 0.53 Overall our results indicate that JUNB expression is downregulated in advanced phase CML through a mechanism independent from DNA methylation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12868, 2297, 4, 2862, 399, 99, 4, 8, 2645, 17, 3210, 13270, 171, 442, 2194, 903, 192, 71, 85, 210, 17, 2475, 1, 12868, 55, 16, 8, 4967, 3936, 4, 7, 5, 903, 520, 1898, 261, 569, 1, 211, 973, 90, 23, 26, 21, 656, 569, 2, 145, 55, 148, 1, 12868, 4, 903, 21, 311, 3, 569, 156, 1, 3, 12868, 145, 4, 49, 31, 285, 2, 4, 2867, 7, 5, 903, 75, 392, 6181, 604, 1013, 12868, 55, 10, 311, 75, 1589, 98, 604, 2, 145, 55, 1080, 12868, 569, 10, 44, 164, 4, 500, 1, 3, 31, 285, 656, 2, 158, 4, 27, 1, 7, 5, 903, 550, 3, 926, 1, 12868, 569, 12868, 10, 570, 28, 154, 148, 110, 4, 903, 31, 285, 52, 19175, 49, 868, 184, 33, 912, 6, 83, 713, 2, 4, 7, 5, 903, 4, 6529, 124, 3044, 52, 19175, 27, 48, 184, 14, 576, 6, 49, 462, 19, 13, 1111, 1368, 21, 194, 12868, 55, 4, 878, 402, 7, 5, 903, 20, 145, 55, 3923, 21, 204, 17, 12868, 10, 97, 3315, 4, 131, 124, 903, 4, 748, 6, 442, 124, 903, 52, 1066, 197, 523, 4, 55, 13, 699, 63, 114, 99, 1008, 17, 12868, 55, 16, 3315, 4, 131, 124, 903, 298, 8, 670, 306, 29, 261, 569]",1270.0,19409613,40
Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer.,International journal of cancer,Int. J. Cancer,2009-08-01,"Hypomethylation of DNA repetitive elements is a common finding in cancer, but very little is known about the DNA methylation changes of different types of DNA repetitive elements, such as interspersed repeats (LINE1 and Alu Yb8) and tandem repeats (Sat-alpha, NBL-2 and D4Z4). We used bisulfite-PCR Pyrosequencing to quantitatively measure the DNA methylation of five different DNA repetitive elements in normal tissue and cancer. In all we studied 10 different tissues from four individuals undergoing autopsy, 34 paired normal and tumor tissues from patients with bladder cancer, 58 patients with chronic myelogenous leukemia and 23 patients with acute promyelocytic leukemia. We found that the DNA methylation of interspersed repeats (LINE1 and Alu Yb8) was very consistent from person to person and tissue to tissue while tandem DNA repeats appeared more variable in normal tissues. In bladder cancer we found clear hypomethylation of LINE1, Alu Yb8, Sat-alpha and NBL-2. Conversely, we found an increase in the DNA methylation levels of D4Z4 from normal to cancer. In contrast leukemia showed no significant changes in the DNA methylation of LINE1 and Alu Yb8, but DNA methylation increases in NBL-2 and D4Z4 tandem repeats. Our findings show that the changes in DNA methylation levels of individual DNA repetitive elements are unique for each repetitive element, which may reflect distinct epigenetic factors and may have important implications in the use of DNA methylation of repetitive elements as global DNA methylation biomarkers.",Journal Article,3825.0,104.0,Hypomethylation of DNA repetitive elements is a common finding in cancer but very little is known about the DNA methylation changes of different types of DNA repetitive elements such as interspersed repeats LINE1 and Alu Yb8 and tandem repeats Sat-alpha NBL-2 and D4Z4 We used bisulfite-PCR Pyrosequencing to quantitatively measure the DNA methylation of five different DNA repetitive elements in normal tissue and cancer In all we studied 10 different tissues from four individuals undergoing autopsy 34 paired normal and tumor tissues from patients with cancer 58 patients with chronic myelogenous and 23 patients with acute promyelocytic We found that the DNA methylation of interspersed repeats LINE1 and Alu Yb8 was very consistent from person to person and tissue to tissue while tandem DNA repeats appeared more variable in normal tissues In cancer we found clear hypomethylation of LINE1 Alu Yb8 Sat-alpha and NBL-2 Conversely we found an increase in the DNA methylation levels of D4Z4 from normal to cancer In contrast showed no significant changes in the DNA methylation of LINE1 and Alu Yb8 but DNA methylation increases in NBL-2 and D4Z4 tandem repeats Our findings show that the changes in DNA methylation levels of individual DNA repetitive elements are unique for each repetitive element which may reflect distinct epigenetic factors and may have important implications in the use of DNA methylation of repetitive elements as global DNA methylation biomarkers,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[4441, 1, 261, 9246, 2531, 16, 8, 186, 1567, 4, 12, 84, 923, 1215, 16, 440, 545, 3, 261, 569, 400, 1, 338, 630, 1, 261, 9246, 2531, 225, 22, 11038, 7197, 17845, 2, 15265, 34683, 2, 2905, 7197, 26824, 950, 12032, 18, 2, 38988, 21, 95, 6181, 604, 6031, 6, 5889, 1463, 3, 261, 569, 1, 365, 338, 261, 9246, 2531, 4, 295, 246, 2, 12, 4, 62, 21, 656, 79, 338, 742, 29, 294, 869, 479, 6270, 562, 2355, 295, 2, 30, 742, 29, 7, 5, 12, 717, 7, 5, 442, 2194, 2, 382, 7, 5, 286, 4300, 21, 204, 17, 3, 261, 569, 1, 11038, 7197, 17845, 2, 15265, 34683, 10, 923, 925, 29, 2719, 6, 2719, 2, 246, 6, 246, 369, 2905, 261, 7197, 2121, 80, 1347, 4, 295, 742, 4, 12, 21, 204, 885, 4441, 1, 17845, 15265, 34683, 26824, 950, 2, 12032, 18, 3154, 21, 204, 35, 344, 4, 3, 261, 569, 148, 1, 38988, 29, 295, 6, 12, 4, 748, 224, 77, 93, 400, 4, 3, 261, 569, 1, 17845, 2, 15265, 34683, 84, 261, 569, 1106, 4, 12032, 18, 2, 38988, 2905, 7197, 114, 272, 514, 17, 3, 400, 4, 261, 569, 148, 1, 797, 261, 9246, 2531, 32, 991, 9, 296, 9246, 4467, 92, 68, 2694, 834, 1418, 130, 2, 68, 47, 305, 1268, 4, 3, 119, 1, 261, 569, 1, 9246, 2531, 22, 1648, 261, 569, 582]",1474.0,19437537,168
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-06-01,"The aim of this study was to evaluate the clinical relevance of increases in quantitative polymerase chain reaction (QPCR) levels in patients with chronic myelogenous leukemia (CML) who are in complete cytogenetic response (CGCR) on therapy. Patients with Philadelphia chromosome (Ph)-positive CML receiving tyrosine kinase inhibitors (TKIs) are frequently monitored for response by QPCR studies for minimal molecular disease. The clinical significance of increasing levels of QPCR in patients in CGCR is uncertain. One hundred sixteen patients in durable CGCR, and on imatinib therapy for at least 18 months, had increases in QPCR levels (documented at least twice consecutively) as defined by literature reports. These were further analyzed by the achievement of major molecular response (MMR) defined as QPCR < or = 0.05%, as well as by the degree of increase in QPCR. Only 11 (9.5%) of 116 patients with increases in QPCR had CML progression; 10 of them were among 44 patients (23%) who either lost a MMR or never had a MMR, and had more than 1 log increase of QPCR. Most patients with increases in QPCR remain in CGCR. Patients who lose a MMR or never achieve a MMR, and have more than 1 log increase of QPCR, should be monitored more closely, and may be evaluated for mutations of BCR-ABL kinase domain and considered for investigational therapeutic interventions.",Comparative Study,3886.0,53.0,The aim of this study was to evaluate the clinical relevance of increases in quantitative polymerase chain reaction QPCR levels in patients with chronic myelogenous CML who are in complete cytogenetic response CGCR on therapy Patients with Philadelphia chromosome Ph -positive CML receiving tyrosine kinase inhibitors TKIs are frequently monitored for response by QPCR studies for minimal molecular disease The clinical significance of increasing levels of QPCR in patients in CGCR is uncertain One hundred sixteen patients in durable CGCR and on imatinib therapy for at least 18 months had increases in QPCR levels documented at least twice consecutively as defined by literature reports These were further analyzed by the achievement of major molecular response MMR defined as QPCR or 0.05 as well as by the degree of increase in QPCR Only 11 9.5 of 116 patients with increases in QPCR had CML progression 10 of them were among 44 patients 23 who either lost a MMR or never had a MMR and had more than 1 log increase of QPCR Most patients with increases in QPCR remain in CGCR Patients who lose a MMR or never achieve a MMR and have more than 1 log increase of QPCR should be monitored more closely and may be evaluated for mutations of BCR-ABL kinase domain and considered for investigational therapeutic interventions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 376, 3, 38, 2088, 1, 1106, 4, 1156, 1451, 1260, 1329, 6162, 148, 4, 7, 5, 442, 2194, 903, 54, 32, 4, 236, 1266, 51, 25050, 23, 36, 7, 5, 3006, 1170, 2058, 109, 903, 357, 564, 216, 222, 1671, 32, 746, 2909, 9, 51, 20, 6162, 94, 9, 1048, 219, 34, 3, 38, 724, 1, 602, 148, 1, 6162, 4, 7, 4, 25050, 16, 2717, 104, 1128, 3228, 7, 4, 1480, 25050, 2, 23, 577, 36, 9, 28, 506, 203, 53, 42, 1106, 4, 6162, 148, 1405, 28, 506, 936, 7380, 22, 395, 20, 789, 1198, 46, 11, 195, 311, 20, 3, 5088, 1, 458, 219, 51, 2205, 395, 22, 6162, 15, 13, 474, 22, 149, 22, 20, 3, 1444, 1, 344, 4, 6162, 158, 175, 83, 33, 1, 3790, 7, 5, 1106, 4, 6162, 42, 903, 91, 79, 1, 1370, 11, 107, 584, 7, 382, 54, 361, 3009, 8, 2205, 15, 1737, 42, 8, 2205, 2, 42, 80, 76, 14, 1066, 344, 1, 6162, 96, 7, 5, 1106, 4, 6162, 918, 4, 25050, 7, 54, 11027, 8, 2205, 15, 1737, 1359, 8, 2205, 2, 47, 80, 76, 14, 1066, 344, 1, 6162, 257, 40, 2909, 80, 3210, 2, 68, 40, 194, 9, 138, 1, 1062, 1425, 216, 1398, 2, 515, 9, 3093, 189, 1151]",1321.0,19487383,93
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-06-01,"PURPOSE Patients with chronic myelogenous leukemia in accelerated phase (CML-AP) that is resistant or intolerant to imatinib have limited therapeutic options. Dasatinib, a potent inhibitor of BCR-ABL and SRC-family kinases, has efficacy in patients with CML-AP who have experienced treatment failure with imatinib. We now report follow-up data from the full patient cohort of 174 patients enrolled onto a phase II trial to provide a more complete assessment of the efficacy and safety of dasatinib in this population. PATIENTS AND METHODS Patients with imatinib-resistant (n = 161) or -intolerant (n = 13) CML-AP received dasatinib 70 mg orally twice daily. Results At a median follow-up of 14.1 months (treatment duration, 0.1 to 21.7 months), major and complete hematologic responses were attained by 64% and 45% of patients, respectively, and major and complete cytogenetic responses were achieved in 39% and 32% of patients, respectively. Responses were achieved irrespective of imatinib status (resistant or intolerant), prior stem-cell transplantation, or the presence of prior BCR-ABL mutation. The 12-month progression-free survival and overall survival rates were 66% and 82%, respectively. Dasatinib was generally well tolerated; the most frequent nonhematologic severe treatment-related adverse event was diarrhea (52%; grade 3 to 4, 8%). Cytopenias were common, including grade 3 to 4 neutropenia (76%) and thrombocytopenia (82%). Pleural effusion occurred in 27% of patients (grade 3 to 4, 5%). CONCLUSION Dasatinib is effective in patients with CML-AP after imatinib treatment failure.",Clinical Trial,3886.0,150.0,PURPOSE Patients with chronic myelogenous in accelerated phase CML-AP that is resistant or intolerant to imatinib have limited therapeutic options Dasatinib a potent inhibitor of BCR-ABL and SRC-family kinases has efficacy in patients with CML-AP who have experienced treatment failure with imatinib We now report follow-up data from the full patient cohort of 174 patients enrolled onto a phase II trial to provide a more complete assessment of the efficacy and safety of dasatinib in this population PATIENTS AND METHODS Patients with imatinib-resistant n 161 or -intolerant n 13 CML-AP received dasatinib 70 mg orally twice daily Results At a median follow-up of 14.1 months treatment duration 0.1 to 21.7 months major and complete hematologic responses were attained by 64 and 45 of patients respectively and major and complete cytogenetic responses were achieved in 39 and 32 of patients respectively Responses were achieved irrespective of imatinib status resistant or intolerant prior stem-cell transplantation or the presence of prior BCR-ABL mutation The 12-month progression-free survival and overall survival rates were 66 and 82 respectively Dasatinib was generally well tolerated the most frequent nonhematologic severe treatment-related adverse event was diarrhea 52 grade 3 to 4 8 Cytopenias were common including grade 3 to 4 neutropenia 76 and thrombocytopenia 82 Pleural effusion occurred in 27 of patients grade 3 to 4 5 CONCLUSION Dasatinib is effective in patients with CML-AP after imatinib treatment failure,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[743, 7, 5, 442, 2194, 4, 2241, 124, 903, 2517, 17, 16, 436, 15, 4944, 6, 577, 47, 383, 189, 838, 1674, 8, 1157, 230, 1, 1062, 1425, 2, 2023, 607, 1549, 71, 209, 4, 7, 5, 903, 2517, 54, 47, 592, 24, 496, 5, 577, 21, 1134, 414, 166, 126, 74, 29, 3, 1647, 69, 180, 1, 5811, 7, 346, 3301, 8, 124, 215, 160, 6, 377, 8, 80, 236, 455, 1, 3, 209, 2, 367, 1, 1674, 4, 26, 266, 7, 2, 636, 7, 5, 577, 436, 78, 5377, 15, 4944, 78, 233, 903, 2517, 103, 1674, 431, 81, 1428, 936, 391, 99, 28, 8, 52, 166, 126, 1, 213, 14, 53, 24, 654, 13, 14, 6, 239, 67, 53, 458, 2, 236, 813, 253, 11, 5105, 20, 660, 2, 512, 1, 7, 106, 2, 458, 2, 236, 1266, 253, 11, 513, 4, 587, 2, 531, 1, 7, 106, 253, 11, 513, 3500, 1, 577, 156, 436, 15, 4944, 324, 452, 31, 497, 15, 3, 463, 1, 324, 1062, 1425, 258, 3, 133, 811, 91, 115, 25, 2, 63, 25, 151, 11, 700, 2, 878, 106, 1674, 10, 1228, 149, 421, 3, 96, 908, 3534, 905, 24, 139, 290, 774, 10, 1172, 653, 88, 27, 6, 39, 66, 5635, 11, 186, 141, 88, 27, 6, 39, 778, 846, 2, 1340, 878, 2164, 4433, 489, 4, 428, 1, 7, 88, 27, 6, 39, 33, 1221, 1674, 16, 323, 4, 7, 5, 903, 2517, 50, 577, 24, 496]",1530.0,19487385,193
Prolonged chronic phase of greater than 10 years of chronic myelogenous leukemia in a patient with congenital human immunodefeciency virus infection.,Pediatric blood & cancer,Pediatr Blood Cancer,2009-10-01,"A 15-year-old male with congenital HIV infection was diagnosed with chronic myelogenous leukemia (CML) at age 4 years 9 months. HIV was initially treated with zidovudine. For the last >10 years he has received didanosine, lamivudine, and nelfinavir. CML was treated with Interferon alfa (INF-alpha) for >10 years and a brief course of hydroxyurea (HU). He remained in chronic phase CML since diagnosis however recent molecular monitoring revealed increased BCR/ABL transcripts necessitating a change in therapy to imatinib. The very prolonged chronic phase of CML in this patient has been unexpected especially in light of the underlying congenital HIV infection.",Case Reports,3764.0,3.0,A 15-year-old male with congenital HIV infection was diagnosed with chronic myelogenous CML at age 4 years 9 months HIV was initially treated with zidovudine For the last 10 years he has received didanosine lamivudine and nelfinavir CML was treated with Interferon alfa INF-alpha for 10 years and a brief course of hydroxyurea HU He remained in chronic phase CML since diagnosis however recent molecular monitoring revealed increased BCR/ABL transcripts necessitating a change in therapy to imatinib The very prolonged chronic phase of CML in this patient has been unexpected especially in light of the underlying congenital HIV infection,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8, 167, 111, 1095, 1045, 5, 6711, 1942, 930, 10, 265, 5, 442, 2194, 903, 28, 89, 39, 60, 83, 53, 1942, 10, 1625, 73, 5, 28018, 9, 3, 1060, 79, 60, 3174, 71, 103, 43582, 25965, 2, 8890, 903, 10, 73, 5, 1688, 4443, 14826, 950, 9, 79, 60, 2, 8, 3190, 906, 1, 5902, 5948, 3174, 958, 4, 442, 124, 903, 1192, 147, 137, 435, 219, 1315, 553, 101, 1062, 1425, 2680, 8365, 8, 707, 4, 36, 6, 577, 3, 923, 1069, 442, 124, 1, 903, 4, 26, 69, 71, 85, 3792, 1093, 4, 1691, 1, 3, 1181, 6711, 1942, 930]",638.0,19492322,263
A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice.,The Journal of molecular diagnostics : JMD,J Mol Diagn,2009-06-04,"Patients with chronic myelogenous leukemia have a t(9;22)(q34;q11.2) or variant translocation that results in a BCR-ABL fusion gene. BCR-ABL detection by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) is the standard practice for monitoring residual disease in patients with chronic myelogenous leukemia who receive tyrosine kinase inhibitor therapies. In this study, we describe a patient who tested positive for the BCR-ABL translocation by fluorescence in situ hybridization and cytogenetic analysis but tested negative by qRT-PCR molecular analysis at the time of diagnosis. Further PCR analysis and DNA sequencing with alternative primer sets demonstrated the presence of an e14a3 (also known as b3a3) BCR-ABL fusion. The e14a3 fusion is rare, but may be underreported as a result of many commercially available and laboratory-developed primer sets that fail to detect breakpoints in the ABL gene that are downstream of intron 1. For this patient, if the qRT-PCR assay had been used to monitor disease response/progression after treatment and not in conjunction with fluorescence in situ hybridization or cytogenetics at the time of diagnosis, the negative result would have been misinterpreted as molecular remission.",Case Reports,3883.0,28.0,Patients with chronic myelogenous have a t 9 22 q34 q11.2 or variant translocation that results in a BCR-ABL fusion gene BCR-ABL detection by quantitative reverse transcriptase-polymerase chain reaction RT-PCR is the standard practice for monitoring residual disease in patients with chronic myelogenous who receive tyrosine kinase inhibitor therapies In this study we describe a patient who tested positive for the BCR-ABL translocation by fluorescence in situ hybridization and cytogenetic analysis but tested negative by qRT-PCR molecular analysis at the time of diagnosis Further PCR analysis and DNA sequencing with alternative primer sets demonstrated the presence of an e14a3 also known as b3a3 BCR-ABL fusion The e14a3 fusion is rare but may be underreported as a result of many commercially available and laboratory-developed primer sets that fail to detect breakpoints in the ABL gene that are downstream of intron 1 For this patient if the qRT-PCR assay had been used to monitor disease response/progression after treatment and not in conjunction with fluorescence in situ hybridization or cytogenetics at the time of diagnosis the negative result would have been misinterpreted as molecular remission,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 5, 442, 2194, 47, 8, 102, 83, 350, 16609, 11532, 18, 15, 1142, 2006, 17, 99, 4, 8, 1062, 1425, 1212, 145, 1062, 1425, 638, 20, 1156, 1772, 4456, 1451, 1260, 1329, 240, 604, 16, 3, 260, 758, 9, 1315, 753, 34, 4, 7, 5, 442, 2194, 54, 560, 564, 216, 230, 235, 4, 26, 45, 21, 897, 8, 69, 54, 650, 109, 9, 3, 1062, 1425, 2006, 20, 1591, 4, 957, 1554, 2, 1266, 65, 84, 650, 199, 20, 5822, 604, 219, 65, 28, 3, 98, 1, 147, 195, 604, 65, 2, 261, 615, 5, 1091, 9684, 2270, 264, 3, 463, 1, 35, 45571, 120, 440, 22, 57952, 1062, 1425, 1212, 3, 45571, 1212, 16, 622, 84, 68, 40, 14900, 22, 8, 757, 1, 445, 5262, 390, 2, 1624, 276, 9684, 2270, 17, 4373, 6, 1426, 7843, 4, 3, 1425, 145, 17, 32, 1489, 1, 6259, 14, 9, 26, 69, 492, 3, 5822, 604, 719, 42, 85, 95, 6, 3334, 34, 51, 91, 50, 24, 2, 44, 4, 3357, 5, 1591, 4, 957, 1554, 15, 2510, 28, 3, 98, 1, 147, 3, 199, 757, 688, 47, 85, 21129, 22, 219, 734]",1212.0,19497989,127
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-06-08,"A subset of patients with chronic myelogenous leukemia (CML) do not respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate. Such primary imatinib resistance is distinguished from secondary resistance which reemerges after attainment of cytogenetic remission. We studied gene expression patterns in total WBCs using a panel of 21 genes previously implicated in TKI handling, resistance, or progression comparing patients who had newly diagnosed TKI-naive CML that had optimal (n = 41), or suboptimal (n = 7) responses to imatinib, or primary resistance (n = 20). Expression patterns were compared to those in secondary TKI-resistant chronic phase CML without ABL1 kinase domain mutations (n = 29), and to lymphoid (n = 15) or myeloid blast phase disease (n = 12). Fifteen genes in the panel distinguished blast phase from chronic phase disease, and 12 genes distinguished newly diagnosed CML from TKI-resistant CML without ABL1 kinase domain mutations, but only a single gene, prostaglandin-endoperoxide synthase 1/cyclooxgenase 1 (PTGS1/COX1; P = .005), differentiated imatinib-responsive from primary imatinib-resistant CML. The association of primary imatinib resistance with higher transcript levels of the drug metabolism gene PTGS1 was confirmed in a separate data set of 68 newly diagnosed, imatinib-treated CML (P = .008). In contrast, up to 11 different genes were identified in a multivariate model that optimally discriminated secondary imatinib resistance lacking ABL1 kinase domain mutation from imatinib-responsive cases, likely related to the more complex pathogenesis of secondary resistance. Gene expression profiling of CML at diagnosis for PTGS1 may be useful in predicting imatinib response and in selecting alternate therapy.",Comparative Study,3879.0,69.0,A subset of patients with chronic myelogenous CML do not respond to the tyrosine kinase inhibitor TKI imatinib mesylate Such primary imatinib resistance is distinguished from secondary resistance which reemerges after attainment of cytogenetic remission We studied gene expression patterns in total WBCs using a panel of 21 genes previously implicated in TKI handling resistance or progression comparing patients who had newly diagnosed TKI-naive CML that had optimal n 41 or suboptimal n 7 responses to imatinib or primary resistance n 20 Expression patterns were compared to those in secondary TKI-resistant chronic phase CML without ABL1 kinase domain mutations n 29 and to lymphoid n 15 or myeloid blast phase disease n 12 Fifteen genes in the panel distinguished blast phase from chronic phase disease and 12 genes distinguished newly diagnosed CML from TKI-resistant CML without ABL1 kinase domain mutations but only a single gene prostaglandin-endoperoxide synthase 1/cyclooxgenase 1 PTGS1/COX1 P .005 differentiated imatinib-responsive from primary imatinib-resistant CML The association of primary imatinib resistance with higher transcript levels of the drug metabolism gene PTGS1 was confirmed in a separate data set of 68 newly diagnosed imatinib-treated CML P .008 In contrast up to 11 different genes were identified in a multivariate model that optimally discriminated secondary imatinib resistance lacking ABL1 kinase domain mutation from imatinib-responsive cases likely related to the more complex pathogenesis of secondary resistance Gene expression profiling of CML at diagnosis for PTGS1 may be useful in predicting imatinib response and in selecting alternate therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8, 697, 1, 7, 5, 442, 2194, 903, 1022, 44, 1892, 6, 3, 564, 216, 230, 1379, 577, 2347, 225, 86, 577, 251, 16, 4735, 29, 568, 251, 92, 57961, 50, 7108, 1, 1266, 734, 21, 656, 145, 55, 764, 4, 181, 17238, 75, 8, 993, 1, 239, 214, 373, 1771, 4, 1379, 13658, 251, 15, 91, 1430, 7, 54, 42, 732, 265, 1379, 2462, 903, 17, 42, 665, 78, 605, 15, 3291, 78, 67, 253, 6, 577, 15, 86, 251, 78, 179, 55, 764, 11, 72, 6, 135, 4, 568, 1379, 436, 442, 124, 903, 187, 3557, 216, 1398, 138, 78, 462, 2, 6, 2303, 78, 167, 15, 533, 3112, 124, 34, 78, 133, 3057, 214, 4, 3, 993, 4735, 3112, 124, 29, 442, 124, 34, 2, 133, 214, 4735, 732, 265, 903, 29, 1379, 436, 903, 187, 3557, 216, 1398, 138, 84, 158, 8, 226, 145, 6068, 21561, 3522, 14, 57962, 14, 34701, 31465, 19, 1614, 1442, 577, 2443, 29, 86, 577, 436, 903, 3, 248, 1, 86, 577, 251, 5, 142, 3268, 148, 1, 3, 234, 1600, 145, 34701, 10, 557, 4, 8, 2282, 74, 916, 1, 806, 732, 265, 577, 73, 903, 19, 2155, 4, 748, 126, 6, 175, 338, 214, 11, 108, 4, 8, 331, 202, 17, 5074, 8752, 568, 577, 251, 1941, 3557, 216, 1398, 258, 29, 577, 2443, 140, 322, 139, 6, 3, 80, 840, 1384, 1, 568, 251, 145, 55, 1080, 1, 903, 28, 147, 9, 34701, 68, 40, 999, 4, 1434, 577, 51, 2, 4, 3675, 4689, 36]",1689.0,19506164,1
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.,Cancer,Cancer,2009-09-01,"Imatinib is the current standard frontline therapy for chronic myelogenous leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic response (CCyR); however, complete molecular responses are infrequent. The Bcr-Abl fusion creates a unique sequence of amino acids that could constitute a target for immunomodulation. A mixture of heteroclitic and native peptides derived from both b3a2 and b2a2 sequences was used to vaccinate patients with CML in CCyR who were receiving imatinib therapy and who had stable Bcr-Abl transcript levels. Ten patients were enrolled, all with b2a2 transcripts (including 2 patients who had coexpression of b2a2 and b3a2). Patients had received imatinib for a median of 62 months. Three of 10 patients achieved 1-log reduction in Bcr-Abl transcript levels, including the 2 patients who had received previous interferon therapy, and 3 other patients achieved a major molecular response. The vaccine was tolerated well, and there were no grade > or =3 adverse events. Vaccination did not affect the leukocyte profiles in peripheral blood except for regulatory T cells, which were down-regulated briefly during the late stage of vaccination in patients who achieved approximately 1-log reduction in Bcr-Abl transcript levels. The current data suggested that vaccination-related transient disruption of immune tolerance may contribute to the reduction in Bcr-Abl transcripts. Clinically, this Bcr-Abl peptide vaccine may transiently improve the molecular response in a subset of patients with CML.","Clinical Trial, Phase II",3794.0,44.0,Imatinib is the current standard frontline therapy for chronic myelogenous CML In the majority of patients imatinib induces a complete cytogenetic response CCyR however complete molecular responses are infrequent The Bcr-Abl fusion creates a unique sequence of amino acids that could constitute a target for immunomodulation A mixture of heteroclitic and native peptides derived from both b3a2 and b2a2 sequences was used to vaccinate patients with CML in CCyR who were receiving imatinib therapy and who had stable Bcr-Abl transcript levels Ten patients were enrolled all with b2a2 transcripts including 2 patients who had coexpression of b2a2 and b3a2 Patients had received imatinib for a median of 62 months Three of 10 patients achieved 1-log reduction in Bcr-Abl transcript levels including the 2 patients who had received previous interferon therapy and 3 other patients achieved a major molecular response The vaccine was tolerated well and there were no grade or =3 adverse events Vaccination did not affect the leukocyte profiles in peripheral blood except for regulatory T cells which were down-regulated briefly during the late stage of vaccination in patients who achieved approximately 1-log reduction in Bcr-Abl transcript levels The current data suggested that vaccination-related transient disruption of immune tolerance may contribute to the reduction in Bcr-Abl transcripts Clinically this Bcr-Abl peptide vaccine may transiently improve the molecular response in a subset of patients with CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 16, 3, 291, 260, 3171, 36, 9, 442, 2194, 903, 4, 3, 686, 1, 7, 577, 1516, 8, 236, 1266, 51, 6412, 137, 236, 219, 253, 32, 4475, 3, 1062, 1425, 1212, 9803, 8, 991, 1532, 1, 3078, 4562, 17, 359, 4999, 8, 283, 9, 12066, 8, 6972, 1, 26148, 2, 4646, 2491, 526, 29, 110, 24460, 2, 28922, 2866, 10, 95, 6, 25022, 7, 5, 903, 4, 6412, 54, 11, 357, 577, 36, 2, 54, 42, 585, 1062, 1425, 3268, 148, 1618, 7, 11, 346, 62, 5, 28922, 2680, 141, 18, 7, 54, 42, 7588, 1, 28922, 2, 24460, 7, 42, 103, 577, 9, 8, 52, 1, 744, 53, 169, 1, 79, 7, 513, 14, 1066, 628, 4, 1062, 1425, 3268, 148, 141, 3, 18, 7, 54, 42, 103, 698, 1688, 36, 2, 27, 127, 7, 513, 8, 458, 219, 51, 3, 1274, 10, 421, 149, 2, 125, 11, 77, 88, 15, 27, 290, 281, 1915, 205, 44, 1158, 3, 3627, 1241, 4, 672, 315, 2187, 9, 1253, 102, 37, 92, 11, 1328, 1065, 6277, 190, 3, 807, 82, 1, 1915, 4, 7, 54, 513, 705, 14, 1066, 628, 4, 1062, 1425, 3268, 148, 3, 291, 74, 1148, 17, 1915, 139, 2473, 3220, 1, 250, 2614, 68, 1248, 6, 3, 628, 4, 1062, 1425, 2680, 505, 26, 1062, 1425, 1389, 1274, 68, 9235, 401, 3, 219, 51, 4, 8, 697, 1, 7, 5, 903]",1511.0,19536894,250
RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression.,Journal of hematology & oncology,J Hematol Oncol,2009-07-14,"RIZ1 expression and activity are reduced in many cancers. In AML cell lines and patient material, RIZ1 expression is reduced relative to normal bone marrow. In chronic myelogenous leukemia (CML), blastic transformation is associated with loss of heterozygosity in the region where RIZ1 is located. RIZ1 is a PR domain methyltransferase that methylates histone H3 lysine 9, a modification important for transcriptional repression. In CML blast crisis cell lines RIZ1 represses insulin-like growth factor-1 expression and autocrine signaling. Together these observations suggest that RIZ1 may have a role in the chronic phase to blast crisis transition in CML. In CML patient material, we observed that RIZ1 expression was decreased during progression from chronic phase to blast crisis. RIZ1 was expressed in mature myeloid and CD34+ cells demonstrating that decreased RIZ1 expression in blast crisis is not due to an increased immature cell population. Expression of RIZ1 CML blast crisis cell lines decreased proliferation, increased apoptosis, and enhanced differentiation. RIZ1 is a candidate tumor suppressor gene whose expression is decreased in blast crisis. Loss of RIZ1 activity results in decreased apoptosis and differentiation and enhanced proliferation. Together these results suggest that loss of RIZ1 expression will lead to an increase in myeloid blast cell population resulting in CML progression.",Journal Article,3843.0,17.0,RIZ1 expression and activity are reduced in many cancers In AML cell lines and patient material RIZ1 expression is reduced relative to normal marrow In chronic myelogenous CML blastic transformation is associated with loss of heterozygosity in the region where RIZ1 is located RIZ1 is a PR domain methyltransferase that methylates histone H3 lysine 9 a modification important for transcriptional repression In CML blast crisis cell lines RIZ1 represses insulin-like growth factor-1 expression and autocrine signaling Together these observations suggest that RIZ1 may have a role in the chronic phase to blast crisis transition in CML In CML patient material we observed that RIZ1 expression was decreased during progression from chronic phase to blast crisis RIZ1 was expressed in mature myeloid and CD34+ cells demonstrating that decreased RIZ1 expression in blast crisis is not due to an increased immature cell population Expression of RIZ1 CML blast crisis cell lines decreased proliferation increased apoptosis and enhanced differentiation RIZ1 is a candidate tumor suppressor gene whose expression is decreased in blast crisis Loss of RIZ1 activity results in decreased apoptosis and differentiation and enhanced proliferation Together these results suggest that loss of RIZ1 expression will lead to an increase in myeloid blast cell population resulting in CML progression,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[18524, 55, 2, 128, 32, 405, 4, 445, 163, 4, 329, 31, 285, 2, 69, 3692, 18524, 55, 16, 405, 580, 6, 295, 581, 4, 442, 2194, 903, 6529, 1392, 16, 41, 5, 407, 1, 3963, 4, 3, 1053, 1257, 18524, 16, 2308, 18524, 16, 8, 998, 1398, 3747, 17, 26616, 1508, 3739, 6041, 83, 8, 2437, 305, 9, 1431, 5255, 4, 903, 3112, 6540, 31, 285, 18524, 10946, 1601, 733, 129, 161, 14, 55, 2, 5297, 314, 1162, 46, 2172, 309, 17, 18524, 68, 47, 8, 200, 4, 3, 442, 124, 6, 3112, 6540, 1970, 4, 903, 4, 903, 69, 3692, 21, 164, 17, 18524, 55, 10, 340, 190, 91, 29, 442, 124, 6, 3112, 6540, 18524, 10, 570, 4, 2908, 533, 2, 2215, 37, 2219, 17, 340, 18524, 55, 4, 3112, 6540, 16, 44, 520, 6, 35, 101, 5733, 31, 266, 55, 1, 18524, 903, 3112, 6540, 31, 285, 340, 457, 101, 351, 2, 651, 910, 18524, 16, 8, 1609, 30, 1245, 145, 1310, 55, 16, 340, 4, 3112, 6540, 407, 1, 18524, 128, 99, 4, 340, 351, 2, 910, 2, 651, 457, 1162, 46, 99, 309, 17, 407, 1, 18524, 55, 303, 1122, 6, 35, 344, 4, 533, 3112, 31, 266, 1113, 4, 903, 91]",1379.0,19602237,3
"Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose.",Blood,Blood,2009-07-16,"We report outcomes of 932 recipients of unrelated donor peripheral blood stem cell hematopoietic cell transplantation (URD-PBSC HCT) for acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome enrolled on a prospective National Marrow Donor Program trial from 1999 through 2003. Preparative regimens included myeloablative (MA; N = 611), reduced-intensity (RI; N = 160), and nonmyeloablative (NMA; N = 161). For MA recipients, CD34(+) counts greater than 3.8 x 10(6)/kg improved neutrophil and platelet engraftment, whereas improved overall survival (OS) and reduced transplant-related mortality (TRM) were seen for all preparative regimens when CD34(+) cell doses exceeded 4.5 x 10(6)/kg. Higher infused doses of CD34(+) cell dose did not result in increased rates of either acute or chronic graft-versus-host disease (GVHD). Three-year OS and disease-free survival (DFS) of recipients of MA, RI, and NMA approaches were similar (33%, 35%, and 32% OS; 33%, 30%, and 29% DFS, respectively). In summary, recipients of URD-PBSC HCT receiving preparative regimens differing in intensity experienced similar survival. Higher CD34(+) cell doses resulted in more rapid engraftment, less TRM, and better 3-year OS (39% versus 25%, MA, P = .004; 38% versus 21% RI/NMA, P = .004) but did not increase the risk of GVHD. This trial was registered at www.clinicaltrials.gov as #NCT00785525.",Clinical Trial,3841.0,91.0,We report outcomes of 932 recipients of unrelated donor peripheral blood stem cell hematopoietic cell transplantation URD-PBSC HCT for acute myeloid acute lymphoblastic chronic myelogenous and syndrome enrolled on a prospective National Marrow Donor Program trial from 1999 through 2003 Preparative regimens included myeloablative MA N 611 reduced-intensity RI N 160 and nonmyeloablative NMA N 161 For MA recipients CD34 counts greater than 3.8 x 10 6 /kg improved neutrophil and platelet engraftment whereas improved overall survival OS and reduced transplant-related mortality TRM were seen for all preparative regimens when CD34 cell doses exceeded 4.5 x 10 6 /kg Higher infused doses of CD34 cell dose did not result in increased rates of either acute or chronic graft-versus-host disease GVHD Three-year OS and disease-free survival DFS of recipients of MA RI and NMA approaches were similar 33 35 and 32 OS 33 30 and 29 DFS respectively In summary recipients of URD-PBSC HCT receiving preparative regimens differing in intensity experienced similar survival Higher CD34 cell doses resulted in more rapid engraftment less TRM and better 3-year OS 39 versus 25 MA P .004 38 versus 21 RI/NMA P .004 but did not increase the risk of GVHD This trial was registered at www.clinicaltrials.gov as NCT00785525,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 414, 123, 1, 15542, 2190, 1, 2092, 1488, 672, 315, 452, 31, 1007, 31, 497, 5847, 6368, 1085, 9, 286, 533, 286, 1275, 442, 2194, 2, 681, 346, 23, 8, 482, 657, 581, 1488, 1243, 160, 29, 2043, 298, 1522, 6085, 472, 159, 3246, 3687, 78, 10711, 405, 837, 9836, 78, 3457, 2, 6094, 10370, 78, 5377, 9, 3687, 2190, 2215, 1911, 378, 76, 27, 66, 1006, 79, 49, 503, 231, 2595, 2, 1596, 2881, 547, 231, 63, 25, 118, 2, 405, 941, 139, 282, 5064, 11, 527, 9, 62, 6085, 472, 198, 2215, 31, 415, 4726, 39, 33, 1006, 79, 49, 503, 142, 4524, 415, 1, 2215, 31, 61, 205, 44, 757, 4, 101, 151, 1, 361, 286, 15, 442, 1599, 185, 1204, 34, 1562, 169, 111, 118, 2, 34, 115, 25, 1010, 1, 2190, 1, 3687, 9836, 2, 10370, 611, 11, 288, 466, 465, 2, 531, 118, 466, 201, 2, 462, 1010, 106, 4, 1962, 2190, 1, 5847, 6368, 1085, 357, 6085, 472, 5276, 4, 837, 592, 288, 25, 142, 2215, 31, 415, 627, 4, 80, 1321, 2881, 299, 5064, 2, 380, 27, 111, 118, 587, 185, 243, 3687, 19, 1520, 519, 185, 239, 9836, 10370, 19, 1520, 84, 205, 44, 344, 3, 43, 1, 1562, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 58080]",1306.0,19608747,263
NCCN task force report: molecular markers in leukemias and lymphomas.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2009-07-01,"The introduction of targeted therapies has revolutionized treatment and improved outcomes in patients with leukemias and lymphomas. However, many patients experience relapse caused by the persistence of residual malignant cells. Cytogenetic and molecular techniques are increasingly being used to assess and quantify minimal residual disease (MRD). The emergence of advanced technologies has led to the discovery of multiple novel molecular markers that can be used to detect MRD and predict outcome in patients with leukemias and lymphomas. Gene expression signatures that predict clinical outcomes in patients with non-Hodgkin's lymphoma have been identified. In chronic myelogenous leukemia, molecular monitoring has become more important in assessing response and detecting resistance to therapy. In acute leukemias, several new markers have shown potential in prognostication and monitoring treatment. In leukemias and lymphomas, microRNAs have been identified that may be useful in diagnostics and prognostication. To address these issues, the National Comprehensive Cancer Network (NCCN) organized a task force consisting of a panel of experts in leukemia and lymphoma to discuss recent advances in the field of molecular markers and monitoring MRD.",Journal Article,3856.0,9.0,The introduction of targeted therapies has revolutionized treatment and improved outcomes in patients with leukemias and lymphomas However many patients experience relapse caused by the persistence of residual malignant cells Cytogenetic and molecular techniques are increasingly being used to assess and quantify minimal residual disease MRD The emergence of advanced technologies has led to the discovery of multiple novel molecular markers that can be used to detect MRD and predict outcome in patients with leukemias and lymphomas Gene expression signatures that predict clinical outcomes in patients with 's have been identified In chronic myelogenous molecular monitoring has become more important in assessing response and detecting resistance to therapy In acute leukemias several new markers have shown potential in prognostication and monitoring treatment In leukemias and lymphomas microRNAs have been identified that may be useful in diagnostics and prognostication To address these issues the National Comprehensive Cancer Network NCCN organized a task force consisting of a panel of experts in and to discuss recent advances in the field of molecular markers and monitoring MRD,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2456, 1, 238, 235, 71, 5746, 24, 2, 231, 123, 4, 7, 5, 2792, 2, 1557, 137, 445, 7, 730, 429, 1546, 20, 3, 4108, 1, 753, 393, 37, 1266, 2, 219, 1092, 32, 1635, 486, 95, 6, 423, 2, 3091, 1048, 753, 34, 2029, 3, 3397, 1, 131, 2590, 71, 836, 6, 3, 1574, 1, 232, 229, 219, 525, 17, 122, 40, 95, 6, 1426, 2029, 2, 678, 228, 4, 7, 5, 2792, 2, 1557, 145, 55, 2210, 17, 678, 38, 123, 4, 7, 5, 292, 47, 85, 108, 4, 442, 2194, 219, 1315, 71, 1417, 80, 305, 4, 1977, 51, 2, 2502, 251, 6, 36, 4, 286, 2792, 392, 217, 525, 47, 443, 174, 4, 4260, 2, 1315, 24, 4, 2792, 2, 1557, 3515, 47, 85, 108, 17, 68, 40, 999, 4, 5197, 2, 4260, 6, 1539, 46, 1553, 3, 657, 949, 12, 1801, 1944, 7511, 8, 3488, 4380, 2273, 1, 8, 993, 1, 3186, 4, 2, 6, 1139, 435, 954, 4, 3, 1067, 1, 219, 525, 2, 1315, 2029]",1191.0,19635230,83
"Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.",Cancer research,Cancer Res.,2009-08-25,"Gastrointestinal stromal tumors (GIST) are characterized by activating mutations of KIT or platelet-derived growth factor receptor A (PDGFRA), and treatment with the tyrosine kinase inhibitor imatinib yields responses in the majority of patients. However, most patients develop secondary resistance, which is associated with a dismal prognosis. Histone deacetylase inhibitors (HDACI) have been shown to enhance imatinib activity in imatinib-resistant chronic myelogenous leukemia. Against this background, we explored whether HDACI might provide an alternative therapeutic strategy to KIT/PDGFRA kinase inhibitors in GIST. Inhibition of cell proliferation by HDACI was seen in KIT-positive but not in KIT-negative GIST cell lines, suggesting that HDACI activity is mainly conferred by targeting oncogenic KIT. KIT activity, expression, and activation of downstream pathways were strongly inhibited by several HDACI (SAHA, LBH589, VPA, trichostatin A, and NaButyrate). SAHA and LBH589 induced apoptosis in KIT-positive GIST, and strong synergism with imatinib was observed at low concentrations of SAHA and LBH589. Mechanistically, treatment with HDACI reduced KIT mRNA transcript levels and led to strong acetylation of HSP90, interfering with its activity as KIT chaperone. These results provide preclinical evidence for a disease-specific effect of HDACI in KIT-positive GIST, which could translate into therapeutic activity.",Journal Article,3801.0,62.0,stromal tumors GIST are characterized by activating mutations of KIT or platelet-derived growth factor receptor A PDGFRA and treatment with the tyrosine kinase inhibitor imatinib yields responses in the majority of patients However most patients develop secondary resistance which is associated with a dismal prognosis Histone deacetylase inhibitors HDACI have been shown to enhance imatinib activity in imatinib-resistant chronic myelogenous Against this background we explored whether HDACI might provide an alternative therapeutic strategy to KIT/PDGFRA kinase inhibitors in GIST Inhibition of cell proliferation by HDACI was seen in KIT-positive but not in KIT-negative GIST cell lines suggesting that HDACI activity is mainly conferred by targeting oncogenic KIT KIT activity expression and activation of downstream pathways were strongly inhibited by several HDACI SAHA LBH589 VPA trichostatin A and NaButyrate SAHA and LBH589 induced apoptosis in KIT-positive GIST and strong synergism with imatinib was observed at low concentrations of SAHA and LBH589 Mechanistically treatment with HDACI reduced KIT mRNA transcript levels and led to strong acetylation of HSP90 interfering with its activity as KIT chaperone These results provide preclinical evidence for a disease-specific effect of HDACI in KIT-positive GIST which could translate into therapeutic activity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[1126, 57, 1394, 32, 765, 20, 1616, 138, 1, 1164, 15, 1596, 526, 129, 161, 153, 8, 4006, 2, 24, 5, 3, 564, 216, 230, 577, 4788, 253, 4, 3, 686, 1, 7, 137, 96, 7, 690, 568, 251, 92, 16, 41, 5, 8, 3929, 356, 1508, 2732, 222, 4265, 47, 85, 443, 6, 1304, 577, 128, 4, 577, 436, 442, 2194, 480, 26, 2426, 21, 1443, 317, 4265, 822, 377, 35, 1091, 189, 692, 6, 1164, 4006, 216, 222, 4, 1394, 297, 1, 31, 457, 20, 4265, 10, 527, 4, 1164, 109, 84, 44, 4, 1164, 199, 1394, 31, 285, 802, 17, 4265, 128, 16, 2615, 3851, 20, 529, 1302, 1164, 1164, 128, 55, 2, 363, 1, 1489, 460, 11, 1327, 879, 20, 392, 4265, 5484, 11339, 6770, 13824, 8, 2, 58193, 5484, 2, 11339, 277, 351, 4, 1164, 109, 1394, 2, 1082, 6494, 5, 577, 10, 164, 28, 154, 1003, 1, 5484, 2, 11339, 4187, 24, 5, 4265, 405, 1164, 956, 3268, 148, 2, 836, 6, 1082, 4145, 1, 2515, 3449, 5, 211, 128, 22, 1164, 7255, 46, 99, 377, 693, 241, 9, 8, 34, 112, 254, 1, 4265, 4, 1164, 109, 1394, 92, 359, 4509, 237, 189, 128]",1369.0,19706776,273
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.,Molecular cancer therapeutics,Mol. Cancer Ther.,2009-09-01,"The advent of Bcr-Abl tyrosine kinase inhibitors (TKI) has revolutionized the treatment of chronic myelogenous leukemia (CML). However, resistance evolves due to BCR-ABL mutations and other mechanisms. Furthermore, patients with blast crisis CML are less responsive and quiescent CML stem cells are insensitive to these inhibitors. We found that triptolide, a diterpenoid, at nanomolar concentrations, promoted equally significant death of KBM5 cells, a cell line derived from a Bcr-Abl-bearing blast crisis CML patient and KBM5STI571 cells, an imatinib-resistant KBM5 subline bearing the T315I mutation. Similarly, Ba/F3 cells harboring mutated BCR-ABL were as sensitive as Ba/F3Bcr-Abl(p210wt) cells to triptolide. Importantly, triptolide induced apoptosis in primary samples from blast crisis CML patients, who showed resistance to Bcr-Abl TKIs in vivo, with less toxicity to normal cells. Triptolide decreased X-linked inhibitor of apoptosis protein, Mcl-1, and Bcr-Abl protein levels in K562, KBM5, and KBM5STI571 cells and in cells from blast crisis CML patients. It sensitized KBM5, but not KBM5STI571, cells to imatinib. More importantly, triptolide also induced death of quiescent CD34(+) CML progenitor cells, a major problem in the therapy of CML with TKIs. Collectively, these results suggest that triptolide potently induces blast crisis CML cell death independent of the cellular responses to Bcr-Abl TKIs, suggesting that triptolide could eradicate residual quiescent CML progenitor cells in TKI-treated patients and benefit TKI-resistant blast crisis CML patients.",Journal Article,3794.0,27.0,The advent of Bcr-Abl tyrosine kinase inhibitors TKI has revolutionized the treatment of chronic myelogenous CML However resistance evolves due to BCR-ABL mutations and other mechanisms Furthermore patients with blast crisis CML are less responsive and quiescent CML stem cells are insensitive to these inhibitors We found that triptolide a diterpenoid at nanomolar concentrations promoted equally significant death of KBM5 cells a cell line derived from a Bcr-Abl-bearing blast crisis CML patient and KBM5STI571 cells an imatinib-resistant KBM5 subline bearing the T315I mutation Similarly Ba/F3 cells harboring mutated BCR-ABL were as sensitive as Ba/F3Bcr-Abl p210wt cells to triptolide Importantly triptolide induced apoptosis in primary samples from blast crisis CML patients who showed resistance to Bcr-Abl TKIs in vivo with less toxicity to normal cells Triptolide decreased X-linked inhibitor of apoptosis protein Mcl-1 and Bcr-Abl protein levels in K562 KBM5 and KBM5STI571 cells and in cells from blast crisis CML patients It sensitized KBM5 but not KBM5STI571 cells to imatinib More importantly triptolide also induced death of quiescent CD34 CML progenitor cells a major problem in the therapy of CML with TKIs Collectively these results suggest that triptolide potently induces blast crisis CML cell death independent of the cellular responses to Bcr-Abl TKIs suggesting that triptolide could eradicate residual quiescent CML progenitor cells in TKI-treated patients and benefit TKI-resistant blast crisis CML patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 4114, 1, 1062, 1425, 564, 216, 222, 1379, 71, 5746, 3, 24, 1, 442, 2194, 903, 137, 251, 10413, 520, 6, 1062, 1425, 138, 2, 127, 483, 798, 7, 5, 3112, 6540, 903, 32, 299, 2443, 2, 6735, 903, 452, 37, 32, 7422, 6, 46, 222, 21, 204, 17, 19212, 8, 25189, 28, 7927, 1003, 2992, 4142, 93, 273, 1, 10822, 37, 8, 31, 328, 526, 29, 8, 1062, 1425, 1894, 3112, 6540, 903, 69, 2, 39089, 37, 35, 577, 436, 10822, 28178, 1894, 3, 6184, 258, 1813, 6669, 6904, 37, 2105, 1185, 1062, 1425, 11, 22, 745, 22, 6669, 58215, 1425, 58216, 37, 6, 19212, 1859, 19212, 277, 351, 4, 86, 347, 29, 3112, 6540, 903, 7, 54, 224, 251, 6, 1062, 1425, 1671, 4, 386, 5, 299, 155, 6, 295, 37, 19212, 340, 1006, 1199, 230, 1, 351, 178, 1308, 14, 2, 1062, 1425, 178, 148, 4, 5208, 10822, 2, 39089, 37, 2, 4, 37, 29, 3112, 6540, 903, 7, 192, 4242, 10822, 84, 44, 39089, 37, 6, 577, 80, 1859, 19212, 120, 277, 273, 1, 6735, 2215, 903, 2520, 37, 8, 458, 2497, 4, 3, 36, 1, 903, 5, 1671, 2535, 46, 99, 309, 17, 19212, 4684, 1516, 3112, 6540, 903, 31, 273, 306, 1, 3, 763, 253, 6, 1062, 1425, 1671, 802, 17, 19212, 359, 5650, 753, 6735, 903, 2520, 37, 4, 1379, 73, 7, 2, 247, 1379, 436, 3112, 6540, 903, 7]",1532.0,19723894,111
The effect of smoking on allogeneic transplant outcomes.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2009-08-03,"Using the Center for International Blood and Marrow Transplant Research (CIBMTR) data, we compared the transplant outcomes of patients with chronic myelogenous leukemia (CML) who were nonsmokers (NS) and past or current smokers (PCS). There were 2193 NS and 625 PCS who received matched sibling and unrelated donor allografts for CML in first chronic phase. We looked for dose effects and identified low and high dose smoking groups (>10 pack years, >1 pack per day). Outcomes were adjusted for known prognostic variables including the European Group for Blood and Marrow Transplant (EBMT) risk score. In multivariate analyses of sibling allograft recipients, relapse risk (RR) was higher (RR=1.67, P=.003) in smokers than NS, but the dose effects were not consistent. High-dose smokers experienced a 50% treatment-related mortality (TRM) versus 28% in the NS group at 5 years on univariate analysis, and the RR was 1.57 (P=.005) on multivariate analysis. Overall survival (OS) at 5 years was 68% in NS versus 62% in the low-dose smoking group versus 50% in the high-dose smoking group (P < .001). Smoking did not significantly affect outcomes in unrelated donor recipients, but numbers were smaller. High-dose smoking is associated with a reduction in OS in patients having sibling allografts for CML. A prospective study with detailed demographic, pulmonary function, and quality-of-life data would improve our understanding of this issue.",Comparative Study,3823.0,18.0,Using the Center for International Blood and Marrow Transplant Research CIBMTR data we compared the transplant outcomes of patients with chronic myelogenous CML who were nonsmokers NS and past or current smokers PCS There were 2193 NS and 625 PCS who received matched sibling and unrelated donor allografts for CML in first chronic phase We looked for dose effects and identified low and high dose smoking groups 10 pack years 1 pack per day Outcomes were adjusted for known prognostic variables including the European Group for Blood and Marrow Transplant EBMT risk score In multivariate analyses of sibling allograft recipients relapse risk RR was higher RR=1.67 P=.003 in smokers than NS but the dose effects were not consistent High-dose smokers experienced a 50 treatment-related mortality TRM versus 28 in the NS group at 5 years on univariate analysis and the RR was 1.57 P=.005 on multivariate analysis Overall survival OS at 5 years was 68 in NS versus 62 in the low-dose smoking group versus 50 in the high-dose smoking group P .001 Smoking did not significantly affect outcomes in unrelated donor recipients but numbers were smaller High-dose smoking is associated with a reduction in OS in patients having sibling allografts for CML A prospective study with detailed demographic pulmonary function and quality-of-life data would improve our understanding of this issue,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[75, 3, 574, 9, 944, 315, 2, 581, 941, 389, 11203, 74, 21, 72, 3, 941, 123, 1, 7, 5, 442, 2194, 903, 54, 11, 8380, 4044, 2, 1219, 15, 291, 1485, 4270, 125, 11, 45689, 4044, 2, 9629, 4270, 54, 103, 655, 3684, 2, 2092, 1488, 10586, 9, 903, 4, 157, 442, 124, 21, 13058, 9, 61, 176, 2, 108, 154, 2, 64, 61, 979, 271, 79, 4668, 60, 14, 4668, 379, 218, 123, 11, 586, 9, 440, 177, 682, 141, 3, 1865, 87, 9, 315, 2, 581, 941, 17195, 43, 368, 4, 331, 318, 1, 3684, 9568, 2190, 429, 43, 861, 10, 142, 861, 14, 598, 19, 1421, 4, 1485, 76, 4044, 84, 3, 61, 176, 11, 44, 925, 64, 61, 1485, 592, 8, 212, 24, 139, 282, 5064, 185, 339, 4, 3, 4044, 87, 28, 33, 60, 23, 880, 65, 2, 3, 861, 10, 14, 696, 19, 1614, 23, 331, 65, 63, 25, 118, 28, 33, 60, 10, 806, 4, 4044, 185, 744, 4, 3, 154, 61, 979, 87, 185, 212, 4, 3, 64, 61, 979, 87, 19, 144, 979, 205, 44, 97, 1158, 123, 4, 2092, 1488, 2190, 84, 1870, 11, 2170, 64, 61, 979, 16, 41, 5, 8, 628, 4, 118, 4, 7, 1041, 3684, 10586, 9, 903, 8, 482, 45, 5, 2455, 1540, 1087, 343, 2, 372, 1, 358, 74, 688, 401, 114, 612, 1, 26, 2537]",1380.0,19747636,141
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.,Clinical lymphoma & myeloma,Clin Lymphoma Myeloma,2009-01-01,"Allogeneic stem cell transplantation (ASCT) is a potentially curative treatment for patients with chronic myelogenous leukemia (CML) and was previously considered the preferred treatment for newly diagnosed CML. The success of imatinib has changed treatment recommendations, and allogeneic transplants are now reserved for imatinib treatment failures. Previous imatinib treatment does not compromise the results of ASCT, but patients with overt transformed disease have poor results. It is unclear whether patients whose disease is considered to have failed imatinib should be referred immediately for ASCT or receive treatment with a second-generation tyrosine kinase inhibitors (TKI). Patients whose disease fails 2 TKIs should receive ASCT if possible. Nonmyeloablative preparative regimens reduce the toxicity and treatment-related mortality associated with the transplantation procedure and allow transplantations to be performed in older and medically infirm patients. This approach, including posttransplantation treatment with TKIs and donor lymphocyte infusion, produces a high fraction of durable molecular complete remissions.",Journal Article,4037.0,12.0,Allogeneic stem cell transplantation ASCT is a potentially curative treatment for patients with chronic myelogenous CML and was previously considered the preferred treatment for newly diagnosed CML The success of imatinib has changed treatment recommendations and allogeneic transplants are now reserved for imatinib treatment failures Previous imatinib treatment does not compromise the results of ASCT but patients with overt transformed disease have poor results It is unclear whether patients whose disease is considered to have failed imatinib should be referred immediately for ASCT or receive treatment with a second-generation tyrosine kinase inhibitors TKI Patients whose disease fails 2 TKIs should receive ASCT if possible Nonmyeloablative preparative regimens reduce the toxicity and treatment-related mortality associated with the transplantation procedure and allow transplantations to be performed in older and medically infirm patients This approach including posttransplantation treatment with TKIs and donor lymphocyte infusion produces a high fraction of durable molecular complete remissions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 452, 31, 497, 1584, 16, 8, 751, 1075, 24, 9, 7, 5, 442, 2194, 903, 2, 10, 373, 515, 3, 2514, 24, 9, 732, 265, 903, 3, 1825, 1, 577, 71, 2368, 24, 883, 2, 1063, 4016, 32, 1134, 6468, 9, 577, 24, 3368, 698, 577, 24, 1097, 44, 4665, 3, 99, 1, 1584, 84, 7, 5, 7192, 2423, 34, 47, 334, 99, 192, 16, 1200, 317, 7, 1310, 34, 16, 515, 6, 47, 1551, 577, 257, 40, 1995, 3467, 9, 1584, 15, 560, 24, 5, 8, 419, 914, 564, 216, 222, 1379, 7, 1310, 34, 7688, 18, 1671, 257, 560, 1584, 492, 899, 6094, 6085, 472, 969, 3, 155, 2, 24, 139, 282, 41, 5, 3, 497, 1299, 2, 1700, 6779, 6, 40, 173, 4, 434, 2, 4381, 33644, 7, 26, 353, 141, 8046, 24, 5, 1671, 2, 1488, 1448, 904, 4042, 8, 64, 1509, 1, 1480, 219, 236, 3166]",1111.0,19778850,47
Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.,Clinical lymphoma & myeloma,Clin Lymphoma Myeloma,2009-10-01,"We report the emergence of chronic myelogenous leukemia (CML) in a patient with JAK2V617F-positive polycythemia vera after 15 years of phlebotomy. The polycythemia vera clinical and molecular findings were suppressed at the time of CML diagnosis, only to re-emerge after the leukemia was successfully treated with imatinib. We explored the potential association between myeloproliferative disorders and CML in the context of the current literature and found a higher-than-expected coincidence based on known epidemiologic data for each specific condition. We hypothesize that myeloproliferative disorder (JAK2V617F or molecular events that cause JAK2V617F) is a risk factor for CML (BCR-ABL translocation). Because of therapeutic implications, clinicians should be aware that the conditions co-occur more frequently than once thought.",Case Reports,3764.0,,We report the emergence of chronic myelogenous CML in a patient with JAK2V617F-positive polycythemia vera after 15 years of phlebotomy The polycythemia vera clinical and molecular findings were suppressed at the time of CML diagnosis only to re-emerge after the was successfully treated with imatinib We explored the potential association between disorders and CML in the context of the current literature and found a higher-than-expected coincidence based on known epidemiologic data for each specific condition We hypothesize that disorder JAK2V617F or molecular events that cause JAK2V617F is a risk factor for CML BCR-ABL translocation Because of therapeutic implications clinicians should be aware that the conditions co-occur more frequently than once thought,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 414, 3, 3397, 1, 442, 2194, 903, 4, 8, 69, 5, 9061, 109, 5755, 5756, 50, 167, 60, 1, 14014, 3, 5755, 5756, 38, 2, 219, 272, 11, 1908, 28, 3, 98, 1, 903, 147, 158, 6, 1491, 6371, 50, 3, 10, 1878, 73, 5, 577, 21, 1443, 3, 174, 248, 59, 1997, 2, 903, 4, 3, 1533, 1, 3, 291, 789, 2, 204, 8, 142, 76, 1336, 26006, 90, 23, 440, 3609, 74, 9, 296, 112, 2850, 21, 4919, 17, 2645, 9061, 15, 219, 281, 17, 708, 9061, 16, 8, 43, 161, 9, 903, 1062, 1425, 2006, 408, 1, 189, 1268, 1490, 257, 40, 4749, 17, 3, 1298, 1269, 1271, 80, 746, 76, 1059, 2739]",765.0,19858050,83
Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).,Leukemia research,Leuk. Res.,2009-12-05,"Imatinib mesylate is used with increasing frequency and duration for the treatment of chronic myelogenous leukemia (CML), gastrointestinal stromal tumor (GIST), and other neoplastic conditions. Although muscular complaints are common, elevations of creatine kinase (CK) are listed as <1% in the product label. We describe here a case of rhabdomyolysis likely related to imatinib as well as the results of a prospective evaluation of CK levels in a cohort of patients on imatinib for CML or GIST. We found a high prevalence of CK abnormalities in this group and believe that CKs should be monitored during therapy with imatinib.",Case Reports,3699.0,19.0,Imatinib mesylate is used with increasing frequency and duration for the treatment of chronic myelogenous CML stromal tumor GIST and other neoplastic conditions Although muscular complaints are common elevations of creatine kinase CK are listed as 1 in the product label We describe here a case of rhabdomyolysis likely related to imatinib as well as the results of a prospective evaluation of CK levels in a cohort of patients on imatinib for CML or GIST We found a high prevalence of CK abnormalities in this group and believe that CKs should be monitored during therapy with imatinib,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[577, 2347, 16, 95, 5, 602, 675, 2, 654, 9, 3, 24, 1, 442, 2194, 903, 1126, 30, 1394, 2, 127, 2000, 1298, 242, 8620, 6938, 32, 186, 4712, 1, 10593, 216, 4925, 32, 8754, 22, 14, 4, 3, 2821, 1756, 21, 897, 467, 8, 473, 1, 20398, 322, 139, 6, 577, 22, 149, 22, 3, 99, 1, 8, 482, 451, 1, 4925, 148, 4, 8, 180, 1, 7, 23, 577, 9, 903, 15, 1394, 21, 204, 8, 64, 1078, 1, 4925, 1171, 4, 26, 87, 2, 4629, 17, 30245, 257, 40, 2909, 190, 36, 5, 577]",586.0,19963273,145
Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.,Leukemia & lymphoma,Leuk. Lymphoma,2009-12-01,"Imatinib is considered standard therapy for patients with chronic myelogenous leukemia (CML), inducing a high rate of hematologic and cytogenetic responses. Despite these excellent results, several patients develop resistance to imatinib. Mechanisms of resistance are varied and include BCR-ABL1 kinase domain mutations, decreased entry of imatinib into cells, acquisition of secondary genetic changes and activation of alternate signaling pathways. Second-generation tyrosine kinase inhibitors (TKI) (dasatinib, nilotinib) were developed as an alternative for patients that develop resistance or are intolerant to imatinib. Dasatinib is a dual Abl/Src kinase TKI that is structurally unrelated to imatinib and is approved for therapy of all phases of CML in patients who are resistant or intolerant to imatinib. Nilotinib is a compound related to imatinib that has greater specificity and improved binding characteristics, and has clinical activity in the setting of imatinib failure. Resistance to multiple TKIs does occur, particularly in patients with the T315I mutation. Several new agents are in development including new TKIs, aurora kinase inhibitors and homoharringtonine.",Evaluation Study,3703.0,19.0,Imatinib is considered standard therapy for patients with chronic myelogenous CML inducing a high rate of hematologic and cytogenetic responses Despite these excellent results several patients develop resistance to imatinib Mechanisms of resistance are varied and include BCR-ABL1 kinase domain mutations decreased entry of imatinib into cells acquisition of secondary genetic changes and activation of alternate signaling pathways Second-generation tyrosine kinase inhibitors TKI dasatinib nilotinib were developed as an alternative for patients that develop resistance or are intolerant to imatinib Dasatinib is a dual Abl/Src kinase TKI that is structurally unrelated to imatinib and is approved for therapy of all phases of CML in patients who are resistant or intolerant to imatinib Nilotinib is a compound related to imatinib that has greater specificity and improved binding characteristics and has clinical activity in the setting of imatinib failure Resistance to multiple TKIs does occur particularly in patients with the T315I mutation Several new agents are in development including new TKIs aurora kinase inhibitors and homoharringtonine,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 16, 515, 260, 36, 9, 7, 5, 442, 2194, 903, 1958, 8, 64, 116, 1, 813, 2, 1266, 253, 550, 46, 1503, 99, 392, 7, 690, 251, 6, 577, 483, 1, 251, 32, 2051, 2, 643, 1062, 3557, 216, 1398, 138, 340, 3001, 1, 577, 237, 37, 3405, 1, 568, 336, 400, 2, 363, 1, 4689, 314, 460, 419, 914, 564, 216, 222, 1379, 1674, 2638, 11, 276, 22, 35, 1091, 9, 7, 17, 690, 251, 15, 32, 4944, 6, 577, 1674, 16, 8, 1828, 1425, 2023, 216, 1379, 17, 16, 8533, 2092, 6, 577, 2, 16, 850, 9, 36, 1, 62, 3523, 1, 903, 4, 7, 54, 32, 436, 15, 4944, 6, 577, 2638, 16, 8, 2823, 139, 6, 577, 17, 71, 378, 1121, 2, 231, 791, 374, 2, 71, 38, 128, 4, 3, 546, 1, 577, 496, 251, 6, 232, 1671, 1097, 1271, 823, 4, 7, 5, 3, 6184, 258, 392, 217, 183, 32, 4, 193, 141, 217, 1671, 4095, 216, 222, 2, 18768]",1150.0,20017607,133
(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.,"Journal of nuclear medicine : official publication, Society of Nuclear Medicine",J. Nucl. Med.,2010-01-01,"Because of the recent development of an iodopyridopyrimidinone Abl protein kinase inhibitor (PKI), (124)I-SKI-212230 ((124)I-SKI230), we investigated the feasibility of a PET-based molecular imaging method for the direct visualization of Abl kinase expression and PKI treatment. In vitro pharmacokinetic properties, including specific and nonspecific binding of (124)I-SKI230 to its Abl kinase target and interaction with other PKIs, were assessed in cell-free medium and chronic myelogenous leukemia (CML) cells overexpressing BCR-Abl (K562), in comparison with BT-474 cells that are low in Abl expression. In a xenograft tumor model, we assessed the in vivo pharmacokinetics of (124)I-SKI230 using PET and postmortem tissue sampling. We also tested a paradigm of (124)I-SKI230 PET after treatment of the animal with a dose of Abl-specific PKI for the monitoring of the tumor response. In vitro studies confirmed that SKI230 binds to Abl kinase with nanomolar affinity, that selective uptake occurs in cell lines known to express Abl kinase, that RNAi knock-down supports specificity of cellular uptake due to Abl kinase, and that imatinib, an archetype Abl PKI, completely displaces SKI230. With SKI230, we obtained successful in vivo PET of Abl-expressing human tumors in a nude rat. We were also able to demonstrate evidence of substrate inhibition of in vivo radiotracer uptake in the xenograft tumor after treatment of the animal as a model of PKI treatment monitoring. These results support the hypothesis that molecular imaging using PET will be useful for the study of in vivo pharmacodynamics of Abl PKI molecular therapy in humans.",Journal Article,3672.0,8.0,Because of the recent development of an iodopyridopyrimidinone Abl protein kinase inhibitor PKI 124 I-SKI-212230 124 I-SKI230 we investigated the feasibility of a PET-based molecular imaging method for the direct visualization of Abl kinase expression and PKI treatment In vitro pharmacokinetic properties including specific and nonspecific binding of 124 I-SKI230 to its Abl kinase target and interaction with other PKIs were assessed in cell-free medium and chronic myelogenous CML cells overexpressing BCR-Abl K562 in comparison with BT-474 cells that are low in Abl expression In a xenograft tumor model we assessed the in vivo pharmacokinetics of 124 I-SKI230 using PET and postmortem tissue sampling We also tested a paradigm of 124 I-SKI230 PET after treatment of the animal with a dose of Abl-specific PKI for the monitoring of the tumor response In vitro studies confirmed that SKI230 binds to Abl kinase with nanomolar affinity that selective uptake occurs in cell lines known to express Abl kinase that RNAi knock-down supports specificity of cellular uptake due to Abl kinase and that imatinib an archetype Abl PKI completely displaces SKI230 With SKI230 we obtained successful in vivo PET of Abl-expressing human tumors in a nude rat We were also able to demonstrate evidence of substrate inhibition of in vivo radiotracer uptake in the xenograft tumor after treatment of the animal as a model of PKI treatment monitoring These results support the hypothesis that molecular imaging using PET will be useful for the study of in vivo pharmacodynamics of Abl PKI molecular therapy in humans,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[408, 1, 3, 435, 193, 1, 35, 58530, 1425, 178, 216, 230, 18215, 2834, 70, 13314, 58531, 2834, 70, 26902, 21, 565, 3, 1437, 1, 8, 495, 90, 219, 270, 596, 9, 3, 1196, 6234, 1, 1425, 216, 55, 2, 18215, 24, 4, 439, 1456, 1571, 141, 112, 2, 5893, 791, 1, 2834, 70, 26902, 6, 211, 1425, 216, 283, 2, 915, 5, 127, 58532, 11, 275, 4, 31, 115, 3759, 2, 442, 2194, 903, 37, 2810, 1062, 1425, 5208, 4, 1155, 5, 3641, 10282, 37, 17, 32, 154, 4, 1425, 55, 4, 8, 1330, 30, 202, 21, 275, 3, 4, 386, 1159, 1, 2834, 70, 26902, 75, 495, 2, 16489, 246, 2874, 21, 120, 650, 8, 2431, 1, 2834, 70, 26902, 495, 50, 24, 1, 3, 2026, 5, 8, 61, 1, 1425, 112, 18215, 9, 3, 1315, 1, 3, 30, 51, 4, 439, 94, 557, 17, 26902, 3333, 6, 1425, 216, 5, 7927, 3601, 17, 1094, 1135, 1780, 4, 31, 285, 440, 6, 1669, 1425, 216, 17, 5881, 6252, 1328, 2304, 1121, 1, 763, 1135, 520, 6, 1425, 216, 2, 17, 577, 35, 31059, 1425, 18215, 2500, 45824, 26902, 5, 26902, 21, 683, 1401, 4, 386, 495, 1, 1425, 1046, 171, 57, 4, 8, 2598, 4008, 21, 11, 120, 1665, 6, 608, 241, 1, 4235, 297, 1, 4, 386, 7610, 1135, 4, 3, 1330, 30, 50, 24, 1, 3, 2026, 22, 8, 202, 1, 18215, 24, 1315, 46, 99, 538, 3, 1492, 17, 219, 270, 75, 495, 303, 40, 999, 9, 3, 45, 1, 4, 386, 3587, 1, 1425, 18215, 219, 36, 4, 3218]",1600.0,20048131,130
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-01-13,"Reduced-intensity-conditioning (RIC) hematopoietic stem cell transplantation (HSCT) is markedly underutilized in the elderly, in part because the impact of advanced age on outcomes is poorly understood. We retrospectively analyzed outcomes in 158 consecutive hematologic malignancy patients aged > or =60 years (median, 63 years; range: 60-71 years) undergoing fludarabine/busulfan-based RIC, with a median-follow-up of 34 months (range: 12.0-85.7). Multivariate analysis was undertaken for factors having an impact on outcome. For the patients aged > or =60 years, 2-year nonrelapse mortality (NRM) and relapse was 10% and 54.6%, respectively. Two-year overall and progression-free survival (OS, PFS) was 46% and 35%, respectively. Grade II-IV acute and chronic graft-versus-host disease (aGVHD, cGVHD) incidence was 19.6% and 45.9%, respectively. Comparing 110 patients aged 60-64 years versus 48 patients aged > or =65 years, 2-year NRM and relapse was 10.5% versus 8.3% (P = .84) and 53.5% versus 56.3% (P = .31), respectively. Grade II-IV aGVHD and cGVHD incidence was 19.1% versus 22.9% (P = .52) and 51.8% versus 32.5% (P = .01), respectively. Two-year OS and PFS was 49% versus 41% (P = .11) and 36% versus 35% (P = .24), respectively. In a multivariate Cox-model, high-risk disease associated with poorer PFS (hazard ratio [HR] = 2.1, P = .01) and OS (HR = 1.84, P = .03); acute myelogenous leukemia/myelodysplastic syndrome diagnosis (HR = 1.66, P = .03) and matched-related donor (HR = 1.62, P = .03) associated with poorer PFS. RIC HSCT is well tolerated, with reasonable survival in elderly patients. Age is not associated with impaired outcomes. HSCT should not be excluded solely based on advanced patient age.",Journal Article,3660.0,63.0,Reduced-intensity-conditioning RIC hematopoietic stem cell transplantation HSCT is markedly underutilized in the elderly in part because the impact of advanced age on outcomes is poorly understood We retrospectively analyzed outcomes in 158 consecutive hematologic malignancy patients aged or =60 years median 63 years range 60-71 years undergoing fludarabine/busulfan-based RIC with a median-follow-up of 34 months range 12.0-85.7 Multivariate analysis was undertaken for factors having an impact on outcome For the patients aged or =60 years 2-year nonrelapse mortality NRM and relapse was 10 and 54.6 respectively Two-year overall and progression-free survival OS PFS was 46 and 35 respectively Grade II-IV acute and chronic graft-versus-host disease aGVHD cGVHD incidence was 19.6 and 45.9 respectively Comparing 110 patients aged 60-64 years versus 48 patients aged or =65 years 2-year NRM and relapse was 10.5 versus 8.3 P .84 and 53.5 versus 56.3 P .31 respectively Grade II-IV aGVHD and cGVHD incidence was 19.1 versus 22.9 P .52 and 51.8 versus 32.5 P .01 respectively Two-year OS and PFS was 49 versus 41 P .11 and 36 versus 35 P .24 respectively In a multivariate Cox-model high-risk disease associated with poorer PFS hazard ratio HR 2.1 P .01 and OS HR 1.84 P .03 acute myelogenous leukemia/myelodysplastic syndrome diagnosis HR 1.66 P .03 and matched-related donor HR 1.62 P .03 associated with poorer PFS RIC HSCT is well tolerated with reasonable survival in elderly patients Age is not associated with impaired outcomes HSCT should not be excluded solely based on advanced patient age,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[405, 837, 1933, 3365, 1007, 452, 31, 497, 1703, 16, 2195, 10398, 4, 3, 1216, 4, 760, 408, 3, 345, 1, 131, 89, 23, 123, 16, 1240, 1784, 21, 894, 311, 123, 4, 5162, 935, 813, 710, 7, 1032, 15, 335, 60, 52, 676, 60, 184, 335, 792, 60, 479, 2027, 3906, 90, 3365, 5, 8, 52, 166, 126, 1, 562, 53, 184, 133, 13, 772, 67, 331, 65, 10, 2789, 9, 130, 1041, 35, 345, 23, 228, 9, 3, 7, 1032, 15, 335, 60, 18, 111, 4640, 282, 4296, 2, 429, 10, 79, 2, 667, 49, 106, 100, 111, 63, 2, 91, 115, 25, 118, 300, 10, 641, 2, 465, 106, 88, 215, 478, 286, 2, 442, 1599, 185, 1204, 34, 5873, 6670, 287, 10, 326, 49, 2, 512, 83, 106, 1430, 3129, 7, 1032, 335, 660, 60, 185, 576, 7, 1032, 15, 556, 60, 18, 111, 4296, 2, 429, 10, 79, 33, 185, 66, 27, 19, 874, 2, 699, 33, 185, 664, 27, 19, 456, 106, 88, 215, 478, 5873, 2, 6670, 287, 10, 326, 14, 185, 350, 83, 19, 653, 2, 725, 66, 185, 531, 33, 19, 355, 106, 100, 111, 118, 2, 300, 10, 739, 185, 605, 19, 175, 2, 511, 185, 465, 19, 259, 106, 4, 8, 331, 418, 202, 64, 43, 34, 41, 5, 1769, 300, 360, 197, 168, 18, 14, 19, 355, 2, 118, 168, 14, 874, 19, 680, 286, 2194, 2647, 10589, 681, 147, 168, 14, 700, 19, 680, 2, 655, 139, 1488, 168, 14, 744, 19, 680, 41, 5, 1769, 300, 3365, 1703, 16, 149, 421, 5, 3203, 25, 4, 1216, 7, 89, 16, 44, 41, 5, 2364, 123, 1703, 257, 44, 40, 1800, 5558, 90, 23, 131, 69, 89]",1601.0,20074656,280
Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.,Cancer research,Cancer Res.,2010-01-26,"Curative effects of graft-versus-leukemia-based therapies such as donor lymphocyte infusion (DLI) for chronic myelogenous leukemia (CML) may result from immunologic ablation of self-renewing CML progenitor cells. Patients who achieved durable remissions after DLI developed a significant B-cell lymphocytosis after treatment, which did not occur in patients who were unresponsive to DLI. In this study, we identified antigen targets of this B-cell response by probing two immunoproteomic platforms with plasma immunoglobulins from seven CML patients with clinically apparent graft-versus-leukemia responses after DLI. In total, 62 antigens elicited greater reactivity from post-DLI versus pre-DLI plasma. Microarray analysis revealed that >70% of the antigens were expressed in CML CD34(+) cells, suggesting that expression in malignant progenitor cells is a feature common to antibody targets of DLI. We confirmed elevated expression of three target antigens (RAB38, TBCE, and DUSP12) in CML that together consistently elicited antibody responses in 18 of 21 of an additional cohort of CML patients with therapeutic responses, but not in normal donors and rarely in non-CML patients. In summary, immunologic targets of curative DLI responses include multiple antigens on CML progenitor cells, identifying them as potential immunogens for vaccination and/or monitoring of immunotherapeutics designed to eliminate myeloid leukemia stem cells.",Journal Article,3647.0,40.0,Curative effects of graft-versus-leukemia-based therapies such as donor lymphocyte infusion DLI for chronic myelogenous CML may result from immunologic ablation of self-renewing CML progenitor cells Patients who achieved durable remissions after DLI developed a significant B-cell lymphocytosis after treatment which did not occur in patients who were unresponsive to DLI In this study we identified antigen targets of this B-cell response by probing two immunoproteomic platforms with plasma immunoglobulins from seven CML patients with clinically apparent graft-versus-leukemia responses after DLI In total 62 antigens elicited greater reactivity from post-DLI versus pre-DLI plasma Microarray analysis revealed that 70 of the antigens were expressed in CML CD34 cells suggesting that expression in malignant progenitor cells is a feature common to antibody targets of DLI We confirmed elevated expression of three target antigens RAB38 TBCE and DUSP12 in CML that together consistently elicited antibody responses in 18 of 21 of an additional cohort of CML patients with therapeutic responses but not in normal donors and rarely in non-CML patients In summary immunologic targets of curative DLI responses include multiple antigens on CML progenitor cells identifying them as potential immunogens for vaccination and/or monitoring of immunotherapeutics designed to eliminate myeloid stem cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1075, 176, 1, 1599, 185, 2647, 90, 235, 225, 22, 1488, 1448, 904, 4676, 9, 442, 2194, 903, 68, 757, 29, 3042, 1650, 1, 1074, 13350, 903, 2520, 37, 7, 54, 513, 1480, 3166, 50, 4676, 276, 8, 93, 132, 31, 8125, 50, 24, 92, 205, 44, 1271, 4, 7, 54, 11, 7244, 6, 4676, 4, 26, 45, 21, 108, 448, 637, 1, 26, 132, 31, 51, 20, 15492, 100, 58583, 4364, 5, 554, 13373, 29, 648, 903, 7, 5, 505, 2235, 1599, 185, 2647, 253, 50, 4676, 4, 181, 744, 1575, 5179, 378, 4601, 29, 539, 4676, 185, 671, 4676, 554, 1727, 65, 553, 17, 431, 1, 3, 1575, 11, 570, 4, 903, 2215, 37, 802, 17, 55, 4, 393, 2520, 37, 16, 8, 2705, 186, 6, 548, 637, 1, 4676, 21, 557, 804, 55, 1, 169, 283, 1575, 58584, 58585, 2, 58586, 4, 903, 17, 1162, 2433, 5179, 548, 253, 4, 203, 1, 239, 1, 35, 402, 180, 1, 903, 7, 5, 189, 253, 84, 44, 4, 295, 2344, 2, 2416, 4, 220, 903, 7, 4, 1962, 3042, 637, 1, 1075, 4676, 253, 643, 232, 1575, 23, 903, 2520, 37, 1386, 1370, 22, 174, 24461, 9, 1915, 2, 15, 1315, 1, 9362, 1114, 6, 4964, 533, 452, 37]",1396.0,20103624,87
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.,Cancer,Cancer,2010-03-01,"Identification of BCR-ABL as the defining leukemogenic event in chronic myelogenous leukemia (CML) revolutionized the treatment of the disease. Imatinib, a potent BCR-ABL inhibitor, is the standard of care for the first-line treatment of patients with chronic-phase CML because of its high long-term response rates and favorable tolerability profile compared with previous standard therapies. However, resistance to imatinib develops in 2% to 4% of patients annually. For patients with acquired cytogenetic resistance to standard-dose imatinib (400 mg daily), imatinib dose escalation (600-800 mg daily) is an excellent first option for managing patients and achieving cytogenetic responses. However, for patients with primary resistance to imatinib, hematologic disease recurrence, or emergent BCR-ABL kinase domain mutations, imatinib dose escalation may not be sufficient to control the disease. For these patients, the potent second-generation tyrosine kinase inhibitors dasatinib and nilotinib are available. Both agents provide effective therapeutic options for patients with imatinib resistance or intolerance. For the current overview, the authors reviewed the data supporting the use of both dasatinib and nilotinib in imatinib-resistant or imatinib-intolerant patients, and they have highlighted the future of CML therapy. Overall, the article is intended to offer physicians a comprehensive review of the current literature and to provide data supporting various treatment options for patients with CML throughout the course of imatinib therapy and beyond.",Journal Article,3613.0,31.0,Identification of BCR-ABL as the defining leukemogenic event in chronic myelogenous CML revolutionized the treatment of the disease Imatinib a potent BCR-ABL inhibitor is the standard of care for the first-line treatment of patients with chronic-phase CML because of its high long-term response rates and favorable tolerability profile compared with previous standard therapies However resistance to imatinib develops in 2 to 4 of patients annually For patients with acquired cytogenetic resistance to standard-dose imatinib 400 mg daily imatinib dose escalation 600-800 mg daily is an excellent first option for managing patients and achieving cytogenetic responses However for patients with primary resistance to imatinib hematologic disease recurrence or emergent BCR-ABL kinase domain mutations imatinib dose escalation may not be sufficient to control the disease For these patients the potent second-generation tyrosine kinase inhibitors dasatinib and nilotinib are available Both agents provide effective therapeutic options for patients with imatinib resistance or intolerance For the current overview the authors reviewed the data supporting the use of both dasatinib and nilotinib in imatinib-resistant or imatinib-intolerant patients and they have highlighted the future of CML therapy Overall the article is intended to offer physicians a comprehensive review of the current literature and to provide data supporting various treatment options for patients with CML throughout the course of imatinib therapy and beyond,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[911, 1, 1062, 1425, 22, 3, 2847, 13519, 774, 4, 442, 2194, 903, 5746, 3, 24, 1, 3, 34, 577, 8, 1157, 1062, 1425, 230, 16, 3, 260, 1, 165, 9, 3, 157, 328, 24, 1, 7, 5, 442, 124, 903, 408, 1, 211, 64, 319, 337, 51, 151, 2, 913, 1543, 800, 72, 5, 698, 260, 235, 137, 251, 6, 577, 4734, 4, 18, 6, 39, 1, 7, 4226, 9, 7, 5, 1294, 1266, 251, 6, 260, 61, 577, 1524, 81, 391, 577, 61, 1125, 2383, 2796, 81, 391, 16, 35, 1503, 157, 1501, 9, 3969, 7, 2, 1785, 1266, 253, 137, 9, 7, 5, 86, 251, 6, 577, 813, 34, 146, 15, 4348, 1062, 1425, 216, 1398, 138, 577, 61, 1125, 68, 44, 40, 1952, 6, 182, 3, 34, 9, 46, 7, 3, 1157, 419, 914, 564, 216, 222, 1674, 2, 2638, 32, 390, 110, 183, 377, 323, 189, 838, 9, 7, 5, 577, 251, 15, 5266, 9, 3, 291, 2901, 3, 738, 446, 3, 74, 1912, 3, 119, 1, 110, 1674, 2, 2638, 4, 577, 436, 15, 577, 4944, 7, 2, 491, 47, 3681, 3, 508, 1, 903, 36, 63, 3, 946, 16, 4081, 6, 1918, 1261, 8, 949, 206, 1, 3, 291, 789, 2, 6, 377, 74, 1912, 747, 24, 838, 9, 7, 5, 903, 2432, 3, 906, 1, 577, 36, 2, 1654]",1529.0,20120030,210
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.,American journal of hematology,Am. J. Hematol.,2010-03-01,"Dasatinib 70 mg twice daily is indicated for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) intolerant or resistant to imatinib. In patients with chronic-phase chronic myelogenous leukemia, once-daily dosing has similar efficacy with improved safety, compared with twice-daily dosing. A phase 3 study (n = 611) assessed the efficacy and safety of dasatinib 140 mg once daily versus 70 mg twice-daily in patients with advanced phase chronic myelogenous leukemia or Ph+ ALL resistant or intolerant to imatinib. Here, results from the Ph+ ALL subset (n = 84) with a 2-year follow-up are reported. Patients were randomly assigned to receive dasatinib either 140 mg once daily (n = 40) or 70 mg twice daily (n = 44). The rate of confirmed major hematologic response with once-daily dosing (38%) was similar to that with twice-daily dosing (32%). The rate of major cytogenetic response with once-daily dosing (70%) was higher than that with twice-daily dosing (52%). Compared with the twice-daily schedule, the once-daily schedule had longer progression-free survival (median, 3.0 months versus 4.0 months, respectively) and shorter overall survival (median, 9.1 months versus 6.5 months, respectively). Overall safety profiles were similar between two groups, with nonhematologic adverse events being mostly grade 1 or 2. Pleural effusion was less frequent with once-daily dosing than with twice-daily dosing (all grades, 18% versus 32%). Notably, none of the differences between the two schedules was statistically significant. Compared with the 70 mg twice daily, dasatinib 140 mg once daily had similar overall efficacy and safety in patients with imatinib-resistant or intolerant Ph+ ALL. (clinicaltrials.gov identifier: NCT00123487).","Clinical Trial, Phase III",3613.0,67.0,Dasatinib 70 mg twice daily is indicated for Philadelphia chromosome-positive acute lymphoblastic Ph+ ALL intolerant or resistant to imatinib In patients with chronic-phase chronic myelogenous once-daily dosing has similar efficacy with improved safety compared with twice-daily dosing A phase 3 study n 611 assessed the efficacy and safety of dasatinib 140 mg once daily versus 70 mg twice-daily in patients with advanced phase chronic myelogenous or Ph+ ALL resistant or intolerant to imatinib Here results from the Ph+ ALL subset n 84 with a 2-year follow-up are reported Patients were randomly assigned to receive dasatinib either 140 mg once daily n 40 or 70 mg twice daily n 44 The rate of confirmed major hematologic response with once-daily dosing 38 was similar to that with twice-daily dosing 32 The rate of major cytogenetic response with once-daily dosing 70 was higher than that with twice-daily dosing 52 Compared with the twice-daily schedule the once-daily schedule had longer progression-free survival median 3.0 months versus 4.0 months respectively and shorter overall survival median 9.1 months versus 6.5 months respectively Overall safety profiles were similar between two groups with nonhematologic adverse events being mostly grade 1 or 2 Pleural effusion was less frequent with once-daily dosing than with twice-daily dosing all grades 18 versus 32 Notably none of the differences between the two schedules was statistically significant Compared with the 70 mg twice daily dasatinib 140 mg once daily had similar overall efficacy and safety in patients with imatinib-resistant or intolerant Ph+ ALL clinicaltrials.gov identifier NCT00123487,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1674, 431, 81, 936, 391, 16, 1103, 9, 3006, 1170, 109, 286, 1275, 2058, 62, 4944, 15, 436, 6, 577, 4, 7, 5, 442, 124, 442, 2194, 1059, 391, 1280, 71, 288, 209, 5, 231, 367, 72, 5, 936, 391, 1280, 8, 124, 27, 45, 78, 10711, 275, 3, 209, 2, 367, 1, 1674, 3304, 81, 1059, 391, 185, 431, 81, 936, 391, 4, 7, 5, 131, 124, 442, 2194, 15, 2058, 62, 436, 15, 4944, 6, 577, 467, 99, 29, 3, 2058, 62, 697, 78, 874, 5, 8, 18, 111, 166, 126, 32, 210, 7, 11, 1108, 896, 6, 560, 1674, 361, 3304, 81, 1059, 391, 78, 327, 15, 431, 81, 936, 391, 78, 584, 3, 116, 1, 557, 458, 813, 51, 5, 1059, 391, 1280, 519, 10, 288, 6, 17, 5, 936, 391, 1280, 531, 3, 116, 1, 458, 1266, 51, 5, 1059, 391, 1280, 431, 10, 142, 76, 17, 5, 936, 391, 1280, 653, 72, 5, 3, 936, 391, 1055, 3, 1059, 391, 1055, 42, 589, 91, 115, 25, 52, 27, 13, 53, 185, 39, 13, 53, 106, 2, 985, 63, 25, 52, 83, 14, 53, 185, 49, 33, 53, 106, 63, 367, 1241, 11, 288, 59, 100, 271, 5, 3534, 290, 281, 486, 2754, 88, 14, 15, 18, 2164, 4433, 10, 299, 908, 5, 1059, 391, 1280, 76, 5, 936, 391, 1280, 62, 2276, 203, 185, 531, 2552, 1292, 1, 3, 362, 59, 3, 100, 2314, 10, 712, 93, 72, 5, 3, 431, 81, 936, 391, 1674, 3304, 81, 1059, 391, 42, 288, 63, 209, 2, 367, 4, 7, 5, 577, 436, 15, 4944, 2058, 62, 1252, 1239, 3719, 58630]",1665.0,20131302,53
Targeted agents for chronic myelogenous leukemia: will that be the end of allogeneic bone marrow transplantation for that disease?,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-02-04,"Although the drug imatinib has been accepted as the treatment of choice for chronic myelogenous leukemia (CML) in chronic phase (CP) throughout the Western world, allogeneic stem cell transplantation (allo-SCT) continues to remain a widely practiced first-line treatment in countries with limited health care budgets. The rationale is not scientific, but largely economically based. We analyzed a cohort of 46 CML patients who participated in a graft-versus-host disease (GVHD) prophylaxis clinical trial and underwent related HLA-matched allogeneic peripheral blood stem cell transplantation. The median time of follow-up in surviving patients was 43 months (range: 4-89 months). Risk stratification of the population was done by European Blood and Marrow Transplant (EBMT) criteria. The estimated probabilities of overall survival (OS) and leukemia-free survival (LFS) at 3 years in low EBMT risk score (0-2) patients were both 91%, respectively. We conclude that in countries with restricted access to imatinib, allo-SCT should be considered early on as front-line therapy. Continued research support for bone marrow transplantation will be needed to make a global impact on this disease.",Clinical Trial,3638.0,1.0,Although the drug imatinib has been accepted as the treatment of choice for chronic myelogenous CML in chronic phase CP throughout the Western world allogeneic stem cell transplantation allo-SCT continues to remain a widely practiced first-line treatment in countries with limited health care budgets The rationale is not scientific but largely economically based We analyzed a cohort of 46 CML patients who participated in a graft-versus-host disease GVHD prophylaxis clinical trial and underwent related HLA-matched allogeneic peripheral blood stem cell transplantation The median time of follow-up in surviving patients was 43 months range 4-89 months Risk stratification of the population was done by European Blood and Marrow Transplant EBMT criteria The estimated probabilities of overall survival OS and leukemia-free survival LFS at 3 years in low EBMT risk score 0-2 patients were both 91 respectively We conclude that in countries with restricted access to imatinib allo-SCT should be considered early on as front-line therapy Continued research support for marrow transplantation will be needed to make a global impact on this disease,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[242, 3, 234, 577, 71, 85, 3058, 22, 3, 24, 1, 1866, 9, 442, 2194, 903, 4, 442, 124, 2541, 2432, 3, 1521, 1956, 1063, 452, 31, 497, 2564, 1988, 2274, 6, 918, 8, 1792, 11121, 157, 328, 24, 4, 2115, 5, 383, 341, 165, 26656, 3, 1728, 16, 44, 3138, 84, 1733, 18514, 90, 21, 311, 8, 180, 1, 641, 903, 7, 54, 3025, 4, 8, 1599, 185, 1204, 34, 1562, 2049, 38, 160, 2, 208, 139, 1160, 655, 1063, 672, 315, 452, 31, 497, 3, 52, 98, 1, 166, 126, 4, 3050, 7, 10, 601, 53, 184, 39, 887, 53, 43, 1541, 1, 3, 266, 10, 1822, 20, 1865, 315, 2, 581, 941, 17195, 371, 3, 661, 3518, 1, 63, 25, 118, 2, 2647, 115, 25, 5674, 28, 27, 60, 4, 154, 17195, 43, 368, 13, 18, 7, 11, 110, 970, 106, 21, 2060, 17, 4, 2115, 5, 2016, 1655, 6, 577, 2564, 1988, 257, 40, 515, 191, 23, 22, 3007, 328, 36, 1351, 389, 538, 9, 581, 497, 303, 40, 575, 6, 2378, 8, 1648, 345, 23, 26, 34]",1145.0,20138227,110
Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006.,Journal of experimental & clinical cancer research : CR,J. Exp. Clin. Cancer Res.,2010-03-03,"To retrospectively review the incidence, treatment efficacy, we followed up newly diagnosed chronic myelogenous leukemia (CML) patients residing in Shanghai during 2001-2006. All eligible cases were reviewed with the data of efficacy responses as well as overall survival (OS) and progression-free survival (PFS) time. A total of 615 cases entered the study. CML mainly afflicted those aged 40-60 years old and was slightly more frequent in males than females. More than 85% of the patients were in chronic phase (CP) when diagnosed. All patients were divided into four groups based on the main regimens - hydroxyurea, interferon alpha (IFN-alpha), imatinib, and hemopoietic stem cell transplantation (HSCT). With the median follow-up of 18 months, imatinib treatment induced 92.2% complete hematologic responses, and 64.3% complete cytogenetic responses among CML-CP patients. Overall the therapeutic efficacy in the imatinib group was higher than that in the hydroxyurea or IFN-alpha group. Meanwhile, in the imatinib group, all response rates of patients in CP were significantly greater than that in accelerated or blastic crisis phase. The patients treated with imatinib also showed the most promising results regarding OS and PFS. Patients receiving HSCT decreased markedly in number with the introduction of imatinib. The number of new patients arising in Shanghai increased from 2001 to 2006. There were still patients receiving hydroxyurea and IFN-alpha. As the first-line regime for CML, imatinib was less administered in Shanghai before, but has received considerable development and great responses since 2003.",Journal Article,3611.0,7.0,To retrospectively review the incidence treatment efficacy we followed up newly diagnosed chronic myelogenous CML patients residing in Shanghai during 2001-2006 All eligible cases were reviewed with the data of efficacy responses as well as overall survival OS and progression-free survival PFS time A total of 615 cases entered the study CML mainly afflicted those aged 40-60 years old and was slightly more frequent in males than females More than 85 of the patients were in chronic phase CP when diagnosed All patients were divided into four groups based on the main regimens hydroxyurea interferon alpha IFN-alpha imatinib and hemopoietic stem cell transplantation HSCT With the median follow-up of 18 months imatinib treatment induced 92.2 complete hematologic responses and 64.3 complete cytogenetic responses among CML-CP patients Overall the therapeutic efficacy in the imatinib group was higher than that in the hydroxyurea or IFN-alpha group Meanwhile in the imatinib group all response rates of patients in CP were significantly greater than that in accelerated or blastic crisis phase The patients treated with imatinib also showed the most promising results regarding OS and PFS Patients receiving HSCT decreased markedly in number with the introduction of imatinib The number of new patients arising in Shanghai increased from 2001 to 2006 There were still patients receiving hydroxyurea and IFN-alpha As the first-line regime for CML imatinib was less administered in Shanghai before but has received considerable development and great responses since 2003,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 894, 206, 3, 287, 24, 209, 21, 370, 126, 732, 265, 442, 2194, 903, 7, 8230, 4, 16962, 190, 1758, 1324, 62, 625, 140, 11, 446, 5, 3, 74, 1, 209, 253, 22, 149, 22, 63, 25, 118, 2, 91, 115, 25, 300, 98, 8, 181, 1, 11970, 140, 2836, 3, 45, 903, 2615, 15224, 135, 1032, 327, 335, 60, 1095, 2, 10, 3223, 80, 908, 4, 2296, 76, 2451, 80, 76, 772, 1, 3, 7, 11, 4, 442, 124, 2541, 198, 265, 62, 7, 11, 2176, 237, 294, 271, 90, 23, 3, 1895, 472, 5902, 1688, 950, 1256, 950, 577, 2, 19411, 452, 31, 497, 1703, 5, 3, 52, 166, 126, 1, 203, 53, 577, 24, 277, 937, 18, 236, 813, 253, 2, 660, 27, 236, 1266, 253, 107, 903, 2541, 7, 63, 3, 189, 209, 4, 3, 577, 87, 10, 142, 76, 17, 4, 3, 5902, 15, 1256, 950, 87, 8197, 4, 3, 577, 87, 62, 51, 151, 1, 7, 4, 2541, 11, 97, 378, 76, 17, 4, 2241, 15, 6529, 6540, 124, 3, 7, 73, 5, 577, 120, 224, 3, 96, 721, 99, 666, 118, 2, 300, 7, 357, 1703, 340, 2195, 4, 207, 5, 3, 2456, 1, 577, 3, 207, 1, 217, 7, 2635, 4, 16962, 101, 29, 1758, 6, 1324, 125, 11, 1234, 7, 357, 5902, 2, 1256, 950, 22, 3, 157, 328, 20286, 9, 903, 577, 10, 299, 468, 4, 16962, 348, 84, 71, 103, 2658, 193, 2, 2797, 253, 1192, 1522]",1571.0,20199658,116
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-03-08,"PURPOSE Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) primarily afflict older individuals. Hematopoietic cell transplantation (HCT) is generally not offered because of concerns of excess morbidity and mortality. Reduced-intensity conditioning (RIC) regimens allow increased use of allogeneic HCT for older patients. To define prognostic factors impacting long-term outcomes of RIC regimens in patients older than age 40 years with AML in first complete remission or MDS and to determine the impact of age, we analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR). PATIENTS AND METHODS We reviewed data reported to the CIBMTR (1995 to 2005) on 1,080 patients undergoing RIC HCT. Outcomes analyzed included neutrophil recovery, incidence of acute or chronic graft-versus-host disease (GVHD), nonrelapse mortality (NRM), relapse, disease-free survival (DFS), and overall survival (OS). RESULTS Univariate analyses demonstrated no age group differences in NRM, grade 2 to 4 acute GVHD, chronic GVHD, or relapse. Patients age 40 to 54, 55 to 59, 60 to 64, and > or = 65 years had 2-year survival rates as follows: 44% (95% CI, 37% to 52%), 50% (95% CI, 41% to 59%), 34% (95% CI, 25% to 43%), and 36% (95% CI, 24% to 49%), respectively, for patients with AML (P = .06); and 42% (95% CI, 35% to 49%), 35% (95% CI, 27% to 43%), 45% (95% CI, 36% to 54%), and 38% (95% CI, 25% to 51%), respectively, for patients with MDS (P = .37). Multivariate analysis revealed no significant impact of age on NRM, relapse, DFS, or OS (all P > .3). Greater HLA disparity adversely affected 2-year NRM, DFS, and OS. Unfavorable cytogenetics adversely impacted relapse, DFS, and OS. Better pre-HCT performance status predicted improved 2-year OS. CONCLUSION With these similar outcomes observed in older patients, we conclude that older age alone should not be considered a contraindication to HCT.",Journal Article,3606.0,312.0,"PURPOSE Acute myelogenous AML and syndrome MDS primarily afflict older individuals Hematopoietic cell transplantation HCT is generally not offered because of concerns of excess morbidity and mortality Reduced-intensity conditioning RIC regimens allow increased use of allogeneic HCT for older patients To define prognostic factors impacting long-term outcomes of RIC regimens in patients older than age 40 years with AML in first complete remission or MDS and to determine the impact of age we analyzed data from the Center for International Blood and Marrow Transplant Research CIBMTR PATIENTS AND METHODS We reviewed data reported to the CIBMTR 1995 to 2005 on 1,080 patients undergoing RIC HCT Outcomes analyzed included neutrophil recovery incidence of acute or chronic graft-versus-host disease GVHD nonrelapse mortality NRM relapse disease-free survival DFS and overall survival OS RESULTS Univariate analyses demonstrated no age group differences in NRM grade 2 to 4 acute GVHD chronic GVHD or relapse Patients age 40 to 54 55 to 59 60 to 64 and or 65 years had 2-year survival rates as follows 44 95 CI 37 to 52 50 95 CI 41 to 59 34 95 CI 25 to 43 and 36 95 CI 24 to 49 respectively for patients with AML P .06 and 42 95 CI 35 to 49 35 95 CI 27 to 43 45 95 CI 36 to 54 and 38 95 CI 25 to 51 respectively for patients with MDS P .37 Multivariate analysis revealed no significant impact of age on NRM relapse DFS or OS all P .3 Greater HLA disparity adversely affected 2-year NRM DFS and OS Unfavorable cytogenetics adversely impacted relapse DFS and OS Better pre-HCT performance status predicted improved 2-year OS CONCLUSION With these similar outcomes observed in older patients we conclude that older age alone should not be considered a contraindication to HCT",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[743, 286, 2194, 329, 2, 681, 1223, 1561, 31469, 434, 869, 1007, 31, 497, 1085, 16, 1228, 44, 2216, 408, 1, 2061, 1, 2612, 787, 2, 282, 405, 837, 1933, 3365, 472, 1700, 101, 119, 1, 1063, 1085, 9, 434, 7, 6, 1107, 177, 130, 8661, 319, 337, 123, 1, 3365, 472, 4, 7, 434, 76, 89, 327, 60, 5, 329, 4, 157, 236, 734, 15, 1223, 2, 6, 223, 3, 345, 1, 89, 21, 311, 74, 29, 3, 574, 9, 944, 315, 2, 581, 941, 389, 11203, 7, 2, 636, 21, 446, 74, 210, 6, 3, 11203, 2323, 6, 1242, 23, 14, 15490, 7, 479, 3365, 1085, 123, 311, 159, 2595, 1602, 287, 1, 286, 15, 442, 1599, 185, 1204, 34, 1562, 4640, 282, 4296, 429, 34, 115, 25, 1010, 2, 63, 25, 118, 99, 880, 318, 264, 77, 89, 87, 362, 4, 4296, 88, 18, 6, 39, 286, 1562, 442, 1562, 15, 429, 7, 89, 327, 6, 667, 614, 6, 728, 335, 6, 660, 2, 15, 556, 60, 42, 18, 111, 25, 151, 22, 2962, 584, 48, 58, 567, 6, 653, 212, 48, 58, 605, 6, 728, 562, 48, 58, 243, 6, 601, 2, 511, 48, 58, 259, 6, 739, 106, 9, 7, 5, 329, 19, 1460, 2, 595, 48, 58, 465, 6, 739, 465, 48, 58, 428, 6, 601, 512, 48, 58, 511, 6, 667, 2, 519, 48, 58, 243, 6, 725, 106, 9, 7, 5, 1223, 19, 567, 331, 65, 553, 77, 93, 345, 1, 89, 23, 4296, 429, 1010, 15, 118, 62, 19, 27, 378, 1160, 4326, 4311, 1424, 18, 111, 4296, 1010, 2, 118, 2483, 2510, 4311, 4619, 429, 1010, 2, 118, 380, 671, 1085, 528, 156, 783, 231, 18, 111, 118, 1221, 5, 46, 288, 123, 164, 4, 434, 7, 21, 2060, 17, 434, 89, 279, 257, 44, 40, 515, 8, 8363, 6, 1085]",1772.0,20212255,220
Molecular targeted therapies in head and neck cancer--an update of recent developments-.,Head & neck oncology,Head Neck Oncol,2010-04-14,"Targeted therapies have made their way into clinical practice during the past decade. They have caused a major impact on the survival of cancer patients in many areas of clinical oncology and hematology. Indeed, in some hematologic malignancies, such as chronic myelogenous leukemia or non-Hodgkin's lymphomas, biologicals and antibodies specifically designed to target tumour-specific proteins have revolutionized treatment standards. In solid tumours, new drugs targeting EGF- or VEGF- receptors are now approved and are entering clinical practise for treatment of colon, lung, kidney and other cancers, either alone or in combination with conventional treatment approaches. Recent data have now shown that molecular targeted therapy might display efficacy in patients with head and neck squamous cell carcinoma (HNSCC) as well. The evaluated biologicals are generally well tolerated from HNSCC patients, who usually have the burden of multiple co-morbidities that interfere with conventional systemic treatment options. Therefore, molecular targeted therapies offer new treatment options even for heavily pretreated and seriously ill patients usually unable to tolerate chemotherapy or radiation therapy. The two most promising and advanced strategies are the blockage of growth-factor based cellular signalling and interference with angiogenesis-related pathways. But inhibitors of alternative targets, such as Scr and proteasomes, have already been evaluated in early clinical trials with HNSCC patients.",Journal Article,3569.0,55.0,Targeted therapies have made their way into clinical practice during the past decade They have caused a major impact on the survival of cancer patients in many areas of clinical oncology and hematology Indeed in some hematologic malignancies such as chronic myelogenous or 's lymphomas biologicals and antibodies specifically designed to target tumour-specific proteins have revolutionized treatment standards In solid tumours new drugs targeting EGF- or VEGF- receptors are now approved and are entering clinical practise for treatment of and other cancers either alone or in combination with conventional treatment approaches Recent data have now shown that molecular targeted therapy might display efficacy in patients with head and squamous cell carcinoma HNSCC as well The evaluated biologicals are generally well tolerated from HNSCC patients who usually have the burden of multiple co-morbidities that interfere with conventional systemic treatment options Therefore molecular targeted therapies offer new treatment options even for heavily pretreated and seriously ill patients usually unable to tolerate chemotherapy or radiation therapy The two most promising and advanced strategies are the blockage of growth-factor based cellular signalling and interference with angiogenesis-related pathways But inhibitors of alternative targets such as Scr and proteasomes have already been evaluated in early clinical trials with HNSCC patients,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[238, 235, 47, 1229, 136, 2255, 237, 38, 758, 190, 3, 1219, 2025, 491, 47, 1546, 8, 458, 345, 23, 3, 25, 1, 12, 7, 4, 445, 1361, 1, 38, 413, 2, 6216, 4462, 4, 476, 813, 441, 225, 22, 442, 2194, 15, 292, 1557, 45980, 2, 890, 1225, 1114, 6, 283, 770, 112, 652, 47, 5746, 24, 3371, 4, 537, 1319, 217, 600, 529, 3114, 15, 618, 1186, 32, 1134, 850, 2, 32, 7653, 38, 45981, 9, 24, 1, 2, 127, 163, 361, 279, 15, 4, 150, 5, 809, 24, 611, 435, 74, 47, 1134, 443, 17, 219, 238, 36, 822, 3640, 209, 4, 7, 5, 718, 2, 691, 31, 134, 1209, 22, 149, 3, 194, 45980, 32, 1228, 149, 421, 29, 1209, 7, 54, 2082, 47, 3, 892, 1, 232, 1269, 5655, 17, 6178, 5, 809, 403, 24, 838, 673, 219, 238, 235, 1918, 217, 24, 838, 871, 9, 2447, 2193, 2, 13158, 4993, 7, 2082, 4253, 6, 5010, 56, 15, 121, 36, 3, 100, 96, 721, 2, 131, 422, 32, 3, 12501, 1, 129, 161, 90, 763, 3128, 2, 3182, 5, 1056, 139, 460, 84, 222, 1, 1091, 637, 225, 22, 9218, 2, 24715, 47, 3298, 85, 194, 4, 191, 38, 143, 5, 1209, 7]",1444.0,20398256,5
Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2010-05-11,"The target antigens of graft-versus-leukemia that are tumor associated are incompletely characterized. We examined responses developing against CML66, an immunogenic antigen preferentially expressed in myeloid progenitor cells identified from a patient with chronic myelogenous leukemia who attained long-lived remission following CD4+ donor lymphocyte infusion (DLI). From this patient, CML66-reactive CD8+ T-cell clones were detected against an endogenously presented HLA-B*4403-restricted epitope (HDVDALLW). Neither CML66-specific antibody nor T-cell responses were detectable in peripheral blood before DLI. However, by 1 month after DLI, CD8+ T cells were present in peripheral blood and at 10-fold higher frequency in marrow. Subsequently, plasma antibody to CML66 developed in association with disease remission. Donor-derived CML66-reactive T cells were detected at low levels in vivo in marrow before DLI by ELISpot and by a nested PCR-based assay to detect clonotypic T-cell receptor sequences but not in blood of the patient pre-DLI nor of the graft donor. CD4+ DLI results in rapid expansion of preexisting marrow-resident leukemia-specific donor CD8+ T cells, followed by a cascade of antigen-specific immune responses detectable in blood. Our single-antigen analysis thus shows that durable posttransplant tumor immunity is directed in part against nonpolymorphic overexpressed leukemia antigens that elicit coordinated cellular and humoral immunity.",Case Reports,3542.0,25.0,The target antigens of graft-versus-leukemia that are tumor associated are incompletely characterized We examined responses developing against CML66 an immunogenic antigen preferentially expressed in myeloid progenitor cells identified from a patient with chronic myelogenous who attained long-lived remission following CD4+ donor lymphocyte infusion DLI From this patient CML66-reactive CD8+ T-cell clones were detected against an endogenously presented HLA-B*4403-restricted epitope HDVDALLW Neither CML66-specific antibody nor T-cell responses were detectable in peripheral blood before DLI However by 1 month after DLI CD8+ T cells were present in peripheral blood and at 10-fold higher frequency in marrow Subsequently plasma antibody to CML66 developed in association with disease remission Donor-derived CML66-reactive T cells were detected at low levels in vivo in marrow before DLI by ELISpot and by a nested PCR-based assay to detect clonotypic T-cell receptor sequences but not in blood of the patient pre-DLI nor of the graft donor CD4+ DLI results in rapid expansion of preexisting marrow-resident leukemia-specific donor CD8+ T cells followed by a cascade of antigen-specific immune responses detectable in blood Our single-antigen analysis thus shows that durable posttransplant tumor immunity is directed in part against nonpolymorphic overexpressed antigens that elicit coordinated cellular and humoral immunity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 283, 1575, 1, 1599, 185, 2647, 17, 32, 30, 41, 32, 5252, 765, 21, 409, 253, 931, 480, 12826, 35, 4190, 448, 3509, 570, 4, 533, 2520, 37, 108, 29, 8, 69, 5, 442, 2194, 54, 5105, 319, 4813, 734, 366, 1440, 1488, 1448, 904, 4676, 29, 26, 69, 12826, 2163, 968, 102, 31, 2749, 11, 530, 480, 35, 11748, 917, 1160, 132, 58938, 2016, 4430, 58939, 2174, 12826, 112, 548, 2110, 102, 31, 253, 11, 2083, 4, 672, 315, 348, 4676, 137, 20, 14, 811, 50, 4676, 968, 102, 37, 11, 364, 4, 672, 315, 2, 28, 79, 1116, 142, 675, 4, 581, 1611, 554, 548, 6, 12826, 276, 4, 248, 5, 34, 734, 1488, 526, 12826, 2163, 102, 37, 11, 530, 28, 154, 148, 4, 386, 4, 581, 348, 4676, 20, 7662, 2, 20, 8, 4789, 604, 90, 719, 6, 1426, 10959, 102, 31, 153, 2866, 84, 44, 4, 315, 1, 3, 69, 671, 4676, 2110, 1, 3, 1599, 1488, 1440, 4676, 99, 4, 1321, 1422, 1, 5004, 581, 8185, 2647, 112, 1488, 968, 102, 37, 370, 20, 8, 4678, 1, 448, 112, 250, 253, 2083, 4, 315, 114, 226, 448, 65, 631, 1949, 17, 1480, 7346, 30, 1604, 16, 1166, 4, 760, 480, 42829, 1711, 1575, 17, 5487, 5725, 763, 2, 5498, 1604]",1428.0,20460482,123
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.,Cancer,Cancer,2010-07-01,"Imatinib 400 mg daily is the standard treatment for patients with chronic myelogenous leukemia (CML). The safety and efficacy of imatinib in CML patients with pre-existing liver and/or renal dysfunction has not been analyzed. The authors analyzed the outcome of 259 patients with early chronic phase CML treated with imatinib (starting dose 400 mg in 50, 800 mg in 209). Pre-existing liver and/or renal dysfunction was seen in 38 (15%) and 11 (4%) patients, respectively. Dose reductions were required in 91 (43%) of 210 patients with normal organ function, compared with 8 (73%) of 11 (P = .065) with renal dysfunction, and 19 (50%) of 38 (P = .271) with liver dysfunction. Grade 3-4 hematologic toxicities including anemia (29%, 10%, and 7% of patients with renal dysfunction, liver dysfunction, and normal organ function, respectively), neutropenia (57%, 30%, and 30%), and thrombocytopenia (43%, 30%, and 26%) were more frequent in patients with pre-existing renal dysfunction treated with high-dose imatinib. Grade 3-4 nonhematologic toxicities were observed at similar frequencies. Complete cytogenetic response rates, event-free survival, and overall survival were similar in all groups. Although patients with pre-existing liver and/or renal dysfunction might have a higher rate of hematologic toxicity and require more frequent dose reductions, most patients can be adequately managed, resulting in response rates and survival similar to those without pre-existing organ dysfunction.",Clinical Trial,3491.0,13.0,Imatinib 400 mg daily is the standard treatment for patients with chronic myelogenous CML The safety and efficacy of imatinib in CML patients with pre-existing and/or dysfunction has not been analyzed The authors analyzed the outcome of 259 patients with early chronic phase CML treated with imatinib starting dose 400 mg in 50 800 mg in 209 Pre-existing and/or dysfunction was seen in 38 15 and 11 4 patients respectively Dose reductions were required in 91 43 of 210 patients with normal organ function compared with 8 73 of 11 P .065 with dysfunction and 19 50 of 38 P .271 with dysfunction Grade 3-4 hematologic toxicities including anemia 29 10 and 7 of patients with dysfunction dysfunction and normal organ function respectively neutropenia 57 30 and 30 and thrombocytopenia 43 30 and 26 were more frequent in patients with pre-existing dysfunction treated with high-dose imatinib Grade 3-4 nonhematologic toxicities were observed at similar frequencies Complete cytogenetic response rates event-free survival and overall survival were similar in all groups Although patients with pre-existing and/or dysfunction might have a higher rate of hematologic toxicity and require more frequent dose reductions most patients can be adequately managed resulting in response rates and survival similar to those without pre-existing organ dysfunction,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 1524, 81, 391, 16, 3, 260, 24, 9, 7, 5, 442, 2194, 903, 3, 367, 2, 209, 1, 577, 4, 903, 7, 5, 671, 1692, 2, 15, 1527, 71, 44, 85, 311, 3, 738, 311, 3, 228, 1, 7696, 7, 5, 191, 442, 124, 903, 73, 5, 577, 1723, 61, 1524, 81, 4, 212, 2796, 81, 4, 5941, 671, 1692, 2, 15, 1527, 10, 527, 4, 519, 167, 2, 175, 39, 7, 106, 61, 2153, 11, 616, 4, 970, 601, 1, 5376, 7, 5, 295, 1259, 343, 72, 5, 66, 803, 1, 175, 19, 15675, 5, 1527, 2, 326, 212, 1, 519, 19, 8957, 5, 1527, 88, 27, 39, 813, 385, 141, 1545, 462, 79, 2, 67, 1, 7, 5, 1527, 1527, 2, 295, 1259, 343, 106, 778, 696, 201, 2, 201, 2, 1340, 601, 201, 2, 432, 11, 80, 908, 4, 7, 5, 671, 1692, 1527, 73, 5, 64, 61, 577, 88, 27, 39, 3534, 385, 11, 164, 28, 288, 2722, 236, 1266, 51, 151, 774, 115, 25, 2, 63, 25, 11, 288, 4, 62, 271, 242, 7, 5, 671, 1692, 2, 15, 1527, 822, 47, 8, 142, 116, 1, 813, 155, 2, 1353, 80, 908, 61, 2153, 96, 7, 122, 40, 4215, 2231, 1113, 4, 51, 151, 2, 25, 288, 6, 135, 187, 671, 1692, 1259, 1527]",1347.0,20564631,41
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.,Leukemia & lymphoma,Leuk. Lymphoma,2010-08-01,"The introduction of BCR-ABL tyrosine kinase inhibitors such as imatinib has changed the treatment of chronic myelogenous leukemia (CML). More than 75% of patients achieve complete cytogenetic remission (CCR) after treatment with imatinib, which provides an opportunity to collect minimally involved hematopoietic progenitor stem cell (HPC) products. In order to assess the feasibility of HPC collection in patients with CML, we prospectively enrolled 24 patients who achieved CCR on therapy with imatinib. Two patients could not undergo HPC collection because of coagulopathy. A CD34+ cell yield of > or =2.0 x 10(6)/kg body weight was obtained in 16/22 (73%) patients. Patients who stopped imatinib for at least 3 weeks prior to HPC collection had significantly higher CD34+ cell yields (median: 6.52 x 10(6)/kg body weight) when compared with patients who continued imatinib through the collection (median: 3.74 x 10(6)/kg body weight). Mobilization with granulocyte colony-stimulating factor (G-CSF) did not increase the levels of BCR-ABL transcript. With a mean follow-up of 46 months, all patients but one were in CCR. In conclusion, a significant number of CD34+ cells can be safely collected in patients with CML who are on imatinib therapy, but CD34+ cell yields improve when imatinib is temporarily withheld.",Journal Article,3460.0,4.0,The introduction of BCR-ABL tyrosine kinase inhibitors such as imatinib has changed the treatment of chronic myelogenous CML More than 75 of patients achieve complete cytogenetic remission CCR after treatment with imatinib which provides an opportunity to collect minimally involved hematopoietic progenitor stem cell HPC products In order to assess the feasibility of HPC collection in patients with CML we prospectively enrolled 24 patients who achieved CCR on therapy with imatinib Two patients could not undergo HPC collection because of coagulopathy A CD34+ cell yield of or =2.0 x 10 6 /kg body weight was obtained in 16/22 73 patients Patients who stopped imatinib for at least 3 weeks prior to HPC collection had significantly higher CD34+ cell yields median 6.52 x 10 6 /kg body weight when compared with patients who continued imatinib through the collection median 3.74 x 10 6 /kg body weight Mobilization with granulocyte colony-stimulating factor G-CSF did not increase the levels of BCR-ABL transcript With a mean follow-up of 46 months all patients but one were in CCR In conclusion a significant number of CD34+ cells can be safely collected in patients with CML who are on imatinib therapy but CD34+ cell yields improve when imatinib is temporarily withheld,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2456, 1, 1062, 1425, 564, 216, 222, 225, 22, 577, 71, 2368, 3, 24, 1, 442, 2194, 903, 80, 76, 481, 1, 7, 1359, 236, 1266, 734, 4992, 50, 24, 5, 577, 92, 777, 35, 2666, 6, 6248, 2144, 646, 1007, 2520, 452, 31, 10736, 2766, 4, 1732, 6, 423, 3, 1437, 1, 10736, 2442, 4, 7, 5, 903, 21, 1143, 346, 259, 7, 54, 513, 4992, 23, 36, 5, 577, 100, 7, 359, 44, 1251, 10736, 2442, 408, 1, 10029, 8, 2215, 31, 2309, 1, 15, 18, 13, 1006, 79, 49, 503, 642, 924, 10, 683, 4, 245, 350, 803, 7, 7, 54, 4403, 577, 9, 28, 506, 27, 244, 324, 6, 10736, 2442, 42, 97, 142, 2215, 31, 4788, 52, 49, 653, 1006, 79, 49, 503, 642, 924, 198, 72, 5, 7, 54, 1351, 577, 298, 3, 2442, 52, 27, 794, 1006, 79, 49, 503, 642, 924, 4030, 5, 2764, 1975, 2122, 161, 499, 1211, 205, 44, 344, 3, 148, 1, 1062, 1425, 3268, 5, 8, 313, 166, 126, 1, 641, 53, 62, 7, 84, 104, 11, 4, 4992, 4, 1221, 8, 93, 207, 1, 2215, 37, 122, 40, 2268, 786, 4, 7, 5, 903, 54, 32, 23, 577, 36, 84, 2215, 31, 4788, 401, 198, 577, 16, 17734, 16741]",1274.0,20658954,59
One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-07-30,"Approximately 13% of patients lacking an HLA-identical sibling have a one-antigen-mismatched related donor (MMRD). Historically, outcomes from the use of a one-antigen MMRD were considered equivalent to those from the use of a matched unrelated donor (UD). Recent improvements in UD stem cell transplantation (SCT) resulting from better molecular HLA matching justifies investigating whether UD should be preferred over MMRD in adult patients with acute leukemia. Here, we compared the outcomes of MMRD (n = 89) and HLA-A, -B, -C, and -DRB1 allele-matched UD (n = 700) SCT reported to the Center for International Blood and Marrow Transplant Research between 1995 and 2005. The patients underwent transplantation for acute myelogenous leukemia or acute lymphoblastic leukemia in first or second complete remission. Donor type was not associated with hematologic recovery. Univariate and multivariate comparisons of MMRD versus HLA-matched UD transplants showed no statistically significant differences in overall survival, disease-free survival, treatment-related mortality, relapse, or 100-day grade III-IV acute graft-versus-host disease (GVHD). MMRD SCT was associated with a lower rate of chronic GVHD at 1 year (35% vs 47%; P = .03), which was confirmed by multivariate analysis (relative risk, 0.58; 95% confidence interval, 0.39-0.85; P < .01). According to our data, HLA-matched UD and MMRD SCT are associated with comparable survival. Given that less chronic GVHD was observed in the MMRD transplantations, this option, when available, remains the first choice in patients with acute leukemia without an HLA-identical sibling in need of allogeneic SCT.",Journal Article,3462.0,39.0,Approximately 13 of patients lacking an HLA-identical sibling have a one-antigen-mismatched related donor MMRD Historically outcomes from the use of a one-antigen MMRD were considered equivalent to those from the use of a matched unrelated donor UD Recent improvements in UD stem cell transplantation SCT resulting from better molecular HLA matching justifies investigating whether UD should be preferred over MMRD in adult patients with acute Here we compared the outcomes of MMRD n 89 and HLA-A -B -C and -DRB1 allele-matched UD n 700 SCT reported to the Center for International Blood and Marrow Transplant Research between 1995 and 2005 The patients underwent transplantation for acute myelogenous or acute lymphoblastic in first or second complete remission Donor type was not associated with hematologic recovery Univariate and multivariate comparisons of MMRD versus HLA-matched UD transplants showed no statistically significant differences in overall survival disease-free survival treatment-related mortality relapse or 100-day grade III-IV acute graft-versus-host disease GVHD MMRD SCT was associated with a lower rate of chronic GVHD at 1 year 35 vs 47 P .03 which was confirmed by multivariate analysis relative risk 0.58 95 confidence interval 0.39-0.85 P .01 According to our data HLA-matched UD and MMRD SCT are associated with comparable survival Given that less chronic GVHD was observed in the MMRD transplantations this option when available remains the first choice in patients with acute without an HLA-identical sibling in need of allogeneic SCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[705, 233, 1, 7, 1941, 35, 1160, 3038, 3684, 47, 8, 104, 448, 5095, 139, 1488, 14341, 3578, 123, 29, 3, 119, 1, 8, 104, 448, 14341, 11, 515, 2017, 6, 135, 29, 3, 119, 1, 8, 655, 2092, 1488, 15574, 435, 1474, 4, 15574, 452, 31, 497, 1988, 1113, 29, 380, 219, 1160, 2616, 13299, 3103, 317, 15574, 257, 40, 2514, 252, 14341, 4, 780, 7, 5, 286, 467, 21, 72, 3, 123, 1, 14341, 78, 887, 2, 1160, 8, 132, 256, 2, 8147, 1254, 655, 15574, 78, 5692, 1988, 210, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 59, 2323, 2, 1242, 3, 7, 208, 497, 9, 286, 2194, 15, 286, 1275, 4, 157, 15, 419, 236, 734, 1488, 267, 10, 44, 41, 5, 813, 1602, 880, 2, 331, 2213, 1, 14341, 185, 1160, 655, 15574, 4016, 224, 77, 712, 93, 362, 4, 63, 25, 34, 115, 25, 24, 139, 282, 429, 15, 394, 218, 88, 316, 478, 286, 1599, 185, 1204, 34, 1562, 14341, 1988, 10, 41, 5, 8, 280, 116, 1, 442, 1562, 28, 14, 111, 465, 105, 662, 19, 680, 92, 10, 557, 20, 331, 65, 580, 43, 13, 717, 48, 307, 268, 13, 587, 13, 772, 19, 355, 768, 6, 114, 74, 1160, 655, 15574, 2, 14341, 1988, 32, 41, 5, 1279, 25, 447, 17, 299, 442, 1562, 10, 164, 4, 3, 14341, 6779, 26, 1501, 198, 390, 469, 3, 157, 1866, 4, 7, 5, 286, 187, 35, 1160, 3038, 3684, 4, 594, 1, 1063, 1988]",1568.0,20674756,271
Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.,Molecular pharmacology,Mol. Pharmacol.,2010-08-06,"Imatinib, a BCR-Abl inhibitor, is a successful front-line treatment for chronic myelogenous leukemia (CML). Despite the success of imatinib, multiple mechanisms of resistance remain a problem, including overexpression of Lyn kinase (Lyn) and Bcl-2 family antiapoptotic proteins. Profiling micro-RNA (miRNA) expression in a model of Lyn-mediated imatinib-resistant CML (MYL-R) identified approximately 30 miRNAs whose expression differed >2-fold compared with drug-sensitive MYL cells. In particular, the expression of the miR181 family (a-d) was significantly reduced (11- to 25-fold) in MYL-R cells. Incubation of MYL-R cells with a Lyn inhibitor (dasatinib) or nucleofection with Lyn-targeting short interfering RNA increased miR181b and miR181d expression. A similar Lyn-dependent regulation of miR181b and miR181d was observed in imatinib-resistant K562 CML cells. Sequence analysis of potential targets for miR181 regulation predicted myeloid cell leukemia-1 (Mcl-1), a Bcl-2 family member whose expression is increased in MYL-R cells and drug-resistant leukemias. Inhibition of Lyn or rescue of miR181b expression reduced Mcl-1 expression in the MYL-R cells. To further investigate the mechanism of Mcl-1 repression by miR181, a luciferase reporter construct incorporating the Mcl-1 3'-untranslated region was tested. Overexpression of miR181b reduced luciferase activity, whereas these effects were ablated by the mutation of the seed region of the miR181 target site. Finally, stimulation of Lyn expression by 1,25-dihydroxyvitamin D(3) treatment in HL-60 cells, a cell model of acute myelogenous leukemia, decreased miR181b expression and increased Mcl-1 expression. In summary, our results suggest that Lyn-dependent regulation of miR181 is a novel mechanism of regulating Mcl-1 expression and cell survival.",Journal Article,3455.0,57.0,"Imatinib a BCR-Abl inhibitor is a successful front-line treatment for chronic myelogenous CML Despite the success of imatinib multiple mechanisms of resistance remain a problem including overexpression of Lyn kinase Lyn and Bcl-2 family antiapoptotic proteins Profiling micro-RNA miRNA expression in a model of Lyn-mediated imatinib-resistant CML MYL-R identified approximately 30 miRNAs whose expression differed 2-fold compared with drug-sensitive MYL cells In particular the expression of the miR181 family a-d was significantly reduced 11- to 25-fold in MYL-R cells Incubation of MYL-R cells with a Lyn inhibitor dasatinib or nucleofection with Lyn-targeting short interfering RNA increased miR181b and miR181d expression A similar Lyn-dependent regulation of miR181b and miR181d was observed in imatinib-resistant K562 CML cells Sequence analysis of potential targets for miR181 regulation predicted myeloid cell leukemia-1 Mcl-1 a Bcl-2 family member whose expression is increased in MYL-R cells and drug-resistant leukemias Inhibition of Lyn or rescue of miR181b expression reduced Mcl-1 expression in the MYL-R cells To further investigate the mechanism of Mcl-1 repression by miR181 a luciferase reporter construct incorporating the Mcl-1 3'-untranslated region was tested Overexpression of miR181b reduced luciferase activity whereas these effects were ablated by the mutation of the seed region of the miR181 target site Finally stimulation of Lyn expression by 1,25-dihydroxyvitamin D 3 treatment in HL-60 cells a cell model of acute myelogenous decreased miR181b expression and increased Mcl-1 expression In summary our results suggest that Lyn-dependent regulation of miR181 is a novel mechanism of regulating Mcl-1 expression and cell survival",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 8, 1062, 1425, 230, 16, 8, 1401, 3007, 328, 24, 9, 442, 2194, 903, 550, 3, 1825, 1, 577, 232, 483, 1, 251, 918, 8, 2497, 141, 851, 1, 8309, 216, 8309, 2, 1044, 18, 607, 4176, 652, 1080, 4659, 893, 2053, 55, 4, 8, 202, 1, 8309, 517, 577, 436, 903, 29041, 668, 108, 705, 201, 2028, 1310, 55, 2512, 18, 1116, 72, 5, 234, 745, 29041, 37, 4, 1454, 3, 55, 1, 3, 25275, 607, 8, 427, 10, 97, 405, 26972, 6, 243, 1116, 4, 29041, 668, 37, 7797, 1, 29041, 668, 37, 5, 8, 8309, 230, 1674, 15, 39400, 5, 8309, 529, 978, 3449, 893, 101, 29042, 2, 46161, 55, 8, 288, 8309, 470, 863, 1, 29042, 2, 46161, 10, 164, 4, 577, 436, 5208, 903, 37, 1532, 65, 1, 174, 637, 9, 25275, 863, 783, 533, 31, 2647, 14, 1308, 14, 8, 1044, 18, 607, 2693, 1310, 55, 16, 101, 4, 29041, 668, 37, 2, 234, 436, 2792, 297, 1, 8309, 15, 4256, 1, 29042, 55, 405, 1308, 14, 55, 4, 3, 29041, 668, 37, 6, 195, 963, 3, 670, 1, 1308, 14, 5255, 20, 25275, 8, 3864, 3674, 3883, 2570, 3, 1308, 14, 5435, 7379, 1053, 10, 650, 851, 1, 29042, 405, 3864, 128, 547, 46, 176, 11, 9463, 20, 3, 258, 1, 3, 5467, 1053, 1, 3, 25275, 283, 606, 1368, 2503, 1, 8309, 55, 20, 14, 243, 11430, 427, 27, 24, 4, 1718, 335, 37, 8, 31, 202, 1, 286, 2194, 340, 29042, 55, 2, 101, 1308, 14, 55, 4, 1962, 114, 99, 309, 17, 8309, 470, 863, 1, 25275, 16, 8, 229, 670, 1, 2681, 1308, 14, 55, 2, 31, 25]",1759.0,20693279,18
"NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-08-10,"Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the majority of patients ultimately die of their disease. There is no standard approach to treating relapse after alloHSCT. Withdrawal of immune suppression and donor lymphocyte infusions are commonly used for all diseases; although these interventions are remarkably effective for relapsed chronic myelogenous leukemia, they have limited efficacy in other hematologic malignancies. Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies, and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are generally anecdotal and retrospective. As such, there is an immediate need for well-designed, disease-specific trials for treatment of relapse after alloHSCT. This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease-specific manner. In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT.",Journal Article,3451.0,93.0,Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation alloHSCT Treatment options for relapse have been inadequate and the majority of patients ultimately die of their disease There is no standard approach to treating relapse after alloHSCT Withdrawal of immune suppression and donor lymphocyte infusions are commonly used for all diseases although these interventions are remarkably effective for relapsed chronic myelogenous they have limited efficacy in other hematologic malignancies Conventional and novel chemotherapy monoclonal antibody therapy targeted therapies and second transplants have been utilized in a variety of relapsed diseases but reports on these therapies are generally anecdotal and retrospective As such there is an immediate need for well-designed disease-specific trials for treatment of relapse after alloHSCT This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease-specific manner In addition recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[429, 16, 8, 458, 708, 1, 24, 496, 50, 1063, 1007, 452, 31, 497, 10248, 24, 838, 9, 429, 47, 85, 3358, 2, 3, 686, 1, 7, 2050, 3384, 1, 136, 34, 125, 16, 77, 260, 353, 6, 1367, 429, 50, 10248, 3683, 1, 250, 1332, 2, 1488, 1448, 3435, 32, 841, 95, 9, 62, 1342, 242, 46, 1151, 32, 4856, 323, 9, 591, 442, 2194, 491, 47, 383, 209, 4, 127, 813, 441, 809, 2, 229, 56, 848, 548, 36, 238, 235, 2, 419, 4016, 47, 85, 2080, 4, 8, 1362, 1, 591, 1342, 84, 1198, 23, 46, 235, 32, 1228, 9244, 2, 459, 22, 225, 125, 16, 35, 2181, 594, 9, 149, 1114, 34, 112, 143, 9, 24, 1, 429, 50, 10248, 26, 414, 2869, 291, 24, 838, 669, 940, 9, 429, 50, 10248, 4, 8, 34, 112, 1708, 4, 352, 883, 32, 1052, 9, 112, 1361, 1, 389, 1493, 4, 3, 24, 1, 429, 50, 10248]",1134.0,20699125,101
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.,Cancer,Cancer,2010-09-30,"Most patients with chronic myelogenous leukemia (CML) harbor residual disease, as evidenced by molecular techniques even after treatment with high-dose imatinib (ie, 800 mg/d). Interferon alpha (IFN ) is efficacious in CML likely due to its immunomodulatory properties, and is synergistic in vitro with imatinib and granulocyte macrophage-colony stimulating factor (GM-CSF). A study was undertaken to determine whether adding pegylated (PEG) IFN -2b and GM-CSF to high-dose imatinib may improve the complete molecular response rate in patients with CML in chronic phase. Ninety-four patients were treated with imatinib 800 mg/d for the first 6 months, then randomly assigned to continue high-dose imatinib alone (n = 49) or in combination with PEG IFN -2b 0.5 g/kg/wk and GM-CSF 125 mg/m 3 weekly (n = 45). The median follow-up for all patients was 54 months (range, 7-70 months). There were no differences in the rates of complete cytogenetic response (87% vs 90%; P = 1.0), or of major (77% vs 77%; P = 1.0) or complete (11% vs 13%; P = 1.0) molecular response (on the international scale) at 12 months between the 2 arms, or at any time during the study. Adverse events led to PEG IFN -2b discontinuation in all patients. The addition of PEG IFN -2b and GM-CSF to high-dose imatinib therapy does not improve significantly the cytogenetic or molecular response rates compared with high-dose imatinib alone. The high dropout rate in the PEG IFN -2b arm may have compromised its potential immunomodulatory benefit.","Clinical Trial, Phase II",3400.0,37.0,Most patients with chronic myelogenous CML harbor residual disease as evidenced by molecular techniques even after treatment with high-dose imatinib ie 800 mg/d Interferon alpha IFN is efficacious in CML likely due to its immunomodulatory properties and is synergistic in vitro with imatinib and granulocyte macrophage-colony stimulating factor GM-CSF A study was undertaken to determine whether adding pegylated PEG IFN -2b and GM-CSF to high-dose imatinib may improve the complete molecular response rate in patients with CML in chronic phase Ninety-four patients were treated with imatinib 800 mg/d for the first 6 months then randomly assigned to continue high-dose imatinib alone n 49 or in combination with PEG IFN -2b 0.5 g/kg/wk and GM-CSF 125 mg/m 3 weekly n 45 The median follow-up for all patients was 54 months range 7-70 months There were no differences in the rates of complete cytogenetic response 87 vs 90 P 1.0 or of major 77 vs 77 P 1.0 or complete 11 vs 13 P 1.0 molecular response on the international scale at 12 months between the 2 arms or at any time during the study Adverse events led to PEG IFN -2b discontinuation in all patients The addition of PEG IFN -2b and GM-CSF to high-dose imatinib therapy does not improve significantly the cytogenetic or molecular response rates compared with high-dose imatinib alone The high dropout rate in the PEG IFN -2b arm may have compromised its potential immunomodulatory benefit,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[96, 7, 5, 442, 2194, 903, 2760, 753, 34, 22, 4728, 20, 219, 1092, 871, 50, 24, 5, 64, 61, 577, 2523, 2796, 81, 427, 1688, 950, 1256, 16, 3289, 4, 903, 322, 520, 6, 211, 2555, 1571, 2, 16, 1806, 4, 439, 5, 577, 2, 2764, 2674, 1975, 2122, 161, 2147, 1211, 8, 45, 10, 2789, 6, 223, 317, 2726, 4424, 3145, 1256, 2014, 3381, 2, 2147, 1211, 6, 64, 61, 577, 68, 401, 3, 236, 219, 51, 116, 4, 7, 5, 903, 4, 442, 124, 2493, 294, 7, 11, 73, 5, 577, 2796, 81, 427, 9, 3, 157, 49, 53, 818, 1108, 896, 6, 1906, 64, 61, 577, 279, 78, 739, 15, 4, 150, 5, 3145, 1256, 2014, 3381, 13, 33, 3802, 503, 3293, 2, 2147, 1211, 1731, 81, 4709, 22635, 709, 78, 512, 3, 52, 166, 126, 9, 62, 7, 10, 667, 53, 184, 67, 431, 53, 125, 11, 77, 362, 4, 3, 151, 1, 236, 1266, 51, 912, 105, 424, 19, 14, 13, 15, 1, 458, 849, 105, 849, 19, 14, 13, 15, 236, 175, 105, 233, 19, 14, 13, 219, 51, 23, 3, 944, 1124, 28, 133, 53, 59, 3, 18, 1335, 15, 28, 500, 98, 190, 3, 45, 290, 281, 836, 6, 3145, 1256, 2014, 3381, 2007, 4, 62, 7, 3, 352, 1, 3145, 1256, 2014, 3381, 2, 2147, 1211, 6, 64, 61, 577, 36, 1097, 44, 401, 97, 3, 1266, 15, 219, 51, 151, 72, 5, 64, 61, 577, 279, 3, 64, 13929, 116, 4, 3, 3145, 1256, 2014, 3381, 475, 68, 47, 4867, 211, 174, 2555, 247]",1453.0,20886606,56
Clofarabine  fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-10-11,"Although a combination of i.v. busulfan (Bu) and fludarabine (Flu) is a safe, reduced-toxicity conditioning program for acute myelogenous leukemia/myelodysplastic syndromes (AML/MDS), recurrent leukemia posttransplantation remains a problem. To enhance the conditioning regimen's antileukemic effect, we decided to supplant Flu with clofarabine (Clo), and assayed the interactions of these nucleoside analogs alone and in combination with Bu in Bu-resistant human cell lines in vitro. We found pronounced synergy between each nucleoside and the alkylator but even more enhanced cytotoxic synergy when the nucleoside analogs were combined prior to exposing the cells to Bu. We then designed a 4-arm clinical trial in patients with myeloid leukemia undergoing allogeneic stem cell transplantation (allo-SCT). Patients were adaptively randomized as follows: Arm I-Clo:Flu 10:30 mg/m(2), Arm II-20:20 mg/m(2), Arm III-30:10 mg/m(2), and Arm IV-single-agent Clo at 40 mg/m(2). The nucleoside analog(s) were/was infused over 1 hour once daily for 4 days, followed on each day by Bu, infused over 3 hours to a pharmacokinetically targeted daily area under the curve (AUC) of 6000 Mol-min  10%. Fifty-one patients have been enrolled with a minimum follow-up exceeding 100 days. There were 32 males and 19 females, with a median age of 45 years (range: 6-59). Nine patients had chronic myeloid leukemia (CML) (BC: 2, second AP: 3, and tyrosine-kinase inhibitor refractory first chronic phase [CP]: 4). Forty-two patients had AML: 14 were induction failures, 8 in first chemotherapy-refractory relapse, 7 in untreated relapse, 3 in second or subsequent relapse, 4 were in second complete remission (CR), and 3 in second CR without platelet recovery (CRp), 2 were in high-risk CR1. Finally, 1 patient was in first CRp. Graft-versus-host disease (GVHD) prophylaxis was tacrolimus and mini-methorexate (MTX), and those who had an unrelated or 1 antigen-mismatched donor received low-dose rabbit-ATG (Thymoglobulin). All patients engrafted. Forty-one patients had active leukemia at the time of transplant, and 35 achieved CR (85%). Twenty of the 42 AML patients and 5 of 9 CML patients are alive with a projected median overall survival (OS) of 23 months. Marrow and blood (T cell) chimerism studies at day +100 revealed that both in the lower-dose Clo groups (groups 1+2) and the higher-dose Clo groups (groups 3+4), the patients had a median of 100% donor (T cell)-derived DNA. There has been no secondary graft failure. In the first 100 days, 1 patient died of pneumonia, and 1 of liver GVHD. We conclude that (1) Clo  Flu with i.v. Bu as pretransplant conditioning is safe in high-risk myeloid leukemia patients; (2) clofarabine is sufficiently immunosuppressive to support allo-SCT in myeloid leukemia; and (3) the median OS of 23 months in this high-risk patient population is encouraging. Additional studies to evaluate the antileukemic efficacy of Clo  Flu with i.v. Bu as pretransplant conditioning therapy are warranted.",Journal Article,3389.0,65.0,Although a combination of i.v busulfan Bu and fludarabine Flu is a safe reduced-toxicity conditioning program for acute myelogenous leukemia/myelodysplastic syndromes AML/MDS recurrent posttransplantation remains a problem To enhance the conditioning regimen 's antileukemic effect we decided to supplant Flu with clofarabine Clo and assayed the interactions of these nucleoside analogs alone and in combination with Bu in Bu-resistant human cell lines in vitro We found pronounced synergy between each nucleoside and the alkylator but even more enhanced cytotoxic synergy when the nucleoside analogs were combined prior to exposing the cells to Bu We then designed a 4-arm clinical trial in patients with myeloid undergoing allogeneic stem cell transplantation allo-SCT Patients were adaptively randomized as follows Arm I-Clo Flu 10:30 mg/m 2 Arm II-20:20 mg/m 2 Arm III-30:10 mg/m 2 and Arm IV-single-agent Clo at 40 mg/m 2 The nucleoside analog s were/was infused over 1 hour once daily for 4 days followed on each day by Bu infused over 3 hours to a pharmacokinetically targeted daily area under the curve AUC of 6000 Mol-min  10 Fifty-one patients have been enrolled with a minimum follow-up exceeding 100 days There were 32 males and 19 females with a median age of 45 years range 6-59 Nine patients had chronic myeloid CML BC 2 second AP 3 and tyrosine-kinase inhibitor refractory first chronic phase CP 4 Forty-two patients had AML 14 were induction failures 8 in first chemotherapy-refractory relapse 7 in untreated relapse 3 in second or subsequent relapse 4 were in second complete remission CR and 3 in second CR without platelet recovery CRp 2 were in high-risk CR1 Finally 1 patient was in first CRp Graft-versus-host disease GVHD prophylaxis was tacrolimus and mini-methorexate MTX and those who had an unrelated or 1 antigen-mismatched donor received low-dose rabbit-ATG Thymoglobulin All patients engrafted Forty-one patients had active at the time of transplant and 35 achieved CR 85 Twenty of the 42 AML patients and 5 of 9 CML patients are alive with a projected median overall survival OS of 23 months Marrow and blood T cell chimerism studies at day +100 revealed that both in the lower-dose Clo groups groups 1+2 and the higher-dose Clo groups groups 3+4 the patients had a median of 100 donor T cell -derived DNA There has been no secondary graft failure In the first 100 days 1 patient died of pneumonia and 1 of GVHD We conclude that 1 Clo  Flu with i.v Bu as pretransplant conditioning is safe in high-risk myeloid patients 2 clofarabine is sufficiently immunosuppressive to support allo-SCT in myeloid and 3 the median OS of 23 months in this high-risk patient population is encouraging Additional studies to evaluate the antileukemic efficacy of Clo  Flu with i.v Bu as pretransplant conditioning therapy are warranted,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[242, 8, 150, 1, 70, 603, 3906, 3667, 2, 2027, 5119, 16, 8, 1165, 405, 155, 1933, 1243, 9, 286, 2194, 2647, 10589, 2040, 329, 1223, 387, 8046, 469, 8, 2497, 6, 1304, 3, 1933, 477, 292, 4512, 254, 21, 10561, 6, 20329, 5119, 5, 4149, 7676, 2, 4499, 3, 1286, 1, 46, 4032, 4063, 279, 2, 4, 150, 5, 3667, 4, 3667, 436, 171, 31, 285, 4, 439, 21, 204, 3517, 3439, 59, 296, 4032, 2, 3, 9346, 84, 871, 80, 651, 759, 3439, 198, 3, 4032, 4063, 11, 397, 324, 6, 14548, 3, 37, 6, 3667, 21, 818, 1114, 8, 39, 475, 38, 160, 4, 7, 5, 533, 479, 1063, 452, 31, 497, 2564, 1988, 7, 11, 17198, 384, 22, 2962, 475, 70, 7676, 5119, 79, 201, 81, 188, 18, 475, 215, 179, 179, 81, 188, 18, 475, 316, 201, 79, 81, 188, 18, 2, 475, 478, 226, 420, 7676, 28, 327, 81, 188, 18, 3, 4032, 3497, 695, 11, 10, 4524, 252, 14, 2583, 1059, 391, 9, 39, 162, 370, 23, 296, 218, 20, 3667, 4524, 252, 27, 1459, 6, 8, 14920, 238, 391, 965, 669, 3, 1496, 1376, 1, 16187, 7674, 1538, 810, 79, 1461, 104, 7, 47, 85, 346, 5, 8, 2499, 166, 126, 5178, 394, 162, 125, 11, 531, 2296, 2, 326, 2451, 5, 8, 52, 89, 1, 512, 60, 184, 49, 728, 762, 7, 42, 442, 533, 903, 1402, 18, 419, 2517, 27, 2, 564, 216, 230, 430, 157, 442, 124, 2541, 39, 1213, 100, 7, 42, 329, 213, 11, 504, 3368, 66, 4, 157, 56, 430, 429, 67, 4, 1278, 429, 27, 4, 419, 15, 706, 429, 39, 11, 4, 419, 236, 734, 684, 2, 27, 4, 419, 684, 187, 1596, 1602, 3162, 18, 11, 4, 64, 43, 4516, 1368, 14, 69, 10, 4, 157, 3162, 1599, 185, 1204, 34, 1562, 2049, 10, 5643, 2, 7313, 59449, 3453, 2, 135, 54, 42, 35, 2092, 15, 14, 448, 5095, 1488, 103, 154, 61, 11079, 7168, 59450, 62, 7, 6914, 1213, 104, 7, 42, 544, 28, 3, 98, 1, 941, 2, 465, 513, 684, 772, 737, 1, 3, 595, 329, 7, 2, 33, 1, 83, 903, 7, 32, 1701, 5, 8, 5633, 52, 63, 25, 118, 1, 382, 53, 581, 2, 315, 102, 31, 6047, 94, 28, 218, 394, 553, 17, 110, 4, 3, 280, 61, 7676, 271, 271, 14, 18, 2, 3, 142, 61, 7676, 271, 271, 27, 39, 3, 7, 42, 8, 52, 1, 394, 1488, 102, 31, 526, 261, 125, 71, 85, 77, 568, 1599, 496, 4, 3, 157, 394, 162, 14, 69, 1016, 1, 3485, 2, 14, 1, 1562, 21, 2060, 17, 14, 7676, 810, 5119, 5, 70, 603, 3667, 22, 7763, 1933, 16, 1165, 4, 64, 43, 533, 7, 18, 4149, 16, 5938, 2989, 6, 538, 2564, 1988, 4, 533, 2, 27, 3, 52, 118, 1, 382, 53, 4, 26, 64, 43, 69, 266, 16, 2269, 402, 94, 6, 376, 3, 4512, 209, 1, 7676, 810, 5119, 5, 70, 603, 3667, 22, 7763, 1933, 36, 32, 1197]",2853.0,20946966,144
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-11-01,"Reduced-intensity conditioning (RIC) extends the curative potential of allogeneic hematopoietic cell transplantation (HCT) to patients with hematologic malignancies unable to withstand myeloablative conditioning. We prospectively analyzed the outcomes of 123 patients (median age, 57 years; range, 23-70 years) with hematologic malignancies treated with a uniform RIC regimen of cyclophosphamide, fludarabine, and total-body irradiation (200 cGy) with or without antithymocyte globulin followed by related donor allogeneic HCT at the University of Minnesota between 2002 and 2008. The cohort included 45 patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS), 27 with aggressive non-Hodgkin lymphoma (NHL), 8 with indolent NHL, 10 with Hodgkin lymphoma (HL), 10 with myeloma, and 23 with acute lymphocytic leukemia, chronic myelogenous leukemia, other leukemias, or myeloproliferative disorders. The probability of 4-year overall survival was 73% for patients with indolent NHL, 58% for those with aggressive NHL, 67% for those with HL, 30% for those with AML/MDS, and only 10% for those with myeloma. Corresponding outcomes for relapse in these patients were 0%, 32%, 50%, 33%, and 38%, and those for progression-free survival were 73%, 45%, 27%, 27%, and 10%. The incidence of treatment-related mortality was 14% at day +100 and 22% at 1 year. The incidence of grade II-IV acute graft-versus-host disease was 38% at day +100, and that of chronic graft-versus-host disease was 50% at 2 years. Multivariate analysis revealed superior overall survival and progression-free survival in patients with both indolent and aggressive NHL compared with those with AML/MDS, HL, or myeloma. Worse 1-year treatment-related mortality was observed in patients with a Hematopoietic Cell Transplantation Comorbidity Index score  3 and in cytomegalovirus-seropositive recipients. These results suggest that (1) RIC conditioning was well tolerated by an older, heavily pretreated population; (2) patients with indolent and aggressive NHL respond well to RIC conditioning, highlighting the importance of the graft-versus-lymphoma effect; and (3) additional peri-transplantation manipulations are needed to improve outcomes for patients with AML/MDS or myeloma receiving RIC conditioning before HCT.",Clinical Trial,3368.0,27.0,Reduced-intensity conditioning RIC extends the curative potential of allogeneic hematopoietic cell transplantation HCT to patients with hematologic malignancies unable to withstand myeloablative conditioning We prospectively analyzed the outcomes of 123 patients median age 57 years range 23-70 years with hematologic malignancies treated with a uniform RIC regimen of cyclophosphamide fludarabine and total-body irradiation 200 cGy with or without antithymocyte globulin followed by related donor allogeneic HCT at the University of Minnesota between 2002 and 2008 The cohort included 45 patients with acute myelogenous AML or syndrome MDS 27 with aggressive NHL 8 with indolent NHL 10 with HL 10 with and 23 with acute lymphocytic chronic myelogenous other leukemias or disorders The probability of 4-year overall survival was 73 for patients with indolent NHL 58 for those with aggressive NHL 67 for those with HL 30 for those with AML/MDS and only 10 for those with Corresponding outcomes for relapse in these patients were 0 32 50 33 and 38 and those for progression-free survival were 73 45 27 27 and 10 The incidence of treatment-related mortality was 14 at day +100 and 22 at 1 year The incidence of grade II-IV acute graft-versus-host disease was 38 at day +100 and that of chronic graft-versus-host disease was 50 at 2 years Multivariate analysis revealed superior overall survival and progression-free survival in patients with both indolent and aggressive NHL compared with those with AML/MDS HL or Worse 1-year treatment-related mortality was observed in patients with a Hematopoietic Cell Transplantation Comorbidity Index score  3 and in cytomegalovirus-seropositive recipients These results suggest that 1 RIC conditioning was well tolerated by an older heavily pretreated population 2 patients with indolent and aggressive NHL respond well to RIC conditioning highlighting the importance of the graft-versus-lymphoma effect and 3 additional peri-transplantation manipulations are needed to improve outcomes for patients with AML/MDS or receiving RIC conditioning before HCT,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[405, 837, 1933, 3365, 8464, 3, 1075, 174, 1, 1063, 1007, 31, 497, 1085, 6, 7, 5, 813, 441, 4253, 6, 21330, 3246, 1933, 21, 1143, 311, 3, 123, 1, 2698, 7, 52, 89, 696, 60, 184, 382, 431, 60, 5, 813, 441, 73, 5, 8, 3490, 3365, 477, 1, 1112, 2027, 2, 181, 642, 1104, 1250, 3071, 5, 15, 187, 11016, 7819, 370, 20, 139, 1488, 1063, 1085, 28, 3, 1652, 1, 8297, 59, 1544, 2, 1375, 3, 180, 159, 512, 7, 5, 286, 2194, 329, 15, 681, 1223, 428, 5, 571, 1176, 66, 5, 2316, 1176, 79, 5, 1718, 79, 5, 2, 382, 5, 286, 1193, 442, 2194, 127, 2792, 15, 1997, 3, 1320, 1, 39, 111, 63, 25, 10, 803, 9, 7, 5, 2316, 1176, 717, 9, 135, 5, 571, 1176, 598, 9, 135, 5, 1718, 201, 9, 135, 5, 329, 1223, 2, 158, 79, 9, 135, 5, 1734, 123, 9, 429, 4, 46, 7, 11, 13, 531, 212, 466, 2, 519, 2, 135, 9, 91, 115, 25, 11, 803, 512, 428, 428, 2, 79, 3, 287, 1, 24, 139, 282, 10, 213, 28, 218, 394, 2, 350, 28, 14, 111, 3, 287, 1, 88, 215, 478, 286, 1599, 185, 1204, 34, 10, 519, 28, 218, 394, 2, 17, 1, 442, 1599, 185, 1204, 34, 10, 212, 28, 18, 60, 331, 65, 553, 1123, 63, 25, 2, 91, 115, 25, 4, 7, 5, 110, 2316, 2, 571, 1176, 72, 5, 135, 5, 329, 1223, 1718, 15, 639, 14, 111, 24, 139, 282, 10, 164, 4, 7, 5, 8, 1007, 31, 497, 1879, 558, 368, 749, 27, 2, 4, 7314, 9909, 2190, 46, 99, 309, 17, 14, 3365, 1933, 10, 149, 421, 20, 35, 434, 2447, 2193, 266, 18, 7, 5, 2316, 2, 571, 1176, 1892, 149, 6, 3365, 1933, 4051, 3, 1187, 1, 3, 1599, 185, 4763, 254, 2, 27, 402, 6164, 497, 13775, 32, 575, 6, 401, 123, 9, 7, 5, 329, 1223, 15, 357, 3365, 1933, 348, 1085]",2091.0,21047561,230
"Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?",Cancer treatment reviews,Cancer Treat. Rev.,2010-11-24,"Imatinib is the standard of care for patients with advanced metastatic gastrointestinal stromal tumors (GIST), and is also approved for adjuvant treatment in patients at substantial risk of relapse. Studies have shown that maximizing benefit from imatinib depends on long-term administration at recommended doses. Pharmacokinetic (PK) and pharmacodynamic factors, adherence, and drug-drug interactions can affect exposure to imatinib and impact clinical outcomes. This article reviews the relevance of these factors to imatinib's clinical activity and response in the context of what has been demonstrated in chronic myelogenous leukemia (CML), and in light of new data correlating imatinib exposure to response in patients with GIST. Because of the wide inter-patient variability in drug exposure with imatinib in both CML and GIST, blood level testing (BLT) may play a role in investigating instances of suboptimal response, unusually severe toxicities, drug-drug interactions, and suspected non-adherence. Published clinical data in CML and in GIST were considered, including data from a PK substudy of the B2222 trial correlating imatinib blood levels with clinical responses in patients with GIST. Imatinib trough plasma levels < 1100 ng/mL were associated with lower rates of objective response and faster development of progressive disease in patients with GIST. These findings have been supported by other analyses correlating free imatinib (unbound) levels with response. These results suggest a future application for imatinib BLT in predicting and optimizing therapeutic response. Nevertheless, early estimates of threshold imatinib blood levels must be confirmed prospectively in future studies and elaborated for different patient subgroups.",Journal Article,3345.0,45.0,Imatinib is the standard of care for patients with advanced metastatic stromal tumors GIST and is also approved for adjuvant treatment in patients at substantial risk of relapse Studies have shown that maximizing benefit from imatinib depends on long-term administration at recommended doses Pharmacokinetic PK and pharmacodynamic factors adherence and drug-drug interactions can affect exposure to imatinib and impact clinical outcomes This article reviews the relevance of these factors to imatinib 's clinical activity and response in the context of what has been demonstrated in chronic myelogenous CML and in light of new data correlating imatinib exposure to response in patients with GIST Because of the wide inter-patient variability in drug exposure with imatinib in both CML and GIST blood level testing BLT may play a role in investigating instances of suboptimal response unusually severe toxicities drug-drug interactions and suspected non-adherence Published clinical data in CML and in GIST were considered including data from a PK substudy of the B2222 trial correlating imatinib blood levels with clinical responses in patients with GIST Imatinib trough plasma levels 1100 ng/mL were associated with lower rates of objective response and faster development of progressive disease in patients with GIST These findings have been supported by other analyses correlating free imatinib unbound levels with response These results suggest a future application for imatinib BLT in predicting and optimizing therapeutic response Nevertheless early estimates of threshold imatinib blood levels must be confirmed prospectively in future studies and elaborated for different patient subgroups,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[577, 16, 3, 260, 1, 165, 9, 7, 5, 131, 113, 1126, 57, 1394, 2, 16, 120, 850, 9, 249, 24, 4, 7, 28, 1281, 43, 1, 429, 94, 47, 443, 17, 8260, 247, 29, 577, 3828, 23, 319, 337, 634, 28, 793, 415, 1456, 2395, 2, 2424, 130, 2149, 2, 234, 234, 1286, 122, 1158, 645, 6, 577, 2, 345, 38, 123, 26, 946, 2004, 3, 2088, 1, 46, 130, 6, 577, 292, 38, 128, 2, 51, 4, 3, 1533, 1, 2067, 71, 85, 264, 4, 442, 2194, 903, 2, 4, 1691, 1, 217, 74, 5637, 577, 645, 6, 51, 4, 7, 5, 1394, 408, 1, 3, 1019, 3606, 69, 1982, 4, 234, 645, 5, 577, 4, 110, 903, 2, 1394, 315, 301, 471, 35007, 68, 1343, 8, 200, 4, 3103, 5342, 1, 3291, 51, 15499, 905, 385, 234, 234, 1286, 2, 2768, 220, 2149, 983, 38, 74, 4, 903, 2, 4, 1394, 11, 515, 141, 74, 29, 8, 2395, 13843, 1, 3, 33496, 160, 5637, 577, 315, 148, 5, 38, 253, 4, 7, 5, 1394, 577, 6000, 554, 148, 13079, 997, 542, 11, 41, 5, 280, 151, 1, 461, 51, 2, 5308, 193, 1, 1014, 34, 4, 7, 5, 1394, 46, 272, 47, 85, 2708, 20, 127, 318, 5637, 115, 577, 9589, 148, 5, 51, 46, 99, 309, 8, 508, 1581, 9, 577, 35007, 4, 1434, 2, 4336, 189, 51, 3873, 191, 1423, 1, 2390, 577, 315, 148, 1642, 40, 557, 1143, 4, 508, 94, 2, 26589, 9, 338, 69, 1453]",1697.0,21078547,107
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.,Blood,Blood,2010-12-14,"Hematopoietic stem cell transplantation (HSCT) is effective therapy for patients with chronic myelogenous leukemia (CML) but is now mostly indicated for patients who develop resistance to tyrosine kinase inhibitors (TKIs), which can be associated with point mutations in BCR-ABL1. We reviewed the outcomes of imatinib-resistant CML patients (chronic phase, n = 34; accelerated phase [AP], n = 9; and blast phase [BP], n = 4) who underwent HSCT and had BCR-ABL1 sequencing. Mutations were found in 19 patients (40%); 15 of 19 had advanced CML (AP + BP + second chronic phase). Patients with mutations were more likely to transform to AP/BP at time of imatinib failure (69% vs 35%, P = .03). Forty-two patients (89%) responded to HSCT: 32 (68%) had at least a major molecular response. The 2-year event-free survival was 36% and 58% (P = .05) for the mutant and nonmutant groups, respectively; and the 2-year overall survival was 44% and 76% (P = .02), respectively. HSCT is an important salvage option for TKI-resistant patients with or without BCR-ABL1 mutations. Patients with mutations were more likely to develop advanced disease and had worse outcomes after HSCT. HSCT should be considered early for patients deemed to have a low probability of responding to second-generation TKI.",Evaluation Study,3325.0,54.0,Hematopoietic stem cell transplantation HSCT is effective therapy for patients with chronic myelogenous CML but is now mostly indicated for patients who develop resistance to tyrosine kinase inhibitors TKIs which can be associated with point mutations in BCR-ABL1 We reviewed the outcomes of imatinib-resistant CML patients chronic phase n 34 accelerated phase AP n 9 and blast phase BP n 4 who underwent HSCT and had BCR-ABL1 sequencing Mutations were found in 19 patients 40 15 of 19 had advanced CML AP BP second chronic phase Patients with mutations were more likely to transform to AP/BP at time of imatinib failure 69 vs 35 P .03 Forty-two patients 89 responded to HSCT 32 68 had at least a major molecular response The 2-year event-free survival was 36 and 58 P .05 for the mutant and nonmutant groups respectively and the 2-year overall survival was 44 and 76 P .02 respectively HSCT is an important salvage option for TKI-resistant patients with or without BCR-ABL1 mutations Patients with mutations were more likely to develop advanced disease and had worse outcomes after HSCT HSCT should be considered early for patients deemed to have a low probability of responding to second-generation TKI,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1007, 452, 31, 497, 1703, 16, 323, 36, 9, 7, 5, 442, 2194, 903, 84, 16, 1134, 2754, 1103, 9, 7, 54, 690, 251, 6, 564, 216, 222, 1671, 92, 122, 40, 41, 5, 741, 138, 4, 1062, 3557, 21, 446, 3, 123, 1, 577, 436, 903, 7, 442, 124, 78, 562, 2241, 124, 2517, 78, 83, 2, 3112, 124, 3044, 78, 39, 54, 208, 1703, 2, 42, 1062, 3557, 615, 138, 11, 204, 4, 326, 7, 327, 167, 1, 326, 42, 131, 903, 2517, 3044, 419, 442, 124, 7, 5, 138, 11, 80, 322, 6, 7136, 6, 2517, 3044, 28, 98, 1, 577, 496, 790, 105, 465, 19, 680, 1213, 100, 7, 887, 2211, 6, 1703, 531, 806, 42, 28, 506, 8, 458, 219, 51, 3, 18, 111, 774, 115, 25, 10, 511, 2, 717, 19, 474, 9, 3, 620, 2, 35023, 271, 106, 2, 3, 18, 111, 63, 25, 10, 584, 2, 846, 19, 588, 106, 1703, 16, 35, 305, 992, 1501, 9, 1379, 436, 7, 5, 15, 187, 1062, 3557, 138, 7, 5, 138, 11, 80, 322, 6, 690, 131, 34, 2, 42, 639, 123, 50, 1703, 1703, 257, 40, 515, 191, 9, 7, 3779, 6, 47, 8, 154, 1320, 1, 3261, 6, 419, 914, 1379]",1204.0,21156844,233
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-12-27,"As success of reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) relies primarily on graft-versus-leukemia (GVL) activity, increased minor HLA disparity in unrelated compared to related donors could have a significant impact on transplant outcomes. To assess whether use of unrelated donors (URD) engenders more potent GVL in RIC HSCT compared to matched related donors (MRD), we retrospectively studied 433 consecutive T-replete 6/6 HLA matched URD (n = 246) and MRD (n = 187) RIC HSCT for hematologic malignancies at our institution. Diseases included: acute myelogenous leukemia (AML) (127), non-Hodgkin lymphoma (NHL) (71), chronic lymphocytic leukemia (CLL) (68), myelodysplastic syndrome (MDS) (64), Hodgkin disease (HD) (40), chronic myeloid leukemia (CML) (25), multiple myeloma (MM) (23), myeloproliferative disorder (MPD) (12), acute lymphoblastic leukemia (ALL) (7), and other leukemia (1). All received uniform fludarabine and intravenous busulfan conditioning, and GVHD prophylaxis with tacrolimus/mini-methroxate (mini-MTX) or tacrolimus/sirolimus  mini-MTX. Unrelated donors were younger compared to MRD (median donor age: 33 years versus 52 years, P < .0001), and provided larger CD34(+) products (median CD34(+) cells infused: 8.7  10(6)/kg versus 7.5  10(6)/kg, P = .002). Distribution of diseases, disease risk, prior transplant, and cytomegalovirus (CMV) status was similar in both cohorts. Cumulative incidence of grade II-IV acute GVHD (at day +180), 2-year chronic GVHD, and 2-year nonrelapse mortality (NRM) were 20% versus 16%, 55% versus 50%, and 8% versus 6% in URD and MRD, respectively (P= NS). Cumulative incidence of relapse at 2 years was lower in URD, 52% versus 65% (P = .005). With median follow-up of 26.5 and 35.8 months, 2-year progression-free survival (PFS) was significantly better in unrelated donor transplants, 39.5% for URD, and 29% for MRD (P = .01). Overall survival (OS) at 2years were 56% for URD versus 50% for MRD (P = .53). In multivariable analysis, URD was associated with a lower risk of relapse (hazard ratio [HR] 0.67, P = .002) and superior PFS (HR 0.69, P = .002). These results suggest that URD is associated with greater GVL activity than MRD, and could have practice changing impact on future donor selection in RIC HSCT.",Comparative Study,3312.0,45.0,As success of reduced-intensity conditioning RIC hematopoietic stem cell transplantation HSCT relies primarily on graft-versus-leukemia GVL activity increased minor HLA disparity in unrelated compared to related donors could have a significant impact on transplant outcomes To assess whether use of unrelated donors URD engenders more potent GVL in RIC HSCT compared to matched related donors MRD we retrospectively studied 433 consecutive T-replete 6/6 HLA matched URD n 246 and MRD n 187 RIC HSCT for hematologic malignancies at our institution Diseases included acute myelogenous AML 127 NHL 71 chronic lymphocytic CLL 68 syndrome MDS 64 disease HD 40 chronic myeloid CML 25 multiple MM 23 disorder MPD 12 acute lymphoblastic ALL 7 and other 1 All received uniform fludarabine and intravenous busulfan conditioning and GVHD prophylaxis with tacrolimus/mini-methroxate mini-MTX or tacrolimus/sirolimus  mini-MTX Unrelated donors were younger compared to MRD median donor age 33 years versus 52 years P .0001 and provided larger CD34 products median CD34 cells infused 8.7 10 6 /kg versus 7.5 10 6 /kg P .002 Distribution of diseases disease risk prior transplant and cytomegalovirus CMV status was similar in both cohorts Cumulative incidence of grade II-IV acute GVHD at day +180 2-year chronic GVHD and 2-year nonrelapse mortality NRM were 20 versus 16 55 versus 50 and 8 versus 6 in URD and MRD respectively P NS Cumulative incidence of relapse at 2 years was lower in URD 52 versus 65 P .005 With median follow-up of 26.5 and 35.8 months 2-year progression-free survival PFS was significantly better in unrelated donor transplants 39.5 for URD and 29 for MRD P .01 Overall survival OS at 2 years were 56 for URD versus 50 for MRD P .53 In multivariable analysis URD was associated with a lower risk of relapse hazard ratio HR 0.67 P .002 and superior PFS HR 0.69 P .002 These results suggest that URD is associated with greater GVL activity than MRD and could have practice changing impact on future donor selection in RIC HSCT,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[22, 1825, 1, 405, 837, 1933, 3365, 1007, 452, 31, 497, 1703, 6495, 1561, 23, 1599, 185, 2647, 8149, 128, 101, 2278, 1160, 4326, 4, 2092, 72, 6, 139, 2344, 359, 47, 8, 93, 345, 23, 941, 123, 6, 423, 317, 119, 1, 2092, 2344, 5847, 39508, 80, 1157, 8149, 4, 3365, 1703, 72, 6, 655, 139, 2344, 2029, 21, 894, 656, 13224, 935, 102, 11151, 49, 49, 1160, 655, 5847, 78, 6907, 2, 2029, 78, 5568, 3365, 1703, 9, 813, 441, 28, 114, 731, 1342, 159, 286, 2194, 329, 4080, 1176, 792, 442, 1193, 552, 806, 681, 1223, 660, 34, 2701, 327, 442, 533, 903, 243, 232, 321, 382, 2645, 7712, 133, 286, 1275, 62, 67, 2, 127, 14, 62, 103, 3490, 2027, 2, 1262, 3906, 1933, 2, 1562, 2049, 5, 5643, 7313, 59688, 7313, 3453, 15, 5643, 4519, 810, 7313, 3453, 2092, 2344, 11, 773, 72, 6, 2029, 52, 1488, 89, 466, 60, 185, 653, 60, 19, 488, 2, 1052, 1077, 2215, 2766, 52, 2215, 37, 4524, 66, 67, 79, 49, 503, 185, 67, 33, 79, 49, 503, 19, 1111, 1395, 1, 1342, 34, 43, 324, 941, 2, 7314, 3879, 156, 10, 288, 4, 110, 736, 967, 287, 1, 88, 215, 478, 286, 1562, 28, 218, 3172, 18, 111, 442, 1562, 2, 18, 111, 4640, 282, 4296, 11, 179, 185, 245, 614, 185, 212, 2, 66, 185, 49, 4, 5847, 2, 2029, 106, 19, 4044, 967, 287, 1, 429, 28, 18, 60, 10, 280, 4, 5847, 653, 185, 556, 19, 1614, 5, 52, 166, 126, 1, 432, 33, 2, 465, 66, 53, 18, 111, 91, 115, 25, 300, 10, 97, 380, 4, 2092, 1488, 4016, 587, 33, 9, 5847, 2, 462, 9, 2029, 19, 355, 63, 25, 118, 28, 18, 60, 11, 664, 9, 5847, 185, 212, 9, 2029, 19, 699, 4, 658, 65, 5847, 10, 41, 5, 8, 280, 43, 1, 429, 360, 197, 168, 13, 598, 19, 1111, 2, 1123, 300, 168, 13, 790, 19, 1111, 46, 99, 309, 17, 5847, 16, 41, 5, 378, 8149, 128, 76, 2029, 2, 359, 47, 758, 3600, 345, 23, 508, 1488, 881, 4, 3365, 1703]",2034.0,21193054,264
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.,Blood,Blood,2011-01-13,"The transcription factor STAT5 is an essential mediator of the pathogenesis of chronic myelogenous leukemia (CML). In CML, the BCR/ABL fusion kinase causes the constitutive activation of STAT5, thereby driving the expression of genes promoting survival. BCR/ABL kinase inhibitors have become the mainstay of therapy for CML, although CML cells can develop resistance through mutations in BCR/ABL. To overcome this problem, we used a cell-based screen to identify drugs that inhibit STAT-dependent gene expression. Using this approach, we identified the psychotropic drug pimozide as a STAT5 inhibitor. Pimozide decreases STAT5 tyrosine phosphorylation, although it does not inhibit BCR/ABL or other tyrosine kinases. Furthermore, pimozide decreases the expression of STAT5 target genes and induces cell cycle arrest and apoptosis in CML cell lines. Pimozide also selectively inhibits colony formation of CD34(+) bone marrow cells from CML patients. Importantly, pimozide induces similar effects in the presence of the T315I BCR/ABL mutation that renders the kinase resistant to presently available inhibitors. Simultaneously inhibiting STAT5 with pimozide and the kinase inhibitors imatinib or nilotinib shows enhanced effects in inhibiting STAT5 phosphorylation and in inducing apoptosis. Thus, targeting STAT5 may be an effective strategy for the treatment of CML and other myeloproliferative diseases.",Journal Article,3295.0,162.0,The transcription factor STAT5 is an essential mediator of the pathogenesis of chronic myelogenous CML In CML the BCR/ABL fusion kinase causes the constitutive activation of STAT5 thereby driving the expression of genes promoting survival BCR/ABL kinase inhibitors have become the mainstay of therapy for CML although CML cells can develop resistance through mutations in BCR/ABL To overcome this problem we used a cell-based screen to identify drugs that inhibit STAT-dependent gene expression Using this approach we identified the psychotropic drug pimozide as a STAT5 inhibitor Pimozide decreases STAT5 tyrosine phosphorylation although it does not inhibit BCR/ABL or other tyrosine kinases Furthermore pimozide decreases the expression of STAT5 target genes and induces cell cycle arrest and apoptosis in CML cell lines Pimozide also selectively inhibits colony formation of CD34 marrow cells from CML patients Importantly pimozide induces similar effects in the presence of the T315I BCR/ABL mutation that renders the kinase resistant to presently available inhibitors Simultaneously inhibiting STAT5 with pimozide and the kinase inhibitors imatinib or nilotinib shows enhanced effects in inhibiting STAT5 phosphorylation and in inducing apoptosis Thus targeting STAT5 may be an effective strategy for the treatment of CML and other diseases,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 866, 161, 5517, 16, 35, 1452, 3810, 1, 3, 1384, 1, 442, 2194, 903, 4, 903, 3, 1062, 1425, 1212, 216, 1626, 3, 3178, 363, 1, 5517, 2267, 4057, 3, 55, 1, 214, 2388, 25, 1062, 1425, 216, 222, 47, 1417, 3, 4041, 1, 36, 9, 903, 242, 903, 37, 122, 690, 251, 298, 138, 4, 1062, 1425, 6, 1768, 26, 2497, 21, 95, 8, 31, 90, 2413, 6, 255, 600, 17, 1433, 4168, 470, 145, 55, 75, 26, 353, 21, 108, 3, 24470, 234, 27017, 22, 8, 5517, 230, 27017, 2140, 5517, 564, 982, 242, 192, 1097, 44, 1433, 1062, 1425, 15, 127, 564, 1549, 798, 27017, 2140, 3, 55, 1, 5517, 283, 214, 2, 1516, 31, 417, 1854, 2, 351, 4, 903, 31, 285, 27017, 120, 2382, 1576, 1975, 1264, 1, 2215, 581, 37, 29, 903, 7, 1859, 27017, 1516, 288, 176, 4, 3, 463, 1, 3, 6184, 1062, 1425, 258, 17, 8080, 3, 216, 436, 6, 9083, 390, 222, 3074, 2062, 5517, 5, 27017, 2, 3, 216, 222, 577, 15, 2638, 1949, 651, 176, 4, 2062, 5517, 982, 2, 4, 1958, 351, 631, 529, 5517, 68, 40, 35, 323, 692, 9, 3, 24, 1, 903, 2, 127, 1342]",1346.0,21233313,182
Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.,Pediatric blood & cancer,Pediatr Blood Cancer,2010-12-22,"Chronic myelogenous leukemia (CML) is caused by the BCR-ABL1 fusion gene that encodes for a constitutively-active tyrosine kinase. Adults and children with CML are typically treated with imatinib mesylate, a BCR-ABL1 tyrosine kinase inhibitor (TKI), or a second-generation TKI. Several case reports have documented growth delay of unknown mechanism in children with CML treated with imatinib. We report a seven-year-old identical twin with CML who developed significant growth delay, as compared to her twin, during five years of TKI therapy. Detailed endocrine evaluation showed acquired growth hormone deficiency, a pathway potentially inhibited by TKIs.",Case Reports,3317.0,34.0,Chronic myelogenous CML is caused by the BCR-ABL1 fusion gene that encodes for a constitutively-active tyrosine kinase Adults and children with CML are typically treated with imatinib mesylate a BCR-ABL1 tyrosine kinase inhibitor TKI or a second-generation TKI Several case reports have documented growth delay of unknown mechanism in children with CML treated with imatinib We report a seven-year-old identical twin with CML who developed significant growth delay as compared to her twin during five years of TKI therapy Detailed endocrine evaluation showed acquired growth hormone deficiency a pathway potentially inhibited by TKIs,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 16, 1546, 20, 3, 1062, 3557, 1212, 145, 17, 4322, 9, 8, 2818, 544, 564, 216, 857, 2, 541, 5, 903, 32, 1969, 73, 5, 577, 2347, 8, 1062, 3557, 564, 216, 230, 1379, 15, 8, 419, 914, 1379, 392, 473, 1198, 47, 1405, 129, 1984, 1, 860, 670, 4, 541, 5, 903, 73, 5, 577, 21, 414, 8, 648, 111, 1095, 3038, 13305, 5, 903, 54, 276, 93, 129, 1984, 22, 72, 6, 1084, 13305, 190, 365, 60, 1, 1379, 36, 2455, 1293, 451, 224, 1294, 129, 785, 2299, 8, 308, 751, 879, 20, 1671]",633.0,21298759,223
Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2011-02-12,"Graft-versus-host disease (GVHD) is most effectively prevented by ex vivo T cell depletion (TCD) of the allograft, but its role in the treatment of patients undergoing allogeneic hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in complete remission (CR) remains unclear. We performed a phase 2 single-arm multicenter study to evaluate the role of TCD in AML patients in CR1 or CR2 up to age 65 years. The primary objective was to achieve a disease-free survival (DFS) rate of >75% at 6 months posttransplantation. A total of 44 patients with AML in CR1 (n = 37) or CR2 (n = 7) with a median age of 48.5 years (range, 21-59 years) received myeloablative chemotherapy and fractionated total body irradiation (1375 cGy) followed by immunomagnetically selected CD34-enriched, T celldepleted allografts from HLA-identical siblings. No pharmacologic GVHD prophylaxis was given. All patients engrafted. The incidence of acute GVHD grade II-IV was 22.7%, and the incidence of extensive chronic GVHD was 6.8% at 24 months. The relapse rate for patients in CR1 was 17.4% at 36 months. With a median follow-up of 34 months, DFS for all patients was 82% at 6 months, and DFS for patients in CR1 was 72.8% at 12 months and 58% at 36 months. HCT after myeloablative chemoradiotherapy can be performed in a multicenter setting using a uniform method of TCD, resulting in a low risk of extensive chronic GVHD and relapse for patients with AML in CR1.","Clinical Trial, Phase II",3265.0,87.0,Graft-versus-host disease GVHD is most effectively prevented by ex vivo T cell depletion TCD of the allograft but its role in the treatment of patients undergoing allogeneic hematopoietic cell transplantation HCT for acute myelogenous AML in complete remission CR remains unclear We performed a phase 2 single-arm multicenter study to evaluate the role of TCD in AML patients in CR1 or CR2 up to age 65 years The primary objective was to achieve a disease-free survival DFS rate of 75 at 6 months posttransplantation A total of 44 patients with AML in CR1 n 37 or CR2 n 7 with a median age of 48.5 years range 21-59 years received myeloablative chemotherapy and fractionated total body irradiation 1375 cGy followed by immunomagnetically selected CD34-enriched T celldepleted allografts from HLA-identical siblings No pharmacologic GVHD prophylaxis was given All patients engrafted The incidence of acute GVHD grade II-IV was 22.7 and the incidence of extensive chronic GVHD was 6.8 at 24 months The relapse rate for patients in CR1 was 17.4 at 36 months With a median follow-up of 34 months DFS for all patients was 82 at 6 months and DFS for patients in CR1 was 72.8 at 12 months and 58 at 36 months HCT after myeloablative chemoradiotherapy can be performed in a multicenter setting using a uniform method of TCD resulting in a low risk of extensive chronic GVHD and relapse for patients with AML in CR1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1599, 185, 1204, 34, 1562, 16, 96, 1856, 3902, 20, 2581, 386, 102, 31, 2286, 8827, 1, 3, 9568, 84, 211, 200, 4, 3, 24, 1, 7, 479, 1063, 1007, 31, 497, 1085, 9, 286, 2194, 329, 4, 236, 734, 684, 469, 1200, 21, 173, 8, 124, 18, 226, 475, 1570, 45, 6, 376, 3, 200, 1, 8827, 4, 329, 7, 4, 4516, 15, 7865, 126, 6, 89, 556, 60, 3, 86, 461, 10, 6, 1359, 8, 34, 115, 25, 1010, 116, 1, 481, 28, 49, 53, 8046, 8, 181, 1, 584, 7, 5, 329, 4, 4516, 78, 567, 15, 7865, 78, 67, 5, 8, 52, 89, 1, 576, 33, 60, 184, 239, 728, 60, 103, 3246, 56, 2, 3950, 181, 642, 1104, 26164, 3071, 370, 20, 24451, 715, 2215, 2220, 102, 59837, 10586, 29, 1160, 3038, 2758, 77, 2788, 1562, 2049, 10, 447, 62, 7, 6914, 3, 287, 1, 286, 1562, 88, 215, 478, 10, 350, 67, 2, 3, 287, 1, 1344, 442, 1562, 10, 49, 66, 28, 259, 53, 3, 429, 116, 9, 7, 4, 4516, 10, 269, 39, 28, 511, 53, 5, 8, 52, 166, 126, 1, 562, 53, 1010, 9, 62, 7, 10, 878, 28, 49, 53, 2, 1010, 9, 7, 4, 4516, 10, 720, 66, 28, 133, 53, 2, 717, 28, 511, 53, 1085, 50, 3246, 1464, 122, 40, 173, 4, 8, 1570, 546, 75, 8, 3490, 596, 1, 8827, 1113, 4, 8, 154, 43, 1, 1344, 442, 1562, 2, 429, 9, 7, 5, 329, 4, 4516]",1407.0,21320619,270
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2011-02-01,"The advent of imatinib has dramatically improved outcomes in patients with chronic myelogenous leukemia (CML). It has become the standard of care for all patients with newly diagnosed chronic-phase CML based on its successful induction of durable responses in most patients. However, its use is complicated by the development of resistance in some patients. Dose escalation might overcome this resistance if detected early. The second-generation tyrosine kinase inhibitors (TKIs) dasatinib and nilotinib provide effective therapeutic options for managing patients resistant or intolerant to imatinib. Recent studies have shown that dasatinib and nilotinib provide quicker and potentially better responses than standard-dose imatinib when used as a first-line treatment. The goal of therapy for patients with CML is the achievement of a complete cytogenetic response, and eventually a major molecular response, to prevent disease progression to accelerated or blast phase. Selecting the appropriate TKI depends on many factors, including disease phase, primary or secondary resistance to TKI, the agent's side effect profile and its relative effectiveness against BCR-ABL mutations, and the patient's tolerance to therapy. In October 2010, NCCN organized a task force consisting of a panel of experts from NCCN Member Institutions with expertise in the management of patients with CML to discuss these issues. This report provides recommendations regarding the selection of TKI therapy for the management of patients with CML based on the evaluation of available published clinical data and expert opinion among the task force members.",Journal Article,3276.0,36.0,The advent of imatinib has dramatically improved outcomes in patients with chronic myelogenous CML It has become the standard of care for all patients with newly diagnosed chronic-phase CML based on its successful induction of durable responses in most patients However its use is complicated by the development of resistance in some patients Dose escalation might overcome this resistance if detected early The second-generation tyrosine kinase inhibitors TKIs dasatinib and nilotinib provide effective therapeutic options for managing patients resistant or intolerant to imatinib Recent studies have shown that dasatinib and nilotinib provide quicker and potentially better responses than standard-dose imatinib when used as a first-line treatment The goal of therapy for patients with CML is the achievement of a complete cytogenetic response and eventually a major molecular response to prevent disease progression to accelerated or blast phase Selecting the appropriate TKI depends on many factors including disease phase primary or secondary resistance to TKI the agent 's side effect profile and its relative effectiveness against BCR-ABL mutations and the patient 's tolerance to therapy In October 2010 NCCN organized a task force consisting of a panel of experts from NCCN Member Institutions with expertise in the management of patients with CML to discuss these issues This report provides recommendations regarding the selection of TKI therapy for the management of patients with CML based on the evaluation of available published clinical data and expert opinion among the task force members,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 4114, 1, 577, 71, 2729, 231, 123, 4, 7, 5, 442, 2194, 903, 192, 71, 1417, 3, 260, 1, 165, 9, 62, 7, 5, 732, 265, 442, 124, 903, 90, 23, 211, 1401, 504, 1, 1480, 253, 4, 96, 7, 137, 211, 119, 16, 4286, 20, 3, 193, 1, 251, 4, 476, 7, 61, 1125, 822, 1768, 26, 251, 492, 530, 191, 3, 419, 914, 564, 216, 222, 1671, 1674, 2, 2638, 377, 323, 189, 838, 9, 3969, 7, 436, 15, 4944, 6, 577, 435, 94, 47, 443, 17, 1674, 2, 2638, 377, 20573, 2, 751, 380, 253, 76, 260, 61, 577, 198, 95, 22, 8, 157, 328, 24, 3, 1326, 1, 36, 9, 7, 5, 903, 16, 3, 5088, 1, 8, 236, 1266, 51, 2, 3124, 8, 458, 219, 51, 6, 1682, 34, 91, 6, 2241, 15, 3112, 124, 3675, 3, 870, 1379, 3828, 23, 445, 130, 141, 34, 124, 86, 15, 568, 251, 6, 1379, 3, 420, 292, 1152, 254, 800, 2, 211, 580, 1236, 480, 1062, 1425, 138, 2, 3, 69, 292, 2614, 6, 36, 4, 2551, 1120, 1944, 7511, 8, 3488, 4380, 2273, 1, 8, 993, 1, 3186, 29, 1944, 2693, 1764, 5, 4935, 4, 3, 284, 1, 7, 5, 903, 6, 1139, 46, 1553, 26, 414, 777, 883, 666, 3, 881, 1, 1379, 36, 9, 3, 284, 1, 7, 5, 903, 90, 23, 3, 451, 1, 390, 983, 38, 74, 2, 2005, 3564, 107, 3, 3488, 4380, 1684]",1605.0,21335443,130
Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans.,The Journal of clinical investigation,J. Clin. Invest.,2011-03-14,"Donor lymphocyte infusion (DLI), whereby donor mononuclear cells are infused into patients, is one of the few effective immunotherapeutic strategies that generate long-lasting tumor remissions. We previously demonstrated that chronic myelogenous leukemia (CML) patients treated with DLI develop high-titer plasma antibodies specific for CML-associated antigens, the majority of which have been reported to bind nucleic acids These observations led us to predict that circulating antibody-antigen complexes in DLI-responsive patients carry nucleic acids that can engage innate immune sensors. Consistent with this, we report here that post-DLI plasma from 5 CML patients that responded to DLI treatment induced massive upregulation of MIP-1, IP-10, and IFN- in normal blood mononuclear cells. Importantly, this was not observed with plasma obtained before DLI and from DLI nonresponders and imatinib-treated patients. This endogenous immunostimulatory activity required nucleic acid and protein for its adjuvant effect and activated antigen-presenting cells through the RNA and DNA sensors TLR8 and TLR9. Presence of the immunoglobulin Fc receptor CD32 enhanced cellular responses, suggesting that immunoglobulins associate with this activity. Finally, a TLR-induced expression signature was detectable in post-DLI but not pre-DLI blood, consistent with an active circulating TLR8/9-stimulating factor. We have therefore demonstrated that effective tumor immunity correlates with the presence of endogenous nucleic acid-immunoglobulin complexes in patient plasma, thus providing a putative mechanism for the induction of potent antigen-specific immunity against malignant cells.",Clinical Trial,3235.0,15.0,Donor lymphocyte infusion DLI whereby donor mononuclear cells are infused into patients is one of the few effective immunotherapeutic strategies that generate long-lasting tumor remissions We previously demonstrated that chronic myelogenous CML patients treated with DLI develop high-titer plasma antibodies specific for CML-associated antigens the majority of which have been reported to bind nucleic acids These observations led us to predict that circulating antibody-antigen complexes in DLI-responsive patients carry nucleic acids that can engage innate immune sensors Consistent with this we report here that post-DLI plasma from 5 CML patients that responded to DLI treatment induced massive upregulation of MIP-1 IP-10 and IFN- in normal blood mononuclear cells Importantly this was not observed with plasma obtained before DLI and from DLI nonresponders and imatinib-treated patients This endogenous immunostimulatory activity required nucleic acid and protein for its adjuvant effect and activated antigen-presenting cells through the RNA and DNA sensors TLR8 and TLR9 Presence of the immunoglobulin Fc receptor CD32 enhanced cellular responses suggesting that immunoglobulins associate with this activity Finally a TLR-induced expression signature was detectable in post-DLI but not pre-DLI blood consistent with an active circulating TLR8/9-stimulating factor We have therefore demonstrated that effective tumor immunity correlates with the presence of endogenous nucleic acid-immunoglobulin complexes in patient plasma thus providing a putative mechanism for the induction of potent antigen-specific immunity against malignant cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1488, 1448, 904, 4676, 6131, 1488, 3041, 37, 32, 4524, 237, 7, 16, 104, 1, 3, 1021, 323, 3222, 422, 17, 2562, 319, 3443, 30, 3166, 21, 373, 264, 17, 442, 2194, 903, 7, 73, 5, 4676, 690, 64, 8444, 554, 890, 112, 9, 903, 41, 1575, 3, 686, 1, 92, 47, 85, 210, 6, 4060, 7895, 4562, 46, 2172, 836, 843, 6, 678, 17, 1033, 548, 448, 3817, 4, 4676, 2443, 7, 3542, 7895, 4562, 17, 122, 7430, 3939, 250, 18867, 925, 5, 26, 21, 414, 467, 17, 539, 4676, 554, 29, 33, 903, 7, 17, 2211, 6, 4676, 24, 277, 7929, 2218, 1, 7076, 3305, 2445, 79, 2, 1256, 2014, 4, 295, 315, 3041, 37, 1859, 26, 10, 44, 164, 5, 554, 683, 348, 4676, 2, 29, 4676, 4498, 2, 577, 73, 7, 26, 2682, 9374, 128, 616, 7895, 971, 2, 178, 9, 211, 249, 254, 2, 735, 448, 1656, 37, 298, 3, 893, 2, 261, 18867, 18599, 2, 11202, 463, 1, 3, 2593, 4127, 153, 28849, 651, 763, 253, 802, 17, 13373, 6446, 5, 26, 128, 1368, 8, 8701, 277, 55, 1651, 10, 2083, 4, 539, 4676, 84, 44, 671, 4676, 315, 925, 5, 35, 544, 1033, 18599, 83, 2122, 161, 21, 47, 673, 264, 17, 323, 30, 1604, 1871, 5, 3, 463, 1, 2682, 7895, 971, 2593, 3817, 4, 69, 554, 631, 1736, 8, 2743, 670, 9, 3, 504, 1, 1157, 448, 112, 1604, 480, 393, 37]",1647.0,21403403,54
"Nilotinib: a novel, selective tyrosine kinase inhibitor.",Seminars in oncology,Semin. Oncol.,2011-04-01,"The development of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myelogenous leukemia (CML) was based on the discovery that CML stem and progenitor cells overexpress the abnormal fusion protein kinase BCR-ABL. The prototype TKI, imatinib, selectively inhibits BCR-ABL, as well as several other kinases, including stem cell factor receptor (KIT), discoidin domain receptor (DDR), platelet-derived growth factor receptor (PDGFR), and colony-stimulating factor receptor-1 (CSF-1R). Although the management of CML improved dramatically with the introduction of imatinib, not all patients benefit from treatment because of resistance or intolerance. Consequently, research efforts have focused on developing more potent TKIs with the ability to circumvent imatinib resistance. Nilotinib, a second-generation oral TKI, was rationally designed based on the crystal structure of imatinib to be highly active against a wide range of imatinib-resistant BCR-ABL mutants and is approved for the treatment of newly diagnosed or imatinib-resistant or -intolerant CML, and has shown superiority over imatinib in first-line treatment for newly diagnosed CML. Furthermore, the activity of nilotinib against KIT and PDGFR has led to its evaluation in advanced gastrointestinal stromal tumors (GIST). The purpose of this review is to describe the development of nilotinib, providing a structural explanation for the differential activity of nilotinib and imatinib in GIST. Activity of nilotinib against KIT and PDGFR and emerging evidence of differences in cellular uptake between nilotinib and imatinib are discussed.",Journal Article,3217.0,67.0,The development of tyrosine kinase inhibitors TKIs for the treatment of chronic myelogenous CML was based on the discovery that CML stem and progenitor cells overexpress the abnormal fusion protein kinase BCR-ABL The prototype TKI imatinib selectively inhibits BCR-ABL as well as several other kinases including stem cell factor receptor KIT discoidin domain receptor DDR platelet-derived growth factor receptor PDGFR and colony-stimulating factor receptor-1 CSF-1R Although the management of CML improved dramatically with the introduction of imatinib not all patients benefit from treatment because of resistance or intolerance Consequently research efforts have focused on developing more potent TKIs with the ability to circumvent imatinib resistance Nilotinib a second-generation oral TKI was rationally designed based on the crystal structure of imatinib to be highly active against a wide range of imatinib-resistant BCR-ABL mutants and is approved for the treatment of newly diagnosed or imatinib-resistant or -intolerant CML and has shown superiority over imatinib in first-line treatment for newly diagnosed CML Furthermore the activity of nilotinib against KIT and PDGFR has led to its evaluation in advanced stromal tumors GIST The purpose of this review is to describe the development of nilotinib providing a structural explanation for the differential activity of nilotinib and imatinib in GIST Activity of nilotinib against KIT and PDGFR and emerging evidence of differences in cellular uptake between nilotinib and imatinib are discussed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[3, 193, 1, 564, 216, 222, 1671, 9, 3, 24, 1, 442, 2194, 903, 10, 90, 23, 3, 1574, 17, 903, 452, 2, 2520, 37, 5612, 3, 1668, 1212, 178, 216, 1062, 1425, 3, 8743, 1379, 577, 2382, 1576, 1062, 1425, 22, 149, 22, 392, 127, 1549, 141, 452, 31, 161, 153, 1164, 21654, 1398, 153, 5630, 1596, 526, 129, 161, 153, 4103, 2, 1975, 2122, 161, 153, 14, 1211, 2994, 242, 3, 284, 1, 903, 231, 2729, 5, 3, 2456, 1, 577, 44, 62, 7, 247, 29, 24, 408, 1, 251, 15, 5266, 3244, 389, 1413, 47, 1649, 23, 931, 80, 1157, 1671, 5, 3, 801, 6, 8602, 577, 251, 2638, 8, 419, 914, 518, 1379, 10, 6352, 1114, 90, 23, 3, 9197, 2772, 1, 577, 6, 40, 561, 544, 480, 8, 1019, 184, 1, 577, 436, 1062, 1425, 3423, 2, 16, 850, 9, 3, 24, 1, 732, 265, 15, 577, 436, 15, 4944, 903, 2, 71, 443, 5233, 252, 577, 4, 157, 328, 24, 9, 732, 265, 903, 798, 3, 128, 1, 2638, 480, 1164, 2, 7458, 71, 836, 6, 211, 451, 4, 131, 1126, 57, 1394, 3, 743, 1, 26, 206, 16, 6, 897, 3, 193, 1, 2638, 1736, 8, 3281, 6603, 9, 3, 1777, 128, 1, 2638, 2, 577, 4, 1394, 128, 1, 2638, 480, 1164, 2, 4103, 2, 1478, 241, 1, 362, 4, 763, 1135, 59, 2638, 2, 577, 32, 1588]",1555.0,21419934,52
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2011-04-07,"The purpose of this study was to determine whether histone deacetylase (HDAC) inhibitors (HDACI) such as vorinostat or entinostat (SNDX-275) could increase the lethality of the dual Bcr/Abl-Aurora kinase inhibitor KW-2449 in various Bcr/Abl(+) human leukemia cells, including those resistant to imatinib mesylate (IM). Bcr/Abl(+) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) cells, including those resistant to IM (T315I, E255K), were exposed to KW-2449 in the presence or absence of vorinostat or SNDX-275, after which apoptosis and effects on signaling pathways were examined. In vivo studies combining HDACIs and KW2449 were carried out by using a systemic IM-resistant ALL xenograft model. Coadministration of HDACIs synergistically increased KW-2449 lethality in vitro in multiple CML and Ph(+) ALL cell types including human IM resistant cells (e.g., BV-173/E255K and Adult/T315I). Combined treatment resulted in inactivation of Bcr/Abl and downstream targets (e.g., STAT5 and CRKL), as well as increased reactive oxygen species (ROS) generation and DNA damage (H2A.X). The latter events and cell death were significantly attenuated by free radical scavengers (TBAP). Increased lethality was also observed in primary CD34(+) cells from patients with CML, but not in normal CD34(+) cells. Finally, minimally active vorinostat or SNDX275 doses markedly increased KW2449 antitumor effects and significantly prolonged the survival of murine xenografts bearing IM-resistant ALL cells (BV173/E255K). HDACIs increase KW-2449 lethality in Bcr/Abl(+) cells in association with inhibition of Bcr/Abl, generation of ROS, and induction of DNA damage. This strategy preferentially targets primary Bcr/Abl(+) hematopoietic cells and exhibits enhanced in vivo activity. Combining KW-2449 with HDACIs warrants attention in IM-resistant Bcr/Abl(+) leukemias.",Journal Article,3211.0,55.0,The purpose of this study was to determine whether histone deacetylase HDAC inhibitors HDACI such as vorinostat or entinostat SNDX-275 could increase the lethality of the dual Bcr/Abl-Aurora kinase inhibitor KW-2449 in various Bcr/Abl human cells including those resistant to imatinib mesylate IM Bcr/Abl chronic myelogenous CML and acute lymphoblastic ALL cells including those resistant to IM T315I E255K were exposed to KW-2449 in the presence or absence of vorinostat or SNDX-275 after which apoptosis and effects on signaling pathways were examined In vivo studies combining HDACIs and KW2449 were carried out by using a systemic IM-resistant ALL xenograft model Coadministration of HDACIs synergistically increased KW-2449 lethality in vitro in multiple CML and Ph ALL cell types including human IM resistant cells e.g. BV-173/E255K and Adult/T315I Combined treatment resulted in inactivation of Bcr/Abl and downstream targets e.g. STAT5 and CRKL as well as increased reactive oxygen species ROS generation and DNA damage H2A.X The latter events and cell death were significantly attenuated by free radical scavengers TBAP Increased lethality was also observed in primary CD34 cells from patients with CML but not in normal CD34 cells Finally minimally active vorinostat or SNDX275 doses markedly increased KW2449 antitumor effects and significantly prolonged the survival of murine xenografts bearing IM-resistant ALL cells BV173/E255K HDACIs increase KW-2449 lethality in Bcr/Abl cells in association with inhibition of Bcr/Abl generation of ROS and induction of DNA damage This strategy preferentially targets primary Bcr/Abl hematopoietic cells and exhibits enhanced in vivo activity Combining KW-2449 with HDACIs warrants attention in IM-resistant Bcr/Abl leukemias,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 223, 317, 1508, 2732, 2654, 222, 4265, 225, 22, 2371, 15, 7616, 16941, 5620, 359, 344, 3, 3266, 1, 3, 1828, 1062, 1425, 4095, 216, 230, 10963, 23890, 4, 747, 1062, 1425, 171, 37, 141, 135, 436, 6, 577, 2347, 2820, 1062, 1425, 442, 2194, 903, 2, 286, 1275, 62, 37, 141, 135, 436, 6, 2820, 6184, 16677, 11, 2234, 6, 10963, 23890, 4, 3, 463, 15, 1127, 1, 2371, 15, 16941, 5620, 50, 92, 351, 2, 176, 23, 314, 460, 11, 409, 4, 386, 94, 1525, 6250, 2, 46521, 11, 2629, 1205, 20, 75, 8, 403, 2820, 436, 62, 1330, 202, 5777, 1, 6250, 4240, 101, 10963, 23890, 3266, 4, 439, 4, 232, 903, 2, 2058, 62, 31, 630, 141, 171, 2820, 436, 37, 563, 499, 3835, 5785, 16677, 2, 780, 6184, 397, 24, 627, 4, 2297, 1, 1062, 1425, 2, 1489, 637, 563, 499, 5517, 2, 13765, 22, 149, 22, 101, 2163, 2848, 2915, 2609, 914, 2, 261, 1350, 25344, 1006, 3, 3286, 281, 2, 31, 273, 11, 97, 2656, 20, 115, 711, 26237, 28455, 101, 3266, 10, 120, 164, 4, 86, 2215, 37, 29, 7, 5, 903, 84, 44, 4, 295, 2215, 37, 1368, 2144, 544, 2371, 15, 60007, 415, 2195, 101, 46521, 579, 176, 2, 97, 1069, 3, 25, 1, 1471, 1348, 1894, 2820, 436, 62, 37, 46522, 16677, 6250, 344, 10963, 23890, 3266, 4, 1062, 1425, 37, 4, 248, 5, 297, 1, 1062, 1425, 914, 1, 2609, 2, 504, 1, 261, 1350, 26, 692, 3509, 637, 86, 1062, 1425, 1007, 37, 2, 4273, 651, 4, 386, 128, 1525, 10963, 23890, 5, 6250, 2782, 2111, 4, 2820, 436, 1062, 1425, 2792]",1777.0,21474579,82
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2011-07-11,"Different definitions of progression-free survival (PFS) and event-free survival (EFS) may result in perceived differences in outcomes with tyrosine kinase inhibitor (TKI) therapies in chronic myelogenous leukemia (CML). We analyzed the outcome of 435 patients with early chronic-phase, Philadelphia chromosome-positive CML treated with imatinib (n = 281), nilotinib (n = 78), and dasatinib (n = 76) using definitions of PFS and EFS used in the International Randomized Study of Interferon Versus STI571 (IRIS), Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENEST-nd), Dasatinib Versus Imatinib Study in Treatment-Nave CML Patients (DASISION), and MD Anderson Cancer Center (MDACC) trials. Definitions for EFS-IRIS, time without progression in ENEST-nd, PFS-DASISION, and EFS-MDACC were as previously reported. The EFS-MDACC considered an event any instance of toxicity or death from any cause on or off therapy (if not counted before death as progression/event). Of the 435 patients, 123 (28%) were taken off TKI therapy (resistance/loss of response, n = 33; blastic phase on TKI therapy, n = 6; intolerance/toxicity, n = 29; other causes, n = 55). Thirty-three patients (7.6%) have died; eight patients died on TKI therapy, two patients died within 60 days of being off TKIs, and 23 patients died after being off TKIs for more than 60 days. Of the 33 deaths, 19 deaths (eight deaths on TKI, two deaths within 60 days, and nine deaths off for resistance/relapse/transformation) would be counted as progression/events on the IRIS/ENEST-nd/DASISION studies, whereas 14 deaths would be censored at time off TKI. On the basis of the four definitions used by IRIS, ENEST-nd, DASISION, and MDACC trials, the corresponding 5-year PFS/EFS rates were 96%, 90%, 89%, and 81%. Uniform definitions of PFS and EFS are needed to compare the long-term efficacy and potential use of different TKIs in CML.",Journal Article,3116.0,40.0,Different definitions of progression-free survival PFS and event-free survival EFS may result in perceived differences in outcomes with tyrosine kinase inhibitor TKI therapies in chronic myelogenous CML We analyzed the outcome of 435 patients with early chronic-phase Philadelphia chromosome-positive CML treated with imatinib n 281 nilotinib n 78 and dasatinib n 76 using definitions of PFS and EFS used in the International Randomized Study of Interferon Versus STI571 IRIS Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients ENEST-nd Dasatinib Versus Imatinib Study in Treatment-Nave CML Patients DASISION and MD Anderson Cancer Center MDACC trials Definitions for EFS-IRIS time without progression in ENEST-nd PFS-DASISION and EFS-MDACC were as previously reported The EFS-MDACC considered an event any instance of toxicity or death from any cause on or off therapy if not counted before death as progression/event Of the 435 patients 123 28 were taken off TKI therapy resistance/loss of response n 33 blastic phase on TKI therapy n 6 intolerance/toxicity n 29 other causes n 55 Thirty-three patients 7.6 have died eight patients died on TKI therapy two patients died within 60 days of being off TKIs and 23 patients died after being off TKIs for more than 60 days Of the 33 deaths 19 deaths eight deaths on TKI two deaths within 60 days and nine deaths off for resistance/relapse/transformation would be counted as progression/events on the IRIS/ENEST-nd/DASISION studies whereas 14 deaths would be censored at time off TKI On the basis of the four definitions used by IRIS ENEST-nd DASISION and MDACC trials the corresponding 5-year PFS/EFS rates were 96 90 89 and 81 Uniform definitions of PFS and EFS are needed to compare the long-term efficacy and potential use of different TKIs in CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[338, 3833, 1, 91, 115, 25, 300, 2, 774, 115, 25, 1683, 68, 757, 4, 2588, 362, 4, 123, 5, 564, 216, 230, 1379, 235, 4, 442, 2194, 903, 21, 311, 3, 228, 1, 9002, 7, 5, 191, 442, 124, 3006, 1170, 109, 903, 73, 5, 577, 78, 8970, 2638, 78, 833, 2, 1674, 78, 846, 75, 3833, 1, 300, 2, 1683, 95, 4, 3, 944, 384, 45, 1, 1688, 185, 5735, 15950, 1435, 2638, 209, 2, 367, 4, 38, 143, 732, 265, 7, 35152, 7175, 1674, 185, 577, 45, 4, 24, 2809, 903, 7, 19256, 2, 2244, 1929, 12, 574, 7412, 143, 3833, 9, 1683, 15950, 98, 187, 91, 4, 35152, 7175, 300, 19256, 2, 1683, 7412, 11, 22, 373, 210, 3, 1683, 7412, 515, 35, 774, 500, 10642, 1, 155, 15, 273, 29, 500, 708, 23, 15, 1889, 36, 492, 44, 12252, 348, 273, 22, 91, 774, 1, 3, 9002, 7, 2698, 339, 11, 1633, 1889, 1379, 36, 251, 407, 1, 51, 78, 466, 6529, 124, 23, 1379, 36, 78, 49, 5266, 155, 78, 462, 127, 1626, 78, 614, 977, 169, 7, 67, 49, 47, 1016, 659, 7, 1016, 23, 1379, 36, 100, 7, 1016, 262, 335, 162, 1, 486, 1889, 1671, 2, 382, 7, 1016, 50, 486, 1889, 1671, 9, 80, 76, 335, 162, 1, 3, 466, 1043, 326, 1043, 659, 1043, 23, 1379, 100, 1043, 262, 335, 162, 2, 762, 1043, 1889, 9, 251, 429, 1392, 688, 40, 12252, 22, 91, 281, 23, 3, 15950, 35152, 7175, 19256, 94, 547, 213, 1043, 688, 40, 7534, 28, 98, 1889, 1379, 23, 3, 877, 1, 3, 294, 3833, 95, 20, 15950, 35152, 7175, 19256, 2, 7412, 143, 3, 1734, 33, 111, 300, 1683, 151, 11, 921, 424, 887, 2, 865, 3490, 3833, 1, 300, 2, 1683, 32, 575, 6, 932, 3, 319, 337, 209, 2, 174, 119, 1, 338, 1671, 4, 903]",1830.0,21747082,119
"Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.",PloS one,PLoS ONE,2011-07-08,"The epigenetic impact of DNA methylation in chronic myelogenous leukemia (CML) is not completely understood. To elucidate its role we analyzed 120 patients with CML for methylation of promoter-associated CpG islands of 10 genes. Five genes were identified by DNA methylation screening in the K562 cell line and 3 genes in patients with myeloproliferative neoplasms. The CDKN2B gene was selected for its frequent methylation in myeloid malignancies and ABL1 as the target of BCR-ABL translocation. Thirty patients were imatinib-nave (mostly treated by interferon-alpha before the imatinib era), 30 were imatinib-responsive, 50 were imatinib-resistant, and 10 were imatinib-intolerant. We quantified DNA methylation by bisulfite pyrosequencing. The average number of methylated genes was 4.5 per patient in the chronic phase, increasing significantly to 6.2 in the accelerated and 6.4 in the blastic phase. Higher numbers of methylated genes were also observed in patients resistant or intolerant to imatinib. These patients also showed almost exclusive methylation of a putative transporter OSCP1. Abnormal methylation of a Src suppressor gene PDLIM4 was associated with shortened survival independently of CML stage and imatinib responsiveness. We conclude that aberrant DNA methylation is associated with CML progression and that DNA methylation could be a marker associated with imatinib resistance. Finally, DNA methylation of PDLIM4 may help identify a subset of CML patients that would benefit from treatment with Src/Abl inhibitors.",Journal Article,3119.0,73.0,The epigenetic impact of DNA methylation in chronic myelogenous CML is not completely understood To elucidate its role we analyzed 120 patients with CML for methylation of promoter-associated CpG islands of 10 genes Five genes were identified by DNA methylation screening in the K562 cell line and 3 genes in patients with neoplasms The CDKN2B gene was selected for its frequent methylation in myeloid malignancies and ABL1 as the target of BCR-ABL translocation Thirty patients were imatinib-nave mostly treated by interferon-alpha before the imatinib era 30 were imatinib-responsive 50 were imatinib-resistant and 10 were imatinib-intolerant We quantified DNA methylation by bisulfite pyrosequencing The average number of methylated genes was 4.5 per patient in the chronic phase increasing significantly to 6.2 in the accelerated and 6.4 in the blastic phase Higher numbers of methylated genes were also observed in patients resistant or intolerant to imatinib These patients also showed almost exclusive methylation of a putative transporter OSCP1 Abnormal methylation of a Src suppressor gene PDLIM4 was associated with shortened survival independently of CML stage and imatinib responsiveness We conclude that aberrant DNA methylation is associated with CML progression and that DNA methylation could be a marker associated with imatinib resistance Finally DNA methylation of PDLIM4 may help identify a subset of CML patients that would benefit from treatment with Src/Abl inhibitors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1418, 345, 1, 261, 569, 4, 442, 2194, 903, 16, 44, 2500, 1784, 6, 3061, 211, 200, 21, 311, 2031, 7, 5, 903, 9, 569, 1, 973, 41, 2075, 6046, 1, 79, 214, 365, 214, 11, 108, 20, 261, 569, 453, 4, 3, 5208, 31, 328, 2, 27, 214, 4, 7, 5, 1179, 3, 12634, 145, 10, 715, 9, 211, 908, 569, 4, 533, 441, 2, 3557, 22, 3, 283, 1, 1062, 1425, 2006, 977, 7, 11, 577, 2809, 2754, 73, 20, 1688, 950, 348, 3, 577, 1713, 201, 11, 577, 2443, 212, 11, 577, 436, 2, 79, 11, 577, 4944, 21, 2790, 261, 569, 20, 6181, 6031, 3, 1011, 207, 1, 2963, 214, 10, 39, 33, 379, 69, 4, 3, 442, 124, 602, 97, 6, 49, 18, 4, 3, 2241, 2, 49, 39, 4, 3, 6529, 124, 142, 1870, 1, 2963, 214, 11, 120, 164, 4, 7, 436, 15, 4944, 6, 577, 46, 7, 120, 224, 2214, 4804, 569, 1, 8, 2743, 5246, 60351, 1668, 569, 1, 8, 2023, 1245, 145, 46675, 10, 41, 5, 6151, 25, 1042, 1, 903, 82, 2, 577, 3642, 21, 2060, 17, 1898, 261, 569, 16, 41, 5, 903, 91, 2, 17, 261, 569, 359, 40, 8, 952, 41, 5, 577, 251, 1368, 261, 569, 1, 46675, 68, 987, 255, 8, 697, 1, 903, 7, 17, 688, 247, 29, 24, 5, 2023, 1425, 222]",1490.0,21760961,215
Candida albicans cervical lymphadenitis in patients who have acute myeloid leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2011-08-01,We describe two patients with acute myelogenous leukemia who developed cervical lymphadenitis and chronic disseminated infection due to Candida albicans. Candida albicans infection should be considered in leukemic patients with acute lymphadenitis. Evaluation for visceral dissemination is warranted even in the absence of fungemia.,Case Reports,3095.0,2.0,We describe two patients with acute myelogenous who developed lymphadenitis and chronic disseminated infection due to Candida albicans Candida albicans infection should be considered in leukemic patients with acute lymphadenitis Evaluation for visceral dissemination is warranted even in the absence of fungemia,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 897, 100, 7, 5, 286, 2194, 54, 276, 25375, 2, 442, 3605, 930, 520, 6, 13321, 24644, 13321, 24644, 930, 257, 40, 515, 4, 2015, 7, 5, 286, 25375, 451, 9, 2737, 3430, 16, 1197, 871, 4, 3, 1127, 1, 34088]",311.0,21816377,6
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2011-10-11,"The response definitions proposed by the European LeukemiaNet (ELN) are defined on the basis of imatinib front-line therapy. It is unknown whether these definitions apply to patients treated with second-generation tyrosine kinase inhibitors (TKIs). One hundred sixty-seven patients with newly diagnosed chronic myelogenous leukemia (CML) in chronic phase were treated with second-generation TKIs in phase II trials (nilotinib, 81; dasatinib, 86). Median follow-up was 33 months. Event-free survival (EFS) was measured from the start of treatment to the date of loss of complete hematologic response, loss of complete or major cytogenetic response, discontinuation of therapy for toxicity or lack of efficacy, progression to accelerated or blastic phases, or death at any time. Overall, 155 patients (93%) achieved complete cytogenetic response (CCyR), including 146 (87%) with major molecular response (MMR; complete in 46 patients [28%]). According to the ELN definitions, the rates of suboptimal response were 0%, 2%, 1%, and 12% at 3, 6, 12, and 18 months of therapy, respectively. There was no difference in EFS and CCyR duration between patients who achieved CCyR with and without MMR across all the landmark times of 3, 6, 12, and 18 months. The use of second-generation TKIs as initial therapy in CML induces high rates of CCyR at early time points. The ELN definitions of response proposed for imatinib therapy are not applicable in this setting. We propose that achievement of CCyR and partial cytogenetic response at 3 months should be considered optimal and suboptimal responses, respectively. The achievement of MMR offered no advantage over CCyR in defining long-term outcome in patients with newly diagnosed CML treated with second-generation TKIs.","Clinical Trial, Phase II",3024.0,50.0,The response definitions proposed by the European LeukemiaNet ELN are defined on the basis of imatinib front-line therapy It is unknown whether these definitions apply to patients treated with second-generation tyrosine kinase inhibitors TKIs One hundred sixty-seven patients with newly diagnosed chronic myelogenous CML in chronic phase were treated with second-generation TKIs in phase II trials nilotinib 81 dasatinib 86 Median follow-up was 33 months Event-free survival EFS was measured from the start of treatment to the date of loss of complete hematologic response loss of complete or major cytogenetic response discontinuation of therapy for toxicity or lack of efficacy progression to accelerated or blastic phases or death at any time Overall 155 patients 93 achieved complete cytogenetic response CCyR including 146 87 with major molecular response MMR complete in 46 patients 28 According to the ELN definitions the rates of suboptimal response were 0 2 1 and 12 at 3 6 12 and 18 months of therapy respectively There was no difference in EFS and CCyR duration between patients who achieved CCyR with and without MMR across all the landmark times of 3 6 12 and 18 months The use of second-generation TKIs as initial therapy in CML induces high rates of CCyR at early time points The ELN definitions of response proposed for imatinib therapy are not applicable in this setting We propose that achievement of CCyR and partial cytogenetic response at 3 months should be considered optimal and suboptimal responses respectively The achievement of MMR offered no advantage over CCyR in defining long-term outcome in patients with newly diagnosed CML treated with second-generation TKIs,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 51, 3833, 1587, 20, 3, 1865, 10631, 9217, 32, 395, 23, 3, 877, 1, 577, 3007, 328, 36, 192, 16, 860, 317, 46, 3833, 4930, 6, 7, 73, 5, 419, 914, 564, 216, 222, 1671, 104, 1128, 1746, 648, 7, 5, 732, 265, 442, 2194, 903, 4, 442, 124, 11, 73, 5, 419, 914, 1671, 4, 124, 215, 143, 2638, 865, 1674, 868, 52, 166, 126, 10, 466, 53, 774, 115, 25, 1683, 10, 644, 29, 3, 2435, 1, 24, 6, 3, 1244, 1, 407, 1, 236, 813, 51, 407, 1, 236, 15, 458, 1266, 51, 2007, 1, 36, 9, 155, 15, 926, 1, 209, 91, 6, 2241, 15, 6529, 3523, 15, 273, 28, 500, 98, 63, 3735, 7, 966, 513, 236, 1266, 51, 6412, 141, 4909, 912, 5, 458, 219, 51, 2205, 236, 4, 641, 7, 339, 768, 6, 3, 9217, 3833, 3, 151, 1, 3291, 51, 11, 13, 18, 14, 2, 133, 28, 27, 49, 133, 2, 203, 53, 1, 36, 106, 125, 10, 77, 523, 4, 1683, 2, 6412, 654, 59, 7, 54, 513, 6412, 5, 2, 187, 2205, 716, 62, 3, 3829, 1072, 1, 27, 49, 133, 2, 203, 53, 3, 119, 1, 419, 914, 1671, 22, 388, 36, 4, 903, 1516, 64, 151, 1, 6412, 28, 191, 98, 862, 3, 9217, 3833, 1, 51, 1587, 9, 577, 36, 32, 44, 3801, 4, 26, 546, 21, 2548, 17, 5088, 1, 6412, 2, 450, 1266, 51, 28, 27, 53, 257, 40, 515, 665, 2, 3291, 253, 106, 3, 5088, 1, 2205, 2216, 77, 1874, 252, 6412, 4, 2847, 319, 337, 228, 4, 7, 5, 732, 265, 903, 73, 5, 419, 914, 1671]",1692.0,21990394,48
Pigmentary changes in a patient treated with imatinib.,Journal of drugs in dermatology : JDD,J Drugs Dermatol,2011-09-01,"Imatinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase with additional inhibitory effects on platelet derived growth factor (PDGF) receptors alpha and beta, and KIT. It has revolutionized the treatment of adult and pediatric patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML) and is also FDA-approved for KIT-positive advanced gastrointestinal tumor (GIST) and dermatofibrosarcoma protuberans. A wide spectrum of dermatologic toxicities has been associated with this agent, among which a maculopapular rash is the most common event. In addition, a variety of pigmentary abnormalities of the skin and mucosal surfaces have been reported. Hypopigmentation is a well-recognized adverse effect. In contrast, paradoxical hyperpigmentation has only rarely been documented. In this case report we describe imatinib-induced cutaneous hyperpigmentation and graying of hair occurring in the same patient with dermatofibrosarcoma protuberans treated with imatinib.",Case Reports,3064.0,19.0,Imatinib mesylate STI 571 Gleevec Novartis Pharmaceuticals Basel Switzerland is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase with additional inhibitory effects on platelet derived growth factor PDGF receptors alpha and beta and KIT It has revolutionized the treatment of adult and pediatric patients with Philadelphia chromosome positive chronic myelogenous CML and is also FDA-approved for KIT-positive advanced tumor GIST and dermatofibrosarcoma protuberans A wide spectrum of dermatologic toxicities has been associated with this agent among which a maculopapular rash is the most common event In addition a variety of pigmentary abnormalities of the and mucosal surfaces have been reported Hypopigmentation is a well-recognized adverse effect In contrast paradoxical hyperpigmentation has only rarely been documented In this case report we describe imatinib-induced cutaneous hyperpigmentation and graying of hair occurring in the same patient with dermatofibrosarcoma protuberans treated with imatinib,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[577, 2347, 10640, 7846, 8569, 7855, 5888, 21102, 17175, 16, 35, 1428, 390, 564, 216, 230, 17, 637, 8, 2818, 735, 1062, 1425, 564, 216, 5, 402, 1810, 176, 23, 1596, 526, 129, 161, 4546, 1186, 950, 2, 1090, 2, 1164, 192, 71, 5746, 3, 24, 1, 780, 2, 815, 7, 5, 3006, 1170, 109, 442, 2194, 903, 2, 16, 120, 2078, 850, 9, 1164, 109, 131, 30, 1394, 2, 11922, 11923, 8, 1019, 1873, 1, 4722, 385, 71, 85, 41, 5, 26, 420, 107, 92, 8, 16289, 1641, 16, 3, 96, 186, 774, 4, 352, 8, 1362, 1, 18858, 1171, 1, 3, 2, 3068, 8835, 47, 85, 210, 18279, 16, 8, 149, 1904, 290, 254, 4, 748, 9330, 17249, 71, 158, 2416, 85, 1405, 4, 26, 473, 414, 21, 897, 577, 277, 1486, 17249, 2, 60760, 1, 6845, 1821, 4, 3, 827, 69, 5, 11922, 11923, 73, 5, 577]",1071.0,22052279,221
Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2011-10-01,"In the pre-tyrosine kinase (TKI) era, allogeneic stem cell transplant (allo-SCT) was the front-line treatment of choice for young patients with chronic myelogenous leukemia (CML). Today, imatinib is well established as front-line therapy for CML, with excellent long-term outcomes. This has changed the role of allo-SCT and the number of patients undergoing allo-SCT has declined dramatically. Allo-SCT is currently recommended for patients in accelerated/blast phase disease, those who have failed a second-generation TKI and those with TKI-resistant mutations such as T315I. The role of allo-SCT in the management of CML will require continual reappraisal as medical therapies continue to evolve.",Journal Article,3034.0,10.0,In the pre-tyrosine kinase TKI era allogeneic stem cell transplant allo-SCT was the front-line treatment of choice for young patients with chronic myelogenous CML Today imatinib is well established as front-line therapy for CML with excellent long-term outcomes This has changed the role of allo-SCT and the number of patients undergoing allo-SCT has declined dramatically Allo-SCT is currently recommended for patients in accelerated/blast phase disease those who have failed a second-generation TKI and those with TKI-resistant mutations such as T315I The role of allo-SCT in the management of CML will require continual reappraisal as medical therapies continue to evolve,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 3, 671, 564, 216, 1379, 1713, 1063, 452, 31, 941, 2564, 1988, 10, 3, 3007, 328, 24, 1, 1866, 9, 1169, 7, 5, 442, 2194, 903, 5665, 577, 16, 149, 635, 22, 3007, 328, 36, 9, 903, 5, 1503, 319, 337, 123, 26, 71, 2368, 3, 200, 1, 2564, 1988, 2, 3, 207, 1, 7, 479, 2564, 1988, 71, 3054, 2729, 2564, 1988, 16, 694, 793, 9, 7, 4, 2241, 3112, 124, 34, 135, 54, 47, 1551, 8, 419, 914, 1379, 2, 135, 5, 1379, 436, 138, 225, 22, 6184, 3, 200, 1, 2564, 1988, 4, 3, 284, 1, 903, 303, 1353, 9451, 27989, 22, 484, 235, 1906, 6, 4800]",674.0,22054733,7
Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease.,Archives of pathology & laboratory medicine,Arch. Pathol. Lab. Med.,2012-01-01,"Monitoring minimal residual disease by quantitative reverse transcription polymerase chain reaction has proven clinically useful, but as yet there are no Food and Drug Administration-approved tests. Guidelines have been published that provide important information on validation of such tests; however, no practical examples have previously been published. To provide an example of the design and validation of a quantitative reverse transcription polymerase chain reaction test. To describe the approach used by an individual laboratory for development and validation of a laboratory-developed quantitative reverse transcription polymerase chain reaction test for BCR-ABL1 fusion transcripts. Elements of design and analytic validation of a laboratory-developed quantitative molecular test are discussed using quantitative detection of BCR-ABL1 fusion transcripts as an example. Validation of laboratory-developed quantitative molecular tests requires careful planning and execution to adequately address all required analytic performance parameters. How these are addressed depends on the potential for technical errors and confidence required for a given test result. We demonstrate how one laboratory validated and clinically implemented a quantitative BCR-ABL1 assay that can be used for the management of patients with chronic myelogenous leukemia.",Journal Article,2942.0,20.0,Monitoring minimal residual disease by quantitative reverse transcription polymerase chain reaction has proven clinically useful but as yet there are no Food and Drug Administration-approved tests Guidelines have been published that provide important information on validation of such tests however no practical examples have previously been published To provide an example of the design and validation of a quantitative reverse transcription polymerase chain reaction test To describe the approach used by an individual laboratory for development and validation of a laboratory-developed quantitative reverse transcription polymerase chain reaction test for BCR-ABL1 fusion transcripts Elements of design and analytic validation of a laboratory-developed quantitative molecular test are discussed using quantitative detection of BCR-ABL1 fusion transcripts as an example Validation of laboratory-developed quantitative molecular tests requires careful planning and execution to adequately address all required analytic performance parameters How these are addressed depends on the potential for technical errors and confidence required for a given test result We demonstrate how one laboratory validated and clinically implemented a quantitative BCR-ABL1 assay that can be used for the management of patients with chronic myelogenous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1315, 1048, 753, 34, 20, 1156, 1772, 866, 1451, 1260, 1329, 71, 1930, 505, 999, 84, 22, 1145, 125, 32, 77, 1773, 2, 234, 634, 850, 895, 677, 47, 85, 983, 17, 377, 305, 487, 23, 929, 1, 225, 895, 137, 77, 3320, 4416, 47, 373, 85, 983, 6, 377, 35, 2685, 1, 3, 771, 2, 929, 1, 8, 1156, 1772, 866, 1451, 1260, 1329, 412, 6, 897, 3, 353, 95, 20, 35, 797, 1624, 9, 193, 2, 929, 1, 8, 1624, 276, 1156, 1772, 866, 1451, 1260, 1329, 412, 9, 1062, 3557, 1212, 2680, 2531, 1, 771, 2, 5146, 929, 1, 8, 1624, 276, 1156, 219, 412, 32, 1588, 75, 1156, 638, 1, 1062, 3557, 1212, 2680, 22, 35, 2685, 929, 1, 1624, 276, 1156, 219, 895, 1706, 3465, 1349, 2, 16382, 6, 4215, 1539, 62, 616, 5146, 528, 1038, 832, 46, 32, 2814, 3828, 23, 3, 174, 9, 3359, 4612, 2, 307, 616, 9, 8, 447, 412, 757, 21, 608, 832, 104, 1624, 938, 2, 505, 3426, 8, 1156, 1062, 3557, 719, 17, 122, 40, 95, 9, 3, 284, 1, 7, 5, 442, 2194]",1334.0,22208485,11
"How to choose frontline therapy for chronic myelogenous leukemia: so many drugs, not so many patients.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2012-01-01,"With the development of tyrosine kinase inhibitors (TKIs), the management and outlook for patients with chronic myelogenous leukemia (CML) have completely changed over the past 10 years. Imatinib was the first TKI approved to treat CML in the chronic phase. After their initial approval as second-line agents, dasatinib and nilotinib were compared with imatinib in the first-line setting in 2 randomized trials. Both trials showed that therapeutic milestones (complete cytogenetic remission and major molecular remission) occurred earlier with these newer agents, leading to their approval for the treatment of newly diagnosed CML. Therefore, 3 different TKIs are now available for treating CML. Long-term follow-up of patients treated with imatinib shows that the attainment of therapeutic milestones by 12 months of therapy leads to better long-term outcomes. Most patients who experience disease progression on imatinib do so within the first 3 years of therapy. Therefore, one can argue that dasatinib or nilotinib should be chosen to treat patients with newly diagnosed CML. However, these agents do not have the long-term track record of imatinib. This article summarizes the published data and reviews the rationale in choosing the appropriate TKI for first-line treatment of CML in the chronic phase.",Journal Article,2942.0,,With the development of tyrosine kinase inhibitors TKIs the management and outlook for patients with chronic myelogenous CML have completely changed over the past 10 years Imatinib was the first TKI approved to treat CML in the chronic phase After their initial approval as second-line agents dasatinib and nilotinib were compared with imatinib in the first-line setting in 2 randomized trials Both trials showed that therapeutic milestones complete cytogenetic remission and major molecular remission occurred earlier with these newer agents leading to their approval for the treatment of newly diagnosed CML Therefore 3 different TKIs are now available for treating CML Long-term follow-up of patients treated with imatinib shows that the attainment of therapeutic milestones by 12 months of therapy leads to better long-term outcomes Most patients who experience disease progression on imatinib do so within the first 3 years of therapy Therefore one can argue that dasatinib or nilotinib should be chosen to treat patients with newly diagnosed CML However these agents do not have the long-term track record of imatinib This article summarizes the published data and reviews the rationale in choosing the appropriate TKI for first-line treatment of CML in the chronic phase,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[5, 3, 193, 1, 564, 216, 222, 1671, 3, 284, 2, 8628, 9, 7, 5, 442, 2194, 903, 47, 2500, 2368, 252, 3, 1219, 79, 60, 577, 10, 3, 157, 1379, 850, 6, 943, 903, 4, 3, 442, 124, 50, 136, 388, 1814, 22, 419, 328, 183, 1674, 2, 2638, 11, 72, 5, 577, 4, 3, 157, 328, 546, 4, 18, 384, 143, 110, 143, 224, 17, 189, 12118, 236, 1266, 734, 2, 458, 219, 734, 489, 1677, 5, 46, 2246, 183, 1049, 6, 136, 1814, 9, 3, 24, 1, 732, 265, 903, 673, 27, 338, 1671, 32, 1134, 390, 9, 1367, 903, 319, 337, 166, 126, 1, 7, 73, 5, 577, 1949, 17, 3, 7108, 1, 189, 12118, 20, 133, 53, 1, 36, 1940, 6, 380, 319, 337, 123, 96, 7, 54, 730, 34, 91, 23, 577, 1022, 1743, 262, 3, 157, 27, 60, 1, 36, 673, 104, 122, 7004, 17, 1674, 15, 2638, 257, 40, 4695, 6, 943, 7, 5, 732, 265, 903, 137, 46, 183, 1022, 44, 47, 3, 319, 337, 7446, 3237, 1, 577, 26, 946, 2869, 3, 983, 74, 2, 2004, 3, 1728, 4, 5065, 3, 870, 1379, 9, 157, 328, 24, 1, 903, 4, 3, 442, 124]",1277.0,22223871,65
Predictors of response to targeted therapies for gastrointestinal stromal tumors.,Archives of pathology & laboratory medicine,Arch. Pathol. Lab. Med.,2012-01-09,"The inhibition of oncogenic kinase signaling is a successful strategy to treat both hematologic and solid malignancies. Patients with chronic myelogenous leukemia, lung adenocarcinoma, renal cell carcinoma, and gastrointestinal stromal tumors are experiencing tremendous clinical benefits from targeted therapies in the form of kinase inhibitors. These drugs marked a revolution in cancer treatment, not only for their safety and efficacy, but also because they continue to expand our knowledge of the pathophysiology of cancer. To provide a summary of the biologic predictors of gastrointestinal stromal tumor behavior and response to targeted therapies that currently help guide clinical decision making. Published articles pertaining to the diagnosis, molecular genetics, prognostication, clinical behavior, and treatment of gastrointestinal stromal tumors, as well as experiences in a multidisciplinary sarcoma clinic. In gastrointestinal stromal tumors, the strongest predictor of response to targeted therapies is the mutational status of KIT or PDGFRA. Patients whose tumors harbor a KIT exon 11 mutation benefit the most from imatinib mesylate therapy, in terms of response rate, progression-free survival, and overall survival. Conversely, tumors without detectable mutations in either gene (""wild-type"" gastrointestinal stromal tumors) are generally not responsive to imatinib mesylate.",Journal Article,2934.0,27.0,The inhibition of oncogenic kinase signaling is a successful strategy to treat both hematologic and solid malignancies Patients with chronic myelogenous adenocarcinoma cell carcinoma and stromal tumors are experiencing tremendous clinical benefits from targeted therapies in the form of kinase inhibitors These drugs marked a revolution in cancer treatment not only for their safety and efficacy but also because they continue to expand our knowledge of the pathophysiology of cancer To provide a summary of the biologic predictors of stromal tumor behavior and response to targeted therapies that currently help guide clinical decision making Published articles pertaining to the diagnosis molecular genetics prognostication clinical behavior and treatment of stromal tumors as well as experiences in a multidisciplinary clinic In stromal tumors the strongest predictor of response to targeted therapies is the mutational status of KIT or PDGFRA Patients whose tumors harbor a KIT exon 11 mutation benefit the most from imatinib mesylate therapy in terms of response rate progression-free survival and overall survival Conversely tumors without detectable mutations in either gene `` wild-type '' stromal tumors are generally not responsive to imatinib mesylate,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,"[3, 297, 1, 1302, 216, 314, 16, 8, 1401, 692, 6, 943, 110, 813, 2, 537, 441, 7, 5, 442, 2194, 449, 31, 134, 2, 1126, 57, 32, 2985, 6678, 38, 1141, 29, 238, 235, 4, 3, 1297, 1, 216, 222, 46, 600, 2003, 8, 11030, 4, 12, 24, 44, 158, 9, 136, 367, 2, 209, 84, 120, 408, 491, 1906, 6, 4082, 114, 922, 1, 3, 4320, 1, 12, 6, 377, 8, 1962, 1, 3, 1283, 674, 1, 1126, 30, 1710, 2, 51, 6, 238, 235, 17, 694, 987, 1597, 38, 948, 1079, 983, 2384, 6553, 6, 3, 147, 219, 2894, 4260, 38, 1710, 2, 24, 1, 1126, 57, 22, 149, 22, 4031, 4, 8, 1643, 1188, 4, 1126, 57, 3, 3311, 980, 1, 51, 6, 238, 235, 16, 3, 1619, 156, 1, 1164, 15, 4006, 7, 1310, 57, 2760, 8, 1164, 1725, 175, 258, 247, 3, 96, 29, 577, 2347, 36, 4, 1794, 1, 51, 116, 91, 115, 25, 2, 63, 25, 3154, 57, 187, 2083, 138, 4, 361, 145, 955, 267, 522, 1126, 57, 32, 1228, 44, 2443, 6, 577, 2347]",1262.0,22229850,59
Underreporting of myeloid malignancies by United States cancer registries.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2012-01-11,"The recent decrease in myeloid leukemia incidence may be directly attributed to changes in the population-based cancer registries 2001 guidelines, which required the capture of only one malignancy in the myeloid lineage per person and the simultaneous adoption of myelodysplastic syndrome registration in the United States. We constructed four claims-based algorithms to assess myeloid leukemia incidence, applied the algorithms to the 1999-2008 Surveillance Epidemiology and End Results (SEER)-Medicare database, and assessed algorithm validity using SEER-registered cases. Each had moderate sensitivities (75%-94%) and high specificities (>99.0%), with the 2+BCBM algorithm showing the highest specificity. On the basis of the 2+BCBM algorithm, SEER registered only 50% of the acute myelogenous leukemia cases and a third of the chronic myelogenous leukemia (CML) cases. The annual incidence of myeloid leukemia in 2005 was 26 per 100,000 persons 66 years or older, much higher than the 15 per 100,000 reported by SEER using the same sample. Our findings suggest underreporting of myeloid leukemias in SEER by a magnitude of 50% to 70% as well as validate and support the use of the 2+BCBM claims algorithm in identifying myeloid leukemia cases. Use of this algorithm identified a high number of uncaptured myeloid leukemia cases, particularly CML cases. Our results call for the commitment of more resources for centralized cancer registries so that they may improve myeloid leukemia case ascertainment, which would empower policy makers with ability to properly allocate limited health care resources.",Journal Article,2932.0,47.0,"The recent decrease in myeloid incidence may be directly attributed to changes in the population-based cancer registries 2001 guidelines which required the capture of only one malignancy in the myeloid lineage per person and the simultaneous adoption of syndrome registration in the United States We constructed four claims-based algorithms to assess myeloid incidence applied the algorithms to the 1999-2008 Surveillance Epidemiology and End Results SEER -Medicare database and assessed algorithm validity using SEER-registered cases Each had moderate sensitivities 75 -94 and high specificities 99.0 with the 2+BCBM algorithm showing the highest specificity On the basis of the 2+BCBM algorithm SEER registered only 50 of the acute myelogenous cases and a third of the chronic myelogenous CML cases The annual incidence of myeloid in 2005 was 26 per 100,000 persons 66 years or older much higher than the 15 per 100,000 reported by SEER using the same sample Our findings suggest underreporting of myeloid leukemias in SEER by a magnitude of 50 to 70 as well as validate and support the use of the 2+BCBM claims algorithm in identifying myeloid cases Use of this algorithm identified a high number of uncaptured myeloid cases particularly CML cases Our results call for the commitment of more resources for centralized cancer registries so that they may improve myeloid case ascertainment which would empower policy makers with ability to properly allocate limited health care resources",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 435, 775, 4, 533, 287, 68, 40, 1606, 3073, 6, 400, 4, 3, 266, 90, 12, 3768, 1758, 677, 92, 616, 3, 2891, 1, 158, 104, 710, 4, 3, 533, 2542, 379, 2719, 2, 3, 2824, 4350, 1, 681, 3169, 4, 3, 1088, 907, 21, 2776, 294, 2770, 90, 3529, 6, 423, 533, 287, 1498, 3, 3529, 6, 3, 2043, 1375, 617, 1284, 2, 396, 99, 1605, 1378, 609, 2, 275, 2124, 3099, 75, 1605, 1653, 140, 296, 42, 1163, 6202, 481, 960, 2, 64, 10571, 1058, 13, 5, 3, 18, 7517, 2124, 2069, 3, 1076, 1121, 23, 3, 877, 1, 3, 18, 7517, 2124, 1605, 1653, 158, 212, 1, 3, 286, 2194, 140, 2, 8, 1282, 1, 3, 442, 2194, 903, 140, 3, 2114, 287, 1, 533, 4, 1242, 10, 432, 379, 394, 984, 4327, 700, 60, 15, 434, 1802, 142, 76, 3, 167, 379, 394, 984, 210, 20, 1605, 75, 3, 827, 1000, 114, 272, 309, 25408, 1, 533, 2792, 4, 1605, 20, 8, 3131, 1, 212, 6, 431, 22, 149, 22, 2183, 2, 538, 3, 119, 1, 3, 18, 7517, 2770, 2124, 4, 1386, 533, 140, 119, 1, 26, 2124, 108, 8, 64, 207, 1, 60984, 533, 140, 823, 903, 140, 114, 99, 7715, 9, 3, 11082, 1, 80, 2892, 9, 10826, 12, 3768, 1743, 17, 491, 68, 401, 533, 473, 10798, 92, 688, 21138, 4196, 10888, 5, 801, 6, 6785, 22715, 383, 341, 165, 2892]",1488.0,22237987,4
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.,Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2012-02-15,"Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. We investigated this novel combination regimen in patients with Bcr-Abl(+) malignancies. In a phase I dose-escalation study, imatinib was administered orally daily, and flavopiridol by 1h intravenous infusion weekly for 3weeks every 4weeks. Adults with chronic myelogenous leukemia or Philadelphia chromosome-positive acute leukemia were eligible. Patients were divided into two strata based on peripheral blood and bone marrow blast counts. The primary objective was to identify the recommended phase II doses for the combination. Correlative pharmacokinetic and pharmacodynamic studies were also performed. A total of 21 patients received study treatment. Four dose levels were evaluated before the study was closed following the approval of the second-generation Bcr-Abl tyrosine kinase inhibitors (TKIs). Five patients responded, including four sustained responses. Four patients had stable disease. All but one responder, and all patients with stable disease had previously been treated with imatinib. One patient had a complete response sustained for 30months. Changes in expression of phospho-Bcr/Abl, -Stat5, and Mcl-1 were monitored. No major pharmacokinetic interaction was observed. This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans. The combination of flavopiridol and imatinib is tolerable and produces encouraging responses, including in some patients with imatinib-resistant disease.","Clinical Trial, Phase I",2897.0,14.0,Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase however resistance is common Flavopiridol a cyclin-dependent kinase CDK inhibitor down-regulates short-lived anti-apoptotic proteins via inhibition of transcription In preclinical studies flavopiridol synergizes with imatinib to induce apoptosis We investigated this novel combination regimen in patients with Bcr-Abl malignancies In a phase I dose-escalation study imatinib was administered orally daily and flavopiridol by 1 h intravenous infusion weekly for 3 weeks every 4 weeks Adults with chronic myelogenous or Philadelphia chromosome-positive acute were eligible Patients were divided into two strata based on peripheral blood and marrow blast counts The primary objective was to identify the recommended phase II doses for the combination Correlative pharmacokinetic and pharmacodynamic studies were also performed A total of 21 patients received study treatment Four dose levels were evaluated before the study was closed following the approval of the second-generation Bcr-Abl tyrosine kinase inhibitors TKIs Five patients responded including four sustained responses Four patients had stable disease All but one responder and all patients with stable disease had previously been treated with imatinib One patient had a complete response sustained for 30 months Changes in expression of phospho-Bcr/Abl -Stat5 and Mcl-1 were monitored No major pharmacokinetic interaction was observed This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans The combination of flavopiridol and imatinib is tolerable and produces encouraging responses including in some patients with imatinib-resistant disease,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 16, 35, 230, 1, 3, 1062, 1425, 564, 216, 137, 251, 16, 186, 3030, 8, 1226, 470, 216, 3954, 230, 1328, 2468, 978, 4813, 312, 1631, 652, 847, 297, 1, 866, 4, 693, 94, 3030, 10824, 5, 577, 6, 1290, 351, 21, 565, 26, 229, 150, 477, 4, 7, 5, 1062, 1425, 441, 4, 8, 124, 70, 61, 1125, 45, 577, 10, 468, 1428, 391, 2, 3030, 20, 14, 555, 1262, 904, 709, 9, 27, 244, 454, 39, 244, 857, 5, 442, 2194, 15, 3006, 1170, 109, 286, 11, 625, 7, 11, 2176, 237, 100, 5758, 90, 23, 672, 315, 2, 581, 3112, 1911, 3, 86, 461, 10, 6, 255, 3, 793, 124, 215, 415, 9, 3, 150, 3679, 1456, 2, 2424, 94, 11, 120, 173, 8, 181, 1, 239, 7, 103, 45, 24, 294, 61, 148, 11, 194, 348, 3, 45, 10, 3745, 366, 3, 1814, 1, 3, 419, 914, 1062, 1425, 564, 216, 222, 1671, 365, 7, 2211, 141, 294, 2275, 253, 294, 7, 42, 585, 34, 62, 84, 104, 8735, 2, 62, 7, 5, 585, 34, 42, 373, 85, 73, 5, 577, 104, 69, 42, 8, 236, 51, 2275, 9, 201, 53, 400, 4, 55, 1, 3125, 1062, 1425, 5517, 2, 1308, 14, 11, 2909, 77, 458, 1456, 915, 10, 164, 26, 16, 3, 157, 45, 6, 376, 3, 150, 1, 8, 3954, 230, 2, 8, 1379, 4, 3218, 3, 150, 1, 3030, 2, 577, 16, 2668, 2, 4042, 2269, 253, 141, 4, 476, 7, 5, 577, 436, 34]",1694.0,22349810,106
Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.,Blood,Blood,2012-03-09,"Tyrosine kinase inhibitors (TKIs) and reduced intensity conditioning (RIC)/nonmyeloablative (NMA) conditioning hematopoietic cell transplants (HCTs) have changed the therapeutic strategy for chronic myelogenous leukemia (CML) patients. We analyzed post-HCT outcomes of 306 CML patients reported to the Center for International Blood and Marrow Transplant Research aged 40 years and older undergoing RIC/NMA HCT from 2001 to 2007: 117 (38%) aged 40 to 49 years, 119 (39%) 50 to 59 years, and 70 (23%) 60 years or older. The majority (74%) had treatment with imatinib before HCT. At HCT, most patients aged 40 to 49 years were in chronic phase (CP) 1 (74%), compared with 31% aged 60 years or older. Siblings were donors for 56% aged 40 to 49 years; older cohorts had more unrelated donors. The majority received peripheral blood grafts and RIC across all age groups. 3 year overall survival (54%, 52%, and 41%), day + 100 grade II-IV acute GVHD (26%, 32%, and 32%), chronic GVHD (58%, 51%, and 43%), and 1-year treatment-related mortality (18%, 20%, and 13%) were similar across ages. The 3-year relapse incidence (36%, 43%, and 66%) and disease-free survival (35%, 32%, and 16%) were inferior in the oldest cohort. Importantly, for CP1 patients, relapse and disease-free survival were similar across age cohorts. Allogeneic RIC HCT for older patients with CML can control relapse with acceptable toxicity and survival in TKI-exposed CML, especially if still in CP1.",Journal Article,2874.0,38.0,Tyrosine kinase inhibitors TKIs and reduced intensity conditioning RIC /nonmyeloablative NMA conditioning hematopoietic cell transplants HCTs have changed the therapeutic strategy for chronic myelogenous CML patients We analyzed post-HCT outcomes of 306 CML patients reported to the Center for International Blood and Marrow Transplant Research aged 40 years and older undergoing RIC/NMA HCT from 2001 to 2007 117 38 aged 40 to 49 years 119 39 50 to 59 years and 70 23 60 years or older The majority 74 had treatment with imatinib before HCT At HCT most patients aged 40 to 49 years were in chronic phase CP 1 74 compared with 31 aged 60 years or older Siblings were donors for 56 aged 40 to 49 years older cohorts had more unrelated donors The majority received peripheral blood grafts and RIC across all age groups 3 year overall survival 54 52 and 41 day 100 grade II-IV acute GVHD 26 32 and 32 chronic GVHD 58 51 and 43 and 1-year treatment-related mortality 18 20 and 13 were similar across ages The 3-year relapse incidence 36 43 and 66 and disease-free survival 35 32 and 16 were inferior in the oldest cohort Importantly for CP1 patients relapse and disease-free survival were similar across age cohorts Allogeneic RIC HCT for older patients with CML can control relapse with acceptable toxicity and survival in TKI-exposed CML especially if still in CP1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[564, 216, 222, 1671, 2, 405, 837, 1933, 3365, 6094, 10370, 1933, 1007, 31, 4016, 19584, 47, 2368, 3, 189, 692, 9, 442, 2194, 903, 7, 21, 311, 539, 1085, 123, 1, 9974, 903, 7, 210, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 1032, 327, 60, 2, 434, 479, 3365, 10370, 1085, 29, 1758, 6, 1307, 3843, 519, 1032, 327, 6, 739, 60, 4299, 587, 212, 6, 728, 60, 2, 431, 382, 335, 60, 15, 434, 3, 686, 794, 42, 24, 5, 577, 348, 1085, 28, 1085, 96, 7, 1032, 327, 6, 739, 60, 11, 4, 442, 124, 2541, 14, 794, 72, 5, 456, 1032, 335, 60, 15, 434, 2758, 11, 2344, 9, 664, 1032, 327, 6, 739, 60, 434, 736, 42, 80, 2092, 2344, 3, 686, 103, 672, 315, 4713, 2, 3365, 716, 62, 89, 271, 27, 111, 63, 25, 667, 653, 2, 605, 218, 394, 88, 215, 478, 286, 1562, 432, 531, 2, 531, 442, 1562, 717, 725, 2, 601, 2, 14, 111, 24, 139, 282, 203, 179, 2, 233, 11, 288, 716, 2165, 3, 27, 111, 429, 287, 511, 601, 2, 700, 2, 34, 115, 25, 465, 531, 2, 245, 11, 1663, 4, 3, 10849, 180, 1859, 9, 22525, 7, 429, 2, 34, 115, 25, 11, 288, 716, 89, 736, 1063, 3365, 1085, 9, 434, 7, 5, 903, 122, 182, 429, 5, 1595, 155, 2, 25, 4, 1379, 2234, 903, 1093, 492, 1234, 4, 22525]",1362.0,22408257,185
Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells.,Leukemia & lymphoma,Leuk. Lymphoma,2012-04-23,"Survival of chronic myelogenous leukemia (CML) cells is dependent on BCR-ABL kinase, the activity of which is contingent on the level of BCR-ABL protein and the availability of adenosine triphosphate (ATP). We hypothesized that 8-amino-adenosine (8-amino-Ado)-mediated reduction in cellular ATP level and inhibition of mRNA synthesis leading to a decrease in protein level would result in a multifaceted targeting of BCR-ABL. Using K562 cells, we demonstrated that there was a dose- and time-dependent increase in 8-amino-ATP accompanied by a >95% decline in the endogenous ATP pool. In parallel, 8-amino-Ado inhibited RNA synthesis and resulted in a depletion of BCR-ABL transcript. Consistent with this, BCR-ABL and ABL protein levels were also decreased. These effects were associated with the initiation of cell death as visualized by poly(ADP-ribose) polymerase (PARP) cleavage, decreased clonogenicity and greater than additive interaction with imatinib. In imatinib-sensitive and -resistant KBM5 cells, 8-amino-Ado treatment augmented the imatinib effect on growth inhibition.",Journal Article,2829.0,2.0,Survival of chronic myelogenous CML cells is dependent on BCR-ABL kinase the activity of which is contingent on the level of BCR-ABL protein and the availability of adenosine triphosphate ATP We hypothesized that 8-amino-adenosine 8-amino-Ado -mediated reduction in cellular ATP level and inhibition of mRNA synthesis leading to a decrease in protein level would result in a multifaceted targeting of BCR-ABL Using K562 cells we demonstrated that there was a dose- and time-dependent increase in 8-amino-ATP accompanied by a 95 decline in the endogenous ATP pool In parallel 8-amino-Ado inhibited RNA synthesis and resulted in a depletion of BCR-ABL transcript Consistent with this BCR-ABL and ABL protein levels were also decreased These effects were associated with the initiation of cell death as visualized by poly ADP-ribose polymerase PARP cleavage decreased clonogenicity and greater than additive interaction with imatinib In imatinib-sensitive and -resistant KBM5 cells 8-amino-Ado treatment augmented the imatinib effect on growth inhibition,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[25, 1, 442, 2194, 903, 37, 16, 470, 23, 1062, 1425, 216, 3, 128, 1, 92, 16, 15270, 23, 3, 301, 1, 1062, 1425, 178, 2, 3, 2550, 1, 4938, 7345, 3918, 21, 1237, 17, 66, 3078, 4938, 66, 3078, 8614, 517, 628, 4, 763, 3918, 301, 2, 297, 1, 956, 2525, 1049, 6, 8, 775, 4, 178, 301, 688, 757, 4, 8, 10076, 529, 1, 1062, 1425, 75, 5208, 37, 21, 264, 17, 125, 10, 8, 61, 2, 98, 470, 344, 4, 66, 3078, 3918, 2756, 20, 8, 48, 1858, 4, 3, 2682, 3918, 6545, 4, 2755, 66, 3078, 8614, 879, 893, 2525, 2, 627, 4, 8, 2286, 1, 1062, 1425, 3268, 925, 5, 26, 1062, 1425, 2, 1425, 178, 148, 11, 120, 340, 46, 176, 11, 41, 5, 3, 1118, 1, 31, 273, 22, 6326, 20, 2699, 3638, 3507, 1451, 2041, 3155, 340, 9880, 2, 378, 76, 3396, 915, 5, 577, 4, 577, 745, 2, 436, 10822, 37, 66, 3078, 8614, 24, 4277, 3, 577, 254, 23, 129, 297]",1051.0,22448923,103
Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining.,Blood,Blood,2012-04-04,"Chromosomal aberrations are an important consequence of genotoxic exposure and contribute to pathogenesis and progression of several malignancies. We investigated the susceptibility to chromosomal aberrations in chronic myelogenous leukemia (CML) progenitors after exposure to ionizing radiation. In normal progenitors, ionizing radiation induced both stable and unstable chromosomal lesions, but only stable aberrations persisted after multiple divisions. In contrast, radiation of chronic phase CML progenitors resulted in enhanced generation of unstable lesions that persisted after multiple divisions. CML progenitors demonstrated active cell cycle checkpoints and increased nonhomologous end joining DNA repair, suggesting that persistence of unstable aberrations was the result of continued generation of these lesions. CML progenitors demonstrated enhanced susceptibility to repeated cycles of chromosome damage, repair, and damage through a breakage-fusion-bridge mechanism. Perpetuation of breakage-fusion-bridge cycles in CML progenitors was mediated by classic nonhomologous end joining repair. These studies reveal a previously unrecognized mechanism of chromosomal instability in leukemia progenitors because of continued generation of unstable chromosomal lesions through repeated cycles of breakage and repair of such lesions.",Evaluation Study,2848.0,29.0,Chromosomal aberrations are an important consequence of genotoxic exposure and contribute to pathogenesis and progression of several malignancies We investigated the susceptibility to chromosomal aberrations in chronic myelogenous CML progenitors after exposure to ionizing radiation In normal progenitors ionizing radiation induced both stable and unstable chromosomal lesions but only stable aberrations persisted after multiple divisions In contrast radiation of chronic phase CML progenitors resulted in enhanced generation of unstable lesions that persisted after multiple divisions CML progenitors demonstrated active cell cycle checkpoints and increased nonhomologous end joining DNA repair suggesting that persistence of unstable aberrations was the result of continued generation of these lesions CML progenitors demonstrated enhanced susceptibility to repeated cycles of chromosome damage repair and damage through a breakage-fusion-bridge mechanism Perpetuation of breakage-fusion-bridge cycles in CML progenitors was mediated by classic nonhomologous end joining repair These studies reveal a previously unrecognized mechanism of chromosomal instability in progenitors because of continued generation of unstable chromosomal lesions through repeated cycles of breakage and repair of such lesions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1860, 2152, 32, 35, 305, 4177, 1, 7876, 645, 2, 1248, 6, 1384, 2, 91, 1, 392, 441, 21, 565, 3, 1432, 6, 1860, 2152, 4, 442, 2194, 903, 4321, 50, 645, 6, 4341, 121, 4, 295, 4321, 4341, 121, 277, 110, 585, 2, 7705, 1860, 406, 84, 158, 585, 2152, 3760, 50, 232, 30191, 4, 748, 121, 1, 442, 124, 903, 4321, 627, 4, 651, 914, 1, 7705, 406, 17, 3760, 50, 232, 30191, 903, 4321, 264, 544, 31, 417, 4704, 2, 101, 16858, 396, 10690, 261, 972, 802, 17, 4108, 1, 7705, 2152, 10, 3, 757, 1, 1351, 914, 1, 46, 406, 903, 4321, 264, 651, 1432, 6, 2113, 410, 1, 1170, 1350, 972, 2, 1350, 298, 8, 14101, 1212, 7728, 670, 39325, 1, 14101, 1212, 7728, 410, 4, 903, 4321, 10, 517, 20, 3168, 16858, 396, 10690, 972, 46, 94, 2396, 8, 373, 6055, 670, 1, 1860, 1753, 4, 4321, 408, 1, 1351, 914, 1, 7705, 1860, 406, 298, 2113, 410, 1, 14101, 2, 972, 1, 225, 406]",1307.0,22493298,11
Tyrosine kinase inhibitors in acute and chronic leukemias.,Expert opinion on pharmacotherapy,Expert Opin Pharmacother,2012-05-01,"Since the initial approval of imatinib much has been learned about its resistance mechanisms, and efforts have continued to improve upon BCR-ABL tyrosine kinase inhibitor therapy. Targeted therapy with TKIs has continued to be an area of active research and development in the care of acute and chronic leukemia patients. This article reviews current approved and investigational TKI treatments for chronic myelogenous leukemia (CML), Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph + ALL) and acute myelogenous leukemia (AML). There are now more potent BCR-ABL TKIs approved, which allow for additional options when determining front-line and second-line CML and Ph + ALL treatments. The T315I mutation is an ever-present challenge. Ponatinib, a pan BCR-ABL TKI, while still under investigation, is very hopeful with its ability to overcome T315I mutations in resistant CML and Ph + ALL patients. Because nilotinib and dasatinib have not been directly compared, at present we recommend selecting one or the other based on the side-effect profile, drug interactions, patient comorbidities, and mutational status. FLT-3 inhibition is of particular interest in AML patients with FLT-3 internal tandem duplication mutations; this type of targeted therapy continues to be studied.",Journal Article,2821.0,44.0,Since the initial approval of imatinib much has been learned about its resistance mechanisms and efforts have continued to improve upon BCR-ABL tyrosine kinase inhibitor therapy Targeted therapy with TKIs has continued to be an area of active research and development in the care of acute and chronic patients This article reviews current approved and investigational TKI treatments for chronic myelogenous CML Philadelphia-chromosome positive acute lymphoblastic Ph ALL and acute myelogenous AML There are now more potent BCR-ABL TKIs approved which allow for additional options when determining front-line and second-line CML and Ph ALL treatments The T315I mutation is an ever-present challenge Ponatinib a pan BCR-ABL TKI while still under investigation is very hopeful with its ability to overcome T315I mutations in resistant CML and Ph ALL patients Because nilotinib and dasatinib have not been directly compared at present we recommend selecting one or the other based on the side-effect profile drug interactions patient comorbidities and mutational status FLT-3 inhibition is of particular interest in AML patients with FLT-3 internal tandem duplication mutations this type of targeted therapy continues to be studied,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1192, 3, 388, 1814, 1, 577, 1802, 71, 85, 6426, 545, 211, 251, 483, 2, 1413, 47, 1351, 6, 401, 1548, 1062, 1425, 564, 216, 230, 36, 238, 36, 5, 1671, 71, 1351, 6, 40, 35, 965, 1, 544, 389, 2, 193, 4, 3, 165, 1, 286, 2, 442, 7, 26, 946, 2004, 291, 850, 2, 3093, 1379, 640, 9, 442, 2194, 903, 3006, 1170, 109, 286, 1275, 2058, 62, 2, 286, 2194, 329, 125, 32, 1134, 80, 1157, 1062, 1425, 1671, 850, 92, 1700, 9, 402, 838, 198, 2196, 3007, 328, 2, 419, 328, 903, 2, 2058, 62, 640, 3, 6184, 258, 16, 35, 3353, 364, 1745, 5715, 8, 3055, 1062, 1425, 1379, 369, 1234, 669, 940, 16, 923, 19712, 5, 211, 801, 6, 1768, 6184, 138, 4, 436, 903, 2, 2058, 62, 7, 408, 2638, 2, 1674, 47, 44, 85, 1606, 72, 28, 364, 21, 2237, 3675, 104, 15, 3, 127, 90, 23, 3, 1152, 254, 800, 234, 1286, 69, 1909, 2, 1619, 156, 4368, 27, 297, 16, 1, 1454, 1333, 4, 329, 7, 5, 4368, 27, 2329, 2905, 4616, 138, 26, 267, 1, 238, 36, 2274, 6, 40, 656]",1227.0,22519766,185
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2012-07-09,"Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) is a controversial diagnosis, as others propose that it represents chronic myelogenous leukemia in blast phase (CML-BP). NPM1 mutations occur in 25-35% of patients with AML but are absent in patients with CML. Conversely, ABL1 mutations occur in 25% of imatinib-naive patients with CML-BP but are not described in patients with AML. We analyzed for NPM1 and ABL1 mutations in nine Ph+ patients with AML and five patients with CML-BP initially presenting in BP. In six cases of Ph+ AML, we screened for a panel of gene mutations using Sequenome()-based methods including AKT1, AKT2, AKT3, BRAF, EGFR, GNAQ, GNAS, IDH1, IDH2, KRAS, MET, NRAS, PIK3CA and RET. Two of nine (22%) patients with Ph+ AML had NPM1 mutations and were alive 36 and 71 months after diagnosis. All cases of Ph+ AML were negative for ABL1 and other gene mutations. One (20%) patient with CML-BP had ABL1 mutation; no patients had NPM1 mutations. These data suggest that Ph+ AML is distinct from CML-BP.",Journal Article,2752.0,52.0,Philadelphia chromosome-positive Ph+ acute myeloid AML is a controversial diagnosis as others propose that it represents chronic myelogenous in blast phase CML-BP NPM1 mutations occur in 25-35 of patients with AML but are absent in patients with CML Conversely ABL1 mutations occur in 25 of imatinib-naive patients with CML-BP but are not described in patients with AML We analyzed for NPM1 and ABL1 mutations in nine Ph+ patients with AML and five patients with CML-BP initially presenting in BP In six cases of Ph+ AML we screened for a panel of gene mutations using Sequenome  -based methods including AKT1 AKT2 AKT3 BRAF EGFR GNAQ GNAS IDH1 IDH2 KRAS MET NRAS PIK3CA and RET Two of nine 22 patients with Ph+ AML had NPM1 mutations and were alive 36 and 71 months after diagnosis All cases of Ph+ AML were negative for ABL1 and other gene mutations One 20 patient with CML-BP had ABL1 mutation no patients had NPM1 mutations These data suggest that Ph+ AML is distinct from CML-BP,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3006, 1170, 109, 2058, 286, 533, 329, 16, 8, 2010, 147, 22, 1749, 2548, 17, 192, 1449, 442, 2194, 4, 3112, 124, 903, 3044, 4318, 138, 1271, 4, 243, 465, 1, 7, 5, 329, 84, 32, 3269, 4, 7, 5, 903, 3154, 3557, 138, 1271, 4, 243, 1, 577, 2462, 7, 5, 903, 3044, 84, 32, 44, 1027, 4, 7, 5, 329, 21, 311, 9, 4318, 2, 3557, 138, 4, 762, 2058, 7, 5, 329, 2, 365, 7, 5, 903, 3044, 1625, 1656, 4, 3044, 4, 437, 140, 1, 2058, 329, 21, 2261, 9, 8, 993, 1, 145, 138, 75, 47239, 6081, 90, 636, 141, 4958, 10911, 12429, 566, 227, 9713, 8624, 2662, 4520, 723, 543, 2845, 1506, 2, 2412, 100, 1, 762, 350, 7, 5, 2058, 329, 42, 4318, 138, 2, 11, 1701, 511, 2, 792, 53, 50, 147, 62, 140, 1, 2058, 329, 11, 199, 9, 3557, 2, 127, 145, 138, 104, 179, 69, 5, 903, 3044, 42, 3557, 258, 77, 7, 42, 4318, 138, 46, 74, 309, 17, 2058, 329, 16, 834, 29, 903, 3044]",984.0,22691121,212
Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2012-07-23,"Cancer-associated thrombosis often lacks a clear etiology. However, it is linked to a poor prognosis and represents the second-leading cause of death in cancer patients. Recent studies have shown that chromatin released into blood, through the generation of neutrophil extracellular traps (NETs), is procoagulant and prothrombotic. Using a murine model of chronic myelogenous leukemia, we show that malignant and nonmalignant neutrophils are more prone to NET formation. This increased sensitivity toward NET generation is also observed in mammary and lung carcinoma models, suggesting that cancers, through a systemic effect on the host, can induce an increase in peripheral blood neutrophils, which are predisposed to NET formation. In addition, in the late stages of the breast carcinoma model, NETosis occurs concomitant with the appearance of venous thrombi in the lung. Moreover, simulation of a minor systemic infection in tumor-bearing, but not control, mice results in the release of large quantities of chromatin and a prothrombotic state. The increase in neutrophil count and their priming is mediated by granulocyte colony-stimulating factor (G-CSF), which accumulates in the blood of tumor-bearing mice. The prothrombotic state in cancer can be reproduced by treating mice with G-CSF combined with low-dose LPS and leads to thrombocytopenia and microthrombosis. Taken together, our results identify extracellular chromatin released through NET formation as a cause for cancer-associated thrombosis and unveil a target in the effort to decrease the incidence of thrombosis in cancer patients.",Journal Article,2738.0,318.0,Cancer-associated thrombosis often lacks a clear etiology However it is linked to a poor prognosis and represents the second-leading cause of death in cancer patients Recent studies have shown that chromatin released into blood through the generation of neutrophil extracellular traps NETs is procoagulant and prothrombotic Using a murine model of chronic myelogenous we show that malignant and nonmalignant neutrophils are more prone to NET formation This increased sensitivity toward NET generation is also observed in mammary and carcinoma models suggesting that cancers through a systemic effect on the host can induce an increase in peripheral blood neutrophils which are predisposed to NET formation In addition in the late stages of the carcinoma model NETosis occurs concomitant with the appearance of venous thrombi in the Moreover simulation of a minor systemic infection in tumor-bearing but not control mice results in the release of large quantities of chromatin and a prothrombotic state The increase in neutrophil count and their priming is mediated by granulocyte colony-stimulating factor G-CSF which accumulates in the blood of tumor-bearing mice The prothrombotic state in cancer can be reproduced by treating mice with G-CSF combined with low-dose LPS and leads to thrombocytopenia and microthrombosis Taken together our results identify extracellular chromatin released through NET formation as a cause for cancer-associated thrombosis and unveil a target in the effort to decrease the incidence of thrombosis in cancer patients,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12, 41, 2839, 629, 6856, 8, 885, 2855, 137, 192, 16, 1199, 6, 8, 334, 356, 2, 1449, 3, 419, 1049, 708, 1, 273, 4, 12, 7, 435, 94, 47, 443, 17, 2287, 5394, 237, 315, 298, 3, 914, 1, 2595, 1976, 23997, 2883, 16, 21284, 2, 23142, 75, 8, 1471, 202, 1, 442, 2194, 21, 514, 17, 393, 2, 5967, 5700, 32, 80, 7104, 6, 2587, 1264, 26, 101, 485, 1317, 2587, 914, 16, 120, 164, 4, 1903, 2, 134, 274, 802, 17, 163, 298, 8, 403, 254, 23, 3, 1204, 122, 1290, 35, 344, 4, 672, 315, 5700, 92, 32, 11072, 6, 2587, 1264, 4, 352, 4, 3, 807, 1153, 1, 3, 134, 202, 61693, 1780, 1781, 5, 3, 3592, 1, 2167, 13622, 4, 3, 1393, 4026, 1, 8, 2278, 403, 930, 4, 30, 1894, 84, 44, 182, 399, 99, 4, 3, 2008, 1, 375, 11972, 1, 2287, 2, 8, 23142, 1309, 3, 344, 4, 2595, 1276, 2, 136, 4903, 16, 517, 20, 2764, 1975, 2122, 161, 499, 1211, 92, 14390, 4, 3, 315, 1, 30, 1894, 399, 3, 23142, 1309, 4, 12, 122, 40, 14538, 20, 1367, 399, 5, 499, 1211, 397, 5, 154, 61, 6310, 2, 1940, 6, 1340, 2, 61694, 1633, 1162, 114, 99, 255, 1976, 2287, 5394, 298, 2587, 1264, 22, 8, 708, 9, 12, 41, 2839, 2, 16019, 8, 283, 4, 3, 2919, 6, 775, 3, 287, 1, 2839, 4, 12, 7]",1549.0,22826226,9
Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2012-08-21,"Characterization of an approach to identify leukemia neoantigens arising in the context of drug resistance. We assessed whether leukemia neoantigens could be generated from drug-resistant mutations in BCR-ABL after imatinib relapse in patients with chronic myelogenous leukemia (CML). We computationally predicted that approximately 70 peptides derived from 26 BCR-ABL mutations would bind eight common alleles of MHC class I (IC(50) < 1,000 nmol/L). Seven of nine imatinib-resistant CML patients were predicted to generate at least 1 peptide that binds autologous HLA alleles. We predicted and confirmed that an E255K mutation-derived peptide would bind HLA-A3 with high affinity (IC(50) = 28 nmol/L), and showed that this peptide is endogenously processed and presented. Polyfunctional E255K-specific CD8+ T cells were detected in two imatinib-resistant HLA-A3+ CML patients concurrent with an effective anti-CML response to further therapy. Our in vitro studies support the hypothesis that leukemia-driven genetic alterations are targeted by the immune system in association with a clinical response, and suggest the possibility of immunizing relapsed patients with CML against newly acquired tumor neoantigens.",Journal Article,2709.0,29.0,"Characterization of an approach to identify neoantigens arising in the context of drug resistance We assessed whether neoantigens could be generated from drug-resistant mutations in BCR-ABL after imatinib relapse in patients with chronic myelogenous CML We computationally predicted that approximately 70 peptides derived from 26 BCR-ABL mutations would bind eight common alleles of MHC class I IC 50 1,000 nmol/L Seven of nine imatinib-resistant CML patients were predicted to generate at least 1 peptide that binds autologous HLA alleles We predicted and confirmed that an E255K mutation-derived peptide would bind HLA-A3 with high affinity IC 50 28 nmol/L and showed that this peptide is endogenously processed and presented Polyfunctional E255K-specific CD8+ T cells were detected in two imatinib-resistant HLA-A3+ CML patients concurrent with an effective anti-CML response to further therapy Our in vitro studies support the hypothesis that leukemia-driven genetic alterations are targeted by the immune system in association with a clinical response and suggest the possibility of immunizing relapsed patients with CML against newly acquired tumor neoantigens",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2136, 1, 35, 353, 6, 255, 6561, 2635, 4, 3, 1533, 1, 234, 251, 21, 275, 317, 6561, 359, 40, 1419, 29, 234, 436, 138, 4, 1062, 1425, 50, 577, 429, 4, 7, 5, 442, 2194, 903, 21, 16933, 783, 17, 705, 431, 2491, 526, 29, 432, 1062, 1425, 138, 688, 4060, 659, 186, 2558, 1, 3658, 1040, 70, 2340, 212, 14, 984, 4694, 805, 648, 1, 762, 577, 436, 903, 7, 11, 783, 6, 2562, 28, 506, 14, 1389, 17, 3333, 1028, 1160, 2558, 21, 783, 2, 557, 17, 35, 16677, 258, 526, 1389, 688, 4060, 1160, 7024, 5, 64, 3601, 2340, 212, 339, 4694, 805, 2, 224, 17, 26, 1389, 16, 11748, 5232, 2, 917, 20621, 16677, 112, 968, 102, 37, 11, 530, 4, 100, 577, 436, 1160, 7024, 903, 7, 750, 5, 35, 323, 312, 903, 51, 6, 195, 36, 114, 4, 439, 94, 538, 3, 1492, 17, 2647, 1621, 336, 593, 32, 238, 20, 3, 250, 398, 4, 248, 5, 8, 38, 51, 2, 309, 3, 2526, 1, 16213, 591, 7, 5, 903, 480, 732, 1294, 30, 6561]",1166.0,22912393,11
Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia.,Human pathology,Hum. Pathol.,2012-08-29,"Skeletal integrity is sustained by osteoblast-osteoclast interactions, controlled by several signaling pathways that include tyrosine kinases. Imatinib is a tyrosine kinase inhibitor with an extended therapeutic range based on its ability to differentially bind to receptor and nonreceptor tyrosine kinases. In this study, we used digital image analysis to assess changes in trabecular bone surface area within bone marrow biopsy specimens of 34 patients with chronic phase chronic myelogenous leukemia treated with single-agent imatinib. These patients were 25 men and 9 women with a median age of 59 years. We selected representative areas of paired bone marrow biopsy specimens obtained at baseline and within the subsequent 48 months. Computer-assisted analysis was performed to calculate trabecular bone area (TBA) within the sample by using the equation TBA% = sum of trabecular area/total biopsy specimen area. Percentage changes were defined as TBA% and were arbitrarily subdivided into marked (>50%), moderate (10%-50%), and mild (<10%). During the study interval, TBA% increased in 24 patients (71%) and decreased in 10 patients (29%). Overall, there was a significant increase in TBA% (P = .02). No correlation was found between changes in trabecular bone area and either clinical or cytogenetic response (P = .25). The results show that imatinib therapy can alter trabecular bone in bone marrow biopsy specimens of chronic myelogenous leukemia patients, most often resulting in an increase in TBA%.",Journal Article,2701.0,4.0,Skeletal integrity is sustained by osteoblast-osteoclast interactions controlled by several signaling pathways that include tyrosine kinases Imatinib is a tyrosine kinase inhibitor with an extended therapeutic range based on its ability to differentially bind to receptor and nonreceptor tyrosine kinases In this study we used digital image analysis to assess changes in trabecular surface area within marrow biopsy specimens of 34 patients with chronic phase chronic myelogenous treated with single-agent imatinib These patients were 25 men and 9 women with a median age of 59 years We selected representative areas of paired marrow biopsy specimens obtained at baseline and within the subsequent 48 months Computer-assisted analysis was performed to calculate trabecular area TBA within the sample by using the equation TBA sum of trabecular area/total biopsy specimen area Percentage changes were defined as TBA and were arbitrarily subdivided into marked 50 moderate 10 -50 and mild 10 During the study interval TBA increased in 24 patients 71 and decreased in 10 patients 29 Overall there was a significant increase in TBA P .02 No correlation was found between changes in trabecular area and either clinical or cytogenetic response P .25 The results show that imatinib therapy can alter trabecular in marrow biopsy specimens of chronic myelogenous patients most often resulting in an increase in TBA,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2621, 4797, 16, 2275, 20, 7418, 6382, 1286, 1149, 20, 392, 314, 460, 17, 643, 564, 1549, 577, 16, 8, 564, 216, 230, 5, 35, 1747, 189, 184, 90, 23, 211, 801, 6, 2478, 4060, 6, 153, 2, 17242, 564, 1549, 4, 26, 45, 21, 95, 3271, 1482, 65, 6, 423, 400, 4, 12853, 1255, 965, 262, 581, 411, 623, 1, 562, 7, 5, 442, 124, 442, 2194, 73, 5, 226, 420, 577, 46, 7, 11, 243, 325, 2, 83, 117, 5, 8, 52, 89, 1, 728, 60, 21, 715, 3724, 1361, 1, 2355, 581, 411, 623, 683, 28, 330, 2, 262, 3, 706, 576, 53, 4236, 2927, 65, 10, 173, 6, 3232, 12853, 965, 21736, 262, 3, 1000, 20, 75, 3, 5747, 21736, 3216, 1, 12853, 965, 181, 411, 2360, 965, 1150, 400, 11, 395, 22, 61821, 2, 11, 23165, 10676, 237, 2003, 212, 1163, 79, 212, 2, 1980, 79, 190, 3, 45, 268, 21736, 101, 4, 259, 7, 792, 2, 340, 4, 79, 7, 462, 63, 125, 10, 8, 93, 344, 4, 21736, 19, 588, 77, 816, 10, 204, 59, 400, 4, 12853, 965, 2, 361, 38, 15, 1266, 51, 19, 243, 3, 99, 514, 17, 577, 36, 122, 2688, 12853, 4, 581, 411, 623, 1, 442, 2194, 7, 96, 629, 1113, 4, 35, 344, 4, 21736]",1406.0,22939577,7
T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2012-09-13,"Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) provides a survival benefit to patients with acute lymphoblastic leukemia (ALL). We have previously reported comparable survival and relapse rates after T cell-depleted (TCD) allo-HSCT compared with unmodified transplantations for acute myelogenous leukemia, myelodysplastic syndrome, and non-Hodgkin lymphoma with significantly decreased graft-versus-host disease (GVHD). We performed a 56-patient retrospective study to evaluate TCD allo-HSCT for the treatment of ALL after myeloablative total body irradiation-based therapy. The 2-year and 5-year overall survival rates for patients with ALL after TCD allo-HSCT were 0.39 (95% confidence interval [CI], 0.26-0.52) and 0.32 (95% CI, 0.19-0.44), respectively, and the 2-year and 5-year disease-free survival rates were 0.38 (95% CI, 0.25-0.50) and 0.32 (95% CI, 0.20-0.44). There was a trend toward improved survival of patients who underwent TCD allo-HSCT in first complete remission compared with those who did so in other remission states. The cumulative incidence of grade II-IV acute GVHD at 1 year was 0.20 (95% CI, 0.10-0.31), and no patients developed grade IV acute GVHD. The cumulative incidence of chronic GVHD in 41 evaluable patients at 2 and 5 years was 0.15 (95% CI, 0.04-0.26), and that of extensive chronic GVHD at 2 and 5 years was 0.05 (95% CI, 0-11.6). We demonstrate OS and DFS rates that compare favorably to unmodified allo-HSCT with lower rates of GVHD.",Journal Article,2686.0,28.0,Consolidation with allogeneic hematopoietic stem cell transplantation allo-HSCT provides a survival benefit to patients with acute lymphoblastic ALL We have previously reported comparable survival and relapse rates after T cell-depleted TCD allo-HSCT compared with unmodified transplantations for acute myelogenous syndrome and with significantly decreased graft-versus-host disease GVHD We performed a 56-patient retrospective study to evaluate TCD allo-HSCT for the treatment of ALL after myeloablative total body irradiation-based therapy The 2-year and 5-year overall survival rates for patients with ALL after TCD allo-HSCT were 0.39 95 confidence interval CI 0.26-0.52 and 0.32 95 CI 0.19-0.44 respectively and the 2-year and 5-year disease-free survival rates were 0.38 95 CI 0.25-0.50 and 0.32 95 CI 0.20-0.44 There was a trend toward improved survival of patients who underwent TCD allo-HSCT in first complete remission compared with those who did so in other remission states The cumulative incidence of grade II-IV acute GVHD at 1 year was 0.20 95 CI 0.10-0.31 and no patients developed grade IV acute GVHD The cumulative incidence of chronic GVHD in 41 evaluable patients at 2 and 5 years was 0.15 95 CI 0.04-0.26 and that of extensive chronic GVHD at 2 and 5 years was 0.05 95 CI 0-11.6 We demonstrate OS and DFS rates that compare favorably to unmodified allo-HSCT with lower rates of GVHD,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2173, 5, 1063, 1007, 452, 31, 497, 2564, 1703, 777, 8, 25, 247, 6, 7, 5, 286, 1275, 62, 21, 47, 373, 210, 1279, 25, 2, 429, 151, 50, 102, 31, 4358, 8827, 2564, 1703, 72, 5, 10424, 6779, 9, 286, 2194, 681, 2, 5, 97, 340, 1599, 185, 1204, 34, 1562, 21, 173, 8, 664, 69, 459, 45, 6, 376, 8827, 2564, 1703, 9, 3, 24, 1, 62, 50, 3246, 181, 642, 1104, 90, 36, 3, 18, 111, 2, 33, 111, 63, 25, 151, 9, 7, 5, 62, 50, 8827, 2564, 1703, 11, 13, 587, 48, 307, 268, 58, 13, 432, 13, 653, 2, 13, 531, 48, 58, 13, 326, 13, 584, 106, 2, 3, 18, 111, 2, 33, 111, 34, 115, 25, 151, 11, 13, 519, 48, 58, 13, 243, 13, 212, 2, 13, 531, 48, 58, 13, 179, 13, 584, 125, 10, 8, 853, 1317, 231, 25, 1, 7, 54, 208, 8827, 2564, 1703, 4, 157, 236, 734, 72, 5, 135, 54, 205, 1743, 4, 127, 734, 907, 3, 967, 287, 1, 88, 215, 478, 286, 1562, 28, 14, 111, 10, 13, 179, 48, 58, 13, 79, 13, 456, 2, 77, 7, 276, 88, 478, 286, 1562, 3, 967, 287, 1, 442, 1562, 4, 605, 859, 7, 28, 18, 2, 33, 60, 10, 13, 167, 48, 58, 13, 755, 13, 432, 2, 17, 1, 1344, 442, 1562, 28, 18, 2, 33, 60, 10, 13, 474, 48, 58, 13, 175, 49, 21, 608, 118, 2, 1010, 151, 17, 932, 5001, 6, 10424, 2564, 1703, 5, 280, 151, 1, 1562]",1403.0,22982534,199
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2012-01-01,"The ability of immune-competent donor T cells to mediate a beneficial graft-versus-leukemia (GVL) effect was first identified in the setting of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for hematologic malignancies. Unfortunately, with the exception of chronic myelogenous leukemia and EBV-induced lymphoproliferative disease, allo-HSCT GVL lacks the potency to significantly affect disease progression or recurrence in most other hematologic malignancies. The inadequacy of a GVL effect using past approaches is particularly evident in patients with lymphoid malignancies. However, with the advent of improved gene transfer technology, genetically modified tumor-specific immune effectors have extended cellular immunotherapy to lymphoid malignancies. One promising strategy entails the introduction of genes encoding artificial receptors called chimeric antigen receptors (CARs), which redirect the specificity and function of immune effectors. CAR-modified T cells targeted to the B cell-specific CD19 antigen have demonstrated promising results in multiple early clinical trials, supporting further investigation in patients with B-cell cancers. However, disparities in clinical trial design and CAR structure have complicated the discovery of the optimal application of this technology. Recent preclinical studies support additional genetic modifications of CAR-modified T cells to achieve optimal clinical efficacy using this novel adoptive cellular therapy.",Journal Article,2942.0,43.0,The ability of immune-competent donor T cells to mediate a beneficial graft-versus-leukemia GVL effect was first identified in the setting of allogeneic hematopoietic stem cell transplantation allo-HSCT for hematologic malignancies Unfortunately with the exception of chronic myelogenous and EBV-induced lymphoproliferative disease allo-HSCT GVL lacks the potency to significantly affect disease progression or recurrence in most other hematologic malignancies The inadequacy of a GVL effect using past approaches is particularly evident in patients with lymphoid malignancies However with the advent of improved gene transfer technology genetically modified tumor-specific immune effectors have extended cellular immunotherapy to lymphoid malignancies One promising strategy entails the introduction of genes encoding artificial receptors called chimeric antigen receptors CARs which redirect the specificity and function of immune effectors CAR-modified T cells targeted to the B cell-specific CD19 antigen have demonstrated promising results in multiple early clinical trials supporting further investigation in patients with B-cell cancers However disparities in clinical trial design and CAR structure have complicated the discovery of the optimal application of this technology Recent preclinical studies support additional genetic modifications of CAR-modified T cells to achieve optimal clinical efficacy using this novel adoptive cellular therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 801, 1, 250, 6299, 1488, 102, 37, 6, 3367, 8, 2524, 1599, 185, 2647, 8149, 254, 10, 157, 108, 4, 3, 546, 1, 1063, 1007, 452, 31, 497, 2564, 1703, 9, 813, 441, 3869, 5, 3, 4188, 1, 442, 2194, 2, 2672, 277, 4192, 34, 2564, 1703, 8149, 6856, 3, 3593, 6, 97, 1158, 34, 91, 15, 146, 4, 96, 127, 813, 441, 3, 24543, 1, 8, 8149, 254, 75, 1219, 611, 16, 823, 2853, 4, 7, 5, 2303, 441, 137, 5, 3, 4114, 1, 231, 145, 2602, 2033, 2301, 1230, 30, 112, 250, 4926, 47, 1747, 763, 726, 6, 2303, 441, 104, 721, 692, 14080, 3, 2456, 1, 214, 2362, 8757, 1186, 3472, 2897, 448, 1186, 7441, 92, 14744, 3, 1121, 2, 343, 1, 250, 4926, 1881, 1230, 102, 37, 238, 6, 3, 132, 31, 112, 3158, 448, 47, 264, 721, 99, 4, 232, 191, 38, 143, 1912, 195, 940, 4, 7, 5, 132, 31, 163, 137, 2227, 4, 38, 160, 771, 2, 1881, 2772, 47, 4286, 3, 1574, 1, 3, 665, 1581, 1, 26, 2033, 435, 693, 94, 538, 402, 336, 2916, 1, 1881, 1230, 102, 37, 6, 1359, 665, 38, 209, 75, 26, 229, 3159, 763, 36]",1455.0,23233573,25
Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2012-12-01,"Approximately 5,000 cases of chronic myelogenous leukemia (CML) are diagnosed each year in the United States. The introduction of tyrosine kinase inhibitors (TKIs) has dramatically improved survival time for many CML patients. Current first-line treatment options include imatinib and the second-generation agents nilotinib and dasatinib. Second- and third-line agents include nilotinib, dasatinib, bosutinib, and the new agent ponatinib. Despite the effectiveness of TKIs, some patients develop resistance or intolerance to these agents. A number of mutations of the BCR-ABL gene have been identified and are associated with TKI resistance. Patients may benefit from switching to a second-line TKI, undergoing hematopoietic stem cell transplant, or receiving newly emerging agents. Although early response is associated with improved patient outcome, clinicians lack tests that can determine which patients will benefit from which therapies. To ensure adequate response, patients should be monitored by both polymerase chain reaction and cytogenetic analysis of the bone marrow. This roundtable monograph reviews key unmet needs in patients with CML related to disease management and treatment options.",Journal Article,2607.0,1.0,"Approximately 5,000 cases of chronic myelogenous CML are diagnosed each year in the United States The introduction of tyrosine kinase inhibitors TKIs has dramatically improved survival time for many CML patients Current first-line treatment options include imatinib and the second-generation agents nilotinib and dasatinib Second- and third-line agents include nilotinib dasatinib bosutinib and the new agent ponatinib Despite the effectiveness of TKIs some patients develop resistance or intolerance to these agents A number of mutations of the BCR-ABL gene have been identified and are associated with TKI resistance Patients may benefit from switching to a second-line TKI undergoing hematopoietic stem cell transplant or receiving newly emerging agents Although early response is associated with improved patient outcome clinicians lack tests that can determine which patients will benefit from which therapies To ensure adequate response patients should be monitored by both polymerase chain reaction and cytogenetic analysis of the marrow This roundtable monograph reviews key unmet needs in patients with CML related to disease management and treatment options",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[705, 33, 984, 140, 1, 442, 2194, 903, 32, 265, 296, 111, 4, 3, 1088, 907, 3, 2456, 1, 564, 216, 222, 1671, 71, 2729, 231, 25, 98, 9, 445, 903, 7, 291, 157, 328, 24, 838, 643, 577, 2, 3, 419, 914, 183, 2638, 2, 1674, 419, 2, 1282, 328, 183, 643, 2638, 1674, 5936, 2, 3, 217, 420, 5715, 550, 3, 1236, 1, 1671, 476, 7, 690, 251, 15, 5266, 6, 46, 183, 8, 207, 1, 138, 1, 3, 1062, 1425, 145, 47, 85, 108, 2, 32, 41, 5, 1379, 251, 7, 68, 247, 29, 7718, 6, 8, 419, 328, 1379, 479, 1007, 452, 31, 941, 15, 357, 732, 1478, 183, 242, 191, 51, 16, 41, 5, 231, 69, 228, 1490, 926, 895, 17, 122, 223, 92, 7, 303, 247, 29, 92, 235, 6, 3478, 1658, 51, 7, 257, 40, 2909, 20, 110, 1451, 1260, 1329, 2, 1266, 65, 1, 3, 581, 26, 14446, 17923, 2004, 825, 3715, 1891, 4, 7, 5, 903, 139, 6, 34, 284, 2, 24, 838]",1167.0,23271195,54
Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors.,Leukemia research,Leuk. Res.,2013-03-06,"Patients with chronic myelogenous leukemia (CML) or gastrointestinal stromal tumors (GIST) who take imatinib have abnormalities of bone metabolism. However, it is unclear what impact these changes have on bone mineral density (BMD). We prospectively analayzed levels of osteocalcin, a marker of bone formation secreted by osteoblasts, and serum N-telopeptide of type I collagen (NTX), a marker of bone resorption, as well as other minerals involved in bone metabolism in 19 patients with either CML or GIST We correlated these results with changes in bone mineral density as measured by serial dual energy X-ray absorptiometry (DEXA) scans over a two year period. Osteocalcin levels were low in 95% of patients and 37% had no measurable amount. Levels of NTX were less consistent. Nine patients (47%) had a decrease in BMD, four patients (2%) had an increase in BMD, and six patients (32%) had no change. There was no correlation between metabolic markers and change in BMD. We suggest that ongoing management of patients who take imatinib should include monitoring of bone health on a long term basis.",Journal Article,2512.0,20.0,Patients with chronic myelogenous CML or stromal tumors GIST who take imatinib have abnormalities of metabolism However it is unclear what impact these changes have on mineral density BMD We prospectively analayzed levels of osteocalcin a marker of formation secreted by osteoblasts and serum N-telopeptide of type I collagen NTX a marker of resorption as well as other minerals involved in metabolism in 19 patients with either CML or GIST We correlated these results with changes in mineral density as measured by serial dual energy X-ray absorptiometry DEXA scans over a two year period Osteocalcin levels were low in 95 of patients and 37 had no measurable amount Levels of NTX were less consistent Nine patients 47 had a decrease in BMD four patients 2 had an increase in BMD and six patients 32 had no change There was no correlation between metabolic markers and change in BMD We suggest that ongoing management of patients who take imatinib should include monitoring of health on a long term basis,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[7, 5, 442, 2194, 903, 15, 1126, 57, 1394, 54, 3585, 577, 47, 1171, 1, 1600, 137, 192, 16, 1200, 2067, 345, 46, 400, 47, 23, 5033, 1263, 3503, 21, 1143, 62551, 148, 1, 15282, 8, 952, 1, 1264, 3613, 20, 5965, 2, 524, 78, 9466, 1, 267, 70, 3945, 8110, 8, 952, 1, 8143, 22, 149, 22, 127, 33613, 646, 4, 1600, 4, 326, 7, 5, 361, 903, 15, 1394, 21, 438, 46, 99, 5, 400, 4, 5033, 1263, 22, 644, 20, 2108, 1828, 2803, 1006, 5520, 14257, 31814, 1441, 252, 8, 100, 111, 727, 15282, 148, 11, 154, 4, 48, 1, 7, 2, 567, 42, 77, 1884, 3108, 148, 1, 8110, 11, 299, 925, 762, 7, 662, 42, 8, 775, 4, 3503, 294, 7, 18, 42, 35, 344, 4, 3503, 2, 437, 7, 531, 42, 77, 707, 125, 10, 77, 816, 59, 1436, 525, 2, 707, 4, 3503, 21, 309, 17, 942, 284, 1, 7, 54, 3585, 577, 257, 643, 1315, 1, 341, 23, 8, 319, 337, 877]",1005.0,23473999,90
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.,Current medical research and opinion,Curr Med Res Opin,2013-04-08,"This study compared progression, progression-free survival (PFS), overall survival (OS), and treatment changes among chronic myelogenous leukemia patients in chronic phase (CML-CP) receiving nilotinib or dasatinib as second-line therapy. Information on CML-CP patients switched from imatinib to nilotinib or dasatinib as second-line therapy was collected retrospectively from 122 US hematologists and oncologists through an online medical chart review. Progression, PFS, and OS were compared using multivariate Cox proportional hazard models, and treatment changes using chi-square tests. Of 597 imatinib resistant or intolerant patients, 301 initiated nilotinib and 296 dasatinib as second-line therapy. Nilotinib was associated with a lower risk of progression (hazard ratio [HR] = 0.27; p = 0.021) and longer PFS (HR = 0.48; p = 0.030) than dasatinib, with a median follow-up time of 11 months for nilotinib and 10 months for dasatinib. Nilotinib patients had a lower estimated hazard of mortality than dasatinib patients, though not statistically significant (HR = 0.46; p = 0.067). When treatment changes were classified by the physicians' justifications, fewer nilotinib patients had treatment changes due to ineffectiveness (2.0% vs. 5.1%, p = 0.041) or drug holidays due to intolerance (0.0% vs. 1.7%, p = 0.024) than dasatinib patients. Among CML-CP patients in this retrospective chart review who switched from imatinib to either nilotinib or dasatinib, nilotinib was associated with a significantly lower risk of progression and longer PFS than dasatinib. Nilotinib patients were also less likely than dasatinib patients to subsequently have treatment changes due to ineffectiveness or drug holidays due to intolerance. These findings could be subject to unobserved confounders.",Comparative Study,2479.0,8.0,This study compared progression progression-free survival PFS overall survival OS and treatment changes among chronic myelogenous patients in chronic phase CML-CP receiving nilotinib or dasatinib as second-line therapy Information on CML-CP patients switched from imatinib to nilotinib or dasatinib as second-line therapy was collected retrospectively from 122 US hematologists and oncologists through an online medical chart review Progression PFS and OS were compared using multivariate Cox proportional hazard models and treatment changes using chi-square tests Of 597 imatinib resistant or intolerant patients 301 initiated nilotinib and 296 dasatinib as second-line therapy Nilotinib was associated with a lower risk of progression hazard ratio HR 0.27 p 0.021 and longer PFS HR 0.48 p 0.030 than dasatinib with a median follow-up time of 11 months for nilotinib and 10 months for dasatinib Nilotinib patients had a lower estimated hazard of mortality than dasatinib patients though not statistically significant HR 0.46 p 0.067 When treatment changes were classified by the physicians justifications fewer nilotinib patients had treatment changes due to ineffectiveness 2.0 vs. 5.1 p 0.041 or drug holidays due to intolerance 0.0 vs. 1.7 p 0.024 than dasatinib patients Among CML-CP patients in this retrospective chart review who switched from imatinib to either nilotinib or dasatinib nilotinib was associated with a significantly lower risk of progression and longer PFS than dasatinib Nilotinib patients were also less likely than dasatinib patients to subsequently have treatment changes due to ineffectiveness or drug holidays due to intolerance These findings could be subject to unobserved confounders,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[26, 45, 72, 91, 91, 115, 25, 300, 63, 25, 118, 2, 24, 400, 107, 442, 2194, 7, 4, 442, 124, 903, 2541, 357, 2638, 15, 1674, 22, 419, 328, 36, 487, 23, 903, 2541, 7, 7883, 29, 577, 6, 2638, 15, 1674, 22, 419, 328, 36, 10, 786, 894, 29, 3285, 843, 11474, 2, 1339, 298, 35, 4123, 484, 2937, 206, 91, 300, 2, 118, 11, 72, 75, 331, 418, 831, 360, 274, 2, 24, 400, 75, 3163, 3219, 895, 1, 14507, 577, 436, 15, 4944, 7, 5721, 1917, 2638, 2, 10340, 1674, 22, 419, 328, 36, 2638, 10, 41, 5, 8, 280, 43, 1, 91, 360, 197, 168, 13, 428, 19, 13, 4630, 2, 589, 300, 168, 13, 576, 19, 13, 6542, 76, 1674, 5, 8, 52, 166, 126, 98, 1, 175, 53, 9, 2638, 2, 79, 53, 9, 1674, 2638, 7, 42, 8, 280, 661, 360, 1, 282, 76, 1674, 7, 2471, 44, 712, 93, 168, 13, 641, 19, 13, 10668, 198, 24, 400, 11, 1373, 20, 3, 1261, 47666, 1497, 2638, 7, 42, 24, 400, 520, 6, 27888, 18, 13, 105, 33, 14, 19, 13, 5937, 15, 234, 23526, 520, 6, 5266, 13, 13, 105, 14, 67, 19, 13, 4247, 76, 1674, 7, 107, 903, 2541, 7, 4, 26, 459, 2937, 206, 54, 7883, 29, 577, 6, 361, 2638, 15, 1674, 2638, 10, 41, 5, 8, 97, 280, 43, 1, 91, 2, 589, 300, 76, 1674, 2638, 7, 11, 120, 299, 322, 76, 1674, 7, 6, 1611, 47, 24, 400, 520, 6, 27888, 15, 234, 23526, 520, 6, 5266, 46, 272, 359, 40, 2974, 6, 24447, 4423]",1715.0,23517347,37
Adherence to targeted oral anticancer medications.,Discovery medicine,Discov Med,2013-04-01,"The use of targeted oral anticancer medications (OAMs) is becoming increasingly prevalent in cancer care. Approximately 25-30% of the oncology drug pipeline involves oral agents and there are now over 50 OAMs approved by the Food and Drug Administration. This change represents a major shift in management of patients with cancer from directly observed, intermittent intravenous therapy to self-administered, oral chronic therapy. The increased prevalence of OAMs raises the issue of adherence in oncology, including understanding the challenges of adherence to OAMs. This review focuses on studies of adherence for patients taking molecularly targeted OAMs for breast cancer, chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GIST), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). We then discuss barriers to adherence and studies performed to date testing interventions for improving adherence. Finally, we discuss future areas of investigation needed to define and improve adherence to OAMs in targeted therapy for cancer.",Journal Article,2486.0,37.0,The use of targeted oral anticancer medications OAMs is becoming increasingly prevalent in cancer care Approximately 25-30 of the oncology drug pipeline involves oral agents and there are now over 50 OAMs approved by the Food and Drug Administration This change represents a major shift in management of patients with cancer from directly observed intermittent intravenous therapy to self-administered oral chronic therapy The increased prevalence of OAMs raises the issue of adherence in oncology including understanding the challenges of adherence to OAMs This review focuses on studies of adherence for patients taking molecularly targeted OAMs for cancer chronic myelogenous CML stromal tumors GIST cell cancer NSCLC and cell carcinoma RCC We then discuss barriers to adherence and studies performed to date testing interventions for improving adherence Finally we discuss future areas of investigation needed to define and improve adherence to OAMs in targeted therapy for cancer,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[3, 119, 1, 238, 518, 1475, 2679, 15060, 16, 4009, 1635, 2485, 4, 12, 165, 705, 243, 201, 1, 3, 413, 234, 8471, 2921, 518, 183, 2, 125, 32, 1134, 252, 212, 15060, 850, 20, 3, 1773, 2, 234, 634, 26, 707, 1449, 8, 458, 3024, 4, 284, 1, 7, 5, 12, 29, 1606, 164, 4102, 1262, 36, 6, 1074, 468, 518, 442, 36, 3, 101, 1078, 1, 15060, 5789, 3, 2537, 1, 2149, 4, 413, 141, 612, 3, 1427, 1, 2149, 6, 15060, 26, 206, 3026, 23, 94, 1, 2149, 9, 7, 2727, 2372, 238, 15060, 9, 12, 442, 2194, 903, 1126, 57, 1394, 31, 12, 304, 2, 31, 134, 796, 21, 818, 1139, 2160, 6, 2149, 2, 94, 173, 6, 1244, 471, 1151, 9, 1673, 2149, 1368, 21, 1139, 508, 1361, 1, 940, 575, 6, 1107, 2, 401, 2149, 6, 15060, 4, 238, 36, 9, 12]",984.0,23636140,170
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2013-06-18,"Allogeneic hematopoietic stem cell transplantation (HSCT) can achieve durable remissions in a number of patients with advanced hematologic malignancies. Little is known about the safety of HSCT in patients age 70 or older. Consecutive patients (n = 54) age 70 or older underwent HSCT between 2007 and 2012. Diseases included acute myelogenous leukemia (n = 25), myelodysplastic syndrome (n = 12), chronic lymphocytic leukemia (n = 5), non-Hodgkin lymphoma (n = 4), acute lymphoblastic leukemia (n = 3), myeloproliferative neoplasm (n = 4), and chronic myelogenous leukemia (n = 1). Median follow-up for survivors was 21 months. All patients received reduced-intensity conditioning regimens, primarily busulfan/fludarabine. All patients received unmanipulated peripheral blood stem cell grafts: 44 from 8/8 matched unrelated donors, 8 from matched related donors, and 2 from 7/8 matched unrelated donors. Graft-versus-host disease (GVHD) prophylaxis was calcineurin inhibitor-based in all patients. The median age at transplantation was 71 years (range, 70 to 76); the median HCT comorbidity index score was 1 (range, 0 to 5). Two patients died before hematopoietic recovery (1 with graft failure and 1 with disease progression), and 1 patient relapsed before hematopoietic recovery; otherwise, all engrafted with median donor chimerism of 94% at 1 month. Cumulative incidence of grades II to IV acute GVHD was 13% and of grades III to IV acute GVHD, 9.3%. At 2 years, the cumulative incidence of chronic GVHD was 36%, progression-free survival was 39%, overall survival was 39%, and relapse was 56%. Nonrelapse mortality was 3.7% at day +100 and 5.6% at 2 years. We conclude that allogeneic HSCT is a safe and effective option for carefully selected patients age 70 or older.",Journal Article,2408.0,46.0,Allogeneic hematopoietic stem cell transplantation HSCT can achieve durable remissions in a number of patients with advanced hematologic malignancies Little is known about the safety of HSCT in patients age 70 or older Consecutive patients n 54 age 70 or older underwent HSCT between 2007 and 2012 Diseases included acute myelogenous n 25 syndrome n 12 chronic lymphocytic n 5 n 4 acute lymphoblastic n 3 neoplasm n 4 and chronic myelogenous n 1 Median follow-up for survivors was 21 months All patients received reduced-intensity conditioning regimens primarily busulfan/fludarabine All patients received unmanipulated peripheral blood stem cell grafts 44 from 8/8 matched unrelated donors 8 from matched related donors and 2 from 7/8 matched unrelated donors Graft-versus-host disease GVHD prophylaxis was calcineurin inhibitor-based in all patients The median age at transplantation was 71 years range 70 to 76 the median HCT comorbidity index score was 1 range 0 to 5 Two patients died before hematopoietic recovery 1 with graft failure and 1 with disease progression and 1 patient relapsed before hematopoietic recovery otherwise all engrafted with median donor chimerism of 94 at 1 month Cumulative incidence of grades II to IV acute GVHD was 13 and of grades III to IV acute GVHD 9.3 At 2 years the cumulative incidence of chronic GVHD was 36 progression-free survival was 39 overall survival was 39 and relapse was 56 Nonrelapse mortality was 3.7 at day +100 and 5.6 at 2 years We conclude that allogeneic HSCT is a safe and effective option for carefully selected patients age 70 or older,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[1063, 1007, 452, 31, 497, 1703, 122, 1359, 1480, 3166, 4, 8, 207, 1, 7, 5, 131, 813, 441, 1215, 16, 440, 545, 3, 367, 1, 1703, 4, 7, 89, 431, 15, 434, 935, 7, 78, 667, 89, 431, 15, 434, 208, 1703, 59, 1307, 2, 1195, 1342, 159, 286, 2194, 78, 243, 681, 78, 133, 442, 1193, 78, 33, 78, 39, 286, 1275, 78, 27, 2131, 78, 39, 2, 442, 2194, 78, 14, 52, 166, 126, 9, 332, 10, 239, 53, 62, 7, 103, 405, 837, 1933, 472, 1561, 3906, 2027, 62, 7, 103, 14413, 672, 315, 452, 31, 4713, 584, 29, 66, 66, 655, 2092, 2344, 66, 29, 655, 139, 2344, 2, 18, 29, 67, 66, 655, 2092, 2344, 1599, 185, 1204, 34, 1562, 2049, 10, 12028, 230, 90, 4, 62, 7, 3, 52, 89, 28, 497, 10, 792, 60, 184, 431, 6, 846, 3, 52, 1085, 1879, 558, 368, 10, 14, 184, 13, 6, 33, 100, 7, 1016, 348, 1007, 1602, 14, 5, 1599, 496, 2, 14, 5, 34, 91, 2, 14, 69, 591, 348, 1007, 1602, 2632, 62, 6914, 5, 52, 1488, 6047, 1, 960, 28, 14, 811, 967, 287, 1, 2276, 215, 6, 478, 286, 1562, 10, 233, 2, 1, 2276, 316, 6, 478, 286, 1562, 83, 27, 28, 18, 60, 3, 967, 287, 1, 442, 1562, 10, 511, 91, 115, 25, 10, 587, 63, 25, 10, 587, 2, 429, 10, 664, 4640, 282, 10, 27, 67, 28, 218, 394, 2, 33, 49, 28, 18, 60, 21, 2060, 17, 1063, 1703, 16, 8, 1165, 2, 323, 1501, 9, 3900, 715, 7, 89, 431, 15, 434]",1597.0,23791626,247
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.,Cancer research,Cancer Res.,2013-07-25,"Imatinib and other BCR-ABL1 inhibitors are effective therapies for chronic myelogenous leukemia (CML), but these inhibitors target additional kinases including KIT, raising the question of whether off-target effects contribute to clinical efficacy. On the basis of its involvement in CML pathogenesis, we hypothesized that KIT may govern responses of CML cells to imatinib. To test this, we assessed the growth of primary CML progenitor cells under conditions of sole BCR-ABL1, sole KIT, and dual BCR-ABL1/KIT inhibition. Sole BCR-ABL1 inhibition suppressed mature CML progenitor cells, but these effects were largely abolished by stem cell factor (SCF) and maximal suppression required dual BCR-ABL1/KIT inhibition. In contrast, KIT inhibition did not add to the effects of BCR-ABL1 inhibition in primitive progenitors, represented by CD34(+)38(-) cells. Long-term culture-initiating cell assays on murine stroma revealed profound depletion of primitive CML cells by sole BCR-ABL1 inhibition despite the presence of SCF, suggesting that primitive CML cells are unable to use SCF as a survival factor upon BCR-ABL1 inhibition. In CD34(+)38(+) cells, SCF strongly induced pAKT(S473) in a phosphoinositide 3-kinase (PI3K)-dependent manner, which was further enhanced by inhibition of BCR-ABL1 and associated with increased colony survival. In contrast, pAKT(S473) levels remained low in CD34(+)38(-) cells cultured under the same conditions. Consistent with reduced response to SCF, KIT surface expression was significantly lower on CD34(+)38(-) compared with CD34(+)38(+) CML cells, suggesting a possible mechanism for the differential effects of SCF on mature and primitive CML progenitor cells.",Journal Article,2371.0,12.0,Imatinib and other BCR-ABL1 inhibitors are effective therapies for chronic myelogenous CML but these inhibitors target additional kinases including KIT raising the question of whether off-target effects contribute to clinical efficacy On the basis of its involvement in CML pathogenesis we hypothesized that KIT may govern responses of CML cells to imatinib To test this we assessed the growth of primary CML progenitor cells under conditions of sole BCR-ABL1 sole KIT and dual BCR-ABL1/KIT inhibition Sole BCR-ABL1 inhibition suppressed mature CML progenitor cells but these effects were largely abolished by stem cell factor SCF and maximal suppression required dual BCR-ABL1/KIT inhibition In contrast KIT inhibition did not add to the effects of BCR-ABL1 inhibition in primitive progenitors represented by CD34 38 cells Long-term culture-initiating cell assays on murine stroma revealed profound depletion of primitive CML cells by sole BCR-ABL1 inhibition despite the presence of SCF suggesting that primitive CML cells are unable to use SCF as a survival factor upon BCR-ABL1 inhibition In CD34 38 cells SCF strongly induced pAKT S473 in a phosphoinositide 3-kinase PI3K -dependent manner which was further enhanced by inhibition of BCR-ABL1 and associated with increased colony survival In contrast pAKT S473 levels remained low in CD34 38 cells cultured under the same conditions Consistent with reduced response to SCF KIT surface expression was significantly lower on CD34 38 compared with CD34 38 CML cells suggesting a possible mechanism for the differential effects of SCF on mature and primitive CML progenitor cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 2, 127, 1062, 3557, 222, 32, 323, 235, 9, 442, 2194, 903, 84, 46, 222, 283, 402, 1549, 141, 1164, 6627, 3, 2840, 1, 317, 1889, 283, 176, 1248, 6, 38, 209, 23, 3, 877, 1, 211, 799, 4, 903, 1384, 21, 1237, 17, 1164, 68, 13779, 253, 1, 903, 37, 6, 577, 6, 412, 26, 21, 275, 3, 129, 1, 86, 903, 2520, 37, 669, 1298, 1, 4991, 1062, 3557, 4991, 1164, 2, 1828, 1062, 3557, 1164, 297, 4991, 1062, 3557, 297, 1908, 2908, 903, 2520, 37, 84, 46, 176, 11, 1733, 6020, 20, 452, 31, 161, 8447, 2, 2725, 1332, 616, 1828, 1062, 3557, 1164, 297, 4, 748, 1164, 297, 205, 44, 4178, 6, 3, 176, 1, 1062, 3557, 297, 4, 5594, 4321, 3324, 20, 2215, 519, 37, 319, 337, 2099, 2637, 31, 1013, 23, 1471, 2477, 553, 4399, 2286, 1, 5594, 903, 37, 20, 4991, 1062, 3557, 297, 550, 3, 463, 1, 8447, 802, 17, 5594, 903, 37, 32, 4253, 6, 119, 8447, 22, 8, 25, 161, 1548, 1062, 3557, 297, 4, 2215, 519, 37, 8447, 1327, 277, 6724, 17019, 4, 8, 4497, 27, 216, 974, 470, 1708, 92, 10, 195, 651, 20, 297, 1, 1062, 3557, 2, 41, 5, 101, 1975, 25, 4, 748, 6724, 17019, 148, 958, 154, 4, 2215, 519, 37, 3197, 669, 3, 827, 1298, 925, 5, 405, 51, 6, 8447, 1164, 1255, 55, 10, 97, 280, 23, 2215, 519, 72, 5, 2215, 519, 903, 37, 802, 8, 899, 670, 9, 3, 1777, 176, 1, 8447, 23, 2908, 2, 5594, 903, 2520, 37]",1630.0,23887971,161
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2013-07-26,"The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to respond, respond suboptimally, or experience disease relapse after treatment with imatinib. A key factor is drug resistance. The molecular mechanisms implicated in this resistance include those that involve upregulation or mutation of BCR-ABL kinase and those that are BCR-ABL independent. The clinical consequences of these molecular mechanisms of resistance for disease pathogenesis remain open for debate. This review summarizes the molecular mechanisms and clinical consequences of TKI resistance and addresses the current and future treatment approaches for patients with TKI-resistant CML. ",Journal Article,2370.0,51.0,The development of tyrosine kinase inhibitors TKIs has led to extended lifespans for many patients with chronic myelogenous CML However 20 to 30 of patients fail to respond respond suboptimally or experience disease relapse after treatment with imatinib A key factor is drug resistance The molecular mechanisms implicated in this resistance include those that involve upregulation or mutation of BCR-ABL kinase and those that are BCR-ABL independent The clinical consequences of these molecular mechanisms of resistance for disease pathogenesis remain open for debate This review summarizes the molecular mechanisms and clinical consequences of TKI resistance and addresses the current and future treatment approaches for patients with TKI-resistant CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 193, 1, 564, 216, 222, 1671, 71, 836, 6, 1747, 47863, 9, 445, 7, 5, 442, 2194, 903, 137, 179, 6, 201, 1, 7, 4373, 6, 1892, 1892, 14800, 15, 730, 34, 429, 50, 24, 5, 577, 8, 825, 161, 16, 234, 251, 3, 219, 483, 1771, 4, 26, 251, 643, 135, 17, 3882, 2218, 15, 258, 1, 1062, 1425, 216, 2, 135, 17, 32, 1062, 1425, 306, 3, 38, 3255, 1, 46, 219, 483, 1, 251, 9, 34, 1384, 918, 1020, 9, 5220, 26, 206, 2869, 3, 219, 483, 2, 38, 3255, 1, 1379, 251, 2, 5437, 3, 291, 2, 508, 24, 611, 9, 7, 5, 1379, 436, 903]",753.0,23890944,10
Differential regulation of myeloid leukemias by the bone marrow microenvironment.,Nature medicine,Nat. Med.,2013-10-27,"Like their normal hematopoietic stem cell counterparts, leukemia stem cells (LSCs) in chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML) are presumed to reside in specific niches in the bone marrow microenvironment (BMM) and may be the cause of relapse following chemotherapy. Targeting the niche is a new strategy to eliminate persistent and drug-resistant LSCs. CD44 (refs. 3,4) and interleukin-6 (ref. 5) have been implicated previously in the LSC niche. Transforming growth factor-1 (TGF-1) is released during bone remodeling and plays a part in maintenance of CML LSCs, but a role for TGF-1 from the BMM has not been defined. Here, we show that alteration of the BMM by osteoblastic cell-specific activation of the parathyroid hormone (PTH) receptor attenuates BCR-ABL1 oncogene-induced CML-like myeloproliferative neoplasia (MPN) but enhances MLL-AF9 oncogene-induced AML in mouse transplantation models, possibly through opposing effects of increased TGF-1 on the respective LSCs. PTH treatment caused a 15-fold decrease in LSCs in wild-type mice with CML-like MPN and reduced engraftment of immune-deficient mice with primary human CML cells. These results demonstrate that LSC niches in CML and AML are distinct and suggest that modulation of the BMM by PTH may be a feasible strategy to reduce LSCs, a prerequisite for the cure of CML. ",Journal Article,2277.0,141.0,"Like their normal hematopoietic stem cell counterparts stem cells LSCs in chronic myelogenous CML and acute myeloid AML are presumed to reside in specific niches in the marrow microenvironment BMM and may be the cause of relapse following chemotherapy Targeting the niche is a new strategy to eliminate persistent and drug-resistant LSCs CD44 refs 3,4 and interleukin-6 ref 5 have been implicated previously in the LSC niche Transforming growth factor-1 TGF-1 is released during remodeling and plays a part in maintenance of CML LSCs but a role for TGF-1 from the BMM has not been defined Here we show that alteration of the BMM by osteoblastic cell-specific activation of the hormone PTH receptor attenuates BCR-ABL1 oncogene-induced CML-like neoplasia MPN but enhances MLL-AF9 oncogene-induced AML in mouse transplantation models possibly through opposing effects of increased TGF-1 on the respective LSCs PTH treatment caused a 15-fold decrease in LSCs in wild-type mice with CML-like MPN and reduced engraftment of immune-deficient mice with primary human CML cells These results demonstrate that LSC niches in CML and AML are distinct and suggest that modulation of the BMM by PTH may be a feasible strategy to reduce LSCs a prerequisite for the cure of CML",0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[733, 136, 295, 1007, 452, 31, 3953, 452, 37, 7033, 4, 442, 2194, 903, 2, 286, 533, 329, 32, 5472, 6, 10114, 4, 112, 8005, 4, 3, 581, 995, 22445, 2, 68, 40, 3, 708, 1, 429, 366, 56, 529, 3, 4385, 16, 8, 217, 692, 6, 4964, 1882, 2, 234, 436, 7033, 3035, 22067, 27, 39, 2, 1603, 49, 7357, 33, 47, 85, 1771, 373, 4, 3, 6643, 4385, 3621, 129, 161, 5386, 2387, 5386, 16, 5394, 190, 4429, 2, 1698, 8, 760, 4, 1146, 1, 903, 7033, 84, 8, 200, 9, 2387, 5386, 29, 3, 22445, 71, 44, 85, 395, 467, 21, 514, 17, 2611, 1, 3, 22445, 20, 7522, 31, 112, 363, 1, 3, 785, 17293, 153, 9100, 1062, 3557, 1836, 277, 903, 733, 2298, 4125, 84, 2519, 3049, 12004, 1836, 277, 329, 4, 830, 497, 274, 2150, 298, 9187, 176, 1, 101, 2387, 5386, 23, 3, 3847, 7033, 17293, 24, 1546, 8, 167, 1116, 775, 4, 7033, 4, 955, 267, 399, 5, 903, 733, 4125, 2, 405, 2881, 1, 250, 1971, 399, 5, 86, 171, 903, 37, 46, 99, 608, 17, 6643, 8005, 4, 903, 2, 329, 32, 834, 2, 309, 17, 2356, 1, 3, 22445, 20, 17293, 68, 40, 8, 1313, 692, 6, 969, 7033, 8, 12088, 9, 3, 1722, 1, 903]",1266.0,24162813,259
"Chronic Myelogenous Leukemia, Version 1.2014.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2013-11-01,"The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level 10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months). ",Journal Article,2272.0,46.0,The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous recommend quantitative reverse-transcription polymerase chain reaction QPCR standardized to International Scale IS as the preferred method for monitoring molecular response to tyrosine kinase inhibitor TKI therapy A BCR-ABL1 transcript level of 10 or less IS is now included as the response milestone at 3 and 6 months Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10 IS at 3 months after primary treatment with imatinib Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10 IS at 3 months after primary treatment with dasatinib or nilotinib The guidelines recommend 6-month evaluation with QPCR IS for patients with BCR-ABL1 transcript levels greater than 10 at 3 months Monitoring with QPCR IS every 3 months is recommended for all patients including those who meet response milestones at 3 6 12 and 18 months BCR-ABL1 transcript level 10 IS at 3 and 6 months complete cytogenetic response at 12 and 18 months,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1409, 1944, 38, 758, 677, 4, 413, 9, 442, 2194, 2237, 1156, 1772, 866, 1451, 1260, 1329, 6162, 1670, 6, 944, 1124, 16, 22, 3, 2514, 596, 9, 1315, 219, 51, 6, 564, 216, 230, 1379, 36, 8, 1062, 3557, 3268, 301, 1, 79, 15, 299, 16, 16, 1134, 159, 22, 3, 51, 12821, 28, 27, 2, 49, 53, 707, 1, 36, 6, 35, 4689, 1379, 16, 793, 9, 7, 5, 1062, 3557, 3268, 148, 378, 76, 79, 16, 28, 27, 53, 50, 86, 24, 5, 577, 4346, 3, 827, 61, 1, 1379, 15, 7718, 6, 35, 4689, 1379, 32, 838, 9, 7, 5, 1062, 3557, 3268, 148, 378, 76, 79, 16, 28, 27, 53, 50, 86, 24, 5, 1674, 15, 2638, 3, 677, 2237, 49, 811, 451, 5, 6162, 16, 9, 7, 5, 1062, 3557, 3268, 148, 378, 76, 79, 28, 27, 53, 1315, 5, 6162, 16, 454, 27, 53, 16, 793, 9, 62, 7, 141, 135, 54, 3362, 51, 12118, 28, 27, 49, 133, 2, 203, 53, 1062, 3557, 3268, 301, 11209, 16, 28, 27, 2, 49, 53, 236, 1266, 51, 28, 133, 2, 203, 53]",1140.0,24225967,204
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.,Blood,Blood,2013-12-19,"Increasing evidence across malignancies suggests that infiltrating T cells at the site of disease are crucial to tumor control. We hypothesized that marrow-infiltrating immune populations play a critical role in response to donor lymphocyte infusion (DLI), an established and potentially curative immune therapy whose precise mechanism remains unknown. We therefore analyzed marrow-infiltrating immune populations in 29 patients (22 responders, 7 nonresponders) with relapsed chronic myelogenous leukemia who received CD4(+) DLI in the pre-tyrosine kinase inhibitor era. Immunohistochemical analysis of pretreatment marrow revealed that the presence of >4% marrow-infiltrating CD8(+) (but not CD4(+)) T cells predicted DLI response, even in the setting of high leukemia burden. Furthermore, mRNA expression profiling of marrow-infiltrating T cells of a subset of responders compared with nonresponders revealed enrichment of T-cell exhaustion-specific genes in pretreatment T cells of DLI responders and significant downregulation of gene components in the same pathway in responders in conjunction with clinical response. Our data demonstrate that response to DLI is associated with quantity of preexisting marrow CD8(+) T cells and local reversal of T-cell exhaustion. Our studies implicate T-cell exhaustion as a therapeutic target of DLI and support the potential use of novel anti-PD1/PDL1 agents in lieu of DLI. ",Journal Article,2224.0,45.0,Increasing evidence across malignancies suggests that infiltrating T cells at the site of disease are crucial to tumor control We hypothesized that marrow-infiltrating immune populations play a critical role in response to donor lymphocyte infusion DLI an established and potentially curative immune therapy whose precise mechanism remains unknown We therefore analyzed marrow-infiltrating immune populations in 29 patients 22 responders 7 nonresponders with relapsed chronic myelogenous who received CD4 DLI in the pre-tyrosine kinase inhibitor era Immunohistochemical analysis of pretreatment marrow revealed that the presence of 4 marrow-infiltrating CD8 but not CD4 T cells predicted DLI response even in the setting of high burden Furthermore mRNA expression profiling of marrow-infiltrating T cells of a subset of responders compared with nonresponders revealed enrichment of T-cell exhaustion-specific genes in pretreatment T cells of DLI responders and significant downregulation of gene components in the same pathway in responders in conjunction with clinical response Our data demonstrate that response to DLI is associated with quantity of preexisting marrow CD8 T cells and local reversal of T-cell exhaustion Our studies implicate T-cell exhaustion as a therapeutic target of DLI and support the potential use of novel anti-PD1/PDL1 agents in lieu of DLI,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[602, 241, 716, 441, 844, 17, 2097, 102, 37, 28, 3, 606, 1, 34, 32, 2653, 6, 30, 182, 21, 1237, 17, 581, 2097, 250, 1184, 1343, 8, 740, 200, 4, 51, 6, 1488, 1448, 904, 4676, 35, 635, 2, 751, 1075, 250, 36, 1310, 3260, 670, 469, 860, 21, 673, 311, 581, 2097, 250, 1184, 4, 462, 7, 350, 1983, 67, 4498, 5, 591, 442, 2194, 54, 103, 1440, 4676, 4, 3, 671, 564, 216, 230, 1713, 1382, 65, 1, 1194, 581, 553, 17, 3, 463, 1, 39, 581, 2097, 968, 84, 44, 1440, 102, 37, 783, 4676, 51, 871, 4, 3, 546, 1, 64, 892, 798, 956, 55, 1080, 1, 581, 2097, 102, 37, 1, 8, 697, 1, 1983, 72, 5, 4498, 553, 3020, 1, 102, 31, 7960, 112, 214, 4, 1194, 102, 37, 1, 4676, 1983, 2, 93, 2475, 1, 145, 1628, 4, 3, 827, 308, 4, 1983, 4, 3357, 5, 38, 51, 114, 74, 608, 17, 51, 6, 4676, 16, 41, 5, 7701, 1, 5004, 581, 968, 102, 37, 2, 293, 5933, 1, 102, 31, 7960, 114, 94, 5545, 102, 31, 7960, 22, 8, 189, 283, 1, 4676, 2, 538, 3, 174, 119, 1, 229, 312, 4893, 8830, 183, 4, 14575, 1, 4676]",1368.0,24357730,260
Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.,Journal of hematology & oncology,J Hematol Oncol,2014-03-27,"The FIP1L1-PDGFRA rearrangement results in constitutive activation of the tyrosine kinase PDGFRA. Neoplasms harboring this rearrangement are responsive to imatinib mesylate at doses much lower than those recommended for the treatment of chronic myelogenous leukemia. Only a single report has described the identification of FIP1L1-PDGFRA in chronic myelomonocytic leukemia (CMML). Herein, we present a case report of a patient in whom the FIP1L1-PDGFRA was discovered as he evolved from CMML to acute myeloid leukemia (AML). The presence of a dominant neoplastic clone with FIP1L1-PDGFRA rearrangement was suspected on the basis of sudden onset of peripheral and bone marrow eosinophilia and confirmed by fluorescence in situ hybridization and molecular diagnostic tests. Whereas the patient was initially refractory to chemotherapy before the rearrangement was detected, subsequent therapy with imatinib led to complete remission. ",Case Reports,2126.0,9.0,The FIP1L1-PDGFRA rearrangement results in constitutive activation of the tyrosine kinase PDGFRA Neoplasms harboring this rearrangement are responsive to imatinib mesylate at doses much lower than those recommended for the treatment of chronic myelogenous Only a single report has described the identification of FIP1L1-PDGFRA in chronic myelomonocytic CMML Herein we present a case report of a patient in whom the FIP1L1-PDGFRA was discovered as he evolved from CMML to acute myeloid AML The presence of a dominant neoplastic clone with FIP1L1-PDGFRA rearrangement was suspected on the basis of sudden onset of peripheral and marrow eosinophilia and confirmed by fluorescence in situ hybridization and molecular diagnostic tests Whereas the patient was initially refractory to chemotherapy before the rearrangement was detected subsequent therapy with imatinib led to complete remission,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 21746, 4006, 2675, 99, 4, 3178, 363, 1, 3, 564, 216, 4006, 1179, 2105, 26, 2675, 32, 2443, 6, 577, 2347, 28, 415, 1802, 280, 76, 135, 793, 9, 3, 24, 1, 442, 2194, 158, 8, 226, 414, 71, 1027, 3, 911, 1, 21746, 4006, 4, 442, 5451, 3382, 1986, 21, 364, 8, 473, 414, 1, 8, 69, 4, 953, 3, 21746, 4006, 10, 2747, 22, 3174, 3937, 29, 3382, 6, 286, 533, 329, 3, 463, 1, 8, 2156, 2000, 3910, 5, 21746, 4006, 2675, 10, 2768, 23, 3, 877, 1, 10643, 1707, 1, 672, 2, 581, 13555, 2, 557, 20, 1591, 4, 957, 1554, 2, 219, 752, 895, 547, 3, 69, 10, 1625, 430, 6, 56, 348, 3, 2675, 10, 530, 706, 36, 5, 577, 836, 6, 236, 734]",887.0,24669761,249
Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressings in two bone marrow transplant recipients with cutaneous graft-versus-host disease.,Pharmacotherapy,Pharmacotherapy,2014-04-03,"Tacrolimus, a macrolide immunosuppressant, is used topically for the treatment of cutaneous manifestations of graft-versus-host disease (GVHD) for rapid, symptomatic relief of pruritus and erythema. Despite the manufacturer's product information reporting minimal systemic effects of topical tacrolimus, this has not been evaluated in patients with cutaneous GVHD and with occlusive dressings. We describe two patients with cutaneous GVHD who developed toxic tacrolimus levels after receiving several applications of tacrolimus ointment along with occlusive dressings to enhance skin effectiveness. The first patient was a 62-year-old woman with a history of acute myelogenous leukemia (AML) who underwent allogeneic bone marrow transplantation and developed chronic GVHD involving 70% of her body surface area. Her GVHD treatment plan consisted of oral corticosteroids, oral tacrolimus, topical corticosteroids, topical tacrolimus 0.1% ointment twice/day, emollient creams, intravenous rituximab, and photopheresis. The patient's tacrolimus trough levels rose rapidly over the course of 6 days from less than 2 ng/ml to 23 ng/ml, despite oral tacrolimus dosage adjustments. The second patient was a 25-year-old man who developed severe, chronic skin GVHD after undergoing allogeneic sibling bone marrow transplantation for AML. In addition to intravenous corticosteroids, corticosteroid creams, and oral tacrolimus, the patient also received topical tacrolimus twice/day with occlusive dressings. Over the course of 2 days, his tacrolimus trough levels increased from 7.10 ng/ml to 22.10 ng/ml. Although improvement was noted in both patients' skin GVHD with application of the occlusive dressings, the practice was discontinued due to increased and erratic systemic tacrolimus absorption. These case reports suggest that substantial use of topical tacrolimus with occlusive dressings in patients with cutaneous GVHD may contribute to increased systemic absorption resulting in toxic tacrolimus levels. Based on the findings from our two patients as well as published case reports, systemic absorption appears to increase with greater skin permeability, skin barrier dysfunction, amount of body surface area applied, and use of occlusive dressings. When one or more of these factors are present, it may be prudent to monitor tacrolimus levels.",Case Reports,2119.0,9.0,Tacrolimus a macrolide immunosuppressant is used topically for the treatment of cutaneous manifestations of graft-versus-host disease GVHD for rapid symptomatic relief of pruritus and erythema Despite the manufacturer 's product information reporting minimal systemic effects of topical tacrolimus this has not been evaluated in patients with cutaneous GVHD and with occlusive dressings We describe two patients with cutaneous GVHD who developed toxic tacrolimus levels after receiving several applications of tacrolimus ointment along with occlusive dressings to enhance effectiveness The first patient was a 62-year-old woman with a history of acute myelogenous AML who underwent allogeneic marrow transplantation and developed chronic GVHD involving 70 of her body surface area Her GVHD treatment plan consisted of oral corticosteroids oral tacrolimus topical corticosteroids topical tacrolimus 0.1 ointment twice/day emollient creams intravenous rituximab and photopheresis The patient 's tacrolimus trough levels rose rapidly over the course of 6 days from less than 2 ng/ml to 23 ng/ml despite oral tacrolimus dosage adjustments The second patient was a 25-year-old man who developed severe chronic GVHD after undergoing allogeneic sibling marrow transplantation for AML In addition to intravenous corticosteroids corticosteroid creams and oral tacrolimus the patient also received topical tacrolimus twice/day with occlusive dressings Over the course of 2 days his tacrolimus trough levels increased from 7.10 ng/ml to 22.10 ng/ml Although improvement was noted in both patients GVHD with application of the occlusive dressings the practice was discontinued due to increased and erratic systemic tacrolimus absorption These case reports suggest that substantial use of topical tacrolimus with occlusive dressings in patients with cutaneous GVHD may contribute to increased systemic absorption resulting in toxic tacrolimus levels Based on the findings from our two patients as well as published case reports systemic absorption appears to increase with greater permeability barrier dysfunction amount of body surface area applied and use of occlusive dressings When one or more of these factors are present it may be prudent to monitor tacrolimus levels,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[5643, 8, 28247, 20343, 16, 95, 21012, 9, 3, 24, 1, 1486, 4282, 1, 1599, 185, 1204, 34, 1562, 9, 1321, 1704, 4586, 1, 6858, 2, 9167, 550, 3, 18245, 292, 2821, 487, 1760, 1048, 403, 176, 1, 5879, 5643, 26, 71, 44, 85, 194, 4, 7, 5, 1486, 1562, 2, 5, 8376, 29550, 21, 897, 100, 7, 5, 1486, 1562, 54, 276, 1812, 5643, 148, 50, 357, 392, 2911, 1, 5643, 32217, 1510, 5, 8376, 29550, 6, 1304, 1236, 3, 157, 69, 10, 8, 744, 111, 1095, 2854, 5, 8, 532, 1, 286, 2194, 329, 54, 208, 1063, 581, 497, 2, 276, 442, 1562, 1267, 431, 1, 1084, 642, 1255, 965, 1084, 1562, 24, 2242, 1695, 1, 518, 3876, 518, 5643, 5879, 3876, 5879, 5643, 13, 14, 32217, 936, 218, 37898, 48283, 1262, 855, 2, 22166, 3, 69, 292, 5643, 6000, 148, 7370, 1755, 252, 3, 906, 1, 49, 162, 29, 299, 76, 18, 997, 542, 6, 382, 997, 542, 550, 518, 5643, 3323, 6017, 3, 419, 69, 10, 8, 243, 111, 1095, 3628, 54, 276, 905, 442, 1562, 50, 479, 1063, 3684, 581, 497, 9, 329, 4, 352, 6, 1262, 3876, 5654, 48283, 2, 518, 5643, 3, 69, 120, 103, 5879, 5643, 936, 218, 5, 8376, 29550, 252, 3, 906, 1, 18, 162, 3224, 5643, 6000, 148, 101, 29, 67, 79, 997, 542, 6, 350, 79, 997, 542, 242, 767, 10, 1051, 4, 110, 7, 1562, 5, 1581, 1, 3, 8376, 29550, 3, 758, 10, 2402, 520, 6, 101, 2, 35785, 403, 5643, 6125, 46, 473, 1198, 309, 17, 1281, 119, 1, 5879, 5643, 5, 8376, 29550, 4, 7, 5, 1486, 1562, 68, 1248, 6, 101, 403, 6125, 1113, 4, 1812, 5643, 148, 90, 23, 3, 272, 29, 114, 100, 7, 22, 149, 22, 983, 473, 1198, 403, 6125, 1233, 6, 344, 5, 378, 4757, 3318, 1527, 3108, 1, 642, 1255, 965, 1498, 2, 119, 1, 8376, 29550, 198, 104, 15, 80, 1, 46, 130, 32, 364, 192, 68, 40, 10263, 6, 3334, 5643, 148]",2260.0,24700567,23
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.,American journal of hematology,Am. J. Hematol.,2014-03-01,"Dasatinib is a second generation tyrosine kinase inhibitor, with activity in imatinib resistant Ph-positive ALL.We have treated 34 patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia(ALL) (n519) or lymphoid blast phase of chronic myelogenous leukemia (CML-LB) (n515) with the combination of dasatinib and the hyper CVAD regimen. Prior regimens included hyper CVAD plus imatinib(n511, 4 had transplant in first CR), other combination chemotherapy (n512), monotherapy with kinase inhibitors other than dasatinib (n59), and investigational agents (n52). Pretreatment ABL mutations were noted in 10 patients. The overall response rate was 91%, with 24 patients (71%) achieving complete response(CR), and 7(21%) CR with incomplete platelet recovery (CRp). Two patients died during induction and one had progressive disease. Twenty-six patients (84%) achieved complete cytogenetic remission after one cycle of therapy. Overall, 13 patients (42%) achieved complete molecular response, and 11 patients (35%) had major molecular response (BCR-ABL/ABL<0.1%). Nine patients proceeded to allogeneic transplantation.Grades 3 and 4 toxicities included hemorrhage, pleural and pericardial effusions and infections. The median follow-up for patients with CML-LB is 37.5 months (range, 770 months) with a 3-year overall survival of 70%;68% remained in CR at 3 years. For ALL patients, the median follow-up is 52 months (range, 4559 months)with a 3-year survival of 26%; 30% remain in CR at 3 years. The combination of Hyper CVAD regimen with dasatinib is effective in patients with relapsed Ph-positive ALL and CML-LB.","Clinical Trial, Phase II",2152.0,35.0,Dasatinib is a second generation tyrosine kinase inhibitor with activity in imatinib resistant Ph-positive ALL.We have treated 34 patients with relapsed Philadelphia chromosome positive acute lymphoblastic ALL n519 or lymphoid blast phase of chronic myelogenous CML-LB n515 with the combination of dasatinib and the hyper CVAD regimen Prior regimens included hyper CVAD plus imatinib n511 4 had transplant in first CR other combination chemotherapy n512 monotherapy with kinase inhibitors other than dasatinib n59 and investigational agents n52 Pretreatment ABL mutations were noted in 10 patients The overall response rate was 91 with 24 patients 71 achieving complete response CR and 7 21 CR with incomplete platelet recovery CRp Two patients died during induction and one had progressive disease Twenty-six patients 84 achieved complete cytogenetic remission after one cycle of therapy Overall 13 patients 42 achieved complete molecular response and 11 patients 35 had major molecular response BCR-ABL/ABL 0.1 Nine patients proceeded to allogeneic transplantation.Grades 3 and 4 toxicities included hemorrhage pleural and pericardial effusions and infections The median follow-up for patients with CML-LB is 37.5 months range 770 months with a 3-year overall survival of 70 68 remained in CR at 3 years For ALL patients the median follow-up is 52 months range 4559 months with a 3-year survival of 26 30 remain in CR at 3 years The combination of Hyper CVAD regimen with dasatinib is effective in patients with relapsed Ph-positive ALL and CML-LB,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1674, 16, 8, 419, 914, 564, 216, 230, 5, 128, 4, 577, 436, 2058, 109, 62, 21, 47, 73, 562, 7, 5, 591, 3006, 1170, 109, 286, 1275, 62, 64282, 15, 2303, 3112, 124, 1, 442, 2194, 903, 13121, 64283, 5, 3, 150, 1, 1674, 2, 3, 4855, 5574, 477, 324, 472, 159, 4855, 5574, 349, 577, 64284, 39, 42, 941, 4, 157, 684, 127, 150, 56, 64285, 1411, 5, 216, 222, 127, 76, 1674, 64286, 2, 3093, 183, 64287, 1194, 1425, 138, 11, 1051, 4, 79, 7, 3, 63, 51, 116, 10, 970, 5, 259, 7, 792, 1785, 236, 51, 684, 2, 67, 239, 684, 5, 2610, 1596, 1602, 3162, 100, 7, 1016, 190, 504, 2, 104, 42, 1014, 34, 737, 437, 7, 874, 513, 236, 1266, 734, 50, 104, 417, 1, 36, 63, 233, 7, 595, 513, 236, 219, 51, 2, 175, 7, 465, 42, 458, 219, 51, 1062, 1425, 1425, 13, 14, 762, 7, 6406, 6, 1063, 497, 2276, 27, 2, 39, 385, 159, 3599, 2164, 2, 6657, 5154, 2, 1875, 3, 52, 166, 126, 9, 7, 5, 903, 13121, 16, 567, 33, 53, 184, 64288, 53, 5, 8, 27, 111, 63, 25, 1, 431, 806, 958, 4, 684, 28, 27, 60, 9, 62, 7, 3, 52, 166, 126, 16, 653, 53, 184, 64289, 53, 5, 8, 27, 111, 25, 1, 432, 201, 918, 4, 684, 28, 27, 60, 3, 150, 1, 4855, 5574, 477, 5, 1674, 16, 323, 4, 7, 5, 591, 2058, 109, 62, 2, 903, 13121]",1551.0,24779033,50
"Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2014-08-01,"Retrospective review of imatinib monitoring through electronic health records (EHR) can provide valuable insight into the current management of chronic myelogenous leukemia (CML). This study retrospectively reviewed EHRs from 2001 to 2010 of patients with chronic phase CML (CP-CML) treated with first-line imatinib. Chart evaluations included a review of cytogenetic and molecular testing, overall survival, adverse drug events (ADEs), and therapy modifications. A total of 54 patients with CP-CML were treated with first-line imatinib and had either cytogenetic or molecular testing within 18 months of imatinib initiation. Within the first 18 months of treatment, 33 of 45 patients (73%) undergoing cytogenetic testing experienced a complete cytogenetic response (median, 241 days; range, 110-542 days) and 24 of 48 patients (50%) receiving molecular testing achieved at least a major molecular response (median, 253 days; range, 99-546 days). The average number of cytogenetic and molecular tests conducted within the first 18 months was 2.5 and 3.8, respectively. Nineteen of 54 (35%) had a dose increase of imatinib (>400 mg; median, 329 days; range, 21-1968 days). The 5-year estimated overall survival rate was 88.5%. Between 2006 and 2010 (n=30; 56%), 7 patients (23%) transitioned to dasatinib or nilotinib (median, 399 days from diagnosis; range, 180-1046 days) because of suboptimal response or treatment failure (n=5) and imatinib ADEs (n=2). Forty-six imatinib-associated ADEs occurred in 31 patients (57%), of which 10 (32%) received dose reductions (median, 52 days) and 6 (19%) had discontinuations (median, 139 days). Closely monitored patients with CML treated with imatinib at an NCCN Member Institution experienced outcomes comparable to those reported in key clinical trials. ",Journal Article,1999.0,4.0,Retrospective review of imatinib monitoring through electronic health records EHR can provide valuable insight into the current management of chronic myelogenous CML This study retrospectively reviewed EHRs from 2001 to 2010 of patients with chronic phase CML CP-CML treated with first-line imatinib Chart evaluations included a review of cytogenetic and molecular testing overall survival adverse drug events ADEs and therapy modifications A total of 54 patients with CP-CML were treated with first-line imatinib and had either cytogenetic or molecular testing within 18 months of imatinib initiation Within the first 18 months of treatment 33 of 45 patients 73 undergoing cytogenetic testing experienced a complete cytogenetic response median 241 days range 110-542 days and 24 of 48 patients 50 receiving molecular testing achieved at least a major molecular response median 253 days range 99-546 days The average number of cytogenetic and molecular tests conducted within the first 18 months was 2.5 and 3.8 respectively Nineteen of 54 35 had a dose increase of imatinib 400 mg median 329 days range 21-1968 days The 5-year estimated overall survival rate was 88.5 Between 2006 and 2010 n=30 56 7 patients 23 transitioned to dasatinib or nilotinib median 399 days from diagnosis range 180-1046 days because of suboptimal response or treatment failure n=5 and imatinib ADEs n=2 Forty-six imatinib-associated ADEs occurred in 31 patients 57 of which 10 32 received dose reductions median 52 days and 6 19 had discontinuations median 139 days Closely monitored patients with CML treated with imatinib at an NCCN Member Institution experienced outcomes comparable to those reported in key clinical trials,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[459, 206, 1, 577, 1315, 298, 3098, 341, 1064, 16158, 122, 377, 2926, 2670, 237, 3, 291, 284, 1, 442, 2194, 903, 26, 45, 894, 446, 20858, 29, 1758, 6, 1120, 1, 7, 5, 442, 124, 903, 2541, 903, 73, 5, 157, 328, 577, 2937, 3816, 159, 8, 206, 1, 1266, 2, 219, 471, 63, 25, 290, 234, 281, 22775, 2, 36, 2916, 8, 181, 1, 667, 7, 5, 2541, 903, 11, 73, 5, 157, 328, 577, 2, 42, 361, 1266, 15, 219, 471, 262, 203, 53, 1, 577, 1118, 262, 3, 157, 203, 53, 1, 24, 466, 1, 512, 7, 803, 479, 1266, 471, 592, 8, 236, 1266, 51, 52, 7086, 162, 184, 3129, 10895, 162, 2, 259, 1, 576, 7, 212, 357, 219, 471, 513, 28, 506, 8, 458, 219, 51, 52, 8105, 162, 184, 1058, 11912, 162, 3, 1011, 207, 1, 1266, 2, 219, 895, 426, 262, 3, 157, 203, 53, 10, 18, 33, 2, 27, 66, 106, 3498, 1, 667, 465, 42, 8, 61, 344, 1, 577, 1524, 81, 52, 8766, 162, 184, 239, 17767, 162, 3, 33, 111, 661, 63, 25, 116, 10, 889, 33, 59, 1324, 2, 1120, 78, 201, 664, 67, 7, 382, 13987, 6, 1674, 15, 2638, 52, 9623, 162, 29, 147, 184, 3172, 29394, 162, 408, 1, 3291, 51, 15, 24, 496, 78, 33, 2, 577, 22775, 78, 18, 1213, 437, 577, 41, 22775, 489, 4, 456, 7, 696, 1, 92, 79, 531, 103, 61, 2153, 52, 653, 162, 2, 49, 326, 42, 8692, 52, 4929, 162, 3210, 2909, 7, 5, 903, 73, 5, 577, 28, 35, 1944, 2693, 731, 592, 123, 1279, 6, 135, 210, 4, 825, 38, 143]",1704.0,25099443,11
Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.,Blood,Blood,2014-08-26,"We examined current outcomes of unrelated donor allogeneic hematopoietic cell transplantation (HCT) to determine the clinical implications of donor-recipient HLA matching. Adult and pediatric patients who had first undergone myeloablative-unrelated bone marrow or peripheral blood HCT for acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome between 1999 and 2011 were included. All had high-resolution typing for HLA-A, -B, -C, and -DRB1. Of the total (n = 8003), cases were 8/8 (n = 5449), 7/8 (n = 2071), or 6/8 (n = 483) matched. HLA mismatch (6-7/8) conferred significantly increased risk for grades II to IV and III to IV acute graft vs host disease (GVHD), chronic GVHD, transplant-related mortality (TRM), and overall mortality compared with HLA-matched cases (8/8). Type (allele/antigen) and locus (HLA-A, -B, -C, and -DRB1) of mismatch were not associated with overall mortality. Among 8/8 matched cases, HLA-DPB1 and -DQB1 mismatch resulted in increased acute GVHD, and HLA-DPB1 mismatch had decreased relapse. Nonpermissive HLA-DPB1 allele mismatch was associated with higher TRM compared with permissive HLA-DPB1 mismatch or HLA-DPB1 match and increased overall mortality compared with permissive HLA-DPB1 mismatch in 8/8 (and 10/10) matched cases. Full matching at HLA-A, -B, -C, and -DRB1 is required for optimal unrelated donor HCT survival, and avoidance of nonpermissive HLA-DPB1 mismatches in otherwise HLA-matched pairs is indicated. ",Journal Article,1974.0,118.0,We examined current outcomes of unrelated donor allogeneic hematopoietic cell transplantation HCT to determine the clinical implications of donor-recipient HLA matching Adult and pediatric patients who had first undergone myeloablative-unrelated marrow or peripheral blood HCT for acute myelogenous acute lymphoblastic chronic myelogenous and syndrome between 1999 and 2011 were included All had high-resolution typing for HLA-A -B -C and -DRB1 Of the total n 8003 cases were 8/8 n 5449 7/8 n 2071 or 6/8 n 483 matched HLA mismatch 6-7/8 conferred significantly increased risk for grades II to IV and III to IV acute graft vs host disease GVHD chronic GVHD transplant-related mortality TRM and overall mortality compared with HLA-matched cases 8/8 Type allele/antigen and locus HLA-A -B -C and -DRB1 of mismatch were not associated with overall mortality Among 8/8 matched cases HLA-DPB1 and -DQB1 mismatch resulted in increased acute GVHD and HLA-DPB1 mismatch had decreased relapse Nonpermissive HLA-DPB1 allele mismatch was associated with higher TRM compared with permissive HLA-DPB1 mismatch or HLA-DPB1 match and increased overall mortality compared with permissive HLA-DPB1 mismatch in 8/8 and 10/10 matched cases Full matching at HLA-A -B -C and -DRB1 is required for optimal unrelated donor HCT survival and avoidance of nonpermissive HLA-DPB1 mismatches in otherwise HLA-matched pairs is indicated,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 409, 291, 123, 1, 2092, 1488, 1063, 1007, 31, 497, 1085, 6, 223, 3, 38, 1268, 1, 1488, 5783, 1160, 2616, 780, 2, 815, 7, 54, 42, 157, 1989, 3246, 2092, 581, 15, 672, 315, 1085, 9, 286, 2194, 286, 1275, 442, 2194, 2, 681, 59, 2043, 2, 1132, 11, 159, 62, 42, 64, 2125, 10656, 9, 1160, 8, 132, 256, 2, 8147, 1, 3, 181, 78, 64809, 140, 11, 66, 66, 78, 64810, 67, 66, 78, 48547, 15, 49, 66, 78, 10661, 655, 1160, 2617, 49, 67, 66, 3851, 97, 101, 43, 9, 2276, 215, 6, 478, 2, 316, 6, 478, 286, 1599, 105, 1204, 34, 1562, 442, 1562, 941, 139, 282, 5064, 2, 63, 282, 72, 5, 1160, 655, 140, 66, 66, 267, 1254, 448, 2, 2474, 1160, 8, 132, 256, 2, 8147, 1, 2617, 11, 44, 41, 5, 63, 282, 107, 66, 66, 655, 140, 1160, 13735, 2, 25301, 2617, 627, 4, 101, 286, 1562, 2, 1160, 13735, 2617, 42, 340, 429, 24146, 1160, 13735, 1254, 2617, 10, 41, 5, 142, 5064, 72, 5, 11080, 1160, 13735, 2617, 15, 1160, 13735, 5364, 2, 101, 63, 282, 72, 5, 11080, 1160, 13735, 2617, 4, 66, 66, 2, 79, 79, 655, 140, 1647, 2616, 28, 1160, 8, 132, 256, 2, 8147, 16, 616, 9, 665, 2092, 1488, 1085, 25, 2, 5863, 1, 24146, 1160, 13735, 11828, 4, 2632, 1160, 655, 2773, 16, 1103]",1407.0,25161269,8
"Chronic myelogenous leukemia, version 1.2015.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2014-11-01,"Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML. ",Journal Article,1907.0,40.0,Chronic myelogenous CML is usually diagnosed in the chronic phase Untreated chronic phase CML will eventually progress to advanced phase accelerated or blast phase CML Tyrosine kinase inhibitors TKIs have been shown to induce favorable response rates in patients with accelerated and blast phase CML The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML although treatment with a course of TKIs will be beneficial as a bridge to transplant This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 16, 2082, 265, 4, 3, 442, 124, 1278, 442, 124, 903, 303, 3124, 1466, 6, 131, 124, 2241, 15, 3112, 124, 903, 564, 216, 222, 1671, 47, 85, 443, 6, 1290, 913, 51, 151, 4, 7, 5, 2241, 2, 3112, 124, 903, 3, 352, 1, 1671, 6, 56, 71, 120, 85, 41, 5, 231, 123, 4, 7, 5, 3112, 124, 903, 1063, 1007, 452, 31, 941, 469, 8, 751, 1075, 1501, 9, 7, 5, 131, 124, 903, 242, 24, 5, 8, 906, 1, 1671, 303, 40, 2524, 22, 8, 7728, 6, 941, 26, 5825, 2759, 3, 883, 6394, 4, 3, 1944, 677, 9, 3, 147, 2, 284, 1, 7, 5, 131, 124, 903]",771.0,25361806,138
Where exactly does ponatinib fit in chronic myelogenous leukemia?,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2014-11-01,"Ponatinib holds a unique place in the spectrum of drugs in use for the treatment of chronic myelogenous leukemia. It is perhaps the most active tyrosine kinase inhibitor (TKI) among those currently licensed; 51% of patients resistant to or intolerant of second-generation TKIs experienced a major cytogenetic response and 70% of patients with the highly resistant T315I BCR-ABL1 mutation experienced a major cytogenetic response. However, 1 year after its accelerated approval by the FDA, and midway through its phase III pivotal trial, a high number of vascular occlusive events began to be reported. The FDA put a partial clinical hold on the drug and the phase III trial was halted. Dose-reduction recommendations were made, and the drug is now used in patients for whom no alternative TKI is available and those who have the T315I mutation. Currently, the substantial and durable responses that this drug provides are difficult to balance against the late-in-course vascular occlusive events. The hope is that ongoing research into the mechanism of presumed endothelial damage will provide a better understanding of how to position this drug for optimal use. ",Journal Article,1907.0,1.0,Ponatinib holds a unique place in the spectrum of drugs in use for the treatment of chronic myelogenous It is perhaps the most active tyrosine kinase inhibitor TKI among those currently licensed 51 of patients resistant to or intolerant of second-generation TKIs experienced a major cytogenetic response and 70 of patients with the highly resistant T315I BCR-ABL1 mutation experienced a major cytogenetic response However 1 year after its accelerated approval by the FDA and midway through its phase III pivotal trial a high number of vascular occlusive events began to be reported The FDA put a partial clinical hold on the drug and the phase III trial was halted Dose-reduction recommendations were made and the drug is now used in patients for whom no alternative TKI is available and those who have the T315I mutation Currently the substantial and durable responses that this drug provides are difficult to balance against the late-in-course vascular occlusive events The hope is that ongoing research into the mechanism of presumed endothelial damage will provide a better understanding of how to position this drug for optimal use,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[5715, 5253, 8, 991, 3536, 4, 3, 1873, 1, 600, 4, 119, 9, 3, 24, 1, 442, 2194, 192, 16, 4434, 3, 96, 544, 564, 216, 230, 1379, 107, 135, 694, 12722, 725, 1, 7, 436, 6, 15, 4944, 1, 419, 914, 1671, 592, 8, 458, 1266, 51, 2, 431, 1, 7, 5, 3, 561, 436, 6184, 1062, 3557, 258, 592, 8, 458, 1266, 51, 137, 14, 111, 50, 211, 2241, 1814, 20, 3, 2078, 2, 30444, 298, 211, 124, 316, 3754, 160, 8, 64, 207, 1, 756, 8376, 281, 4603, 6, 40, 210, 3, 2078, 8795, 8, 450, 38, 4164, 23, 3, 234, 2, 3, 124, 316, 160, 10, 9473, 61, 628, 883, 11, 1229, 2, 3, 234, 16, 1134, 95, 4, 7, 9, 953, 77, 1091, 1379, 16, 390, 2, 135, 54, 47, 3, 6184, 258, 694, 3, 1281, 2, 1480, 253, 17, 26, 234, 777, 32, 1740, 6, 3459, 480, 3, 807, 4, 906, 756, 8376, 281, 3, 3045, 16, 17, 942, 389, 237, 3, 670, 1, 5472, 845, 1350, 303, 377, 8, 380, 612, 1, 832, 6, 3559, 26, 234, 9, 665, 119]",1136.0,25361807,223
New perspectives on type I IFNs in cancer.,Cytokine & growth factor reviews,Cytokine Growth Factor Rev.,2015-01-07,"Although type I IFNs were initially described based on their anti-viral properties, it was quickly realized that these cytokines had anti-proliferative and anti-cancer activities. These observations ultimately led to the clinical development and utility of IFN-2b for the treatment of patients with melanoma, renal cell carcinoma, and chronic myelogenous leukemia, among others. However, the mechanism of action of type I IFNs in vivo was never fully elucidated, and the pleiotropic effects of IFNs on multiple cell types had made it challenging to decipher. Advancement of genetically engineered mouse models has provided new tools for interrogating these mechanisms. Recent evidence has indicated that spontaneous innate immune sensing of cancers that leads to adaptive immune responses is dependent on host type I IFN production and signaling. The major innate immune receptor pathway that leads to type I IFN production in response to a growing tumor appears to be the STING pathway of cytosolic DNA sensing. STING agonists drive type I IFN production and are impressively therapeutic in mouse tumor models. Targeting low doses of type I IFNs to the tumor microenvironment also promotes anti-tumor activity via host adaptive immunity that is T cell-dependent. However, high doses of intratumoral type I IFNs largely function via an anti-angiogenic effect. Understanding these mechanistic details should enable improved clinical manipulation of the type I IFN system in cancer. ",Journal Article,1840.0,27.0,Although type I IFNs were initially described based on their anti-viral properties it was quickly realized that these cytokines had anti-proliferative and anti-cancer activities These observations ultimately led to the clinical development and utility of IFN-2b for the treatment of patients with cell carcinoma and chronic myelogenous among others However the mechanism of action of type I IFNs in vivo was never fully elucidated and the pleiotropic effects of IFNs on multiple cell types had made it challenging to decipher Advancement of genetically engineered mouse models has provided new tools for interrogating these mechanisms Recent evidence has indicated that spontaneous innate immune sensing of cancers that leads to adaptive immune responses is dependent on host type I IFN production and signaling The major innate immune receptor pathway that leads to type I IFN production in response to a growing tumor appears to be the STING pathway of cytosolic DNA sensing STING agonists drive type I IFN production and are impressively therapeutic in mouse tumor models Targeting low doses of type I IFNs to the tumor microenvironment also promotes anti-tumor activity via host adaptive immunity that is T cell-dependent However high doses of intratumoral type I IFNs largely function via an anti-angiogenic effect Understanding these mechanistic details should enable improved clinical manipulation of the type I IFN system in cancer,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[242, 267, 70, 11808, 11, 1625, 1027, 90, 23, 136, 312, 1667, 1571, 192, 10, 7325, 8340, 17, 46, 1886, 42, 312, 2441, 2, 312, 12, 2042, 46, 2172, 2050, 836, 6, 3, 38, 193, 2, 1207, 1, 1256, 16994, 9, 3, 24, 1, 7, 5, 31, 134, 2, 442, 2194, 107, 1749, 137, 3, 670, 1, 1578, 1, 267, 70, 11808, 4, 386, 10, 1737, 1910, 3901, 2, 3, 7872, 176, 1, 11808, 23, 232, 31, 630, 42, 1229, 192, 1950, 6, 11805, 7496, 1, 2301, 2794, 830, 274, 71, 1052, 217, 1896, 9, 16989, 46, 483, 435, 241, 71, 1103, 17, 3280, 3939, 250, 8350, 1, 163, 17, 1940, 6, 2454, 250, 253, 16, 470, 23, 1204, 267, 70, 1256, 1529, 2, 314, 3, 458, 3939, 250, 153, 308, 17, 1940, 6, 267, 70, 1256, 1529, 4, 51, 6, 8, 1921, 30, 1233, 6, 40, 3, 8429, 308, 1, 7698, 261, 8350, 8429, 4774, 3279, 267, 70, 1256, 1529, 2, 32, 35522, 189, 4, 830, 30, 274, 529, 154, 415, 1, 267, 70, 11808, 6, 3, 30, 995, 120, 2148, 312, 30, 128, 847, 1204, 2454, 1604, 17, 16, 102, 31, 470, 137, 64, 415, 1, 2074, 267, 70, 11808, 1733, 343, 847, 35, 312, 2068, 254, 612, 46, 2716, 3791, 257, 3047, 231, 38, 6239, 1, 3, 267, 70, 1256, 398, 4, 12]",1440.0,25630967,48
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?,Expert opinion on pharmacotherapy,Expert Opin Pharmacother,2015-04-03,"Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder distinctly characterized by the presence of the Philadelphia chromosome, which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22)]. The resulting translocation leads to the development of the BCR-ABL1 oncogene, a constitutively active fusion protein, which leads to uncontrolled cell proliferation and reduced apoptosis and has a clear association with driving the malignant activity of CML cells. Given that the BCR-ABL1 oncogene is a known key cause of CML, it has led to the development of numerous small molecule tyrosine-kinase inhibitors (TKIs), which target the specific oncogene mutation in CML. Presently, there are three FDA-approved TKI agents, imatinib, dasatinib and nilotinib, for the treatment of frontline CML. Herein, we review the frontline options for the management of patients with CML and how to best choose these agents. Imatinib, dasatinib and nilotinib are all effective at yielding hematological, molecular and cytogenetic responses in patients with newly diagnosed CML. Frontline therapy may depend on physician experience, patient age and ability to tolerate therapy, and with the lack of data comparing all three agents alongside each other, imatinib, dasatinib, or nilotinib may all be suitable frontline choices.",Journal Article,1754.0,10.0,Chronic myelogenous CML is a clonal disorder distinctly characterized by the presence of the Philadelphia chromosome which results from a reciprocal translocation between chromosomes 9 and 22 t 9 22 The resulting translocation leads to the development of the BCR-ABL1 oncogene a constitutively active fusion protein which leads to uncontrolled cell proliferation and reduced apoptosis and has a clear association with driving the malignant activity of CML cells Given that the BCR-ABL1 oncogene is a known key cause of CML it has led to the development of numerous small molecule tyrosine-kinase inhibitors TKIs which target the specific oncogene mutation in CML Presently there are three FDA-approved TKI agents imatinib dasatinib and nilotinib for the treatment of frontline CML Herein we review the frontline options for the management of patients with CML and how to best choose these agents Imatinib dasatinib and nilotinib are all effective at yielding hematological molecular and cytogenetic responses in patients with newly diagnosed CML Frontline therapy may depend on physician experience patient age and ability to tolerate therapy and with the lack of data comparing all three agents alongside each other imatinib dasatinib or nilotinib may all be suitable frontline choices,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 16, 8, 1946, 2645, 9452, 765, 20, 3, 463, 1, 3, 3006, 1170, 92, 99, 29, 8, 8020, 2006, 59, 3560, 83, 2, 350, 102, 83, 350, 3, 1113, 2006, 1940, 6, 3, 193, 1, 3, 1062, 3557, 1836, 8, 2818, 544, 1212, 178, 92, 1940, 6, 6180, 31, 457, 2, 405, 351, 2, 71, 8, 885, 248, 5, 4057, 3, 393, 128, 1, 903, 37, 447, 17, 3, 1062, 3557, 1836, 16, 8, 440, 825, 708, 1, 903, 192, 71, 836, 6, 3, 193, 1, 2331, 302, 1354, 564, 216, 222, 1671, 92, 283, 3, 112, 1836, 258, 4, 903, 9083, 125, 32, 169, 2078, 850, 1379, 183, 577, 1674, 2, 2638, 9, 3, 24, 1, 3171, 903, 1986, 21, 206, 3, 3171, 838, 9, 3, 284, 1, 7, 5, 903, 2, 832, 6, 824, 6009, 46, 183, 577, 1674, 2, 2638, 32, 62, 323, 28, 4949, 2890, 219, 2, 1266, 253, 4, 7, 5, 732, 265, 903, 3171, 36, 68, 4533, 23, 1473, 730, 69, 89, 2, 801, 6, 5010, 36, 2, 5, 3, 926, 1, 74, 1430, 62, 169, 183, 10150, 296, 127, 577, 1674, 15, 2638, 68, 62, 40, 2884, 3171, 5218]",1286.0,25840461,89
GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-04-27,"A confluence of factors, most prominently the recognition of GI stromal tumor (GIST) as a specific sarcoma subtype and the availability of imatinib, led to the ""Big Bang"" of GIST therapy (ie, the successful treatment of the first patient with GIST with imatinib in 2000). The trail blazed by imatinib for chronic myelogenous leukemia and GIST has become a desired route to regulatory approval of an increasing number of oral kinase inhibitors and other novel therapeutics. In this review, the status of GIST management before and after GIST's ""Big Bang"" and new steps being taken to further improve on therapy are reviewed. ",Journal Article,1730.0,30.0,A confluence of factors most prominently the recognition of GI stromal tumor GIST as a specific subtype and the availability of imatinib led to the `` Big Bang '' of GIST therapy ie the successful treatment of the first patient with GIST with imatinib in 2000 The trail blazed by imatinib for chronic myelogenous and GIST has become a desired route to regulatory approval of an increasing number of oral kinase inhibitors and other novel therapeutics In this review the status of GIST management before and after GIST 's `` Big Bang '' and new steps being taken to further improve on therapy are reviewed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,"[8, 15845, 1, 130, 96, 14550, 3, 2335, 1, 2104, 1126, 30, 1394, 22, 8, 112, 875, 2, 3, 2550, 1, 577, 836, 6, 3, 10864, 49016, 522, 1, 1394, 36, 2523, 3, 1401, 24, 1, 3, 157, 69, 5, 1394, 5, 577, 4, 1081, 3, 2585, 66037, 20, 577, 9, 442, 2194, 2, 1394, 71, 1417, 8, 6115, 5841, 6, 1253, 1814, 1, 35, 602, 207, 1, 518, 216, 222, 2, 127, 229, 1943, 4, 26, 206, 3, 156, 1, 1394, 284, 348, 2, 50, 1394, 292, 10864, 49016, 522, 2, 217, 4022, 486, 1633, 6, 195, 401, 23, 36, 32, 446]",604.0,25918303,147
Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.,The oncologist,Oncologist,2015-06-12,"After the revelation of kinase targeting with orally available small molecules, the use of imatinib in chronic myelogenous leukemia and in gastrointestinal stromal tumor (GIST) has now become commonplace and just two of many examples of the use of kinase inhibitors in cancer. In this article, we discuss important practice points that may impact upon questions of therapy of primary and metastatic GIST, with the hope that the questions addressed in this rare solid tumor can serve as examples of what can be achieved with kinase-directed therapies in other cancers. We present cases that highlight some of the key issues in GIST management and afterward discuss both points of consensus and controversial issues in what is now recognized as one of the most common forms of sarcoma. The treatment of gastrointestinal stromal tumor (GIST) has become sophisticated with the availability of three approved agents in many countries and 15 years of experience with primary and metastatic disease. Important lessons from tyrosine-kinase inhibitors in GIST can be gleaned from this experience and will impact implementation of similar agents for other cancers.",Case Reports,1684.0,17.0,After the revelation of kinase targeting with orally available small molecules the use of imatinib in chronic myelogenous and in stromal tumor GIST has now become commonplace and just two of many examples of the use of kinase inhibitors in cancer In this article we discuss important practice points that may impact upon questions of therapy of primary and metastatic GIST with the hope that the questions addressed in this rare solid tumor can serve as examples of what can be achieved with kinase-directed therapies in other cancers We present cases that highlight some of the key issues in GIST management and afterward discuss both points of consensus and controversial issues in what is now recognized as one of the most common forms of The treatment of stromal tumor GIST has become sophisticated with the availability of three approved agents in many countries and 15 years of experience with primary and metastatic disease Important lessons from tyrosine-kinase inhibitors in GIST can be gleaned from this experience and will impact implementation of similar agents for other cancers,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,"[50, 3, 66289, 1, 216, 529, 5, 1428, 390, 302, 1598, 3, 119, 1, 577, 4, 442, 2194, 2, 4, 1126, 30, 1394, 71, 1134, 1417, 21107, 2, 4673, 100, 1, 445, 4416, 1, 3, 119, 1, 216, 222, 4, 12, 4, 26, 946, 21, 1139, 305, 758, 862, 17, 68, 345, 1548, 1937, 1, 36, 1, 86, 2, 113, 1394, 5, 3, 3045, 17, 3, 1937, 2814, 4, 26, 622, 537, 30, 122, 1833, 22, 4416, 1, 2067, 122, 40, 513, 5, 216, 1166, 235, 4, 127, 163, 21, 364, 140, 17, 1817, 476, 1, 3, 825, 1553, 4, 1394, 284, 2, 14752, 1139, 110, 862, 1, 1391, 2, 2010, 1553, 4, 2067, 16, 1134, 1904, 22, 104, 1, 3, 96, 186, 2377, 1, 3, 24, 1, 1126, 30, 1394, 71, 1417, 8023, 5, 3, 2550, 1, 169, 850, 183, 4, 445, 2115, 2, 167, 60, 1, 730, 5, 86, 2, 113, 34, 305, 8268, 29, 564, 216, 222, 4, 1394, 122, 40, 23845, 29, 26, 730, 2, 303, 345, 2393, 1, 288, 183, 9, 127, 163]",1091.0,26070915,16
"Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.",Cancer,Cancer,2015-07-28,"Fludarabine, cyclophosphamide, and rituximab (FCR) result in durable responses in patients with previously untreated chronic lymphocytic leukemia (CLL). Previous reports have suggested that in patients with relapsed CLL, a dose-intensified rituximab regimen increases response rates in comparison with standard-dose rituximab. It is unknown whether rituximab intensification of the FCR regimen will result in improved response rates and patient outcomes in patients with previously untreated CLL. A single-arm study was conducted to evaluate the safety and efficacy of a modified FCR regimen with multiple-dose rituximab (FCR3) in 65 patients with previously untreated CLL. The results were compared with those for a historical cohort treated with FCR. The overall response rate to FCR3 was 97%, with 75% of the patients achieving a complete remission. Minimal residual disease negativity was achieved for 62% of the patients according to flow cytometry. The median time to progression (TTP) was 81 months, and the median overall survival (OS) was not reached, with 58% of the patients still alive at a median survivor follow-up of 9.7 years. Grade 3 or 4 neutropenia, grade 3 or 4 thrombocytopenia, and major infections were observed with 45%, 5%, and 1.9% of the FCR3 courses, respectively. Therapy-related myelodysplastic syndrome (t-MDS) or therapy-related acute myelogenous leukemia (t-AML) developed in 7 patients (11%; P < .01 vs the historical FCR cohort). In patients with previously untreated CLL, FCR3 resulted in response rates, TTP, and OS similar to those of a historical cohort of patients treated with FCR. FCR3 was associated with an increased incidence of t-MDS/t-AML.","Clinical Trial, Phase II",1638.0,8.0,Fludarabine cyclophosphamide and rituximab FCR result in durable responses in patients with previously untreated chronic lymphocytic CLL Previous reports have suggested that in patients with relapsed CLL a dose-intensified rituximab regimen increases response rates in comparison with standard-dose rituximab It is unknown whether rituximab intensification of the FCR regimen will result in improved response rates and patient outcomes in patients with previously untreated CLL A single-arm study was conducted to evaluate the safety and efficacy of a modified FCR regimen with multiple-dose rituximab FCR3 in 65 patients with previously untreated CLL The results were compared with those for a historical cohort treated with FCR The overall response rate to FCR3 was 97 with 75 of the patients achieving a complete remission Minimal residual disease negativity was achieved for 62 of the patients according to flow cytometry The median time to progression TTP was 81 months and the median overall survival OS was not reached with 58 of the patients still alive at a median survivor follow-up of 9.7 years Grade 3 or 4 neutropenia grade 3 or 4 thrombocytopenia and major infections were observed with 45 5 and 1.9 of the FCR3 courses respectively Therapy-related syndrome t-MDS or therapy-related acute myelogenous t-AML developed in 7 patients 11 P .01 vs the historical FCR cohort In patients with previously untreated CLL FCR3 resulted in response rates TTP and OS similar to those of a historical cohort of patients treated with FCR FCR3 was associated with an increased incidence of t-MDS/t-AML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2027, 1112, 2, 855, 4953, 757, 4, 1480, 253, 4, 7, 5, 373, 1278, 442, 1193, 552, 698, 1198, 47, 1148, 17, 4, 7, 5, 591, 552, 8, 61, 7311, 855, 477, 1106, 51, 151, 4, 1155, 5, 260, 61, 855, 192, 16, 860, 317, 855, 5091, 1, 3, 4953, 477, 303, 757, 4, 231, 51, 151, 2, 69, 123, 4, 7, 5, 373, 1278, 552, 8, 226, 475, 45, 10, 426, 6, 376, 3, 367, 2, 209, 1, 8, 1230, 4953, 477, 5, 232, 61, 855, 32471, 4, 556, 7, 5, 373, 1278, 552, 3, 99, 11, 72, 5, 135, 9, 8, 2252, 180, 73, 5, 4953, 3, 63, 51, 116, 6, 32471, 10, 1015, 5, 481, 1, 3, 7, 1785, 8, 236, 734, 1048, 753, 34, 6014, 10, 513, 9, 744, 1, 3, 7, 768, 6, 1412, 1914, 3, 52, 98, 6, 91, 2422, 10, 865, 53, 2, 3, 52, 63, 25, 118, 10, 44, 1300, 5, 717, 1, 3, 7, 1234, 1701, 28, 8, 52, 2628, 166, 126, 1, 83, 67, 60, 88, 27, 15, 39, 778, 88, 27, 15, 39, 1340, 2, 458, 1875, 11, 164, 5, 512, 33, 2, 14, 83, 1, 3, 32471, 1993, 106, 36, 139, 681, 102, 1223, 15, 36, 139, 286, 2194, 102, 329, 276, 4, 67, 7, 175, 19, 355, 105, 3, 2252, 4953, 180, 4, 7, 5, 373, 1278, 552, 32471, 627, 4, 51, 151, 2422, 2, 118, 288, 6, 135, 1, 8, 2252, 180, 1, 7, 73, 5, 4953, 32471, 10, 41, 5, 35, 101, 287, 1, 102, 1223, 102, 329]",1599.0,26218678,224
CML in pregnancy: A case report using leukapheresis and literature review.,Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis,Transfus. Apher. Sci.,2015-07-14,"Chronic myelogenous leukemia (CML) complicating pregnancy is uncommon. Literature search demonstrates only a few case reports and some case series but large studies are lacking due to its uncommon presentation. Management of these patients is particularly challenging due to limited available options as several chemotherapy drugs could potentially lead to adverse outcomes and fetal malformations. Leukapheresis has been used in these situations; however paucity of data exists regarding the outcome and complications associated with the procedure. Using leukapheresis alone for extended period to manage CML during pregnancy is also rare. Here we report a case of CML complicating pregnancy which was successfully managed utilizing leukapheresis, followed by a review of literature addressing this controversial issue. ",Case Reports,1652.0,6.0,Chronic myelogenous CML complicating pregnancy is uncommon Literature search demonstrates only a few case reports and some case series but large studies are lacking due to its uncommon presentation Management of these patients is particularly challenging due to limited available options as several chemotherapy drugs could potentially lead to adverse outcomes and fetal malformations Leukapheresis has been used in these situations however paucity of data exists regarding the outcome and complications associated with the procedure Using leukapheresis alone for extended period to manage CML during pregnancy is also rare Here we report a case of CML complicating pregnancy which was successfully managed utilizing leukapheresis followed by a review of literature addressing this controversial issue,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 13630, 2290, 16, 2052, 789, 1901, 1902, 158, 8, 1021, 473, 1198, 2, 476, 473, 988, 84, 375, 94, 32, 1941, 520, 6, 211, 2052, 1031, 284, 1, 46, 7, 16, 823, 1950, 520, 6, 383, 390, 838, 22, 392, 56, 600, 359, 751, 1122, 6, 290, 123, 2, 6698, 11756, 12554, 71, 85, 95, 4, 46, 5990, 137, 4832, 1, 74, 2481, 666, 3, 228, 2, 521, 41, 5, 3, 1299, 75, 12554, 279, 9, 1747, 727, 6, 4001, 903, 190, 2290, 16, 120, 622, 467, 21, 414, 8, 473, 1, 903, 13630, 2290, 92, 10, 1878, 2231, 2600, 12554, 370, 20, 8, 206, 1, 789, 3432, 26, 2010, 2537]",801.0,26231323,230
High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-07-31,"Double-unit cord blood (DCB) grafts are a rapidly available stem cell source for adults with high-risk leukemias. However, how disease-free survival (DFS) after DCB transplantation (DCBT) compares to that of unrelated donor transplantation (URDT) is not fully established. We analyzed 166 allograft recipients (66 8/8 HLA-matched URDT, 45 7/8 HLA-matched URDT, and 55 DCBT) ages 16 to 60 years with high-risk acute leukemia or chronic myelogenous leukemia (CML). URDT and DCBT recipients were similar except DCBT recipients were more likely to have lower weight and non-European ancestry and to receive intermediate-intensity conditioning. All URDT recipients received a CD34(+) cell-selected (T cell-depleted) graft. Overall, differences between the 3-year transplantation-related mortality were not significant (8/8 URDT, 18%; 7/8 URDT, 39%; and DCBT, 24%; P= .108), whereas the 3-year relapse risk was decreased after DCBT (8/8 URDT, 23%; 7/8 URDT, 20%; and DCBT 9%, P= .037). Three-year DFS was 57% in 8/8 URDT, 41% in 7/8 URDT, and 68% in DCBT recipients (P= .068), and the 3-year DFS in DCBT recipients was higher than that of 7/8 URDT recipients (P= .021). In multivariate analysis in acute leukemia patients, factors adversely associated with DFS were female gender (hazard ratio [HR], 1.68; P= .031), diagnosis of acute lymphoblastic leukemia (HR, 2.09; P= .004), and 7/8 T cell-depleted URDT (HR, 1.91; P= .037). High DFS can be achieved in adults with acute leukemia and CML with low relapse rates after DCBT. Our findings support performing DCBT in adults in preference to HLA-mismatched T cell-depleted URDT and suggest DCBT is a readily available alternative to T cell-depleted 8/8 URDT, especially in patients requiring urgent transplantation. ",Clinical Trial,1635.0,18.0,Double-unit cord blood DCB grafts are a rapidly available stem cell source for adults with high-risk leukemias However how disease-free survival DFS after DCB transplantation DCBT compares to that of unrelated donor transplantation URDT is not fully established We analyzed 166 allograft recipients 66 8/8 HLA-matched URDT 45 7/8 HLA-matched URDT and 55 DCBT ages 16 to 60 years with high-risk acute or chronic myelogenous CML URDT and DCBT recipients were similar except DCBT recipients were more likely to have lower weight and non-European ancestry and to receive intermediate-intensity conditioning All URDT recipients received a CD34 cell-selected T cell-depleted graft Overall differences between the 3-year transplantation-related mortality were not significant 8/8 URDT 18 7/8 URDT 39 and DCBT 24 P .108 whereas the 3-year relapse risk was decreased after DCBT 8/8 URDT 23 7/8 URDT 20 and DCBT 9 P .037 Three-year DFS was 57 in 8/8 URDT 41 in 7/8 URDT and 68 in DCBT recipients P .068 and the 3-year DFS in DCBT recipients was higher than that of 7/8 URDT recipients P .021 In multivariate analysis in acute patients factors adversely associated with DFS were female gender hazard ratio HR 1.68 P .031 diagnosis of acute lymphoblastic HR 2.09 P .004 and 7/8 T cell-depleted URDT HR 1.91 P .037 High DFS can be achieved in adults with acute and CML with low relapse rates after DCBT Our findings support performing DCBT in adults in preference to HLA-mismatched T cell-depleted URDT and suggest DCBT is a readily available alternative to T cell-depleted 8/8 URDT especially in patients requiring urgent transplantation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1627, 2712, 1885, 315, 18701, 4713, 32, 8, 1755, 390, 452, 31, 2353, 9, 857, 5, 64, 43, 2792, 137, 832, 34, 115, 25, 1010, 50, 18701, 497, 15075, 5815, 6, 17, 1, 2092, 1488, 497, 18702, 16, 44, 1910, 635, 21, 311, 5812, 9568, 2190, 700, 66, 66, 1160, 655, 18702, 512, 67, 66, 1160, 655, 18702, 2, 614, 15075, 2165, 245, 6, 335, 60, 5, 64, 43, 286, 15, 442, 2194, 903, 18702, 2, 15075, 2190, 11, 288, 2187, 15075, 2190, 11, 80, 322, 6, 47, 280, 924, 2, 220, 1865, 3535, 2, 6, 560, 919, 837, 1933, 62, 18702, 2190, 103, 8, 2215, 31, 715, 102, 31, 4358, 1599, 63, 362, 59, 3, 27, 111, 497, 139, 282, 11, 44, 93, 66, 66, 18702, 203, 67, 66, 18702, 587, 2, 15075, 259, 19, 3590, 547, 3, 27, 111, 429, 43, 10, 340, 50, 15075, 66, 66, 18702, 382, 67, 66, 18702, 179, 2, 15075, 83, 19, 5171, 169, 111, 1010, 10, 696, 4, 66, 66, 18702, 605, 4, 67, 66, 18702, 2, 806, 4, 15075, 2190, 19, 13402, 2, 3, 27, 111, 1010, 4, 15075, 2190, 10, 142, 76, 17, 1, 67, 66, 18702, 2190, 19, 4630, 4, 331, 65, 4, 286, 7, 130, 4311, 41, 5, 1010, 11, 1061, 1632, 360, 197, 168, 14, 806, 19, 5304, 147, 1, 286, 1275, 168, 18, 1730, 19, 1520, 2, 67, 66, 102, 31, 4358, 18702, 168, 14, 970, 19, 5171, 64, 1010, 122, 40, 513, 4, 857, 5, 286, 2, 903, 5, 154, 429, 151, 50, 15075, 114, 272, 538, 3620, 15075, 4, 857, 4, 3863, 6, 1160, 5095, 102, 31, 4358, 18702, 2, 309, 15075, 16, 8, 3860, 390, 1091, 6, 102, 31, 4358, 66, 66, 18702, 1093, 4, 7, 1888, 5013, 497]",1625.0,26238810,31
Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.,Blood,Blood,2015-08-04,"Chromosome 3q26.2 abnormalities in acute myeloid leukemia, including inv(3)/t(3;3) and t(3;21), have been studied and are associated with a poor prognosis. Their prevalence, response to tyrosine kinase inhibitor (TKI) treatment, and prognostic significance in chronic myelogenous leukemia (CML) are largely unknown. In this study, we explored these aspects using a cohort of 2013 patients with CML diagnosed in the era of TKI therapy. Chromosome 3 abnormalities were observed in 116 (5.8%) of 2013 cases. These cases were divided into 5 distinct groups: A, inv(3)(q21q26.2)/t(3;3)(q21;q26.2), 26%; B, t(3;21)(q26.2;q22), 17%; C, other 3q26.2 rearrangements, 7%; D, rearrangements involving chromosome 3 other than 3q26.2 locus, 32%; and E, gain or loss of partial or whole chromosome 3, 18%. In all, 3q26.2 rearrangements were the most common chromosome 3 abnormalities (50%, groups A-C). 3q26.2 rearrangements emerged at different leukemic phases. For cases with 3q26.2 rearrangements that initially emerged in chronic or accelerated phase, they had a high rate of transformation to blast phase. Patients with 3q26.2 abnormalities showed a marginal response to TKI treatment, and no patients achieved a long-term sustainable response at a cytogenetic or molecular level. Compared with other chromosomal abnormalities in CML, patients with 3q26.2 rearrangements had poorer overall survival. The presence or absence of other concurrent chromosomal abnormalities did not affect survival in these patients, reflecting the predominant role of 3q26.2 rearrangements in determining prognosis. Interestingly, although heterogeneous, chromosome 3 abnormalities involving non-3q26.2 loci (groups D, E) also conferred a worse prognosis compared with changes involving other chromosomes in this cohort. ",Journal Article,1631.0,26.0,Chromosome 3q26.2 abnormalities in acute myeloid including inv 3 /t 3 3 and t 3 21 have been studied and are associated with a poor prognosis Their prevalence response to tyrosine kinase inhibitor TKI treatment and prognostic significance in chronic myelogenous CML are largely unknown In this study we explored these aspects using a cohort of 2013 patients with CML diagnosed in the era of TKI therapy Chromosome 3 abnormalities were observed in 116 5.8 of 2013 cases These cases were divided into 5 distinct groups A inv 3 q21q26.2 /t 3 3 q21 q26.2 26 B t 3 21 q26.2 q22 17 C other 3q26.2 rearrangements 7 D rearrangements involving chromosome 3 other than 3q26.2 locus 32 and E gain or loss of partial or whole chromosome 3 18 In all 3q26.2 rearrangements were the most common chromosome 3 abnormalities 50 groups A-C 3q26.2 rearrangements emerged at different leukemic phases For cases with 3q26.2 rearrangements that initially emerged in chronic or accelerated phase they had a high rate of transformation to blast phase Patients with 3q26.2 abnormalities showed a marginal response to TKI treatment and no patients achieved a long-term sustainable response at a cytogenetic or molecular level Compared with other chromosomal abnormalities in CML patients with 3q26.2 rearrangements had poorer overall survival The presence or absence of other concurrent chromosomal abnormalities did not affect survival in these patients reflecting the predominant role of 3q26.2 rearrangements in determining prognosis Interestingly although heterogeneous chromosome 3 abnormalities involving non-3q26.2 loci groups D E also conferred a worse prognosis compared with changes involving other chromosomes in this cohort,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1170, 10678, 18, 1171, 4, 286, 533, 141, 6397, 27, 102, 27, 27, 2, 102, 27, 239, 47, 85, 656, 2, 32, 41, 5, 8, 334, 356, 136, 1078, 51, 6, 564, 216, 230, 1379, 24, 2, 177, 724, 4, 442, 2194, 903, 32, 1733, 860, 4, 26, 45, 21, 1443, 46, 2695, 75, 8, 180, 1, 1346, 7, 5, 903, 265, 4, 3, 1713, 1, 1379, 36, 1170, 27, 1171, 11, 164, 4, 3790, 33, 66, 1, 1346, 140, 46, 140, 11, 2176, 237, 33, 834, 271, 8, 6397, 27, 47865, 18, 102, 27, 27, 10524, 35629, 18, 432, 132, 102, 27, 239, 35629, 18, 8026, 269, 256, 127, 10678, 18, 2072, 67, 427, 2072, 1267, 1170, 27, 127, 76, 10678, 18, 2474, 531, 2, 563, 1803, 15, 407, 1, 450, 15, 902, 1170, 27, 203, 4, 62, 10678, 18, 2072, 11, 3, 96, 186, 1170, 27, 1171, 212, 271, 8, 256, 10678, 18, 2072, 2054, 28, 338, 2015, 3523, 9, 140, 5, 10678, 18, 2072, 17, 1625, 2054, 4, 442, 15, 2241, 124, 491, 42, 8, 64, 116, 1, 1392, 6, 3112, 124, 7, 5, 10678, 18, 1171, 224, 8, 3450, 51, 6, 1379, 24, 2, 77, 7, 513, 8, 319, 337, 13226, 51, 28, 8, 1266, 15, 219, 301, 72, 5, 127, 1860, 1171, 4, 903, 7, 5, 10678, 18, 2072, 42, 1769, 63, 25, 3, 463, 15, 1127, 1, 127, 750, 1860, 1171, 205, 44, 1158, 25, 4, 46, 7, 4777, 3, 2750, 200, 1, 10678, 18, 2072, 4, 2196, 356, 2873, 242, 1564, 1170, 27, 1171, 1267, 220, 10678, 18, 2012, 271, 427, 563, 120, 3851, 8, 639, 356, 72, 5, 400, 1267, 127, 3560, 4, 26, 180]",1708.0,26243778,154
Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.,International journal of cancer,Int. J. Cancer,2015-10-28,"Tyrosine kinase inhibitors (TKI) are the initial treatment for majority of newly diagnosed patients with chronic myelogenous leukemia (CML) in chronic phase (CP) and are associated with marked improvement in hematological, cytogenetic, molecular response and survival rates compared with other therapies. In this review, we summarize the evidence of TKI efficacy for patients with newly diagnosed CP-CML. Six trials at low risk of bias evaluating TKIs as an initial treatment in adults with newly diagnosed CP-CML and enrolling 2,456 patients were included. Follow-up times ranged from a median of 3 months to 5 years. Direct comparison showed statistically higher rates of major molecular response (MMR  0.1%(IS)) achievement with second-generation TKIs at 12 months which was sustained throughout treatment period. Bayesian mixed-treatment comparison (MTC) analysis demonstrated superiority of both nilotinib and dasatinib over imatinib in terms of efficacy. Nilotinib was associated with higher deeper molecular responses (MR(4.5)  0.0032%(IS)) at 60 months than dasatinib but no difference in MMR. The differences between nilotinib and dasatinib are likely clinically trivial. Among TKIs, nilotinib was found to have the best survival profile. Both nilotinib and dasatinib are associated with significantly better MMR compared to imatinib that is sustained over 60 months. This analysis shows that new-generation TKIs are not only showing faster response but also maintaining a more potent one through longer follow-up period. It is important to note out that MTC is not a substitute for well-conducted RCTs investigating direct comparisons.",Journal Article,1546.0,11.0,"Tyrosine kinase inhibitors TKI are the initial treatment for majority of newly diagnosed patients with chronic myelogenous CML in chronic phase CP and are associated with marked improvement in hematological cytogenetic molecular response and survival rates compared with other therapies In this review we summarize the evidence of TKI efficacy for patients with newly diagnosed CP-CML Six trials at low risk of bias evaluating TKIs as an initial treatment in adults with newly diagnosed CP-CML and enrolling 2,456 patients were included Follow-up times ranged from a median of 3 months to 5 years Direct comparison showed statistically higher rates of major molecular response MMR  0.1 IS achievement with second-generation TKIs at 12 months which was sustained throughout treatment period Bayesian mixed-treatment comparison MTC analysis demonstrated superiority of both nilotinib and dasatinib over imatinib in terms of efficacy Nilotinib was associated with higher deeper molecular responses MR 4.5  0.0032 IS at 60 months than dasatinib but no difference in MMR The differences between nilotinib and dasatinib are likely clinically trivial Among TKIs nilotinib was found to have the best survival profile Both nilotinib and dasatinib are associated with significantly better MMR compared to imatinib that is sustained over 60 months This analysis shows that new-generation TKIs are not only showing faster response but also maintaining a more potent one through longer follow-up period It is important to note out that MTC is not a substitute for well-conducted RCTs investigating direct comparisons",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[564, 216, 222, 1379, 32, 3, 388, 24, 9, 686, 1, 732, 265, 7, 5, 442, 2194, 903, 4, 442, 124, 2541, 2, 32, 41, 5, 2003, 767, 4, 2890, 1266, 219, 51, 2, 25, 151, 72, 5, 127, 235, 4, 26, 206, 21, 2479, 3, 241, 1, 1379, 209, 9, 7, 5, 732, 265, 2541, 903, 437, 143, 28, 154, 43, 1, 2947, 1435, 1671, 22, 35, 388, 24, 4, 857, 5, 732, 265, 2541, 903, 2, 6280, 18, 10981, 7, 11, 159, 166, 126, 1072, 1869, 29, 8, 52, 1, 27, 53, 6, 33, 60, 1196, 1155, 224, 712, 142, 151, 1, 458, 219, 51, 2205, 1552, 13, 14, 16, 5088, 5, 419, 914, 1671, 28, 133, 53, 92, 10, 2275, 2432, 24, 727, 5032, 1739, 24, 1155, 3959, 65, 264, 5233, 1, 110, 2638, 2, 1674, 252, 577, 4, 1794, 1, 209, 2638, 10, 41, 5, 142, 6029, 219, 253, 1638, 39, 33, 1552, 13, 12116, 16, 28, 335, 53, 76, 1674, 84, 77, 523, 4, 2205, 3, 362, 59, 2638, 2, 1674, 32, 322, 505, 35226, 107, 1671, 2638, 10, 204, 6, 47, 3, 824, 25, 800, 110, 2638, 2, 1674, 32, 41, 5, 97, 380, 2205, 72, 6, 577, 17, 16, 2275, 252, 335, 53, 26, 65, 1949, 17, 217, 914, 1671, 32, 44, 158, 2069, 5308, 51, 84, 120, 3284, 8, 80, 1157, 104, 298, 589, 166, 126, 727, 192, 16, 305, 6, 5739, 1205, 17, 3959, 16, 44, 8, 12577, 9, 149, 426, 4335, 3103, 1196, 2213]",1605.0,26455714,91
"Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2015-10-12,"RG7112 is a small-molecule MDM2 antagonist. MDM2 is a negative regulator of the tumor suppressor p53 and frequently overexpressed in leukemias. Thus, a phase I study of RG7112 in patients with hematologic malignancies was conducted. Primary study objectives included determination of the dose and safety profile of RG7112. Secondary objectives included evaluation of pharmacokinetics; pharmacodynamics, such as TP53-mutation status and MDM2 expression; and preliminary clinical activity. Patients were divided into two cohorts: Stratum A [relapsed/refractory acute myeloid leukemia (AML; except acute promyelocytic leukemia), acute lymphoblastic leukemia, and chronic myelogenous leukemia] and Stratum B (relapsed/refractory chronic lymphocytic leukemia/small cell lymphocytic leukemia; CLL/sCLL). Some Stratum A patients were treated at the MTD to assess clinical activity. RG7112 was administered to 116 patients (96 patients in Stratum A and 20 patients in Stratum B). All patients experienced at least 1 adverse event, and 3 dose-limiting toxicities were reported. Pharmacokinetic analysis indicated that twice-daily dosing enhanced daily exposure. Antileukemia activity was observed in the 30 patients with AML assessed at the MTD, including 5 patients who met International Working Group (IWG) criteria for response. Exploratory analysis revealed TP53 mutations in 14% of Stratum A patients and in 40% of Stratum B patients. Two patients with TP53 mutations exhibited clinical activity. p53 target genes were induced only in TP53 wild-type leukemic cells. Baseline expression levels of MDM2 correlated positively with clinical response. RG7112 demonstrated clinical activity against relapsed/refractory AML and CLL/sCLL. MDM2 inhibition resulted in p53 stabilization and transcriptional activation of p53-target genes. We provide proof-of-concept that MDM2 inhibition restores p53 function and generates clinical responses in hematologic malignancies.","Clinical Trial, Phase I",1562.0,93.0,RG7112 is a small-molecule MDM2 antagonist MDM2 is a negative regulator of the tumor suppressor p53 and frequently overexpressed in leukemias Thus a phase I study of RG7112 in patients with hematologic malignancies was conducted Primary study objectives included determination of the dose and safety profile of RG7112 Secondary objectives included evaluation of pharmacokinetics pharmacodynamics such as TP53-mutation status and MDM2 expression and preliminary clinical activity Patients were divided into two cohorts Stratum A relapsed/refractory acute myeloid AML except acute promyelocytic acute lymphoblastic and chronic myelogenous and Stratum B relapsed/refractory chronic lymphocytic leukemia/small cell lymphocytic CLL/sCLL Some Stratum A patients were treated at the MTD to assess clinical activity RG7112 was administered to 116 patients 96 patients in Stratum A and 20 patients in Stratum B All patients experienced at least 1 adverse event and 3 dose-limiting toxicities were reported Pharmacokinetic analysis indicated that twice-daily dosing enhanced daily exposure Antileukemia activity was observed in the 30 patients with AML assessed at the MTD including 5 patients who met International Working Group IWG criteria for response Exploratory analysis revealed TP53 mutations in 14 of Stratum A patients and in 40 of Stratum B patients Two patients with TP53 mutations exhibited clinical activity p53 target genes were induced only in TP53 wild-type leukemic cells Baseline expression levels of MDM2 correlated positively with clinical response RG7112 demonstrated clinical activity against relapsed/refractory AML and CLL/sCLL MDM2 inhibition resulted in p53 stabilization and transcriptional activation of p53-target genes We provide proof-of-concept that MDM2 inhibition restores p53 function and generates clinical responses in hematologic malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[22908, 16, 8, 302, 1354, 3277, 3137, 3277, 16, 8, 199, 2452, 1, 3, 30, 1245, 624, 2, 746, 1711, 4, 2792, 631, 8, 124, 70, 45, 1, 22908, 4, 7, 5, 813, 441, 10, 426, 86, 45, 2409, 159, 3104, 1, 3, 61, 2, 367, 800, 1, 22908, 568, 2409, 159, 451, 1, 1159, 3587, 225, 22, 1206, 258, 156, 2, 3277, 55, 2, 1676, 38, 128, 7, 11, 2176, 237, 100, 736, 4897, 8, 591, 430, 286, 533, 329, 2187, 286, 4300, 286, 1275, 2, 442, 2194, 2, 4897, 132, 591, 430, 442, 1193, 2647, 302, 31, 1193, 552, 49333, 476, 4897, 8, 7, 11, 73, 28, 3, 961, 6, 423, 38, 128, 22908, 10, 468, 6, 3790, 7, 921, 7, 4, 4897, 8, 2, 179, 7, 4, 4897, 132, 62, 7, 592, 28, 506, 14, 290, 774, 2, 27, 61, 817, 385, 11, 210, 1456, 65, 1103, 17, 936, 391, 1280, 651, 391, 645, 9169, 128, 10, 164, 4, 3, 201, 7, 5, 329, 275, 28, 3, 961, 141, 33, 7, 54, 543, 944, 2644, 87, 14620, 371, 9, 51, 2386, 65, 553, 1206, 138, 4, 213, 1, 4897, 8, 7, 2, 4, 327, 1, 4897, 132, 7, 100, 7, 5, 1206, 138, 1416, 38, 128, 624, 283, 214, 11, 277, 158, 4, 1206, 955, 267, 2015, 37, 330, 55, 148, 1, 3277, 438, 2375, 5, 38, 51, 22908, 264, 38, 128, 480, 591, 430, 329, 2, 552, 49333, 3277, 297, 627, 4, 624, 3184, 2, 1431, 363, 1, 624, 283, 214, 21, 377, 3840, 1, 2545, 17, 3277, 297, 8489, 624, 343, 2, 7919, 38, 253, 4, 813, 441]",1871.0,26459177,126
Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia.,American journal of clinical oncology,Am. J. Clin. Oncol.,2018-03-01,"This study assessed treatment responses and economic consequences of limiting access to the second-generation BCR-ABL1 tyrosine kinase inhibitors (2G-TKI), dasatinib and nilotinib, for treatment of chronic myelogenous leukemia, while taking into account frequencies of genetic mutations that exhibit different sensitivities to the 2G-TKIs. Frequencies of BCR-ABL1 mutations and the impact of mutations on responses to 2G-TKIs were obtained from published literature and used as inputs in a decision analytics model. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were estimated after 12 months of 2G-TKI treatment. Total annual 2G-TKI drug costs per CHR and MCyR were estimated and compared among 3 2G-TKI access scenarios: (1) open access to both 2G-TKIs; (2) access restricted to dasatinib (DASA-only); and (3) access restricted to nilotinib (NILO-only). Among a hypothetical cohort of 1000 2G-TKI-treated chronic myelogenous leukemia patients, the percentage of patients with CHR and MCyR were greatest for the open access plan (CHR: 93%, MCyR: 56%), followed by DASA-only (88%, 53%) and NILO-only (67%, 47%). Compared with the 2G-TKI costs per CHR in open access ($120,706/CHR), the costs were 5% higher ($126,753/CHR) in DASA-only and 41% higher ($169,990/CHR) in NILO-only. Likewise, compared with the 2G-TKI costs per MCyR in open access ($198,284/MCyR), the costs were 6% higher ($209,259/MCyR) in DASA-only and 22% higher ($241,515/MCyR) in NILO-only. Open access to both 2G-TKIs is associated with improved clinical and economic outcomes: greater treatment response rates (CHR and MCyR) and lower drug costs compared with restricted access to 2G-TKIs.",Journal Article,691.0,1.0,"This study assessed treatment responses and economic consequences of limiting access to the second-generation BCR-ABL1 tyrosine kinase inhibitors 2G-TKI dasatinib and nilotinib for treatment of chronic myelogenous while taking into account frequencies of genetic mutations that exhibit different sensitivities to the 2G-TKIs Frequencies of BCR-ABL1 mutations and the impact of mutations on responses to 2G-TKIs were obtained from published literature and used as inputs in a decision analytics model Complete hematologic response CHR and major cytogenetic response MCyR were estimated after 12 months of 2G-TKI treatment Total annual 2G-TKI drug costs per CHR and MCyR were estimated and compared among 3 2G-TKI access scenarios 1 open access to both 2G-TKIs 2 access restricted to dasatinib DASA-only and 3 access restricted to nilotinib NILO-only Among a hypothetical cohort of 1000 2G-TKI-treated chronic myelogenous patients the percentage of patients with CHR and MCyR were greatest for the open access plan CHR 93 MCyR 56 followed by DASA-only 88 53 and NILO-only 67 47 Compared with the 2G-TKI costs per CHR in open access 120,706/CHR the costs were 5 higher 126,753/CHR in DASA-only and 41 higher 169,990/CHR in NILO-only Likewise compared with the 2G-TKI costs per MCyR in open access 198,284/MCyR the costs were 6 higher 209,259/MCyR in DASA-only and 22 higher 241,515/MCyR in NILO-only Open access to both 2G-TKIs is associated with improved clinical and economic outcomes greater treatment response rates CHR and MCyR and lower drug costs compared with restricted access to 2G-TKIs",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[26, 45, 275, 24, 253, 2, 3875, 3255, 1, 817, 1655, 6, 3, 419, 914, 1062, 3557, 564, 216, 222, 15755, 1379, 1674, 2, 2638, 9, 24, 1, 442, 2194, 369, 2727, 237, 1967, 2722, 1, 336, 138, 17, 2239, 338, 6202, 6, 3, 15755, 1671, 2722, 1, 1062, 3557, 138, 2, 3, 345, 1, 138, 23, 253, 6, 15755, 1671, 11, 683, 29, 983, 789, 2, 95, 22, 11785, 4, 8, 948, 20025, 202, 236, 813, 51, 8158, 2, 458, 1266, 51, 10240, 11, 661, 50, 133, 53, 1, 15755, 1379, 24, 181, 2114, 15755, 1379, 234, 1201, 379, 8158, 2, 10240, 11, 661, 2, 72, 107, 27, 15755, 1379, 1655, 3964, 14, 1020, 1655, 6, 110, 15755, 1671, 18, 1655, 2016, 6, 1674, 36141, 158, 2, 27, 1655, 2016, 6, 2638, 36142, 158, 107, 8, 7045, 180, 1, 2345, 15755, 1379, 73, 442, 2194, 7, 3, 1150, 1, 7, 5, 8158, 2, 10240, 11, 2199, 9, 3, 1020, 1655, 2242, 8158, 966, 10240, 664, 370, 20, 36141, 158, 889, 699, 2, 36142, 158, 598, 662, 72, 5, 3, 15755, 1379, 1201, 379, 8158, 4, 1020, 1655, 2031, 10964, 8158, 3, 1201, 11, 33, 142, 3927, 13401, 8158, 4, 36141, 158, 2, 605, 142, 5436, 15650, 8158, 4, 36142, 158, 6269, 72, 5, 3, 15755, 1379, 1201, 379, 10240, 4, 1020, 1655, 6189, 8843, 10240, 3, 1201, 11, 49, 142, 5941, 7696, 10240, 4, 36141, 158, 2, 350, 142, 7086, 12576, 10240, 4, 36142, 158, 1020, 1655, 6, 110, 15755, 1671, 16, 41, 5, 231, 38, 2, 3875, 123, 378, 24, 51, 151, 8158, 2, 10240, 2, 280, 234, 1201, 72, 5, 2016, 1655, 6, 15755, 1671]",1593.0,26580245,0
Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2015-09-30,"The National Comprehensive Cancer Network (NCCN) guidelines state that based on toxicity profiles, 1 second-generation tyrosine kinase inhibitor (TKI) indicated for first-line therapy (ie, dasatinib, nilotinib) may be preferred over the other for treatment of chronic myelogenous leukemia (CML) patients with certain comorbidities. This study assessed the prevalence of comorbid conditions relevant to TKI treatment choice among CML patients in the US real-world setting. Patients who had CML and initiated TKI treatment were identified from the MarketScan Commercial and Medicare databases (January 1, 2006, to June 30, 2013). Demographics and prevalence of comorbid conditions relevant to TKI treatment choice per NCCN guidelines (heart disease, arrhythmia, diabetes, pancreatitis, pleural effusion, lung disease) were assessed among the overall study population and among subgroups. The median age of the CML study population newly initiated on TKI treatment (ie, imatinib, dasatinib, or nilotinib; n= 2296) was 56 years. Approximately 41% of the CML study population had at least 1 comorbid condition that may influence the choice of TKI treatment as recommended by NCCN guidelines. The most prevalent comorbid condition was heart disease (23%), followed by diabetes (18%) and lung disease (13%). The prevalence of comorbid conditions relevant to TKI treatment choice varied among patients of different age groups, gender, and US regions. The results of this analysis provide real-world evidence that the prevalence of relevant comorbid conditions is substantial among CML patients in the US managed care setting and therefore needs to be considered throughout various health care decision-making processes related to CML.",Journal Article,1574.0,16.0,The National Comprehensive Cancer Network NCCN guidelines state that based on toxicity profiles 1 second-generation tyrosine kinase inhibitor TKI indicated for first-line therapy ie dasatinib nilotinib may be preferred over the other for treatment of chronic myelogenous CML patients with certain comorbidities This study assessed the prevalence of comorbid conditions relevant to TKI treatment choice among CML patients in the US real-world setting Patients who had CML and initiated TKI treatment were identified from the MarketScan Commercial and Medicare databases January 1 2006 to June 30 2013 Demographics and prevalence of comorbid conditions relevant to TKI treatment choice per NCCN guidelines disease arrhythmia diabetes pancreatitis pleural effusion disease were assessed among the overall study population and among subgroups The median age of the CML study population newly initiated on TKI treatment ie imatinib dasatinib or nilotinib n 2296 was 56 years Approximately 41 of the CML study population had at least 1 comorbid condition that may influence the choice of TKI treatment as recommended by NCCN guidelines The most prevalent comorbid condition was disease 23 followed by diabetes 18 and disease 13 The prevalence of comorbid conditions relevant to TKI treatment choice varied among patients of different age groups gender and US regions The results of this analysis provide real-world evidence that the prevalence of relevant comorbid conditions is substantial among CML patients in the US managed care setting and therefore needs to be considered throughout various health care decision-making processes related to CML,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,"[3, 657, 949, 12, 1801, 1944, 677, 1309, 17, 90, 23, 155, 1241, 14, 419, 914, 564, 216, 230, 1379, 1103, 9, 157, 328, 36, 2523, 1674, 2638, 68, 40, 2514, 252, 3, 127, 9, 24, 1, 442, 2194, 903, 7, 5, 1840, 1909, 26, 45, 275, 3, 1078, 1, 3952, 1298, 867, 6, 1379, 24, 1866, 107, 903, 7, 4, 3, 843, 1589, 1956, 546, 7, 54, 42, 903, 2, 1917, 1379, 24, 11, 108, 29, 3, 10246, 4860, 2, 1378, 2348, 1024, 14, 1324, 6, 1924, 201, 1346, 2221, 2, 1078, 1, 3952, 1298, 867, 6, 1379, 24, 1866, 379, 1944, 677, 34, 12103, 1978, 4535, 2164, 4433, 34, 11, 275, 107, 3, 63, 45, 266, 2, 107, 1453, 3, 52, 89, 1, 3, 903, 45, 266, 732, 1917, 23, 1379, 24, 2523, 577, 1674, 15, 2638, 78, 48996, 10, 664, 60, 705, 605, 1, 3, 903, 45, 266, 42, 28, 506, 14, 3952, 2850, 17, 68, 1054, 3, 1866, 1, 1379, 24, 22, 793, 20, 1944, 677, 3, 96, 2485, 3952, 2850, 10, 34, 382, 370, 20, 1978, 203, 2, 34, 233, 3, 1078, 1, 3952, 1298, 867, 6, 1379, 24, 1866, 2051, 107, 7, 1, 338, 89, 271, 1632, 2, 843, 1374, 3, 99, 1, 26, 65, 377, 1589, 1956, 241, 17, 3, 1078, 1, 867, 3952, 1298, 16, 1281, 107, 903, 7, 4, 3, 843, 2231, 165, 546, 2, 673, 1891, 6, 40, 515, 2432, 747, 341, 165, 948, 1079, 1849, 139, 6, 903]",1643.0,26603185,150
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2015-12-18,"The safety and efficacy of front-line nilotinib and dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CML-CP) with pre-existing liver and/or renal dysfunction are unknown. We analyzed the adverse event rates, response rates, and survival rates of 215 patients with CML-CP with or without renal and/or liver dysfunction who had been treated with front-line nilotinib (n = 108) or dasatinib (n = 107). The overall median follow-up period was 49 months. At baseline, 6 dasatinib-treated patients (6%) had mild renal dysfunction and 13 (12%) had mild liver dysfunction. Also, 8 nilotinib-treated patients (7%) had mild renal dysfunction, 1 (1%) moderate renal dysfunction, and 9 (8%) mild liver dysfunction. No significant differences were found in the rate of complete cytogenetic response, major molecular response, or molecular response by a 4.5 log reduction on the international scale between the organ function cohorts. Dasatinib- or nilotinib-treated patients with baseline renal dysfunction had a greater incidence of transient reversible acute kidney injury (P = .011 and P < .001), and nilotinib-treated patients with renal dysfunction had a greater incidence of bleeding (P < .001). Patients with CML-CP and mild to moderate renal or liver dysfunction can be safely treated with front-line dasatinib or nilotinib and can achieve response rates similar to those of patients with CML-CP without organ dysfunction.",Journal Article,1495.0,5.0,The safety and efficacy of front-line nilotinib and dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous CML-CP with pre-existing and/or dysfunction are unknown We analyzed the adverse event rates response rates and survival rates of 215 patients with CML-CP with or without and/or dysfunction who had been treated with front-line nilotinib n 108 or dasatinib n 107 The overall median follow-up period was 49 months At baseline 6 dasatinib-treated patients 6 had mild dysfunction and 13 12 had mild dysfunction Also 8 nilotinib-treated patients 7 had mild dysfunction 1 1 moderate dysfunction and 9 8 mild dysfunction No significant differences were found in the rate of complete cytogenetic response major molecular response or molecular response by a 4.5 log reduction on the international scale between the organ function cohorts Dasatinib- or nilotinib-treated patients with baseline dysfunction had a greater incidence of transient reversible acute injury P .011 and P .001 and nilotinib-treated patients with dysfunction had a greater incidence of bleeding P .001 Patients with CML-CP and mild to moderate or dysfunction can be safely treated with front-line dasatinib or nilotinib and can achieve response rates similar to those of patients with CML-CP without organ dysfunction,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 367, 2, 209, 1, 3007, 328, 2638, 2, 1674, 4, 7, 5, 732, 265, 442, 124, 442, 2194, 903, 2541, 5, 671, 1692, 2, 15, 1527, 32, 860, 21, 311, 3, 290, 774, 151, 51, 151, 2, 25, 151, 1, 6511, 7, 5, 903, 2541, 5, 15, 187, 2, 15, 1527, 54, 42, 85, 73, 5, 3007, 328, 2638, 78, 3590, 15, 1674, 78, 3650, 3, 63, 52, 166, 126, 727, 10, 739, 53, 28, 330, 49, 1674, 73, 7, 49, 42, 1980, 1527, 2, 233, 133, 42, 1980, 1527, 120, 66, 2638, 73, 7, 67, 42, 1980, 1527, 14, 14, 1163, 1527, 2, 83, 66, 1980, 1527, 77, 93, 362, 11, 204, 4, 3, 116, 1, 236, 1266, 51, 458, 219, 51, 15, 219, 51, 20, 8, 39, 33, 1066, 628, 23, 3, 944, 1124, 59, 3, 1259, 343, 736, 1674, 15, 2638, 73, 7, 5, 330, 1527, 42, 8, 378, 287, 1, 2473, 2786, 286, 2730, 19, 3651, 2, 19, 144, 2, 2638, 73, 7, 5, 1527, 42, 8, 378, 287, 1, 2294, 19, 144, 7, 5, 903, 2541, 2, 1980, 6, 1163, 15, 1527, 122, 40, 2268, 73, 5, 3007, 328, 1674, 15, 2638, 2, 122, 1359, 51, 151, 288, 6, 135, 1, 7, 5, 903, 2541, 187, 1259, 1527]",1309.0,26796981,45
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.,Blood,Blood,2016-03-22,"Clonal cytogenetic evolution with additional chromosomal abnormalities (ACAs) in chronic myelogenous leukemia (CML) is generally associated with decreased response to tyrosine kinase inhibitor (TKI) therapy and adverse survival. Although ACAs are considered as a sign of disease progression and have been used as one of the criteria for accelerated phase, the differential prognostic impact of individual ACAs in CML is unknown, and a classification system to reflect such prognostic impact is lacking. In this study, we aimed to address these questions using a large cohort of CML patients treated in the era of TKIs. We focused on cases with single chromosomal changes at the time of ACA emergence and stratified the 6 most common ACAs into 2 groups: group 1 with a relatively good prognosis including trisomy 8, -Y, and an extra copy of Philadelphia chromosome; and group 2 with a relatively poor prognosis including i(17)(q10), -7/del7q, and 3q26.2 rearrangements. Patients in group 1 showed much better treatment response and survival than patients in group 2. When compared with cases with no ACAs, ACAs in group 2 conferred a worse survival irrelevant to the emergence phase and time. In contrast, ACAs in group 1 had no adverse impact on survival when they emerged from chronic phase or at the time of CML diagnosis. The concurrent presence of 2 or more ACAs conferred an inferior survival and can be categorized into the poor prognostic group.",Clinical Trial,1400.0,50.0,Clonal cytogenetic evolution with additional chromosomal abnormalities ACAs in chronic myelogenous CML is generally associated with decreased response to tyrosine kinase inhibitor TKI therapy and adverse survival Although ACAs are considered as a sign of disease progression and have been used as one of the criteria for accelerated phase the differential prognostic impact of individual ACAs in CML is unknown and a classification system to reflect such prognostic impact is lacking In this study we aimed to address these questions using a large cohort of CML patients treated in the era of TKIs We focused on cases with single chromosomal changes at the time of ACA emergence and stratified the 6 most common ACAs into 2 groups group 1 with a relatively good prognosis including trisomy 8 -Y and an extra copy of Philadelphia chromosome and group 2 with a relatively poor prognosis including i 17 q10 -7/del7q and 3q26.2 rearrangements Patients in group 1 showed much better treatment response and survival than patients in group 2 When compared with cases with no ACAs ACAs in group 2 conferred a worse survival irrelevant to the emergence phase and time In contrast ACAs in group 1 had no adverse impact on survival when they emerged from chronic phase or at the time of CML diagnosis The concurrent presence of 2 or more ACAs conferred an inferior survival and can be categorized into the poor prognostic group,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1946, 1266, 2554, 5, 402, 1860, 1171, 12238, 4, 442, 2194, 903, 16, 1228, 41, 5, 340, 51, 6, 564, 216, 230, 1379, 36, 2, 290, 25, 242, 12238, 32, 515, 22, 8, 7636, 1, 34, 91, 2, 47, 85, 95, 22, 104, 1, 3, 371, 9, 2241, 124, 3, 1777, 177, 345, 1, 797, 12238, 4, 903, 16, 860, 2, 8, 947, 398, 6, 2694, 225, 177, 345, 16, 1941, 4, 26, 45, 21, 1295, 6, 1539, 46, 1937, 75, 8, 375, 180, 1, 903, 7, 73, 4, 3, 1713, 1, 1671, 21, 1649, 23, 140, 5, 226, 1860, 400, 28, 3, 98, 1, 6285, 3397, 2, 1173, 3, 49, 96, 186, 12238, 237, 18, 271, 87, 14, 5, 8, 1352, 1178, 356, 141, 6317, 66, 2055, 2, 35, 3420, 1337, 1, 3006, 1170, 2, 87, 18, 5, 8, 1352, 334, 356, 141, 70, 269, 19649, 67, 67853, 2, 10678, 18, 2072, 7, 4, 87, 14, 224, 1802, 380, 24, 51, 2, 25, 76, 7, 4, 87, 18, 198, 72, 5, 140, 5, 77, 12238, 12238, 4, 87, 18, 3851, 8, 639, 25, 20237, 6, 3, 3397, 124, 2, 98, 4, 748, 12238, 4, 87, 14, 42, 77, 290, 345, 23, 25, 198, 491, 2054, 29, 442, 124, 15, 28, 3, 98, 1, 903, 147, 3, 750, 463, 1, 18, 15, 80, 12238, 3851, 35, 1663, 25, 2, 122, 40, 2320, 237, 3, 334, 177, 87]",1416.0,27006386,181
Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2016-04-16,"Allogeneic stem cell transplantation is an effective treatment for high-risk myeloid malignancies, but relapse remains the major post-transplantation cause of treatment failure. Alloreactive natural killer (NK) cells mediate a potent antileukemic effect and may also enhance engraftment and reduce graft-versus-host disease (GVHD). Haploidentical transplantations provide a setting in which NK cell alloreactivity can be manipulated, but they are associated with high rates of GVHD. We performed a phase I study infusing escalating doses of NK cells from an HLA haploidentical-related donor-selected for alloreactivity when possible-as a component of the preparative regimen for allotransplantation from a separate HLA-identical donor. The goal of infusing third-party alloreactive NK cells was to augment the antileukemic effect of the transplantation without worsening GVHD and, thus, improve the overall outcome of hematopoietic transplantation. Twenty-one patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous leukemia refractory or beyond first remission received a preparative regimen with busulfan and fludarabine followed by infusion of apheresis-derived, antibody-selected, and IL-2-activated NK cells. Doses were initially based on total nucleated cell (TNC) content and later based on CD56(+) cells to reduce variability. CD56(+) content ranged from .02 to 8.3210(6)/kg. IL-2, .510(6) units/m(2) subcutaneously was administered daily for 5days in the final cohort (n=10). CD3(+) cells in the NK cell product were required to be<10(5)/kg. Median relapse-free, overall, and GVHD-free/relapse-free survival for all patients enrolled was 102, 233, and 89days, respectively. Five patients are alive, 5 patients died of transplantation-related causes, and 11 patients died of relapse. Despite the small sample size, survival was highly associated with CD56(+) cells delivered (P= .022) and development of  grade 3 GVHD (P= .006). There were nonsignificant trends toward higher survival rates in those receiving NK cells from KIR ligand-mismatched donors and KIR-B haplotype donors. There was no association with disease type, remission at time of transplantation, or KIR content. GVHD was not associated with TNC, CD56(+), or CD3(+) cells infused in the NK cell product or the stem cell product. This trial demonstrates a lack of major toxicity attributable to third-party NK cell infusions delivered in combination with an HLA-compatible allogeneic transplantation. The infusion of haploidentical alloreactive NK cells was well tolerated and did not interfere with engraftment or increase the rate of GVHD after allogeneic hematopoietic transplantation. Durable complete remissions occurred in 5 patients at high risk for disease recurrence. This approach is being further developed in a phase I/II trial with exvivo-expanded NK cells to increase the NK cell dose with the objective of reducing relapse and improving the outcome of allogeneic hematopoietic transplantation for AML/MDS.","Clinical Trial, Phase I",1375.0,41.0,Allogeneic stem cell transplantation is an effective treatment for high-risk myeloid malignancies but relapse remains the major post-transplantation cause of treatment failure Alloreactive natural killer NK cells mediate a potent antileukemic effect and may also enhance engraftment and reduce graft-versus-host disease GVHD Haploidentical transplantations provide a setting in which NK cell alloreactivity can be manipulated but they are associated with high rates of GVHD We performed a phase I study infusing escalating doses of NK cells from an HLA haploidentical-related donor-selected for alloreactivity when possible-as a component of the preparative regimen for allotransplantation from a separate HLA-identical donor The goal of infusing third-party alloreactive NK cells was to augment the antileukemic effect of the transplantation without worsening GVHD and thus improve the overall outcome of hematopoietic transplantation Twenty-one patients with high-risk acute myeloid AML syndrome MDS or chronic myelogenous refractory or beyond first remission received a preparative regimen with busulfan and fludarabine followed by infusion of apheresis-derived antibody-selected and IL-2-activated NK cells Doses were initially based on total nucleated cell TNC content and later based on CD56 cells to reduce variability CD56 content ranged from .02 to 8.32 10 6 /kg IL-2 .5 10 6 units/m 2 subcutaneously was administered daily for 5 days in the final cohort n 10 CD3 cells in the NK cell product were required to be 10 5 /kg Median relapse-free overall and GVHD-free/relapse-free survival for all patients enrolled was 102 233 and 89 days respectively Five patients are alive 5 patients died of transplantation-related causes and 11 patients died of relapse Despite the small sample size survival was highly associated with CD56 cells delivered P .022 and development of  grade 3 GVHD P .006 There were nonsignificant trends toward higher survival rates in those receiving NK cells from KIR ligand-mismatched donors and KIR-B haplotype donors There was no association with disease type remission at time of transplantation or KIR content GVHD was not associated with TNC CD56 or CD3 cells infused in the NK cell product or the stem cell product This trial demonstrates a lack of major toxicity attributable to third-party NK cell infusions delivered in combination with an HLA-compatible allogeneic transplantation The infusion of haploidentical alloreactive NK cells was well tolerated and did not interfere with engraftment or increase the rate of GVHD after allogeneic hematopoietic transplantation Durable complete remissions occurred in 5 patients at high risk for disease recurrence This approach is being further developed in a phase I/II trial with ex vivo-expanded NK cells to increase the NK cell dose with the objective of reducing relapse and improving the outcome of allogeneic hematopoietic transplantation for AML/MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 452, 31, 497, 16, 35, 323, 24, 9, 64, 43, 533, 441, 84, 429, 469, 3, 458, 539, 497, 708, 1, 24, 496, 13831, 1504, 3458, 1765, 37, 3367, 8, 1157, 4512, 254, 2, 68, 120, 1304, 2881, 2, 969, 1599, 185, 1204, 34, 1562, 5802, 6779, 377, 8, 546, 4, 92, 1765, 31, 22039, 122, 40, 13222, 84, 491, 32, 41, 5, 64, 151, 1, 1562, 21, 173, 8, 124, 70, 45, 21343, 2922, 415, 1, 1765, 37, 29, 35, 1160, 5802, 139, 1488, 715, 9, 22039, 198, 899, 22, 8, 1249, 1, 3, 6085, 477, 9, 37175, 29, 8, 2282, 1160, 3038, 1488, 3, 1326, 1, 21343, 1282, 11429, 13831, 1765, 37, 10, 6, 4369, 3, 4512, 254, 1, 3, 497, 187, 4323, 1562, 2, 631, 401, 3, 63, 228, 1, 1007, 497, 737, 104, 7, 5, 64, 43, 286, 533, 329, 681, 1223, 15, 442, 2194, 430, 15, 1654, 157, 734, 103, 8, 6085, 477, 5, 3906, 2, 2027, 370, 20, 904, 1, 9456, 526, 548, 715, 2, 501, 18, 735, 1765, 37, 415, 11, 1625, 90, 23, 181, 9862, 31, 20000, 2457, 2, 1559, 90, 23, 5803, 37, 6, 969, 1982, 5803, 2457, 1869, 29, 588, 6, 66, 531, 79, 49, 503, 501, 18, 33, 79, 49, 2960, 188, 18, 3928, 10, 468, 391, 9, 33, 162, 4, 3, 1457, 180, 78, 79, 3117, 37, 4, 3, 1765, 31, 2821, 11, 616, 6, 40, 79, 33, 503, 52, 429, 115, 63, 2, 1562, 115, 429, 115, 25, 9, 62, 7, 346, 10, 2867, 7005, 2, 887, 162, 106, 365, 7, 32, 1701, 33, 7, 1016, 1, 497, 139, 1626, 2, 175, 7, 1016, 1, 429, 550, 3, 302, 1000, 444, 25, 10, 561, 41, 5, 5803, 37, 1623, 19, 4773, 2, 193, 1, 749, 88, 27, 1562, 19, 1861, 125, 11, 5542, 1963, 1317, 142, 25, 151, 4, 135, 357, 1765, 37, 29, 6989, 1232, 5095, 2344, 2, 6989, 132, 4179, 2344, 125, 10, 77, 248, 5, 34, 267, 734, 28, 98, 1, 497, 15, 6989, 2457, 1562, 10, 44, 41, 5, 20000, 5803, 15, 3117, 37, 4524, 4, 3, 1765, 31, 2821, 15, 3, 452, 31, 2821, 26, 160, 1902, 8, 926, 1, 458, 155, 2971, 6, 1282, 11429, 1765, 31, 3435, 1623, 4, 150, 5, 35, 1160, 7293, 1063, 497, 3, 904, 1, 5802, 13831, 1765, 37, 10, 149, 421, 2, 205, 44, 6178, 5, 2881, 15, 344, 3, 116, 1, 1562, 50, 1063, 1007, 497, 1480, 236, 3166, 489, 4, 33, 7, 28, 64, 43, 9, 34, 146, 26, 353, 16, 486, 195, 276, 4, 8, 124, 70, 215, 160, 5, 2581, 386, 2064, 1765, 37, 6, 344, 3, 1765, 31, 61, 5, 3, 461, 1, 1818, 429, 2, 1673, 3, 228, 1, 1063, 1007, 497, 9, 329, 1223]",2939.0,27090958,238
Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2016-08-01,"We assessed patients with chronic myelogenous leukemia (CML) for serum calcium (Ca), phosphate (PO4), bone alkaline phosphatase, N-telopeptide (NTx), osteoprotegerin (OPG) levels, and trabecular bone area (TBA) in bone marrow (BM) specimens before and after treatment with dasatinib. We identified a significant increase in percentage of TBA in postdasatinib BM (P= .022). This suggests that dasatinib therapy can increase TBA without significant changes in bone and mineral metabolism. Interferences with bone homeostasis and mineral metabolism have been described in patients receiving imatinib for CML or gastrointestinal stromal tumors. Dasatinib is a potent second-generation tyrosine kinase inhibitor designed to inhibit ABL and SRC kinases while also interfering with the c-Kit, platelet-derived growth factor receptor, and STAT5 pathways. We used a multiparameter approach to examine the off-target effects of dasatinib in 30 patients with CML treated between 2009 and 2012. We recorded serum Ca and PO4 levels, analyzed markers of bone formation (bone alkaline phosphatase/bone-specific alkaline phosphatase [BAP]) and bone resorption (NTx), measured OPG levels, and digitally analyzed changes in TBA in paired BM biopsy specimens before and after treatment. We correlated all findings with each other and with the results of conventional cytogenetic and molecular analyses. We identified a significant increase in the percentage of TBA in postdasatinib BM biopsy specimens (P= .022) and noted a decrease in serum OPG levels in 75% of patients. Ca, PO4, BAP, and NTx levels remained steady, without significant changes. There was no correlation between biomarker levels, percentage of TBA, and/or cytogenetic or molecular response. These findings suggest that dasatinib therapy (within the therapeutic range) can increase trabecular bone, without causing significant changes in bone and mineral metabolism. Nonetheless, monitoring of bone health and skeletal integrity should be included into the long-term management of patients treated with dasatinib to further enhance our understanding of its safety profile and its potential role as a treatment modality for other bone diseases.",Journal Article,1268.0,0.0,We assessed patients with chronic myelogenous CML for serum calcium Ca phosphate PO4 alkaline phosphatase N-telopeptide NTx osteoprotegerin OPG levels and trabecular area TBA in marrow BM specimens before and after treatment with dasatinib We identified a significant increase in percentage of TBA in postdasatinib BM P .022 This suggests that dasatinib therapy can increase TBA without significant changes in and mineral metabolism Interferences with homeostasis and mineral metabolism have been described in patients receiving imatinib for CML or stromal tumors Dasatinib is a potent second-generation tyrosine kinase inhibitor designed to inhibit ABL and SRC kinases while also interfering with the c-Kit platelet-derived growth factor receptor and STAT5 pathways We used a multiparameter approach to examine the off-target effects of dasatinib in 30 patients with CML treated between 2009 and 2012 We recorded serum Ca and PO4 levels analyzed markers of formation alkaline phosphatase/bone-specific alkaline phosphatase BAP and resorption NTx measured OPG levels and digitally analyzed changes in TBA in paired BM biopsy specimens before and after treatment We correlated all findings with each other and with the results of conventional cytogenetic and molecular analyses We identified a significant increase in the percentage of TBA in postdasatinib BM biopsy specimens P .022 and noted a decrease in serum OPG levels in 75 of patients Ca PO4 BAP and NTx levels remained steady without significant changes There was no correlation between biomarker levels percentage of TBA and/or cytogenetic or molecular response These findings suggest that dasatinib therapy within the therapeutic range can increase trabecular without causing significant changes in and mineral metabolism Nonetheless monitoring of health and skeletal integrity should be included into the long-term management of patients treated with dasatinib to further enhance our understanding of its safety profile and its potential role as a treatment modality for other diseases,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[21, 275, 7, 5, 442, 2194, 903, 9, 524, 3299, 1568, 4849, 41526, 5355, 2577, 78, 9466, 8110, 22010, 11448, 148, 2, 12853, 965, 21736, 4, 581, 1246, 623, 348, 2, 50, 24, 5, 1674, 21, 108, 8, 93, 344, 4, 1150, 1, 21736, 4, 49949, 1246, 19, 4773, 26, 844, 17, 1674, 36, 122, 344, 21736, 187, 93, 400, 4, 2, 5033, 1600, 68770, 5, 4975, 2, 5033, 1600, 47, 85, 1027, 4, 7, 357, 577, 9, 903, 15, 1126, 57, 1674, 16, 8, 1157, 419, 914, 564, 216, 230, 1114, 6, 1433, 1425, 2, 2023, 1549, 369, 120, 3449, 5, 3, 256, 1164, 1596, 526, 129, 161, 153, 2, 5517, 460, 21, 95, 8, 10757, 353, 6, 1004, 3, 1889, 283, 176, 1, 1674, 4, 201, 7, 5, 903, 73, 59, 1238, 2, 1195, 21, 1872, 524, 1568, 2, 41526, 148, 311, 525, 1, 1264, 5355, 2577, 3417, 112, 5355, 2577, 19800, 2, 8143, 8110, 644, 11448, 148, 2, 16815, 311, 400, 4, 21736, 4, 2355, 1246, 411, 623, 348, 2, 50, 24, 21, 438, 62, 272, 5, 296, 127, 2, 5, 3, 99, 1, 809, 1266, 2, 219, 318, 21, 108, 8, 93, 344, 4, 3, 1150, 1, 21736, 4, 49949, 1246, 411, 623, 19, 4773, 2, 1051, 8, 775, 4, 524, 11448, 148, 4, 481, 1, 7, 1568, 41526, 19800, 2, 8110, 148, 958, 4152, 187, 93, 400, 125, 10, 77, 816, 59, 901, 148, 1150, 1, 21736, 2, 15, 1266, 15, 219, 51, 46, 272, 309, 17, 1674, 36, 262, 3, 189, 184, 122, 344, 12853, 187, 3440, 93, 400, 4, 2, 5033, 1600, 4648, 1315, 1, 341, 2, 2621, 4797, 257, 40, 159, 237, 3, 319, 337, 284, 1, 7, 73, 5, 1674, 6, 195, 1304, 114, 612, 1, 211, 367, 800, 2, 211, 174, 200, 22, 8, 24, 1396, 9, 127, 1342]",2046.0,27521332,12
A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors.,Oncotarget,Oncotarget,2016-09-01,"Whether tyrosine kinase inhibitors (TKIs) can be safely discontinued is a key focus of chronic myelogenous leukemia (CML) at present. We report a clinical observation of TKIs cessation in Chinese CML patients and a probable connection between CML leukemia stem cells (LSCs) and relapse. In all, 22 of 1057 patients consented to participate in this observation. The average time of complete molecular response was 12.73 months after TKI withdrawal. LSCs could be flow cytometrically detected in most of the patients. However, the number of LSCs did not differ between the relapsers and non-relapsers. We evaluated the leukemogenetic ability of the LSCs by transplanting bone marrow into irradiated NOD/SCID mice. The results indicated that part of the bone marrow from the relapsers lead to leukemogensis in the mice. Besides, we found that LSCs-derived microvesicles might serve as a novel factor for the stratification of undetectable minimal residual disease and an early warning sign of relapse. In summary, post-TKI cessation relapse seems to show none association with the number of LSCs. A mouse xenograft model would provide a novel and useful method of analyzing LSCs function and predicting relapse. Microvesicles may provide important information about optimal molecular monitoring schedules in TKI discontinuation strategies.",Journal Article,1237.0,5.0,Whether tyrosine kinase inhibitors TKIs can be safely discontinued is a key focus of chronic myelogenous CML at present We report a clinical observation of TKIs cessation in Chinese CML patients and a probable connection between CML stem cells LSCs and relapse In all 22 of 1057 patients consented to participate in this observation The average time of complete molecular response was 12.73 months after TKI withdrawal LSCs could be flow cytometrically detected in most of the patients However the number of LSCs did not differ between the relapsers and non-relapsers We evaluated the leukemogenetic ability of the LSCs by transplanting marrow into irradiated NOD/SCID mice The results indicated that part of the marrow from the relapsers lead to leukemogensis in the mice Besides we found that LSCs-derived microvesicles might serve as a novel factor for the stratification of undetectable minimal residual disease and an early warning sign of relapse In summary post-TKI cessation relapse seems to show none association with the number of LSCs A mouse xenograft model would provide a novel and useful method of analyzing LSCs function and predicting relapse Microvesicles may provide important information about optimal molecular monitoring schedules in TKI discontinuation strategies,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[317, 564, 216, 222, 1671, 122, 40, 2268, 2402, 16, 8, 825, 1222, 1, 442, 2194, 903, 28, 364, 21, 414, 8, 38, 1664, 1, 1671, 3345, 4, 3656, 903, 7, 2, 8, 8782, 10158, 59, 903, 452, 37, 7033, 2, 429, 4, 62, 350, 1, 28168, 7, 8199, 6, 3506, 4, 26, 1664, 3, 1011, 98, 1, 236, 219, 51, 10, 133, 803, 53, 50, 1379, 3683, 7033, 359, 40, 1412, 68804, 530, 4, 96, 1, 3, 7, 137, 3, 207, 1, 7033, 205, 44, 1505, 59, 3, 28054, 2, 220, 28054, 21, 194, 3, 68805, 801, 1, 3, 7033, 20, 28926, 581, 237, 2398, 7324, 4129, 399, 3, 99, 1103, 17, 760, 1, 3, 581, 29, 3, 28054, 1122, 6, 68806, 4, 3, 399, 7301, 21, 204, 17, 7033, 526, 25307, 822, 1833, 22, 8, 229, 161, 9, 3, 1541, 1, 3920, 1048, 753, 34, 2, 35, 191, 15986, 7636, 1, 429, 4, 1962, 539, 1379, 3345, 429, 2744, 6, 514, 1292, 248, 5, 3, 207, 1, 7033, 8, 830, 1330, 202, 688, 377, 8, 229, 2, 999, 596, 1, 4449, 7033, 343, 2, 1434, 429, 25307, 68, 377, 305, 487, 545, 665, 219, 1315, 2314, 4, 1379, 2007, 422]",1286.0,27533462,23
Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).,Leukemia research,Leuk. Res.,2016-08-12,"In patients with chronic myelogenous leukemia (CML), point mutations in the BCR-ABL1 kinase domain are the most common cause of treatment failure with a tyrosine kinase inhibitor (TKI). It is not clear whether the splice variant BCR-ABL1(35INS) is also associated with treatment failure. We reviewed all CML patients who had BCR-ABL1 kinase mutation analysis performed between August 1, 2007, and January 15, 2014. Patients who had BCR-ABL1(35INS) detected had their medical records reviewed to determine response to TKI therapy. Two hundred and eighty four patients had kinase mutation testing performed; of these, 64 patients (23%) had BCR-ABL1(35INS) detected. Forty-five patients were in chronic phase (70%), 10 were in accelerated phase (16%), 6 were in blastic phase (9%), and 3 were in other settings (5%). Of the 34 chronic phase patients who began therapy with imatinib, 23 patients (68%) failed therapy: 8 patients (24%) had primary refractory disease, 11 patients (32%) progressed, and 4 patients (12%) had disease progression after dose interruption. In contrast to the patients with disease progression or lack of response, none of 23 patients who were responding to imatinib had BCR-ABL1(35INS) detected. DNA sequencing of commonly mutated spliceosomal genes SF3B1, U2AF1, SRSF2, ZRSR2, SFA31, PRPF408, U2A565, and SF1 did not reveal mutations in seven BCR-ABL1(35INS) -positive patients tested. The splice variant BCR-ABL1(35INS) is frequently found in patients who are resistant to imatinib. Mutations in the commonly mutated spliceosomal proteins do not contribute to this association.",Journal Article,1257.0,10.0,In patients with chronic myelogenous CML point mutations in the BCR-ABL1 kinase domain are the most common cause of treatment failure with a tyrosine kinase inhibitor TKI It is not clear whether the splice variant BCR-ABL1 35INS is also associated with treatment failure We reviewed all CML patients who had BCR-ABL1 kinase mutation analysis performed between August 1 2007 and January 15 2014 Patients who had BCR-ABL1 35INS detected had their medical records reviewed to determine response to TKI therapy Two hundred and eighty four patients had kinase mutation testing performed of these 64 patients 23 had BCR-ABL1 35INS detected Forty-five patients were in chronic phase 70 10 were in accelerated phase 16 6 were in blastic phase 9 and 3 were in other settings 5 Of the 34 chronic phase patients who began therapy with imatinib 23 patients 68 failed therapy 8 patients 24 had primary refractory disease 11 patients 32 progressed and 4 patients 12 had disease progression after dose interruption In contrast to the patients with disease progression or lack of response none of 23 patients who were responding to imatinib had BCR-ABL1 35INS detected DNA sequencing of commonly mutated spliceosomal genes SF3B1 U2AF1 SRSF2 ZRSR2 SFA31 PRPF408 U2A565 and SF1 did not reveal mutations in seven BCR-ABL1 35INS -positive patients tested The splice variant BCR-ABL1 35INS is frequently found in patients who are resistant to imatinib Mutations in the commonly mutated spliceosomal proteins do not contribute to this association,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 7, 5, 442, 2194, 903, 741, 138, 4, 3, 1062, 3557, 216, 1398, 32, 3, 96, 186, 708, 1, 24, 496, 5, 8, 564, 216, 230, 1379, 192, 16, 44, 885, 317, 3, 4371, 1142, 1062, 3557, 29839, 16, 120, 41, 5, 24, 496, 21, 446, 62, 903, 7, 54, 42, 1062, 3557, 216, 258, 65, 173, 59, 2480, 14, 1307, 2, 1024, 167, 1409, 7, 54, 42, 1062, 3557, 29839, 530, 42, 136, 484, 1064, 446, 6, 223, 51, 6, 1379, 36, 100, 1128, 2, 2207, 294, 7, 42, 216, 258, 471, 173, 1, 46, 660, 7, 382, 42, 1062, 3557, 29839, 530, 1213, 365, 7, 11, 4, 442, 124, 431, 79, 11, 4, 2241, 124, 245, 49, 11, 4, 6529, 124, 83, 2, 27, 11, 4, 127, 1947, 33, 1, 3, 562, 442, 124, 7, 54, 4603, 36, 5, 577, 382, 7, 806, 1551, 36, 66, 7, 259, 42, 86, 430, 34, 175, 7, 531, 1839, 2, 39, 7, 133, 42, 34, 91, 50, 61, 4823, 4, 748, 6, 3, 7, 5, 34, 91, 15, 926, 1, 51, 1292, 1, 382, 7, 54, 11, 3261, 6, 577, 42, 1062, 3557, 29839, 530, 261, 615, 1, 841, 1185, 17448, 214, 10132, 11522, 9830, 40947, 69049, 69050, 69051, 2, 50017, 205, 44, 2396, 138, 4, 648, 1062, 3557, 29839, 109, 7, 650, 3, 4371, 1142, 1062, 3557, 29839, 16, 746, 204, 4, 7, 54, 32, 436, 6, 577, 138, 4, 3, 841, 1185, 17448, 652, 1022, 44, 1248, 6, 26, 248]",1524.0,27658269,254
3'-Geranyl-mono-substituted chalcone Xanthoangelovl induces apoptosis in human leukemia K562cells via activation of mitochondrial pathway.,Chemico-biological interactions,Chem. Biol. Interact.,2016-11-29,"3'-Geranyl-mono-substituted chalcone Xanthoangelol (1b), a chalcone derivative, was previously reported to show selective cytotoxicity against human chronic myelogenous leukemia K562cells with a half-maximal inhibitory concentration (IC<sub>50</sub>) of 3.98M. In the present study, we investigated the molecular mechanism underlying the cytotoxicity of 1b in K562cells. Treatment with compound 1b caused K562cells to adopt a typical apoptotic morphology. Flow cytometric analysis also confirmed the presence of an apoptotic cell population following treatment of Annexin-V-FITC and propidium iodide (PI) double-labeled K562cells with 1b. Furthermore, we observed dissipation of the mitochondrial membrane potential, caspase-3 activation, and a reduction of the Bcl-2/Bax ratio in these cells, which suggest that the mitochondrial apoptotic pathway is induced by 1b in K562cells. Collectively, our findings demonstrate that compound 1b notably induces mitochondrial-mediated apoptosis in K562cells, which might have a potential anticancer activity.",Journal Article,1148.0,7.0,3'-Geranyl-mono-substituted chalcone Xanthoangelol 1b a chalcone derivative was previously reported to show selective cytotoxicity against human chronic myelogenous K562 cells with a half-maximal inhibitory concentration IC sub 50 /sub of 3.98 M In the present study we investigated the molecular mechanism underlying the cytotoxicity of 1b in K562 cells Treatment with compound 1b caused K562 cells to adopt a typical apoptotic morphology Flow cytometric analysis also confirmed the presence of an apoptotic cell population following treatment of Annexin-V-FITC and propidium iodide PI double-labeled K562 cells with 1b Furthermore we observed dissipation of the mitochondrial membrane potential caspase-3 activation and a reduction of the Bcl-2/Bax ratio in these cells which suggest that the mitochondrial apoptotic pathway is induced by 1b in K562 cells Collectively our findings demonstrate that compound 1b notably induces mitochondrial-mediated apoptosis in K562 cells which might have a potential anticancer activity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[5435, 69434, 8231, 10536, 41615, 69435, 4693, 8, 41615, 4819, 10, 373, 210, 6, 514, 1094, 1408, 480, 171, 442, 2194, 5208, 37, 5, 8, 1303, 2725, 1810, 1227, 2340, 551, 212, 551, 1, 27, 1096, 4810, 4, 3, 364, 45, 21, 565, 3, 219, 670, 1181, 3, 1408, 1, 4693, 4, 5208, 37, 24, 5, 2823, 4693, 1546, 5208, 37, 6, 11462, 8, 3476, 1631, 2567, 1412, 6226, 65, 120, 557, 3, 463, 1, 35, 1631, 31, 266, 366, 24, 1, 4850, 603, 12990, 2, 10839, 8456, 2928, 1627, 2841, 5208, 37, 5, 4693, 798, 21, 164, 30734, 1, 3, 2019, 1905, 174, 1469, 27, 363, 2, 8, 628, 1, 3, 1044, 18, 3119, 197, 4, 46, 37, 92, 309, 17, 3, 2019, 1631, 308, 16, 277, 20, 4693, 4, 5208, 37, 2535, 114, 272, 608, 17, 2823, 4693, 2552, 1516, 2019, 517, 351, 4, 5208, 37, 92, 822, 47, 8, 174, 1475, 128]",1025.0,27908776,80
CD34<sup>+</sup> Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2018-01-02,"Reduced-intensity conditioning (RIC) and T cell depletion (TCD) through CD34<sup>+</sup> cell selection without the use of post-transplantation immunosuppression are 2 strategies used to reduce nonrelapse mortality (NRM) in older patients after allogeneic hematopoietic cell transplantation (allo-HCT). To compare the efficacy of the RIC and TCD approaches, we evaluated the outcomes of patients age >50 years with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) who underwent allo-HCT from an HLA-matched donor with one of these strategies. Baseline characteristics were comparable in the patients receiving TCD (n=204) and those receiving RIC (n=151), except for a higher proportion of unrelated donors (68% versus 40%; P<.001) and a higher comorbidity burden (Hematopoietic Cell Transplantation Comorbidity Index [HCT-CI] 3: 51% versus 38%; P<.001) in the TCD cohort. Analysis of outcomes at 3 years showed a higher chronic graft-versus-host disease (GVHD)/relapse-free survival (CRFS) (51% versus 7%; P<.001), lower incidences of grade II-IV acute GVHD (18% versus 46% at day +180) and chronic GVHD (6% versus 55% at 3 years; P<.001), and a lower incidence of relapse (19% versus 33% at 3 years; P=.001) in the TCD group compared with the RIC group. Relapse-free survival (RFS), overall survival (OS), and NRM were similar in the 2 groups. Combining transplantation approach (RIC versus TCD) and comorbidity burden (HCT-CI 0-2 versus 3), patients with an HCT-CI score of 0-2 seemed to benefit from the TCD approach. In conclusion, in this retrospective study, the use of a CD34<sup>+</sup> cell-selected graft and a myeloablative conditioning regimen was associated with higher CRFS and similar RFS and OS compared with unmodified allo-RIC in patients age >50 years with AML and MDS.",Comparative Study,749.0,4.0,Reduced-intensity conditioning RIC and T cell depletion TCD through CD34 sup /sup cell selection without the use of post-transplantation immunosuppression are 2 strategies used to reduce nonrelapse mortality NRM in older patients after allogeneic hematopoietic cell transplantation allo-HCT To compare the efficacy of the RIC and TCD approaches we evaluated the outcomes of patients age 50 years with acute myelogenous AML and syndrome MDS who underwent allo-HCT from an HLA-matched donor with one of these strategies Baseline characteristics were comparable in the patients receiving TCD n 204 and those receiving RIC n 151 except for a higher proportion of unrelated donors 68 versus 40 P .001 and a higher comorbidity burden Hematopoietic Cell Transplantation Comorbidity Index HCT-CI 3 51 versus 38 P .001 in the TCD cohort Analysis of outcomes at 3 years showed a higher chronic graft-versus-host disease GVHD /relapse-free survival CRFS 51 versus 7 P .001 lower incidences of grade II-IV acute GVHD 18 versus 46 at day +180 and chronic GVHD 6 versus 55 at 3 years P .001 and a lower incidence of relapse 19 versus 33 at 3 years P .001 in the TCD group compared with the RIC group Relapse-free survival RFS overall survival OS and NRM were similar in the 2 groups Combining transplantation approach RIC versus TCD and comorbidity burden HCT-CI 0-2 versus 3 patients with an HCT-CI score of 0-2 seemed to benefit from the TCD approach In conclusion in this retrospective study the use of a CD34 sup /sup cell-selected graft and a myeloablative conditioning regimen was associated with higher CRFS and similar RFS and OS compared with unmodified allo-RIC in patients age 50 years with AML and MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[405, 837, 1933, 3365, 2, 102, 31, 2286, 8827, 298, 2215, 172, 172, 31, 881, 187, 3, 119, 1, 539, 497, 3646, 32, 18, 422, 95, 6, 969, 4640, 282, 4296, 4, 434, 7, 50, 1063, 1007, 31, 497, 2564, 1085, 6, 932, 3, 209, 1, 3, 3365, 2, 8827, 611, 21, 194, 3, 123, 1, 7, 89, 212, 60, 5, 286, 2194, 329, 2, 681, 1223, 54, 208, 2564, 1085, 29, 35, 1160, 655, 1488, 5, 104, 1, 46, 422, 330, 374, 11, 1279, 4, 3, 7, 357, 8827, 78, 5996, 2, 135, 357, 3365, 78, 5075, 2187, 9, 8, 142, 920, 1, 2092, 2344, 806, 185, 327, 19, 144, 2, 8, 142, 1879, 892, 1007, 31, 497, 1879, 558, 1085, 58, 2608, 725, 185, 519, 19, 144, 4, 3, 8827, 180, 65, 1, 123, 28, 27, 60, 224, 8, 142, 442, 1599, 185, 1204, 34, 1562, 429, 115, 25, 21779, 725, 185, 67, 19, 144, 280, 3981, 1, 88, 215, 478, 286, 1562, 203, 185, 641, 28, 218, 3172, 2, 442, 1562, 49, 185, 614, 28, 27, 60, 19, 144, 2, 8, 280, 287, 1, 429, 326, 185, 466, 28, 27, 60, 19, 144, 4, 3, 8827, 87, 72, 5, 3, 3365, 87, 429, 115, 25, 1272, 63, 25, 118, 2, 4296, 11, 288, 4, 3, 18, 271, 1525, 497, 353, 3365, 185, 8827, 2, 1879, 892, 1085, 58, 13, 18, 185, 2608, 7, 5, 35, 1085, 58, 368, 1, 13, 18, 5025, 6, 247, 29, 3, 8827, 353, 4, 1221, 4, 26, 459, 45, 3, 119, 1, 8, 2215, 172, 172, 31, 715, 1599, 2, 8, 3246, 1933, 477, 10, 41, 5, 142, 21779, 2, 288, 1272, 2, 118, 72, 5, 10424, 2564, 3365, 4, 7, 89, 212, 60, 5, 329, 2, 1223]",1701.0,29305194,243
Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.,Nature medicine,Nat. Med.,2018-03-05,"Leukemia stem cells (LSCs) in individuals with chronic myelogenous leukemia (CML) (hereafter referred to as CML LSCs) are responsible for initiating and maintaining clonal hematopoiesis. These cells persist in the bone marrow (BM) despite effective inhibition of BCR-ABL kinase activity by tyrosine kinase inhibitors (TKIs). Here we show that although the microRNA (miRNA) miR-126 supported the quiescence, self-renewal and engraftment capacity of CML LSCs, miR-126 levels were lower in CML LSCs than in long-term hematopoietic stem cells (LT-HSCs) from healthy individuals. Downregulation of miR-126 levels in CML LSCs was due to phosphorylation of Sprouty-related EVH1-domain-containing 1 (SPRED1) by BCR-ABL, which led to inhibition of the RAN-exportin-5-RCC1 complex that mediates miRNA maturation. Endothelial cells (ECs) in the BM supply miR-126 to CML LSCs to support quiescence and leukemia growth, as shown using mouse models of CML in which Mir126a (encoding miR-126) was conditionally knocked out in ECs and/or LSCs. Inhibition of BCR-ABL by TKI treatment caused an undesired increase in endogenous miR-126 levels, which enhanced LSC quiescence and persistence. Mir126a knockout in LSCs and/or ECs, or treatment with a miR-126 inhibitor that targets miR-126 expression in both LSCs and ECs, enhanced the in vivo anti-leukemic effects of TKI treatment and strongly diminished LSC leukemia-initiating capacity, providing a new strategy for the elimination of LSCs in individuals with CML.",Journal Article,687.0,14.0,stem cells LSCs in individuals with chronic myelogenous CML hereafter referred to as CML LSCs are responsible for initiating and maintaining clonal hematopoiesis These cells persist in the marrow BM despite effective inhibition of BCR-ABL kinase activity by tyrosine kinase inhibitors TKIs Here we show that although the microRNA miRNA miR-126 supported the quiescence self-renewal and engraftment capacity of CML LSCs miR-126 levels were lower in CML LSCs than in long-term hematopoietic stem cells LT-HSCs from healthy individuals Downregulation of miR-126 levels in CML LSCs was due to phosphorylation of Sprouty-related EVH1-domain-containing 1 SPRED1 by BCR-ABL which led to inhibition of the RAN-exportin-5-RCC1 complex that mediates miRNA maturation Endothelial cells ECs in the BM supply miR-126 to CML LSCs to support quiescence and growth as shown using mouse models of CML in which Mir126a encoding miR-126 was conditionally knocked out in ECs and/or LSCs Inhibition of BCR-ABL by TKI treatment caused an undesired increase in endogenous miR-126 levels which enhanced LSC quiescence and persistence Mir126a knockout in LSCs and/or ECs or treatment with a miR-126 inhibitor that targets miR-126 expression in both LSCs and ECs enhanced the in vivo anti-leukemic effects of TKI treatment and strongly diminished LSC leukemia-initiating capacity providing a new strategy for the elimination of LSCs in individuals with CML,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[452, 37, 7033, 4, 869, 5, 442, 2194, 903, 12394, 1995, 6, 22, 903, 7033, 32, 2327, 9, 2637, 2, 3284, 1946, 5114, 46, 37, 5589, 4, 3, 581, 1246, 550, 323, 297, 1, 1062, 1425, 216, 128, 20, 564, 216, 222, 1671, 467, 21, 514, 17, 242, 3, 3213, 2053, 722, 3927, 2708, 3, 13957, 1074, 4495, 2, 2881, 2162, 1, 903, 7033, 722, 3927, 148, 11, 280, 4, 903, 7033, 76, 4, 319, 337, 1007, 452, 37, 4980, 6185, 29, 1331, 869, 2475, 1, 722, 3927, 148, 4, 903, 7033, 10, 520, 6, 982, 1, 26364, 139, 72306, 1398, 1101, 14, 32472, 20, 1062, 1425, 92, 836, 6, 297, 1, 3, 22354, 18663, 33, 43830, 840, 17, 3961, 2053, 4537, 845, 37, 5861, 4, 3, 1246, 6296, 722, 3927, 6, 903, 7033, 6, 538, 13957, 2, 129, 22, 443, 75, 830, 274, 1, 903, 4, 92, 50911, 2362, 722, 3927, 10, 12704, 10237, 1205, 4, 5861, 2, 15, 7033, 297, 1, 1062, 1425, 20, 1379, 24, 1546, 35, 25210, 344, 4, 2682, 722, 3927, 148, 92, 651, 6643, 13957, 2, 4108, 50911, 5687, 4, 7033, 2, 15, 5861, 15, 24, 5, 8, 722, 3927, 230, 17, 637, 722, 3927, 55, 4, 110, 7033, 2, 5861, 651, 3, 4, 386, 312, 2015, 176, 1, 1379, 24, 2, 1327, 2849, 6643, 2647, 2637, 2162, 1736, 8, 217, 692, 9, 3, 3730, 1, 7033, 4, 869, 5, 903]",1430.0,29505034,73
"A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2018-03-16,"With improvement in transplantation practices in the modern era, nonrelapse mortality (NRM) following allogeneic hematopoietic stem cell transplantation (HSCT) has improved, while disease relapse rates have remained unchanged. Survival outcomes are therefore driven by NRM in the modern era. Myeloablative conditioning (MAC) regimens are used to maximize disease control and facilitate engraftment; however, their use is often limited by toxicity. The commonly used MAC regimens incorporate either chemotherapy plus total body irradiation (TBI) or combination chemotherapy. Furthermore, reduced-toxicity myeloablative (RTM) regimens, such as fludarabine/busulfan (FluBu), have emerged as alternatives to traditional MAC and their impact on outcomes in the current era have not been fully investigated. In this study, we compare outcomes following HSCT, using the chemotherapy only RTM MAC regimens FluBu with the chemoradiotherapy regimen cyclophosphamide/TBI (CyTBI), for patients with hematologic malignancies who underwent MAC HSCT at the Dana-Farber Cancer Institute. We hypothesized that the chemotherapy-only regimen would fare better, primarily due to improved NRM. A retrospective cohort analysis was performed on 387 patients with myeloid or lymphoid hematologic malignancies who underwent HLA-matched related (8/8), matched unrelated (8/8), or single-antigen mismatched unrelated (7/8) HSCT following myeloablative conditioning. Patients received FluBu (n=158) or CyTBI (n=229). The primary outcome was overall survival (OS) and all other outcomes were regarded as secondary. A subset analysis was performed for patients <55 years of age and for acute myelogenous leukemia/myelodysplastic syndrome patients of age<55 years. For the whole cohort, 3-year OS was similar for FluBu compared with CyTBI in unadjusted analysis. However, in multivariable analysis, FluBu resulted in superior OS compared with CyTBI (3-year adjusted estimate: 65% versus 55%, respectively; HR for death, .62; 95% CI, .40 to .97; P=.036). While relapse rates were similar between the 2 regimens, NRM and acute graft-versus-host disease (GVHD) (grade II to IV) were significantly worse with CyTBI compared with FluBu. Rates of chronic GVHD were similar between 2 regimens. These results were consistent in a subset of patients <55 years of age and in acute myelogenous leukemia/myelodysplastic syndrome patients below 55 years of age. The RTM chemotherapy-only regimen FluBu appears to be as effective and more tolerable than the chemoradiotherapy regimen CyTBI, leading to better OS driven by better NRM. The improvement in NRM was attributable chiefly to lower rates of grade II to IV acute GVHD. Relapse rates were not increased with FluBu. In the absence of randomized data, FluBu appears to be the optimal regimen for myeloablative HSCT in patients of all age groups.",Comparative Study,676.0,3.0,With improvement in transplantation practices in the modern era nonrelapse mortality NRM following allogeneic hematopoietic stem cell transplantation HSCT has improved while disease relapse rates have remained unchanged Survival outcomes are therefore driven by NRM in the modern era Myeloablative conditioning MAC regimens are used to maximize disease control and facilitate engraftment however their use is often limited by toxicity The commonly used MAC regimens incorporate either chemotherapy plus total body irradiation TBI or combination chemotherapy Furthermore reduced-toxicity myeloablative RTM regimens such as fludarabine/busulfan FluBu have emerged as alternatives to traditional MAC and their impact on outcomes in the current era have not been fully investigated In this study we compare outcomes following HSCT using the chemotherapy only RTM MAC regimens FluBu with the chemoradiotherapy regimen cyclophosphamide/TBI CyTBI for patients with hematologic malignancies who underwent MAC HSCT at the Dana-Farber Cancer Institute We hypothesized that the chemotherapy-only regimen would fare better primarily due to improved NRM A retrospective cohort analysis was performed on 387 patients with myeloid or lymphoid hematologic malignancies who underwent HLA-matched related 8/8 matched unrelated 8/8 or single-antigen mismatched unrelated 7/8 HSCT following myeloablative conditioning Patients received FluBu n 158 or CyTBI n 229 The primary outcome was overall survival OS and all other outcomes were regarded as secondary A subset analysis was performed for patients 55 years of age and for acute myelogenous leukemia/myelodysplastic syndrome patients of age 55 years For the whole cohort 3-year OS was similar for FluBu compared with CyTBI in unadjusted analysis However in multivariable analysis FluBu resulted in superior OS compared with CyTBI 3-year adjusted estimate 65 versus 55 respectively HR for death .62 95 CI .40 to .97 P .036 While relapse rates were similar between the 2 regimens NRM and acute graft-versus-host disease GVHD grade II to IV were significantly worse with CyTBI compared with FluBu Rates of chronic GVHD were similar between 2 regimens These results were consistent in a subset of patients 55 years of age and in acute myelogenous leukemia/myelodysplastic syndrome patients below 55 years of age The RTM chemotherapy-only regimen FluBu appears to be as effective and more tolerable than the chemoradiotherapy regimen CyTBI leading to better OS driven by better NRM The improvement in NRM was attributable chiefly to lower rates of grade II to IV acute GVHD Relapse rates were not increased with FluBu In the absence of randomized data FluBu appears to be the optimal regimen for myeloablative HSCT in patients of all age groups,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[5, 767, 4, 497, 2634, 4, 3, 2366, 1713, 4640, 282, 4296, 366, 1063, 1007, 452, 31, 497, 1703, 71, 231, 369, 34, 429, 151, 47, 958, 4639, 25, 123, 32, 673, 1621, 20, 4296, 4, 3, 2366, 1713, 3246, 1933, 7492, 472, 32, 95, 6, 4116, 34, 182, 2, 1876, 2881, 137, 136, 119, 16, 629, 383, 20, 155, 3, 841, 95, 7492, 472, 3360, 361, 56, 349, 181, 642, 1104, 4889, 15, 150, 56, 798, 405, 155, 3246, 42009, 472, 225, 22, 2027, 3906, 17063, 47, 2054, 22, 6295, 6, 1847, 7492, 2, 136, 345, 23, 123, 4, 3, 291, 1713, 47, 44, 85, 1910, 565, 4, 26, 45, 21, 932, 123, 366, 1703, 75, 3, 56, 158, 42009, 7492, 472, 17063, 5, 3, 1464, 477, 1112, 4889, 19524, 9, 7, 5, 813, 441, 54, 208, 7492, 1703, 28, 3, 4932, 4979, 12, 1377, 21, 1237, 17, 3, 56, 158, 477, 688, 11470, 380, 1561, 520, 6, 231, 4296, 8, 459, 180, 65, 10, 173, 23, 9513, 7, 5, 533, 15, 2303, 813, 441, 54, 208, 1160, 655, 139, 66, 66, 655, 2092, 66, 66, 15, 226, 448, 5095, 2092, 67, 66, 1703, 366, 3246, 1933, 7, 103, 17063, 78, 5162, 15, 19524, 78, 7584, 3, 86, 228, 10, 63, 25, 118, 2, 62, 127, 123, 11, 7217, 22, 568, 8, 697, 65, 10, 173, 9, 7, 614, 60, 1, 89, 2, 9, 286, 2194, 2647, 10589, 681, 7, 1, 89, 614, 60, 9, 3, 902, 180, 27, 111, 118, 10, 288, 9, 17063, 72, 5, 19524, 4, 4487, 65, 137, 4, 658, 65, 17063, 627, 4, 1123, 118, 72, 5, 19524, 27, 111, 586, 1191, 556, 185, 614, 106, 168, 9, 273, 744, 48, 58, 327, 6, 1015, 19, 5395, 369, 429, 151, 11, 288, 59, 3, 18, 472, 4296, 2, 286, 1599, 185, 1204, 34, 1562, 88, 215, 6, 478, 11, 97, 639, 5, 19524, 72, 5, 17063, 151, 1, 442, 1562, 11, 288, 59, 18, 472, 46, 99, 11, 925, 4, 8, 697, 1, 7, 614, 60, 1, 89, 2, 4, 286, 2194, 2647, 10589, 681, 7, 2736, 614, 60, 1, 89, 3, 42009, 56, 158, 477, 17063, 1233, 6, 40, 22, 323, 2, 80, 2668, 76, 3, 1464, 477, 19524, 1049, 6, 380, 118, 1621, 20, 380, 4296, 3, 767, 4, 4296, 10, 2971, 25694, 6, 280, 151, 1, 88, 215, 6, 478, 286, 1562, 429, 151, 11, 44, 101, 5, 17063, 4, 3, 1127, 1, 384, 74, 17063, 1233, 6, 40, 3, 665, 477, 9, 3246, 1703, 4, 7, 1, 62, 89, 271]",2772.0,29555313,186
The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.,Annals of hematology,Ann. Hematol.,2018-06-27,"Myeloproliferative neoplasms (MPNs) are clonal disorders characterized by proliferation of one or more elements of the myeloid lineage. Key genetic aberrations include the BCR-ABL1 gene rearrangement in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and JAK2/MPL/CALR aberrations in Philadelphia chromosome-negative MPNs. While thought to be mutually exclusive, occasional isolated reports of coexistence of BCR-ABL1 and JAK2, and JAK2 with MPL or CALR aberrations have been described. Given the paucity of data, clinical characteristics and outcome of patients harboring concurrent Philadelphia-positive and Philadelphia-negative mutations or dual Philadelphia-negative driver mutations have not been systematically evaluated, and their clinical relevance is largely unknown. It is difficult to determine the true relevance of co-existing driver mutations on outcomes given the rarity of its occurrence. In this case series, we describe those patients who had dual driver mutations detected at any point during the course of their disease and characterized their clinical and laboratory features, bone marrow pathology, and overall disease course.",Case Reports,573.0,7.0,neoplasms MPNs are clonal disorders characterized by proliferation of one or more elements of the myeloid lineage Key genetic aberrations include the BCR-ABL1 gene rearrangement in Philadelphia chromosome-positive chronic myelogenous CML and JAK2/MPL/CALR aberrations in Philadelphia chromosome-negative MPNs While thought to be mutually exclusive occasional isolated reports of coexistence of BCR-ABL1 and JAK2 and JAK2 with MPL or CALR aberrations have been described Given the paucity of data clinical characteristics and outcome of patients harboring concurrent Philadelphia-positive and Philadelphia-negative mutations or dual Philadelphia-negative driver mutations have not been systematically evaluated and their clinical relevance is largely unknown It is difficult to determine the true relevance of co-existing driver mutations on outcomes given the rarity of its occurrence In this case series we describe those patients who had dual driver mutations detected at any point during the course of their disease and characterized their clinical and laboratory features marrow pathology and overall disease course,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1179, 6880, 32, 1946, 1997, 765, 20, 457, 1, 104, 15, 80, 2531, 1, 3, 533, 2542, 825, 336, 2152, 643, 3, 1062, 3557, 145, 2675, 4, 3006, 1170, 109, 442, 2194, 903, 2, 2509, 16440, 11222, 2152, 4, 3006, 1170, 199, 6880, 369, 2739, 6, 40, 5575, 4804, 9753, 1355, 1198, 1, 15587, 1, 1062, 3557, 2, 2509, 2, 2509, 5, 16440, 15, 11222, 2152, 47, 85, 1027, 447, 3, 4832, 1, 74, 38, 374, 2, 228, 1, 7, 2105, 750, 3006, 109, 2, 3006, 199, 138, 15, 1828, 3006, 199, 2228, 138, 47, 44, 85, 3390, 194, 2, 136, 38, 2088, 16, 1733, 860, 192, 16, 1740, 6, 223, 3, 2501, 2088, 1, 1269, 1692, 2228, 138, 23, 123, 447, 3, 4989, 1, 211, 2291, 4, 26, 473, 988, 21, 897, 135, 7, 54, 42, 1828, 2228, 138, 530, 28, 500, 741, 190, 3, 906, 1, 136, 34, 2, 765, 136, 38, 2, 1624, 404, 581, 1117, 2, 63, 34, 906]",1119.0,29951914,28
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2018-08-25,"The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. We evaluated 1564 adult patients who underwent RIC alloHCT for acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS) from 2000 to 2013 using HLA-identical sibling (matched related donor [MRD]) or unrelated donor (URD) peripheral blood graft and received CYSP or TAC with MTX or MMF for GVHD prophylaxis. Primary outcomes of the study were acute and chronic GVHD and overall survival (OS). The study divided the patient population into 4 cohorts based on regimen: MMF-TAC, MMF-CYSP, MTX-TAC, and MTX-CYSP. In the URD group, MMF-CYSP was associated with increased risk of grade II to IV acute GVHD (relative risk [RR], 1.78; P < .001) and grade III to IV acute GVHD (RR, 1.93; P = .006) compared with MTX-TAC. In the URD group, use of MMF-TAC (versus MTX-TAC) lead to higher nonrelapse mortality. (hazard ratio, 1.48; P = .008). In either group, no there was no difference in chronic GVHD, disease-free survival, and OS among the GVHD prophylaxis regimens. For RIC alloHCT using MRD, there are no differences in outcomes based on GVHD prophylaxis. However, with URD RIC alloHCT, MMF-CYSP was inferior to MTX-based regimens for acute GVHD prevention, but all the regimens were equivalent in terms of chronic GVHD and OS. Prospective studies, targeting URD recipients are needed to confirm these results.",Clinical Trial,514.0,2.0,The combination of a calcineurin inhibitor CNI such as tacrolimus TAC or cyclosporine CYSP with methotrexate MTX or with mycophenolate mofetil MMF has been commonly used for graft-versus-host disease GVHD prophylaxis after reduced-intensity conditioning RIC allogeneic hematopoietic cell transplantation alloHCT but there are limited data comparing efficacy of the 2 regimens We evaluated 1564 adult patients who underwent RIC alloHCT for acute myelogenous AML and acute lymphoblastic ALL chronic myelogenous CML and syndrome MDS from 2000 to 2013 using HLA-identical sibling matched related donor MRD or unrelated donor URD peripheral blood graft and received CYSP or TAC with MTX or MMF for GVHD prophylaxis Primary outcomes of the study were acute and chronic GVHD and overall survival OS The study divided the patient population into 4 cohorts based on regimen MMF-TAC MMF-CYSP MTX-TAC and MTX-CYSP In the URD group MMF-CYSP was associated with increased risk of grade II to IV acute GVHD relative risk RR 1.78 P .001 and grade III to IV acute GVHD RR 1.93 P .006 compared with MTX-TAC In the URD group use of MMF-TAC versus MTX-TAC lead to higher nonrelapse mortality hazard ratio 1.48 P .008 In either group no there was no difference in chronic GVHD disease-free survival and OS among the GVHD prophylaxis regimens For RIC alloHCT using MRD there are no differences in outcomes based on GVHD prophylaxis However with URD RIC alloHCT MMF-CYSP was inferior to MTX-based regimens for acute GVHD prevention but all the regimens were equivalent in terms of chronic GVHD and OS Prospective studies targeting URD recipients are needed to confirm these results,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 150, 1, 8, 12028, 230, 16942, 225, 22, 5643, 7364, 15, 9112, 29992, 5, 2116, 3453, 15, 5, 11902, 13246, 9889, 71, 85, 841, 95, 9, 1599, 185, 1204, 34, 1562, 2049, 50, 405, 837, 1933, 3365, 1063, 1007, 31, 497, 5514, 84, 125, 32, 383, 74, 1430, 209, 1, 3, 18, 472, 21, 194, 73484, 780, 7, 54, 208, 3365, 5514, 9, 286, 2194, 329, 2, 286, 1275, 62, 442, 2194, 903, 2, 681, 1223, 29, 1081, 6, 1346, 75, 1160, 3038, 3684, 655, 139, 1488, 2029, 15, 2092, 1488, 5847, 672, 315, 1599, 2, 103, 29992, 15, 7364, 5, 3453, 15, 9889, 9, 1562, 2049, 86, 123, 1, 3, 45, 11, 286, 2, 442, 1562, 2, 63, 25, 118, 3, 45, 2176, 3, 69, 266, 237, 39, 736, 90, 23, 477, 9889, 7364, 9889, 29992, 3453, 7364, 2, 3453, 29992, 4, 3, 5847, 87, 9889, 29992, 10, 41, 5, 101, 43, 1, 88, 215, 6, 478, 286, 1562, 580, 43, 861, 14, 833, 19, 144, 2, 88, 316, 6, 478, 286, 1562, 861, 14, 966, 19, 1861, 72, 5, 3453, 7364, 4, 3, 5847, 87, 119, 1, 9889, 7364, 185, 3453, 7364, 1122, 6, 142, 4640, 282, 360, 197, 14, 576, 19, 2155, 4, 361, 87, 77, 125, 10, 77, 523, 4, 442, 1562, 34, 115, 25, 2, 118, 107, 3, 1562, 2049, 472, 9, 3365, 5514, 75, 2029, 125, 32, 77, 362, 4, 123, 90, 23, 1562, 2049, 137, 5, 5847, 3365, 5514, 9889, 29992, 10, 1663, 6, 3453, 90, 472, 9, 286, 1562, 1070, 84, 62, 3, 472, 11, 2017, 4, 1794, 1, 442, 1562, 2, 118, 482, 94, 529, 5847, 2190, 32, 575, 6, 1843, 46, 99]",1659.0,30153491,121
"Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2018-10-03,"Peripheral blood (PB) and bone marrow (BM) from unrelated donors can serve as a graft source for hematopoietic cell transplantation (HCT). Currently, PB is most commonly used in roughly 80% of adult recipients. Determining the long-term impact of graft source on outcomes would inform this decision. Data collected by the Center for International Blood and Marrow Transplant Research from 5200 adult recipients of a first HCT from an 8/8 or 7/8 HLA antigen-matched unrelated donor for treatment of acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome between 2001 and 2011 were analyzed to determine the impact of graft source on graft-versus-host disease (GVHD) relapse-free survival (GRFS), defined as freedom from grade III/IV acute GVHD, chronic GVHD requiring immunosuppressive therapy, relapse, and death, and overall survival. GRFS at 2 years was superior in BM recipients compared with PB recipients (16%; 95% confidence interval [CI], 14% to 18% versus 10%; 95% CI, 8% to 11%; P <.0001) in the 8/8 HLA-matched cohort and 7/8 HLA-matched cohort (11%; 95% CI, 8% to 14% versus 5%; 95% CI, 4% to 7%; P=.001). With 8/8 HLA-matched unrelated donors, overall survival at 5 years was superior in recipients of BM (43%; 95% CI, 40% to 46% versus 38%; 95% CI, 36% to 40%; P=.014). The inferior 5-year survival in the PB cohort was attributable to a higher frequency of deaths while in remission compared with the BM cohort. For recipients of 7/8 HLA-matched grafts, survival at 5 years was similar in BM recipients and PB recipients (32% versus 29%; P=.329). BM grafts are associated with improved long-term GRFS and overall survival in recipients of matched unrelated donor HCT and should be considered the unrelated allograft of choice, when available, for adults with acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome.",Clinical Trial,475.0,2.0,Peripheral blood PB and marrow BM from unrelated donors can serve as a graft source for hematopoietic cell transplantation HCT Currently PB is most commonly used in roughly 80 of adult recipients Determining the long-term impact of graft source on outcomes would inform this decision Data collected by the Center for International Blood and Marrow Transplant Research from 5200 adult recipients of a first HCT from an 8/8 or 7/8 HLA antigen-matched unrelated donor for treatment of acute chronic myelogenous or syndrome between 2001 and 2011 were analyzed to determine the impact of graft source on graft-versus-host disease GVHD relapse-free survival GRFS defined as freedom from grade III/IV acute GVHD chronic GVHD requiring immunosuppressive therapy relapse and death and overall survival GRFS at 2 years was superior in BM recipients compared with PB recipients 16 95 confidence interval CI 14 to 18 versus 10 95 CI 8 to 11 P .0001 in the 8/8 HLA-matched cohort and 7/8 HLA-matched cohort 11 95 CI 8 to 14 versus 5 95 CI 4 to 7 P .001 With 8/8 HLA-matched unrelated donors overall survival at 5 years was superior in recipients of BM 43 95 CI 40 to 46 versus 38 95 CI 36 to 40 P .014 The inferior 5-year survival in the PB cohort was attributable to a higher frequency of deaths while in remission compared with the BM cohort For recipients of 7/8 HLA-matched grafts survival at 5 years was similar in BM recipients and PB recipients 32 versus 29 P .329 BM grafts are associated with improved long-term GRFS and overall survival in recipients of matched unrelated donor HCT and should be considered the unrelated allograft of choice when available for adults with acute chronic myelogenous and syndrome,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[672, 315, 3767, 2, 581, 1246, 29, 2092, 2344, 122, 1833, 22, 8, 1599, 2353, 9, 1007, 31, 497, 1085, 694, 3767, 16, 96, 841, 95, 4, 7954, 493, 1, 780, 2190, 2196, 3, 319, 337, 345, 1, 1599, 2353, 23, 123, 688, 2295, 26, 948, 74, 786, 20, 3, 574, 9, 944, 315, 2, 581, 941, 389, 29, 73743, 780, 2190, 1, 8, 157, 1085, 29, 35, 66, 66, 15, 67, 66, 1160, 448, 655, 2092, 1488, 9, 24, 1, 286, 442, 2194, 15, 681, 59, 1758, 2, 1132, 11, 311, 6, 223, 3, 345, 1, 1599, 2353, 23, 1599, 185, 1204, 34, 1562, 429, 115, 25, 36678, 395, 22, 3060, 29, 88, 316, 478, 286, 1562, 442, 1562, 1888, 2989, 36, 429, 2, 273, 2, 63, 25, 36678, 28, 18, 60, 10, 1123, 4, 1246, 2190, 72, 5, 3767, 2190, 245, 48, 307, 268, 58, 213, 6, 203, 185, 79, 48, 58, 66, 6, 175, 19, 488, 4, 3, 66, 66, 1160, 655, 180, 2, 67, 66, 1160, 655, 180, 175, 48, 58, 66, 6, 213, 185, 33, 48, 58, 39, 6, 67, 19, 144, 5, 66, 66, 1160, 655, 2092, 2344, 63, 25, 28, 33, 60, 10, 1123, 4, 2190, 1, 1246, 601, 48, 58, 327, 6, 641, 185, 519, 48, 58, 511, 6, 327, 19, 3618, 3, 1663, 33, 111, 25, 4, 3, 3767, 180, 10, 2971, 6, 8, 142, 675, 1, 1043, 369, 4, 734, 72, 5, 3, 1246, 180, 9, 2190, 1, 67, 66, 1160, 655, 4713, 25, 28, 33, 60, 10, 288, 4, 1246, 2190, 2, 3767, 2190, 531, 185, 462, 19, 8766, 1246, 4713, 32, 41, 5, 231, 319, 337, 36678, 2, 63, 25, 4, 2190, 1, 655, 2092, 1488, 1085, 2, 257, 40, 515, 3, 2092, 9568, 1, 1866, 198, 390, 9, 857, 5, 286, 442, 2194, 2, 681]",1707.0,30292009,11
CML with Megakaryocytic Blast Crisis: Report of 3 Cases.,Pathology oncology research : POR,Pathol. Oncol. Res.,2018-10-25,"Chronic myelogenous leukemia (CML) is a chronic myeloproliferative neoplasm consistently associated with the BCR-ABL1 fusion gene located in the Philadelphia chromosome. The Blast Phase is diagnosed when blasts are 20% of the peripheral blood white cell count or of bone marrow nucleated cells or when there is an extramedullary blast proliferation. Megakaryocytic blast crisis as the presenting manifestation of CML is extremely rare and only 7 reported cases were found in the literature. Out of 34 cases of CML-Blast Phase between April 2015 and June 2016, 3 cases showed megakaryocytic differentiation. 2 of these presented in Blast phase as the first manifestation of CML and the third case was a known case of CML-Chronic phase. Flow cytometric immunophenotyping was performed on peripheral blood/bone marrow using 6- color flow cytometer Navios. On CD45 vs SSC two distinct populations of blasts were seen in two cases and single population in the third case. All the 3 cases were positive for CD61, cCD41, cCD61 confirming the megakaryocytic lineage. The clinical features, morphologic and cytogenetic findings help in the identification and distinction of megakaryocytic blast phase of CML from Acute Megakayoblastic Leukemia. The diagnosis of such rare presentation of CML is essential for determining the choice of treatment. Therefore including a megakaryocytic marker in the primary flow cytometry panel is important so that these cases are not under-diagnosed as Acute myeloid leukemia because of expression of CD13 and CD33 only.",Case Reports,453.0,0.0,Chronic myelogenous CML is a chronic neoplasm consistently associated with the BCR-ABL1 fusion gene located in the Philadelphia chromosome The Blast Phase is diagnosed when blasts are 20 of the peripheral blood white cell count or of marrow nucleated cells or when there is an extramedullary blast proliferation Megakaryocytic blast crisis as the presenting manifestation of CML is extremely rare and only 7 reported cases were found in the literature Out of 34 cases of CML-Blast Phase between April 2015 and June 2016 3 cases showed megakaryocytic differentiation 2 of these presented in Blast phase as the first manifestation of CML and the third case was a known case of CML-Chronic phase Flow cytometric immunophenotyping was performed on peripheral blood/bone marrow using 6- color flow cytometer Navios On CD45 vs SSC two distinct populations of blasts were seen in two cases and single population in the third case All the 3 cases were positive for CD61 cCD41 cCD61 confirming the megakaryocytic lineage The clinical features morphologic and cytogenetic findings help in the identification and distinction of megakaryocytic blast phase of CML from Acute Megakayoblastic The diagnosis of such rare presentation of CML is essential for determining the choice of treatment Therefore including a megakaryocytic marker in the primary flow cytometry panel is important so that these cases are not under-diagnosed as Acute myeloid because of expression of CD13 and CD33 only,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 2194, 903, 16, 8, 442, 2131, 2433, 41, 5, 3, 1062, 3557, 1212, 145, 2308, 4, 3, 3006, 1170, 3, 3112, 124, 16, 265, 198, 2438, 32, 8076, 1, 3, 672, 315, 886, 31, 1276, 15, 1, 581, 9862, 37, 15, 198, 125, 16, 35, 5508, 3112, 457, 14385, 3112, 6540, 22, 3, 1656, 6746, 1, 903, 16, 2938, 622, 2, 158, 67, 210, 140, 11, 204, 4, 3, 789, 1205, 1, 562, 140, 1, 903, 3112, 124, 59, 2292, 1483, 2, 1924, 1390, 27, 140, 224, 14385, 910, 18, 1, 46, 917, 4, 3112, 124, 22, 3, 157, 6746, 1, 903, 2, 3, 1282, 473, 10, 8, 440, 473, 1, 903, 442, 124, 1412, 6226, 9416, 10, 173, 23, 672, 315, 3417, 581, 75, 49, 6052, 1412, 23187, 73846, 23, 5280, 105, 25624, 100, 834, 1184, 1, 2438, 11, 527, 4, 100, 140, 2, 226, 266, 4, 3, 1282, 473, 62, 3, 27, 140, 11, 109, 9, 32926, 73847, 73848, 5030, 3, 14385, 2542, 3, 38, 404, 2815, 2, 1266, 272, 987, 4, 3, 911, 2, 6628, 1, 14385, 3112, 124, 1, 903, 29, 286, 73849, 3, 147, 1, 225, 622, 1031, 1, 903, 16, 1452, 9, 2196, 3, 1866, 1, 24, 673, 141, 8, 14385, 952, 4, 3, 86, 1412, 1914, 993, 16, 305, 1743, 17, 46, 140, 32, 44, 669, 265, 22, 286, 533, 408, 1, 55, 1, 13518, 2, 6353, 158]",1476.0,30357754,4
"The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer.",Cancer,Cancer,2019-01-03,"The concomitant use of tyrosine kinase inhibitors (TKIs) and proton pump inhibitors (PPIs) is a significant concern because of potential drug-drug interaction that reduces TKI absorption, thus potentially reducing the effectiveness of TKIs. The objective of this study was to evaluate the prevalence and predictors of concomitant TKI-PPI receipt and its impact on survival and therapy discontinuation in older adults with cancer. This retrospective study used linked Surveillance, Epidemiology, and End Results-Medicare data for the years 2007 through 2012. In total, 12,538 patients with lung cancer, renal cell cancer, chronic myelogenous leukemia, liver cancer, or pancreatic cancer were included. The primary exposure variable was concomitant receipt of TKI-PPI, defined as at least 30 days of PPI use in the first 90 days from the start of the TKI (exposure period). The outcomes measured were overall survival and discontinuation of therapy in 90 days and 1 year after the end of the exposure period. Cox proportional-hazards regression with inverse probability of treatment weighting was used to evaluate the association between exposure and outcome. The overall prevalence of TKI-PPI receipt was 22.7%. Predictors that were associated with increased use included polypharmacy and prior PPI receipt. TKI-PPI use decreased survival in 90 days (hazard ratio, 1.16; 95% confidence interval, 1.05-1.28) and in 1 year (hazard ratio, 1.10; 95% confidence interval, 1.04-1.18) but was not associated with discontinuation. Nearly 1 in 4 older adults with cancer who receive TKIs also receive PPIs concomitantly, and concomitant use is associated with an increased risk of death. Concerted efforts to manage medications are needed to identify and reduce the receipt of PPIs when TKIs are initiated.",Journal Article,383.0,3.0,"The concomitant use of tyrosine kinase inhibitors TKIs and proton pump inhibitors PPIs is a significant concern because of potential drug-drug interaction that reduces TKI absorption thus potentially reducing the effectiveness of TKIs The objective of this study was to evaluate the prevalence and predictors of concomitant TKI-PPI receipt and its impact on survival and therapy discontinuation in older adults with cancer This retrospective study used linked Surveillance Epidemiology and End Results-Medicare data for the years 2007 through 2012 In total 12,538 patients with cancer cell cancer chronic myelogenous cancer or cancer were included The primary exposure variable was concomitant receipt of TKI-PPI defined as at least 30 days of PPI use in the first 90 days from the start of the TKI exposure period The outcomes measured were overall survival and discontinuation of therapy in 90 days and 1 year after the end of the exposure period Cox proportional-hazards regression with inverse probability of treatment weighting was used to evaluate the association between exposure and outcome The overall prevalence of TKI-PPI receipt was 22.7 Predictors that were associated with increased use included polypharmacy and prior PPI receipt TKI-PPI use decreased survival in 90 days hazard ratio 1.16 95 confidence interval 1.05-1.28 and in 1 year hazard ratio 1.10 95 confidence interval 1.04-1.18 but was not associated with discontinuation Nearly 1 in 4 older adults with cancer who receive TKIs also receive PPIs concomitantly and concomitant use is associated with an increased risk of death Concerted efforts to manage medications are needed to identify and reduce the receipt of PPIs when TKIs are initiated",0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1781, 119, 1, 564, 216, 222, 1671, 2, 2095, 6320, 222, 19274, 16, 8, 93, 2893, 408, 1, 174, 234, 234, 915, 17, 2389, 1379, 6125, 631, 751, 1818, 3, 1236, 1, 1671, 3, 461, 1, 26, 45, 10, 6, 376, 3, 1078, 2, 674, 1, 1781, 1379, 9384, 1699, 2, 211, 345, 23, 25, 2, 36, 2007, 4, 434, 857, 5, 12, 26, 459, 45, 95, 1199, 617, 1284, 2, 396, 99, 1378, 74, 9, 3, 60, 1307, 298, 1195, 4, 181, 133, 10901, 7, 5, 12, 31, 12, 442, 2194, 12, 15, 12, 11, 159, 3, 86, 645, 1347, 10, 1781, 1699, 1, 1379, 9384, 395, 22, 28, 506, 201, 162, 1, 9384, 119, 4, 3, 157, 424, 162, 29, 3, 2435, 1, 3, 1379, 645, 727, 3, 123, 644, 11, 63, 25, 2, 2007, 1, 36, 4, 424, 162, 2, 14, 111, 50, 3, 396, 1, 3, 645, 727, 418, 831, 1017, 320, 5, 2931, 1320, 1, 24, 7775, 10, 95, 6, 376, 3, 248, 59, 645, 2, 228, 3, 63, 1078, 1, 1379, 9384, 1699, 10, 350, 67, 674, 17, 11, 41, 5, 101, 119, 159, 12410, 2, 324, 9384, 1699, 1379, 9384, 119, 340, 25, 4, 424, 162, 360, 197, 14, 245, 48, 307, 268, 14, 474, 14, 339, 2, 4, 14, 111, 360, 197, 14, 79, 48, 307, 268, 14, 755, 14, 203, 84, 10, 44, 41, 5, 2007, 1857, 14, 4, 39, 434, 857, 5, 12, 54, 560, 1671, 120, 560, 19274, 6485, 2, 1781, 119, 16, 41, 5, 35, 101, 43, 1, 273, 12645, 1413, 6, 4001, 2679, 32, 575, 6, 255, 2, 969, 3, 1699, 1, 19274, 198, 1671, 32, 1917]",1718.0,30605231,51
Biology and treatment of chronic myelogenous leukemia.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",1997-09-01,"Chronic myelogenous leukemia (CML) involves the clonal expansion of hemopoietic progenitor cells associated with a characteristic translocation between chromosomes 9 and 22, resulting in the generation of an aberrant bcr-abl protein with enhanced tyrosine kinase activity. Although the precise molecular events leading to malignant expansion of the myeloid cell line are as yet undetermined, bcr-abl can induce cell proliferation, transformation of immature hemopoietic cells, and suppression of apoptosis in vitro. Abnormalities of stromal/progenitor cell interaction may be central to the pathogenesis of the abnormal hemopoiesis in CML. In chronic-phase CML, therapy with interferon-alfa (Intron A, Roferon-A) produces hematologic responses in up to 70% to 80% of patients and partial or complete cytogenetic responses in up to 50%, with many studies showing a significant overall survival advantage for responding patients. Allogeneic marrow transplantation can result in long-term survival and cure in patients with CML, particularly younger patients transplanted early in the course of the disease, and unrelated-donor or autologous marrow transplantation may be an option for patients without a matched sibling donor. Future therapy will likely involve selection and ex vivo expansion of nonleukemic stem cells for reinfusion as part of a strategy for autologous marrow transplantation.",Journal Article,8177.0,8.0,Chronic myelogenous CML involves the clonal expansion of hemopoietic progenitor cells associated with a characteristic translocation between chromosomes 9 and 22 resulting in the generation of an aberrant bcr-abl protein with enhanced tyrosine kinase activity Although the precise molecular events leading to malignant expansion of the myeloid cell line are as yet undetermined bcr-abl can induce cell proliferation transformation of immature hemopoietic cells and suppression of apoptosis in vitro Abnormalities of stromal/progenitor cell interaction may be central to the pathogenesis of the abnormal hemopoiesis in CML In chronic-phase CML therapy with interferon-alfa Intron A Roferon-A produces hematologic responses in up to 70 to 80 of patients and partial or complete cytogenetic responses in up to 50 with many studies showing a significant overall survival advantage for responding patients Allogeneic marrow transplantation can result in long-term survival and cure in patients with CML particularly younger patients transplanted early in the course of the disease and unrelated-donor or autologous marrow transplantation may be an option for patients without a matched sibling donor Future therapy will likely involve selection and ex vivo expansion of nonleukemic stem cells for reinfusion as part of a strategy for autologous marrow transplantation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[442, 2194, 903, 2921, 3, 1946, 1422, 1, 19411, 2520, 37, 41, 5, 8, 2037, 2006, 59, 3560, 83, 2, 350, 1113, 4, 3, 914, 1, 35, 1898, 1062, 1425, 178, 5, 651, 564, 216, 128, 242, 3, 3260, 219, 281, 1049, 6, 393, 1422, 1, 3, 533, 31, 328, 32, 22, 1145, 5206, 1062, 1425, 122, 1290, 31, 457, 1392, 1, 5733, 19411, 37, 2, 1332, 1, 351, 4, 439, 1171, 1, 1126, 2520, 31, 915, 68, 40, 854, 6, 3, 1384, 1, 3, 1668, 52662, 4, 903, 4, 442, 124, 903, 36, 5, 1688, 4443, 6259, 8, 42793, 8, 4042, 813, 253, 4, 126, 6, 431, 6, 493, 1, 7, 2, 450, 15, 236, 1266, 253, 4, 126, 6, 212, 5, 445, 94, 2069, 8, 93, 63, 25, 1874, 9, 3261, 7, 1063, 581, 497, 122, 757, 4, 319, 337, 25, 2, 1722, 4, 7, 5, 903, 823, 773, 7, 4600, 191, 4, 3, 906, 1, 3, 34, 2, 2092, 1488, 15, 1028, 581, 497, 68, 40, 35, 1501, 9, 7, 187, 8, 655, 3684, 1488, 508, 36, 303, 322, 3882, 881, 2, 2581, 386, 1422, 1, 20986, 452, 37, 9, 20145, 22, 760, 1, 8, 692, 9, 1028, 581, 497]",1362.0,9306419,157
